0001047469-20-003880.txt : 20200626 0001047469-20-003880.hdr.sgml : 20200626 20200626163617 ACCESSION NUMBER: 0001047469-20-003880 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 42 FILED AS OF DATE: 20200626 DATE AS OF CHANGE: 20200626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiromic Biopharma, Inc. CENTRAL INDEX KEY: 0001792581 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464762913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-238153 FILM NUMBER: 20994553 BUSINESS ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 832-968-4888 MAIL ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Kiromic, Inc. DATE OF NAME CHANGE: 20191029 S-1/A 1 a2241635zs-1a.htm S-1/A

Use these links to rapidly review the document
TABLE OF CONTENTS
FINANCIAL STATEMENTS

Table of Contents

As filed with the Securities and Exchange Commission on June 26, 2020.

Registration No. 333-238153


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



AMENDMENT NO. 1
TO

FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
  2836
(Primary Standard Industrial
Classification Code Number)
  46-4762913
(I.R.S. Employer
Identification No.)



7707 Fannin, Suite 140
Houston, TX 77054
(832) 968-4888

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)



Maurizio Chiriva Internati, DBSc., Ph.Ds.
Chief Executive Officer
7707 Fannin, Suite 140
Houston, TX 77054
(832) 968-4888

(Names, address, including zip code, and telephone number, including area code, of agent for service)



Copies to:

Jeffrey J. Fessler, Esq.
Justin Anslow, Esq.
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, NY 10112
Tel.: (212) 634-3067

 

William N. Haddad, Esq
Venable, LLP
1270 Avenue of the Americas, 24th Floor
New York, NY, 10020
Tel.:(212) 503-9812

Approximate date of commencement of proposed sale to public:
From time to time after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.    o

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o   Accelerated filer o   Non-accelerated filer ý   Smaller reporting company ý

Emerging growth company ý

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. o

CALCULATION OF REGISTRATION FEE

       
 
 
  Proposed Maximum
Aggregate Offering
Price(1)(2)

  Amount of
Registration Fee

 

Common Stock, $0.001 par value per share

  $25,000,000   $3,245(3)

 

(1)
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act.

(2)
Includes initial public offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any.

(3)
$2,596 Previously Paid.

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

   


Table of Contents

The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS   SUBJECT TO COMPLETION   DATED JUNE 26, 2020

1,923,100 Shares

Common Stock

GRAPHIC

Kiromic BioPharma, Inc.


This is a firm commitment initial public offering of shares of common stock of Kiromic BioPharma, Inc. Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price of our shares will be between $12.00 and $14.00.

We have applied to list our common stock on the Nasdaq Capital Market under the symbol "KRBP."

We are an "emerging growth company" under the federal securities laws and have elected to comply with certain reduced public company reporting requirements.

Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 29.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 
  Per Share   Total

Initial public offering price

  $                 $              

Underwriting discounts and commissions(1)

  $                 $              

Proceeds to us, before expenses

  $                 $              
(1)
Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the underwriters. We refer you to "Underwriting" beginning on page 167 for additional information regarding underwriters' compensation.

We have granted a 45-day option to the representative of the underwriters to purchase up to                  additional shares of common stock solely to cover over-allotments, if any.

The underwriters expect to deliver the shares to purchasers on or about                  , 2020.

ThinkEquity
a division of Fordham Financial Management, Inc.

The date of this prospectus is                  , 2020


Table of Contents

GRAPHIC


Table of Contents

GRAPHIC


Table of Contents


TABLE OF CONTENTS

Prospectus Summary

    1  

Risk Factors

    29  

Special Note Regarding Forward-Looking Statements

    71  

Use of Proceeds

    72  

Dividend Policy

    73  

Capitalization

    74  

Dilution

    75  

Management's Discussion and Analysis of Financial Condition and Results of Operations

    77  

Business

    97  

Management

    142  

Executive Compensation

    148  

Principal Stockholders

    153  

Transactions with Related Persons

    155  

Description of Securities

    156  

Shares Eligible for Future Sale

    162  

Material U.S. Federal Tax Considerations for Non-U.S. Holders of our Common Stock

    163  

Underwriting

    167  

Legal Matters

    176  

Experts

    176  

Where You Can Find More Information

    177  

Financial Statements

    F-1  

You should rely only on the information contained in this prospectus or in any amended prospectus that we may authorize to be delivered or made available to you. We and the underwriter have not authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of its delivery or any sale of shares of our common stock.

Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of the prospectus outside the United States. See "Underwriting."

i


Table of Contents



PROSPECTUS SUMMARY

This summary highlights information that we present more fully in the rest of this prospectus. This summary does not contain all of the information you should consider before buying our shares in this offering. This summary contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements. See "Special Note Regarding Forward-Looking Statements." You should read the entire prospectus carefully, including the "Risk Factors" section and the financial statements and the notes to those statements.


THE COMPANY

Overview

We are a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology.

Our proprietary target discovery engine is called "Diamond."

Kiromic's Diamond is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug.

Without Kiromic's Diamond, the management of all the data required to solve the Target Identification puzzle is both challenging and inefficient. Normal data required for target identification would require manual analysis of thousands of cancer tissue samples with billions of data points, looking at millions of mutations, and poring over thousands of publications on oncology and targets.

Diamond (Screening, Prioritizing, and Harmonizing)

Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells. Diamond is an artificial intelligence and machine learning approach that can identify novel surface tumor targets. It uses public and proprietary samples and can expand into the tumor target space.

Diamond addresses the main challenges in today's clinical pipeline: target identification.

GRAPHIC

1


Table of Contents

Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR-T cell therapies and vaccine therapies.

Diamond's cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets, which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution and methylation status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

GRAPHIC

Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

2


Table of Contents

See our Diagram below which will walk readers through our process of going from antigens and target libraries to finish with target selection by our artificial intelligence engine.

GRAPHIC

3


Table of Contents

GRAPHIC

Prioritizing T and B Cell Targets.    Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR T cell therapies and vaccine therapies.

Identify Highly Expressed Genes.    Diamond's cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

Performs Meta Analysis.    Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

Predict Isoform Targets.    Cancer cells will down regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). These variations are known as isoforms. CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then directly fed to Diamond's artificial neural capsule network for peptide design and prioritization.

GRAPHIC

CancerSplice (Isoform Target Prediction)

Cancer cells will down-regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). One mechanism for this tumor defense is the selection for alternative splice forms of target proteins. These variations are known as isoforms. Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by pre-existing and modified T cells. Within a heterogeneous cancer cell population, isoforms can preferentially expand to avoid detection and destruction by T cells. These

4


Table of Contents

isoforms can make it impossible for T cells to outright bind the targets on cancer cells. No binding to the target means no killing of cancer cells.

GRAPHIC

To solve the problem of identifying shared, common cancer-specific antigens derived from alternative splicing and cancer-specific isoform formation, we have developed a fully integrated in silico methodology to predict cancer-specific isoforms called CancerSplice.

CancerSplice allows for the prediction and prioritization of iso-antigens which could serve as a novel source of tumor targets, highly specific for neoplastic cells but without the drawback of also being highly patient-specific.

CancerSplice allows the user to select a tissue type from the cancer genome atlas along with thresholds for filtering isoforms (minimum and maximum tumor and normal cell transcript parts per million). Based on the tissue selected, CancerSplice displays a sorted list of isoforms that are elevated in high-expressing tumors versus normal tissues which have low expression. Differential analysis is then performed and used to generate two types of lists: (1) isoforms expressed in tumor but not expressed in normal tissues; and (2) isoforms expressed in normal tissues but yet at a much higher level in tumors. CancerSplice then allows the user to click on an isoform in the list to select a specific isoform to display in a detailed panel, which shows the multi-sequence alignment for the isoform, as well as all the other isoforms of that gene.

Finally, CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then

5


Table of Contents

directly fed to Diamond's artificial neural capsule network for peptide design and prioritization. Therefore, we believe that we have developed unique tools to address the issue with tumor-specific iso-antigens through CancerSplice and Diamond.

Target isoforms are protein variants of the same targets that occur during the normal processing of immature gene transcripts to the mature form.

Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by modified T cells (autologous/allogeneic) and other cells, such as NK or invariant NKT cells (often used in the allogeneic setting).

If they are the predominate form on the cell surface, these isoforms can make it impossible for T cells to outright bind the targets on cancer cells.

No binding or insufficient binding to the isoform results in no killing of cancer cells.

Our CancerSplice accurately predicts the most appropriate isoforms for T cells to bind and destroy cancer cells.

GRAPHIC

Immune Therapies Using Our Artificial Intelligence Selected Targets

With our artificial intelligence (Diamond), we seek to use our targets to train immune cells. The trained immune cells generate a therapeutic immune response in patients. These peptide sequences, known as tumor-specific iso-antigens, generate an immunological response and therefore eradicate cancer cells.

We are developing our brand of CAR cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). These are designed to treat cancer by capitalizing on the immune system's ability to destroy cancer cells. These products are in the pre-IND stage of the FDA clinical trial process. We are currently going through the validation process and expect that IND enabling studies will commence in the second half of 2020.

CAR-T cell therapy, a form of cancer immunotherapy, has recently emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, two autologous anti-CD19 CAR-T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., (now part of Gilead), were approved by the FDA for the treatment of relapsing/remitting B cell precursor acute lymphoblastic leukemia and relapsing/remitting

6


Table of Contents

large B cell lymphoma, respectively. Autologous CAR-T cell therapies are manufactured individually for the patient's use by modifying the patient's own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient's T cells and takes approximately three to four weeks. Allogenic T cell therapies involve engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world.

We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since we began principal business operations in 2012.

Engineered T Cell Therapy

White blood cells are a component of the immune system and are responsible for defending the body against infectious pathogens and other foreign material. T cells are a type of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating the activation of other cells in an immune response.

T cells can be distinguished from other white blood cells by T cell receptors present on their cell surface. These receptors contribute to tumor surveillance by directing T cells to recognize infected and destroy cancerous cells. When T cells with cancer-specific receptors are absent, present in low numbers, of poor quality or rendered inactive by suppressive mechanisms, cancer may grow and spread. In addition, standard of care treatments, such as chemotherapy regimens, as well as disease specific factors can damage the patient's immune system, thereby inhibiting the ability of T cells to kill cancer.

Engineered T cell therapy is a type of immunotherapy treatment whereby human T cells are removed from the body and engineered to express CARs which, when infused into a patient, may recognize and destroy cancer cells in a more targeted manner.

CARs are engineered molecules that, when present on the surface of a T cell, enable the T cell to recognize specific proteins or antigens that are present on the surface of other cells.

There are two primary approaches to engineered T cell therapy: autologous and allogenic. Autologous therapies use engineered T cells derived from the individual patient, while allogenic therapies use engineered T cells derived from healthy donor T cells.

The autologous approach, pioneered by Novartis, Kite and others, has been highly successful in engineering patients' immune systems to fight cancer, in particular CD19 positive cancers, resulting in significant remission rates. Autologous products are manufactured by first collecting a patient's white blood cells, through a process known as leukapheresis, separating the T cells from the patient's blood sample and proliferating the isolated T cells. After the cells have multiplied, the CAR construct is virally transduced into the T cells and the engineered T cells are then propagated until a sufficient number of cells are available for infusion into the patient. Finally, the engineered T cells are frozen, and then shipped back to the clinical center for administration to the patient. The process from leukapheresis to delivery to the clinical center takes approximately three to four weeks.

Allogenic engineered T cells are manufactured in a similar manner as autologous, but with two key differences: (1) allogenic T cells are derived from healthy donors, not cancer patients, and (2) allogenic T cells must also be genetically engineered to minimize the risk of graft-versus-host disease, a condition where allogenic T cells can recognize the patient's normal tissue as foreign and cause damage in the patient.

7


Table of Contents

Our Approach

Our operating motto is Better Target, Better Life TM.

Our goal is to defeat cancer by developing immunotherapies that rely on improving target discovery and validation. With better targets, we believe our therapies will be more effective than the current crop of immunotherapies using older targets.

We are currently in the process of validating different tumor-specific immunotherapy product candidates for refractory CAR-T cell patients. Refractory CAR-T cell patients are those who have received CAR-T cell treatments for their indication, however, they either showed low or no benefit from this treatment. We validate biomarkers for these product candidates using the technologies and processes discussed in the sections below. The development schema below describes the path forward for developing our novel product candidates.

8


Table of Contents


GRAPHIC

9


Table of Contents


ABBIE (Delivery Vehicle)

ABBIE Summary

ABBIE is a novel gene-editing system for inserting therapeutic genes safely into the genome of a host cell.

ABBIE technology comprises two main components, (i) a genome template (extracted from the ALEXIS plasmid), containing the therapeutic genes needed to retrain tumor-killing cells, and (ii) the gene-editing machinery required to safely insert this template into the genome of the therapeutic cells.

The ABBIE protein accompanies the CAR-containing genome template as it passes through the cell membrane into the nucleus and guides the template-flanking sequences (the "glue") safely into the target genome.

Due to this targeting ability, ABBIE can also be used to remove unwanted, inhibitory genes. CAR expression on the Gamma-Delta T cells allows them to detect and destroy the antigen-expressing targeted cells.

The OFF switch permits fast shutdown in the event of an unexpected toxicity. Additional Anti-tumor factors can help neutralize the toxic tumor microenvironment.

ABBIE: Development

We are currently developing ABBIE (A Binding-Based Integrase Enzyme) for delivering our product candidates. ABBIE is a non-viral gene-editing mechanism to insert the target DNA template information into the T cell genome at a predetermined locus. ABBIE allows for insertion of the genome template into the T cells so that they could express the CAR protein and other accessory proteins while possibly eliminating unwanted inhibitory proteins.

The non-viral vector template is simultaneously physically comingled with the patient's T/NK cells. The non-viral vector transfers the target's genomic information into the T/NK cells, where it is integrated into the T/NK cell's genome. T/NK cells now have been reprogramed with the genomic information for targeting and can successfully identify the targets on the cancer cells. This T/NK cell therapy is infused into the patient. T/NK cells will hunt down cancer cells with the known targets and destroy these cancer cells.

GRAPHIC

We believe that this gene delivery platform will deliver the DNA template to the T/NK cell genomes at a lower cost and shorter timeframe versus a viral vector. By comparison, a retroviral vector would have a longer development lead time (~12 months) with an increased insertional mutagenesis risk. Insertional mutagenesis means that a random insertion of the DNA could activate uncontrolled cell growth. ABBIE allows for a more consistent expression and will have a shorter development lead time (3-6 months). It avoids unnecessary risks by targeting a single locus and produces more predictable cell-to-cell expressions.

10


Table of Contents

The development of ABBIE involves a multi-step process, which includes preparation of an integration-deficient lentivirus, a sensitive, targeted gene knock-out assay system, optimization of an inducible ABBIE protein expression system, a powerful screen for gene targeting efficiency, and a sensitive screen of additional ABBIE mutants to further improve efficacy. Altogether, the development plan involves construction of dozens of plasmid constructs, which are complete. To date, we have successfully completed the high transduction efficiency lentivirus system for our assays along with the non-integrating lentivirus system. Optimization of the selection schema is over 70% complete and the construction of the inducible expression and knock-out systems are well underway. If no major obstacles are encountered, we expect to be able to begin producing effector cells for in vitro testing using ABBIE by December 2020.

11


Table of Contents

GRAPHIC

12


Table of Contents

GRAPHIC

SWITCHES

ACTIVATION Switch.    A rapidly deployed activation switch can provide a survival and proliferation signal to the therapeutic cells to enhance their efficacy and persistence in vivo.

ATTENUATION Switch.    A rapidly deployed attenuation switch can intercept activation signals transiently to minimize toxicity following successful anti-tumor interactions. Choice of two non-mutually exclusive Attenuation Switch approaches: (a) a protein-based switch that rapidly triggers attenuation of target cells in a dose-dependent fashion. (b) a small molecule-based approach to rapidly and reversibly attenuate cell signaling.

SAFETY Switch.    A rapidly deployed, protein-based safety switch can eliminate therapeutic cells in case of acute toxicity. The safety switch is designed to eliminate either: (a) essentially all active therapeutic cells. (b) only the most active cells, preserving a cohort of backup therapeutic cells for long-term control of residual relapsing tumor cells. The Safety Switch will be co-expressed along with the bioactive chimeric activation receptor (CAR), the Activation Switch, and the Attenuation Switch.

13


Table of Contents

Manufacturing Allogeneic Effector Cells

The three primary steps to creating our engineered effector cells are: (1) collection, (2) gene editing, and (3) purification, formulation, and storage.

GRAPHIC

PD-1: Avoiding Antigen Escape

To further boost the potency of our effector cells, we plan to explore an additional targeting element that interferes with the inhibitory "checkpoint" protein, PD-1 found on most activated T cells and other effector cells. By interacting with the PD-L1 and PD-L2 inhibitory ligands often found at high levels within the tumor microenvironment, PD-1 normally sends a suppressive signal to the cell to shut down its activity in a process known as exhaustion. However, using a "flipped" signaling receptor, we plan to turn PD-1 "inside-out," changing this inhibitory signal to a stimulatory signal. Thus, with two ways to activate the anti-tumor cells, the chances for the tumor to escape treatment are greatly reduced.

14


Table of Contents

GRAPHIC

The chPD1 Receptor is activated by engagement with PD-L1+ or PD-L2+ tumors.

chPD1-expressing T cells can efficiently lyse both hematologic and solid tumors expressing PD-L1 and/or PD-L2, leading to greatly improved survival with minimal toxicity in animal models.

chPD1 Receptor signaling also leads to cytokine release that can have widespread anti-tumor effects in the tumor microenvironment.

Step 1. Collection

The starting material for our engineered T/NK cell products is white blood cells. For our allogenic products, the T/NK cells are collected from a healthy donor. These are collected using a standard blood bank procedure known as leukapheresis. The collected cells are then sent to a central processing facility, where the peripheral blood mononuclear cells, including T/NK cells, are isolated from the other sample components. The T/NK cells for our allogenic products are isolated and stored frozen, creating an inventory of starting healthy donor cells for manufacturing.

15


Table of Contents

 

Step 2. Gene Editing

These cells are stimulated to proliferate, then transduced with a non-replicating retroviral vector to introduce the CAR gene into the patient's T/NK cells.

We are also currently developing ABBIE, which is a non-viral gene-editing mechanism to insert the target DNA template information into the T/NK cell genome. The CAR sequence will direct the expression of CAR proteins on the cell surface that allows the transduced T/NK cells to recognize and bind to a target molecule that is present on cancer cells.

Step 3. Purification, Formulation, and Storage

These engineered cells are then propagated in cell culture bags until sufficient cells are available. The engineered T/NK cells are then washed and frozen at the cell processing site.

For our allogenic products, the engineered cells are frozen and sent to long-term storage in the vapor phase of liquid nitrogen. This inventory will be securely stored and then shipped to oncology centers as needed.

16


Table of Contents

GRAPHIC

Note that we have not yet completed our ABBIE (gene editing) technology as shown in Step No. 5 above. Our clinical trial will be using the current industry standard retroviral vector.

17


Table of Contents

Our Product Pipeline and Development

Using our proprietary technologies, we are researching and developing multiple product candidates for the treatment of blood cancers and solid tumors. Our product candidates are allogenic engineered cells to be used for specific patients or as off-the-shelf treatments for any patient with a particular cancer type. Each product candidate targets a selected antigen expressed on tumor cells and bears specific engineered attributes.

In the near term, we are progressing multiple product candidates directed at promising targets for blood cancers, including refractory large B cell lymphoma, and targets associated with solid tumors, such as malignant pleural mesothelioma (lung) and epithelial ovarian cancer.

Our product pipeline is represented in the diagram below:

GRAPHIC

GRAPHIC

18


Table of Contents

ALEXIS Isoform Mesothelin EOC

ALEXIS Isoform Mesothelin is our allogenic CAR cell product candidate targeting Isoform Mesothelin. We are still planning clinical trials before submitting this product for authorization.

ALEXIS Isoform Mesothelin represents an innovative approach for stage III to stage IV platinum resistant epithelial ovarian cancer and involves the use of effector cells.

Target Indications

ALEXIS Isoform Mesothelin targets epithelial ovarian cancer, or EOC. According to the American Cancer Society, approximately 21,750 individuals are diagnosed with EOC in the U.S. each year, and 300,000 worldwide.

EOC generally affects elderly women over 60 years old. Genetic mutations and/or a family history of ovarian/breast/colorectal cancer increase the risk of EOC. EOC can metastasize to abdominal peritoneum, which is extremely difficult to treat. The median life expectancy after local recurrence is approximately 15 months.

In total, the standard treatment can cost approximately $100,000. Ovarian cancer is a deadly disease with stage IV patients having a 5-year overall survival rate of only 30%.

Out of 21,750 U.S. patients who are initially diagnosed with EOC each year, we believe that up to 15,400 (70%) will potentially be eligible for our CAR cell therapy.

In 2018, this market size reached $1.2 billion according to Grand View Research (July 2019).

This market is expected to grow at 6.2% annually compounded from 2019 to 2026 according to Data Monitor Healthcare.

Development Plan

ALEXIS Isoform Mesothelin will be studied in a Phase 1 clinical trial for EOC patients. We plan to submit an IND and initiate a Phase 1 clinical trial in 2021. We will be the sponsor of the clinical trials, which will be conducted by industry-standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open-label, single arm, multi-center, dose-escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with EOC who have progressed on at least two lines of salvage chemotherapy and/or additional surgical/radiation therapy cell reduction.

The primary goal will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (Isoform Mesothelin).

ALEXIS Isoform Mesothelin MPM

ALEXIS Isoform Mesothelin MPM is our allogenic effector cell product candidate targeting Isoform Mesothelin. We are still planning clinical trials before submitting this product for authorization.

ALEXIS Isoform Mesothelin MPM represents an innovative approach for malignant pleural mesothelioma and involves the use of effector cells.

19


Table of Contents

Target Indications

ALEXIS Isoform Mesothelin MPM targets malignant pleural mesothelioma, or MPM. Mesothelioma is a disease in which malignant (cancer) cells form in the thin layer of tissue that covers organs typically in the chest or abdomen. Pleura refers to the thin layer of tissue that lines the chest cavity and covers the lungs. The tumors often spread over the surface of organs often without spreading into the organ. They may spread to nearby lymph nodes or in other parts of the body. Malignant mesothelioma may also form in the testicles or heart, but this is rare.

According to the American Cancer Society, approximately 3,000 individuals are diagnosed with MPM in the U.S. each year, and 43,000 deaths globally each year.

MPM rates are high in the military, particularly for those involved in ship building, construction, mechanics, and insulation/textile production and installation. Due to these higher rates, corporations have set aside approximately $30 billion each year to settle job-related asbestos MPM for their personnel.

The standard treatment for MPM involves chemotherapy that costs approximately $90,000, surgery that costs approximately $20,000 - $30,000, and radiation that costs approximately $10,000 - $50,000. In total, the standard treatment can cost up to $170,000. Approximately 80% of patients undergoing this treatment will eventually relapse. The average life expectancy after refractory is approximately 7 months.

Out of the 3,000 U.S. patients who are initially diagnosed with MPM each year, we believe that approximately 2,400 (80%) will eventually be eligible for our effector cell therapy.

Mesothelioma statistics show there are about 3,000 new cases of mesothelioma diagnosed in the United States each year. According to the most recent data, 57,657 mesothelioma cases were reported between 1999 and 2016. Between 1999 and 2017, there were more than 47,600 mesothelioma-related deaths. Pleural mesothelioma is the most common form, accounting for 80 - 90% of all cases. (Source: https://www.mesothelioma.com/mesothelioma/statistics/)

The global mesothelioma burden is unclear. Driscoll et al. estimated that as many as 43,000 people worldwide die from the disease each year. It has also been estimated that there are around 10,000 mesothelioma cases annually in Australia, Japan, North America and western Europe combined. (Source: See Bulletin of the Delgermaa et. al, World Health Organization 2011;89:716-724C.)

This market is expected to grow at 7.60% annually compounded from 2020 to 2026 according to MarketWatch (April 2, 2020).

This market size is expected to reach $300 million by 2025 according to Persistent Market Research (July 2017).

Development Plan

ALEXIS Isoform Mesothelin MPM will be studied in a Phase 1 clinical trial for mesothelioma, including pleural and peritoneal mesotheliomas. We plan to submit an IND and initiate a Phase 1 clinical trial in 2021. We will be the sponsor of the clinical trials, which will be conducted by industry-standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open label, single arm, multi-center, dose escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with mesothelioma, who are relapsed/refractory to maximal surgical and/or radiation therapy reduction and standard first line chemotherapy.

The primary goal will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

20


Table of Contents

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (Isoform Mesothelin).

ALEXIS AIDT-1

ALEXIS AIDT-1 is our allogenic CAR cell product candidate targeting AIDT-1. This product is currently undergoing pre-IND studies. Following subsequent IND-enabling studies, we will be applying for an IND with the FDA. The clinical trial for this product candidate is expected to launch during the first half of 2022. We will be the sponsor of the program and lead the clinical development program.

ALEXIS AIDT-1 targets AIDT-1, an antigen expressed on the surface of B cells, including malignant B cells. The product represents an innovative approach for relapsed hematologic malignancies such as B cell acute lymphoblastic leukemia and for diffuse large B cell lymphoma and involves the use of adoptive T cells expressing CARs against AIDT-1. We expect our strategy to target B cell malignancies that have become refractory to currently available CAR cell therapies.

Target Indications

ALEXIS AIDT-1 targets NHL (ie, diffuse large B cell lymphoma, or DLBCL). According to the American Cancer Society, approximately 25,000 - 30,000 individuals are diagnosed with DLBCL in the U.S. each year, and 200,000 worldwide. The growth rate for DLBCL is relatively stable.

The standard treatment is R-CHOP chemotherapy, which is a combination treatment consisting of five separate drugs: rituximab (Rituxan), cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin), and prednisolone. R-CHOP chemotherapy costs approximately $100,000 per year. Average life expectancy following the failure of R-CHOP chemotherapy is approximately 6 months.

The failure rate for R-CHOP chemotherapy is 30 - 50%. Up to 50% of failures cannot get stem cell transplants and are potential candidates for CAR therapy. Standard CAR-T therapy costs between approximately $375,000 to $475,000.

Out of the 30,000 U.S. patients who are initially diagnosed with DLBCL each year, we believe that approximately 3,000 will eventually be eligible for our CAR-T cell therapy.

Worldwide number of patients for Non-Hodgkin's Lymphoma is estimated at 509,590. (Source: Global cancer statistics 2018: Globocan estimates of incidence & mortality world-wide for 36 cancers in 185 countries) with 77,240 cases in the U.S. in 2020 according to the American Cancer Society 2020).

The number of diagnosed hematologic cases is expected to grow at 10.5% annually compounded according to Data Monitor Healthcare (Source: See Hematologic Malignancies Market Size, Share & Trends Analysis Report by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2018 - 2025.)

The market size for hematologic cancers is expected to reach $4.6 billion by 2025 according to BIS Research (November 21, 2019).

Development Plan

ALEXIS AIDT-1 will be studied in a Phase 1 clinical trial for DLBCL, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. We plan to submit an IND and initiate a Phase 1 clinical trial in 2022. We will be the sponsor of the clinical trials, which will be conducted by industry standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open-label, single-arm, multi-center, dose escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with DLBCL, who are relapsed or

21


Table of Contents

refractory to prior treatment with an anti-CD20 monoclonal antibody therapy and an anthracycline containing chemotherapy and/or an autologous stem cell transplant.

The primary endpoint will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (AIDT-1).

GRAPHIC

Our Risks and Challenges

Our prospects should be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by similar companies. Our ability to realize our business objectives and execute our strategies is subject to risks and uncertainties, including, among others, the following:

    We have never been profitable and may never achieve or maintain profitability.

    If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.

    We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

    Our business is dependent on the successful development, regulatory approval and commercialization of our personalized immunotherapy product candidates, which are in the early stages of development and have not been tested in humans.

    Our tumor-specific cancer immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.

    We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our immunotherapy candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.

22


Table of Contents

 

    The genome editing field is relatively new and evolving rapidly, and other existing or future technologies may provide significant advantages over our Diamond, CancerSplice and ABBIE technologies, which could materially harm our business.

    If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed.

    Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators. We plan to enter into significant arrangements with collaborators and expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.

    We plan to enter into significant arrangements with collaborators and expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.

    We expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.

    We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business.

    The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.

    We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.

    Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.

    The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.

    Our ability to compete effectively in our markets may decline if we do not adequately protect our patents and proprietary rights, and our patents and proprietary rights do not necessarily address all potential threats to our competitive advantage.

In addition, we face other risks and uncertainties that may materially affect our business prospects, financial condition, and results of operations. You should consider the risks discussed in "Risk Factors" and elsewhere in this prospectus before investing in our common stock.

Our Corporate History

We were first organized as a corporation in the State of Texas on August 6, 2006 under the name "Kiromic, Inc." Between 2006 and 2012, we had minimal operations. On March 15, 2013, we converted to a limited liability company in the State of Texas under the name "Kiromic, LLC." On May 27, 2016, we converted to a corporation in the State of Delaware under the name "Kiromic, Inc." On December 16, 2019, we changed our name to "Kiromic BioPharma, Inc."

23


Table of Contents

We have one wholly-owned subsidiary, GreenPlanet Pharma, Inc., which was incorporated in the State of Delaware on November 26, 2018. GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This subsidiary has not generated any revenues.

Corporate Information

Our principal executive office is 7707 Fannin, Suite 140, Houston, TX 77054. Our telephone number is (832) 968-4888. Our website is www.kiromic.com. The information contained on our website is not a part of this prospectus, nor is such content incorporated by reference herein, and should not be relied upon in determining whether to make an investment in our common stock.

Implications of Being an Emerging Growth Company

Upon the completion of this offering, we will qualify as an "emerging growth company" under Jumpstart Our Business Act of 2012, as amended, or the JOBS Act. As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

    have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

    comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

    submit certain executive compensation matters to stockholder advisory votes, such as "say-on-pay" and "say-on-frequency;" and

    disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer's compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an emerging growth company for up to five years from the date of the first sale of equity securities pursuant to an effective registration statement, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

24


Table of Contents

Reverse Stock Splits

On December 17, 2019, we completed a 1-for-10 reverse stock split of our outstanding common stock. As a result of this stock split, our issued and outstanding common stock decreased from 100,060,000 to shares 10,006,005 shares.

On June 17, 2020, we completed a 1-for-3.494 reverse stock split of our outstanding common stock. As a result of this stock split, our issued and outstanding common stock decreased from 14,909,663 to 4,267,269 shares. Accordingly, unless otherwise noted, all share and per share information contained in this prospectus has been recast to retroactively show the effect of these stock splits.

25


Table of Contents

 


THE OFFERING

Common stock offered by us

  1,923,100 shares of common stock, $0.001 par value per share.

Assumed offering price

 

$13.00 per share, the midpoint of the range set forth on the cover page of this prospectus.

Over-allotment option

 

The underwriters have an option for a period of 45 days to acquire up to an additional 288,465 shares of common stock from us at the public offering price, less the underwriting discount, solely for the purpose of covering over-allotments, if any.

Shares of common stock outstanding before this offering(1)

 

4,989,269 shares of common stock.

Shares outstanding after this offering

 

8,006,099 shares of common stock (or 8,294,564 shares of common stock if the underwriters exercise their over-allotment option in full), after the sale of 1,923,100 shares in this offering and after the Preferred Stock Automatic Conversions.

Use of proceeds

 

We estimate that we will receive net proceeds of approximately $21,963,000 from our sale of common stock in this offering, or approximately $25,394,300 if the underwriters exercise their over-allotment option in full.

 

We plan to use the net proceeds of this offering primarily for clinical trials for our ALEXIS Isoform Mesothelin EOC and PD-1 product candidates, intellectual property protection and reinforcement, IND applications and IND enabling trials and working capital and general corporate purposes. The details of our plans are set forth in the "Use of Proceeds" section

Risk factors

 

Investing in our common stock involves a high degree of risk and purchasers of our common stock may lose part or all of their investment. See "Risk Factors" for a discussion of factors you should carefully consider before deciding to invest in our common stock.

Proposed trading market and symbol

 

We have applied to list our common stock for trading on the Nasdaq Capital Market under the symbol "KRBP." No assurance can be given that our application will be approved.


(1)
The number of shares outstanding is based on shares outstanding as of June 26, 2020 and excludes the following:

624,868 shares of our common stock issuable upon the exercise of outstanding options with a weighted-average exercise price of $11.90 per share;

709,334 shares of our common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $19.00 per share;

21,822,301 shares of Series A-1 Preferred Stock and 16,391,397 shares of Series B Preferred Stock which is automatically convertible into 624,594 and 469,136 shares of common stock, respectively, upon the closing of this offering (the "Preferred Stock Automatic Conversions");

up to an additional 372,694 shares of our common stock issuable under our 2017 Equity Incentive Plan; and

26


Table of Contents

    96,155 shares of our common stock underlying the warrants to be issued to the representative of the underwriters in connection with this offering.

Except as otherwise indicated herein, all information in this prospectus assumes the following:

    no exercise of the underwriters' option to purchase up to an additional 288,465 shares of common stock to cover allotments, if any.

27


Table of Contents



SUMMARY FINANCIAL INFORMATION

The following tables summarize our consolidated financial data. We have derived the summary consolidated statement of operations data for the years ended December 31, 2019 and 2018 and the balance sheet data as of December 31, 2019 from our audited consolidated financial statements included elsewhere in this prospectus. The interim consolidated statements of operations data for the three months ended March 31, 2020 and 2019 and interim condensed consolidated balance sheet data as of March 31, 2020 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Such information should be read in conjunction with our financial statements and related notes included elsewhere in the prospectus and the information contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" below.

Our financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. Our historical results for any period are not necessarily indicative of our future performance.

 
  Years Ended December 31,   Three Months Ended
March 31,
 
 
  2019   2018   2020   2019  

Statements of Operations Data

                         

Operating expenses:

                         

Research and development

  $ 1,201,700   $ 1,424,900   $ 1,028,100   $ 203,500  

General and administrative

    2,503,700     1,757,700     824,600     183,800  

Total operating expenses

    3,705,400     3,182,600     1,852,700     387,300  

Loss from operations

    (3,705,400 )   (3,182,600 )   (1,852,700 )   (387,300 )

Other expense

    (22,500 )   (633,100 )       (3,600 )

Net loss

  $ (3,727,900 ) $ (3,815,700 ) $ (1,852,700 ) $ (390,900 )

Net loss per share—basic and diluted

  $ (1.39 ) $ (1.33 ) $ (0.78 ) $ (0.14 )

 

 
  March 31, 2020  
 
  Actual   Pro forma(1)   Pro forma, as
adjusted(2)
 

Balance Sheet Data

                   

Cash and cash equivalents

  $ 3,042,500   $ 3,047,400   $ 25,010,400  

Working capital

    2,366,800     2,371,700     24,334,700  

Total assets

    4,469,000     4,473,900     26,436,900  

Total liabilities

    886,700     886,700     886,700  

Total stockholders' equity

    3,582,300     3,587,200     25,550,200  

(1)
Gives effect on a pro forma basis to the exercise of 1,399,921 warrants at an exercise price of $0.003494 per share and the subsequent issuance of 1,399,921 shares of common stock in June 2020.

(2)
Gives effect on a pro forma, as adjusted basis to (i) the Preferred Stock Automatic Conversions and (ii) the sale and issuance by us of 1,923,100 shares of common stock in this offering at the assumed initial public offering price of $13.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

28


Table of Contents


RISK FACTORS

The shares being offered by us are highly speculative in nature, involve a high degree of risk and should be purchased only by persons who can afford to lose the entire amount invested. Before purchasing any of our shares, you should carefully consider the following factors relating to our business and prospects. If any of the following risks actually occurs, our business, financial condition or operating results will suffer, the trading price of our stock could decline, and you may lose all or part of your investment.

Risks Related to Our Business and Industry

We have never been profitable and may never achieve or maintain profitability.

We have not commercialized any products and have yet to generate any revenue from product sales. The amount of our future net losses will depend, in part, on our expenses and our ability to generate revenues. Our current and future product candidates will require substantial additional development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

    continue our current research and development programs, including conducting laboratory, preclinical and greenhouse studies for product candidates;

    initiate clinical or field trials for product candidates;

    seek to identify, assess, acquire or develop additional research programs or product candidates;

    maintain, expand and protect our intellectual property portfolio;

    seek marketing approvals for any product candidates that may successfully complete development;

    establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval;

    further develop and refine the manufacturing process for our product candidates;

    change or add additional manufacturers or suppliers of biological materials or product candidates;

    validate a commercial-scale manufacturing facility compliant with current good manufacturing practices, or cGMP;

    further develop our genome editing technology;

    acquire or in-license other technologies;

    seek to attract and retain new and existing personnel; and

    expand our facilities.

No clinical studies have begun on any of our new therapeutic product candidates, and it will be several years, if ever, before we obtain regulatory approval for a therapeutic product candidate, at which time any revenues for such product candidate will depend upon many factors, including, market conditions, costs and effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, and the terms of any collaboration or other strategic arrangement we may have with respect to such product candidate and levels of reimbursement from third-party payors.

If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability or sustain profitability, which would have an adverse effect on the value of our common stock will be materially adversely affected.

29


Table of Contents

If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.

The process of identifying product candidates and conducting preclinical and clinical trials is time consuming, expensive, uncertain and takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical or field trials of, and seek marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution efforts. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and/or commercialization efforts.

Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects.

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

We are a genome editing company with a limited operating history. We began principal business operations in 2012 and spent the first three years of our company's history developing and refining our core technology, and only since then have we focused our efforts on advancing the development of product candidates.

Investment in biopharmaceutical product development is a highly speculative endeavor and entails substantial upfront capital expenditures. There is significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our platforms and the technologies we are using are new and unproven. We have not yet commenced human clinical trials for any of our product candidates, nor have we demonstrated an ability to initiate or successfully complete any clinical trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to do any of the foregoing on our behalf.

Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. Our limited operating history, particularly in light of the rapidly evolving nature of the biopharmaceutical industries and the genome editing field, may make it difficult to evaluate our technology and business prospects or to predict our future performance.

We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates.

Research programs to identify new product candidates and product development platforms require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs, product candidates or product development platforms that ultimately prove to be unsuccessful. Clinical trials of any of our product candidates is not assured despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs, product candidates and product development platforms may not yield any commercially viable products.

30


Table of Contents

Additionally, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

Our financial situation creates doubt whether we will continue as a going concern.

The Company has not generated any revenues to date. For the years ended December 31, 2019 and 2018, the Company had a net loss of $3,727,900 and $3,815,700 respectively. For the three months ended March 31, 2020, the Company had a net loss of $1,852,700. There can be no assurances that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations or obtain funding from this offering or additional financing through private placements, public offerings and/or bank financing necessary to support our working capital requirements. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern.

Our business may be adversely affected by the ongoing coronavirus pandemic.

The outbreak of the novel Coronavirus ("COVID-19") has evolved into a global pandemic. COVID-19 has spread to many regions of the world. The extent to which COVID-19 impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain COVID-19 or treat its impact, among others.

Should COVID-19 continue to spread, our business operations could be delayed or interrupted. For instance, our research and development may be affected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our research activities, including clinical trials.

Infections and deaths related to the pandemic may disrupt the United States' healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.

In the event of a shelter-in-place order or other mandated local travel restrictions, our employees conducting research and development or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.

The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common stock.

31


Table of Contents

The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.

We will incur increased costs as a result of becoming a public company and in the administration of our organizational structure.

As a public company, we will incur significant legal, accounting, insurance, and other expenses that we have not incurred as a private company, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with the Sarbanes-Oxley Act and related rules implemented by SEC. Following the consummation of this offering, we will incur ongoing periodic expenses in connection with the administration of our organizational structure. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although we are currently unable to estimate these costs with any significant degree of certainty. In estimating these costs however, we took into account expenses related to insurance, legal, accounting, and compliance activities, as well as other expenses not currently incurred. These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.

We identified material weaknesses in our internal control over financial reporting at December 31, 2019, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.

We are not currently required to comply with the rules of the SEC implementing Section 404 of the Sarbanes- Oxley Act and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC's rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Though we will be required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section 404 until the year following our first annual report required to be filed with the SEC. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not effective.

Notwithstanding the foregoing, in connection with the audit of our financial statements for the year ended December 31, 2019, we and our auditors identified certain control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A

32


Table of Contents

material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

The material weaknesses resulted from (i) our lack of a formalized internal control framework, (ii) our lack of segregation of duties in the financial reporting process, and (iii) our lack of qualified technical accounting personnel. These remain material weakness as of the date of this prospectus. In order to remediate this material weakness, we have hired and plan to continue to hire additional accounting, finance, system engineers, and data analysts. We have implemented, and plan to continue to implement, new controls, new processes and technologies to implement formalized internal controls framework and procedures. We cannot assure you that the measures that we have taken to remediate, and that will be taken to remediate, these material weaknesses will be sufficient to prevent future material weaknesses from occurring. We also cannot assure you that we have identified all of our existing material weaknesses.

In light of the control deficiencies and the resulting material weaknesses that were identified, we believe that it is possible that, had we and our registered public accounting firm performed an assessment or audit, respectively, of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.

When evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we are unable to remediate our existing material weaknesses or identify additional material weaknesses and are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting once we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources.

Risks Related to our Product Candidates

Our business is dependent on the successful development, regulatory approval and commercialization of our personalized immunotherapy product candidates, which are in the early stages of development and has not been tested in humans.

We have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of ALEXIS Isoform Mesothelin EOC, PD-1, AIDT-1, as well as other product candidates derived from our tumor-specific immunotherapy approach, which may never occur.

In the future, we may also become dependent on other product candidates that we may develop or acquire; however, no product candidates based on our tumor-specific immunotherapy approach have been tested in humans and given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy of a personalized immunotherapy treatment sufficient to warrant approval for commercialization.

We have not previously submitted a biologics license application, or BLA, to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be

33


Table of Contents

able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.

We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.

The clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:

    our ability to raise any additional required capital on acceptable terms, or at all;

    our ability to complete IND-enabling studies and successfully submit an IND;

    timely completion of our preclinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;

    whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates;

    acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;

    our ability to consistently manufacture our product candidates on a timely basis;

    our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;

    our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates;

    the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;

    the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;

    achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our lead product candidates or any future product candidates or approved products, if any;

    the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our cancer immunotherapy approach;

    our ability to successfully develop a commercial strategy and thereafter commercialize our current product candidates or any future product candidates in the United States and

34


Table of Contents

      internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;

    the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;

    the convenience of our treatment or dosing regimen;

    acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;

    patient demand for our current or future product candidates, if approved;

    our ability to establish and enforce intellectual property rights in and to our product candidates; and

    our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.

These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidate or any future product candidates to continue our business or achieve profitability.

Our tumor-specific cancer immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.

We are using our proprietary technologies to develop tumor-specific immunotherapy product candidates to treat cancer. Our foundational science and product development approach are based on our ability to predict the presence of a patient's tumor-specific iso-antigens, or TSIAs, and develop a TSIA-directed therapy that will elicit a meaningful specific immune-system cell response (T or NK cells). We believe that this approach may offer an improved therapeutic effect by driving an intense, focused attack selectively upon a patient's tumor. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to predict the presence of TSIA and to develop a CAR that targets TSIA-directed cancer immunotherapy candidates is both preliminary and limited.

Our tumor-specific immunotherapy product candidates have experienced limited testing in humans. We are currently in the process of validating different tumor-specific immunotherapy product candidates. When we validate adequate biomarkers for these product candidates, we will commence preclinical animal studies, and the results of our preclinical animal studies may not translate into humans. For example, our prediction model may fail to accurately predict the presence of TSIAs, resulting in little or no T cell activity, or our therapy may fail to elicit a significant or durable enough T or NK cell response to effectively destroy a tumor.

As such, we cannot assure you that even if we are able to develop cancer immunotherapy candidates capable of recognizing TSIA and eliciting a T cell response, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.

Furthermore, no regulatory authority has granted approval for a cancer immunotherapy based on a heterologous prime-boost approach. As such, we believe the FDA has limited experience with

35


Table of Contents

evaluating our approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.

We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our immunotherapy candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.

Diamond, CancerSplice and ABBIE are novel technologies, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of any product candidates in humans. Our success depends on our ability to develop and commercialize product candidates using our novel genome editing technology ABBIE. The novel nature of our technology makes it difficult to accurately predict the developmental challenges we may face for product candidates as they proceed through research, preclinical or greenhouse studies and clinical or field trials.

There have been a limited number of clinical trials of products created with genome editing technologies, none of which has utilized our technology, and no therapeutic product candidates created with other genome editing technologies have received marketing approval in the United States or Europe. Because our therapeutic research programs are all in research or preclinical stages, we have not yet been able to assess the safety or efficacy of any product candidates in humans.

Current or future product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause significant adverse events or toxicities. All of our product candidates are designed to act at the level of DNA, and because animal DNA differs from human DNA, it will be difficult for us to test our therapeutic product candidates in animal models for either safety or efficacy, and any testing that we conduct may not translate to their effects in humans. Moreover, animal models may not exist for some of the targets, diseases or indications that we intend to pursue.

Our product candidates may not be able to properly implement desired genetic edits with sufficient accuracy to be viable therapeutic products, and there may be long-term effects associated with them that we cannot predict at this time. Any problems we experience related to the development of our genome editing technology or any of our or our collaborators' research programs or product candidates may cause significant delays or unanticipated costs, and we may not be able to satisfactorily solve such problems. These factors may prevent us or our collaborators from completing our preclinical studies or any clinical trials that we or our collaborators may initiate, or profitably commercializing any product candidates on a timely basis, or at all.

The genome editing field is relatively new and evolving rapidly, and other existing or future technologies may provide significant advantages over our Diamond, CancerSplice and ABBIE technologies, which could materially harm our business.

To date, we have focused our efforts on optimizing our proprietary genome editing technology and exploring its potential applications. Other companies have previously undertaken research and development of genome editing technologies using sequence-specific DNA-cutting enzymes, or nucleases, that are designed to perform modifications in the DNA of living cells and organisms, or using zinc finger nucleases, transcription activator- like effector nucleases, or TALENs, and clustered regularly interspaced short palindromic repeats associated protein-9 nuclease, or CRISPR/Cas9,

36


Table of Contents

although none has obtained marketing approval for a product candidate developed using such technologies. Other genome editing technologies, or other existing or future technologies, may lead to the development of treatments or products that may be considered better suited for use in human therapeutics, which could reduce or eliminate our commercial opportunity.

We are heavily dependent on the successful development and translation of our technologies, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized. To date, we have invested substantially all of our efforts and financial resources to develop our technologies and advance our current product development programs, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations.

Our future success is dependent on our ability to successfully develop and, where applicable, obtain regulatory approval for, including marketing approval for, and then successfully commercialize, product candidates, either alone or with collaborators. We have not yet developed and commercialized any product candidates, and we may not be able to do so, alone or with collaborators. Our research and development programs may not lead to the successful identification, development or commercialization of any products.

The success of our business depends primarily upon our ability to identify, develop and commercialize products using our proprietary technologies.

All of our current product candidates and product development programs are still in the IND validation process. We may be unsuccessful in advancing those product candidates into clinical development or in identifying any developing additional product candidates.

Our ability to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biotechnology development activities, including that:

    the use of Diamond and CancerSplice may be ineffective in identifying additional product candidates;

    the use of ABBIE may be ineffective in accurately inserting the product candidate into tumor-targeting effector cells;

    we may not be able to assemble sufficient resources to acquire or discover additional product candidates;

    we may not be able to enter into collaborative arrangements to facilitate development of product candidates;

    competitors may develop alternatives that render our product candidates obsolete or less attractive;

    our product candidates may be covered by third parties' patents or other exclusive rights;

    the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully; or

    our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate's benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization.

Even if we do commence clinical trials of product candidates and continue to identify new product candidates, such product candidates may never be approved. Failure to successfully identify and develop

37


Table of Contents

new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease operations.

If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed.

We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical or field trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives.

The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates.

If our collaborators or ourselves fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price of our common stock may decline.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.

We face an inherent risk of product liability and professional indemnity exposure related to the testing in clinical trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use.

Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the deterioration of a patient's condition, patient injury or even death.

Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities.

Clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities.

Product liability insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if our collaborators or ourselves successfully commercialize any products.

38


Table of Contents

Risks Related to Our Organization, Structure and Operations

Our future success depends on our ability to retain our Chief Executive Officer, and other key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on the research and development experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Maurizio Chiriva Internati, our Chief Executive Officer, Scott Dahlbeck, our Chief Medical Officer, Gianluca Rotino, our Chief Strategy and Innovation Officer, and Tony Tontat, our Chief Financial Officer and Chief Operating Officer.

Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. We maintain a $10 million "key man" life insurance policy for Dr. Chiriva Internati, our Chief Executive Officer, but not for any of our other team members. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.

Recruiting and retaining qualified scientific, clinical, manufacturing and, if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel, will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business.

We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

We will need to significantly expand our organization, and our future financial performance, ability to develop and commercialize product candidates alone or with collaborators and ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel.

Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited.

Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel.

39


Table of Contents

Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity.

Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.

Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers.

Insurance coverage is becoming increasingly expensive, and in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.

We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.

We are subject to income and non-income taxes in the United States. Income tax accounting often involves complex issues, and judgment is required in determining our provision for income taxes and other tax liabilities. We could become subject to income and non-income taxes in non-US jurisdictions as well. In addition, many operating foreign jurisdictions have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm's length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes and other non-income taxes is not always clear and we may be subject to tax audits relating to such withholding or non-income taxes. We believe that our tax positions are reasonable, and our tax reserves are adequate to cover any potential liability. We are currently not subject to any tax audits.

However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as

40


Table of Contents

applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow.

Our business and operations would suffer in the event of system failures or security breaches.

Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. If we were to experience a system failure, accident or security breach such an event caused interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs.

For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.

The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties with which we have relationships collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators' security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions, and any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost or stolen.

Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties' ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs.

We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Natural or manmade disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities could be setback or delayed.

The disaster recovery and business continuity plan(s) we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse

41


Table of Contents

effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or third parties' ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs.

Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:

    the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

    the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

    the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

    HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

    the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, certain other healthcare providers starting in 2022 and teaching hospitals, as well as

42


Table of Contents

      information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and

    analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.

Some state laws require biotechnology companies to comply with the biotechnology industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products.

State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom's departure from the EU on January 31, 2020 without a deal. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom's departure from the EU. In addition, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance

43


Table of Contents

with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Risks Related to Our Reliance on Third Parties

We expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.

Working with collaborators poses several significant risks, including the following:

    limited availability of resource allocation and other developmental decisions made by our collaborators about the product candidates or technologies that we seek to develop with them may result in the delay or termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any product candidates that may receive approval;

    collaborators could independently develop, or develop with third parties, product candidates or technologies that compete directly or indirectly with our product candidates or technologies if the collaborators believe that competitive products or technologies are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

    collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and

    disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources.

Our ability to generate revenues from these arrangements will depend on our collaborators' abilities to successfully perform the functions assigned to them in these arrangements. If our collaborations do not result in the successful development and commercialization of product candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding or milestone or royalty payments under the collaboration.

If we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed, and we may need additional resources to develop such product candidates or technologies. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may need to raise additional capital to pursue further development or commercialization of the applicable product candidates or technologies.

These events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which we operate.

Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the

44


Table of Contents

development and commercialization of product candidates and inhibit or preclude our ability to realize any revenues.

We expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.

We expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations, or CROs, to conduct preclinical studies and future clinical trials for our product candidates. Nevertheless, we will be responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.

Although we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials. As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors.

We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

If we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

If our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. If we are required to repeat, extend the duration of or increase the

45


Table of Contents

size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures.

As a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed.

If we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm our business.

We are dependent on third parties for the supply of various biological materials, such as cells, cytokines and antibodies, and the manufacture of product supplies, such as media, plasmids, mRNA and viral vectors, that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all.

Changing suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all.

If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur additional costs in procuring such materials.

We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business.

We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and expect that we will rely on outside vendors for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the product candidates.

We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel.

If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to

46


Table of Contents

find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators' potential products.

If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.

Our research and product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements for the development and potential commercialization of current and future product candidates or the development of ancillary technologies.

We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.

Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense.

Risks Related to Government Regulation

The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.

The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a BLA from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate's safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.

We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogenic T cell therapies for cancer. We may also request regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and

47


Table of Contents

efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee's recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.

We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:

    obtaining regulatory authorization to begin a trial, if applicable;

    the availability of financial resources to commence and complete the planned trials;

    reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

    obtaining approval at each clinical trial site by an independent institutional review board, or IRB;

    recruiting suitable patients to participate in a trial;

    having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;

    clinical trial sites deviating from trial protocol or dropping out of a trial;

    addressing any patient safety concerns that arise during the course of a trial;

    adding new clinical trial sites; or

    manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials.

We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA's review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.

Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.

48


Table of Contents

We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.

The Biologics Price Competition and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as "interchangeable" based on its similarity to an approved biologic. Under the Biologics Price Competition and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the Biologics Price Competition and Innovation Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.

We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.

Because we are developing novel CAR T cell immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies, formerly known as the Office of Cellular, Tissue and Gene Therapies, within its Center for Biologics Evaluation and Research to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise the Center for Biologics Evaluation and Research on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.

49


Table of Contents

Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies was established within the European Medicines Agency in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products to assess the quality, safety and efficacy of advanced-therapy medicinal products, and to follow scientific developments in the field. Advanced-therapy medicinal products include gene therapy products as well as somatic cell therapy products and tissue engineered products.

These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.

Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.

The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.

If and when our planned Phase 1 clinical trials for ALEXIS ISOFORM and our other initial product candidates are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. If the results from our clinical trials are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.

The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe an accelerated approval strategy is warranted given the limited alternatives for patients that our initial product candidates target, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are

50


Table of Contents

studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.

Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:

    the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

    we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;

    the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;

    we may be unable to demonstrate that our product candidates' clinical and other benefits outweigh their safety risks;

    the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

    the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;

    the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and

    the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of

51


Table of Contents

clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.

We may seek orphan drug designation for at least one of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.

Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek Regenerative Medicine Advanced Therapy, or RMAT, designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA's standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or

52


Table of Contents

clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product's approved uses (known as "off-label use"), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media.

Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things:

    restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;

    fines, warning letters or holds on clinical trials;

    refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;

53


Table of Contents

    product seizure or detention, or refusal to permit the import or export of our product candidates; and

    injunctions or the imposition of civil or criminal penalties.

The FDA's and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President's administration may impact our business and industry. Namely, the current U.S. President's administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA's ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA's ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA's ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

The gene editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.

Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.

The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We expect physicians in the large bone marrow transplant centers to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:

    the clinical indications for which our product candidates are approved;

54


Table of Contents

    physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;

    the potential and perceived advantages of our product candidates over alternative treatments;

    the prevalence and severity of any side effects;

    product labeling or product insert requirements of the FDA or other regulatory authorities;

    limitations or warnings contained in the labeling approved by the FDA;

    the timing of market introduction of our product candidates as well as competitive products;

    the cost of treatment in relation to alternative treatments;

    the availability of coverage and adequate reimbursement by third-party payors and government authorities;

    the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;

    relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and

    the effectiveness of our sales and marketing efforts.

If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete

Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.

Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.

Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.

Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor's determination that use of a product is:

    a covered benefit under its health plan;

    safe, effective and medically necessary;

    appropriate for the specific patient;

    cost-effective; and

    neither experimental nor investigational.

55


Table of Contents

Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time- consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare & Medicaid Services, or the CMS, revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates.

In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor's determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.

Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by

56


Table of Contents

manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government's comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. We are still unsure of the full impact that the Affordable Care Act will have on our business.

Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the U.S. President has signed two Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual's failure to maintain Affordable Care Act-mandated health insurance, commonly known as the "individual mandate", as part of the Tax Cuts and Jobs Act of 2017, or the Tax Act. On January 22, 2018, the U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called "Cadillac" tax on certain high cost employer- sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole". In July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the "individual mandate" was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.

Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2027, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms

57


Table of Contents

may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President's administration's budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current U.S. President's administration released a "Blueprint", or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or the HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. While some of these and other proposed measures may require authorization through additional legislation to become effective, Congress and the current U.S. President's administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.

Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

    the demand for our product candidates, if we obtain regulatory approval;

    our ability to set a price that we believe is fair for our products;

    our ability to generate revenue and achieve or maintain profitability;

    the level of taxes that we are required to pay; and

    the availability of capital.

58


Table of Contents

Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.

Risks Related to Intellectual Property

Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our business position.

The patent positions of biopharmaceutical and biotechnology companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office (the USPTO) and its foreign counterparts are sometimes uncertain and could change in the future.

Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or designed around. U.S. patents and patent applications may also be subject to interference or derivation proceedings, and U.S. patents may be subject to reexamination, post-grant review and/ or inter parties review proceedings in the USPTO.

International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes.

Furthermore, even if not challenged, our patents and patent applications may not adequately protect our technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications that we hold with respect to our product candidates or potential products is threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product candidates or potential products.

In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We rely on our outside counsel and employ an outside firm to pay these fees due to USPTO and non-US patent agencies. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market which would have a material adverse effect on our business.

59


Table of Contents

If the patent applications we hold or have in-licensed with respect to our current and future research and development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators' ability to commercialize future product candidates. Any such outcome could have a material adverse effect on our business.

Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages.

We rely on patent protection as well as trademark, trade secret and other intellectual property rights protection and contractual restrictions to protect Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates. Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets cover them.

Our ability to obtain and maintain patent protection for Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates is uncertain due to a number of factors, including the following factors:

    we may not have been the first to invent the technology covered by our pending patent applications or issued patents;

    we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing;

    our compositions and methods may not be patentable;

    our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;

    any or all of our pending patent applications may not result in issued patents;

    others may independently develop identical, similar or alternative technologies, products or compositions, or methods of use thereof;

    others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents;

    we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection;

    we may not seek or obtain patent protection in countries and jurisdictions that may eventually provide us a significant business opportunity;

    we may decide not to maintain or pursue patents and patent applications that, at some point in time, may cover our products, potential products, or product candidates;

    any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged by third parties;

60


Table of Contents

    others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable;

    the growing scientific and patent literature relating to engineered endonucleases and modified CAR-T/NK cells, including our own patents and publications, may make it increasingly difficult or impossible to patent new engineered nucleases and modified CAR-T/NK cells in the future;

    our representatives or their agents may fail to apply for patents in a timely fashion; and

    despite our efforts to enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership and chain of title in patents and patent applications, an inventorship or ownership dispute could arise that may permit one or more third parties to practice our technologies or enforce our patent rights, including possible efforts to enforce patent rights against.

Even if we have or obtain patents covering Diamond, CancerSplice, ABBIE, and ALEXIS or any other product candidates or compositions, others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that may cover Diamond, CancerSplice, ABBIE, and ALEXIS or any other product candidates or compositions. These patent applications may have priority over patent applications filed by us.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products.

In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited.

Without patent protection for current or future product candidates, we may be open to competition from generic versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop.

In addition, we also try to protect our trade secrets, know-how and other proprietary information through non-disclosure and confidentiality provisions in our agreements with parties who have access to them, such as our employees, consultants and research partners. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets, know-how and/or other proprietary information in the event of unauthorized uses or disclosure or other breaches of the provisions, and we may not be able to prevent such unauthorized uses or disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure and uses is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. In addition, monitoring unauthorized disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and

61


Table of Contents

time-consuming, and the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the United States may be less willing to protect trade secrets.

We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

Because we may rely on third parties to manufacture our potential product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our current and potential product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, are used inappropriately to create new inventions or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor's discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Additionally, we may need to outsource and rely on third parties for many aspects of the development, sales and marketing of any products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license.

In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology.

62


Table of Contents

If we are unable to do so, we or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners.

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:

    the scope of rights granted under the license agreement and other interpretation-related issues;

    the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;

    the sublicensing of patent and other rights under our collaborative development relationships;

    our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

    the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

    the priority of invention of patented technology.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially extending the term of marketing exclusivity for such product candidates, our business may be harmed.

In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process.

In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements.

Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some

63


Table of Contents

foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk.

Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology is common, including patent infringement lawsuits, and such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings before the USPTO and corresponding international patent offices.

The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors.

Numerous United States, EU and other internationally issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.

For example, we are aware of certain patents held by third parties relating to the modification of CAR-T/NK cells, including the production of CAR-T/NK cells. Although conducting clinical trials and other development activities with respect to our CAR-T/NK product candidates is not considered an act of infringement in the United States, if and when any of our CAR-T/NK product candidates are

64


Table of Contents

approved by the FDA, those third parties may seek to enforce their patents by filing a patent infringement lawsuit against us.

As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from a third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights.

These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly.

We or our collaborators might also be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party's patent rights.

These damages potentially include increased damages and attorneys' fees if we are found to have infringed such rights willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.

We have been and may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators' ability to further develop or commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.

Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our or our collaborators' ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or our collaborators obtain a license.

Competitors may infringe our patents. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents.

65


Table of Contents

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology.

Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We may now and in the future employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee's former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Our Company's governing documents designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of state law actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.

Our Fourth Amended and Restated Certificate of Incorporation, which will be effective immediately prior to the closing of this offering, dictates that the Delaware Court of Chancery is the sole and exclusive forum for certain state law based actions including certain derivative actions or proceedings brought on behalf of us; an action asserting a breach of fiduciary duty owed by an officer, a director, employee or to our shareholders; any claim arising under Delaware corporate law; and any action asserting a claim governed by the internal affairs doctrine.

66


Table of Contents

This exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or other federal securities laws for which there is exclusive federal or concurrent federal and state jurisdiction.

This choice of forum provision may limit our stockholders' ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.

Risks Related to this Offering and the Market for Our Common Stock

Our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.

After this offering, the market price for our common stock is likely to be volatile, in part because our shares have not been traded publicly. In addition, the market price of our common stock may fluctuate significantly in response to several factors, most of which we cannot control, including:

    quarterly variations in our operating results compared to market expectations;

    adverse publicity about us, the industries we participate in or individual scandals;

    announcements of new offerings or significant price reductions by us or our competitors;

    stock price performance of our competitors;

    fluctuations in stock market prices and volumes;

    changes in senior management or key personnel;

    changes in financial estimates by securities analysts;

    the market's reaction to our reduced disclosure as a result of being an "emerging growth company" under the JOBS Act;

    negative earnings or other announcements by us or our competitors;

    defaults on indebtedness, incurrence of additional indebtedness, or issuances of additional capital stock;

    global economic, legal and regulatory factors unrelated to our performance; and

    the other factors listed in this "Risk Factors" section.

The public offering price of our common stock has been determined by us based upon many factors and may not be indicative of prices that will prevail following the closing of this offering. Volatility in the market price of our common stock may prevent investors from being able to sell their shares at or above the initial public offering price. As a result, you may suffer a loss on your investment.

67


Table of Contents

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, the market price for our common stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock to decline.

As our initial public offering price is substantially higher than our net tangible book value per share, you will experience immediate and substantial dilution.

If you purchase shares in this offering, you will pay more for your shares of common stock than the amount paid by our existing stockholders for their shares on a per share basis. As a result, you will experience immediate and substantial dilution in net tangible book value per share in relation to the price that you paid for your shares. We expect the dilution as a result of the offering to be $9.49 per share to new investors purchasing our shares in this offering. In addition, you will experience further dilution to the extent that our shares are issued upon the exercise of any warrants or exercise of stock options under any stock incentive plans. See "Dilution" for a more complete description of how the value of your investment in our shares will be diluted upon completion of this offering.

We have considerable discretion as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree.

We intend to the proceeds from this offering primarily for the clinical trials for our ALEXIS Isoform Mesothelin EOC and PD-1 product candidates, intellectual property protection and reinforcement, IND applications and IND enabling trials and working capital and general corporate purposes. However, we have considerable discretion in the application of the proceeds. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may be used for corporate or other purposes with which you do not agree or that do not improve our profitability or increase our share price. The net proceeds from this offering may also be placed in investments that do not produce income or that lose value.

We do not expect to pay dividends in the foreseeable future after this offering, and you must rely on price appreciation of your shares for return on your investment.

We have paid no cash dividends on any class of our stock to date and we do not anticipate paying cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant.

We may issue additional debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock.

In the future, we may attempt to increase our capital resources by entering into additional debt or debt-like financing that is secured by all or up to all of our assets, or issuing debt or equity securities,

68


Table of Contents

which could include issuances of commercial paper, medium-term notes, senior notes, subordinated notes or shares. In the event of our liquidation, our lenders and holders of our debt securities would receive a distribution of our available assets before distributions to our stockholders. In addition, any additional preferred stock, if issued by our company, may have a preference with respect to distributions and upon liquidation, which could further limit our ability to make distributions to our stockholders. Because our decision to incur debt and issue securities in our future offerings will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings and debt financing.

Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. Thus, you will bear the risk of our future offerings reducing the value of your common stock and diluting your interest in our company.

We will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies.

Upon the completion of this offering, we will be required to publicly report on an ongoing basis as an "emerging growth company" (as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth companies, including but not limited to:

    not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;

    being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

    being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We would remain an emerging growth company for up to five years from the date of the first sale of equity securities pursuant to an effective registration statement, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.

Because we will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result in less active trading or more volatility in the price of our common stock.

69


Table of Contents

Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and/or debt financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder.

To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends.

To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our technologies, research programs, product development activities, product candidates and/or future revenue streams, license our technologies and/or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates.

70


Table of Contents


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited to, the sections entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

    our goals and strategies;

    our future business development, financial condition and results of operations;

    expected changes in our revenue, costs or expenditures;

    growth of and competition trends in our industry;

    our expectations regarding demand for, and market acceptance of, our products;

    our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;

    our expectation regarding the use of proceeds from this offering;

    fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and

    relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as "may," "could," "will," "should," "would," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "project" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading "Risk Factors" and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

This prospectus also contains certain data and information, which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications includes projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions.

The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Although we will become a public company after this offering and have ongoing disclosure obligations under United States federal securities laws, we do not intend to update or otherwise revise the forward-looking statements in this prospectus, whether as a result of new information, future events or otherwise.

71


Table of Contents


USE OF PROCEEDS

We estimate that the net proceeds from the sale of the 1,923,100 shares of common stock that we are selling in this offering will be approximately $21,963,000, or approximately $25,394,300 if the underwriters exercise their over-allotment option in full, and after deducting estimated underwriting discounts and commissions and our estimated offering expenses.

We plan to use the net proceeds of this offering for (i) the initiation clinical trials for our ALEXIS Isoform Mesothelin EOC and PD-1 product candidates (approximately $5,593,400), (ii) intellectual property protection and reinforcement (approximately $242,000), and the remainder for (iii) working capital and general corporate purposes.

With anticipated net proceeds of $21,963,000, we believe we can complete approximately 18.5% of clinical trials for ALEXIS Isoform Mesothelin EOC and approximately 18.5% of clinical trials for PD-1.

We may also use a portion of the net proceeds of this offering to acquire or invest in complementary businesses, products, or technologies, or to obtain the right to use such complementary technologies. We have no commitments with respect to any acquisition or investment, and we are not currently involved in any negotiations with respect to any such transaction.

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The amounts and timing of our actual expenditures will depend on numerous factors, including the status of our product development efforts, sales and marketing activities, technological advances, amount of cash generated or used by our operations and competition. Accordingly, our management will have broad discretion in the application of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds of this offering.

Pending use of the proceeds from this offering as described above, we intend to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade securities or certificates of deposit.

72


Table of Contents


DIVIDEND POLICY

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the near future. See also "Risk Factors—Risks Related to this Offering and the Market for Our Common Stock—Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of your shares for return on your investment." We may enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock.

Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.

73


Table of Contents


CAPITALIZATION

The following table sets forth our total capitalization as of March 31, 2020:

    on an actual basis;

    on a pro forma basis to give effect to the exercise of 1,399,921 warrants at an exercise price of $0.003494 per share and the subsequent issuance of 1,399,921 shares of common stock in June 2020; and

    on a pro forma, as adjusted basis giving further effect to (i) the Preferred Stock Automatic Conversions and (ii) the sale and issuance by us of 1,923,100 shares of common stock in this offering at the initial public offering price of $13.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

You should read this table together with our consolidated financial statements, the related notes included elsewhere in this prospectus and the information under "Management's Discussion and Analysis of Financial Condition and Results of Operations."

 
  March 31, 2020  
 
  Actual   Pro forma   Pro forma,
as adjusted
 

Cash and cash equivalents

  $ 3,042,500   $ 3,047,400   $ 25,010,400  

Long-term debt

             

Stockholders' equity:

                   

Series A-1 Preferred Stock

    9,134,700     9,134,700      

Series B Preferred Stock

    2,007,000     2,007,000      

Common Stock

             

Additional paid-in capital

    16,720,900     16,725,800     49,830,500  

Accumulated deficit

    (24,280,300 )   (24,280,300 )   (24,280,300 )

Total stockholders' equity

    3,582,300     3,587,200     25,550,200  

Total capitalization

    3,582,300     3,587,200     25,550,200  

Each $1.00 increase (decrease) in the assumed initial public offering price of $13.00 per share, the midpoint of the price range listed on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders' equity by approximately $1,923,100, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000 shares in the number of shares offered by us at the assumed initial public offering price of $13.00 per share, the midpoint of the price range listed on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders' equity by approximately $1,300,000.

74


Table of Contents


DILUTION

If you purchase shares of our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per share and our net tangible book value per share after this offering. Dilution results from the fact that the assumed initial public offering price per share is substantially in excess of the net tangible book value per share attributable to the existing stockholders for our presently outstanding common stock.

Our net tangible book value was approximately $3,582,300, or $0.91 per share, as of March 31, 2020. Our net tangible book value represents the amount of our total consolidated tangible assets (which is calculated by subtracting net intangible assets, deferred tax assets, and prepaid offering expenses from our total consolidated assets), less the amount of our total consolidated liabilities.

Our pro forma net tangible book value was approximately $3,587,200, or approximately $0.67 per share, as of March 31, 2020, giving effect to the exercise of 1,399,921 warrants at an exercise price of $0.003494 per share and the subsequent issuance of 1,399,921 shares of common stock in June 2020.

After giving effect to (i) the Preferred Stock Automatic Conversions and (ii) the sale and issuance by us of 1,923,100 shares of common stock in this offering at the initial public offering price of $13.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma, as adjusted net tangible book value as of March 31, 2020 would have been $25,550,200 or $3.51 per share. This represents an immediate increase in net tangible book value of $2.84 per share to our existing stockholders, and an immediate dilution in net tangible book value of $9.49 per share to new investors. The following table illustrates this per share dilution:

Assumed initial public offering price per share

        $ 13.00  

Pro forma, net tangible book value per share as of March 31, 2020

  $ 0.67        

Increase in net tangible book value attributable to this offering

  $ 2.84        

Pro forma, as adjusted net tangible book value, after this offering

        $ 3.51  

Dilution to new investors in this offering

        $ 9.49  

If the underwriters' over-allotment option is exercised in full, our pro forma, as adjusted net tangible book value per share after this offering would be $3.83 and dilution per share to new investors purchasing common stock in this offering would be $9.17 at an initial public offering price of $13.00 per share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The pro forma as adjusted information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our shares and other terms of this offering determined at pricing.

The following tables summarize the differences between our existing stockholders and the investors purchasing shares in this offering with respect to the number of shares purchased from us, the total consideration paid and the average price per share paid, at the assumed initial public offering price of

75


Table of Contents


$13.00 per share, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 
  Shares Purchased   Total Consideration    
 
 
  Average
Price
Per Share
 
 
  Number   %   Amount   %  

Common Stock

    4,989,269     62.32 % $ 6,219,700     13.00 % $ 1.25  

Series A-1 Preferred Stock

    624,594     7.80 %   9,132,700     19.09 %   14.62  

Series B Preferred Stock

    469,136     5.86 %   7,500,000     15.67 %   15.99  

New investors

    1,923,100     24.02 %   25,000,000     52.24 %   13.00  

Total

    8,006,099     100.00 % $ 47,852,400     100.00 %      

The number of shares outstanding is based on shares outstanding as of June 26, 2020 and except as noted above, excludes the following currently outstanding securities:

    624,868 shares of our common stock issuable upon the exercise of outstanding options with a weighted-average exercise price of $11.90 per share;

    709,334 shares of our common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $19.00 per share;

    up to an additional 372,694 shares of our common stock issuable under our 2017 Equity Incentive Plan; and

    96,115 shares of our common stock underlying the warrants to be issued to the representative of the underwriters in connection with this offering.

The table above assumes no exercise of the underwriters' over-allotment option. If the underwriters' over-allotment option is exercised in full, upon completion of this offering, the percentage of common stock held by existing common stockholders would be reduced to 60.15%, and the percentage of common stock held by new investors purchasing common stock in this offering would be increased to 26.66%.

76


Table of Contents


MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion together with our financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under "Risk Factors" and elsewhere in this prospectus. See "Special Note Regarding Forward-Looking Statements."

Overview

We are a pre-clinical stage immuno-oncology, target discovery and gene editing company developing tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. We are focused on extending the benefits of immunotherapy by leveraging our proprietary technologies. Our approach seeks to generate a therapeutic immune response in patients by unleashing the demonstrated natural power of a patient's own immune system to recognize tumor-specific peptide sequences presented on cancer cells, known as tumor specific iso-antigens, capable of generating an immunological response and therefore eradicate cancer cells. We are developing our brand of CAR T cell product candidates known as ALEXIS. These are designed to treat cancer by capitalizing on the immune system's ability to destroy cancer cells. These products are in the pre-IND stage. We are currently going through the IND validation process and we expect that IND enabling trials will commence in the second half of 2020.

CAR T cell therapy, a form of cancer immunotherapy, has recently emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, two autologous anti-CD19 CAR T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., were approved by the FDA for the treatment of relapsing/remitting B-cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively. Autologous CAR T cell therapies are manufactured individually for the patient's use by modifying the patient's own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient's T cells and takes approximately two to four weeks. Allogenic T cell therapies involve engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world.

We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since we began principal business operations in 2012.

Trends and Uncertainties—COVID-19

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's service providers, suppliers, contract research organizations

77


Table of Contents

and our clinical trials, all of which are uncertain and cannot be predicted. As of the date of this filing, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.

Recent Developments

As of the date of the audit report on our 2019 financial statements, conditions and events existed that raised substantial doubt with respect to the going concern assumption on the financial statements. Based on proceeds obtained from the Series B Preferred Stock round of financing and our plans to reduce discretionary spending, management projected it would have sufficient cash to support operations through at least April 7, 2021. As a result, the Company concluded that management's plans were probable of being implemented and alleviated substantial doubt about its ability to continue as a going concern.

After considering the registration statement filing date of June 26, 2020, management extended its consideration of the going concern assumption through June 26, 2021. Management's plans were updated to further finance operations through additional equity or debt financing arrangements, and/or third party collaboration funding; however, if the Company is unable to raise additional funding to meet its working capital needs, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations. The negative cash flows and lack of financial resources of the Company raise substantial doubt as to the Company's ability to continue as a going concern.

Principal Factors Affecting Our Financial Performance

Our operating results are primarily affected by the following factors:

    slow or delayed IND applications;

    slow or delayed clinical trial enrollment;

    patent reinforcement and prosecution; and

    changes in laws or the regulatory environment affecting our company.

Emerging Growth Company

Upon the completion of this offering, we will qualify as an "emerging growth company" under the JOBS Act. As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

    have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

    comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

    submit certain executive compensation matters to stockholder advisory votes, such as "say-on-pay" and "say-on-frequency;" and

    disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer's compensation to median employee compensation.

78


Table of Contents

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an emerging growth company for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

Components of Results of Operations

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. We will record revenue from collaboration agreements, including amounts related to upfront payments, annual fees for licenses of our intellectual property and research and development funding.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates. These include the following:

    salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;

    expenses incurred under agreements with third parties, including CROs and other third parties that conduct preclinical research and development activities and clinical trials on our behalf;

    costs of developing and scaling our manufacturing process and manufacturing drug products for use in our preclinical studies and future clinical trials, including the costs of contract manufacturing organizations, or CMOs, that will manufacture our clinical trial material for use in our preclinical studies and potential future clinical trials;

    costs of outside consultants, including their fees and related travel expenses;

    costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;

    license payments made for intellectual property used in research and development activities; and

    facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we initiate a Phase 1/2a clinical trial for our ALEXIS AIDT-1 product candidate and continue to discover and develop additional product candidates.

79


Table of Contents

We cannot determine with certainty the duration and costs of future clinical trials of our ALEXIS AIDT-1 product candidate or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our ALEXIS AIDT-1 product candidate and any other our product candidate we may develop will depend on a variety of factors, including:

    the scope, rate of progress, expense and results of clinical trials of our ALEXIS AIDT-1 product candidate, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;

    uncertainties in clinical trial design and patient enrollment rates;

    the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability;

    significant and changing government regulation and regulatory guidance;

    the timing and receipt of any marketing approvals; and

    the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, operations and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs that are not specifically attributable to research activities.

We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. Following this offering, we also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs.

80


Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2020 and 2019

The following table sets forth key components of our results of operations for the three months ended March 31, 2020 and 2019.

 
  Three Months Ended March 31,   Increase (Decrease)  
 
  2020   2019   $   %  

Operating expenses:

                         

Research and development

  $ 1,028,100   $ 203,500   $ 824,600     405.21 %

General and administrative

    824,600     183,800     640,800     348.64 %

Total operating expenses

    1,852,700     387,300     1,465,400     378.36 %

Loss from operations

    (1,852,700 )   (387,300 )   (1,465,400 )   378.36 %

Other expense

                         

Interest expense

        (3,600 )   3,600     n/m  

Total other expense

        (3,600 )   3,600     n/m  

Net loss

  $ (1,852,700 ) $ (390,900 ) $ 1,461,800     373.96 %

Research and development expenses.    Our research and development expenses increased by $824,600, or 405.21%, to $1,028,100 for the three months ended March 31, 2020 from $203,500 for the three months ended March 31, 2019. The following table summarizes our research and development expenses by product candidate or development program:

 
  Three Months Ended March 31,   Increase (Decrease)  
 
  2020   2019   $   %  

Direct research and development expenses by product candidate:

                         

AIDT-1 external development costs

  $ 3,000   $ 800   $ 2,200     275.00 %

AIDT-2 external development costs

    30,400     5,800     24,600     424.14 %

Platform development, early-stage research and unallocated expenses:

                         

Employee-related costs

    423,900     39,500     384,400     973.16 %

Laboratory supplies and services

    61,800     12,900     48,900     379.07 %

Outsourced research and development

    382,100     104,300     277,800     266.35 %

Laboratory equipment and maintenance

    14,400         14,400     100.00 %

Facility-related costs

    78,700     40,100     38,600     96.26 %

Other research and development costs

    33,800     100     33,700     n/m  

Total research and development expenses

  $ 1,028,100   $ 203,500   $ 824,600     405.21 %

n/m = not meaningful

As illustrated above, the increase in research and development expenses resulted from (i) a $384,400 increase in employee related costs, which primarily included a $275,200 increase in wages, benefits and payroll taxes and a $99,000 increase in stock compensation expenses attributable to research and development employees; (ii) a $277,800 increase in outsourced research and development costs, which primarily included a $284,000 increase in stock compensation expenses attributable to non-employees; (iii) a $48,900 increase in laboratory supplies in services, which primarily included a $40,900 increase in spending on disposables and consumables for in-vitro testing and validation of pipeline candidates;

81


Table of Contents

(iv) a $38,600 increase in facility-related costs, primarily driven by a $27,500 increase in allocated rent net of granting agency reimbursements, and a $12,400 increase in allocated depreciation expenses; (v) a $33,700 increase in other research and development costs, which were driven by intellectual property legal expenses and intellectual property filings; and (vi) a $14,400 increase in laboratory equipment and maintenance, driven entirely by new non-capitalizable equipment purchases and maintenance to support in-vitro testing and validation by our research and development scientists.

These cost increases were primarily incurred to support in-vitro testing and validation of our product candidates. We:

    1.
    Augmented our research and development team: In the three months ended March 31, 2020 and 2019, our average headcount increased to 5.5 employees from 2 employees allocable to research and development and clinical trials preparation.

    2.
    Amended lease agreements: We amended our Houston facility lease agreement to expand the leased property by 4,100 square feet.

    3.
    Signed intellectual property license agreement: Longwood University, granted us the exclusive right to negotiate a worldwide, exclusive license for certain patent rights. The patent rights pertain to "T-cells expressing a chimeric -PD l-CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer." As compensation for this right, we agreed to pay Longwood University an upfront fee of $15,000. We also agreed to reimburse Longwood University for fees and expenses incurred for the preparation, filing, prosecution and maintenance of such patent rights.

The cost increases were also partially due to the difference in grant reimbursements in the three months ended March 31, 2020 and 2019. In August 2018, the National Institute of Health (NIH), the primary agency of the United States government responsible for biomedical and public health research, awarded a Phase I/II grant in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and which covers the period September 2018 through August 2019, entitles us to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. Starting in 2020, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000. During the three months ended March 31, 2020 and 2019, we recognized $0 and $101,600, respectively, as reductions to research and development expense within the statements of operations pursuant to the grant from the NIH.

General and administrative expenses.    Our general and administrative expenses increased by $640,800, or 348.64%, to $824,600 for the three months ended March 31, 2020 from $183,800 for the three months ended March 31, 2019. The increase primarily resulted from an increase in corporate finance and development expenses of $307,500, a $166,500 increase in professional services costs, increased employee related expenses of $127,700 and increased legal expenses of $46,900. These increases were offset by decreased stock based compensation expenses of $31,000. The remaining expense increases totaling $5,400 are associated with activities such as depreciation, supplies, and other costs associated with our business development.

The increase in corporate finance and development expenses are driven by consulting fees owed to our Chief Scientific and Innovation Officer and Chief Financial Officer. The increase in professional fees and legal expense were primarily driven by increased accounting expenses from auditing, tax, our offering counsel's fees to complete SEC filings that had previously not been required by us.

Employee related expenses were impacted by increases to headcount and employee salary rates. During the three months ended March 31, 2020 and 2019, the headcount for employees allocated to general and administrative purposes increased to 4 employees from 3 employees, respectively. In addition, the Chief Executive Officer's salary increased to an annual rate of $380,000 from $280,000 for the three months ended March 31, 2020 and 2019, respectively.

82


Table of Contents

Stock compensation expense decreased due to reduced options vesting attributable to general and administrative individuals. During the three months ended March 31, 2020 and 2019, general and administrative individuals vested 14,300 options and 40,388 options, respectively.

Interest expense.    Interest expense decreased by $3,600, or 100%, to $0 for the three months ended March 31, 2020 from $3,600 for the three months ended March 31, 2019. The decrease is driven by the variance in the balance of convertible promissory notes during the three months ended March 31, 2020 and 2019.

During the three months ended March 31, 2019, we issued an additional $225,000 of convertible promissory notes. The issued notes accrued interest at a rate of 17% per annum. Total interest expense accrued on the notes as of March 31, 2019 totaled $3,600. On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See "—Liquidity and Capital Resources" below for more information.

Net loss.    As a result of the cumulative effect of the factors described above, our net loss increased to $1,852,700 for three months ended March 31, 2020 from $390,900 for the prior year.

Comparison of the Years Ended December 31, 2019 and 2018

The following table sets forth key components of our results of operations for the years ended December 31, 2019 and 2018.

 
  Years Ended December 31,   Increase (Decrease)  
 
  2019   2018   $   %  

Operating expenses:

                         

Research and development

  $ 1,201,700   $ 1,424,900   $ (223,200 )   15.66 %

General and administrative

    2,503,700     1,757,700     746,000     42.44 %

Total operating expenses

    3,705,400     3,182,600     522,800     16.43 %

Loss from operations

    (3,705,400 )   (3,182,600 )   (522,800 )   16.43 %

Other expense

                         

Interest expense

    (22,500 )   (633,100 )   610,600     96.45 %

Total other expense

    (22,500 )   (633,100 )   610,600     96.45 %

Net loss

  $ (3,727,900 ) $ (3,815,700 ) $ 87,800     2.30 %

Research and development expenses.    Our research and development expenses decreased by $223,200, or 15.66%, to $1,201,700 for the year ended December 31, 2019 from $1,424,900 for the year ended

83


Table of Contents

December 31, 2018. The following table summarizes our research and development expenses by product candidate or development program:

 
  Years Ended December 31,   Increase (Decrease)  
 
  2019   2018   $   %  

Direct research and development expenses by product candidate:

                         

AIDT-1 external development costs

  $ 66,900   $ 3,900   $ 63,000     1,615.38 %

Platform development, early-stage research and unallocated expenses:

                         

Employee-related costs

    574,300     615,600     (41,300 )   6.71 %

Laboratory supplies and services

    167,600     85,000     82,600     97.18 %

Outsourced research and development

    321,700     609,200     (287,500 )   47.19 %

Laboratory equipment and maintenance

    17,100     6,400     10,700     167.19 %

Facility-related costs

    40,700     103,200     (62,500 )   60.56 %

Other research and development costs

    13,400     1,600     11,800     737.50 %

Total research and development expenses

  $ 1,201,700   $ 1,424,900   $ (223,200 )   15.66 %

As illustrated above, the decrease in research and development expenses resulted from (i) a $287,500 decrease in outsourced research and development costs, which primarily included a $273,600 decrease in data administration fees, (ii) a $41,300 decrease in employee related costs driven primarily by reimbursements from granting agencies of $26,500 and reimbursements of social security payroll tax credits totaling $15,100 (ii) a $62,500 decrease in facility-related costs, primarily driven by a $52,700 decrease in clinical trials facility fees. These decreases were as a result of management concluding initial clinical trials testing in May 2019, which halted almost all expenses related to drug manufacturing and data administration that was associated with clinical trials. We also significantly reduced our research and development facility-related costs by obtaining a grant from the National Institute of Health (NIH). In August 2018, NIH, the primary agency of the United States government responsible for biomedical and public health research, awarded a Phase I/II grant in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and which covers the period September 2018 through August 2019, entitles us to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. Starting in 2020, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000. During the years ended December 31, 2019 and 2018, we recognized $298,000 and $258,000, respectively, as reductions to research and development expense within the statements of operations pursuant to the grant from the NIH.

Those reductions were offset by a (i) $63,000 increase in AIDT-1 external development costs, primarily driven by increased spending on disposables and consumables attributable to AIDT-1; and (ii) a $82,600 increase in laboratory supplies and services, primarily driven by a $110,800 increase in disposables and consumables used for experimentation and validation, offset by reduced spending on supplies of $41,100 and reduced shipping, and postage costs. During 2019, we began in vitro testing and validation of our ABBIE delivery vehicle. Thus, higher laboratory supply costs and services were incurred.

General and administrative expenses.    Our general and administrative expenses increased by $746,000, or 42.44%, to $2,503,700 for the year ended December 31, 2019 from $1,757,700 for the year ended December 31, 2018. The increase primarily resulted from an increase in professional services related expenses of $873,100, a $387,700 increase in corporate finance and development costs, and increased travel expenses of $34,100. These increases were offset by decreased employee related expenses of

84


Table of Contents

$354,200 from wages salaries and benefits and $112,000 reduced expenses from stock based compensation. Additionally, there were decreases of $32,800 from reduced intellectual property administrative expenses, and a $13,600 reduction to professional development costs. The remaining expense increases totaling $3,900 are associated with activities such as, supplies, and other costs associated with our business development.

The increase in professional fees was primarily driven by increased accounting expenses from auditing, tax, and accounting consulting fees to complete SEC filings that had previously not been required by us. Corporate development costs increases were directly related to corporate's legal counsel, SEC filing costs, and increased executive consulting fees compared to prior year. Increased travel expenses were incurred to attend medical conferences, and meetings with potential underwriters and market makers.

The reduction in wages and benefits was primarily driven a reduction in headcount expenses allocated to general and administrative expense January 1, 2018 and December 31, 2019. During those 24 months, headcount allocated to general and administrative expense decreased from 7 employees to 2 employees. Average headcount allocated to general and administrative activity in the years ended December 31, 2019 and 2018 was 2.5 and 5, respectively. The total number of options vesting attributed to general and administrative in the year ended December 31, 2019 and 2018 totaled 26,465 options and 42,819, respectively. That reduction in vested grants drove the decrease in stock compensation expense.

The reduction in intellectual property costs was driven by less required intellectual property filing and maintenance activity compared to prior years. The reduction in professional development costs was driven by fewer education and training requirements in the year ended December 31, 2019 compared to the year ended December 31, 2018.

Interest expense.    Interest expense decreased by $610,600, or 96.45%, to $22,500 for the year ended December 31, 2019 from $633,100 for the year ended December 31, 2018. The decrease is driven by the variance in the balance of convertible promissory notes during the years ended December 31, 2019 and 2018. At December 20, 2018, there were outstanding convertible promissory notes totaling $6,725,000 which accrued interest at a rate of 7% and incurred $453,300 of interest expense. In addition, the convertible promissory notes embedded derivative liability increased interest expenses by approximately $167,000 during 2018 based on increases in the fair value of the liability prior to conversion.

The outstanding balance of convertible promissory notes converted into Series A-1 Preferred Stock on December 20, 2018. The remaining interest expense balance of $12,800 was driven by issuances of Series A-1 Preferred Stock. Between June 8, 2018 and August 14, 2018, we entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. See "—Liquidity and Capital Resources" below.

During the year ended December 31, 2019, we issued and additional $250,000 convertible promissory notes, and we settled an account payable to a vendor for a convertible promissory note of $134,800. The issued notes accrued interest at a rate of 17% per annum, and the vendor settlement accrued interest at a rate of 6% per annum. Total interest expense accrued on the notes as of August 15, 2019 totaled $20,500. On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. The remaining interest of $2,000 is attributable to increases to the fair value of the associated embedded derivable liability prior to conversion. See "—Liquidity and Capital Resources" below for more information.

85


Table of Contents

Net loss.    As a result of the cumulative effect of the factors described above, our net loss decreased to $3,727,900 for year ended December 31, 2019 from $3,815,700 for the prior year.

Liquidity and Capital Resources

As of March 31, 2020, we had cash and cash equivalents of $3,042,500. As of December 31, 2019 and 2018, we had cash and cash equivalents of $1,929,100 and $384,300, respectively. We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily with proceeds from the sale of our convertible promissory notes and preferred stock.

Following our recent offering of Series B Preferred Stock discussed below and increased expenditures related to our ongoing research and development efforts as well as our pursuit of an initial public offering through the date of this filing, we determined that our current levels of cash will not be sufficient to meet our anticipated cash needs for our operations through June 26, 2021. We have incurred significant operating losses since inception, and we expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with CMOs and building out internal capacity to have product manufactured to support preclinical studies and clinical trials, expanding our intellectual property portfolio and providing general and administrative support for our operations. As a result, substantial doubt exists regarding the going concern assumption on our financial statements.

We are seeking significant additional capital funding to develop our platform and Pre-IND product lines, additional hiring of scientific professionals and other general and administrative employees, and clinical trials. However, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. Management has the ability to eliminate certain forecasted discretionary costs that would not be in violation of the intended use of proceeds outlined in the Series B Preferred Stock purchase agreements. In consideration of our plans, substantial doubt cannot be alleviated with respect to our continued operations through June 26, 2021. Management's plans, of which the raising additional capital is not within management's control and cannot be assured, do not alleviate such substantial doubt through June 26, 2021.

Summary of Cash Flow for the three months ended March 31, 2020 and 2019

The following table sets forth a summary of our cash flows for the periods presented:

 
  Three Months Ended
March 31,
 
 
  2020   2019  

Net cash used in operating activities

  $ (1,480,300 ) $ (231,300 )

Net cash used in investing activities

    (406,300 )   (20,000 )

Net cash provided by financing activities

    3,000,000     150,000  

Net increase (decrease) in cash and cash equivalents

    1,113,400     (101,300 )

Cash and cash equivalents at beginning of the year

    1,929,100     384,300  

Cash and cash equivalents at end of the year

    3,042,500     283,000  

Cash flows from operating activities

Net cash used in operating activities was $1,480,300 for the three months ended March 31, 2020, as compared to $231,300 for three months ended March 31, 2019. For the three months ended March 31, 2020, the net loss of $1,852,700 and outflows from prepaid expenses in the amount of $99,700, offset by

86


Table of Contents

stock compensation expenses in the amount of $456,000, and accrued expenses and other liabilities in the amount of $17,500. For the three months ended March 31, 2019, the net loss of $390,900 and NIH grant receivables of $23,600, offset by stock compensation expenses in the amount of $104,000, and prepaid expenses and other current assets in the amount of $54,100 were the primary drivers of the net cash used in operating activities.

Net cash used in operating activities increased by a total of $1,249,000 period-over-period. The main driver for the increase is the $1,461,800 increase in net loss. We primarily used cash to augment our research and development team, expand our leased property, expand our intellectual property portfolio, and pay for corporate development costs related to obtaining additional financing. See the "—Results of Operations" above for further details.

Cash flows from investing activities

Net cash used in investing activities was $406,300 for the three months ended March 31, 2020, as compared to $20,000 for the three months ended March 31, 2019. Our net cash used in investing activities consisted entirely of purchases of property and equipment.

Net cash used in investing activities increased by a total of $386,300 in the three months ended March 31, 2020 from March 31, 2019. This was driven by $389,500 in cash outflows attributed to construction in progress on our Good Manufacturing Practices and Vivarium facilities ("GMP and Vivarium") in our Houston Facility. Those assets have not been placed in service yet.

Cash flows from financing activities

Net cash provided by financing activities was $3,000,000 during the three months ended March 31, 2020 as compared to $150,000 for the three months ended March 31, 2019. For the three months ended March 31, 2020, the net cash provided by financing activities consisted of proceeds from preferred stock issuance in the amount of $3,000,000. During the three months ended March 31, 2019, the net cash provided by financing activities consisted of proceeds from the sale of convertible promissory notes in the amount of $150,000.

Summary of Cash Flow for the years ended December 31, 2019 and 2018

The following table sets forth a summary of our cash flows for the periods presented:

 
  Years Ended December 31,  
 
  2019   2018  

Net cash used in operating activities

  $ (2,913,900 ) $ (2,152,900 )

Net cash used in investing activities

    (302,700 )   (137,300 )

Net cash provided by financing activities

    4,761,400     1,625,000  

Net increase (decrease) in cash and cash equivalents

    1,544,800     (665,200 )

Cash and cash equivalents at beginning of the year

    384,300     1,049,500  

Cash and cash equivalents at end of the year

  $ 1,929,100   $ 384,300  

Net cash used in operating activities was $2,913,900 for the year ended December 31, 2019, as compared to $2,152,900 for year ended December 31, 2018. For the year ended December 31, 2019, the net loss of $3,727,900 and outflows from accrued expenses and other current liabilities in the amount of $151,300, offset by stock compensation expenses in the amount of $522,900, accounts payable of $293,400, depreciation expenses of $87,500, prepaid expenses and other current assets in the amount of $46,200, and NIH grant receivables of $24,300, were the primary drivers of the net cash used in operating activities. For the year ended December 31, 2018, the net loss of $3,815,700 and interest payable in the amount of $363,400, offset by stock compensation expenses in the amount of $633,000, non-cash interest of 633,100, prepaid expenses and other current assets in the amount of $212,500,

87


Table of Contents

convertible promissory notes derivative liability in the amount of $369,000, and accrued expenses and other current liabilities in the amount of $149,400, were the primary drivers of the net cash used in operating activities.

Net cash used in operating activities decreased by a total of $761,000 year-over-year. However, this variance was primarily driven by non-cash transactions. The main driver for the decrease is $612,600 decrease in non-cash interest. See the "—Results of Operations" above for further details. However, it is noted that management decided to finance operations primarily using preferred stock instead of interest bearing convertible promissory notes. Accordingly, fewer interest expense was incurred as a result. In addition, reductions to stock compensation expense resulted in a reduction of $110,100 of cash inflows. These reductions to cash inflows were offset by $6,600 of increased cash inflows from depreciation expense.

This remaining reduction in cash flows from operations was driven by reduced cash outflows from net loss and reduced cash inflows from changes in operating assets, offset by increased cash inflows from operating liabilities.

Cash outflows from net loss were reduced by $87,800. See the "—Results of Operations" above for further details.

Reduced cash inflows from changes in operating assets were driven by $166,300 from decreased prepaid and other current assets. Most of this impact is driven by a reclassification of prepaid expenses to accounts payable of $134,800. We ultimately settled that accounts payable with the vendor by converting the balance to a convertible note payable. In addition, there was reduced cash flow impact of $5,900 from inventories, and $3,600 from other non-current assets. These were offset by increased cash inflows of $43,200 from reimbursements under the NIH Grant.

Increased cash inflows from operating liabilities were impacted by $297,800 in accounts payable. This inflow is primarily driven by our management reaching terms with a vendor to delay payment totaling $176,900. In addition, there was increased cash inflow impact of $363,400 from interest payable. These were offset by decreased cash inflows from the convertible promissory notes derivative liability of $367,000. There were also offsetting increases in cash outflows of $300,700 from accrued expenses and other current liabilities.

Net cash used in investing activities was $302,700 for the year ended December 31, 2019, as compared to $137,300 for the year ended December 31, 2018. Our net cash used in investing activities consisted entirely of purchases of property and equipment.

Net cash provided by financing activities was $4,761,400 during the year ended December 31, 2019 as compared to $1,625,000 for the year ended December 31, 2018. For the year ended December 31, 2019, the net cash provided by financing activities consisted of proceeds from the sale of convertible promissory notes for $250,000, proceeds from preferred stock issuance in the amount of $4,500,000, and exercise of stock options to purchase common stock for $11,400. During the year ended December 31, 2018, the net cash provided by financing activities consisted of proceeds from the sale of convertible promissory notes in the amount of $725,000 and proceeds from preferred stock issuance in the amount of $900,000.

Convertible Promissory Notes

Starting in June 2016, we sold convertible promissory notes to certain investors to help finance our operations. The notes were in amounts ranging from $12,500 to $500,000, earning annual interest at 7% and all maturing on either June 1, 2019 or January 1, 2020. As of December 31, 2017, the combined carrying amount of the convertible promissory notes and the carrying amount of the related embedded derivative liability on the convertible promissory notes was $6,106,000. During the year ended December 31, 2018, an additional $725,000 convertible promissory notes were issued, earning

88


Table of Contents

annual interest at 7% and all maturing on June 1, 2019. The notes were convertible into shares issued in our next financing (as defined in the notes) by dividing the total amount of notes payable, plus accrued interest, by the applicable conversion price (defined generally as 80% of the lowest per share selling price in the next financing).

On December 20, 2018, following the issuance of shares of Series A-1 Preferred Stock described below, the outstanding principal and accrued interest was converted into shares of Series A-1 Preferred Stock. At the time of conversion, the outstanding principal and accrued interest of the notes totaled approximately $7,541,600. Accordingly, the notes were converted into an aggregate of 18,854,033 shares of Series A-1 Preferred Stock at a conversion price of $0.40 per share. No additional convertible promissory notes were outstanding as of December 31, 2018 following the conversion on December 20, 2018.

During 2019, we issued additional convertible promissory notes in the aggregate principal amount of $250,000 to certain investors. The notes accrued interest at a rate of 17% and were to mature on June 1, 2021. These notes were convertible into shares issued in our next financing (as defined in the notes) by dividing the total amount of notes payable, plus accrued interest, by the applicable conversion price (defined generally as 85% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), each holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. Therefore, on August 15, 2019, these notes were converted into an aggregate of 632,123 shares of Series A-1 Preferred Stock at a conversion price of $0.43 per share.

In addition, during 2019, we settled an outstanding account payable with a vendor in the amount of $134,600 by issuing to that vendor a convertible promissory note for the amount owed. That convertible promissory note accrued interest at a rate of 6% and was to mature on June 30, 2020. This note was convertible into shares issued in our next financing (as defined in the note) by dividing the total amount of notes payable, plus accrued interest, by the applicable conversion price (defined generally as 90% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), the holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. Therefore, on August 15, 2019, this note was converted into 303,396 shares of Series A-1 Preferred Stock at a conversion price of $0.45 per share.

Series A-1 Preferred Stock Financing

Between June 8, 2018 and August 14, 2018, we entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. On December 20, 2018, 2,032,749 shares of Series A-1 Preferred Stock were issued for $912,800, representing the advances received and accrued interest through September 10, 2018. See "Description of Securities" for more information regarding our Series A-1 Preferred Stock.

Series B Preferred Stock Financing

On September 7, 2019, we entered into a Series B Preferred Stock purchase agreement with certain investors for the sale of shares of our Series B Preferred Stock at a price of $0.46 per share. On September 13, 2019, we sold an aggregate of 7,608,696 shares for total gross proceeds of approximately $3,500,000. On November 13, 2019, we sold an additional 2,173,913 shares for gross proceeds of $1,000,000. The shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. On December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting

89


Table of Contents

all accrued and unpaid dividends, along with all future dividends. In exchange, we issued 87,050 shares of Series B Preferred Stock to the investors.

On January 24, 2020, we issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, we filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, we issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

We also issued each investor a warrant to purchase 0.0859 shares of common stock for each Series B Preferred share purchased, or warrants for an aggregate of 1,399,921 shares of common stock. The warrants have an exercise price of $0.003494 per share and expire ten years after the date of issuance. The warrants are exercisable as follows: (i) 30% of the shares underlying the warrants are exercisable from the date that is six months after the date on which our securities are first listed on a U.S. national securities exchange, (ii) an additional 30% of the shares underlying the warrants are exercisable nine months after such listing date, and (iii) the remaining shares underlying the warrants are exercisable twelve months after such listing date. On June 8, 2020, we agreed to amend the warrant vesting schedule outlined above, such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. See "Description of Securities" for more information regarding our Series B Preferred Stock and the warrants issued in this financing.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements for any of the periods presented.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require management's difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management's current judgments. We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial statements:

Fair Value Measurements—The carrying value of our cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, we take into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

90


Table of Contents

We account for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

    Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

    Level 2—Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.

    Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy leveling during the years ended December 31, 2019 and 2018.

Stock-Based Compensation—We record stock compensation expense related to our 2017 Equity Incentive Plan in accordance with ASC 718, Compensation—Stock Compensation. We measure and recognize stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model. The calculation of stock-based compensation expense requires that we make assumptions and judgments about the variables used in the Black- Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

We estimate the grant-date fair value of stock options using the Black-Scholes option-valuation model and the assumptions used to value such stock options are determined as follows:

Expected Term.    The expected term represents the period that our stock options are expected to be outstanding. Due to limitations on the sale or transfer of our common stock as a privately held company, we do not believe our historical exercise pattern is indicative of the pattern we will experience as a future publicly traded company. We have consequently used the SAB No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. We plan to continue to use the SAB 110 simplified method until we have sufficient trading history as a publicly traded company.

Risk-Free Interest Rate.    We base the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

Volatility.    We determine the price volatility based on the historical volatilities of industry peers as we have no trading history for our common stock price. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

91


Table of Contents

Dividend Yield.    The expected dividend assumption is based on our current expectations about our anticipated dividend policy. To date, we have not declared any dividends and, therefore, we used an expected dividend yield of zero.

Common Stock Valuations.    The fair value of the common stock underlying our stock-based compensation grants has historically been determined by our board of directors, with input from management and third-party valuations. We believe that the board of directors has the relevant experience and expertise to determine the fair value of our common stock. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock at each grant date. These factors include:

    valuations of the common stock performed by third-party specialists;

    the prices, rights, preferences, and privileges of our Series A-1 Preferred Stock and Series B Preferred Stock relative to those of our common stock;

    lack of marketability of the common stock;

    current business conditions and projections;

    hiring of key personnel and the experience of management;

    our stage of development;

    likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of our company given prevailing market conditions, or other liquidation event;

    the market performance of comparable publicly traded companies; and

    the U.S. and global capital market conditions.

In valuing our common stock, the board of directors determined the equity value of our business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in our industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in our cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method, or OPM, or probability—weighted expected return model, or PWERM.

The option pricing method is based on the Black Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

92


Table of Contents

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires us to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values we expect those outcomes could yield. Since in February 2018, we have valued our common stock based on a PWERM.

Application of our approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of our common stock.

For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.

Warrants Underlying Shares of Series B Preferred Stock—We record warrants to purchase shares of common stock underlying our shares of Series B Preferred Stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants is estimated on the purchase date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate.

We estimate the fair value of warrants using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:

Expected Term.    The expected term represents the period that our warrants are expected to be outstanding. The warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

    The remainder of the warrants beginning twelve months after the Listing Date.

Since the vesting schedule is contingent upon completion of an initial public offering, we assessed the expected term of the warrants to be ten years.

Risk-Free Interest Rate.    We base the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.

Volatility.    We determine the price volatility based on the historical volatilities of industry peers as we have no trading history for our common stock price. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which

93


Table of Contents

case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield.    The expected dividend assumption is based on our current expectations about our anticipated dividend policy. To date, we have not declared any dividends and, therefore, we used an expected dividend yield of zero.

Common Stock Valuations.    The fair value of the common stock underlying our warrants has historically been determined by our board of directors, with input from management and third-party valuations. We believe that the board of directors has the relevant experience and expertise to determine the fair value of our common stock. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock at each grant date. These factors include:

    valuations of the common stock performed by third-party specialists;

    the prices, rights, preferences, and privileges of our Series A-1 Preferred Stock and Series B Preferred Stock relative to those of our common stock;

    lack of marketability of the common stock;

    current business conditions and projections;

    hiring of key personnel and the experience of management;

    our stage of development;

    likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of our company given prevailing market conditions, or other liquidation event;

    the market performance of comparable publicly traded companies; and

    the U.S. and global capital market conditions.

In valuing our common stock, the board of directors determined the equity value of our business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in our industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in our cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method, or OPM, or probability—weighted expected return model, or PWERM.

The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the

94


Table of Contents

simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires us to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values we expect those outcomes could yield. Since in February 2018, we have valued our common stock based on a PWERM.

Application of our approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of our common stock.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

In February 2016, the FASB issued Accounting Standards Update, or ASU, No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic's effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On June 3, 2020, the FASB changed the effective date of this standard to January 1, 2022. We are currently evaluating the potential impact of this standard on our financial position, results of operations, and cash flows.

In March 2016, FASB issued ASU 2016-09, Stock Compensation—Improvements to Employee Share-Based Payment Accounting. On January 1, 2018, we adopted the amendments to ASC 718, which simplify accounting for share based payment transactions. As part of the amendment, we have elected to recognize the actual forfeitures by reducing the employee share-based compensation expense in the same period as the forfeitures occur. The adoption did not result in a material impact on our financial statements and related disclosures.

In June 2016, FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets)

95


Table of Contents

measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB changed the effective date of this standard to January 1, 2023. We are currently evaluating the potential impact of this standard on our financial position, results of operations, and cash flows.

On January 1, 2018, we adopted ASU 2018-07, Improvements to Non-employee Share-Based Payment Accounting (Topic 718). This standard expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. FASB clarified that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606, Revenue from Contracts with Customers. Since we have not generated any revenue to date, this adoption did not result in a material impact on our financial statements and related disclosures.

On January 1, 2019, we adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. We determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2019 and 2018, respectively.

96


Table of Contents


BUSINESS

Overview

We are a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology.

Our proprietary target discovery engine is called "Diamond."

Kiromic's Diamond is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug.

Without Kiromic's Diamond, the management of all the data required to solve the Target Identification puzzle is both challenging and inefficient. Normal data required for target identification would require manual analysis of thousands of cancer tissue samples with billions of data points, looking at millions of mutations, and poring over thousands of publications on oncology and targets.

Diamond (Screening, Prioritizing, and Harmonizing)

Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells. Diamond is an artificial intelligence and machine learning approach that can identify novel surface tumor targets. It uses public and proprietary samples and can expand into the tumor target space.

Diamond addresses the main challenges in today's clinical pipeline: target identification.

GRAPHIC

Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR-T cell therapies and vaccine therapies.

Diamond's cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets, which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution and methylation status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

97


Table of Contents

GRAPHIC

Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

98


Table of Contents

See our Diagram below which will walk readers through our process of going from antigens and target libraries to finish with target selection by our artificial intelligence engine.

GRAPHIC

99


Table of Contents

GRAPHIC

Prioritizing T and B Cell Targets.    Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR T cell therapies and vaccine therapies.

Identify Highly Expressed Genes.    Diamond's cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

Performs Meta Analysis.    Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

Predict Isoform Targets.    Cancer cells will down regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). These variations are known as isoforms. CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then directly fed to Diamond's artificial neural capsule network for peptide design and prioritization.

GRAPHIC

CancerSplice (Isoform Target Prediction)

Cancer cells will down-regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). One mechanism for this tumor defense is the selection for alternative splice forms of target proteins. These variations are known as isoforms. Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by pre-existing and modified T cells. Within a heterogeneous cancer cell population, isoforms can preferentially expand to avoid detection and destruction by T cells. These isoforms can make it impossible for T cells to outright bind the targets on cancer cells. No binding to the target means no killing of cancer cells.

100


Table of Contents

GRAPHIC

To solve the problem of identifying shared, common cancer-specific antigens derived from alternative splicing and cancer-specific isoform formation, we have developed a fully integrated in silico methodology to predict cancer-specific isoforms called CancerSplice.

CancerSplice allows for the prediction and prioritization of iso-antigens which could serve as a novel source of tumor targets, highly specific for neoplastic cells but without the drawback of also being highly patient-specific.

CancerSplice allows the user to select a tissue type from the cancer genome atlas along with thresholds for filtering isoforms (minimum and maximum tumor and normal cell transcript parts per million). Based on the tissue selected, CancerSplice displays a sorted list of isoforms that are elevated in high-expressing tumors versus normal tissues which have low expression. Differential analysis is then performed and used to generate two types of lists: (1) isoforms expressed in tumor but not expressed in normal tissues; and (2) isoforms expressed in normal tissues but yet at a much higher level in tumors. CancerSplice then allows the user to click on an isoform in the list to select a specific isoform to display in a detailed panel, which shows the multi-sequence alignment for the isoform, as well as all the other isoforms of that gene.

Finally, CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then directly fed to Diamond's artificial neural capsule network for peptide design and prioritization.

101


Table of Contents

Therefore, we believe that we have developed unique tools to address the issue with tumor-specific iso-antigens through CancerSplice and Diamond.

Target isoforms are protein variants of the same targets that occur during the normal processing of immature gene transcripts to the mature form.

Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by modified T cells (autologous/allogeneic) and other cells, such as NK or invariant NKT cells (often used in the allogeneic setting).

If they are the predominate form on the cell surface, these isoforms can make it impossible for T cells to outright bind the targets on cancer cells.

No binding or insufficient binding to the isoform results in no killing of cancer cells.

Our CancerSplice accurately predicts the most appropriate isoforms for T cells to bind and destroy cancer cells.

GRAPHIC

Immune Therapies Using Our Artificial Intelligence Selected Targets

With our artificial intelligence (Diamond), we seek to use our targets to train immune cells. The trained immune cells generate a therapeutic immune response in patients. These peptide sequences, known as tumor-specific iso-antigens, generate an immunological response and therefore eradicate cancer cells.

We are developing our brand of CAR cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). These are designed to treat cancer by capitalizing on the immune system's ability to destroy cancer cells. These products are in the pre-IND stage of the FDA clinical trial process. We are currently going through the validation process and expect that IND enabling studies will commence in the second half of 2020.

102


Table of Contents

CAR-T cell therapy, a form of cancer immunotherapy, has recently emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, two autologous anti-CD19 CAR-T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., (now part of Gilead), were approved by the FDA for the treatment of relapsing/remitting B cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively. Autologous CAR-T cell therapies are manufactured individually for the patient's use by modifying the patient's own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient's T cells and takes approximately three to four weeks. Allogenic T cell therapies involve engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world.

We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since we began principal business operations in 2012.

Engineered T Cell Therapy

White blood cells are a component of the immune system and are responsible for defending the body against infectious pathogens and other foreign material. T cells are a type of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating the activation of other cells in an immune response.

T cells can be distinguished from other white blood cells by T cell receptors present on their cell surface. These receptors contribute to tumor surveillance by directing T cells to recognize infected and destroy cancerous cells. When T cells with cancer-specific receptors are absent, present in low numbers, of poor quality or rendered inactive by suppressive mechanisms, cancer may grow and spread. In addition, standard of care treatments, such as chemotherapy regimens, as well as disease specific factors can damage the patient's immune system, thereby inhibiting the ability of T cells to kill cancer.

Engineered T cell therapy is a type of immunotherapy treatment whereby human T cells are removed from the body and engineered to express CARs which, when infused into a patient, may recognize and destroy cancer cells in a more targeted manner.

CARs are engineered molecules that, when present on the surface of a T cell, enable the T cell to recognize specific proteins or antigens that are present on the surface of other cells.

There are two primary approaches to engineered T cell therapy: autologous and allogenic. Autologous therapies use engineered T cells derived from the individual patient, while allogenic therapies use engineered T cells derived from healthy donor T cells.

The autologous approach, pioneered by Novartis, Kite and others, has been highly successful in engineering patients' immune systems to fight cancer, in particular CD19 positive cancers, resulting in significant remission rates. Autologous products are manufactured by first collecting a patient's white blood cells, through a process known as leukapheresis, separating the T cells from the patient's blood sample and proliferating the isolated T cells. After the cells have multiplied, the CAR construct is virally transduced into the T cells and the engineered T cells are then propagated until a sufficient number of cells are available for infusion into the patient. Finally, the engineered T cells are frozen, and then shipped back to the clinical center for administration to the patient. The process from leukapheresis to delivery to the clinical center takes approximately three to four weeks.

Allogenic engineered T cells are manufactured in a similar manner as autologous, but with two key differences: (1) allogenic T cells are derived from healthy donors, not cancer patients, and (2) allogenic T cells must also be genetically engineered to minimize the risk of graft-versus-host disease, a condition

103


Table of Contents

where allogenic T cells can recognize the patient's normal tissue as foreign and cause damage in the patient.

Our Approach

Our operating motto is Better Target, Better Life™.

Our goal is to defeat cancer by developing immunotherapies that rely on improving target discovery and validation. With better targets, we believe our therapies will be more effective than the current crop of immunotherapies using older targets.

We are currently in the process of validating different tumor-specific immunotherapy product candidates for refractory CAR-T cell patients. Refractory CAR-T cell patients are those who have received CAR-T cell treatments for their indication, however, they either showed low or no benefit from this treatment. We validate biomarkers for these product candidates using the technologies and processes discussed in the sections below. The development schema below describes the path forward for developing our novel product candidates.

104


Table of Contents

GRAPHIC

105


Table of Contents


ABBIE (Delivery Vehicle)

ABBIE Summary

ABBIE is a novel gene-editing system for inserting therapeutic genes safely into the genome of a host cell.

ABBIE technology comprises two main components, (i) a genome template (extracted from the ALEXIS plasmid), containing the therapeutic genes needed to retrain tumor-killing cells, and (ii) the gene-editing machinery required to safely insert this template into the genome of the therapeutic cells.

The ABBIE protein accompanies the CAR-containing genome template as it passes through the cell membrane into the nucleus and guides the template-flanking sequences (the "glue") safely into the target genome.

Due to this targeting ability, ABBIE can also be used to remove unwanted, inhibitory genes. CAR expression on the Gamma-Delta T cells allows them to detect and destroy the antigen-expressing targeted cells.

The OFF switch permits fast shutdown in the event of an unexpected toxicity. Additional Anti-tumor factors can help neutralize the toxic tumor microenvironment.

ABBIE: Development

We are currently developing ABBIE (A Binding-Based Integrase Enzyme) for delivering our product candidates. ABBIE is a non-viral gene-editing mechanism to insert the target DNA template information into the T cell genome at a predetermined locus. ABBIE allows for insertion of the genome template into the T cells so that they could express the CAR protein and other accessory proteins while possibly eliminating unwanted inhibitory proteins.

The non-viral vector template is simultaneously physically comingled with the patient's T/NK cells. The non-viral vector transfers the target's genomic information into the T/NK cells, where it is integrated into the T/NK cell's genome. T/NK cells now have been reprogramed with the genomic information for targeting and can successfully identify the targets on the cancer cells. This T/NK cell therapy is infused into the patient. T/NK cells will hunt down cancer cells with the known targets and destroy these cancer cells.

GRAPHIC

We believe that this gene delivery platform will deliver the DNA template to the T/NK cell genomes at a lower cost and shorter timeframe versus a viral vector. By comparison, a retroviral vector would have a longer development lead time (~12 months) with an increased insertional mutagenesis risk. Insertional mutagenesis means that a random insertion of the DNA could activate uncontrolled cell growth. ABBIE allows for a more consistent expression and will have a shorter development lead time (3-6 months). It avoids unnecessary risks by targeting a single locus and produces more predictable cell-to-cell expressions.

106


Table of Contents

The development of ABBIE involves a multi-step process, which includes preparation of an integration-deficient lentivirus, a sensitive, targeted gene knock-out assay system, optimization of an inducible ABBIE protein expression system, a powerful screen for gene targeting efficiency, and a sensitive screen of additional ABBIE mutants to further improve efficacy. Altogether, the development plan involves construction of dozens of plasmid constructs, which are complete. To date, we have successfully completed the high transduction efficiency lentivirus system for our assays along with the non-integrating lentivirus system. Optimization of the selection schema is over 70% complete and the construction of the inducible expression and knock-out systems are well underway. If no major obstacles are encountered, we expect to be able to begin producing effector cells for in vitro testing using ABBIE by December 2020.

107


Table of Contents

GRAPHIC

108


Table of Contents

GRAPHIC

SWITCHES

ACTIVATION Switch.    A rapidly deployed activation switch can provide a survival and proliferation signal to the therapeutic cells to enhance their efficacy and persistence in vivo.

ATTENUATION Switch.    A rapidly deployed attenuation switch can intercept activation signals transiently to minimize toxicity following successful anti-tumor interactions. Choice of two non-mutually exclusive Attenuation Switch approaches: (a) a protein-based switch that rapidly triggers attenuation of target cells in a dose-dependent fashion. (b) a small molecule-based approach to rapidly and reversibly attenuate cell signaling.

SAFETY Switch.    A rapidly deployed, protein-based safety switch can eliminate therapeutic cells in case of acute toxicity. The safety switch is designed to eliminate either: (a) essentially all active therapeutic cells. (b) only the most active cells, preserving a cohort of backup therapeutic cells for long-term control of residual relapsing tumor cells. The Safety Switch will be co-expressed along with the bioactive chimeric activation receptor (CAR), the Activation Switch, and the Attenuation Switch.

109


Table of Contents

Manufacturing Allogeneic Effector Cells

The three primary steps to creating our engineered effector cells are: (1) collection, (2) gene editing, and (3) purification, formulation, and storage.

GRAPHIC

PD-1: Avoiding Antigen Escape

To further boost the potency of our effector cells, we plan to explore an additional targeting element that interferes with the inhibitory "checkpoint" protein, PD-1 found on most activated T cells and other effector cells. By interacting with the PD-L1 and PD-L2 inhibitory ligands often found at high levels within the tumor microenvironment, PD-1 normally sends a suppressive signal to the cell to shut down its activity in a process known as exhaustion. However, using a "flipped" signaling receptor, we plan to turn PD-1 "inside-out," changing this inhibitory signal to a stimulatory signal. Thus, with two ways to activate the anti-tumor cells, the chances for the tumor to escape treatment are greatly reduced.

110


Table of Contents

GRAPHIC

The chPD1 Receptor is activated by engagement with PD-L1+ or PD-L2+ tumors.

chPD1-expressing T cells can efficiently lyse both hematologic and solid tumors expressing PD-L1 and/or PD-L2, leading to greatly improved survival with minimal toxicity in animal models.

chPD1 Receptor signaling also leads to cytokine release that can have widespread anti-tumor effects in the tumor microenvironment.

Step 1. Collection

The starting material for our engineered T/NK cell products is white blood cells. For our allogenic products, the T/NK cells are collected from a healthy donor. These are collected using a standard blood bank procedure known as leukapheresis. The collected cells are then sent to a central processing facility, where the peripheral blood mononuclear cells, including T/NK cells, are isolated from the other sample components. The T/NK cells for our allogenic products are isolated and stored frozen, creating an inventory of starting healthy donor cells for manufacturing.

Step 2. Gene Editing

These cells are stimulated to proliferate, then transduced with a non-replicating retroviral vector to introduce the CAR gene into the patient's T/NK cells.

111


Table of Contents

We are also currently developing ABBIE, which is a non-viral gene-editing mechanism to insert the target DNA template information into the T/NK cell genome. The CAR sequence will direct the expression of CAR proteins on the cell surface that allows the transduced T/NK cells to recognize and bind to a target molecule that is present on cancer cells.

Step 3. Purification, Formulation, and Storage

These engineered cells are then propagated in cell culture bags until sufficient cells are available. The engineered T/NK cells are then washed and frozen at the cell processing site.

For our allogenic products, the engineered cells are frozen and sent to long-term storage in the vapor phase of liquid nitrogen. This inventory will be securely stored and then shipped to oncology centers as needed.

112


Table of Contents

GRAPHIC

Note that we have not yet completed our ABBIE (gene editing) technology as shown in Step No. 5 above. Our clinical trial will be using the current industry standard retroviral vector.

113


Table of Contents

Our Product Pipeline and Development

Using our proprietary technologies, we are researching and developing multiple product candidates for the treatment of blood cancers and solid tumors. Our product candidates are allogenic engineered cells to be used for specific patients or as off-the-shelf treatments for any patient with a particular cancer type. Each product candidate targets a selected antigen expressed on tumor cells and bears specific engineered attributes.

In the near term, we are progressing multiple product candidates directed at promising targets for blood cancers, including refractory large B cell lymphoma, and targets associated with solid tumors, such as malignant pleural mesothelioma (lung) and epithelial ovarian cancer.

Our product pipeline is represented in the diagram below:

GRAPHIC

GRAPHIC

114


Table of Contents

ALEXIS Isoform Mesothelin EOC

ALEXIS Isoform Mesothelin is our allogenic CAR cell product candidate targeting Isoform Mesothelin. We are still planning clinical trials before submitting this product for authorization.

ALEXIS Isoform Mesothelin represents an innovative approach for stage III to stage IV platinum resistant epithelial ovarian cancer and involves the use of effector cells.

Target Indications

ALEXIS Isoform Mesothelin targets epithelial ovarian cancer, or EOC. According to the American Cancer Society, approximately 21,750 individuals are diagnosed with EOC in the U.S. each year, and 300,000 worldwide.

EOC generally affects elderly women over 60 years old. Genetic mutations and/or a family history of ovarian/breast/colorectal cancer increase the risk of EOC. EOC can metastasize to abdominal peritoneum, which is extremely difficult to treat. The median life expectancy after local recurrence is approximately 15 months.

In total, the standard treatment can cost approximately $100,000. Ovarian cancer is a deadly disease with stage IV patients having a 5-year overall survival rate of only 30%.

Out of 21,750 U.S. patients who are initially diagnosed with EOC each year, we believe that up to 15,400 (70%) will potentially be eligible for our CAR cell therapy.

In 2018, this market size reached $1.2 billion according to Grand View Research (July 2019).

This market is expected to grow at 6.2% annually compounded from 2019 to 2026 according to Data Monitor Healthcare.

Development Plan

ALEXIS Isoform Mesothelin will be studied in a Phase 1 clinical trial for EOC patients. We plan to submit an IND and initiate a Phase 1 clinical trial in 2021. We will be the sponsor of the clinical trials, which will be conducted by industry-standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open-label, single arm, multi-center, dose-escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with EOC who have progressed on at least two lines of salvage chemotherapy and/or additional surgical/radiation therapy cell reduction.

The primary goal will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (Isoform Mesothelin).

ALEXIS Isoform Mesothelin MPM

ALEXIS Isoform Mesothelin MPM is our allogenic effector cell product candidate targeting Isoform Mesothelin. We are still planning clinical trials before submitting this product for authorization.

ALEXIS Isoform Mesothelin MPM represents an innovative approach for malignant pleural mesothelioma and involves the use of effector cells.

115


Table of Contents

Target Indications

ALEXIS Isoform Mesothelin MPM targets malignant pleural mesothelioma, or MPM. Mesothelioma is a disease in which malignant (cancer) cells form in the thin layer of tissue that covers organs typically in the chest or abdomen. Pleura refers to the thin layer of tissue that lines the chest cavity and covers the lungs. The tumors often spread over the surface of organs often without spreading into the organ. They may spread to nearby lymph nodes or in other parts of the body. Malignant mesothelioma may also form in the testicles or heart, but this is rare.

According to the American Cancer Society, approximately 3,000 individuals are diagnosed with MPM in the U.S. each year, and 43,000 deaths globally each year.

MPM rates are high in the military, particularly for those involved in ship building, construction, mechanics, and insulation/textile production and installation. Due to these higher rates, corporations have set aside approximately $30 billion each year to settle job-related asbestos MPM for their personnel.

The standard treatment for MPM involves chemotherapy that costs approximately $90,000, surgery that costs approximately $20,000 - $30,000, and radiation that costs approximately $10,000 - $50,000. In total, the standard treatment can cost up to $170,000. Approximately 80% of patients undergoing this treatment will eventually relapse. The average life expectancy after refractory is approximately 7 months.

Out of the 3,000 U.S. patients who are initially diagnosed with MPM each year, we believe that approximately 2,400 (80%) will eventually be eligible for our effector cell therapy.

Mesothelioma statistics show there are about 3,000 new cases of mesothelioma diagnosed in the United States each year. According to the most recent data, 57,657 mesothelioma cases were reported between 1999 and 2016. Between 1999 and 2017, there were more than 47,600 mesothelioma-related deaths. Pleural mesothelioma is the most common form, accounting for 80 - 90% of all cases. (Source: https://www.mesothelioma.com/mesothelioma/statistics/)

The global mesothelioma burden is unclear. Driscoll et al. estimated that as many as 43,000 people worldwide die from the disease each year. It has also been estimated that there are around 10,000 mesothelioma cases annually in Australia, Japan, North America and western Europe combined. (Source: See Bulletin of the Delgermaa et. al, World Health Organization 2011;89:716-724C.)

This market is expected to grow at 7.60% annually compounded from 2020 to 2026 according to MarketWatch (April 2, 2020).

This market size is expected to reach $300 million by 2025 according to Persistent Market Research (July 2017).

Development Plan

ALEXIS Isoform Mesothelin MPM will be studied in a Phase 1 clinical trial for mesothelioma, including pleural and peritoneal mesotheliomas. We plan to submit an IND and initiate a Phase 1 clinical trial in 2021. We will be the sponsor of the clinical trials, which will be conducted by industry-standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open label, single arm, multi-center, dose escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with mesothelioma, who are relapsed/refractory to maximal surgical and/or radiation therapy reduction and standard first line chemotherapy.

The primary goal will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

116


Table of Contents

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (Isoform Mesothelin).

ALEXIS AIDT-1

ALEXIS AIDT-1 is our allogenic CAR cell product candidate targeting AIDT-1. This product is currently undergoing pre-IND studies. Following subsequent IND-enabling studies, we will be applying for an IND with the FDA. The clinical trial for this product candidate is expected to launch during the first half of 2022. We will be the sponsor of the program and lead the clinical development program.

ALEXIS AIDT-1 targets AIDT-1, an antigen expressed on the surface of B cells, including malignant B cells. The product represents an innovative approach for relapsed hematologic malignancies such as B cell acute lymphoblastic leukemia and for diffuse large B cell lymphoma and involves the use of adoptive T cells expressing CARs against AIDT-1. We expect our strategy to target B cell malignancies that have become refractory to currently available CAR cell therapies.

Target Indications

ALEXIS AIDT-1 targets NHL (ie, diffuse large B cell lymphoma, or DLBCL). According to the American Cancer Society, approximately 25,000 - 30,000 individuals are diagnosed with DLBCL in the U.S. each year, and 200,000 worldwide. The growth rate for DLBCL is relatively stable.

The standard treatment is R-CHOP chemotherapy, which is a combination treatment consisting of five separate drugs: rituximab (Rituxan), cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin), and prednisolone. R-CHOP chemotherapy costs approximately $100,000 per year. Average life expectancy following the failure of R-CHOP chemotherapy is approximately 6 months.

The failure rate for R-CHOP chemotherapy is 30 - 50%. Up to 50% of failures cannot get stem cell transplants and are potential candidates for CAR therapy. Standard CAR-T therapy costs between approximately $375,000 to $475,000.

Out of the 30,000 U.S. patients who are initially diagnosed with DLBCL each year, we believe that approximately 3,000 will eventually be eligible for our CAR-T cell therapy.

Worldwide number of patients for Non-Hodgkin's Lymphoma is estimated at 509,590. (Source: Global cancer statistics 2018: Globocan estimates of incidence & mortality world-wide for 36 cancers in 185 countries) with 77,240 cases in the U.S. in 2020 according to the American Cancer Society 2020).

The number of diagnosed hematologic cases is expected to grow at 10.5% annually compounded according to Data Monitor Healthcare (Source: See Hematologic Malignancies Market Size, Share & Trends Analysis Report by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2018 - 2025.)

The market size for hematologic cancers is expected to reach $4.6 billion by 2025 according to BIS Research (November 21, 2019).

Development Plan

ALEXIS AIDT-1 will be studied in a Phase 1 clinical trial for DLBCL, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. We plan to submit an IND and initiate a Phase 1 clinical trial in 2022. We will be the sponsor of the clinical trials, which will be conducted by industry standard CROs and leading academic institutions in the U.S. and Western Europe.

The Phase 1 trial is expected to be an open-label, single-arm, multi-center, dose escalation, safety, pharmacokinetic and pharmacodynamic clinical trial in adult patients with DLBCL, who are relapsed or refractory to prior treatment with an anti-CD20 monoclonal antibody therapy and an anthracycline containing chemotherapy and/or an autologous stem cell transplant.

117


Table of Contents

The primary endpoint will be to assess safety and tolerability at increasing dose levels in successive cohorts of patients in order to estimate the maximum tolerated dose and the recommended Phase 2 dose.

Prior to treatment, all patients are expected to undergo selected screening process to assure than the patients are expressing our intended target (AIDT-1).

GRAPHIC

Our Manufacturing Operations

We have invested resources to optimize our manufacturing process, including the development of improved analytical methods. We plan to continue to invest in process science, product characterization and manufacturing to continuously improve our production and supply chain capabilities over time.

Our product candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The process is gradually developed from small to larger scales, incorporating compliant procedures to create current cGMP conditions. Although we have a platformbased manufacturing model, each product is unique and for each new product candidate, a developmental phase is necessary to individually customize each engineering step and to create a robust procedure that can later be implemented in a cGMP environment to ensure the production of clinical batches. This work is performed in our research and development environment to evaluate and assess variability in each step of the process in order to define the most reliable production conditions.

We will engage third-party CMOs to manufacture the retroviral vector that delivers the applicable CAR gene into the T cells under cGMP. We believe all materials and components utilized in the production of the cell line, retroviral vector and final T cell product are readily available from qualified suppliers.

We believe the use of contract manufacturing and testing for the first clinical product candidates is cost-efficient and has allowed us to rapidly prepare for clinical trials in accordance with our development plans. We expect third-party CMOs will be capable of providing and processing sufficient quantities of product candidates to meet anticipated clinical trial demands.

In addition, we believe we have sufficient space at our headquarters in Houston, Texas, which is being adapted to manufacture clinical grade products.

118


Table of Contents

If any of our product candidates are approved, to meet projected needs for commercial sale quantities, we anticipate that we will need to obtain additional manufacturing capacity through CMOs to be able to supply and process products on a patient-by-patient basis.

We intend to screen multiple manufacturers, including both current and alternate suppliers, to secure sufficient capacity for commercial purposes prior to the filing of a Biological License Application. We believe that commercial requirements can be met, although we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs.

Our Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, product development technologies, and know-how.

Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and applications related to our technology, inventions, and improvements that are important to the development and implementation of our business.

We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.

With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of using and manufacturing the same.

Patents

We are actively building our intellectual property portfolio around our product candidates and our discovery programs, based on our own intellectual property as well as licensed intellectual property. We are the owners of, co-owners of, or the licensee of multiple patents and patent applications in the United States and worldwide. Our patent portfolio includes protection for our lead product candidates, ALEXIS AIDT-1, ALEXIS AIDT-2 EOC and ALEXIS AIDT-2 MPM, as well as our other research-stage candidates. Our patent portfolio and filing strategy is designed to provide multiple layers of protection by pursuing claims directed toward: (1) antigen binding domains directed to the targets of our product candidates; (2) CAR constructs used in our product candidates; (3) methods of treatment for therapeutic indications; (4) manufacturing processes, preconditioning methods, and dosing regimens; and (5) and methods for genetically engineering immune cells suitable for autologous and allogenic use.

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing

119


Table of Contents

of the first non-provisional application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier- filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.

As of June 26, 2020, our patent estate includes three issued U.S. patents and 19 pending patent applications (10 of which are in the U.S.), each of which we either own, jointly own, or for which we have an exclusive commercial license (either in its entirety or within our field of use), as is more fully described below. Our patent families related to our product candidates are described below.

Diamond (Screening, Prioritizing, and Harmonizing) and CancerSplice (Isoform Target Prediction)

Our tumor targets patent estate includes eight patents applications that we developed internally for target identification (1-8) and two patents applications (9 - 10) disclosing methods of use of identified targets, which we developed internally and in part following license agreements.

    1.
    The application titled "Platform for Identification of Tumor-Associated Cancer/Testis Antigens" is a United States utility patent application that is expected to expire on April 25, 2037, absent any patent term adjustment (PTA) or patent term extension (PTE). The claims in this patent application include composition of matter, use and process for a method of identifying cancer/testes antigens (CTAs) useful as cancer treatment targets, the method comprising: identifying human sperm proteins to which patients diagnosed with solid or hematological malignancies have established a humoral immune response.

    2.
    The application titled "Methods for Identifying and Using Diseases-Associated Antigens" is a United States utility patent application that is expected to expire on May 31, 2040. The claims in this patent application include composition of matter, use and process for a method treating a condition (e.g., cancer) with an appropriate immunotherapeutic agent and/or regimen. Also included are methods for the use of effective combinations of proteins encoded by hot-spot mutations and/or tumor-associated mRNA splice variants to optimize the targeting of a patient's condition (e.g., cancer) with immunotherapies.

    3.
    The application titled, "Anti-Human/Mouse Sperm Protein 17 (SP17) Antibody and Derivatives Thereof" is a United States utility patent application that is expected to expire on March 22, 2037, absent any patent term adjustment or patent term extension. The claims in this patent application include composition of matter, use, and method for a novel monoclonal antibody, designated as GD6, and various derivatives thereof, which target an epitope of human and murine Sperm Protein 17 (SP17) which possesses broad expression on cells derived from numerous solid malignancies.

    4.
    The family titled "Compositions and Methods for Treating Cancers" contains one utility patent application that has been filed in the United States and has entered the national phase in Europe, Mexico, and China that are expected to expire on March 13, 2037, absent any patent term adjustment or patent term extension. The claims in these patent applications include composition of matter, uses and methods related to administering to a subject having

120


Table of Contents

      a cancer a therapeutically effective amount of the pharmaceutical composition of combinations of Galectins, which are S-type lectins that bind ß-galactose-containing glycoconjugates.

    5.
    The family titled, "CdS Quantum Dot-Chitosan-Anti-SP17 Nanohybrid as a Potential Cancer Biomarker" contains one utility patent filed in the United States that is expected to expire on February 23, 2038, absent any patent term adjustment or patent term extension. The claims in this patent application include composition of matter of a nanoconjugate consisting of a quantum dot nanoparticle conjugated to an anti-SP17 antibody, wherein the conjugating molecule is chitosan. The claims in this patent application also include methods for detecting cancer cells in biological systems consisting in administering the anti-SP17 nanoconjugate and performing imaging analysis using the quantum-dot fluorescence emission.

    6.
    The family titled, "OroVAX: AI Prediction of SARS-CoV-2 Immune Epitope Peptides for the Development of an Oral Vaccine." It is a United States Provisional Application that is expected to expire on May 8, 2021. No claims were filed with the provisional application. We plan to file a United States utility patent application claiming priority to the provisional application before the provisional application expires.

    7.
    The family titled, "Hydrogen Peroxide-Containing Oral Care Composition for Mitigation, Prevention, or Treatment of Human Coronavirus-Associated Infections." It is a United States Provisional Application that is expected to expire on May 14, 2021. No claims were filed with the provisional application. We plan to file a United States utility patent application claiming priority to the provisional application before the provisional application expires.

    8.
    The family titled, "Novel Nanoparticle—Based Vaccine Targeting Cancer/Testis Antigens (CTA) and its' Use in Solid and Hematological Malignancies" contains one utility application filed in Europe that is expected to expire on November 19, 2035, absent any extension of the patent right by a supplementary protection certificate (SPC). The claim in this patent application includes composition of matter, use and methods for a vaccine composition comprising of particles comprising nanoparticles, microparticles or a mixture thereof.

    9.
    The family has been exclusively in-licensed from Mercer University. It is titled, "Nanospheres Encapsulating Bioactive Material and Method for Formulation of Nanospheres" and contains three issued United States Patents and one pending application. One of the issued patents is expected to expire on September 29, 2029 supplemented by 540 days of patent term adjustment, the remaining two issued patents and the pending application are expected to expire on September 29, 2029. The claims in this patent family include composition of matter and methods for a method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or betacyclodextrin, in an aqueous medium in a first vessel.

    10.
    The family titled, "PD1-Specific Chimeric Antigen Receptor as an Immunotherapy" has been exclusively in-licensed from Longwood University. It is The patent family contains one United States application and one PCT application for which we have entered and plan to enter the national phase in a number of jurisdictions by May 26, 2020 that are expected to expire on September 26, 2038, absent any patent term adjustment or patent term extension. The claims in this patent application contains composition of matter claims for a chimeric antigen receptor (CAR) polypeptide; a vector comprising the CAR polypeptide; and a T lymphocyte genetically modified to express the CAR polypeptide. The claims in the patent application also contain a method of treating cancer using the T lymphocyte genetically modified to express the CAR polypeptide.

121


Table of Contents

ABBIE (Genetic Delivery Vehicle)

ABBIE is the delivery vehicle for our lead product candidates, ALEXIS ISOFORM CD19, ALEXIS ISOFORM Mesothelin EOC and ALEXIS ISOFORM Mesothelin MPM, as well as our other research-stage candidates.

The ABBIE patent family has been exclusively in-licensed from CGA 369, Inc. It is titled, "CAS 9 Retroviral Integrase and CAS 9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism." The patent family contains five utility applications in Europe, China, Japan, Korea, and the United States that are expected to expire on March 31, 2036, absent any patent term adjustment or patent term extension. The claims in this patent family contains composition of matter claims for nucleic acid constructs; organisms comprising nucleic acid constructs; fusion proteins; and nucleic acid vectors. The claims in this patent family also contain methods of inserting a DNA sequence into genomic DNA and inhibiting gene expression.

License Agreements

Mercer University

On December 1, 2016, we entered into a license agreement with Mercer University, or Mercer, pursuant to which Mercer granted to us an exclusive license for certain inventions and technologies related to nanoparticles useful as vaccines. As compensation for this license, we paid Mercer a license fee and agreed to pay royalties of the net selling price of all licensed products sold once we start selling the products developed with the licensed intellectual property. Finally, we also agreed to make the following milestone payments: (i) upon initiation of an FDA Phase II clinical trial; (ii) upon the first dosing in the FDA Phase III clinical trial, and (iii) upon BLA approval. The potential milestone payments total $325,000 in the aggregate. The royalty range for the license agreement is between 1% and 5%. The term of this license agreement continues until all licensed patents expire. The Mercer patents associated with the license agreement contain three issued United States Patents and one pending application, the last of which is expected to expire on September 29, 2029 (with 540 days of patent term adjustment). We may terminate this agreement at any time upon sixty (60) days written notice. Mercer may terminate this agreement upon the occurrence of a material breach of the agreement that is not cured by us within sixty (60) days of notice of such breach.

CGA 369

On September 14, 2018, we entered into a license agreement with CGA 369 Intellectual Holdings, Inc., or CGA, which was amended on October 16, 2019. Pursuant to this license agreement, CGA granted to us an exclusive license for certain inventions and technologies related to the use of engineered DNA binding proteins exhibiting genome specificity such as Cas9, TALE, and Zing finger proteins attached by a linker with viral integrases or a recombinase in older to deliver DNA sequence of interest (or gene of interest) to a targeted site in a genome of a cell or organism. As compensation for this license, we agreed to pay CGA a license fee, which payment is conditioned upon a sublicense and our receipt of upfront fee in connection with such sublicense of at least $5 million. We also agreed to pay royalties based on a percentage of the net selling price of all licensed products sold once we start selling the products developed with the licensed intellectual property. The net selling price is equal, subject to certain exceptions, to the gross selling price less (i) sales and excise taxes, value added taxes, and duties which fall due and are paid by the purchaser as a direct consequence of such sales and any other governmental charges imposed upon the importation, use or sale of such product, but only to the extent that such taxes and duties are actually included and itemized in the gross amounts invoiced to and specifically paid by the purchaser over and above the usual selling price of such product, customarily included and itemized in the gross amounts invoiced to and specifically paid by the purchaser over and above the usual selling price of all comparable products in the relevant market and

122


Table of Contents

are not recovered or recoverable; (ii) trade, quantity and cash discounts that are customary in the pharmaceutical industry and that are actually allowed on such product; (iii) allowances or credits to customers on account of rejection, withdrawal, recall, or return of such product or on account of retroactive price reductions or price protection charges or reprocurement/failure to supply charges affecting such product, to the extent that such allowances, credits or charges are customary in the pharmaceutical industry; and (iv) discounts, rebates and chargebacks specifically related to such product on an accrual basis, which shall be trued up and reconciled in the ordinary course of business, including, but not limited to, those granted to government agencies. Finally, we also agreed to make the following milestone payments: (i) upon completion of a positive Phase III clinical trial; (ii) upon FDA approval; (iii) upon our aggregate net sales of licensed products reaching $100 million in a single calendar year; (iv) upon our aggregate net sales of licensed products reaching $250 million in a single calendar year, and (v) upon our aggregate net sales of licensed products reaching $500 million in a single calendar year. The potential milestone payments total to $9.5 million in the aggregate. The royalty range for the CGA 369 license is between 1% and 5%. The CGA 369 patents associated with the license agreement contains five utility applications in Europe, China, Japan, Korea, and the United States, the last of which is expected to expire on March 31, 2036. The term of this license agreement continues until all licensed patents expire. We may terminate this agreement at any time upon sixty (60) days written notice. CGA may terminate this agreement upon the occurrence of a material breach of the agreement that is not cured by us within ninety (90) days of notice of such breach.

Longwood University

Effective March 25, 2020, we entered into a license agreement with Longwood University, or Longwood. Pursuant to this license agreement, Longwood granted to us the exclusive right to negotiate a worldwide, exclusive license for certain patent rights. The patent rights pertain to "T-cells expressing a chimeric-PD l- CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer." As compensation for this right, we agreed to pay Longwood an upfront fee of $15,000. We also agreed to reimburse Longwood for fees and expenses incurred for the preparation, filing, prosecution and maintenance of such patent rights.

Our Research and Development Collaborations

MDACC Grant

We provided a grant to the University of Texas, MD Anderson Cancer Center ("MDACC"). The arrangement provides for MDACC to test the efficacy of: 1) AIDT-1 isoform targeting (and/or other isoforms for hematological diseases: 2) ALEXIS Isoform Mesothelin Targeting: The anti-mesothelin isoform CAR we plan to test in these pre-clinical studies could be potentially developed for more effective and safer target expression expressing solid malignancies and/or alternative targets for solid tumor. As compensation for this collaboration, we agreed to pay MDACC a fee. The agreement's commencement date was April 1, 2020 and terminates on March 31, 2021. No payments have been made to date for this collaboration agreement.

Molipharma Agreement

On April 3, 2020, we entered into a joint venture agreement ("Joint Venture") with Molipharma, S.R.L. ("Molipharma") to collaborate in (1) a clinical trial program in oncology development ("Oncology") and (2) a clinical trial program in COVID-19 Vaccine ("COVID-19 Vaccine").

With respect to Oncology, we will grant a low single digit royalty to Molipharma for turnover of the marketing of ovarian cancer research in Europe. With respect to COVID-19 Vaccine, economic rights in Europe will transfer to Molipharma, and economic rights in the United States will transfer to us. Molipharma agreed to undertake to financially support the research program for COVID-19 and we

123


Table of Contents

agreed to financially support the research program in oncology. The Joint Venture has a duration of five years, extendable for a further five years, unless notice of non-renewal is sent one year before the expiration date. The parties may withdraw from the Joint Venture only for serious and justified reasons or by mutual consent.

Our Competition

Our products will compete with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.

In 2017, two autologous anti-CD19 CAR T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., were approved by the FDA for the treatment of relapsing/remitting B-cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively.

Due to the promising therapeutic effect of T cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogenic T cell therapies.

Potential cell therapy competitors include:

    Autologous T cell therapy competition:  Adaptimmune Therapeutics PLC, Amgen Inc., Autolus Therapeutics plc, bluebird, Gilead (acquired Kite), Novartis International AG, Celgene (acquired Juno), Tmunity Therapeutics, Inc. and Unum Therapeutics Inc.

    Allogenic T cell therapy competition:  Atara Biotherapeutics, Inc., Celyad S.A., CRISPR Therapeutics AG, Fate Therapeutics Inc., Intellia Therapeutics, Inc., Gilead (acquired Kite), Allogene Therapeutics, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc. and Sangamo Therapeutics, Inc.

Competition will also arise from non-cell based immune and other pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Incyte Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche AG. For instance, we may experience competition from companies, such as Amgen Inc., Regeneron Pharmaceuticals, Inc., Xencor Inc., MacroGenics, Inc., GlaxoSmithKline plc and F. Hoffmann-La Roche AG, that are pursuing bispecific antibodies, which target both the cancer antigen and T cell receptor, thus bringing both cancer cells and T cells in close proximity to maximize the likelihood of an immune response to the cancer cells. Additionally, companies, such as Amgen Inc., GlaxoSmithKline plc and Seattle Genetics, Inc., are pursuing antibody drug conjugates, which utilize the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.

Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, pre-clinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.

Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience.

124


Table of Contents

These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs.

GreenPlanet Pharma

Our wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns.

This business is recently formed and the product was recently developed. This business has not generated any revenues.

Government Regulation

As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a Biologic License Application, or BLA, for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.

Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.

U.S. Product Development Process

In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a

125


Table of Contents

material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:

    completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;

    submission to the FDA of an IND, which must become effective before human clinical trials may begin;

    approval by an independent IRB or ethics committee at each clinical site before the trial is commenced;

    performance of adequate and well-controlled human clinical trials according to the FDA's GCPs, and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;

    submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;

    satisfactory completion of an FDA Advisory Committee review, if applicable;

    satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product's identity, strength, quality and purity and, if applicable, the FDA's current good tissue practices, or GTPs, for the use of human cellular and tissue products;

    potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and

    FDA review and approval, or licensure, of the BLA.

Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.

126


Table of Contents

Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor's control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA's regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Certain clinical trials involving human gene transfer research also must be overseen by an Institutional Biosafety Committee, or IBC, a standing committee to provide peer review of the safety of research plans, procedures, personnel training and environmental risks of work involving recombinant DNA molecules. IBCs are typically assigned certain review responsibilities relating to the use of recombinant DNA molecules, including reviewing potential environmental risks, assessing containment levels, and evaluating the adequacy of facilities, personnel training, and compliance with the National Institutes of Health Guidelines. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

    Phase 1.  The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.

    Phase 2.  The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.

    Phase 3.  Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.

Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a

127


Table of Contents

significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor's initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the biological product has been associated with unexpected serious harm to patients.

Human immunotherapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval.

Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.

U.S. Review and Approval Processes

After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.

Under the Prescription Drug User Fee Act, or the PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.

128


Table of Contents

Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product's identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product.

A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.

Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.

Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.

Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.

If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be

129


Table of Contents

included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product's safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.

In addition, under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, the Pediatric Research Equity Act does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Expedited Development and Review Programs

The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is

130


Table of Contents

acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.

Any product, submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Regenerative Medicine Advanced Therapy, or RMAT, designation was established by FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review.

Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.

Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.

Fast Track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.

131


Table of Contents

Post-Approval Requirements

Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product's approved uses (known as "off-label use"), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physicians deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product's approved labeling.

In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.

The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product's approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures.

Also, new government requirements, including those resulting from new legislation, may be established, or the FDA's policies may change, which could delay or prevent regulatory approval of our products under development.

U.S. Marketing Exclusivity

The Biologics Price Competition and Innovation Act amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The Biologics Price Competition and Innovation Act, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity

132


Table of Contents

may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.

Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.

Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued "Written Request" for such a trial.

Other U.S. Healthcare Laws and Compliance Requirements

In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the CMS, other divisions of the HHS (e.g., the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments). For example, our business practices, including any future sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, transparency requirements, and similar state, local and foreign laws, each as amended.

The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and other individuals and entities on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.

Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative

133


Table of Contents

review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if "one purpose" of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).

The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.

The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies' marketing of the product for unapproved, and thus non-reimbursable, uses.

HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.

Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys' fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of

134


Table of Contents

health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.

In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.

If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private "qui tam" actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in

135


Table of Contents

order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor's determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time.

Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Healthcare Reform

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:

    created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;

    increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;

136


Table of Contents

    created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers' outpatient drugs to be covered under Medicare Part D;

    extended manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

    expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and added new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers' Medicaid rebate liability;

    expanded of the list of entities eligible for discounts under the 340B Drug Discount Program;

    created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;

    expanded healthcare fraud and abuse laws, including the Foreign Corrupt Practices Act, or the FCPA, and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;

    created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;

    required reporting of certain financial arrangements with physicians and teaching hospitals;

    required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to physicians;

    established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and

    created a licensure framework for follow on biologic products.

Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the current U.S. President has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual's failure to maintain Affordable Care Act-mandated health insurance, commonly known as the "individual mandate", as part of the Tax Cuts and Jobs Act of 2017, or the Tax Act.

On January 22, 2018, the current U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called "Cadillac" tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.

The Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole".

Congress is continuing to consider legislation that would alter other aspects of the Affordable Care Act. The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear. In July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers

137


Table of Contents

under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the "individual mandate" was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act.

We anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President's administration's budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the U.S. President's administration released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a rule that would require direct-to-consumer television advertisements of prescription

138


Table of Contents

drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. While some of these and other proposed measures may require authorization through additional legislation to become effective, Congress and the U.S. President's administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

The Foreign Corrupt Practices Act

The FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

Additional Regulation

In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.

Overseas Government Regulation

In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country's national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country's requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.

The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in

139


Table of Contents

accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.

For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

European Union General Data Protection Regulation

In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU's General Data Protection Regulation, or the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.

The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.

California Consumer Privacy Act

California recently enacted legislation that has been dubbed the first "GDPR-like" law in the United States. Known as the California Consumer Privacy Act, or the CPPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. When it goes into effect on January 1, 2020, the CCPA will require covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Legislators have stated that amendments will be proposed to the CCPA before it goes into effect, but it remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of

140


Table of Contents

our business to the evolving regulatory environment related to personal data and protected health information.

Employees

As of June 26, 2020, we had a total of 11 employees. We also utilize a number of consultants for financial reporting, clinical, regulatory, and SEC compliance.

We believe that we maintain a satisfactory working relationship with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None of our employees is represented by a labor union.

Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

141


Table of Contents


MANAGEMENT

Directors and Executive Officers

The following sets forth information about our directors and executive officers as of the date of this prospectus:

Name
  Age   Position
Maurizio Chiriva Internati     51   Chairman, Chief Executive Officer and President
Tony Tontat     54   Chief Financial Officer, Chief Operating Officer and Director
Scott Dahlbeck     58   Chief Medical Officer
Gianluca Rotino     47   Chief Strategy and Innovation Officer and Director
Pietro Bersani     52   Director
Americo Cicchetti     50   Director
Michael Nagel     58   Director
Jerry Schneider     72   Director

Maurizio Chiriva Internati, DBSc, PhDs.    Dr. Chiriva Internati has served as our Chairman and Chief Executive Officer since February 2018 and as our President since October 2019. Between December 2012 and September 2019, he served as Chief Scientific Officer. Between December 2012 and August 2018, he also served as our Director of Clinical Translation Research. Dr. Chiriva Internati has been an Associate Professor at the MD Anderson Cancer Center in Houston, Texas since August 2019. Prior to that, he served as an Associate Professor at Texas Tech University Health Sciences Center from September 2013 to June 2017. His research has led to the identification of novel cancer-testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. This led to the development of the bioinformatic software Diamond CancerSplice, which is a key core platform of our company, leading to the discovery and prioritization of isoform antigens via insilico system.

Dr. Chiriva Internati earned a PhD in Immunology from the University of Nottingham, United Kingdom. He also earned a PhD in Morphological Science from the Università degli Studi di Milano, Italy, and a Doctoral Degree in Biological Sciences from the University of Milan, Italy. Dr. Chiriva-Internati was a Post-Doctoral Fellow in Immunology at the University of Arkansas for Medical Sciences, earned a certificate in Artificial Intelligence from MIT Sloan School of Management and earned a certificate in Financial Technology from Oxford Saïd Business School. Dr. Chiriva Internati was selected to serve on our board of directors due to his tenure with our company and his industry experience.

Tony Tontat.    Mr. Tontat has served as our Chief Operating Officer since August 2019, as our Chief Financial Officer since October 2019 and as a member of our board of directors since January 2020. Prior to joining us, Mr. Tontat worked as a business and financial consultant and Financial Analyst since November 2011 for Exuma Blue Advisors, LLC, where he worked with many private and public companies. He primarily helped these companies raise funds at various stages of life cycle. He worked in financial teams to raise funds for public companies like Sorrento Therapeutics, Inc. and NantKwest. Prior to this, he worked as an investment analyst at healthcare- specialist hedge funds in New York and also worked as investment banker at HSBC Investment Bank in their New York and Paris offices. Mr. Tontat earned his BA in Economics from Harvard University. Mr. Tontat was selected to serve on our board of directors due to his financing experience.

Scott Dahlbeck, MD, PharmD.    Dr. Dahlbeck has served as our Chief Medical Officer since October 2019. He previously served as our President from January 2013 to October 2019. Dr. Dahlbeck is an expert in prostate cancer research and treatment and has served as a Radiation Oncologist for several cancer centers, including as an Adjunct Assistant Professor in Internal Medicine, Pathology, and

142


Table of Contents

Urology at the Texas Tech University Health Sciences Center. Dr. Dahlbeck has also patented, manufactured, and commercialized IP and has more than a decade of experience in medical and oncology commerce. Dr. Dahlbeck earned an MD from the University of Texas Health Science Center at Houston, completed residencies in family practice and radiation oncology, and earned a PharmD degree from the University of Nebraska Medical Center, College of Pharmacy.

Gianluca Rotino.    Mr. Rotino has served as our Chief Strategy and Innovation Officer and as a member of our board of directors since January 2014. Prior to that, he served in various other senior positions, including Chief Business Officer and Executive VP of Corporate Development. Mr. Rotino is a seasoned business executive with experience in corporate strategy, business development, and capital fund raising. Mr. Rotino held positions as both CEO and Chairman of the Board for several Italian companies. His previous experience includes senior level managerial positions for companies in Italy in different fields, such as high tech, international development and corporate consulting. Mr. Rotino also worked in several law firm in Milan, Italy, where he specialized in mergers, acquisitions, intellectual property, and corporate law. Mr. Rotino earned his Business Development Degree in Pharma from the EBD Academy in London, UK, and a B.S. by EBD Group and Pharmaceutical Training International (PTI). He has also completed course work for drug discovery, development and commercialization provided by The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Development. Mr. Rotino as earned his BA in Electronics at the Institute of Technology Feltrinelli in Milan. Mr. Rotino was selected to serve on our board of directors due to his tenure with our company and his corporate strategy, business development, and capital fund raising experience.

Pietro Bersani, CPA, JD.    Mr. Bersani has served as a member of our board of directors since June 2020. Since April 2020, Mr. Bersani is a Partner with B2B CFO Partners, LLC, which provides strategic management advisory services to owners of privately held companies. During October 2016 and July 2018, he served as the President, and Chief Executive Officer at K.P. Diamond Eagle, Inc., a consulting firm specialized in development of innovative commercial and private aviation business models. He also held the same positions at K.P. Diamond Eagle, Inc. between November 2019 and March 2020. He later served as a Senior Director within Alvarez & Marsal's Private Equity Performance Improvement Practice, LLP between August 2018 and October 2019. Prior to those professional experiences, Mr. Bersani served as the Chief Financial Officer of Fuel Systems Solutions, Inc. between April 2011 and October 2016.

Mr. Bersani is a Certified Public Accountant and is also a Certified Public Auditor and a Chartered Certified Accountant in Italy where he developed a significant knowledge of US GAAP and IFRS. Mr. Bersani earned a BA and MA in Business Economics from L. Bocconi University, Italy. Mr. Bersani was designated by certain holders of our Series B Preferred Stock. Except for the foregoing, there is no arrangement or understanding between any director or executive officer and any other person pursuant to which he was or is to be selected as a director.

Americo Cicchetti, PhD.    Dr. Cicchetti has served as a member of our board of directors since March 2020. Dr. Cicchetti has served as a Professor of Management at Università Cattolica del Sacro Cuore, Faculty of Economics, Rome since 2006. He is also currently the Director of the Graduate School of Health Economics and Management at Università Cattolica del Sacro Cuore.

In addition to his academic experience, Dr. Cicchetti was a member of the Price and Reimbursement Committee of the Italian National Drug Agency from 2009-2015.

He is a member of the European Network of Health Technology Assessment; Member of the Innovation Steering Group of the National HTA Program for Medical Devices (Ministry of Health, Italy); Member of the National Immunization Technical Advisory Group at the Ministry of Health, Italy since 2019; Member of the Health and Research Commission of the Rome Foundation since 2007; and a Member of the Board of Directors of the Health and Research Foundation since 2017.

143


Table of Contents

Furthermore, Dr. Cicchetti is the Chief Executive Officer and Director for Molipharma, whose core business is the research and development of new drugs and diagnostics aimed at predicting, detecting and treating female oncological diseases. He also serves as an independent board member for Foundation Health and Research, and Leonida SICAF, a fixed capital investment company. He obtained his PhD in Management from University of Bologna, and his B.A. from University of Rome. Dr. Cicchetti was selected to serve on the board due to his industry experience.

Michael Nagel.    Mr. Nagel has served as a member of our board of directors since June 2020. He has over 30 years of sales and marketing experience in the medical device industry. Since 2012, Mr. Nagel has served as the President and CEO of Vomaris Innovations, Inc, which specializes in wireless microcurrent-generating technologies that are focused on regeneration, healing, and recovery. Previously, Mr. Nagel served as the Chief Commercial Officer of Neomend, a biomaterial company that developed ProGel, a PMA approved surgical sealant for lung surgery. From 1997 to 2005, Mr. Nagel also served as Co-Founder and Vice President of Worldwide Sales and Marketing at Vascular Solutions (VASC).

In addition to Mr. Nagel's executive experience, he also serves as a director for Franklin Mountain Medical, LLC an early stage company in the structural heart market. Mr. Nagel holds both a B.A. in Business and a M.B.A. from the University of St. Thomas. Mr. Nagel was selected to serve on the board of directors due to his industry experience.

Jerry Schneider.    Mr. Schneider has served as a member of our board of directors since June 2020. He has been an independent business and financial consultant since 2014. From 2004 to 2013, he was the Chief Financial Officer of Vistage International, a private equity-owned CEO peer-advisory membership company with over 20,000 global members. Prior to Vistage, Mr. Schneider spent seven years at Fresenius Medical Care—North America in Boston, a global dialysis service and products company owned by Fresenius Medical Care, a German publicly DAX traded company, where he served as Chief Financial Officer and later as Senior Vice President of Strategic Planning. Between 1994 and 1997, Mr. Schneider was the Executive Vice President and Chief Financial Officer of then NYSE publicly held GranCare, Inc. (GC), a healthcare company in the long-term care, assisted living and institutional pharmacy business. He currently serves on the board of directors and audit committee for Cognex, a provider of vision systems, software, sensors, and industrial barcode readers used in manufacturing automation since 2016. Cognex (CGNX) is publicly traded on the Nasdaq stock exchange. He serves on other for-profit and non-profit boards. Mr. Schneider received his Juris Doctor from Loyola Law School, and a B.S. in Accounting from the University of California at Berkeley. He has experience of being a "financial expert" appointed by the U.C. Regents which oversee the University of California's budget of over $30M. In addition to his business and financial experience, Mr. Schneider was selected to serve on the board of directors due to his being an audit committee "financial expert" under the SEC regulations.

Family Relationships

Mr. Rotino is Dr. Chiriva Internati's nephew. There are no other family relationships among any of our officers or directors.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past ten years.

144


Table of Contents

Corporate Governance

Governance Structure

Currently, our Chief Executive Officer is also our Chairman. Our board believes that, at this time, having a combined Chief Executive Officer and Chairman is the appropriate leadership structure for our company. In making this determination, the board considered, among other matters, Dr. Chiriva Internati's tenure, having served with our company since 2012, and his industry experience. Among the benefits of a combined Chief Executive Officer/Chairman considered by the board is that such structure promotes clearer leadership and direction for our company and allows for a single, focused chain of command to execute our strategic initiatives and business plans.

The Board's Role in Risk Oversight

The board of directors oversees that the assets of our company are properly safeguarded, that the appropriate financial and other controls are maintained, and that our business is conducted wisely and in compliance with applicable laws and regulations and proper governance. Included in these responsibilities is the board's oversight of the various risks facing our company. In this regard, our board seeks to understand and oversee critical business risks. Our board does not view risk in isolation. Risks are considered in virtually every business decision and as part of our business strategy. Our board recognizes that it is neither possible nor prudent to eliminate all risk. Indeed, purposeful and appropriate risk-taking is essential for our company to be competitive on a global basis and to achieve its objectives.

While the board oversees risk management, company management is charged with managing risk. Management communicates routinely with the board and individual directors on the significant risks identified and how they are being managed. Directors are free to, and indeed often do, communicate directly with senior management.

Our board administers its risk oversight function as a whole by making risk oversight a matter of collective consideration. Once the board establishes committees, it is anticipated that much of the work will be delegated to such committees, which will meet regularly and report back to the full board. It is anticipated that the audit committee will oversee risks related to our financial statements, the financial reporting process, accounting and legal matters, that the compensation committee will evaluate the risks and rewards associated with our compensation philosophy and programs, and that the nominating and corporate governance committee will evaluate risk associated with management decisions and strategic direction.

Director Independence

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his background, employment and affiliations, our board of directors has determined that Messrs. Bersani, Cicchetti, Nagel and Schneider do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under the listing standards of The Nasdaq Capital Market. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described in the section titled "Certain Relationships and Related Person Transactions."

145


Table of Contents

Committees of the Board of Directors

Our board has established an audit committee, a compensation and nominating and corporate governance committee, each with its own charter that has been approved by the board. Upon completion of this offering, we intend to make each committee's charter available on our website at www.kiromic.com.

Until such committees are established, our entire board of directors will undertake the functions that would otherwise be undertaken by the committees. In addition, our board of directors may, from time to time, designate one or more additional committees, which shall have the duties and powers granted to it by our board of directors.

Audit Committee

The members of our audit committee are Jerry Schneider, Michael Nagel, and Americo Cicchetti. Jerry Schneider serves as chairperson of the committee. All members of our audit committee meet the independence requirements of Rule 10A-3 under the Exchange Act and the applicable rules of Nasdaq Capital Market, or the Nasdaq rules. Our board of directors has determined that Jerry Schneider is an audit committee financial expert, as defined by the rules of the SEC, and satisfies the financial sophistication requirements of the Nasdaq rules.

The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company.

The audit committee will be responsible for, among other things: (i) retaining and overseeing our independent registered public accounting firm; (ii) assisting the board in its oversight of the integrity of our financial statements, the qualifications, independence and performance of our independent registered public accounting firm and our compliance with legal and regulatory requirements; (iii) reviewing and approving the plan and scope of the internal and external audit; (iv) pre-approving any audit and non-audit services provided by our independent registered public accounting firm; (v) approving the fees to be paid to our independent registered public accounting firm; (vi) reviewing with our chief executive officer and chief financial officer and independent registered public accounting firm the adequacy and effectiveness of our internal controls; (vii) reviewing hedging transactions; and (viii) reviewing and assessing annually the audit committee's performance and the adequacy of its charter.

Compensation Committee

The members of our compensation committee are Michael Nagel, Jerry Schneider, and Americo Cicchetti. Michael Nagel serves as the chairperson of the committee. The compensation committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers.

The compensation committee will be responsible for, among other things: (i) reviewing and approving the remuneration of our executive officers; (ii) reviewing the compensation of our independent directors; (iii) making recommendations to the board regarding equity-based and incentive compensation plans, policies and programs; and (iv) reviewing and assessing annually the compensation committee's performance and the adequacy of its charter.

Nominating and Corporate Governance Committee

The members of our nominating and governance committee are Michael Nagel and Jerry Schneider. Michael Nagel serves as the chairperson of the committee. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board and its committees.

146


Table of Contents

The nominating and corporate governance committee will be responsible for, among other things: (i) identifying and evaluating individuals qualified to become members of the board by reviewing nominees for election to the board submitted by stockholders and recommending to the board director nominees for each annual meeting of stockholders and for election to fill any vacancies on the board, (ii) advising the board with respect to board organization, desired qualifications of board members, the membership, function, operation, structure and composition of committees (including any committee authority to delegate to subcommittees), and self-evaluation and policies, (iii) advising on matters relating to corporate governance and monitoring developments in the law and practice of corporate governance, (iv) overseeing compliance with our code of ethics, and (v) approving any related party transactions.

The nominating and corporate governance committee's methods for identifying candidates for election to our board of directors (other than those proposed by our stockholders, as discussed below) will include the solicitation of ideas for possible candidates from a number of sources—members of our board of directors, our executives, individuals personally known to the members of our board of directors, and other research. The nominating and corporate governance committee may also, from time-to-time, retain one or more third-party search firms to identify suitable candidates.

In making director recommendations, the nominating and corporate governance committee may consider some or all of the following factors: (i) the candidate's judgment, skill, experience with other organizations of comparable purpose, complexity and size, and subject to similar legal restrictions and oversight; (ii) the interplay of the candidate's experience with the experience of other board members; (iii) the extent to which the candidate would be a desirable addition to the board and any committee thereof; (iv) whether or not the person has any relationships that might impair his or her independence; and (v) the candidate's ability to contribute to the effective management of our company, taking into account the needs of our company and such factors as the individual's experience, perspective, skills and knowledge of the industry in which we operate.

Code of Ethics

We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. Such code of ethics addresses, among other things, honesty and ethical conduct, conflicts of interest, compliance with laws, regulations and policies, including disclosure requirements under the federal securities laws, and reporting of violations of the code. Upon our listing on the Nasdaq Capital Market, our code of business conduct and ethics will be available under the Corporate Governance section of our website.

We are required to disclose any amendment to, or waiver from, a provision of our code of ethics applicable to our principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. We intend to use our website as a method of disseminating this disclosure, as permitted by applicable SEC rules. Any such disclosure will be posted to our website within four business days following the date of any such amendment to, or waiver from, a provision of our code of ethics.

147


Table of Contents


EXECUTIVE COMPENSATION

Summary Compensation Table

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to the named persons for services rendered in all capacities during the noted periods. No other executive officers received total annual salary and bonus compensation in excess of $100,000.

Name and Principal Position
  Year   Salary
($)
  Option
Awards
($)
  All Other
Compensation
($)
  Total
($)
 

Maurizio Chiriva Internati,

    2019     280,000             280,000  

Chief Executive Officer(1)

    2018     280,000             280,000  

Tony Tontat,

    2019             67,500     67,500  

Chief Operating Officer and Chief Financial

    2018         454,064     22,500     476,564  

Officer(2)

                               

Scott Dahlbeck,

    2019             187,000     187,000  

Chief Medical Officer(3)

    2018     110,000         12,500     122,500  

(1)
Of the salaries owed to Dr. Chiriva Internati, $280,000 and $160,200 was paid in 2019 and 2018, respectively. The difference in 2018 were accrued and paid to Dr. Chiriva Internati as a lump sum in September of 2019.

(2)
The amount included in option awards represents the aggregate grant date fair value for options granted to Mr. Tontat computed in accordance with FASB ASC Topic 718. All Other Compensation includes the consulting fees paid to Mr. Tontat under his consulting agreement.

(3)
Dr. Dahlbeck's compensation structure was changed from salary to a consulting agreement in November 2018. Other compensation includes the consulting fees paid to Dr. Dahlbeck under his consulting agreement, and reimbursement for corporate housing expenses.

Employment Agreements

Maurizio Chiriva Internati

We entered into an employment agreement with Maurizio Chiriva Internati, our Chief Executive Officer that set forth the terms and conditions of his employment with us. The agreement will be effective upon the completion of the initial public offering. The employment agreement establishes an annual base salary of $504,000, which is subject to our discretionary review and adjustment in accordance with our policies, procedures and practices as they may exist from time to time.

Dr. Chiriva Internati will also receive annual stock compensation with a fair market value totaling $499,200. To account for this, on June 19, 2020, the Board of Directors granted Dr. Chiriva Internati 26,274 restricted stock units with a grant date fair value of $19.00 per share, with a quarterly vesting schedule over twelve months. In addition, Dr. Chiriva Internati's employment agreement entitled him to 355,262 restricted stock units which were granted by the Board of Directors on June 19, 2020 with a grant date fair value of $19.00 per share. The restricted stock units vest upon achievement of certain corporate milestones which were approved by the Board of Directors on June 19, 2020.

Dr. Chiriva Internati is also eligible to receive a target bonus at the rate of 40%-50% indexed to the achievement of corporate goals and achievements to be determined by the Board of Directors. Dr. Chiriva Internati is eligible to participate in all medical, personal leave and other employee benefit plans and programs for which he is eligible, subject to the terms and conditions of such plans and programs. We will also reimburse Dr. Chiriva Internati for any attorney's fees in connection with his

148


Table of Contents

employment agreement up to $10,000. In the event of involuntary termination, Dr. Chiriva-Internati is eligible for 24 months of severance pay and immediate vesting of all stock options outstanding on the date of termination. Dr. Chiriva Internati's employment is "at will" and may be terminated by us or Mr. Rotino at any time and for any reason.

Tony Tontat

We entered into an employment agreement with Tony Tontat, our Chief Financial Officer and Chief Operating Officer that set forth the terms and conditions of his employment with us. The agreement will be effective upon the completion of the initial public offering. The employment agreement establishes an annual base salary of $300,000, which is subject to our discretionary review and adjustment in accordance with our policies, procedures and practices as they may exist from time to time.

Mr. Tontat will also receive annual stock compensation with a fair market value totaling $300,000. On June 19, 2020, the Board of Directors granted him 15,790 restricted stock units with a grant date fair value of $19.00 per share, with a quarterly vesting schedule over twelve months. In addition, Mr. Tontat's employment agreement entitled him to 139,213 restricted stock units which were granted by the Board of Directors on June 19, 2020. The restricted stock units vest upon achievement of certain corporate milestones which were approved by the Board of Directors on June 19, 2020. Finally, the Board of Directors issued Mr. Tontat 402,000 shares of common stock on June 19, 2020 in exchange for services rendered.

Mr. Tontat is also eligible to receive a target bonus at the rate of 40%-50% indexed to the achievement of corporate goals and achievements to be determined by the Board of Directors. Mr. Tontat is eligible to participate in all medical, personal leave and other employee benefit plans and programs for which he is eligible, subject to the terms and conditions of such plans and programs. We will also reimburse Mr. Tontat for any attorney's fees in connection with his employment agreement up to $10,000. In addition, in the event of involuntary termination, Mr. Tontat is eligible for 24 months of severance pay and immediate vesting of all stock options outstanding on the date of termination. Mr. Tontat's employment is "at will" and may be terminated by us or Mr. Tontat at any time and for any reason.

Scott Dahlbeck

On January 1, 2020, we entered into an employment agreement with Dr. Scott Dahlbeck, our Chief Medical Officer that set forth the terms and conditions his employment with us. The employment agreement establishes an annual base salary of $100,000, which is subject to our discretionary review and adjustment in accordance with our policies, procedures and practices as they may exist from time to time. Dr. Dahlbeck will also receive annual stock compensation with a fair market value totaling $245,000 based on stock grants approved by the Board of Directors. In addition, Dr. Dahlbeck's employment agreement entitled him to 14,311 stock options which was granted by the board of directors on June 8, 2020. Dr. Dahlbeck is also eligible to receive a target bonus at the rate of 35% indexed to the achievement of corporate goals and achievements to be determined by the Board of Directors. Dr. Dahlbeck is eligible to participate in all medical, personal leave and other employee benefit plans and programs for which he is eligible, subject to the terms and conditions of such plans and programs. We also reimburse Dr. Dahlbeck for corporate housing, and we reimbursed him for $0 and $4,200 in 2018 and 2019, respectively. Dr. Dahlbeck's employment is "at will" and may be terminated by us or Dr. Dahlbeck at any time and for any reason.

Gianluca Rotino

We entered into an employment agreement with Gianluca Rotino, our Chief Strategy and Innovation Officer that set forth the terms and conditions of his employment with us. The agreement will be

149


Table of Contents

effective upon completion of the initial public offering. The employment agreement establishes an annual base salary of $300,000, which is subject to our discretionary review and adjustment in accordance with our policies, procedures and practices as they may exist from time to time.

Mr. Rotino will also receive annual stock compensation with a fair market value totaling $312,000. To account for this, on June 19, 2020, the Board of Directors granted Mr. Rotino 16,422 restricted stock units with a grant date fair value of $19.00 per share, with a quarterly vesting schedule over twelve months. In addition, Mr. Rotino's employment agreement entitled him to 139,213 restricted stock units which were granted by the Board of Directors on June 19, 2020 with a grant date fair value of $19.00 per share. The restricted stock units vest upon achievement of certain corporate milestones which were approved by the Board of Directors on June 19, 2020. Finally, the Board of Directors issued Mr. Rotino 320,000 shares of common stock on June 19, 2020 in exchange for past services rendered.

Mr. Rotino is also eligible to receive a target bonus at the rate of 40%-50% indexed to the achievement of corporate goals and achievements to be determined by the Board of Directors. Mr. Rotino is eligible to participate in all medical, personal leave and other employee benefit plans and programs for which he is eligible, subject to the terms and conditions of such plans and programs. We will also reimburse Mr. Rotino for any attorney's fees in connection with his employment agreement up to $10,000. In the event of involuntary termination, Mr. Rotino is eligible for 24 months of severance pay and immediate vesting of all stock options outstanding on the date of termination. Mr. Rotino's employment is "at will" and may be terminated by us or Mr. Rotino at any time and for any reason.

Outstanding Equity Awards at Fiscal Year-End

The following table includes certain information with respect to the value of all unexercised options and unvested shares of restricted stock previously awarded to the executive officers named above at the fiscal year ended December 31, 2019.

 
  OPTION AWARDS  
Name
  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
  Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
  Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
  Option
Exercise
Price ($)
  Option
Expiration
Date
 

Maurizio Chiriva Internati

                     

Tony Tontat

    8,587           $ 6.64     11/10/2027  

    28,621         28,620 (1) $ 11.70     03/13/2028  

Scott Dahlbeck

                     

(1)
25% of the options vested on the one year anniversary of the vesting start date (December 15, 2017), with the remaining 42,931 shares vesting annually until December 15, 2021 in 50,000 share increments.

Director Compensation

No member of our board of directors received any compensation for his services as a director during the fiscal year ended December 31, 2019.

We entered into Director Services agreements with our independent directors that set forth the terms and conditions of their services to us. The agreements will take effect when we complete the initial public offering. The Director Services agreement establishes cash compensation in the amount of

150


Table of Contents

$25,000 annually, paid on a quarterly basis. Independent directors will also be reimbursed $2,500 per day if travel is required. In addition, if the independent director is on a committee, they will be entitled to $750 per meeting.

The independent directors will also receive annual stock compensation with a fair market value totaling $50,000. On June 19, 2020, the Board of Directors granted all independent directors 3,948 stock options, vesting on a quarterly basis over the next 12 months, at an exercise price of $19.00 per share.

2017 Equity Incentive Plan

On January 20, 2017, our board of directors adopted our 2017 Equity Incentive Plan, or the Plan. The following is a summary of certain significant features of the Plan. The information which follows is subject to, and qualified in its entirety by reference to, the Plan document itself, which is filed as an exhibit to the registration statement of which this prospectus forms a part.

Awards that may be granted include incentive stock options as described in section 422(b) of the Internal Revenue Code of 1986, as amended, non-qualified stock options (i.e., options that are not incentive stock options), stock appreciation rights, or SARs, and awards of restricted stock or restricted stock units, or RSUs. These awards offer our employees, consultants and directors the possibility of future value, depending on the long-term price appreciation of our common stock and the award holder's continuing service with our company or one or more of its subsidiaries.

All of the permissible types of awards under the Plan are described in more detail as follows:

Purposes of Plan:    The purpose of the Plan is to offer selected employees, consultants and directors the opportunity to acquire equity in our company.

Administration of the Plan:    Administration of the Plan is entrusted to the board of directors, which may delegate its duties and responsibilities to one or more committees. Among other things, the board or committee has the authority to select persons who will receive awards, determine the types of awards and the number of shares to be covered by awards, and to establish the terms, conditions, restrictions and other provisions of awards.

Eligible Recipients:    Persons eligible to receive awards under the Plan will be those employees, consultants and directors of our company and its subsidiaries who are selected by the board or committee.

Shares Available Under the Plan:    The maximum number of shares of common stock that may be delivered to participants under the Plan is 1,708,615, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the Plan for which the award is canceled, forfeited or expires again become available for grants under the Plan. Shares subject to an award that is settled in cash will not again be made available for grants under the Plan.

Stock Options:

General.    Subject to the provisions of the Plan, the board or committee has the authority to determine all grants of stock options. That determination will include: (i) the number of shares subject to any option; (ii) the exercise price per share; (iii) the expiration date of the option; (iv) the manner, time and date of permitted exercise; (v) other restrictions, if any, on the option or the shares underlying the option; and (vi) any other terms and conditions as the compensation committee may determine.

Option Price.    The exercise price for stock options will be determined at the time of grant. Normally, the exercise price will not be less than the fair market value on the date of grant, as determined in good faith by the board or committee. As a matter of tax law, the exercise price for any incentive stock option awarded may not be less than the fair market value of the shares on the date of grant. However,

151


Table of Contents

incentive stock option grants to any person owning more than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.

Exercise of Options.    An option may be exercised only in accordance with the terms and conditions for the option agreement as established by the board or committee at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price. Payments may be made in cash or, at the option of the board or committee, by actual or constructive delivery of shares of common stock to the holder of the option based upon the fair market value of the shares on the date of exercise.

Expiration or Termination.    Options, if not previously exercised, will expire on the expiration date established by the board or committee at the time of grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder of more than 10% of our voting stock cannot exceed five years. Options will terminate before their expiration date if the holder's service with us terminates before the expiration date. The option may remain exercisable for specified periods after certain terminations of service, including terminations as a result of death, disability or retirement, with the precise period during which the option may be exercised to be established by the board or committee and reflected in the grant evidencing the award.

SARs.    SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The board or committee will determine the number of shares covered by SAR, the exercise price of each SAR and the conditions and limitations applicable to the exercise of each SAR. The term of a SAR may not be longer than ten years.

Restricted Stock and RSUs.    Restricted stock is an award of nontransferable shares of our common stock that remain forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The board or committee may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the board or committee, subject to the conditions and limitations contained in the Plan.

Other Material Provisions:    Awards will be evidenced by a written agreement, in such form as may be approved by the board or committee. In the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be made by the board or committee to the number of shares covered by outstanding awards or to the exercise price of such awards. The board or committee is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change of control of our company, including acceleration of vesting.

Except as otherwise determined by the board or committee at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. The board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend the Plan or any outstanding award or may terminate the Plan as to further grants, provided that no amendment will, without the approval of our stockholders, increase the number of shares available under the Plan or change the persons eligible for awards under the Plan. No amendment that would adversely affect any outstanding award made under the Plan can be made without the consent of the holder of such award.

Except as set forth above, we do not have any ongoing plan or arrangement for the compensation of directors and executive officers.

152


Table of Contents


PRINCIPAL STOCKHOLDERS

The following table sets forth certain information with respect to the beneficial ownership of our voting stock as of June 26, 2020, and as adjusted to reflect the sale of common stock offered by us and the selling stockholders in our initial public offering, for:

    each of our named executive officers and directors;

    all of our named executive officers and directors as a group; and

    each other stockholder known by us to be the beneficial owner of more than 5% of the outstanding shares of our voting stock.

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares that they beneficially own, subject to applicable community property laws. Unless otherwise indicated in the footnotes below, based on the information provided to us by or on behalf of the selling stockholders, no selling stockholder is a broker-dealer or an affiliate of a broker-dealer.

Applicable percentage ownership is based on 6,082,999 shares of common stock outstanding at June 26, 2020 assuming the Preferred Stock Automatic Conversions. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options or other convertible securities held by that person or entity that are currently exercisable or releasable or that will become exercisable or releasable within 60 days of June 26, 2020. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. No holder of our Series A-1 Preferred Stock holds more than 5% of the outstanding shares of our voting stock before or after this offering. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o our company, 7707 Fannin, Suite 140, Houston, TX 77054.

 
  Number of
Shares
Beneficially
Owned
Prior to
Offering
(As Converted)
  Percentage
of Common Stock
Beneficially Owned
 
 
  Before
Offering
  After
Offering
 

Name of the Beneficial Owner

                   

Maurizio Chiriva Internati(1)

    1,388,409     22.78 %   17.34 %

Tony Tontat(2)

    475,723     7.73 %   5.61 %

Scott Dahlbeck(3)

    451,092     7.39 %   5.63 %

Gianluca Rotino(4)

    476,017     7.63 %   5.61 %

Americo Cicchetti(5)

    2,961     *     *  

Michael Nagel(5)

    1,974     *     *  

Jerry Schneider(5)

    1,974     *     *  

Pietro Bersani(5)

    1,974     *     *  

All executive officers and directors (8 persons named above)

    2,800,124     45.53 %   34.19 %

Other 5% Stockholders:

         
0
       

Angelo Minotti(6)

    1,358,861     22.34 %   16.97 %

Jose A. Figueroa(7)

    478,912     7.87 %   5.98 %

Jui-Lien Chou Ho(8)

    402,109     6.51 %   5.02 %

*
Less than 1%

153


Table of Contents

(1)
Contains 13,137 Restricted Stock Units which will vest in 60 days

(2)
Contains an aggregate of 73,723 options to purchase common stock and Restricted Stock Units which are exercisable or vest within 60 days, respectively.

(3)
Contains an aggregate of 21,575 options to purchase common stock and Restricted Stock Units which are exercisable or vest within 60 days, respectively.

(4)
Contains an aggregate of 156,017 options to purchase common stock and Restricted Stock Units which are exercisable or vest within 60 days, respectively.

(5)
Contains options to purchase common stock which are exercisable within 60 days.

(6)
Includes 169,060 shares of Series B Preferred Stock held directly, 125,021 shares of Series B Preferred Stock held by Encap (Global) Asset Management Limited and 62,824 shares of Series B Preferred Stock held by Interactive Engineering EOOD. Mr. Minotti is the Investment Officer of Encap (Global) Asset Management Limited and Interactive Engineering EOOD and has voting and investment control over the shares held by them. Mr. Minotti disclaims beneficial ownership of the shares held by Encap (Global) Asset Management Limited and Interactive Engineering EOOD except to the extent of his pecuniary interest, if any, in such shares. The address of Encap (Global) Asset Management Limited is 12-S Sebright Plaza, 6-23 Shell Street, North Point, Hong Kong. The address of Interactive Engineering EOOD is 3 Prof. Milko Bichev, Fl 1, District of Oborishet, 1504 Sofia, Region of Sofia, Municipality of Sofia, Bulgaria.

(7)
The address of Jose A. Figueroa is 4504 South Professional Drive, Apt 10208, Edinburg, TX 78539.

(8)
The address of Jui-Lien Chou Ho is 4009 19th Street, Ste D, Lubbock, TX 79410.

154


Table of Contents


TRANSACTIONS WITH RELATED PERSONS

Transactions with Related Persons

Through March 31, 2020, we maintained two separate consulting agreements with our Chief Strategy and Innovation Officer (the "CSO"), and our Chief Financial Officer and Chief Operating Officer (the "CFO and COO").

Beginning in the year ended December 31, 2014, we entered into our first consulting agreement with the CSO. Pursuant to the amended agreement dated July 20, 2018, the CSO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from our Chief Executive Officer. The consulting agreement indicates that the CSO will provide a leadership role for our business development strategies. The consulting fees paid to the CSO totaled $319,300 and $17,800 in the three months ended March 31, 2020 and 2019, respectively. We have entered into an employment agreement with the CSO that set forth the terms and conditions of his employment with us. The agreement will take effect when we complete the initial public offering. The employment agreement establishes an annual base salary of $300,000.

Beginning in the year ended December 31, 2018, we entered into our first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and we changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $30,000 and $0 in the three months ended March 31, 2020 and 2019, respectively. We have entered into an employment agreement with the CFO and COO that set forth the terms and conditions of his employment with us. The agreement will take effect when we complete the initial public offering. The employment agreement establishes an annual base salary of $300,000.

On April 3, 2020, we entered into the Joint Venture with Molipharma. Molipharma was founded in part by one of our directors, Americo Cicchetti. Mr. Cicchetti is also the Chief Executive Officer and Director of Molipharma.

155


Table of Contents


DESCRIPTION OF SECURITIES

General

The following description summarizes important terms of the classes of our capital stock. This summary does not purport to be complete and is qualified in its entirety by the provisions of our current certificate of incorporation, as amended, and our current bylaws, which have been filed as exhibits to the registration statement of which this prospectus is a part.

We are authorized to issue 300,000,000 shares of common stock, par value $0.001 per share, and 60,000,000 shares of preferred stock, $0.0001 par value per share, of which 24,000,000 shares have been designated as Series A-1 Preferred Stock and 16,500,000 have been designated as Series B Preferred Stock.

As of the date of this prospectus, there are 4,989,269 shares of common stock, 21,822,301 shares of Series A-1 Preferred Stock and 16,391,397 shares of Series B Preferred Stock issued and outstanding.

Common Stock

Voting Rights.    The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Under our certificate of incorporation and bylaws, any corporate action to be taken by vote of stockholders other than for election of directors shall be authorized by the affirmative vote of the majority of votes cast. Directors are elected by a plurality of votes. Stockholders do not have cumulative voting rights.

Dividend Rights.    Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation Rights.    In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.

Other Rights.    Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock.

Preferred Stock

21,822,301 shares of Series A-1 Preferred Stock and 16,391,397 shares of Series B Preferred Stock will automatically convert into 624,594 and 469,136 shares of common stock, respectively, upon the closing of this offering (the "Preferred Stock Automatic Conversion"). The below is a summary of the terms of the Preferred Stock prior to the offering.

Ranking.    With respect to rights on liquidation, winding up and dissolution, shares of Series A-1 Preferred Stock and Series B Preferred Stock rank pari passu to each other and senior to all shares of common stock.

Voting Rights.    Shares of preferred stock vote together with the holders of common stock on an as-converted basis on all matters for which the holders of common stock vote at any meeting of stockholders or act by written consent, except as required by law. Notwithstanding the foregoing, so long as at least twenty-five percent (25%) of the Series B Preferred Stock collectively remains outstanding, we may not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or our

156


Table of Contents

certificate of incorporation) the written consent or affirmative vote of the holders of at least sixty-seven percent (67%) of the then outstanding shares of Series B Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class on an as-converted basis, which approval shall not be unreasonably withheld, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect:

    (a)   the amend, alter or repeal any provision of our certificate of incorporation or bylaws in a manner adverse to the rights of the Series B Preferred Stock;

    (b)   create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital stock unless the same ranks junior to the Series B Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of our company, the payment of dividends and rights of redemption, or increase the authorized number of shares of Series B Preferred Stock or increase the authorized number of shares of any additional class or series of capital stock unless the same ranks junior to the Series B Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of our company, the payment of dividends and rights of redemption;

    (c)   reclassify, alter or amend any security that is junior to the Series B Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of our company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Series B Preferred Stock in respect of any such right, preference or privilege;

    (d)   purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of our capital stock other than dividends or other distributions payable on the common stock solely in the form of additional shares of common stock or repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for us or any subsidiary in connection with the cessation of such employment or service at a price per share and other terms approved by the board;

    (e)   increase or decrease the authorized number of directors constituting the board of directors;

    (f)    liquidate, dissolve or wind-up the business and affairs of our company, effect any merger or consolidation or any other deemed liquidation event (as defined in the certificate of incorporation), consummate any public offering of common stock pursuant to an effective registration statement under the Securities Act, or consent to any of the foregoing;

    (g)   grant any lien or security interest in our assets, other than (i) purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similarly persons arising in the ordinary course of business, (ii) security interests in trade accounts receivable arising in the ordinary course of business, (iii) grants in connection with lines of credit with financial institutions or equipment leases or (iv) with the prior approval of the board, including the director that was designated by the holders of the Series B Preferred Stock;

    (h)   elect to change our company's status as a C corporation for United States federal tax purposes;

    (i)    change our principal business, enter into a new line of business or exit our line of business as it existed on September 7, 2019 other than with the prior approval of the board, including the director that was designated by the holders of the Series B Preferred Stock; or

    (j)    enter into or be party to any transaction with any director, officer or employee of our company or any "associate" (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person other than (i) transactions resulting in payments to or by us in an amount less than $100,000 per year, (ii) transactions made in the ordinary course of business and pursuant to

157


Table of Contents

    reasonable requirements of our business and on fair and reasonable terms that receive the prior approval of the board or (iii) with the prior approval of the board, including the director that was designated by the holders of the Series B Preferred Stock;

Dividend Rights.    Holders of preferred stock shall be entitled to receive dividends equal, on an as-converted to common stock basis, to and in the same form as dividends actually paid on shares of common stock when, as and if such dividends are paid on shares of common stock. No other dividends shall be paid on shares of preferred stock.

Liquidation Rights.    In the event of any voluntary or involuntary liquidation, dissolution or winding up of our company or deemed liquidation event, the holders of shares of preferred stock then outstanding shall be entitled to be paid out of the assets of our company available for distribution to its stockholders before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share of preferred stock equal to the applicable original issue price ($17.47 and $16.07 for the Series A-1 Preferred Stock and Series B Preferred Stock, respectively), plus all accrued and unpaid dividends, if applicable, whether or not declared together with any other dividends declared but unpaid thereon. If upon any such liquidation, dissolution or winding up or deemed liquidation event, the assets of our company available for distribution to its stockholders shall be insufficient to pay the holders of shares of preferred stock the full amount to which they shall be entitled, the holders of shares of preferred stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the payment of all preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets available for distribution to stockholders shall be distributed among the holders of the shares of preferred stock and common stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to common stock immediately prior to such liquidation, dissolution or winding up or deemed liquidation event. A "deemed liquidation event" means, unless otherwise determined by the holders of at least a sixty-seven percent (67%) of the Series B Preferred Stock then outstanding (voting separately as a class): (a) a merger or consolidation in which our company or a subsidiary is a constituent party and we issue shares pursuant to such merger or consolidation, except any such merger or consolidation in which our shares of capital stock outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (i) the surviving or resulting corporation; or (ii) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or (b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by our company or any subsidiary of all or substantially all the assets of our company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries if substantially all of the assets of our company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary.

Conversion Rights.    Each share of preferred stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act resulting in at least $20,000,000 of net proceeds to us, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate. All shares of Series A-1 preferred stock or Series B Preferred Stock shall also be automatically converted into shares of common stock at then effective conversion rate upon the vote or written consent of the holders of at least sixty-seven percent (67%) of the then outstanding shares of

158


Table of Contents

Series A-1 Preferred Stock or Series B Preferred Stock, as applicable, voting or consenting, as the case may be, as a single class and on an as-converted basis. The conversion rate for the preferred stock is currently .0286 shares of common stock for each share of preferred stock, calculated by dividing the original issue price of such share ($0.50 and $0.46 for the Series A-1 Preferred Stock and Series B Preferred Stock, respectively) by the conversion price per share then in effect (currently $17.47 and $16.07 for the Series A-1 Preferred Stock and Series B Preferred Stock, respectively), which is subject to customary adjustments in the event of any stock splits, stock dividends, mergers or reorganizations. Subject to certain exceptions, the conversion price is also subject to adjustment in the event that we issue additional shares of common stock or shares convertible into common stock.

Other Rights.    Holders of preferred stock have no preemptive or subscription rights and there are no redemption or sinking fund provisions applicable to the preferred stock.

Investors Rights Agreement

In connection with the Series B Preferred Stock financing, on September 7, 2019, we entered into an investors' rights agreement with the investors, pursuant to which we provided the investors with certain demand registration rights. Pursuant to the investors' rights agreement and subject to certain exceptions set forth therein, if at any time after the earlier of (i) five (5) years after the date of the agreement; or (ii) one hundred eighty (180) days after the effective date of a registration statement for our initial underwritten public offering of our common stock under the Securities Act (which we refer to as an IPO), we receive a request from holders of at least fifty percent (50%) of the securities held by the investors (which we refer to as the registrable securities) then outstanding if prior to an IPO or at least twenty percent (20%) of the registrable securities then outstanding if after an IPO, that we file a Form S-1 registration statement with respect to registrable securities with an anticipated aggregate offering price, net of certain selling expenses, of not less than $10,000,000, then we must (x) within ten (10) days after the date such request is given, give notice thereof to all holders other than the initiating holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the initiating holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. In addition, if we propose to register any of our securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in certain excluded registrations), we must, at such time, promptly give each holder notice of such registration. Upon the request of each holder given within twenty (20) days after such notice is given by us, we must cause to be registered all of the registrable securities that each such holder has requested to be included in such registration. The registrable securities are being registered in the registration statement of which this prospectus forms a part.

In addition, we agreed that we would not, without the prior written consent of the holders of not less than sixty- seven percent (67%) of the registrable securities then outstanding, enter into any agreement with any other holder or prospective holder of any securities of that would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the registrable securities of the Series B investors that are included, or (ii) to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Series B investor who becomes a party to the investors' rights agreement.

Warrants

As of the date of the prospectus, there are no warrants outstanding.

159


Table of Contents

Options

As of the date of this prospectus, there are options for the purchase of 624,868 shares of common stock outstanding under our 2017 Equity Incentive Plan with a weighted average exercise price of $11.90 per share.

Restricted Stock Units

As of the date of this prospectus, there are 709,334 shares of common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $19.00 per share.

Transfer Agent and Registrar

We have appointed VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598, telephone 212-828-8436, as the transfer agent for our common stock.

Anti-Takeover Effects of Provisions of Delaware State Law

Our Fourth Amended and Restated Certificate of Incorporation and our Second Amended and Restated Bylaws, both to be in effect immediately following this offering, or our certificate of incorporation and our bylaws, include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our board of directors or management team, including the following:

Board of Directors Vacancies.    Our bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors will be permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This will make it more difficult to change the composition of our board of directors and will promote continuity of management.

Stockholder Action; Special Meeting of Stockholders.    A holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our bylaws further provide that special meetings of our stockholders may be called only by our board of directors, the chairman of our board of directors, our president or chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.

Advance Notice Requirements for Stockholder Proposals and Director Nominations.    Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our bylaws will also specify certain requirements regarding the form and content of a stockholder's notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of our company.

No Cumulative Voting.    The Delaware General Corporation Law provides that stockholders are not entitled to cumulate votes in the election of directors unless a corporation's certificate of incorporation provides otherwise. Our certificate of incorporation does not provide for cumulative voting.

160


Table of Contents

Issuance of Undesignated Preferred Stock.    Our board of directors will have the authority, without further action by our stockholders, to issue up to 60,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.

161


Table of Contents


SHARES ELIGIBLE FOR FUTURE SALE

Upon completion of this offering, we will have 8,006,099 shares of common stock issued and outstanding. All of the shares sold in this offering will be freely transferable without restriction under the Securities Act unless purchased by one of our affiliates as that term is defined in Rule 144 under the Securities Act, which generally includes directors, executive officers and 10% stockholders. Sales of substantial amounts of our shares in the public market could adversely affect prevailing market prices of our shares.

All outstanding shares prior to this offering are "restricted securities" as that term is defined in Rule 144 and may be sold only if they are sold pursuant to an effective registration statement under the Securities Act or an exemption from the registration requirements of the Securities Act such as those provided in Rules 144 and 701 promulgated under the Securities Act, which rules are summarized below. Restricted shares may also be sold outside of the United States in accordance with Regulation S under the Securities Act. This prospectus may not be used in connection with any resale of our shares acquired in this offering by our affiliates.

Rule 144

In general, under Rule 144 of the Securities Act, a person or entity that has beneficially owned our common stock for at least six months and is not our "affiliate" will be entitled to sell our common stock, subject only to the availability of current public information about us, and will be entitled to sell shares held for at least one year without any restriction. A person or entity that is our "affiliate" and has beneficially owned our common stock for at least six months will be able to sell, within a rolling three month period, the number of shares that does not exceed the greater of the following:

    (i)
    1% of the then outstanding common stock, which immediately after this offering will equal approximately 80,061 shares if the maximum number of shares being offered by us are sold and all shares of Preferred Stock are converted to common stock; and

    (ii)
    the average weekly trading volume of our common stock on the Nasdaq Capital Market during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC.

Sales by affiliates under Rule 144 must be made through unsolicited brokers' transactions. They are also subject to manner of sale provisions, notice requirements and the availability of current public information about us.

Rule 701

In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, directors or consultants who purchases our common stock from us pursuant to a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such common stock 90 days after we become a reporting company under the Exchange Act in reliance on Rule 144, but without compliance with some of the restrictions, such as the holding period, contained in Rule 144. However, the Rule 701 shares would remain subject to lock-up arrangements and would only become eligible for sale when the lock-up period expires.

162


Table of Contents


MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY'S COMMON STOCK

The following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and disposition of the Company's common stock but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, or local tax considerations relevant to the Company's operations or to the purchase, ownership or disposition of its shares, has been requested from the IRS or other tax authority. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax consequences described below.

This summary also does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S. federal gift and estate tax laws, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor's particular circumstances or to investors that may be subject to special tax rules, including, without limitation:

    banks, insurance companies or other financial institutions, regulated investment companies or real estate investment trusts;

    persons subject to the alternative minimum tax or Medicare contribution tax on net investment income;

    tax-exempt organizations or governmental organizations;

    controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax;

    brokers or dealers in securities or currencies;

    traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;

    persons that own, or are deemed to own, more than five percent of the Company's capital stock (except to the extent specifically set forth below);

    US expatriates and certain former citizens or long-term residents of the United States;

    partnerships or entities classified as partnerships for U.S. federal income tax purposes or other pass- through entities (and investors therein);

    persons who hold the Company's common stock as a position in a hedging transaction, "straddle," "conversion transaction" or other risk reduction transaction or integrated investment;

    persons who hold or receive the Company's common stock pursuant to the exercise of any employee stock option or otherwise as compensation;

    persons who do not hold the Company's common stock as a capital asset within the meaning of Section 1221 of the Internal Revenue Code; or

    persons deemed to sell the Company's common stock under the constructive sale provisions of the Internal Revenue Code.

In addition, if a partnership or entity classified as a partnership for U.S. federal income tax purposes holds the Company's common stock, the tax treatment of a partner generally will depend on the status

163


Table of Contents

of the partner and upon the activities of the partnership. Accordingly, partnerships that hold the Company's common stock, and partners in such partnerships, should consult their tax advisors.

You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of the Company's common stock arising under the U.S. federal estate or gift tax rules or under the laws of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty.

Non-U.S. Holder Defined

For purposes of this discussion, you are a non-U.S. holder (other than a partnership) if you are any holder other than:

    an individual citizen or resident of the United States (for U.S. federal income tax purposes);

    a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States, any state thereof, or the District of Columbia;

    an estate whose income is subject to U.S. federal income tax regardless of its source; or

    a trust (x) whose administration is subject to the primary supervision of a U.S. court and which has one or more "U.S. persons" (within the meaning of Section 7701(a)(30) of the Internal Revenue Code) who have the authority to control all substantial decisions of the trust or (y) which has made a valid election to be treated as a U.S. person

Distributions

As described in "Dividend Policy," the Company has never declared or paid cash dividends on its common stock and does not anticipate paying any dividends on its common stock in the foreseeable future. However, if the Company does make distributions on its common stock, those payments will constitute dividends for U.S. tax purposes to the extent paid from the Company's current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both the Company's current and its accumulated earnings and profits, they will constitute a return of capital and will first reduce your basis in the Company's common stock, but not below zero, and then will be treated as gain from the sale of stock as described below under "—Gain on Disposition of common stock."

Subject to the discussion below on effectively connected income, backup withholding and foreign accounts, any dividend paid to a non-U.S. holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a non-U.S. holder must provide us with an IRS Form W-8BEN, IRS Form W-8BEN-E, or other appropriate version of IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of the Company's common stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the non-U.S. holder's behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to the Company or its paying agent, either directly or through other intermediaries.

Dividends received by a non-U.S. holder that are effectively connected with such non-U.S. holder's conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, attributable to a permanent establishment maintained by a non-U.S. holder in the United States) are generally exempt from the withholding tax described above. In order to obtain this exemption, a non-U.S. holder must

164


Table of Contents

provide us with an IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, if a non-U.S. holder is a corporate non-U.S. holder, dividends received by such non-U.S. holder that are effectively connected with such non-U.S. holder's conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor regarding any applicable tax treaties that may provide for different rules.

Gain on Disposition of Common Stock

Subject to the discussion below regarding backup withholding and foreign accounts, a non-U.S. holder generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of the Company's common stock unless:

    the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment maintained by such non-U.S. holder in the United States);

    the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment maintained by such non-U.S. holder in the United States);

    the non-U.S. holder's are a non-resident alien individual who is present in the United States for a period or periods aggregating 183 days or more during the taxable year in which the sale or disposition occurs and certain other conditions are met; or

    the Company's common stock constitutes a United States real property interest by reason of its status as a "United States real property holding corporation," or USRPHC, for U.S. federal income tax purposes at any time within the shorter of (i) the five-year period preceding the non-U.S. holder's disposition of the Company's common stock, or (ii) the non-U.S. holder's holding period for its common stock.

The Company believes that it is not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether it is a USRPHC depends on the fair market value of its U.S. real property relative to the fair market value of its other business assets, there can be no assurance that the Company will not become a USRPHC in the future. Even if it becomes a USRPHC, however, as long as the Company's common stock is regularly traded on an established securities market, such common stock will be treated as U.S. real property interests only if the non-U.S. holder's actually or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of (i) the five-year period preceding the non-U.S. holder's disposition of the Company's common stock, or (ii) the non-U.S. holder's holding period for the Company's common stock.

Gains described in the first bullet point above, generally will be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates, and a corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. An individual non-U.S. holder described in the second bullet above, you will be required to pay a flat 30% tax (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year (provided the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses). You should consult any applicable income tax or other treaties that may provide for different rules.

165


Table of Contents

Backup Withholding and Information Reporting

Generally, the Company must report annually to the IRS, regardless of whether any tax was withheld, the amount of dividends paid to a non-U.S. holder, the non-U.S. holder's name and address and the amount of tax withheld, if any. A similar report will be sent to the non-U.S. holder. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in the non-U.S. holder's country of residence.

Payments of dividends or of proceeds on the disposition of stock made to a non-U.S. holder may be subject to information reporting and backup withholding at a current rate of 24% unless such non-U.S. holder establishes an exemption, for example, by properly certifying such non-U.S. holder's non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E, or another appropriate version of IRS Form W-8.

Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner.

Foreign Account Tax Compliance

The Foreign Account Tax Compliance Act, or FATCA, imposes withholding tax at a rate of 30% on dividends on and gross proceeds from the sale or other disposition of the Company's common stock paid to "foreign financial institutions" (as specially defined under these rules), unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds from the sale or other disposition of the Company's common stock paid to a "non-financial foreign entity" (as specially defined for purposes of these rules) unless such entity provides the withholding agent with a certification identifying certain substantial direct and indirect U.S. owners of the entity, certifies that there are none or otherwise establishes an exemption. The withholding provisions under FATCA generally apply to dividends on our common stock, and under current transition rules, are expected to apply with respect to the gross proceeds from the sale or other disposition of the Company's common stock on or after January 1, 2019. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their own tax advisors regarding the possible implications of this legislation on their investment in the Company's common stock.

Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing of the Company's common stock, including the consequences of any proposed change in applicable laws.

166


Table of Contents


UNDERWRITING

ThinkEquity, a division of Fordham Financial Management, Inc. ("ThinkEquity") is acting as representative of the underwriters of this offering. We have entered into an underwriting agreement dated            , 2020 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase from us, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of common shares listed next to its name in the following table:

Underwriter
  Number of
Shares

ThinkEquity, a division of Fordham Financial Management, Inc

              

Total

              

The underwriters are committed to purchase all shares offered by us other than those covered by the over- allotment option described below, if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters' obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers' certificates and legal opinions.

The underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

The underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of the prospectus. After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various times.

Over-Allotment Option

We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the representative to purchase a maximum of 288,465 additional shares of common stock (15% of the shares sold in this offering) from us to cover over-allotments, if any. If the representative exercises all or part of this option, it will purchase shares covered by the option at the public offering price per share that appears on the cover page of this prospectus, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $            and the total net proceeds, before expenses, to us will be $            .

Discount

The following table shows the public offering price, underwriting discounts and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.

 
  Per Share   Total Without
Over-Allotment
Option
  Total With
Over-Allotment
Option
 

Public offering price

                   

Underwriting discount (7.5%)

                   

Proceeds, before expense, to us

                   

167


Table of Contents

We have agreed to pay a non-accountable expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering (excluding proceeds received from exercise of the underwriters' over-allotment option).

We have paid an expense deposit of $35,000 to the representative for out-of-pocket-accountable expenses, which will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).

In addition, we have agreed to reimburse the representative for fees and expenses of legal counsel to the underwriters in an amount not to exceed $100,000, fees and expenses related to the use of book building, prospectus tracking and compliance software for the offering in the amount of $29,500, up to $15,000 for background checks of our officers and directors, $10,000 for data services and communications expenses, $3,000 for the costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones, and the out-of-pocket fees and expenses of the representative for marketing and roadshows for the offering not to exceed $20,000.

We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense allowance, will be approximately $912,000.

Representative's Warrants

We have agreed to issue to the representative warrants to purchase up to a total of 96,155 shares of our common stock (5% of the aggregate number of shares of common stock sold in this offering, excluding shares of common stock sold upon exercise of underwriters' the over-allotment option) (the "Representative's Warrants"). The Representative's Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. The Representative's Warrants are exercisable at any time, from time to time, in whole or in part, during the four and one half year period commencing six months from the effective date of the registration statement related to this offering.

The Representative's Warrants and the shares of common stock underlying the Representative's Warrants have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or permitted assignees under such rule may not sell, transfer, assign, pledge, or hypothecate the Representative's Warrants or the securities underlying the Representative's Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representative's Warrants or the underlying shares of common stock for a period of 180 days from the effective date of the registration statement. Additionally, the Representative's Warrants may not be sold, transferred, assigned, pledged, or hypothecated for a 180-day period following the effective date of the registration statement, except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners. The Representative's Warrants will provide for adjustment in the number and price of the Representative's Warrants and the shares of common stock underlying the Representative's Warrants in the event of recapitalization, merger, stock split, or other structural transaction, or a future financing undertaken by us.

Discretionary Accounts

The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Lock-Up Agreements

Pursuant to certain "lock-up" agreements, we, our executive officers and directors and our stockholders, have agreed not to, without the prior written consent of the representative, offer, sell,

168


Table of Contents

assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired, for a period of 12 months from the date of this prospectus, in the case of our directors and officers, and 6 months from the date of this prospectus, in the case of our other stockholders.

Right of First Refusal.

Subject to certain limited exceptions, until twelve (12) months after the closing of this initial public offering, ThinkEquity has a right of first refusal to act as sole investment banker, sole book-runner and/or sole placement agent, at ThinkEquity's sole discretion, for each and every future public and private equity and debt offering, including all equity-linked offerings, by us or any of our successors or subsidiaries during such 12-month period on terms customary to the representative.

Indemnification

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities.

Electronic Offer, Sale and Distribution of Shares

A prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representative may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters' websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.

Stabilization

In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.

Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.

Over-allotment transactions involve sales by the underwriters of securities in excess of the number of securities that underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of securities over- allotted by the underwriters is not greater than the number of securities that they may purchase in the over- allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing securities in the open market.

169


Table of Contents

Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared with the price at which they may purchase securities through exercise of the over-allotment option. If the underwriters sell more securities than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in the offering.

Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our securities. These transactions may be effected on the Nasdaq Capital Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.

Passive Market Making

In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Capital Market or on the OTCQB in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker's bid, then that bid must then be lowered when specified purchase limits are exceeded.

Other Relationships

Certain of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have no present arrangements with any of the underwriters for any further services.

Offer restrictions outside the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

170


Table of Contents

Australia

This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus.

China

The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People's Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to "qualified domestic institutional investors."

European Economic Area and the United Kingdom

The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC ("Prospectus Directive"), as implemented in Member States of the European Economic Area (each, a "Relevant Member State") and the United Kingdom, from the requirement to produce a prospectus for offers of securities.

An offer to the public of securities has not been made, and may not be made, in a Relevant Member State and the United Kingdom except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State and the United Kingdom:

    to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;

    to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than €43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than €50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);

    to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or

    in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.

France

This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary

171


Table of Contents

and Financial Code (Code monétaire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorité des marchés financiers ("AMF"). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.

This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.

Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d'investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.

Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.

Ireland

The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the "Prospectus Regulations"). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.

Israel

The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.

Italy

The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ-$$-Aga e la Borsa, "CONSOB" pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public

172


Table of Contents

offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 ("Decree No. 58"), other than:

    to Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 ("Regulation no. 1197l") as amended ("Qualified Investors"); and

    in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended.

Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:

    made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and

    in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.

Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.

Japan

The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the "FIEL") pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.

Portugal

This document is not being distributed in the context of a public offer of financial securities (oferta pública de valores mobiliários) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (Código dos Valores Mobiliários). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissăo do Mercado de Valores Mobiliários) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are "qualified investors" (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

173


Table of Contents

Sweden

This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are "qualified investors" (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

Switzerland

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).

This document is personal to the recipient only and not for general circulation in Switzerland.

United Arab Emirates

Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.

No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.

United Kingdom

Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended ("FSMA")) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to "qualified investors" (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA.

174


Table of Contents

This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 ("FPO"), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together "relevant persons"). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Canada

The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering

175


Table of Contents


LEGAL MATTERS

The validity of the shares of our common stock offered hereby will be passed upon for us by Sheppard, Mullin, Richter & Hampton LLP, New York, New York. Venable, LLP, New York, New York has acted as counsel for the underwriters in connection with certain legal matters related to this offering.


EXPERTS

The financial statements as of December 31, 2019 and 2018, and for each of the two years in the period ended December 31, 2019, included in this Prospectus have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

176


Table of Contents


WHERE YOU CAN FIND MORE INFORMATION

We have filed a registration statement, of which this prospectus is a part, on Form S-1 with the SEC relating to this offering. This prospectus does not contain all of the information in the registration statement and the exhibits included with the registration statement. For further information pertaining to us and the common stock to be sold in this offering, you should refer to the registration statement and its exhibits. References in this prospectus to any of our contracts, agreements or other documents are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contracts, agreements or documents. You may read and copy the registration statement, the related exhibits and other material we file with the SEC at the SEC's public reference room in Washington, D.C. at 100 F Street, Room 1580, N.E., Washington, D.C. 20549. You can also request copies of those documents, upon payment of a duplicating fee, by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file with the SEC. The website address is http://www.sec.gov.

Upon the effectiveness of the registration statement, we will be subject to the informational requirements of the Exchange Act, and, in accordance with the Exchange Act, will file reports, proxy and information statements and other information with the SEC. Such annual, quarterly and special reports, proxy and information statements and other information can be inspected and copied at the locations set forth above. We also anticipate making these documents publicly available, free of charge, on our website as soon as reasonably practicable after filing such documents with the SEC. Information on, or accessible through, our website is not part of this prospectus.

177


Table of Contents


FINANCIAL STATEMENTS

 
  Page

Audited Consolidated Financial Statements for the Years December 31, 2019 and 2018

   

Report of Independent Registered Public Accounting Firm

  F-3

Consolidated Balance Sheets as of December 31, 2019 and 2018

  F-4

Consolidated Statements of Operations for the Years Ended December 31, 2019 and 2018

  F-5

Consolidated Statements of Changes in Stockholders' Equity for the Years Ended December 31, 2019 and 2018

  F-6

Consolidated Statements of Cash Flows for the Years Ended December 31, 2019 and 2018

  F-7

Notes to Consolidated Financial Statements

  F-8 to F-32

For the Three Months Ended March 31, 2020 and 2019

 

 

Condensed Consolidated Balance Sheets as of March 31, 2020, and December 31, 2019

  F-33

Condensed Consolidated Statements of Operations for the Three Months ended March 31, 2020 and 2019—Unaudited

  F-34

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three Months ended March 31, 2020 and 2019—Unaudited

  F-35

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019—Unaudited

  F-36

Notes to Condensed Consolidated Financial Statements

  F-37 to F-59

F-1


Table of Contents


KIROMIC BIOPHARMA, INC. AND SUBSIDIARY

AUDITED CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018

F-2


Table of Contents


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Kiromic BioPharma, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Kiromic BioPharma, Inc. and Subsidiary (the "Company") as of December 31, 2019 and 2018, the related consolidated statements of operations, changes in stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Deloitte & Touche LLP

Houston, Texas

April 6, 2020 (June 25, 2020, as to the effects of the reverse stock split described in notes 2 and 12)

We have served as the Company's auditor since 2016.

F-3


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Consolidated Balance Sheets

 
  December 31,
2019
  December 31,
2018
 

Assets

             

Current Assets:

             

Cash and cash equivalents

  $ 1,929,100   $ 384,300  

Unbilled receivables from granting agency

        24,300  

Inventories

    22,200     16,300  

Prepaid expenses and other current assets

    89,100     135,300  

Total current assets

    2,040,400     560,200  

Property and equipment, net

    587,900     298,000  

Other assets

    24,400     17,800  

Total Assets

  $ 2,652,700   $ 876,000  

Liabilities and Stockholders' Equity:

             

Current Liabilities:

             

Accounts payable

  $ 452,400   $ 219,100  

Accrued expenses and other current liabilities

    221,300     372,600  

Deferred rent, current portion

        19,000  

Total current liabilities

    673,700     610,700  

Total Liabilities

    673,700     610,700  

Commitments and contingencies (Note 7)

             

Stockholders' Equity:

             

Series A-1 Preferred Stock, $0.0001 par value: 24,000,000 shares authorized as of December 31, 2019 and 2018; 21,822,301 and 20,886,782 shares issued and outstanding as of December 31, 2019 and 2018, respectively

    9,134,700     8,727,400  

Series B Preferred Stock, $0.0001 par value: 14,130,435 shares authorized as of December 31, 2019; 9,869,659 shares issued and outstanding as of December 31, 2019

    1,306,900      

Preferred Stock, $0.0001 par value: 21,869,565 shares authorized as of December 31, 2019; 0 shares issued and outstanding as of December 31, 2019

         

Common stock: 300,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 2,863,812 and 2,862,093 shares issued and outstanding as of December 31, 2019 and 2018, respectively

         

Additional paid-in capital

    13,965,000     10,237,600  

Accumulated deficit

    (22,427,600 )   (18,699,700 )

Total Stockholders' Equity

    1,979,000     265,300  

Total Liabilities and Stockholders' Equity

  $ 2,652,700   $ 876,000  

   

See accompanying notes to the consolidated financial statements

F-4


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Consolidated Statements of Operations

 
  Years Ended December 31,  
 
  2019   2018  

Operating expenses:

             

Research and development

  $ 1,201,700   $ 1,424,900  

General and administrative

    2,503,700     1,757,700  

Total operating expenses

    3,705,400     3,182,600  

Loss from operations

    (3,705,400 )   (3,182,600 )

Other expense

             

Interest expense

    (22,500 )   (633,100 )

Other expense

    (22,500 )   (633,100 )

Loss before income taxes

    (3,727,900 )   (3,815,700 )

Income taxes

         

Net loss

  $ (3,727,900 ) $ (3,815,700 )

Net loss per common share, basic and diluted

  $ (1.39 ) $ (1.33 )

Weighted average common shares outstanding, basic and diluted

    2,862,809     2,862,093  

Pro forma net loss per common share, basic and diluted (unaudited)

  $ (1.06 )      

Pro forma weighted-average common shares outstanding, basic and diluted (unaudited)

    3,532,917        

   

See accompanying notes to the consolidated financial statements

F-5


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Consolidated Statements of Changes in Stockholders' Equity

 
  Series A-1 Preferred Stock   Series B Preferred Stock   Common Stock    
   
   
 
 
  Number of
Shares
  Amount   Number of
Shares
  Amount   Number of
Shares
  Amount   Additional
Paid-In
Capital
  Accumulated
Deficit
  Total  

Balance at January 1, 2018

      $       $     2,862,093   $   $ 9,604,600   $ (14,884,000 ) $ (5,279,400 )

Issuance of Series A-1 Preferred Stock

    2,007,000     900,000                             900,000  

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock

    18,879,782     7,827,400                             7,827,400  

Stock compensation expense

                            633,000         633,000  

Net loss

                                (3,815,700 )   (3,815,700 )

Balance at December 31, 2018

    20,886,782     8,727,400             2,862,093         10,237,600     (18,699,700 )   265,300  

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock

    935,519     407,300                             407,300  

Issuance of Series B Preferred Stock

            9,782,609     1,056,300                     1,056,300  

Series B Preferred Stock discount amortization

                210,600             (210,600 )        

Warrants underlying Series B Preferred Stock issuance

                            3,443,700         3,443,700  

Accretion and settlement of Series B Preferred Stock dividend

            87,050     40,000             (40,000 )        

Exercised stock options

                    1,719         11,400         11,400  

Stock compensation expense

                            522,900         522,900  

Net loss

                                (3,727,900 )   (3,727,900 )

Balance at December 31, 2019

    21,822,301   $ 9,134,700     9,869,659   $ 1,306,900     2,863,812   $   $ 13,965,000   $ (22,427,600 ) $ 1,979,000  

   

See accompanying notes to the consolidated financial statements

F-6


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Consolidated Statements of Cash Flows

 
  Years Ended December 31,  
 
  2019   2018  

Cash flows from operating activities:

             

Net loss

  $ (3,727,900 ) $ (3,815,700 )

Adjustments to reconcile net loss to net cash used for operating activities:

             

Depreciation

    87,500     80,900  

Stock compensation expense

    522,900     633,000  

Non-cash interest

    20,500     633,100  

Changes in operating assets and liabilities:

             

Unbilled receivables from granting agency

    24,300     (18,900 )

Inventories

    (5,900 )    

Prepaid expenses and other current assets

    46,200     212,500  

Other assets

    (6,600 )   (3,000 )

Accounts payable

    293,400     (4,400 )

Accrued expenses and other current liabilities

    (151,300 )   149,400  

Interest payable

        (363,400 )

Deferred rent

    (19,000 )   (25,400 )

Convertible promissory notes derivative liability

    2,000     369,000  

Net cash used for operating activities

    (2,913,900 )   (2,152,900 )

Cash flows from investing activities:

             

Purchases of property and equipment

    (302,700 )   (137,300 )

Net cash used for investing activities

    (302,700 )   (137,300 )

Cash flows from financing activities:

             

Proceeds from sale of convertible promissory notes

    250,000     725,000  

Exercise of stock options

    11,400      

Proceeds from Series A-1 Preferred Stock issuance

        900,000  

Proceeds from Series B Preferred Stock issuance

    4,500,000      

Net cash provided by financing activities

    4,761,400     1,625,000  

Net change in cash and cash equivalents

    1,544,800     (665,200 )

Cash and cash equivalents:

             

Beginning of year

    384,300     1,049,500  

End of year

  $ 1,929,100   $ 384,300  

Supplemental disclosures of non-cash investing and financing activities:

             

Conversion of accounts payable into convertible promissory notes

  $ 134,800   $  

Accretion and settlement of Series B Preferred Stock dividend

  $ 40,000   $  

Accruals for property, plant, and equipment

  $ 74,700   $  

Conversion of convertible promissory notes and accrued interest to Series A-1 Preferred Stock

  $ 407,300   $ 7,827,400  

   

See accompanying notes to the consolidated financial statements

F-7


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements

As of and for the Years Ended December 31, 2019 and 2018

1. ORGANIZATION

Nature of Business

Kiromic BioPharma, Inc. and Subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the Company Kiromic BioPharma, Inc.

The Company is focused on discovering, developing, and commercializing novel immune-oncology and small molecule therapy applications through its robust product pipeline, which are in the pre initial new drug ("pre-IND") validation stages of the US Food and Drug Administration clinical trial process. Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.

The Company's wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business is recently formed and the product was recently developed. This business has not generated any revenues.

Going Concern—The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

The Company has incurred losses, negative cash flows from operations, and has not generated any revenues since its inception. In addition to incurring losses from operations, the Company has primarily financed its operations with the proceeds from equity and debt financing arrangements. The Company's long-term success is dependent upon its ability to successfully develop, commercialize and market its products, earn revenue, obtain additional capital when needed, and, ultimately, to achieve profitable operations. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company's research and development activities. The Company does not have sufficient cash on hand or available liquidity that can be utilized to fund future operations for at least twelve months following the date the financial statements were available to be issued. Thus, there are conditions and events that raise substantial doubt regarding the Company's ability to continue as a going concern.

The Company is seeking significant additional capital funding to develop our platform and Pre-IND product lines, additional hiring of scientific professionals and other general and administrative employees, and clinical trials. However, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. Management has the ability to eliminate certain forecasted discretionary costs that would not be in violation of the intended use of proceeds outlined in the Series B Preferred Stock purchase agreements. The Company has concluded that management's plans are probable of being achieved to have the necessary funding to meet its working capital needs to continue operations for at least twelve months following the date the consolidated financial statements were available to be issued. As a result, the Company has concluded that management's plans are probable of being implemented and alleviate substantial doubt about the Company's ability to continue as a going concern.

F-8


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

1. ORGANIZATION (Continued)

The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

NIH Grant—In August 2018, NIH, the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno- associated viral vectors. Phase I of the grant approved amounts of $851,000 and which covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. Starting in 2020, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2019 are not necessarily indicative of results to be expected for any future year. On December 17, 2019, the Company completed a 1-for-10 reverse stock split of our outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of our outstanding common stock. As a result of these stock splits, the Company's issued and outstanding common stock decreased from 100,060,000 shares to 2,863,812 shares. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.

Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents—As of December 31, 2019 and 2018, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Unbilled Receivables from Granting Agency—Unbilled receivables include certain cost reimbursements owed to the Company resulting from a biomedical research grant from the NIH. Direct costs subject to reimbursement are recorded only after actual expenses have been incurred while indirect costs are calculated using the percentage-of-completion accounting method. Unbilled receivables represent qualified cost reimbursements for which reimbursement which have not yet been requested from or

F-9


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

billed to the NIH due to the timing of the accounting invoicing cycle. The Company estimates the amount of probable credit losses from its existing unbilled receivables in the form of an allowance for doubtful accounts. The Company determines the allowance for doubtful accounts based upon an aging of unbilled receivables, historical experience, and management judgment. Unbilled receivable balances are reviewed individually for collectability. For the years ended December 31, 2019 and 2018, the Company has not experienced any credit-related losses.

Concentrations of Credit Risk and Other Uncertainties—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company's cash and cash equivalents were deposited in accounts at a small number of national financial institutions.

Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.

The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company's product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company's ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit—In connection with one of the Company's facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company's consolidated balance sheets.

Inventories—Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2019 and 2018, no such adjustments have been recorded.

Property and Equipment—Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and

F-10


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.

Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description
  Estimated
Lives

Laboratory Equipment

  3 - 8

Leasehold improvements

  1 - 7

Office Furniture, Fixtures, and Equipment

  5

Software

  5

Internal Use Software Development Costs—The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $20,000 and $121,500 for the years ended December 31, 2019 and 2018, respectively.

Impairment of Long-Lived Assets—The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company's long-lived assets since inception.

Comprehensive Loss—Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes—The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.

The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, ("ASC 740") on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the

F-11


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2019 and 2018.

Research and Development Expense—The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company's pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.

The Company accrues and expenses costs of services provided by contract research organizations ("CROs") in connection with preclinical studies and contract manufacturing organizations ("CMOs") engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants—During the years ended December 31, 2019 and 2018, the Company recognized $298,000 and $258,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.

Convertible Promissory Notes Derivative Liability—The Company has recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company's next equity financing ("Next Financing Close"). The embedded derivative liability is initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability is valued using a probability weighted expected return model. See Note 6.

Upon repurchase of convertible promissory notes, ASC 470, Debt with conversion and other options, ("ASC 470") requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.

F-12


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value Measurements—The carrying value of the Company's cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

    Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

    Level 2—Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.

    Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy levels during the years ended December 31, 2019 and 2018.

The Company's liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Stock as of December 31, 2019 and December 31, 2018. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.

F-13


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:

 
  December 31,
2019
  December 31,
2018
 

Convertible promissory notes

             

Beginning balance

  $   $ 5,737,000  

Amounts allocated to the embedded derivative liability at inception (at fair value)

    (21,000 )   (8,000 )

Conversions from accounts payable into convertible promissory notes

    134,800      

Proceeds from issuances of convertible promissory notes

    250,000     725,000  

Conversions into Series A-1 Stock

    (363,800 )   (6,454,000 )

Ending balance

  $   $  

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:

             

Convertible promissory note embedded derivative liability Beginning balance

  $   $ 369,000  

Realized and unrealized gains and losses

    2,000     167,000  

Fair value of embedded derivative liability at inception

    21,000     8,000  

Amounts derecognized upon conversion of the related convertible promissory notes

    (23,000 )   (544,000 )

Ending balance

  $   $  

Nonvested Stock Options—Pursuant to the Company's 2017 Stock Incentive Plan (the "Plan"), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options. The vesting conditions include annual, monthly, and fully vested. Annual vesting conditions are for 4 years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation—The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation—Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the "Black-Scholes model"). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company's common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

The board of directors' approach to estimating the fair value of the Company's common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants' Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.

F-14


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:

Expected Term.    The expected term represents the period that the Company's stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company's common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a future publicly traded company. The Company has consequently used the Staff Accounting Bulletin ("SAB") No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company.

Risk-Free Interest Rate.    The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

Volatility.    The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield.    The expected dividend assumption is based on the Company's current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.

Common Stock Valuations.    The fair value of the common stock underlying the Company's stock-based compensation grants has historically been determined by the Company's board of directors, with input from management and third-party valuations. The Company believes that the board of directors has the relevant experience and expertise to determine the fair value of the Company's common stock. Given the absence of a public trading market of the Company's common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company's common stock at each grant date. These factors include:

    valuations of the common stock performed by third-party specialists;

    the prices, rights, preferences, and privileges of the Company's Series A-1 Preferred Stock and Series B Preferred Stock Series B Preferred Stock relative to those of the Company's common stock;

    lack of marketability of the common stock;

    current business conditions and projections;

    hiring of key personnel and the experience of management;

F-15


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

    the Company's stage of development;

    likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;

    the market performance of comparable publicly traded companies; and

    the US and global capital market conditions.

In valuing the common stock, the board of directors determined the equity value of the Company's business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company's industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company's cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method ("OPM") or probability—weighted expected return model ("PWERM").

The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.

Application of the Company's approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.

F-16


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.

Segment Data—The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Reclassifications—Certain reclassifications have been made to the 2018 financial statements in order to conform to the 2019 presentation. Specifically, inventory balances have now been separately presented from prepaid expenses and other current assets. There were no changes to previously reported shareholders' equity or net loss as a result of the reclassifications.

Recently Issued Accounting Pronouncements—From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic's effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2021. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

In March 2016, FASB issued ASU 2016-09, Stock Compensation—Improvements to Employee Share-Based Payment Accounting. On January 1, 2018, the Company adopted the amendments to ASC 718, which simplify accounting for share based payment transactions. As part of the amendment, the Company has elected to recognize the actual forfeitures by reducing the employee share-based compensation expense in the same period as the forfeitures occur. The adoption did not result in a material impact on the Company's financial statements and related disclosures.

In June 2016, FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive

F-17


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

On January 1, 2018, the Company adopted ASU 2018-07, Improvements to Non-employee Share-Based Payment Accounting (Topic 718). This standard expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. FASB clarified that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606—Revenue from Contracts with Customers. Since the Company has not generated any revenue to date, this adoption did not result in a material impact on the Company's consolidated financial statements and related disclosures.

On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2019 and 2018, respectively.

3. NET LOSS PER COMMON SHARE

Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, the common shares underlying the Series B Preferred Stock, convertible promissory notes, and convertible preferred stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares

F-18


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

3. NET LOSS PER COMMON SHARE (Continued)

outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share :

 
  Years Ended December 31,  
 
  2019   2018  

Net loss per common share, basic and diluted

             

Net loss

  $ (3,727,900 ) $ (3,815,700 )

Less: Accretion and settlement of Series B Preferred Stock dividend

    (40,000 )    

Less: Series B Preferred Stock discount amortization

    (210,600 )    

Net loss attributable to common shareholders, basic and diluted

  $ (3,978,500 ) $ (3,815,700 )

Weighted average common shares outstanding, basic and diluted

    2,862,809     2,862,093  

Net loss per common share, basic and diluted

  $ (1.39 ) $ (1.33 )

For the years ended December 31, 2019 and 2018, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):

 
  2019   2018  

Options to purchase

    75,405     61,785  

Series A-1 Preferred Stock

    624,594     597,816  

Series B Preferred Stock

    282,478      

Warrants underlying Series B Preferred Stock

    839,784      

Total

    1,822,261     659,601  

Unaudited Pro Forma Net Loss Per Common Share

Upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20,000,000 of net proceeds to the Company, all shares of Series A-1 Preferred Stock and Series B Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion rate. In addition, the warrants to purchase shares of common stock underlying Series B Preferred Stock were not considered in the calculation due to duration of the warrant vesting schedule in relation to Series B Preferred Stock issuance dates. No warrants would be exercisable based on the issuance date of the Series B Preferred Stock. The vesting schedule of the warrants is as follows:

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

    The remainder of the warrants beginning twelve months after the Listing Date.

F-19


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

3. NET LOSS PER COMMON SHARE (Continued)

The unaudited pro forma basic and diluted net loss per common share for the year ended December 31, 2019 has been prepared to give effect to adjustments arising upon the completion of such public offering. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per common share does not include any pro forma adjustments to net loss.

The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per common share for the year ended December 31, 2019 has been prepared to give effect, upon such a public offering, to the automatic conversion of all outstanding shares of Series A-1 Preferred Stock and Series B Preferred Stock into common stock as if the proposed public offering had occurred January 1, 2019 for any shares issued and outstanding on December 31, 2018 and on the date of issuance for any shares issued during the year ended December 31, 2019.

Pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 
  Year Ended
December 31,
2019
 

Numerator:

       

Net loss

  $ (3,727,900 )

Pro forma net loss—basic and diluted

  $ (3,727,900 )

Denominator:

       

Weighted-average common stock outstanding—basic and diluted

    2,862,809  

Pro forma adjustment to reflect automatic conversion of Series A-1 Preferred Stock to common stock upon the completion of the proposed initial public offering

    608,014  

Pro forma adjustment to reflect automatic conversion of Series B Preferred Stock to common stock upon the completion of the proposed initial public offering

    62,094  

Pro forma weighted-average common stock outstanding—basic and diluted

    3,532,917  

Pro forma net loss per common share—basic and diluted

  $ (1.06 )

F-20


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

4. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at December 31:

 
  2019   2018  

Equipment

  $ 488,800   $ 158,000  

Leasehold improvements

    302,700     282,600  

Office furniture, fixtures, and equipment

    16,600     10,100  

Software

    141,500     121,500  

    949,600     572,200  

Less: Accumulated depreciation

    (361,700 )   (274,200 )

Total

  $ 587,900   $ 298,000  

Depreciation expense was $87,500 and $80,900 for the years ended December 31, 2019 and 2018, respectively. Depreciation expense is recorded within general and administrative operating expenses on the consolidated statements of operations.

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at December 31:

 
  2019   2018  

Accrued consulting and outside services

  $ 221,300   $ 221,300  

Accrued compensation

        145,000  

Accrued other

        6,300  

Total

  $ 221,300   $ 372,600  

6. CONVERTIBLE PROMISSORY NOTES

Starting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturing either on June 1, 2019, January 2, 2020, or June 30, 2020 (the "Maturity Date").

The convertible promissory notes were convertible into shares issued in the Company's Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the "Balance") by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders' option, the Company shall either repay the Balance then outstanding or convert into the Company's common stock at a set conversion price then in effect, as defined in the convertible promissory notes.

The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the years ended December 31, 2019 and

F-21


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

6. CONVERTIBLE PROMISSORY NOTES (Continued)

2018. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% as of December 31, 2019 and 50% as of December 31, 2018. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the years ended December 31:

 
  2019   2018  

Convertible promissory notes- issuances

  $ 250,000   $ 725,000  

Conversion of accounts payable into convertible promissory notes

    134,800      

Total issuances and conversions into convertible promissory notes

    384,800     725,000  

Embedded derivative liability

   
 
   
 
 

Initial fair value upon issuance of convertible promissory notes

    21,000     271,000  

Change in fair value

    2,000     273,000  

Converted embedded derivative liability into Series A-1 Preferred Stock

    (23,000 )   (544,000 )

Embedded derivative liability balance at December 31

  $   $  

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See Note 8 for further details. No additional convertible promissory notes were issued for the year ended December 31, 2019 following the conversion on August 15, 2019.

On December 20, 2018, the Company closed the capital raise of Series A-1 Preferred Stock, which qualified as the Next Financing Close. In accordance with the convertible promissory notes, all of the convertible promissory notes were converted into Series A-1 Preferred Stock. See Note 8 for further details. No additional convertible promissory notes were issued for the year ended December 31, 2018 following the conversion on December 20, 2018.

7. COMMITMENTS AND CONTINGENCIES

Facility Lease Agreements—The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal which occurred in 2019 resulted in an expansion to the lease of approximately 4,100 square feet. The Company may extend this lease for up to two years. The total lease payments per month will be $21,353 beginning January 1, 2020. The Company records rent expense on a straight-line basis over the term of the respective leases.

F-22


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

7. COMMITMENTS AND CONTINGENCIES (Continued)

As of December 31, 2019, future minimum commitments under facility lease agreements were as follows:

 
  Amount  

2020

    256,200  

2021

    85,400  

Total

  $ 341,600  

Annual rent expense for the facility lease agreements was $129,100 and $156,700 for the years ended December 31, 2019 and 2018, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.

License Agreements—The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of December 31, 2019 and 2018, the Company has not incurred any milestone or royalty liabilities related to these license agreements.

Legal Proceedings—In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company's financial position.

8. STOCKHOLDERS' EQUITY

Third Amended and Restated Certificate of Incorporation

On December 16, 2019, the Company amended and restated its certificate of incorporation,

The amendments to the Charter are the following:

    (i)
    Change the name of the Company to "Kiromic BioPharma, Inc.",

    (ii)
    1-for-10 reverse split of the Company's outstanding shares of Common Stock. Shares of common stock have been retrospectively revised to reflect the reverse split,

    (iii)
    Increase the Company's authorized Preferred Stock to 60,000,000 shares,

    (iv)
    Change the par value of the Preferred Stock, from $0.01 to $0.0001 per share

Following the amendments to the Charter, the Company had 21,869,565 remaining shares of Preferred Stock authorized for issuance. The total authorized 60,000,000 Preferred Stock shares was reduced by 24,000,000 shares designated as Series A-1 Preferred Stock and 14,130,435 shares designated as Series B Preferred Stock.

Common Stock—From inception in December 2012 through May 2016, the Company raised proceeds from capital contributions for common stock at a $0.001 par value, net of redemptions, totaling

F-23


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

8. STOCKHOLDERS' EQUITY (Continued)

$6,214,800. When the Company converted from Kiromic, LLC to Kiromic, Inc., the shares converted from two classes to a single class of common stock. At the time of conversion, the par value on the two classes of common stock eliminated, and the par value of common stock transferred entirely into additional paid-in capital. Other than from proceeds for the exercise of vested stock options, there were no additional raises from common stock that occurred in the years ended December 31, 2019 or 2018.

The Company authorized shares of 300,000,000 as of December 31, 2019 and 2018, respectively. The certificate of incorporation authorizing 600,000,000 shares was dated May 27, 2016. The Company amended its certificate of incorporation on December 20, 2018 to reduce the number of authorized shares. As of December 31, 2019 and 2018, the Company issued 2,863,812 and 2,862,093 shares of common stock, respectively.

Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.

The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 286,205 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the stock splits, the total number of authorized shares was updated to 858,615.

There were 258,813 shares and 51,892 shares available for issuance as of December 31, 2019 and 2018, respectively (see Note 9). In the year ended December 31, 2019, option grantees exercised their option to purchase 1,719 shares of common stock for $6.64 per share for proceeds of $11,400. No options were exercised in 2018.

Series A-1 Preferred Stock—Between June 8, 2018 and August 14, 2018, the Company entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. On December 20, 2018, 2,032,749 shares of Series A-1 Preferred Stock were issued for the $912,800, representing the advances received and accrued interest through September 10, 2018.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the Original Issue Price.

On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock (see above) vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.

F-24


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

8. STOCKHOLDERS' EQUITY (Continued)

With respect rights on liquidation, winding up and dissolution, shares of Series A-1 Preferred Stock rank senior to all shares of common stock.

Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act resulting in at least $20,000,000 of net proceeds to the Company, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

Series B Preferred Stock—On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.3 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.001 per share of common stock ("Warrants"). See below for further details.

Until the effective date of the Charter, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.

The Series B Preferred Stock conversion price shall initially be equal to the Series B Preferred Stock Original Issue Price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company's ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 shall thereafter be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.

F-25


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

8. STOCKHOLDERS' EQUITY (Continued)

On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated the Charter on December 16, 2019, the special redemption right provision was eliminated.

The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum. Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the year ended December 31, 2019:

 
  December 31,
2019
 

Series B Preferred Stock proceeds

  $ 4,500,000  

Series B Preferred Stock discount

    (3,443,700 )

Series B Preferred Stock discount amortization

    210,600  

Accretion and settlement of Series B Preferred Stock dividend

    40,000  

Series B Preferred Stock ending balance

  $ 1,266,900  

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the Original Issue Price.

On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock (see below) vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.

With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.

Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act resulting in at least $20,000,000 of net proceeds to the Company, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

Conversion of Convertible Promissory Notes—On December 20, 2018, the Company's certificate of incorporation was amended to authorize 24,000,000 shares Series A-1 Preferred Stock. This amendment qualified as the Next Financing Close with respect to the convertible promissory notes. Therefore, the

F-26


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

8. STOCKHOLDERS' EQUITY (Continued)

outstanding principal and accrued interest was converted into Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $7,541,600. Per the convertible promissory notes, the conversion price was $0.40. Accordingly, 18,854,033 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.

Warrants Underlying Series B Preferred Stock—In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). The Warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

    The remainder of the warrants beginning twelve months after the Listing Date.

As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $3,233,000 is reflected as additional paid-in capital.

The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the years ended December 31, 2019:

 
  December 31,
2019

Risk-free interest rate

  1.54% - 1.88%

Expected volatility

  71.95% - 72.20%

Expected life (years)

  10.00

Expected dividend yield

  0%

F-27


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

9. STOCK-BASED COMPENSATION

2017 Stock Incentive Plan

In January 2017, the Company's board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 858,615 shares of the Company's common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Stock options granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over an agreed service period.

The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:

 
  2019   2018

Risk-free interest rate

  1.60% - 2.92%   2.24% - 2.92%

Expected volatility

  72.29% - 78.16%   74.54% - 78.16%

Expected life (years)

  4.93 - 6.07   4.93 - 6.01

Expected dividend yield

  0%   0%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for Company's common shares, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company's operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company's common shares, among other factors.

9. STOCK-BASED COMPENSATION (Continued)

The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:

 
  2019   2018  
 
  Shares   Weighted
Average
Exercise Price
  Shares   Weighted
Average
Exercise Price
 

Options outstanding at beginning of year

    520,517   $ 8.64     351,996   $ 6.64  

Granted

    209,505     17.29     250,121     11.37  

Exercised

    (1,719 )   6.64            

Cancelled and forfeited

    (130,220 )   11.56     (81,600 )   8.38  

Balance at December 31

    598,083   $ 11.04     520,517   $ 8.64  

Options exercisable at December 31:

    368,527   $ 7.72     341,056   $ 7.22  

Weighted average grant date fair value for options granted during the year:

        $ 10.82         $ 6.31  

F-28


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

9. STOCK-BASED COMPENSATION (Continued)

The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2019 and 2018 under the Plan: The intrinsic value of options exercised during the year ended December 31, 2019 was $17,600.

 
  Options Outstanding    
   
   
 
 
  Options Exercisable  
 
   
  Weighted
Average
Remaining
Contractual
Life
   
   
 
Year Ended December 31,
  Options
Outstanding
  Weighted
Average
Exercise
Price
  Aggregate
Intrinsic
Value
  Options
Exercisable
  Weighted
Average
Exercise
Price
  Aggregate
Intrinsic
Value
 

2018

    520,517     9.16   $ 8.64   $ 1,687,000     341,056   $ 7.22   $ 1,589,500  

2019

    598,083     8.07   $ 11.04   $ 19,163,700     368,527   $ 7.72   $ 13,031,000  

Total stock compensation expense recognized for all stock-based compensation awards recognized in the consolidated statements of operations for the years ended December 31, 2019 and 2018, is as follows:

 
  2019   2018  

Research and development

  $ 332,000   $ 303,000  

General and administrative

    190,900     330,000  

Total

  $ 522,900   $ 633,000  

As of December 31, 2019, total unrecognized stock compensation expense is $2,354,097, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 3.5 years.

10. INCOME TAXES

For the years ended December 31, 2019 and 2018, the Company recognized no provision or benefit from income taxes.

The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2019 and 2018.

 
  2019   2018  

Federal income tax at statutory rates

    21.00 %   21.00 %

Federal income tax rate reduction

    %   %

Change in valuation allowance

    (21.00 )%   (21.00 )%

Effective income tax rate

    %   %

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company's deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not that the Company will not realize future benefits

F-29


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

10. INCOME TAXES (Continued)

associated with these deferred tax assets as of December 31, 2019 and 2018 due to the significant uncertainty about the realization of the deferred tax asset until the Company can operate profitably.

The Tax Cuts and Jobs Act was enacted on December 22, 2017, and has several key provisions that significantly changed US tax law by, including lowering US corporate income tax rate to 21%, creating a new limitation on deductible interest expense, and changing rules related to use and limitations of net operating loss carryforwards for tax years beginning after December 31, 2017.

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows:

 
  2019   2018  

Deferred tax assets (liabilities):

             

Net operating loss carryforward

  $ 2,605,400   $ 1,941,000  

Stock compensation expense

    597,400     487,600  

Intangible assets

    27,800     36,100  

Total gross deferred tax assets

    3,230,600     2,464,700  

Valuation allowance

    (3,198,100 )   (2,455,100 )

Property and equipment

    (32,500 )   (9,600 )

Net deferred tax assets (liabilities)

  $   $  

As of December 31, 2019 and 2018, the Company has a US net operating loss ("NOL") carryforward of $12,406,800 and $9,242,900, respectively. The NOL carryforwards may be subject to annual limitations due to "change in ownership" provisions of Internal Revenue Code Section 382 ("Section 382") that can be triggered due to future ownership changes. Additionally, the NOL loss carryforwards are subject to examination and adjustments by the Internal Revenue Service until the statute of limitations closes on the year in which the NOL is utilized.

As of December 31, 2019 and 2018, there were no material uncertain tax positions taken by the Company. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months.

As of December 31, 2019, the Company is not currently under audit by any income tax authority.

11. RELATED PARTY TRANSACTIONS

Through December 31, 2019, the Company maintained three separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSO"), the Chief Financial Officer and Chief Operating Officer (the "CFO and COO"), and the Chief Medical Officer (the "CMO").

Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSO. Pursuant to the amended agreement dated July 20, 2018, the CSO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSO will provide a leadership role for the Company's business development

F-30


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

11. RELATED PARTY TRANSACTIONS (Continued)

strategies. The consulting fees paid to the CSO totaled $207,800 and $119,100 in the years ended December 31, 2019 and 2018, respectively.

Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO totaled $67,500 and $22,500 in the years ended December 31, 2019 and 2018, respectively.

Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CMO. Pursuant to the amended agreement on August 1, 2019, the CMO is entitled to a consulting fee of $400 per hour. The consulting agreement indicates that the CMO will direct the development of clinical strategies and plans to integrate the Company's compounds into standard medical practice. The consulting fees paid to the CMO totaled $182,800 and $12,500 in the years ended December 31, 2019 and 2018, respectively.

12. SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the consolidated balance sheet date through April 6, 2020, the date at which the consolidated financial statements were available to be issued and through June 25, 2020 as it relates to the reverse stock split, and determined that other than the events mentioned below, no events or transactions occurred that are required to be disclosed.

Preferred Share Issuance

On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase three shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). The Warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

    The remainder of the warrants beginning twelve months after the Listing Date.

F-31


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Consolidated Financial Statements (Continued)

As of and for the Years Ended December 31, 2019 and 2018

12. SUBSEQUENT EVENTS (Continued)

The Series B Preferred Stock conversion price shall initially be equal to the Series B Preferred Original Issue Price of $16.07 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock.

Capital Expenditures

On January 6, 2020, the Board of Directors approved construction of the Company's Good Manufacturing Practices ("GMP") and Vivarium facility. The GMP and Vivarium are being built on the expansion to the Houston lease, which has approximately 4,100 square feet. The initial approved cost of the facilities totaled $598,900.

On March 17, 2020, the Board of Directors approved additional capital expenditures for two clean rooms and office re-modeling within the Vivarium. The cost of these additions totaled $238,200.

Joint Venture Agreement

On April 3, 2020, the Company entered into a joint venture agreement ("Joint Venture") with Molipharma, S.R.L.("Molipharma") to collaborate in (1) a clinical trial program in oncology development ("Oncology") and (2) a clinical trial program in COVID-19 Vaccine ("COVID-19 Vaccine"). Molipharma was founded in part by one of our directors, Americo Cicchetti. Mr. Cicchetti is also the Chief Executive Officer and Director of Molipharma.

With respect to Oncology, the Company will grant a low single digit royalty to Molipharma for turnover of the marketing of ovarian cancer research in Europe. With respect to COVID-19 Vaccine, economic rights in Europe will transfer to Molipharma, and economic rights in the United States will transfer to the Company. Molipharma agreed to undertake to financially support the research program for COVID-19 and the Company agreed to financially support the research program in oncology. The Joint Venture has a duration of five years, extendable for a further five years, unless notice of non-renewal is sent one year before the expiration date. The parties may withdraw from the Joint Venture only for serious and justified reasons or by mutual consent.

Reverse Stock Split

On June 17, 2020, the Company filed an amendment to the Company's amended and restated certificate of incorporation to effect a reverse split of shares of the Company's common stock, non-voting common stock and convertible preferred stock, each on a 1-for-3.494 basis (Reverse Stock Split). The Reverse Stock Split also applied to any outstanding securities or rights convertible into, or exchangeable or exercisable for, common stock, non-voting common stock or convertible preferred stock. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, non-voting common stock, restricted stock, options to purchase common stock, share data, per share data, convertible preferred stock and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The Reverse Stock Split was effected on June 17, 2020.

F-32


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(unaudited)

 
  March 31,
2020
  December 31,
2019
 

Assets

             

Current Assets:

             

Cash and cash equivalents

  $ 3,042,500   $ 1,929,100  

Inventories

    22,200     22,200  

Prepaid expenses and other current assets

    188,800     89,100  

Total current assets

    3,253,500     2,040,400  

Property and equipment, net

    1,191,100     587,900  

Other assets

    24,400     24,400  

Total Assets

  $ 4,469,000   $ 2,652,700  

Liabilities and Stockholders' Equity:

             

Current Liabilities:

             

Accounts payable

  $ 647,900   $ 452,400  

Accrued expenses and other current liabilities

    238,800     221,300  

Total current liabilities

    886,700     673,700  

Total Liabilities

    886,700     673,700  

Commitments and contingencies (Note 7)

             

Stockholders' Equity:

             

Series A-1 Preferred Stock, $0.0001 par value: 24,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 21,822,301 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

    9,134,700     9,134,700  

Series B Preferred Stock, $0.0001 par value: 16,500,000 and 14,130,435 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 16,391,397 and 9,869,659 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

    2,007,000     1,306,900  

Preferred Stock, $0.0001 par value: 19,500,000 and 21,869,565 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019

         

Common stock: 300,000,000 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 2,863,812 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

         

Additional paid-in capital

    16,720,900     13,965,000  

Accumulated deficit

    (24,280,300 )   (22,427,600 )

Total Stockholders' Equity

    3,582,300     1,979,000  

Total Liabilities and Stockholders' Equity

  $ 4,469,000   $ 2,652,700  

   

See accompanying notes to the condensed consolidated financial statements

F-33


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(unaudited)

 
  Three Months
Ended March 31,
 
 
  2020   2019  

Operating expenses:

             

Research and development

  $ 1,028,100   $ 203,500  

General and administrative

    824,600     183,800  

Total operating expenses

    1,852,700     387,300  

Loss from operations

    (1,852,700 )   (387,300 )

Other expense

             

Interest expense

        (3,600 )

Other expense

        (3,600 )

Loss before income taxes

    (1,852,700 )   (390,900 )

Income taxes

         

Net loss

  $ (1,852,700 ) $ (390,900 )

Net loss per common share, basic and diluted

  $ (0.78 ) $ (0.14 )

Weighted average common shares outstanding, basic and diluted

    2,863,812     2,862,093  

Pro forma net loss per common share, basic and diluted

  $ (0.51 )      

Pro forma weighted-average common shares outstanding, basic and diluted

    3,607,527        

   

See accompanying notes to the condensed consolidated financial statements

F-34


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

(unaudited)

 
  Three months ended March 31, 2020  
 
  Series A-1
Preferred Stock
  Series B
Preferred Stock
  Common Stock    
   
   
 
 
  Number of
Shares
  Amount   Number of
Shares
  Amount   Number of
Shares
  Amount   Additional
Paid-In
Capital
  Accumulated
Deficit
  Total  

Balance at January 1, 2020

    21,822,301   $ 9,134,700     9,869,659   $ 1,306,900     2,863,812   $   $ 13,965,000   $ (22,427,600 ) $ 1,979,000  

Issuance of Series B Preferred Stock

            6,521,738     331,700                     331,700  

Series B Preferred Stock discount amortization

                368,400             (368,400 )        

Warrants underlying Series B Preferred Stock issuance

                            2,668,300         2,668,300  

Stock compensation expense

                            456,000         456,000  

Net loss

                                (1,852,700 )   (1,852,700 )

Balance at March 31, 2020

    21,822,301   $ 9,134,700     16,391,397   $ 2,007,000     2,863,812   $   $ 16,720,900   $ (24,280,300 ) $ 3,582,300  

 

 
  Three months ended March 31, 2019  
 
  Series A-1
Preferred Stock
   
   
   
   
   
 
 
  Common Stock    
   
   
 
 
  Additional
Paid-In
Capital
  Accumulated
Deficit
   
 
 
  Shares   Amount   Shares   Amount   Total  

Balance at January 1, 2019

    20,886,782   $ 8,727,400     2,862,093   $   $ 10,237,600   $ (18,699,700 ) $ 265,300  

Stock compensation expense

                    104,000         104,000  

Net loss

                        (390,900 )   (390,900 )

Balance at March 31, 2019

    20,886,782   $ 8,727,400     2,862,093   $   $ 10,341,600   $ (19,090,600 ) $ (21,600 )

   

See accompanying notes to the condensed consolidated financial statements

F-35


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(unaudited)

 
  Three Months
Ended March 31,
 
 
  2020   2019  

Cash flows from operating activities:

             

Net loss

  $ (1,852,700 ) $ (390,900 )

Adjustments to reconcile net loss to net cash used for operating activities:

             

Depreciation

    33,800     21,800  

Stock compensation expense

    456,000     104,000  

Changes in operating assets and liabilities:

             

Unbilled receivables from granting agency

        (23,600 )

Inventories

        (5,900 )

Prepaid expenses and other current assets

    (99,700 )   54,100  

Accounts payable

    (35,200 )   5,800  

Accrued expenses and other current liabilities

    17,500     6,100  

Interest payable

        3,600  

Deferred rent

        (6,300 )

Net cash used for operating activities

    (1,480,300 )   (231,300 )

Cash flows from investing activities:

             

Purchases of property and equipment

    (406,300 )   (20,000 )

Net cash used for investing activities

    (406,300 )   (20,000 )

Cash flows from financing activities:

             

Proceeds from sale of convertible promissory notes

        150,000  

Proceeds from Series B Preferred Stock issuance

    3,000,000      

Net cash provided by financing activities

    3,000,000     150,000  

Net change in cash and cash equivalents

    1,113,400     (101,300 )

Cash and cash equivalents:

   
 
   
 
 

Beginning of year

    1,929,100     384,300  

End of period

  $ 3,042,500   $ 283,000  

Supplemental disclosures of non-cash investing and financing activities:

             

Accruals for property and equipment

  $ 230,700   $  

Convertible promissory note receivable

        (75,000 )

Convertible promissory notes

        61,000  

Convertible promissory notes derivative liability

        14,000  

Warrants underlying Series B Preferred Stock issuance

    2,668,300      

   

See accompanying notes to the condensed consolidated financial statements

F-36


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. ORGANIZATION

Nature of Business

Kiromic BioPharma, Inc. and Subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the Company Kiromic BioPharma, Inc.

The Company is focused on discovering, developing, and commercializing novel immune-oncology and small molecule therapy applications through its robust product pipeline, which are in the pre initial new drug ("pre-IND") validation stages of the US Food and Drug Administration clinical trial process. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.

The Company's wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business is recently formed and the product was recently developed. This business has not generated any revenues.

Going Concern—These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $1,480,300 for the three months ended March 31, 2020, and an accumulated deficit of $24,280,300 as of March 31, 2020. The Company does not have sufficient cash on hand or available liquidity to meet its obligations through the 12 months following the date the consolidated financial statements are issued. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

To date, the Company has relied on equity and debt financing to fund its operations. The Company's product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the second quarter of 2020 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

F-37


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

1. ORGANIZATION (Continued)

NIH Grant—In August 2018, The National Institute of Health ("NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. Starting in 2020, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.

All intercompany balances were eliminated upon consolidation. Operating results for the three months ended March 31, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020. On December 17, 2019, we completed a 1-for-10 reverse stock split of our outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of our outstanding common stock. As a result of these stock splits, the Company's issued and outstanding common stock decreased from 100,060,000 shares to 2,863,812 shares. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.

Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

F-38


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash and Cash Equivalents—As of March 31, 2020 and December 31, 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Unbilled Receivables from Granting Agency—Unbilled receivables include certain cost reimbursements owed to the Company resulting from a biomedical research grant from the NIH. Direct costs subject to reimbursement are recorded only after actual expenses have been incurred while indirect costs are calculated using the percentage-of-completion accounting method. Unbilled receivables represent qualified cost reimbursements for which reimbursement have not yet been requested from or billed to the NIH due to the timing of the accounting invoicing cycle. The Company estimates the amount of probable credit losses from its existing unbilled receivables in the form of an allowance for doubtful accounts. The Company determines the allowance for doubtful accounts based upon an aging of unbilled receivables, historical experience, and management judgment. Unbilled receivable balances are reviewed individually for collectability. For the three months ended March 31, 2020 and 2019, the Company has not experienced any credit-related losses.

Concentrations of Credit Risk and Other Uncertainties—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company's cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.

The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company's product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company's ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit—In connection with one of the Company's facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company's consolidated balance sheets.

Inventories—Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and

F-39


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of March 31, 2020 and December 31, 2019, no such adjustments have been recorded.

Property and Equipment—Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.

Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description
  Estimated Lives

Laboratory Equipment

  3 - 8

Leasehold Improvements

  1 - 7

Office Furniture, Fixtures, and Equipment

  5

Software

  5

Internal Use Software Development Costs—The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $0 and $20,000 for the three months ended March 31, 2020 and 2019, respectively.

Impairment of Long-Lived Assets—The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company's long-lived assets since inception.

Comprehensive Loss—Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes—The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.

F-40


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.

The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, ("ASC 740") on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2020 and 2019.

Research and Development Expense—The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company's pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.

The Company accrues and expenses costs of services provided by contract research organizations ("CROs") in connection with preclinical studies and contract manufacturing organizations ("CMOs") engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants—During the three months ended March 31, 2020 and 2019, the Company recognized $0 and $101,600, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.

Convertible Promissory Notes Derivative Liability—The Company has recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company's next equity financing ("Next Financing Close"). The embedded derivative liability is initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability is valued using a probability weighted expected return model. See Note 6.

F-41


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Upon repurchase of convertible promissory notes, ASC 470, Debt with conversion and other options, ("ASC 470") requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.

Fair Value Measurements—The carrying value of the Company's cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

    Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

    Level 2—Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.

    Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy levels during the three months ended March 31, 2020 and 2019.

The Company's liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Stock as of March 31, 2020 and December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.

F-42


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:

 
  March 31,
2020
  December 31,
2019
 

Convertible promissory notes

             

Beginning balance

  $   $  

Amounts allocated to the embedded derivative liability at inception (at fair value)

        (21,000 )

Conversions from accounts payable into convertible promissory notes

        134,800  

Proceeds from issuances of convertible promissory notes

        250,000  

Conversions into Series A-1 Stock

        (363,800 )

Ending balance

  $   $  

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:

             

Convertible promissory note embedded derivative liability

             

Beginning balance

  $   $  

Realized and unrealized gains and losses

        2,000  

Fair value of embedded derivative liability at inception

        21,000  

Amounts derecognized upon conversion of the related convertible promissory notes

        (23,000 )

Ending balance

  $   $  

Nonvested Stock Options—Pursuant to the Company's 2017 Stock Incentive Plan (the "Plan"), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options. The vesting conditions include annual, monthly, and fully vested. Annual vesting conditions are for 4 years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation—The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation—Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the "Black-Scholes model"). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company's common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

The board of directors' approach to estimating the fair value of the Company's common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants' Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation.

F-43


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:

Expected Term.    The expected term represents the period that the Company's stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company's common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a future publicly traded company. The Company has consequently used the Staff Accounting Bulletin ("SAB") No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company.

Risk-Free Interest Rate.    The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

Volatility.    The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield.    The expected dividend assumption is based on the Company's current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.

Common Stock Valuations.    The fair value of the common stock underlying the Company's stock-based compensation grants has historically been determined by the Company's board of directors, with input from management and third-party valuations. The Company believes that the board of directors has the relevant experience and expertise to determine the fair value of the Company's common stock. Given the absence of a public trading market of the Company's common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company's common stock at each grant date. These factors include:

    valuations of the common stock performed by third-party specialists;

    the prices, rights, preferences, and privileges of the Company's Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company's common stock;

    lack of marketability of the common stock;

    current business conditions and projections;

    hiring of key personnel and the experience of management;

F-44


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

    the Company's stage of development;

    likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;

    the market performance of comparable publicly traded companies; and

    the US and global capital market conditions.

In valuing the common stock, the board of directors determined the equity value of the Company's business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company's industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company's cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method ("OPM") or probability—weighted expected return model ("PWERM").

The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.

Application of the Company's approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.

F-45


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.

Segment Data—The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Recently Issued Accounting Pronouncements—From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic's effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On June 3, 2020, the FASB changed the effective date of this standard to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

In June 2016, FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

F-46


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

3. NET LOSS PER COMMON SHARE

Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, the common shares underlying the Series B Preferred Stock, convertible promissory notes, and convertible preferred stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:

 
  Three Months
Ended March 31,
 
 
  2020   2019  

Net loss per common share, basic and diluted

             

Net loss

  $ (1,852,700 ) $ (390,900 )

Less: Series B Preferred Stock discount amortization

    (368,400 )    

Net loss attributable to common shareholders, basic and diluted

  $ (2,221,100 ) $ (390,900 )

Weighted average common shares outstanding, basic and diluted

    2,863,812     2,862,093  

Net loss per common share, basic and diluted

  $ (0.78 ) $ (0.14 )

For the three months ended March 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):

 
  March 31,
2020
  March 31,
2019
 

Options to purchase

    404,391     148,489  

Convertible promissory notes

        28,794  

Series A-1 Preferred Stock

    624,594     597,816  

Series B Preferred Stock

    469,136      

Warrants underlying Series B Preferred Stock

    1,399,807      

Total

    2,897,928     775,099  

Pro Forma Net Loss Per Common Share

Upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20,000,000 of net proceeds to the Company, all shares of Series A-1 Preferred Stock and Series B Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion rate. In addition, the warrants to purchase shares of common stock underlying Series B Preferred Stock were not considered in the calculation due to duration of the warrant vesting schedule in relation to Series B Preferred Stock issuance dates. No warrants would be exercisable based on the issuance date of the Series B Preferred Stock. The vesting schedule of the warrants is as follows:

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

F-47


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

3. NET LOSS PER COMMON SHARE (Continued)

    The remainder of the warrants beginning twelve months after the Listing Date.

The pro forma basic and diluted net loss per common share for the three months ended March 31, 2020 has been prepared to give effect to adjustments arising upon the completion of such public offering. The pro forma net loss attributable to common stockholders used in the calculation of pro forma basic and diluted net loss per common share does not include any pro forma adjustments to net loss.

The pro forma basic and diluted weighted-average common shares outstanding used in the calculation of pro forma basic and diluted net loss per common share for the three months ended March 31, 2020 has been prepared to give effect, upon such a public offering, to the automatic conversion of all outstanding shares of Series A-1 Preferred Stock and Series B Preferred Stock into common stock as if the proposed public offering had occurred January 1, 2019 for any shares issued and outstanding on December 31, 2019 and on the date of issuance for any shares issued during the three months ended March 31, 2020.

Pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 
  Three Months
Ended
March 31, 2020
 

Numerator:

       

Net loss

  $ (1,852,700 )

Pro forma net loss—basic and diluted

  $ (1,852,700 )

Denominator:

       

Weighted-average common stock outstanding—basic and diluted

    2,862,973  

Pro forma adjustment to reflect automatic conversion of Series A-1 Preferred Stock to common stock upon the completion of the proposed initial public offering

    611,301  

Pro forma adjustment to reflect automatic conversion of Series B Preferred Stock to common stock upon the completion of the proposed initial public offering

    133,253  

Pro forma weighted-average common stock outstanding—basic and diluted

    3,607,527  

Pro forma net loss per common share—basic and diluted

  $ (0.51 )

F-48


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

4. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2020 and December 31, 2019:

 
  March 31,
2020
  December 31,
2019
 

Equipment

  $ 533,500   $ 488,800  

Leasehold improvements

    307,100     302,700  

Office furniture, fixtures, and equipment

    16,600     16,600  

Software

    141,500     141,500  

Construction in progress

    587,900      

    1,586,600     949,600  

Less: Accumulated depreciation

    (395,500 )   (361,700 )

Total

  $ 1,191,100   $ 587,900  

Depreciation expense was $33,800 and $21,800 for the three months ended March 31, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the consolidated statements of operations.

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at March 31, 2020 and December 31, 2019:

 
  March 31,
2020
  December 31,
2019
 

Accrued consulting and outside services

  $ 221,300   $ 221,300  

Accrued compensation

    8,600      

Accrued other

    8,900      

Total

  $ 238,800   $ 221,300  

6. CONVERTIBLE PROMISSORY NOTES

Starting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturing either on June 1, 2019, January 2, 2020, or June 30, 2020 (the "Maturity Date").

The convertible promissory notes were convertible into shares issued in the Company's Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the "Balance") by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders' option, the Company shall either repay the Balance then outstanding or convert into the Company's common stock at a set conversion price then in effect, as defined in the convertible promissory notes.

F-49


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

6. CONVERTIBLE PROMISSORY NOTES (Continued)

The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the three months ended March 31, 2019. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% in the three months ended March 31, 2019. There have been no convertible promissory note issuances in the three months ended March 31, 2020. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the three months ended March 31, 2020 and 2019:

 
  March 31,
2020
  March 31,
2019
 

Convertible promissory notes- issuances

  $   $ 225,000  

Total issuances and conversions into convertible promissory notes

        225,000  

Embedded derivative liability

             

Initial fair value upon issuance of convertible promissory notes

        14,000  

Change in fair value

         

Embedded derivative liability balance at March 31

  $   $ 14,000  

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See Note 8 for further details. No additional convertible promissory notes were issued for the three months ended March 31, 2020 following the conversion on August 15, 2019.

7. COMMITMENTS AND CONTINGENCIES

Facility Lease Agreements—The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal which occurred in 2019 resulted in an expansion to the lease of approximately 4,100 square feet. The Company may extend this lease for up to two years. The total lease payments per month will be $21,353 beginning January 1, 2020. The Company records rent expense on a straight-line basis over the term of the respective leases.

As of March 31, 2020, future minimum commitments under facility lease agreements were as follows:

 
  Amount  

2020

    192,200  

2021

    85,400  

Total

  $ 277,600  

Rent expense for the facility lease agreements was $60,000 and $37,200 during the three months ended March 31, 2020 and March 31, 2019, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.

F-50


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

7. COMMITMENTS AND CONTINGENCIES (Continued)

License Agreements—The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of March 31, 2020 and December 31, 2019, the Company has not incurred any milestone or royalty liabilities related to these license agreements.

Legal Proceedings—In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company's financial position.

8. STOCKHOLDERS' EQUITY (DEFICIT)

Third Amended and Restated Certificate of Incorporation

On December 16, 2019, the Company amended and restated its certificate of incorporation ("the Charter").

The amendments to the Charter are the following:

    (i)
    Change the name of the Company to "Kiromic BioPharma, Inc.",

    (ii)
    1-for-10 reverse split of the Company's outstanding shares of common stock. Shares of common stock have been retrospectively revised to reflect the reverse split,

    (iii)
    Increase the Company's authorized Preferred Stock to 60,000,000 shares,

    (iv)
    Change the par value of the Preferred Stock, from $0.01 to $0.0001 per share

Following the amendments to the Charter, the Company had 19,500,000 remaining shares of Preferred Stock authorized for issuance. The total authorized 60,000,000 Preferred Stock shares was reduced by 24,000,000 shares designated as Series A-1 Preferred Stock and 16,500,000 shares designated as Series B Preferred Stock as of March 31, 2020.

Following the amendments to the Charter, the Company had 21,869,565 remaining shares of Preferred Stock authorized for issuance. The total authorized 60,000,000 Preferred Stock shares was reduced by 24,000,000 shares designated as Series A-1 Preferred Stock and 14,130,435 shares designated as Series B Preferred Stock as of December 31, 2019.

Common Stock—From inception in December 2012 through May 2016, the Company raised proceeds from capital contributions for common stock at a $0.001 par value, net of redemptions, totaling $6,214,800. When the Company converted from Kiromic, LLC to Kiromic, Inc., the shares converted from two classes to a single class of common stock. At the time of conversion, the par value on the two classes of common stock eliminated, and the par value of common stock transferred entirely into additional paid-in capital. There were no additional raises from common stock that occurred in the three months ended March 31, 2020 or 2019.

F-51


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

8. STOCKHOLDERS' EQUITY (DEFICIT) (Continued)

The Company authorized shares of 300,000,000 as of March 31, 2020 and December 31, 2019, respectively. As of March 31, 2020 and December 31, 2019, the Company issued 2,863,812 shares of common stock.

Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.

The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615.

There were 271,949 shares and 51,892 shares available for issuance as of March 31, 2020 and 2019, respectively (see Note 9).

Series A-1 Preferred Stock—Between June 8, 2018 and August 14, 2018, the Company entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. On December 20, 2018, 2,032,749 shares of Series A-1 Preferred Stock were issued for the $912,800, representing the advances received and accrued interest through September 10, 2018.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the Original Issue Price.

On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock (see above) vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.

With respect rights on liquidation, winding up and dissolution, shares of Series A-1 Preferred Stock rank senior to all shares of common stock.

Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933 resulting in at least $20,000,000 of net proceeds to the Company, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

F-52


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

8. STOCKHOLDERS' EQUITY (DEFICIT) (Continued)

Series B Preferred Stock—On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). See below for further details.

Until the effective date of the Charter, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.

The Series B Preferred Stock conversion price shall initially be equal to the Series B Preferred Stock Original Issue Price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company's ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 shall thereafter be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.

On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated the Charter on December 16, 2019, the special redemption right provision was eliminated.

The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred

F-53


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

8. STOCKHOLDERS' EQUITY (DEFICIT) (Continued)

Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum.

On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the three months ended March 31, 2020 and 2019:

 
  March 31,
2020
  March 31,
2019
 

Series B Preferred Stock

             

Beginning balance

  $ 1,306,900   $  

Series B Preferred Stock proceeds

    3,000,000      

Series B Preferred Stock discount

    (2,668,300 )    

Series B Preferred Stock discount amortization

    368,400      

Ending balance

  $ 2,007,000   $  

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the Original Issue Price.

On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock (see below) vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.

With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.

Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933 resulting in at least $20,000,000 of net proceeds to the Company, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

Conversion of Convertible Promissory Notes—On December 20, 2018, the Company's certificate of incorporation was amended to authorize 24,000,000 shares Series A-1 Preferred Stock. This amendment

F-54


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

8. STOCKHOLDERS' EQUITY (DEFICIT) (Continued)

qualified as the Next Financing Close with respect to the convertible promissory notes. Therefore, the outstanding principal and accrued interest was converted into Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $7,541,600. Per the convertible promissory notes, the conversion price was $0.40. Accordingly, 18,854,033 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.

Warrants Underlying Series B Preferred Stock—In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. The Warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

    30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

    An additional 30% of the warrants beginning nine months after the Listing Date; and

    The remainder of the warrants beginning twelve months after the Listing Date.

As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. As of March 31, 2020, the Company sold an additional 6,521,738 shares of Series B Preferred Stock, which contained 559,969 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $5,533,000 is reflected as additional paid-in capital.

The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the three months ended March 31, 2020 and 2019:

 
  March 31,
2020
  March 31,
2019
 

Risk-free interest rate

  1.54% - 1.88%     %

Expected volatility

  71.95% - 72.71%     %

Expected life (years)

  10.00      

Expected dividend yield

  0%     %

F-55


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

9. STOCK-BASED COMPENSATION

2017 Stock Incentive Plan

In January 2017, the Company's board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 858,615 shares of the Company's common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Stock options granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over an agreed service period.

The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the three months ended March 31:

 
  2020   2019

Risk-free interest rate

  1.59% - 2.92%   2.06% - 2.92%

Expected volatility

  72.29% - 78.16%   74.54% - 78.16%

Expected life (years)

  4.93 - 6.07   4.93 - 6.01

Expected dividend yield

  0%   0%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for Company's common shares, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company's operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company's common shares, among other factors.

The following table summarizes the activity for all stock options outstanding at March 31 under the Plan:

 
  2020   2019  
 
  Shares   Weighted
Average
Exercise
Price
  Shares   Weighted
Average
Exercise
Price
 

Options outstanding at beginning of year

    598,083   $ 11.11     520,517   $ 8.64  

Granted

    17,631     12.02          

Exercised

                 

Cancelled and forfeited

    (30,768 )   11.88          

Balance at March 31

    584,946   $ 11.09     520,517   $ 8.64  

Options exercisable at March 31:

    361,720   $ 7.67     348,882   $ 7.30  

Weighted average grant date fair value for options granted during the year:

        $ 35.62         $  

F-56


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

9. STOCK-BASED COMPENSATION (Continued)

The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2020 and 2019 under the Plan:

 
  Options Outstanding    
   
   
 
 
  Options Exercisable  
 
   
  Weighted
Average
Remaining
Contractual
Life
   
   
 
Three Months
Ended
March 31,
  Options
Outstanding
  Weighted
Average
Exercise
Price
  Aggregate
Intrinsic
Value
  Options
Exercisable
  Weighted
Average
Exercise
Price
  Aggregate
Intrinsic
Value
 
  2019     520,517     8.91   $ 8.64   $ 1,687,000     348,882   $ 7.30   $ 1,599,300  
  2020     584,946     8.02   $ 11.09   $ 18,712,900     361,720   $ 7.67   $ 12,808,800  

Total stock compensation expense recognized for all stock-based compensation awards recognized in the consolidated statements of operations for the three months ended March 31, 2020 and 2019, is as follows:

 
  2020   2019  

Research and development

  $ 425,000   $ 42,000  

General and administrative

    31,000     62,000  

Total

  $ 456,000   $ 104,000  

As of March 31, 2020, total unrecognized stock compensation expense is $2,188,800, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 3.26 years.

10. INCOME TAXES

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities.

11. RELATED PARTY TRANSACTIONS

Through March 31, 2020, the Company maintained two separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSO"), and the Chief Financial Officer and Chief Operating Officer (the "CFO and COO").

Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSO. Pursuant to the amended agreement dated July 20, 2018, the CSO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSO will provide a leadership role for the Company's business development strategies. The consulting fees paid to the CSO totaled $319,300 and $17,800 in the three months ended March 31, 2020 and 2019, respectively.

F-57


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

11. RELATED PARTY TRANSACTIONS (Continued)

Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $30,000 and $0 in the three months ended March 31, 2020 and 2019, respectively.

12. SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the consolidated balance sheet date through June 25, 2020, the date at which the consolidated financial statements were available to be issued, and determined that other than the events mentioned below, no events or transactions occurred that are required to be disclosed.

Joint Venture Agreement

On April 3, 2020, the Company entered into a joint venture agreement ("Joint Venture") with Molipharma, S.R.L.("Molipharma") to collaborate in (1) a clinical trial program in oncology development ("Oncology") and (2) a clinical trial program in COVID-19 Vaccine ("COVID-19 Vaccine"). Molipharma was founded in part by one of our directors, Americo Cicchetti. Mr. Cicchetti is also the Chief Executive Officer and Director of Molipharma. The Company will account for the joint venture under the scope of ASC 323, Investments—Equity Investments and Joint Ventures.

With respect to Oncology, the Company will grant a low single digit royalty to Molipharma for turnover of the marketing of ovarian cancer research in Europe. With respect to COVID-19 Vaccine, economic rights in Europe will transfer to Molipharma, and economic rights in the United States will transfer to the Company. Molipharma agreed to undertake to financially support the research program for COVID-19 and the Company agreed to financially support the research program in oncology. The Joint Venture has a duration of five years, extendable for a further five years, unless notice of non-renewal is sent one year before the expiration date. The parties may withdraw from the Joint Venture only for serious and justified reasons or by mutual consent.

Reverse Stock Split

On June 17, 2020, the Company filed an amendment to the Company's amended and restated certificate of incorporation to effect a reverse split of shares of the Company's common stock, nonvoting common stock and convertible preferred stock, each on a 1-for-3.494 basis (Reverse Stock Split). The Reverse Stock Split also applied to any outstanding securities or rights convertible into, or exchangeable or exercisable for, common stock, non-voting common stock or convertible preferred stock. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, non-voting common stock, restricted stock, options to purchase common stock, share data, per share data, convertible preferred stock and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The Reverse Stock Split was effected on June 17, 2020.

F-58


Table of Contents


Kiromic BioPharma, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

12. SUBSEQUENT EVENTS (Continued)

Warrant Amendment and Exercise

On June 8, 2020 the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700.

Common Stock Issuances

On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company's Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the CFO and COO and the CSO, respectively. The shares were issued in exchange for services rendered and no cash considerations.

2017 Equity Incentive Plan Share Increase

On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.

F-59


Table of Contents

GRAPHIC


Table of Contents

1,923,100 Shares of Common Stock

LOGO

Kiromic BioPharma, Inc.



PROSPECTUS



ThinkEquity
a division of Fordham Financial Management, Inc.

                        , 2020

Through and including                        , 2020 (the 25th day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.


Table of Contents


PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

Item 13.    Other Expenses of Issuance and Distribution

The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of common shares being registered. All amounts, other than the SEC registration fee, Nasdaq Capital Market listing fee and FINRA filing fee, are estimates. We will pay all these expenses.

 
  Amount  

SEC registration fee

  $ 3,245  

FINRA fee

    3,500  

Nasdaq Capital Market listing fee

    55,000  

Accounting fees and expenses

    344,500  

Legal fees and expenses

    255,000  

Transfer agent fees and expenses

    1,000  

Printing and related fees

    244,100  

Miscellaneous fees

    5,655  

Total

  $ 912,000  

Item 14.    Indemnification of Directors and Officers

Section 145 of the General Corporation Law of the State of Delaware provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement in connection with specified actions, suits and proceedings whether civil, criminal, administrative, or investigative, other than a derivative action by or in the right of the corporation, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification extends only to expenses, including attorneys' fees, incurred in connection with the defense or settlement of such action and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation's certificate of incorporation, bylaws, disinterested director vote, stockholder vote, agreement or otherwise.

Our Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws, to be effective upon the closing of this offering, provide for indemnification of directors and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter.

We intend to enter into separate indemnification agreements with our directors and officers. Each indemnification agreement will provide, among other things, for indemnification to the fullest extent permitted by law and our certificate of incorporation and bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our certificate of incorporation and bylaws.

We maintain standard policies of insurance under which coverage is provided (a) to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act, and

II-1


Table of Contents

(b) to us with respect to payments which we may make to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Item 15.    Recent Sales of Unregistered Securities

During the past three years, we issued the following securities, which were not registered under the Securities Act.

Starting in June 2016, we sold convertible promissory notes to certain investors to help finance our operations. The notes were in amounts ranging from $12,500 to $500,000, earning annual interest at 7% and all maturing on June 1, 2019. As of December 31, 2017, the outstanding balance on these notes was $6,106,000. The notes were convertible into shares issued in our next financing (as defined in the notes) by dividing the total amount of convertible promissory notes, plus accrued interest, by the applicable conversion price (defined generally as 80% of the lowest per share selling price in the next financing).

On December 20, 2018, following the issuance of shares of Series A-1 Preferred Stock described below, the outstanding principal and accrued interest was converted into shares of Series A-1 Preferred Stock. At the time of conversion, the outstanding principal and accrued interest of the notes totaled approximately $7,541,600.

Accordingly, the notes were converted into an aggregate of 18,854,033 shares of Series A-1 Preferred Stock at a conversion price of $0.40 per share.

Between June 8, 2018 and August 14, 2018, we entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. On December 20, 2018, 2,032,749 shares of Series A-1 Preferred Stock were issued for $912,800, representing the advances received and accrued interest through September 10, 2018.

During 2019, we issued additional convertible promissory notes in the aggregate principal amount of $250,000 to certain investors. The notes accrued interest at a rate of 17% and were to mature on June 1, 2021. These notes were convertible into shares issued in our next financing (as defined in the notes) by dividing the total amount of notes, plus accrued interest, by the applicable conversion price (defined generally as 85% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), each holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. Therefore, on August 15, 2019, these notes were converted into an aggregate of 632,123 shares of Series A-1 Preferred Stock at a conversion price of $0.43 per share.

In addition, during 2019, we settled an outstanding account payable with a vendor in the amount of $134,600 by issuing to that vendor a convertible promissory note for the amount owed. That convertible promissory note accrued interest at a rate of 6% and was to mature on June 30, 2020. This note was convertible into shares issued in our next financing (as defined in the note) by dividing the total amount of the convertible promissory note, plus accrued interest, by the applicable conversion price (defined generally as 90% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), the holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred

II-2


Table of Contents

Stock. Therefore, on August 15, 2019, this note was converted into 303,396 shares of Series A-1 Preferred Stock at a conversion price of $0.45 per share.

On September 7, 2019, we entered into a Series B Preferred Stock purchase agreement with certain investors for the sale of shares of our Series B Preferred Stock at a price of $0.46 per share. On September 13, 2019, we sold an aggregate of 7,608,696 shares for total gross proceeds of approximately $3,500,000. On November 13, 2019, we sold an additional 2,173,913 shares for gross proceeds of $1,000,000. The shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. On December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, we issued 87,050 shares of Series B Preferred Stock to the investors.

On January 24, 2020, we issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, we filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

We also issued each investor a warrant to purchase 0.0859 shares of common stock for each Series B Preferred Share purchased, or warrants for an aggregate of 1,399,921 shares of common stock (the "Pre-Funded Warrants"). The Pre-Funded warrants had an exercise price of $0.003494 per share and expired ten years after the date of issuance. On June 8, 2020 and June 10, 2020, the holders of all the outstanding Pre-Funded Warrants exercised the warrants for cash and received 1,399,921 shares of common stock upon exercise.

On June 19, 2020, we issued an aggregate of 722,000 shares of common stock to out Chief Financial Officer and Chief Scientific Officer for prior services rendered.

No underwriters were involved in these issuances. We believe that each of the above issuances was exempt from registration under the Securities Act in reliance on Regulation S under the Securities Act or pursuant to Section 4(2) of the Securities Act regarding transactions not involving a public offering.

Item 16.    Exhibits.

    (a)
    Exhibits
Exhibit No.   Description
  1.1 *** Form of Underwriting Agreement
        
  3.1 ** Third Amended and Restated Certificate of Incorporation of Kiromic BioPharma, Inc., as amended
        
  3.2 ** Amended and Restated Bylaws of Kiromic BioPharma, Inc.
        
  3.3 * Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation
        
  3.4 * Fourth Amended and Restated Certificate of Incorporation
        
  3.5 * Second Amended and Restated Bylaws of Kiromic BioPharma, Inc.
        
  4.1 *** Form of Representative's Warrant
        
  5.1 *** Opinion of Sheppard Mullin Richter & Hampton, LLP
        
  10.1 ** Series B Preferred Stock Purchase Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc. and certain investors
 
   

II-3


Table of Contents

Exhibit No.   Description
  10.2 ** Investors' Rights Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc. and certain investors
        
  10.3 *† Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Tony Tontat
        
  10.4 ** Voting Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc., certain investors and certain stockholders
        
  10.5 ** Form of Securities Purchase Agreement for Series A-1 Preferred Stock
        
  10.6 ** Convertible Promissory Note issued by Kiromic BioPharma, Inc. to Prevail Partners on May 30, 2019
        
  10.7 ** Form of 17% Convertible Promissory Note issued by Kiromic BioPharma, Inc. to certain investors
        
  10.8 ** Form of 7% Convertible Promissory Note issued by Kiromic BioPharma, Inc. to certain investors
        
  10.9 ** Stockholders' Agreement, dated May 27, 2016, among Kiromic BioPharma, Inc. and certain stockholders
        
  10.10 **# License Agreement, dated December 1, 2016, between Mercer University and Kiromic BioPharma, Inc.
        
  10.11 **# License Agreement, dated September 14, 2018, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma,  Inc.
        
  10.12 **# Amendment to License Agreement, dated October 16, 2019, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc.
        
  10.13 **# License Agreement, effective as of March 25, 2020, by and between Longwood University and Kiromic Biopharma,  Inc.
        
  10.14 **# Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc.
        
  10.15 ** Lease Agreement, dated October 9, 2015, between Timothy L. Sharma d/b/a Cambridge Properties and Kiromic,  Inc.
        
  10.16 ** Second Amendment to Lease Agreement, dated May 6, 2016, between Cambridge Properties and Kiromic,  Inc.
        
  10.17 ** Third Amendment to Lease Agreement, dated November 7, 2018, between Cambridge Properties and Kiromic,  Inc.
        
  10.18 ** Fourth Amendment to Lease Agreement, dated October 8, 2019, between Cambridge Properties and Kiromic,  Inc.
        
  10.19 *† Employment Agreement dated January 1, 2020 between Kiromic BioPharma, Inc and Scott Dahlbeck
        
  10.20 *† Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Gianluca Rotino
        
  10.21 *† Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Maurizio Chiriva Internati
        
  10.22 **† Kiromic, Inc. 2017 Equity Incentive Plan

II-4


Table of Contents

*
Filed herewith

**
Previously Filed

***
To be filed by amendment

Executive Compensation Plan or Agreement

#
Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).
    (b)
    Financial Statement Schedules

All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.

Item 17.    Undertakings

    (a)
    The undersigned registrant hereby undertakes as follows:

    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

II-5


Table of Contents

      (2)
      That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

      (3)
      To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

      (4)
      That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

      (5)
      That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

      (i)
      Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

      (ii)
      Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

      (iii)
      The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and

      (iv)
      Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

    (b)
    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-6


Table of Contents


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on June 26, 2020.

    KIROMIC BIOPHARMA, INC.

 

 

By:

 

/s/ MAURIZIO CHIRIVA INTERNATI

Maurizio Chiriva Internati
Chief Executive Officer


POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints each of Maurizio Chiriva Internati and Tony Tontat as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him and his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement and to file a new registration statement under Rule 461, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE
 
TITLE
 
DATE

 

 

 

 

 

 

 
/s/ MAURIZIO CHIRIVA INTERNATI

Maurizio Chiriva Internati
  Chairman and Chief Executive Officer (principal executive officer)   June 26, 2020

*

Tony Tontat

 

Chief Financial Officer and Director (principal financial and accounting officer)

 

June 26, 2020

*

Gianluca Rotino

 

Director

 

June 26, 2020

/s/ PIETRO BERSANI

Pietro Bersani

 

Director

 

June 26, 2020

*

Americo Cicchetti

 

Director

 

June 26, 2020

II-7


Table of Contents

SIGNATURE
 
TITLE
 
DATE

 

 

 

 

 

 

 
/s/ MICHAEL NAGEL

Michael Nagel
  Director   June 26, 2020

/s/ JERRY SCHNEIDER

Jerry Schneider

 

Director

 

June 26, 2020

*By:

 

/s/ MAURIZIO CHIRIVA INTERNATI

Maurizio Chiriva Internati,
Attorney-In-Fact

 

 

 

 

II-8



EX-3.3 2 a2241635zex-3_3.htm EX-3.3

Exhibit 3.3

 

SECOND CERTIFICATE OF AMENDMENT
TO THE

THIRD AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF

KIROMIC BIOPHARMA, INC.

(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)

 

Kiromic BioPharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows:

 

1.             The Corporation’s original Certificate of incorporation was filed with the Secretary of State of the State of Delaware on May 27, 2015 under the name Kiromic, Inc. An Amended and Restated Certificate of Incorporation was filed on December 20, 2018. A Second Amended and Restated Certificate of Incorporation was filed on September 13, 2019. A third Amended and Restated Certificate of Incorporation was filed on December 16, 2019 (the “Third A&R Certificate of Incorporation”). Certificates of Correction were filed on October 15, 2019, October 18, 2019, October 29, 2019 and October 29, 2019 and a Certificate of Amendment was filed on January 31, 2020. Capitalized terms used herein but not defined have the meanings ascribed to such terms in the Third A&R Certificate of Incorporation.

 

2.             The Board of Directors of the Corporation duly adopted resolutions proposing to amend the Third A&R Certificate of Incorporation of the Corporation (the “Amended Third A&R COI”), declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment is as follows:

 

RESOLVED, that the Third A&R Certificate of Incorporation of the Corporation be amended as follows:

 

Article IV, Section 4.2 of the Third A&R Certificate of Incorporation of the Corporation is amended and restated in its entirety as follows:

 

“4.2 Common Stock. The holders of the Common Stock are entitled to one (1) vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Amended Third A&R COI that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected Preferred Stock are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Amended Third A&R COI or pursuant to the DGCL. Unless required by law, there shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not

 


 

below the number of shares thereof then outstanding) by, in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Third A&R Certificate of Incorporation, the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.

 

Effective as of 6:00 AM Eastern Time on the filing date (the “Effective Time”) of this Amended Third A&R COI, every 3.494 shares of the Corporation’s Common Stock (the “Old Common Stock”) then issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined, converted and changed into one (1) share of Common Stock of the Company (the “New Common Stock”) (such formula herein, the “Determined Ratio” and such action, the “Reverse Stock Split”). No fractional shares shall be issued upon the Reverse Stock Split. If the Reverse Stock Split would result in the issuance of a fraction of a share of Common Stock, the Corporation shall round up to the nearest whole share. Further, every right, option and warrant to acquire shares of Old Common Stock outstanding immediately prior to the Effective Time shall, as of the Effective Time and without any further action, automatically be reclassified into the right to acquire one (1) share of New Common Stock based on the Determined Ratio of shares of Old Common Stock to shares of New Common Stock, but otherwise upon the terms of such right, option or warrant (except that the exercise or purchase price of such right, option or warrant shall be proportionately adjusted). For the avoidance of doubt, the Conversion Price of the Designated Preferred Stock as set forth in the Third A&R Certificate of Incorporation does not give effect to the stock combination provided for in this paragraph and at the effective time of such stock combination, an adjustment to the Conversion Price of the Designated Preferred Stock shall occur pursuant to Section 4.3.8(b) of the Third A&R Certificate of Incorporation.”

 

3.             All other provisions of the Third A&R Certificate of Incorporation shall remain in full force and effect.

 

4.             The foregoing amendment was approved by the holders of the requisite number of shares of the Corporation in accordance with Section 228 of the DGCL.

 

5.             This Amended Third A&R COI, which amends the provisions of the Corporation’s Third A&R Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the DGCL.

 

2


 

IN WITNESS WHEREOF, this Amended Third A&R COI has been executed by a duly authorized officer of the Corporation on this 17th day of June, 2020.

 

 

By:

/s/ Maurizio Chiriva-Internati

 

Name: Maurizio Chiriva-Internati, DBSc, PhDs

 

Title:President and CEO

 

3



EX-3.4 3 a2241635zex-3_4.htm EX-3.4

Exhibit 3.4

 

Execution Version

 

FOURTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF

KIROMIC BIOPHARMA, INC.

 

(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)

 

Kiromic BioPharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows:

 

1.                                      The Corporation’s original Certificate of incorporation was filed with the Secretary of State of the State of Delaware on May 27, 2015 under the name Kiromic, Inc. An Amended and Restated Certificate of Incorporation was filed on December 20, 2018.  A Second Amended and Restated Certificate of Incorporation was filed on September 13, 2019.  A third Amended and Restated Certificate of Incorporation was filed on December 16, 2019. Certificates of Correction were filed on October 15, 2019, October 18, 2019, October 29, 2019 and October 29, 2019 and a Certificate of Amendment was filed on January 31, 2020.

 

2.                                      The Board of Directors of the Corporation duly adopted resolutions proposing to amend and restate the Third Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment and restatement to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

 

RESOLVED, that the Third Amended and Restated Certificate of Incorporation of the Corporation be amended and restated in its entirety to read as follows:

 

ARTICLE I
NAME

 

The name of the Corporation is Kiromic BioPharma, Inc.

 

ARTICLE II
REGISTERED AGENT AND REGISTERED OFFICE

 

The address of the registered office of the Corporation in the State of Delaware is 160 Greentree Drive, Suite 101, in the City of Dover, 19904, County of Kent.  The name of its registered agent at such address is National Registered Agents, Inc.

 

ARTICLE III
BUSINESS PURPOSE

 

The nature of the business or purpose to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the DGCL.

 


 

ARTICLE IV
CAPITAL STOCK

 

4.1                               Authorized Capital Stock.  The aggregate number of shares which the Corporation shall have authority to issue shall consist of 300,000,000 shares of common stock (“Common Stock”), $0.001 par value, and 60,000,000 shares of preferred stock (“Preferred Stock”), $0.0001 par value.

 

4.2                               Common Stock.

 

4.2.1                     General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors of the Corporation (the “Board of Directors”) upon any issuance of the Preferred Stock of any series.

 

4.2.2                     Voting.  The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one vote for each share thereof held by such holder; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation or the General Corporation Law of the State of Delaware. There shall be no cumulative voting.

 

4.2.3                     Amount. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.

 

4.2.4                     Dividends. Dividends may be declared and paid on the Common Stock if, as and when determined by the Board of Directors subject to any preferential dividend or other rights of any then outstanding Preferred Stock and to the requirements of applicable law.

 

4.2.5                     Liquidation. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any then outstanding Preferred Stock.

 

4.3                               Preferred Stock. Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors as hereinafter provided.

 

2


 

Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the DGCL, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL. The powers, preferences and relative, participating, optional and other special rights of each such series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions providing for the issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.

 

Subject to the rights of the holders of any series of Preferred Stock pursuant to the terms of this Certificate of Incorporation or any resolution or resolutions providing for the issuance of such series of stock adopted by the Board of Directors, the number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.

 

ARTICLE V
BYLAWS

 

In furtherance and not in limitation of the powers conferred upon it by the DGCL, and subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the Bylaws of the Corporation. The stockholders may not adopt, amend, alter or repeal the Bylaws of the Corporation, or adopt any provision inconsistent therewith.

 

ARTICLE VI
DIRECTORS

 

6.1                               General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.

 

6.2                               Number of Directors; Election of Directors. Subject to the rights of holders of any series of Preferred Stock to elect directors, the number of directors of the Corporation shall be established from time to time by the Board of Directors. Election of directors need not be by written ballot, except as and to the extent provided in the Bylaws of the Corporation.

 

6.3                               Quorum.  A majority of the directors in office shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors there shall be less than such a

 

3


 

quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.

 

6.4                               Action at Meeting. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Fourth Amended and Restated Certificate of Incorporation.

 

6.5                               Removal. Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed but only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote at an election of directors.

 

6.6                               Vacancies. Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly created directorship in the Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, or by a sole remaining director and shall not be filled by the stockholders, unless the Board of Directors determines by resolution that any such vacancy or newly created directorship shall be filled by the stockholders. A director elected to fill a vacancy shall hold office until such director’s earlier death, resignation or removal.

 

ARTICLE VII
LIABILITY OF DIRECTORS

 

To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.  If the DGCL or any other law of the State of Delaware is amended after approval by the stockholders of this Article VII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.  Any repeal or modification of the foregoing provisions of this Article VII by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

 

ARTICLE VIII
STOCKHOLDERS

 

8.1                               No action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be effected by written consent of stockholders in lieu of a meeting.

 

8.2                               Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of Directors, the chairperson of the Board of Directors, the chief executive officer or the president (in the absence of a chief executive officer) of the Corporation, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to the purpose or purposes stated in the notice of meeting.

 

4


 

8.3                               Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the Bylaws of the Corporation.

 

8.4                               Notwithstanding any other provisions of law, this Fourth Amended and Restated Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article VIII.

 

ARTICLE IX
EXCLUDED OPPORTUNITY

 

The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity.  An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Designated Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons delineated in (i) and (ii) are “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation.  Any repeal or modification of this Article VIII will only be prospective and will not affect the rights under this Article VIII in effect at the time of the alleged occurrence of any action or omission to act giving rise to liability.

 

ARTICLE X
EXCLUSIVE FORUM IN DELAWARE

 

Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware DGCL or this Restated Certificate or the Bylaws or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction, provided, that the provisions in this Article X shall not apply to suits

 

5


 

brought to enforce any liability or duty created by the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, or other federal securities laws for which there is exclusive federal or concurrent federal and state jurisdiction.  To the fullest extent permitted by applicable law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article X. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article X. If any provision or provisions of this Article X shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article X (including, without limitation, each portion of any sentence of this Article X containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

 

ARTICLE XI
INDEMNIFICATION AND ADVANCEMENT OF EXPENSES

 

11.1                        Right to Indemnification of Directors and Officers.  The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any current or former director or officer of the Corporation (an “Indemnified Person”) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that such person, or a person for whom such person is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, limited liability company, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such Indemnified Person in such Proceeding.  Notwithstanding the preceding sentence, except as otherwise provided in Section 10.3, the Corporation shall be required to indemnity an Indemnified Person in connection with a Proceeding (or part thereof) commenced by such Indemnified Person only if the commencement of such Proceeding (or part thereof) by the Indemnified Person was authorized in advance by the Board.

 

11.2                        Prepayment of Expenses of Officers and Directors.  The Corporation shall pay the expenses (including attorneys’ fees) incurred by an Indemnified Person in defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the Indemnified Person to repay all amounts advanced if it should be ultimately determined that the Indemnified Person is not entitled to be indemnified under this Article X or otherwise.

 

6


 

11.3                        Claims by Directors and Officers.  If a claim for indemnification or advancement of expenses under this Article XI is not paid in full within thirty (30) days after a written claim therefor by the Indemnified Person has been received by the Corporation, the Indemnified Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim.  In any such action the Corporation shall have the burden of proving that the Indemnified Person is not entitled to the requested indemnification or advancement of expenses under applicable law.

 

11.4                        Indemnification of Employees and Agents.  The Corporation may indemnity and advance expenses to any person who was or is made or is threatened to be made or is otherwise involved in any Proceeding by reason of the fact that such person, or a person for whom such person is the legal representative, is or was an employee or agent of the Corporation or, while an employee or agent of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, limited liability company, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such person in connection with such Proceeding.  The ultimate determination of entitlement to indemnification of persons who are non-director or officer employees or agents shall be made in such manner as is determined by the Board in its sole indemnify a person in connection with a Proceeding initiated by such person if the Proceeding was not authorized in advance by the Board.

 

11.5                        Advancement of Expenses of Employees and Agents.  The Corporation may pay the expenses (including attorneys’ fees) incurred by an employee or agent in defending any Proceeding in advance of its final disposition on such terms and conditions as may be determined by the Board.

 

11.6                        Non-Exclusivity of Rights.  The rights conferred on any person by this Article X shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of this Restated Certificate, the Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

 

11.7                        Other Indemnification.  The Corporation’s obligation, if any, to indemnify any person who was or is serving at its request as a director, officer or employee of another Corporation, partnership, limited liability company, joint venture, trust, organization or other enterprise shall be reduced by any amount such person may collect as indemnification from such other Corporation, partnership, limited liability company, joint venture, trust, organization or other enterprise.

 

11.8                        Insurance.  The Board may, to the fullest extent permitted by applicable law as it presently exists, or may hereafter be amended from time to time, authorize an appropriate officer or officers to purchase and maintain at the Corporation’s expense insurance: (a) to indemnify the Corporation for any obligation which it incurs as a result of the indemnification of directors, officers and employees under the provisions of this Article XI; and (b) to indemnify or insure directors, officers and employees against liability in instances in which they may not otherwise be indemnified by the Corporation under the provisions of this Article XI.

 

7


 

11.9                        Amendment or Repeal.  Any repeal or modification of the foregoing provisions of this Article XI shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification.  The rights provided hereunder shall inure to the benefit of any Indemnified Person and such person’s heirs, executors and administrators.

 

ARTICLE XII
AMENDMENT

 

Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders, directors or any other persons herein are granted subject to this reservation.

 

*                                         *                                         *

 

3.                                      The foregoing amendment and restatement was approved by the holders of the requisite number of shares of the Corporation in accordance with Section 228 of the DGCL.

 

4.                                      This Fourth Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of the Corporation’s Third Amended and Restated Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the DGCL.

 

IN WITNESS WHEREOF, this Fourth Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this [  ] day of [   ], 2020.

 

 

By:

 

 

Name:

 

Title:

 

8



EX-3.5 4 a2241635zex-3_5.htm EX-3.5

Exhibit 3.5

 

KIROMIC BIOPHARMA, INC.

a Delaware Corporation

(the “Corporation”)

 

BYLAWS

 

As Adopted June [·], 2020

 

ARTICLE I
MEETINGS OF STOCKHOLDERS

 

Section 1.1                                    Place of Meetings.  Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a) of the General Corporation Law of the State of Delaware (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office.

 

Section 1.2                                    Annual Meetings.  The Board of Directors shall designate the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought before the meeting in accordance with Section 1.4 of these bylaws may be transacted.

 

Section 1.3                                    Special Meetings.  Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of Directors, the chairperson of the Board of Directors, the chief executive officer or the president (in the absence of a chief executive officer) of the Corporation, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to the purpose or purposes stated in the notice of meeting. Nothing contained in this paragraph of this Section 2.3 shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board may be held.

 

Section 1.4                                    Notice of Meetings.  Notice of all meetings of stockholders shall be given in writing or by electronic transmission in the manner provided by law (including, without limitation, as set forth in Section 7.1.1 of these Bylaws) stating the date, time and place, if any, of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called.  Unless otherwise required by applicable law or the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), such notice shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting. Notice of any meeting of stockholders shall be deemed given: (a) if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the Corporation’s records; or (b) if electronically transmitted, as provided in Section 7.1.2 of these bylaws. An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or any other agent of the Corporation that the notice has been given by mail or by a form of

 


 

electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

Section 1.5                                    Adjournments.  The chairperson of the meeting shall have the power to adjourn the meeting to another time, date and place (if any).  Any meeting of stockholders may adjourn from time to time, and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communications (if any) by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided, however, that if the adjournment is for more than thirty (30) days, or if a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.  At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting.  To the fullest extent permitted by law, the Board may postpone or reschedule any previously scheduled special or annual meeting of stockholders before it is to be held, in which case notice shall be provided to the stockholders of the new date, time and place, if any, of the meeting as provided in Section 1.4 above. For the avoidance of doubt, any previously scheduled annual or special meeting of the stockholders may be postponed or adjourned, and any previously scheduled annual or special meeting of the stockholders may be canceled, by resolution of the Board of Directors.

 

Section 1.6                                    Quorum.  Unless otherwise provided by law, the Certificate of Incorporation or these Bylaws, the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then the chairperson of the meeting present in person, or by remote communication, if applicable, shall have power to adjourn the meeting from time to time in the manner provided in Section 1.5 of these bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.

 

Section 1.7                                    Organization.   The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the person presiding over the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the presiding person of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of disruptive persons from the meeting); (c) limitations on attendance at or participation

 

2


 

in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the presiding person of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.

 

Section 1.8                                    Voting; Proxies.  Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three (3) years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL. A proxy may be in the form of a telegram, cablegram or other means of electronic transmission, as permitted by applicable law, which sets forth or is submitted with information from which it can be determined that the telegram, cablegram or other means of electronic transmission was authorized by the stockholder. Except as may be otherwise provided in the Certificate of Incorporation or these Bylaws, each stockholder shall be entitled to one (1) vote for each share of capital stock held by such stockholder. At all duly called or convened meetings of stockholders, at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. All other elections and questions presented to the stockholders at a duly called or convened meeting, at which a quorum is present, shall, unless a different or minimum vote is required by the certificate of incorporation, these bylaws, the rules or regulations of any stock exchange applicable to the Corporation, or any law or regulation applicable to the Corporation or its securities, in which case such different or minimum vote shall be the applicable vote on the matter, be decided by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon.

 

Section 1.9                                    Stockholder Action by Written Consent Without a Meeting. Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.

 

Section 1.10                             Fixing Date for Determination of Stockholders of Record.  In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, unless otherwise required by law, not be more than sixty

 

3


 

(60) nor less than ten (10) days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.

 

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which shall not be more than sixty (60) days prior to such other action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

Section 1.11                             List of Stockholders Entitled to Vote.  The Corporation shall prepare, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth day before the date of the meeting), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10) days prior to the meeting: (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the Corporation’s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Except as otherwise provided by law, the stock ledger shall be the only evidence as to the identity of the stockholders entitled to vote in person or by proxy and the number of shares held by each of them, and as to the stockholders entitled to examine the list of stockholders.

 

4


 

Section 1.12                             Inspectors of Elections.

 

1.12.1              Appointment.  The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof.  The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act.  If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

 

1.12.2              Inspector’s Oath.  Each inspector of election, before entering upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector’s ability.

 

1.12.3              Duties of Inspectors.  At a meeting of stockholders, the inspectors of election shall (a) ascertain the number of shares outstanding and the voting power of each share, (b) determine the shares represented at a meeting and the validity of proxies and ballots, (c) count all votes and ballots, (d) determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (e) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.

 

1.12.4              Opening and Closing of Polls.  The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced by the chairperson of the meeting at the meeting.  No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery upon application by a stockholder shall determine otherwise.

 

1.12.5              Determinations.  In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in connection with proxies in accordance with any information provided pursuant to Section 211(a)(2)(B)(i) of the DGCL, or Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record.  If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section 1.12 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors’ belief that such information is accurate and reliable.

 

Section 1.13          Advance Notice of Stockholder Proposals and Stockholder Nominations. Nominations of persons for election to the Board of Directors of the Corporation

 

5


 

and the proposal of business to be considered by the stockholders may be made at any meeting of stockholders only (a) pursuant to the Corporation’s notice of meeting, (b) by or at the direction of the Board, or (c) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice provided for in these bylaws, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 1.13. To be timely, a stockholder’s notice shall be delivered to the secretary at the principal executive offices of the Corporation not later than the close of business on the 60th day nor earlier than the close of business on the 90th day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than 30 days or delayed by more than 60 days from such anniversary date or if the Corporation has not previously held an annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 90th day prior to such annual meeting and not later than the close of business on the later of the 60th day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall the public announcement of a postponement or adjournment of an annual meeting to a later date or time commence a new time period for the giving of a stockholder’s notice as described above. Such stockholder’s notice shall set forth (I) as to each person whom the stockholder proposes to nominate for election or reelection as a director (a) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (or any successor thereto) and Rule 14a-11 thereunder (or any successor thereto) (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), (b) the name and address of the stockholder who intends to make the nomination and of the person or persons to be nominated, (c) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting and nominate the person or persons specified in the notice; (d) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder; and (e) such other information regarding each nominee proposed by such stockholder as would be required to be included in a proxy statement filed pursuant to the proxy rules of the United States Securities and Exchange Commission had the nominee been nominated, or intended to be nominated, by the Board, (II) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (III) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (a) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, and (b) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner. In addition, the stockholder making such proposal shall promptly provide any other information reasonably requested by the Corporation. The Chairman of any such meeting shall direct that any nomination or business not properly brought before the meeting shall not be considered.

 

6


 

ARTICLE II
BOARD OF DIRECTORS

 

Section 2.1                                    Powers. Subject to the provisions of the DGCL and any limitations in the certificate of incorporation, the business and affairs of the Corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board of Directors.

 

Section 2.2                                    Number of Directors.  The authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall consist of at least one (1) member. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires. Directors need not be stockholders of the Corporation.

 

Section 2.3                                    Election; Qualification and Term of Office. Except as provided in Section 2.4 and Section 2.5 of these Bylaws, each director, including, without limitation, a director elected to fill a vacancy, shall hold office until the expiration of the term for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. Directors need not be stockholders unless so required by the Certificate of Incorporation or these Bylaws. The Corporation may also have, at the discretion of the Board, a chairperson of the Board and a vice chairperson of the Board. The Certificate of Incorporation or these Bylaws may prescribe other qualifications for directors.

 

Section 2.4                                    Resignation and Vacancies.  Any director may resign at any time upon notice given in writing or by electronic transmission to the chairperson of the Board of Directors or the Corporation’s chief executive officer, president or secretary. When one or more directors so resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this Section 2.4 in the filling of other vacancies.

 

Unless otherwise provided in the Certificate of Incorporation or these Bylaws, vacancies and newly created directorships resulting from any increase in the authorized number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under these Bylaws in the case of the death, removal or resignation of any director.

 

Section 2.5                                    Removal of Directors. Subject to the rights of the holders of the shares of any series of preferred stock of the Corporation, the Board or any individual director may be removed from office only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon.

 

7


 

Section 2.6                                    Regular Meetings.  Regular meetings of the Board may be held at such places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board.

 

Section 2.7                                    Special Meetings.  Special meetings of the Board may be called by the Chairperson of the Board, the President or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix.  Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the notice is mailed, or at least twenty-four (24) hours before the meeting if such notice is given by telephone, hand delivery, telegram, telex, mailgram, facsimile, electronic mail or other means of electronic transmission.  Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

 

Section 2.8                                    Remote Meetings Permitted  Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.

 

Section 2.9                                    Quorum; Vote Required for Action.  The majority of the directors at any time in office shall constitute a quorum of the Board of Directors for the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board of Directors, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these Bylaws. If a quorum is not present at any meeting of the Board of Directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

 

Section 2.10                             Organization.  Meetings of the Board shall be presided over by the Chairperson of the Board, or in such person’s absence by a chairperson chosen at the meeting.  The Secretary shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

 

Section 2.11                             Written Action by Directors.  Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee, respectively, in the minute books of the Corporation.  Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

8


 

Section 2.12                             Compensation of Directors.  Members of the Board, as such, may receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board.

 

Section 2.13                             Execution of Corporate Contracts and Instruments. The Board of Directors, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

 

ARTICLE III
COMMITTEES

 

Section 3.1                                    Committees.  The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation.  The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.  In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member.  Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to the following matters: (a) approving, adopting, or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or (b) adopting, amending or repealing any bylaw of the Corporation.

 

Section 3.2                                    Committee Rules.  Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business.  In the absence of such rules each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these Bylaws.

 

ARTICLE IV
OFFICERS

 

Section 4.1                                    Generally.  The officers of the Corporation shall consist of a Chief Executive Officer (who may be the Chairperson of the Board or the President), a Secretary and a Treasurer and may consist of such other officers, including a Chief Financial Officer, Chief Medical Officer and one or more Vice Presidents, as may from time to time be appointed by the Board.  All officers shall be elected by the Board; provided, however, that the Board may empower the Chief Executive Officer of the Corporation to appoint any officer other than the Chairperson of the Board, the Chief Executive Officer, the President, the Chief Financial Officer

 

9


 

or the Treasurer.  Each officer shall hold office until such person’s successor is appointed or until such person’s earlier resignation, death or removal.  Any number of offices may be held by the same person.  Any officer may resign at any time upon written notice to the Corporation.  Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board.

 

Section 4.2                                    Chief Executive Officer.  Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are:

 

(a)                                 To act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business and affairs of the Corporation;

 

(b)                                 Subject to Article I, Section 1.6, to preside at all meetings of the stockholders;

 

(c)                                  Subject to Article I, Section 1.3, to call special meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper; and

 

(d)                                 To affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation; to sign certificates for shares of stock of the Corporation; and, subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation.

 

The President shall be the Chief Executive Officer of the Corporation unless the Board shall designate another officer to be the Chief Executive Officer.  If there is no President, and the Board has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board shall be the Chief Executive Officer.

 

Section 4.3                                    Chairperson of the Board.  The Chairperson of the Board shall have the power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe.

 

Section 4.4                                    President.  The President shall be the Chief Executive Officer of the Corporation unless the Board shall have designated another officer as the Chief Executive Officer of the Corporation.  Subject to the provisions of these Bylaws and to the direction of the Board, and subject to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board, and/or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and

 

10


 

have all powers that are commonly incident to the office of President or that are delegated to the President by the Board.

 

Section 4.5                                    Vice President.  Each Vice President shall have all such powers and duties as are commonly incident to the office of Vice President, or that are delegated to him or her by the Board or the Chief Executive Officer.  A Vice President may be designated by the Board to perform the duties and exercise the powers of the Chief Executive Officer in the event of the Chief Executive Officer’s absence or disability.

 

Section 4.6                                    Chief Financial Officer.  The Chief Financial Officer shall be the Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation.  Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer.

 

Section 4.7                                    Treasurer.  The Treasurer shall have custody of all moneys and securities of the Corporation.  The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions.  The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe.

 

Section 4.8                                    Secretary.  The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders the Board.  The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe.

 

Section 4.9                                    Delegation of Authority.  The Board may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.

 

Section 4.10                             Removal.  Any officer of the Corporation shall serve at the pleasure of the Board and may be removed at any time, with or without cause, by the Board; provided that if the Board has empowered the Chief Executive Officer to appoint any Vice Presidents of the Corporation, then such Vice Presidents may be removed by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

 

ARTICLE V
STOCK

 

Section 5.1                                    Certificates.  The shares of capital stock of the Corporation shall be represented by certificates; provided, however, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock may be uncertificated shares.  Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation (or the transfer agent or registrar, as the case may

 

11


 

be).  Notwithstanding the adoption of such resolution by the Board, every holder of stock that is a certificated security shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation.  Any or all of the signatures on the certificate may be a facsimile.  In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue.  If any holder of uncertificated shares elects to receive a certificate, the Corporation (or the transfer agent or registrar, as the case may be) shall, to the extent permitted under applicable law and rules, regulations and listing requirements of any stock exchange or stock market on which the Corporation’s shares are listed or traded, cease to provide annual statements indicating such holder’s holdings of shares in the Corporation.

 

Section 5.2                                    Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates.  Except as provided in this Section 5.2, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation in accordance with applicable law. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.

 

Section 5.3                                    Multiple Classes or Series of Stock. If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to the DGCL or a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.

 

12


 

Section 5.4                                    Other Regulations.  The issue, transfer, conversion and registration of stock certificates and uncertificated securities shall be governed by such other regulations as the Board of Directors may establish.

 

ARTICLE VI
INDEMNIFICATION

 

Section 6.1                                    Indemnification of Officers and Directors.  Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a member of the Board or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the Corporation or a Reincorporated Predecessor as a member of the board of directors, officer or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (for purposes of this Article VI, an “Indemnitee”), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by applicable law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys’ fees, judgments, fines, Employee Retirement Income Security Act of 1974, as amended (“ERISA”) excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith, provided such Indemnitee acted in good faith and in a manner that the Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful.  Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of such Indemnitees’ heirs, executors and administrators.  Notwithstanding the foregoing, the Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is authorized by an agreement approved by the Board.  As used herein, the term the “Reincorporated Predecessor” means a corporation that is merged with and into the Corporation in a statutory merger where (a) the Corporation is the surviving corporation of such merger; (b) the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware.

 

Section 6.2                                    Partial Indemnification.  If an Indemnitee is entitled under any provision of this Article VI to indemnification by the Corporation for some or a portion of the expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under ERISA or amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising ERISA or amounts paid in settlement to which Indemnitee is entitled.

 

13


 

Section 6.3                                    Advance of Expenses.  The Corporation shall pay all expenses (including attorneys’ fees) incurred by such an Indemnitee in defending any such Proceeding as they are incurred in advance of its final disposition; provided, however, that (a) if the DGCL then so requires, the payment of such expenses incurred by such an Indemnitee in advance of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it should be determined ultimately by final judicial decision from which there is no appeal that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise; and (b) the Corporation shall not be required to advance any expenses to a person against whom the Corporation directly brings a claim, in a Proceeding, alleging that such person has breached such person’s duty of loyalty to the Corporation, committed an act or omission not in good faith or that involves intentional misconduct or a knowing violation of law, or derived an improper personal benefit from a transaction.

 

Section 6.4                                    Non-Exclusivity of Rights.  The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaw, agreement, vote or consent of stockholders or disinterested directors, or otherwise.  Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.

 

Section 6.5                                    Indemnification Contracts.  The Board is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification or advancement rights to such person.  Such rights may be greater than those provided in this Article VI.

 

Section 6.6                                    Right of Indemnitee to Bring Suit.  The following shall apply to the extent not in conflict with any indemnification contract provided for in Section 6.5 above.

 

6.6.1                     Right to Bring Suit.  If a claim under Section 6.1 or Section 6.2 of this Article VI is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim.  If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit.  In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in applicable law.

 

14


 

6.6.2                     Effect of Determination.  Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit.

 

6.6.3                     Burden of Proof.  In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI, or otherwise, shall be on the Corporation.

 

Section 6.7                                    Nature of Rights.  The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators.

 

Section 6.8                                    Subsequent Amendment. No amendment, termination or repeal of this Article VI or of the relevant provisions of the DGCL or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to indemnification or advancement of expenses under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.

 

Section 6.9                                    Insurance.  The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.

 

Section 6.10                             Savings Clause. If this Article VI or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article IX that shall not have been invalidated and to the fullest extent permitted by applicable law.

 

15


 

ARTICLE VII
NOTICES

 

Section 7.1                                    Notice.

 

7.1.1                     Form and Delivery.  Except as otherwise specifically required in these Bylaws (including, without limitation, Section 7.1.2 below) or by law, all notices required to be given pursuant to these Bylaws shall be in writing and may, (a) in every instance in connection with any delivery to a member of the Board, be effectively given by hand delivery (including use of a delivery service), by depositing such notice in the mail, postage prepaid, or by sending such notice by prepaid telegram, cablegram, overnight express courier, facsimile, electronic mail or other form of electronic transmission and (b) be effectively be delivered to a stockholder when given by hand delivery, by depositing such notice in the mail, postage prepaid or, if specifically consented to by the stockholder as described in Section 7.1.2 of this Article VII by sending such notice by telegram, cablegram, facsimile, electronic mail or other form of electronic transmission.  Any such notice shall be addressed to the person to whom notice is to be given at such person’s address as it appears on the records of the Corporation.  The notice shall be deemed given (a) in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person, (b) in the case of delivery by mail, upon deposit in the mail, (c) in the case of delivery by overnight express courier, when dispatched, and (d) in the case of delivery via telegram, cablegram, facsimile, electronic mail or other form of electronic transmission, when dispatched.

 

7.1.2                     Electronic Transmission.  Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation, or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given in accordance with Section 232 of the DGCL.  Any such consent shall be revocable by the stockholder by written notice to the Corporation.  Any such consent shall be deemed revoked if (a) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (b) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.  Notice given pursuant to this Section 7.1.2 shall be deemed given: (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of such posting and the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed to the stockholder.

 

7.1.3                     Affidavit of Giving Notice.  An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given in writing or by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

16


 

Section 7.2                                    Waiver of Notice.  Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.  Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.

 

ARTICLE VIII
INTERESTED DIRECTORS

 

Section 8.1                                    Interested Directors.  No contract or transaction between the Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose, if: (a) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (b) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (c) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders.

 

Section 8.2                                    Quorum.  Interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.

 

ARTICLE IX
MISCELLANEOUS

 

Section 9.1                                    Fiscal Year.  The fiscal year of the Corporation shall be determined by resolution of the Board of Directors and may be changed by the Board of Directors.

 

Section 9.2                                    Seal.  The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.

 

Section 9.3                                    Dividends. The Board of Directors, subject to any restrictions contained in either (a) the DGCL or (b) the Certificate of Incorporation, may declare and pay dividends upon

 

17


 

the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the Corporation’s capital stock.

 

The Board of Directors may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.

 

Section 9.4                                    Form of Records.  Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of, diskettes, CDs, or any other information storage device or method, provided that the records so kept can be converted into clearly legible paper form within a reasonable time.  The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL.

 

Section 9.5                                    Reliance upon Books and Records.  A member of the Board, or a member of any committee designated by the Board shall, in the performance of such person’s duties, be fully protected in relying in good faith upon records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

 

Section 9.6                                    Certificate of Incorporation Governs.  In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

 

Section 9.7                                    Severability.  If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.

 

ARTICLE X
TRANSFERS OF CAPITAL STOCK

 

Section 10.1                             Restriction on Transfer. Shares of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the Corporation shall be transferred on the books of the Corporation only by the holder of record thereof or by such holder’s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock transfer stamps.

 

18


 

To the fullest extent permitted by law, no transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred.

 

Section 10.2                             Stock Transfer Agreements.  The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.

 

Section 10.3                             Registered Stockholders. The Corporation, to the fullest extent permitted by law,

 

(a) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;

 

(b) shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and

 

(c) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware

 

Section 10.4                             Waiver of Notice.  Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the certificate of incorporation or these bylaws.

 

ARTICLE XI
AMENDMENT

 

Subject to the limitations set forth in Section 6.8 of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the bylaws of the Corporation.

 

19


 

CERTIFICATION OF BYLAWS OF
KIROMIC BIOPHARMA, INC.

 

a Delaware Corporation

 

I,              , certify that I am Secretary of Kiromic BioPharma, Inc., a Delaware corporation (the “Corporation”), that I am duly authorized to make and deliver this certification, that the attached Bylaws are a true and complete copy of the Bylaws of the Corporation in effect as of the date of this certificate.

 

Dated:         , 2020

 

20



EX-10.3 5 a2241635zex-10_3.htm EX-10.3

Exhibit 10.3

 

Execution

 

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of the Company’s IPO date (the “Effective Date”) by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Mr. Tony Tontat (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”

 

W I T N E S S E T H:

 

WHEREAS, the Company wishes to employ the Executive, and the Executive desires to accept employment with the Company, upon the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 hereof, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

 

1.                                      Employment.  As of the Effective Date, the Company hereby employs the Executive and the Executive hereby accepts employment as the Chief Financial Officer and Chief Operating Officer (“CFO & COO”) of the Company upon the terms and conditions of this Agreement.  The Executive shall report to the Chief Executive Officer (“CEO”) of the Company.

 

2.                                      Duties.

 

(a)                                 The Executive shall faithfully perform all duties of the Company related to the position held by the Executive, including but not limited to all duties set forth in this Agreement and all additional duties that are prescribed from time to time by the Board, the CEO and in all cases such duties shall be consistent with the position of a Chief Financial Officer, Chief of Operations of a publicly traded company having similar characteristics to the Company.  The Executive shall devote substantially all of the Executive’s business time to the performance of the Executive’s duties and responsibilities on behalf of the Company.  Executive, subject to the Executive’s obligations hereunder, shall also be permitted to make personal investments, perform reasonable volunteer services and, with the written prior consent of the Company, serve on outside boards of directors for non-profit or for profit corporations.  The Executive shall comply in all material respects with all applicable written Company policies, standards, rules and regulations (the “Company Policies”) and all government laws, rules and regulations applicable to the Company’s business that are now or

 

1


 

hereafter in effect.  The Executive acknowledges receipt of copies of all written Company Policies that are in effect as of the date of this Agreement.

 

(b)                                 Executive shall work remotely from his residence in Florida and Houston Texas (The company’s headquarters), subject to reasonable business travel.

 

3.                                      Term.  The term of this Agreement shall continue until terminated by either party as set forth in Section 5 of this Agreement (the “Term”).

 

4.                                      Compensation.  During the Term, as compensation for the services rendered by the Executive under this Agreement, the Executive shall be entitled to receive the following (all payments are subject to applicable tax withholdings):

 

(a)                                 Base Salary.  Executive shall be paid a gross base annual salary in the amount of $300,000 (three hundred thousand) which shall be payable in accordance with the then-current payroll schedule of the Company (the “Base Salary”).  The payment to the Executive will be net of the Executive’s personal applicable tax withholdings.  The Executive’s Base Salary will be reviewed periodically and may be increased from time to time by the Company at its discretion.   See Exhibit A for more information.

 

(b)                                 Target Performance Bonus.  Executive shall be eligible to receive a bonus in stock options in accordance with Exhibit A:  “Schedule of Stock Option Vesting” (less applicable tax withholdings) if the IPO is completed in 2020 (the “Target Event”).  Executive will be paid the bonus within thirty (30) days following the occurrence of the Target Event.

 

(c)                                  Annual Performance Bonuses.  Executive shall be eligible to participate in any bonus or similar incentive plan adopted by the Company as approved by the Board of Directors (“Board”) for executives at Executive’s level, based on a target of 40% to 50% of Executive’s Base Salary.  The amount awarded, if any, to the Executive under any bonus or incentive plan shall be in the discretion of the Board or any committee administering such plan.  Executive’s bonus, if any, shall be subject to the terms and conditions of any plan or program adopted or approved by the Board and applicable to executives at Executive’s level.  Any bonus earned hereunder shall be paid no later than 2.5 months after the end of the calendar year in which it is earned.  For calendar year 2020, Executive’s bonus shall be prorated to reflect the portion of such year that Executive was actually retained by the Company (including, without limitation, as a consultant).  Except as provided in Section 5(c)(ii), Executive must be employed as of December 31 of any calendar year to be eligible for a bonus under this Section 4(c).

 

(d)                                 Equity. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company for executives at the Executive’s level.  The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board, and the applicable award agreement.  On or promptly after the Effective Date, the Company will make an initial grant to Executive of 402,000 shares of common stock of the Company, priced at fair market value at the time of grant.  Such grant will be effective when made and shall be subject to terms and conditions to be imposed by the Board under the Company’s plans, programs or applicable award

 


 

agreement, to include, among other things, vesting on a monthly basis over a three (3) year period conditioned upon continued employment with the Company, with 100% of 402,000 share grant vesting as of the effective date of this employment agreement.

 

(e)                                  Benefits. The Executive shall be entitled to receive those benefits provided from time to time to other executive employees of the Company, in accordance with the terms and conditions of the applicable plan documents; provided that the Executive meets the eligibility requirements thereof.  All such benefits are subject to amendment or termination from time to time by the Company without the consent of the Executive or any other employee of the Company.

 

(f)                                   Paid Time Off.  The Executive shall be entitled to four weeks of paid time off (“PTO”) to be taken in accordance with the Company’s standard PTO policies.

 

(g)                                  Business Expenses.  The Company will reimburse Executive for reasonable travel, entertainment, and other expenses incurred by Executive in the furtherance of the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy for senior executives as in effect from time to time. Provided, however, that the Company will make the reimbursement only if the corresponding expense is incurred during the term of this Agreement and the reimbursement is made on or before the last day of the calendar year following the calendar year in which the expense is incurred, the amount of expenses eligible for such reimbursement during a calendar year will not affect the amount of expenses eligible for such reimbursement in another calendar year, and the right to such reimbursement is not subject to liquidation or exchange for another benefit from the Company.

 

(h)                                 Reimbursement of Attorneys’ Fees.  The Company will reimburse Executive for his reasonable attorneys’ fees incurred in connection with this Agreement of amount of Ten Thousand and 00/100 Dollars ($10,000).  Such amount will be paid within thirty (30) days of Executive’ submission of acceptable documentation of such fees, but in no event later than August 31, 2020. Executive shall be solely responsible for all taxes, if any, associated with this reimbursement.

 

5.                                      Termination.  This Agreement and the Executive’s employment by the Company shall or may be terminated, as the case may be, as follows:

 

(a)                                 Termination by the Executive.  The Executive may terminate this Agreement and Executive’s employment by the Company:

 

(i)                                     for “Good Reason” (as defined herein).  For purposes of this Agreement, “Good Reason” shall mean, the existence, without the consent of the Executive, of any of the following events: (A) the Executive’s duties and responsibilities are substantially reduced or diminished; (B) the Executive’s base salary is materially reduced from the level prior to such reduction, except for an across-the-board reduction in base salary for all executive officers, (C) the Company materially breaches its obligations under this Agreement; or (D) the Executive’s place of employment is relocated outside of the Company’s Houston headquarters.  In addition to any requirements set forth above, in order for any of the above events to constitute “Good Reason”, the Executive must (X) inform the Company of the existence of the event within 90 days of the

 


 

initial existence of the event, after which date the Company shall have no less than 30 days to cure the event which otherwise would constitute “Good Reason” hereunder and (Y) the Executive must terminate employment with the Company for such “Good Reason” no later than two years after the initial existence of the event which prompted the Executive’s termination.

 

(ii)                                  Other than for Good Reason 90-120 days after notice to the Company.

 

(b)                                 Termination by the Company.  The Company may terminate this Agreement and the Executive’s employment by the Company upon notice to the Executive (or personal representative):

 

(i)                                     at any time and for any reason;

 

(ii)                                  upon the death of the Executive, in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive’s spouse or beneficiaries which are fully vested as of the date of death;

 

(iii)                               if the Executive is “permanently disabled” (as defined herein), in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive, the Executive’s spouse or beneficiaries which are fully vested as of the date of the termination of this Agreement.  For purposes of this Agreement, the Executive shall be considered “permanently disabled” when a qualified medical doctor mutually acceptable to the Company and the Executive or the Executive’s personal representative shall have certified in writing that:  (A) the Executive is unable, because of a medically determinable physical or mental disability, to perform substantially all of the Executive’s duties, with or without a reasonable accommodation, for more than 180 calendar days measured from the last full day of work; or (B) by reason of mental or physical disability, it is unlikely that the Executive will be able, within 180 calendar days, to resume substantially all business duties and responsibilities in which the Executive was previously engaged and otherwise discharge the Executive’s duties under this Agreement; or

 

(iv)                              “for cause” (as defined herein).  “For cause” shall be determined by the Company and shall mean:

 

A.                             Any material breach of the terms of this Agreement by the Executive or the material and deliberate failure of the Executive to diligently perform the Executive’s duties for the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(A) and a period of ten (10) business days in which to cure such grounds;

 

B.                              The Executive’s unauthorized use of the Company’s tangible or intangible property (excluding incidental use) that results (or would be reasonably likely to result) in material harm to the Company, or Executive’s material breach of the Proprietary Information Agreement (as defined herein) or any other similar written agreement between Executive and the Company regarding confidentiality, intellectual property rights, non-competition or non-solicitation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(B) and a period of ten (10) business days in which to cure such grounds;

 


 

C.                              Any material failure to comply with applicable material Company Policies, government laws, rules and regulations applicable to the Company’s business and/or directives of the Board consistent with Executive’s position; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(C) and a period of ten (10) business days in which to cure such grounds;

 

D.                              The Executive’s use of illegal drugs or any illegal substance, or the Executive’s use of alcohol, in any case,  in any manner that materially interferes with the performance of the Executive’s duties under this Agreement; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(D) and a period of ten (10) business days in which to cure such grounds;

 

E.                               Any action taken by the Executive in bad faith which is materially detrimental to the interest and well-being of the Company, including, without limitation, material harm to its reputation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(E) and a period of ten (10) business days in which to cure such grounds; or

 

F.                                The Executive’s failure to fully disclose any material conflict of interest that the Executive may have with the Company in a transaction between the Company and any third party which is materially detrimental to the interest and well-being of the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(F) and a period of ten (10) business days in which to cure such grounds.

 

(c)                                  Obligations of the Company Upon Termination.

 

(i)                                     Upon the termination of this Agreement: (A) by the Executive pursuant to paragraph 5(a)(ii); or (B) by the Company pursuant to paragraph 5(b)(ii), (iii), or (iv) the Company shall have no further obligations hereunder other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus under Section 4(b), all of which shall be paid on or before the Company’s next regularly scheduled payday unless such amount is not then-calculable, in which case payment shall be made on the first regularly scheduled payday after the amount is calculable (provided that in the case of a termination by the Company pursuant to paragraph 5(b)(ii) or (iii), then (1) Executive (or his estate, as applicable) shall be entitled to receive payment of any bonus earned in the year prior to the year of termination but that is unpaid as of the termination date, to be paid at the same time such bonus would have been paid if no such termination had occurred (the “Earned But Unpaid Bonus”) and (2) All unvested stock options will all vest upon the Termination Date and the time for the Executive to exercise all options granted and vested shall be equal to the term of the option (the “Termination Options”).

 

(ii)                                  Upon termination of this Agreement:  (A) by the Executive pursuant to paragraph 5(a)(i); or (B) by the Company pursuant to paragraph 5(b)(i) and provided that the Executive first executes and does not revoke a release agreement within the time period then-specified by the Company but in any event no later than twenty (20) days after the date of

 


 

termination (the “Release”):  (1) the Company shall pay the Executive an amount equal to twelve (24) months of Executive’s then-current Base Salary (less all applicable tax withholdings) payable in installments during the one year period immediately following the termination date in accordance with the then-current generally applicable payroll schedule of the Company commencing on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked the Release (with the first payment to include a catchup for any amounts that would have been paid had the Release been effective on the termination date); (2) conditioned on Executive’s proper and timely election to continue the Company’s health insurance benefits under COBRA, or under applicable state law, reimbursement of the additional costs incurred by Executive for continuing such benefits at the same level in which Executive participated prior to the date Executive’s employment terminated  for the shorter of (a) twelve (12) months from the date of termination or (b) until the Executive obtains reasonably comparable coverage, with such reimbursements to begin at the same time as severance pay set forth in Section 5(c)(ii)(A); (3) the Earned But Unpaid Bonus (if any), to be paid at the same time such bonus would have been paid if no such termination had occurred; (4) all stock options, restricted stock unit and other stock-based awards granted to Executive that were scheduled to vest during the 12 month period immediately following Executive’s termination of employment shall become immediately vested and exercisable (if applicable) and with respect to restricted stock units and similar awards, including the RSUs described in Section 4(d) herein, shall be settled within 30 days after the termination date; and (5) Executive shall be entitled to receive his annual bonus for the year of termination as determined by the Board, pro-rated based on the number of days that Executive was employed by the Company during the year in which such termination of employment occurred (to be paid at the same time such bonus would have been paid if no such termination had occurred).

 

(d)                                 Resignation as Officer and Director. Upon termination of this Agreement and the Executive’s employment hereunder for any reason by either party, the Executive shall be deemed to have resigned from all offices and positions the Executive may hold with the Company at such time including without limitation Board membership and/or positions as an officer of the Company.

 

6.                                      Proprietary Information Agreement.  The terms of the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement by and between the Company and the Executive, entered into simultaneously herewith (the “Proprietary Information Agreement”) and any other similar agreement regarding confidentiality, intellectual property rights, non-competition or non-solicitation between the Company and the Executive, are hereby incorporated by reference and are a material part of this Agreement.

 

7.                                      Representations and Warranties.

 

(a)                                 The Executive represents and warrants to the Company that the Executive’s performance of this Agreement and as an employee of the Company does not and will not breach any noncompetition agreement or any agreement to keep in confidence proprietary information acquired by the Executive in confidence or in trust prior to the Executive’s employment by the Company.  The Executive represents and warrants to the Company that the Executive has not

 


 

entered into, and agrees not to enter into, any agreement that conflicts with or violates this Agreement.

 

(b)                                 The Executive represents and warrants to the Company that the Executive has not brought and shall not bring with the Executive to the Company, or use in the performance of the Executive’s responsibilities for the Company, any materials or documents of a former employer which are not generally available to the public or which did not belong to the Executive prior to the Executive’s employment with the Company, unless the Executive has obtained written authorization from the former employer or other owner for their possession and use and provided the Company with a copy thereof.

 

8.                                      Indemnification.  The Company will indemnify and hold harmless the Executive from any liabilities and expenses arising from Executive’s actions as an officer, director or employee of the Company to the fullest extent permitted by law, excepting any unauthorized acts or illegal conduct which breaches the terms of this or any other agreement or Company policy, including but not limited to the Proprietary Information Agreement.  Executive will be entitled to indemnification under the Company’s Directors and Officers insurance policy during his employment with the Company and for the six (6) year period thereafter on terms no less favorable than any other officer of the Company.

 

9.                                            Notices.  All notices, requests, consents, approvals, and other communications to, upon, and between the parties shall be in writing and shall be deemed to have been given, delivered, made, and received when:  (a) personally delivered; (b) deposited for next day delivery by Federal Express, or other similar overnight courier services; (c) transmitted via telefacsimile or other similar device to the attention of the Company President with receipt acknowledged; or (d) three days after being sent or mailed by certified mail, postage prepaid and return receipt requested, addressed

 

If to the Company,

 

Kiromic Biopharma, Inc.

7707 Fannin Street, Suite 140

Houston, TX 77054

Attn: CEO

Email: mchiriva@kiromic.com

 

If to Executive:

 

Tony Tontat

3500 Mystic Point Drive

Building 400, Unit 104

Aventura, FL 33180

Email: tontat@post.harvard.edu

 

10.                                     Effect.  This Agreement may be assigned by the Company to its successors in interests.  This Agreement shall be binding on and inure to the respective benefit of the Company and its successors and assigns and the Executive and Executive’s personal representatives.

 


 

11.                                     Entire Agreement.  This Agreement and the Proprietary Information Agreement and any other similar agreement regarding confidentiality, intellectual property rights, non-competition or non-solicitation constitute the entire agreement between the parties with respect to the matters set forth herein and supersede all prior agreements and understandings between the parties with respect to the same.

 

12.                                     Severability.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision.

 

13.                                     Amendment and Waiver.  A waiver of any breach of this Agreement shall not constitute a waiver of any other provision of this Agreement or any subsequent breach of this Agreement. No provision of this Agreement may be amended, modified, deleted, or waived in any manner except by a written agreement executed by the parties.

 

14.                                     Section 409A Matters.  This Agreement is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended and the Treasury Regulations and other applicable guidance thereunder (“Section 409A”).  To the extent that there is any ambiguity as to whether this Agreement (or any of its provisions) contravenes one or more requirements of Section 409A, such provision shall be interpreted and applied in a matter that does not result in a Section 409A violation.  Without limiting the generality of the above:

 

(a)                                 For clarity, the severance benefits specified in this Agreement (the “Severance Benefits”) are only payable upon a “separation from service” as defined in Section 409A.  The Severance Benefits shall be deemed to be series of separate payments, with each installment being treated as a separate payment.  The time and form of payment of any compensation may not be deferred or accelerated to the extent it would result in an impermissible acceleration or deferral under Section 409A.

 

(b)                                 To the extent this Agreement contains payments which are subject to Section 409A (as opposed to exempt from Section 409A), the Executive’s rights to such payments are not subject to anticipation, alienation, sale, transfer, pledge, encumbrance, attachment or garnishment and, where applicable, may only be transferred by will or the laws of descent and distribution.

 

(c)                                  To the extent the Severance Benefits are intended to be exempt from Section 409A as a result of an “involuntary separation from service” under Section 409A, if all conditions necessary to establish the Executive’s entitlement to such Severance Benefits have been satisfied, all Severance Benefits shall be paid or provided in full no later than December 31st of the first calendar year following the calendar year in which the Executive’s employment terminated unless another time period is applicable.  To the extent required by Section 409A, any portion of the severance benefits payable to Executive under Section 5(c)(ii) that are contingent on the Executive’s execution and non-revocation of the Release and that could be paid in the calendar year in which Executive terminates employment or in the immediately following calendar year, depending on when the Release becomes effective shall be paid on the first payroll date in such immediately following calendar year or such later date required by Section 5(c)(ii) (with all remaining payments of such severance benefits to be paid as if no such delay had occurred).

 


 

(d)                                 If the Executive is a “specified employee” (as defined in Section 409A) on the termination date and a delayed payment is required by Section 409A to avoid a prohibited distribution under Section 409A, then no Severance Benefits that constitute “non-qualified deferred compensation” under Section 409A shall be paid until the earlier of (i) the first day of the 7th month following the date of Employee’s “separation from service” as defined in Section 409A, or (ii) the date of Employee’s death.  Upon the expiration of the applicable deferral period, all payments deferred under this clause shall be paid in a lump sum and any remaining severance benefits shall be paid per the schedule specified in this Agreement.

 

(e)                                  The Company makes no representation that this Agreement will be exempt from or compliant with Section 409A and makes no affirmative undertaking to preclude Section 409A from applying.

 

15.                               Governing Law.  This Agreement shall be construed, interpreted, and governed in accordance with and by Texas law and the applicable provisions of federal law (“Applicable Federal Law”).  Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of Texas, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any Texas conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in Texas have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.

 

16.                               Consent to Jurisdiction and Venue.  Each of the parties agrees that any suit, action, or proceeding arising out of this Agreement may be instituted against it in the state or federal courts located in Texas.  Each of the parties hereby waives any objection that it may have to the venue of any such suit, action, or proceeding, and each of the parties hereby irrevocably consents to the personal jurisdiction of any such court in any such suit, action, or proceeding.

 

17.                               Counterparts.  This Agreement may be executed in more than one counterpart, each of which shall be deemed an original, and all of which shall be deemed a single agreement.

 

18.                               Headings.  The headings herein are for convenience only and shall not affect the interpretation of this Agreement.

 

[The remainder of this page is intentionally left blank.]

 


 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.  The Executive must furnish all legal proofs of eligibility to work in the Company.

 

 

 

ACCEPTED AND AGREED TO:

 

 

KIROMIC BIOPHARMA INC.

 

 

 

 

 

 

/s/ Tony Tontat

 

By:

/s/ Maurizio Chiriva-Internati

(Signature)

 

 

Name: Maurizio Chiriva-Internati

 

 

 

Title: CEO

 

 

 

Tony Tontat

 

 

 


 

CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND
NON-COMPETITION AGREEMENT

 

In consideration of my employment by Kiromic Biopharma Inc., and its subsidiaries, parents, affiliates, successors and assigns (together, “Kiromic” or the “Company”) and the compensation now and later paid to me, I hereby enter into this Employee Confidential Information, Inventions, Non Solicitation and Non-Competition Agreement (the “Agreement”) and agree as follows:

 

1.      CONFIDENTIAL INFORMATION PROTECTIONS.

 

1.1 Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company’s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon or publish any of Company’s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and/or incorporates any Confidential Information. I hereby assign to Kiromic any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Kiromic and its assigns. I will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

1.2 Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, “Confidential Information” includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, “Inventions”); (b)  information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing  policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of Company, including customer lists, names,

 


 

representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non public information relating to customers and potential customers; (d) information regarding any of Company’s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other non public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding  the foregoing, it is understood that, at all such times, I am free to use information which was known to me prior to employment with Company or which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to “whistleblower” statutes or other similar provisions that protect such disclosure.

 

1.3 Third Party Information. I understand, in addition, that Company has received and in the future will receive from third parties their confidential and/or proprietary knowledge, data or information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my  employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such  information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.

 

1.4 Term of Nondisclosure Restrictions. I understand that Confidential Information and Third Party Information is never to be used or disclosed by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two (2) year period after the date my employment ends will be the temporal limitation relevant to the contested restriction, provided, however, that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.

 

1.5 No Improper Use of Information of Prior Employers and Others. During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of

 

12


 

Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 

2.      ASSIGNMENTS OF INVENTIONS

 

2.1 Definitions. As used in this Agreement, the term “Intellectual Property Rights” means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term “Copyright” means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term “Moral Rights” means all  paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.

 

2.2 Excluded Inventions and Other Inventions. Attached hereto as Exhibit A is a list describing all existing Inventions, if any, that may relate to Company’s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (“Excluded Inventions”). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company’s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, “Other Inventions” means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company  under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non exclusive, perpetual, transferable, fully paid and royalty free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.

 

2.3 Assignment of Company Inventions. Inventions assigned to Kiromic, or to a third party as directed by Kiromic pursuant to Section 2.6, are referred to in this Agreement as “Company Inventions.” Subject to Section 2.4 (Unassigned or Nonassignable Inventions)  and except for Excluded Inventions set forth in Exhibit A and Other Inventions, I hereby assign to Kiromic all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the

 

13


 

period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Kiromic and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company’s customers, with respect to such rights. I further acknowledge and agree that neither my successors in interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).

 

2.4 Unassigned or Nonassignable Inventions. I  recognize that this Agreement will not be deemed to require assignment of any Invention  that I developed entirely on my own time without using Company’s equipment, supplies, facilities, trade secrets or Confidential Information, except for those Inventions that either (i) relate to Company’s actual or anticipated business, research or development, or (ii) result from or are connected with work performed by me for Company. In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to Company under any specifically applicable state law, regulation, rule or public policy (“Specific Inventions Law”).

 

2.5 Obligation to Keep Company Informed. During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I  believe fully qualify for protection under the provisions of any applicable Specific Inventions Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep  in confidence and will not use for any purpose or disclose to third parties without my consent any Confidential Information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully  for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.

 

2.6 Government or Third Party. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.

 

2.7 Ownership of Work Product.

 

(a)    I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).

 

(b)    I agree that Kiromic will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I  hereby irrevocably and unconditionally assign to Kiromic all right, title, and interest

 

14


 

worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.

 

2.8 Enforcement of Intellectual Property Rights and Assistance. I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Kiromic or its designee, including the United States or any third party designated by Kiromic. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company’s request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Kiromic.

 

2.9 Incorporation of Software Code. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with Company’s policies regarding the use of such software.

 

3.      RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all  Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.

 

4.      DUTY OF LOYALTY DURING EMPLOYMENT. I agree that during the period of my employment by Company I will not, without Company’s express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.

 

5.      NO SOLICITATION OF EMPLOYEES, CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR POTENTIAL CUSTOMERS. I agree that during the period of my  employment and for the one (1) year period after the date my employment ends for any

 

15


 

reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any  other capacity, either directly or through others, except on behalf of Company:

 

5.1 solicit, induce, encourage, or participate in soliciting, inducing or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company, even if I did not initiate the discussion or seek out the contact;

 

5.2 solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company to render services to me or any other person or entity that researches, develops, markets, sells, performs or provides or is preparing to develop, market, sell, perform or provide Conflicting Services (as defined in Section 6 below);

 

5.3 hire, employ, or engage in a business venture with as partners or owners or other joint capacity, or attempt to hire, employ, or engage in a business venture as partners or owners or other joint capacity, with any person then employed by Company or who has left the employment of Company within the preceding three (3) months to research, develop, market, sell, perform or provide Conflicting Services;

 

5.4 solicit, induce or attempt to induce any Customer or Potential Customer (as defined below), to terminate, diminish, or materially alter in a manner harmful to Company its relationship with Company;

 

5.5 solicit or assist in the solicitation of any Customer or Potential Customer to induce or attempt to induce such Customer or Potential Customer to purchase or contract for any Conflicting Services; or

 

5.6 perform, provide or attempt to perform or provide any Conflicting Services for a Customer or Potential Customer.

 

The parties agree that for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year period prior to my contact with such person or entity as described in Sections 5.4 5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one (1) year period prior to the date my employment with  Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.

 

6.      NON COMPETE PROVISION. I agree that for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit,

 

16


 

perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory (as defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.

 

The parties agree that for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than Company that directly competes with a product, service, or process, including the research and development thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information during my employment by Company.

 

The parties agree that for purposes of this Agreement, “Restricted Territory” means the one hundred (100) mile radius of any of the following locations: (i) any Company  business location at which I have worked on a regular or occasional basis during the preceding year; (ii) my home if I work from home on a regular or occasional basis; (iii)  any potential business location of Company under active consideration by Company to which I have traveled in connection with the consideration of that location; (iv) the primary business location of a Customer or Potential  Customer; or (v) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom I have been in contact in the preceding year are based.

 

7.      REASONABLENESS OF RESTRICTIONS.

 

7.1 I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company’s legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.

 

7.2 In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.

 

7.3 If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I and Company agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

7.4 Furthermore, the parties agree that the market for Company’s products is the entire United States. If, however, after applying the provisions of subsections 7.2  and 7.3, a court still decides that this Agreement or any of its restrictions is unenforceable for lack of reasonable geographic limitation and the Agreement or restriction(s)  cannot otherwise be enforced, the parties hereby agree that the fifty (50) mile radius from any location at which I  worked for Company on either a regular or occasional basis during the one (1) year immediately preceding termination of my employment with Company shall be the geographic limitation relevant to the contested restriction.

 

8.      NO CONFLICTING AGREEMENT OR OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of Company

 

17


 

does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.

 

9.      RETURN OF COMPANY PROPERTY. When I leave the employ of Company, I will deliver to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or e mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company’s personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company’s termination statement if required to do so by Company.

 

10.    LEGAL AND EQUITABLE REMEDIES.

 

10.1              I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.

 

10.2              I agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will be entitled to payment of all costs, including reasonable attorneys’ fees, from me.

 

10.3              In the event Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.

 

11.    NOTICES. Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, labeled “Attention Chief Executive Officer,” and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.

 

18


 

12.    PUBLICATION OF THIS AGREEMENT TO SUBSEQUENT EMPLOYER OR BUSINESS ASSOCIATES OF EMPLOYEE.

 

12.1              If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the restrictions described in Sections 5 and 6 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and also agree to provide such person or persons with a copy  of this Agreement.

 

12.2              I agree to inform Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and 6 of this Agreement are in effect and I also authorize Company to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations under this Agreement.

 

13.    GENERAL PROVISIONS.

 

13.1              Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the State of Texas as such laws are applied to agreements entered into and to be performed entirely within Houston between Houston residents. I hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in Houston for any lawsuit filed there against me by Company arising from or related to this Agreement.

 

13.2              Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.

 

13.3              Successors and Assigns. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.

 

13.4              Survival. The provisions of this Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.

 

13.5              Employment At Will. I agree and understand that my employment with the company will be executed in accordance with terms of my employment agreement as shown on Exhibit C and Section 02 (“Duties”).

 

13.6              Waiver. No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.

 

19


 

13.7              Export. I agree not to export, re-export, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.

 

13.8              Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.

 

13.9              Entire Agreement. The obligations pursuant  to Sections 1 and 2 (except Subsections 2.4 and 2.7(a)) of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs nondisclosure and assignment of Inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

 

20


 

This Agreement will be effective as of the Company’s IPO Date.

 

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.

 

 

 

ACCEPTED AND AGREED TO:

 

 

KIROMIC BIOPHARMA INC.

 

 

 

/s/ Tony Tontat

 

By:

   /s/ Maurizio Chiriva-Internati

(Signature)

 

 

Name: Maurizio Chiriva-Internati

 

 

 

Title: CEO

 

 

 

 

Tony Tontat

 

 

 

21



EX-10.19 6 a2241635zex-10_19.htm EX-10.19

Exhibit 10.19

 

 

Corporate Address

 

Fannin South Professional

Building, Suite 140

7707 Fannin Street

Houston, Texas 77054

t: 832.968.4888

 

EMPLOYMENT AGREEMENT

 

January 1, 2020

 

Scott Dahlbeck

49 Vineyard Dr, San Antonio, TX 78257

 

Dear Scott:

 

Kiromic, Inc, a Delaware corporation (the “Company”) is pleased to offer you employment with the Company on the following terms:

 

1.                                     Position. Your initial title will be Chief Medical Officer and Head of Clinical Operations is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company or that is in any way competitive with the business or proposed business of the Company, nor will you assist any other person or organization in competing with the Company or in preparing to engage in competition with the business or proposed business of the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the  Company  and that you have  provided  the Company copies of any employment or consulting agreements  with ongoing obligations and that you have read and accept the Kiromic company policies.

 

2.                                    Cash Compensation.

 

Base Salary. The Company will pay you a salary at the rate of $365,000 per year with monthly compensation of $10,000 in cash and $20,416 as a stock option award (the “Option”) at the third party price per share ( as of the most recent board approved 409A valuation) of

 

$0.46/share which is equivalent to 44,382 shares per month. Once adequate funding is obtained, and as per board approval, the salary will convert to full cash compensation. Cash compensation will be payable in accordance with the Company’s standard payroll schedule and subject to withholding as legally required. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. (see page 14.)

 

Stock Compensation: Employee shall receive an option (the “Option”) to purchase up to 500,000 of fully vested stock option shares of the Company’s common stock, par value $0.0001 (the “Shares”), subject to the terms and conditions set forth in this Letter Agreement and to terms and conditions consistent with equity granted under the Company’s Equity Incentive Plan (the “Plan”), as described in the Plan and the applicable equity grant agreement.

 

844.KEY.CURE | www.kiromic.com

 


 

Exercise Price. The Option will be exercisable at a price per Share that is granted in reliance on a third party 409A valuation.

 

(a)          Target Annual Bonus. The Company will implement a Bonus Plan and Compensation Policy, and you will be eligible to participate in such Bonus Plan and Compensation Policy, at the rate of 35% indexed to the achievement of corporate goals and performance objectives to be determined by the Company’s Board of Directors (the “Board”). Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company during that fiscal year. Thereafter, you will be eligible to receive an annual bonus in such amount and upon such terms as shall be determined by the Board. Any bonus for a fiscal year will be paid within 2½ months after the close of that fiscal year, but you will only be eligible for a bonus if you are still employed by the Company at the time of payment. The determinations of the Board with respect to your bonus will be final and binding. Bonuses will be granted on a case- by-case basis, pending completion of specific milestones as determined by the Company.

 

3.                                    Employee Benefits. You will be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time. You have the option to participate in the healthcare insurance plan, including dental and vision offered by Kiromic. Company pays for health insurance premium for employee only. Dental, vision and family health plans are paid for by the employee. Benefits include retirement plan as determined by the Board.

 

4.                                    Confidentiality; Employee Invention Assignment and Confidentiality Agreement.

 

Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Employee Invention Assignment and Confidentiality Agreement. We wish to impress upon you that we do not want you to, and we hereby direct you not to, bring with you any confidential or proprietary material of any former employer or to violate any other obligations you may have to any former employer. You will disclose to the Company in writing any other gainful employment, business or activity that you are currently associated with or participate in that competes with the Company. If the Company learns that you are associated with or participate in a competing business without the Company’s written approval, you may be terminated.

 

5.                                    Employment Relationship. Employment with the Company is on “at will” basis upon terms and conditions of this letter agreement. Any contrary representations that may have been made to you are superseded by this letter agreement, which is the full and complete agreement between you and the Company on this term. As an employee at will, you may be

 

2


 

terminated or may terminate your employment with 12 months’ notice at any time for any reason.

 

6.              Severance. In the event your employment is terminated by the Company without reason, you will be provided with severance of one year’s salary, payable in accordance with the Company’s standard payroll schedule, plus health benefits for one year.

 

7.                                    Tax Matters. As follows:

 

(a)                               Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

 

(b)                                   Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.

 

8.                                    Background Check and Authorization to Work. This offer of employment is contingent on the Company’s completion of a satisfactory background check of you. Please note that because of employer regulations adopted in the Immigration Reform and Control Act of 1986, within three (3) business days of starting your new position you will need to present documentation demonstrating that you have authorization to work in the United States. If you have questions about this requirement, which applies to U.S. citizens and non-U.S. citizens alike, please let us know.

 

9.                                     Interpretation, Amendment, and Enforcement. This letter agreement will be effective as of January 1, 2020. This letter agreement and the Company’s standard Proprietary Information and Inventions Agreement supersede and replace any prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and the Company and constitute the complete agreement between you and the Company regarding the subject matter set forth herein. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.

 

10.                             Arbitration Agreement. Any controversy or claim arising out of or relating to this agreement or breach thereof, shall be settled by binding arbitration controlled by the rules of the American Arbitration Association. The number of arbitrator(s) shall be one. The seat of arbitration shall be Houston, Texas. Texas law shall also apply to the extent necessary to fill any gaps created by the rules of the American Arbitration Association. The arbitration award shall be final and binding on the parties. Judgement of the award rendered by the arbitrator(s) may be entered any court of competent jurisdiction. If any provision of this Arbitration Agreement is held

 

3


 

illegal or unenforceable in a arbitration proceeding, such provision shall be severed and shall be inoperative, and the remainder of this Agreement shall remain operative and binding on the Parties. The arbitrator(s) shall have sole kompetenz-kompetenz regarding this Arbitration Agreement.

 

11.                             Severability. If any provision of this Agreement is held illegal or unenforceable in a judicial proceeding, such provision shall be severed and shall be inoperative, and the remainder of this Agreement shall remain operative and binding on the Parties.

 

12.                             Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together will constitute one and the same agreement.

 

13.                             Entire Agreement. This Agreement, Exhibit A, and the documents referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between the parties hereto with respect to such subject matter.

 

* * * * *

 

[SIGNATURE PAGE TO FOLLOW]

 

4


 

You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.

 

Very truly yours,

KIROMIC, INC:

 

 

 

/s/ Tony Tontat

 

Tony Tontat
CFO/COO

 

 

 

I have read and accept this employment offer.

 

 

 

/s/ Scott Dahlbeck

 

Scott Dahlbeck

 

 

 

 

Date:

01.09.2020

 

 

5



EX-10.20 7 a2241635zex-10_20.htm EX-10.20

Exhibit 10.20

 

Execution

 

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of the Company’s IPO date (the “Effective Date”) by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Mr. Gianluca Rotino (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”

 

W I T N E S S E T H:

 

WHEREAS, the Company wishes to employ the Executive, and the Executive desires to accept employment with the Company, upon the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 hereof, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

 

1.                                      Employment.  As of the Effective Date, the Company hereby employs the Executive and the Executive hereby accepts employment as the Chief Strategy and Innovation Officer (“CSIO”) of the Company upon the terms and conditions of this Agreement.  The Executive shall report to the Chief Executive Officer (“CEO”) of the Company.

 

2.                                      Duties.

 

(a)                                 The Executive shall faithfully perform all duties of the Company related to the position held by the Executive, including but not limited to all duties set forth in this Agreement and all additional duties that are prescribed from time to time by the Board, the CEO and in all cases such duties shall be consistent with the position of a Chief Strategy and Innovation Officer of a publicly traded company having similar characteristics to the Company.  The Executive shall devote substantially all of the Executive’s business time to the performance of the Executive’s duties and responsibilities on behalf of the Company.  Executive, subject to the Executive’s obligations hereunder, shall also be permitted to make personal investments, perform reasonable volunteer services and, with the written prior consent of the Company, serve on outside boards of directors for non-profit or for profit corporations.  The Executive shall comply in all material respects with all applicable written Company policies, standards, rules and regulations (the “Company Policies”) and all government laws, rules and regulations applicable to the Company’s business that are now or

 

1


 

hereafter in effect.  The Executive acknowledges receipt of copies of all written Company Policies that are in effect as of the date of this Agreement.

 

(b)                                 Executive shall work remotely from his residence in Milan, Italy and Houston Texas (The company’s headquarters), subject to reasonable business travel.

 

3.                                      Term.  The term of this Agreement shall continue until terminated by either party as set forth in Section 5 of this Agreement (the “Term”).

 

4.                                      Compensation.  During the Term, as compensation for the services rendered by the Executive under this Agreement, the Executive shall be entitled to receive the following (all payments are subject to applicable tax withholdings):

 

(a)                                 Base Salary.  Executive shall be paid a gross base annual salary in the amount of $300,000 (Exhibit A) which shall be payable in accordance with the then-current payroll schedule of the Company (the “Base Salary”).  The payment to the Executive will be net of the Executive’s personal applicable tax withholdings.  The Executive’s Base Salary will be reviewed periodically and may be increased from time to time by the Company at its discretion.   See Exhibit A for more information.

 

(b)                                 Target Performance Bonus.  Executive shall be eligible to receive a bonus in stock options in accordance with Exhibit A:  “Schedule of Stock Option Vesting” (less applicable tax withholdings) if the IPO is completed in 2020 (the “Target Event”).  Executive will be paid the bonus within thirty (30) days following the occurrence of the Target Event.

 

(c)                                  Annual Performance Bonuses.  Executive shall be eligible to participate in any bonus or similar incentive plan adopted by the Company as approved by the Board of Directors (“Board”) for executives at Executive’s level, based on a target of 40% to 50% of Executive’s Base Salary.  The amount awarded, if any, to the Executive under any bonus or incentive plan shall be in the discretion of the Board or any committee administering such plan.  Executive’s bonus, if any, shall be subject to the terms and conditions of any plan or program adopted or approved by the Board and applicable to executives at Executive’s level.  Any bonus earned hereunder shall be paid no later than 2.5 months after the end of the calendar year in which it is earned.  For calendar year 2020, Executive’s bonus shall be prorated to reflect the portion of such year that Executive was actually retained by the Company (including, without limitation, as a consultant).  Except as provided in Section 5(c)(ii), Executive must be employed as of December 31 of any calendar year to be eligible for a bonus under this Section 4(c).

 

(d)                                 Equity. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company for executives at the Executive’s level.  The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board, and the applicable award agreement.  On or promptly after the Effective Date, the Company will make an initial grant to Executive of 320,000 shares of common stock of the Company, priced at fair market value at the time of grant.  Such grant will be effective when made and shall be subject to terms and conditions to be imposed by the Board under the Company’s plans, programs or applicable award

 


 

agreement, to include, among other things, vesting on a monthly basis over a three (3) year period conditioned upon continued employment with the Company, with 100% of 320,000 share grant vesting as of the effective date of this employment agreement.

 

(e)                                  Benefits. The Executive shall be entitled to receive those benefits provided from time to time to other executive employees of the Company, in accordance with the terms and conditions of the applicable plan documents; provided that the Executive meets the eligibility requirements thereof.  All such benefits are subject to amendment or termination from time to time by the Company without the consent of the Executive or any other employee of the Company.

 

(f)                                   Paid Time Off.  The Executive shall be entitled to four weeks of paid time off (“PTO”) to be taken in accordance with the Company’s standard PTO policies.

 

(g)                                  Business Expenses.  The Company will reimburse Executive for reasonable travel, entertainment, and other expenses incurred by Executive in the furtherance of the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy for senior executives as in effect from time to time. Provided, however, that the Company will make the reimbursement only if the corresponding expense is incurred during the term of this Agreement and the reimbursement is made on or before the last day of the calendar year following the calendar year in which the expense is incurred, the amount of expenses eligible for such reimbursement during a calendar year will not affect the amount of expenses eligible for such reimbursement in another calendar year, and the right to such reimbursement is not subject to liquidation or exchange for another benefit from the Company.

 

(h)                                 Reimbursement of Attorneys’ Fees.  The Company will reimburse Executive for his reasonable attorneys’ fees incurred in connection with this Agreement of amount of Ten Thousand and 00/100 Dollars ($10,000).  Such amount will be paid within thirty (30) days of Executive’ submission of acceptable documentation of such fees, but in no event later than August 31, 2020. Executive shall be solely responsible for all taxes, if any, associated with this reimbursement.

 

5.                                      Termination.  This Agreement and the Executive’s employment by the Company shall or may be terminated, as the case may be, as follows:

 

(a)                                 Termination by the Executive.  The Executive may terminate this Agreement and Executive’s employment by the Company:

 

(i)                                     for “Good Reason” (as defined herein).  For purposes of this Agreement, “Good Reason” shall mean, the existence, without the consent of the Executive, of any of the following events: (A) the Executive’s duties and responsibilities are substantially reduced or diminished; (B) the Executive’s base salary is materially reduced from the level prior to such reduction, except for an across-the-board reduction in base salary for all executive officers, (C) the Company materially breaches its obligations under this Agreement; or (D) the Executive’s place of employment is relocated outside of the Company’s Houston headquarters.  In addition to any requirements set forth above, in order for any of the above events to constitute “Good Reason”, the Executive must (X) inform the Company of the existence of the event within 90 days of the

 


 

initial existence of the event, after which date the Company shall have no less than 30 days to cure the event which otherwise would constitute “Good Reason” hereunder and (Y) the Executive must terminate employment with the Company for such “Good Reason” no later than two years after the initial existence of the event which prompted the Executive’s termination.

 

(ii)                                  Other than for Good Reason 90-120 days after notice to the Company.

 

(b)                                 Termination by the Company.  The Company may terminate this Agreement and the Executive’s employment by the Company upon notice to the Executive (or personal representative):

 

(i)                                     at any time and for any reason;

 

(ii)                                  upon the death of the Executive, in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive’s spouse or beneficiaries which are fully vested as of the date of death;

 

(iii)                               if the Executive is “permanently disabled” (as defined herein), in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive, the Executive’s spouse or beneficiaries which are fully vested as of the date of the termination of this Agreement.  For purposes of this Agreement, the Executive shall be considered “permanently disabled” when a qualified medical doctor mutually acceptable to the Company and the Executive or the Executive’s personal representative shall have certified in writing that:  (A) the Executive is unable, because of a medically determinable physical or mental disability, to perform substantially all of the Executive’s duties, with or without a reasonable accommodation, for more than 180 calendar days measured from the last full day of work; or (B) by reason of mental or physical disability, it is unlikely that the Executive will be able, within 180 calendar days, to resume substantially all business duties and responsibilities in which the Executive was previously engaged and otherwise discharge the Executive’s duties under this Agreement; or

 

(iv)                              “for cause” (as defined herein).  “For cause” shall be determined by the Company and shall mean:

 

A.                             Any material breach of the terms of this Agreement by the Executive or the material and deliberate failure of the Executive to diligently perform the Executive’s duties for the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(A) and a period of ten (10) business days in which to cure such grounds;

 

B.                              The Executive’s unauthorized use of the Company’s tangible or intangible property (excluding incidental use) that results (or would be reasonably likely to result) in material harm to the Company, or Executive’s material breach of the Proprietary Information Agreement (as defined herein) or any other similar written agreement between Executive and the Company regarding confidentiality, intellectual property rights, non-competition or non-solicitation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(B) and a period of ten (10) business days in which to cure such grounds;

 


 

C.                              Any material failure to comply with applicable material Company Policies, government laws, rules and regulations applicable to the Company’s business and/or directives of the Board consistent with Executive’s position; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(C) and a period of ten (10) business days in which to cure such grounds;

 

D.                              The Executive’s use of illegal drugs or any illegal substance, or the Executive’s use of alcohol, in any case,  in any manner that materially interferes with the performance of the Executive’s duties under this Agreement; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(D) and a period of ten (10) business days in which to cure such grounds;

 

E.                               Any action taken by the Executive in bad faith which is materially detrimental to the interest and well-being of the Company, including, without limitation, material harm to its reputation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(E) and a period of ten (10) business days in which to cure such grounds; or

 

F.                                The Executive’s failure to fully disclose any material conflict of interest that the Executive may have with the Company in a transaction between the Company and any third party which is materially detrimental to the interest and well-being of the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(F) and a period of ten (10) business days in which to cure such grounds.

 

(c)                                  Obligations of the Company Upon Termination.

 

(i)                                     Upon the termination of this Agreement: (A) by the Executive pursuant to paragraph 5(a)(ii); or (B) by the Company pursuant to paragraph 5(b)(ii), (iii), or (iv) the Company shall have no further obligations hereunder other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus under Section 4(b), all of which shall be paid on or before the Company’s next regularly scheduled payday unless such amount is not then-calculable, in which case payment shall be made on the first regularly scheduled payday after the amount is calculable (provided that in the case of a termination by the Company pursuant to paragraph 5(b)(ii) or (iii), then (1) Executive (or his estate, as applicable) shall be entitled to receive payment of any bonus earned in the year prior to the year of termination but that is unpaid as of the termination date, to be paid at the same time such bonus would have been paid if no such termination had occurred (the “Earned But Unpaid Bonus”) and (2) All unvested stock options will all vest upon the Termination Date and the time for the Executive to exercise all options granted and vested shall be equal to the term of the option (the “Termination Options”).

 

(ii)                                  Upon termination of this Agreement:  (A) by the Executive pursuant to paragraph 5(a)(i); or (B) by the Company pursuant to paragraph 5(b)(i) and provided that the Executive first executes and does not revoke a release agreement within the time period then-specified by the Company but in any event no later than twenty (20) days after the date of

 


 

termination (the “Release”):  (1) the Company shall pay the Executive an amount equal to twelve (24) months of Executive’s then-current Base Salary (less all applicable tax withholdings) payable in installments during the one year period immediately following the termination date in accordance with the then-current generally applicable payroll schedule of the Company commencing on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked the Release (with the first payment to include a catchup for any amounts that would have been paid had the Release been effective on the termination date); (2) conditioned on Executive’s proper and timely election to continue the Company’s health insurance benefits under COBRA, or under applicable state law, reimbursement of the additional costs incurred by Executive for continuing such benefits at the same level in which Executive participated prior to the date Executive’s employment terminated  for the shorter of (a) twelve (12) months from the date of termination or (b) until the Executive obtains reasonably comparable coverage, with such reimbursements to begin at the same time as severance pay set forth in Section 5(c)(ii)(A); (3) the Earned But Unpaid Bonus (if any), to be paid at the same time such bonus would have been paid if no such termination had occurred; (4) all stock options, restricted stock unit and other stock-based awards granted to Executive that were scheduled to vest during the 12 month period immediately following Executive’s termination of employment shall become immediately vested and exercisable (if applicable) and with respect to restricted stock units and similar awards, including the RSUs described in Section 4(d) herein, shall be settled within 30 days after the termination date; and (5) Executive shall be entitled to receive his annual bonus for the year of termination as determined by the Board, pro-rated based on the number of days that Executive was employed by the Company during the year in which such termination of employment occurred (to be paid at the same time such bonus would have been paid if no such termination had occurred).

 

(d)                                 Resignation as Officer and Director. Upon termination of this Agreement and the Executive’s employment hereunder for any reason by either party, the Executive shall be deemed to have resigned from all offices and positions the Executive may hold with the Company at such time including without limitation Board membership and/or positions as an officer of the Company.

 

6.                                      Proprietary Information Agreement.  The terms of the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement by and between the Company and the Executive, entered into simultaneously herewith (the “Proprietary Information Agreement”) and any other similar agreement regarding confidentiality, intellectual property rights, non-competition or non-solicitation between the Company and the Executive, are hereby incorporated by reference and are a material part of this Agreement.

 

7.                                      Representations and Warranties.

 

(a)                                 The Executive represents and warrants to the Company that the Executive’s performance of this Agreement and as an employee of the Company does not and will not breach any noncompetition agreement or any agreement to keep in confidence proprietary information acquired by the Executive in confidence or in trust prior to the Executive’s employment by the Company.  The Executive represents and warrants to the Company that the Executive has not entered into, and agrees not to enter into, any agreement that conflicts with or violates this

 


 

Agreement.

 

(b)                                 The Executive represents and warrants to the Company that the Executive has not brought and shall not bring with the Executive to the Company, or use in the performance of the Executive’s responsibilities for the Company, any materials or documents of a former employer which are not generally available to the public or which did not belong to the Executive prior to the Executive’s employment with the Company, unless the Executive has obtained written authorization from the former employer or other owner for their possession and use and provided the Company with a copy thereof.

 

8.                                      Indemnification.  The Company will indemnify and hold harmless the Executive from any liabilities and expenses arising from Executive’s actions as an officer, director or employee of the Company to the fullest extent permitted by law, excepting any unauthorized acts or illegal conduct which breaches the terms of this or any other agreement or Company policy, including but not limited to the Proprietary Information Agreement.  Executive will be entitled to indemnification under the Company’s Directors and Officers insurance policy during his employment with the Company and for the six (6) year period thereafter on terms no less favorable than any other officer of the Company.

 

9.                                            Notices.  All notices, requests, consents, approvals, and other communications to, upon, and between the parties shall be in writing and shall be deemed to have been given, delivered, made, and received when:  (a) personally delivered; (b) deposited for next day delivery by Federal Express, or other similar overnight courier services; (c) transmitted via telefacsimile or other similar device to the attention of the Company President with receipt acknowledged; or (d) three days after being sent or mailed by certified mail, postage prepaid and return receipt requested, addressed

 

If to the Company,

 

Kiromic Biopharma, Inc.

7707 Fannin Street, Suite 140

Houston, TX 77054

Attn: CEO

Email: mchiriva@kiromic.com

 

If to Executive:

 

Gianluca Rotino

1234 Street

Milan, Italy 007

Email: gianluca.rotino@gmail.com

 

10.                                     Effect.  This Agreement may be assigned by the Company to its successors in interests.  This Agreement shall be binding on and inure to the respective benefit of the Company and its successors and assigns and the Executive and Executive’s personal representatives.

 

11.                                     Entire Agreement.  This Agreement and the Proprietary Information Agreement and

 


 

any other similar agreement regarding confidentiality, intellectual property rights, non-competition or non-solicitation constitute the entire agreement between the parties with respect to the matters set forth herein and supersede all prior agreements and understandings between the parties with respect to the same.

 

12.                                     Severability.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision.

 

13.                                     Amendment and Waiver.  A waiver of any breach of this Agreement shall not constitute a waiver of any other provision of this Agreement or any subsequent breach of this Agreement. No provision of this Agreement may be amended, modified, deleted, or waived in any manner except by a written agreement executed by the parties.

 

14.                                     Section 409A Matters.  This Agreement is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended and the Treasury Regulations and other applicable guidance thereunder (“Section 409A”).  To the extent that there is any ambiguity as to whether this Agreement (or any of its provisions) contravenes one or more requirements of Section 409A, such provision shall be interpreted and applied in a matter that does not result in a Section 409A violation.  Without limiting the generality of the above:

 

(a)                                 For clarity, the severance benefits specified in this Agreement (the “Severance Benefits”) are only payable upon a “separation from service” as defined in Section 409A.  The Severance Benefits shall be deemed to be series of separate payments, with each installment being treated as a separate payment.  The time and form of payment of any compensation may not be deferred or accelerated to the extent it would result in an impermissible acceleration or deferral under Section 409A.

 

(b)                                 To the extent this Agreement contains payments which are subject to Section 409A (as opposed to exempt from Section 409A), the Executive’s rights to such payments are not subject to anticipation, alienation, sale, transfer, pledge, encumbrance, attachment or garnishment and, where applicable, may only be transferred by will or the laws of descent and distribution.

 

(c)                                  To the extent the Severance Benefits are intended to be exempt from Section 409A as a result of an “involuntary separation from service” under Section 409A, if all conditions necessary to establish the Executive’s entitlement to such Severance Benefits have been satisfied, all Severance Benefits shall be paid or provided in full no later than December 31st of the first calendar year following the calendar year in which the Executive’s employment terminated unless another time period is applicable.  To the extent required by Section 409A, any portion of the severance benefits payable to Executive under Section 5(c)(ii) that are contingent on the Executive’s execution and non-revocation of the Release and that could be paid in the calendar year in which Executive terminates employment or in the immediately following calendar year, depending on when the Release becomes effective shall be paid on the first payroll date in such immediately following calendar year or such later date required by Section 5(c)(ii) (with all remaining payments of such severance benefits to be paid as if no such delay had occurred).

 

(d)                                 If the Executive is a “specified employee” (as defined in Section 409A) on the

 


 

termination date and a delayed payment is required by Section 409A to avoid a prohibited distribution under Section 409A, then no Severance Benefits that constitute “non-qualified deferred compensation” under Section 409A shall be paid until the earlier of (i) the first day of the 7th month following the date of Employee’s “separation from service” as defined in Section 409A, or (ii) the date of Employee’s death.  Upon the expiration of the applicable deferral period, all payments deferred under this clause shall be paid in a lump sum and any remaining severance benefits shall be paid per the schedule specified in this Agreement.

 

(e)                                  The Company makes no representation that this Agreement will be exempt from or compliant with Section 409A and makes no affirmative undertaking to preclude Section 409A from applying.

 

15.                               Governing Law.  This Agreement shall be construed, interpreted, and governed in accordance with and by Texas law and the applicable provisions of federal law (“Applicable Federal Law”).  Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of Texas, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any Texas conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in Texas have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.

 

16.                               Consent to Jurisdiction and Venue.  Each of the parties agrees that any suit, action, or proceeding arising out of this Agreement may be instituted against it in the state or federal courts located in Texas.  Each of the parties hereby waives any objection that it may have to the venue of any such suit, action, or proceeding, and each of the parties hereby irrevocably consents to the personal jurisdiction of any such court in any such suit, action, or proceeding.

 

17.                               Counterparts.  This Agreement may be executed in more than one counterpart, each of which shall be deemed an original, and all of which shall be deemed a single agreement.

 

18.                               Headings.  The headings herein are for convenience only and shall not affect the interpretation of this Agreement.

 

[The remainder of this page is intentionally left blank.]

 


 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.  The Executive must furnish all legal proofs of eligibility to work in the Company.

 

 

 

ACCEPTED AND AGREED TO:

 

 

KIROMIC BIOPHARMA INC.

 

 

 

 

/s/ Gianluca Rotino

 

By:

/s/ Tony Tontat

(Signature)

 

 

Name:

Tony Tontat

 

 

 

Title:

CFO, COO

 

 

 

 

 

 

Gianluca Rotino

 

 

 


 

CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND
NON-COMPETITION AGREEMENT

 

In consideration of my employment by Kiromic Biopharma Inc., and its subsidiaries, parents, affiliates, successors and assigns (together, “Kiromic” or the “Company”) and the compensation now and later paid to me, I hereby enter into this Employee Confidential Information, Inventions, Non Solicitation and Non Competition Agreement (the “Agreement”) and agree as follows:

 

1.      CONFIDENTIAL INFORMATION PROTECTIONS.

 

1.1 Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company’s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon or publish any of Company’s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and/or incorporates any Confidential Information. I hereby assign to Kiromic any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Kiromic and its assigns. I will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

1.2 Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, “Confidential Information” includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, “Inventions”); (b)  information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing  policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of Company, including customer lists, names,

 


 

representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non public information relating to customers and potential customers; (d) information regarding any of Company’s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other non public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding  the foregoing, it is understood that, at all such times, I am free to use information which was known to me prior to employment with Company or which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to “whistleblower” statutes or other similar provisions that protect such disclosure.

 

1.3 Third Party Information. I understand, in addition, that Company has received and in the future will receive from third parties their confidential and/or proprietary knowledge, data or information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my  employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such  information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.

 

1.4 Term of Nondisclosure Restrictions. I understand that Confidential Information and Third Party Information is never to be used or disclosed by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two (2) year period after the date my employment ends will be the temporal limitation relevant to the contested restriction, provided, however, that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.

 

1.5 No Improper Use of Information of Prior Employers and Others. During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of

 

12


 

Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 

2.      ASSIGNMENTS OF INVENTIONS

 

2.1 Definitions. As used in this Agreement, the term “Intellectual Property Rights” means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term “Copyright” means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term “Moral Rights” means all  paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.

 

2.2 Excluded Inventions and Other Inventions. Attached hereto as Exhibit A is a list describing all existing Inventions, if any, that may relate to Company’s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (“Excluded Inventions”). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company’s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, “Other Inventions” means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company  under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non exclusive, perpetual, transferable, fully paid and royalty free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.

 

2.3 Assignment of Company Inventions. Inventions assigned to Kiromic, or to a third party as directed by Kiromic pursuant to Section 2.6, are referred to in this Agreement as “Company Inventions.” Subject to Section 2.4 (Unassigned or Nonassignable Inventions)  and except for Excluded Inventions set forth in Exhibit A and Other Inventions, I hereby assign to Kiromic all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the

 

13


 

period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Kiromic and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company’s customers, with respect to such rights. I further acknowledge and agree that neither my successors in interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).

 

2.4 Unassigned or Nonassignable Inventions. I  recognize that this Agreement will not be deemed to require assignment of any Invention  that I developed entirely on my own time without using Company’s equipment, supplies, facilities, trade secrets or Confidential Information, except for those Inventions that either (i) relate to Company’s actual or anticipated business, research or development, or (ii) result from or are connected with work performed by me for Company. In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to Company under any specifically applicable state law, regulation, rule or public policy (“Specific Inventions Law”).

 

2.5 Obligation to Keep Company Informed. During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I  believe fully qualify for protection under the provisions of any applicable Specific Inventions Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep  in confidence and will not use for any purpose or disclose to third parties without my consent any Confidential Information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully  for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.

 

2.6 Government or Third Party. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.

 

2.7 Ownership of Work Product.

 

(a)    I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).

 

(b)    I agree that Kiromic will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I  hereby irrevocably and unconditionally assign to Kiromic all right, title, and interest

 

14


 

worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.

 

2.8 Enforcement of Intellectual Property Rights and Assistance. I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Kiromic or its designee, including the United States or any third party designated by Kiromic. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company’s request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Kiromic.

 

2.9 Incorporation of Software Code. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with Company’s policies regarding the use of such software.

 

3.      RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all  Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.

 

4.      DUTY OF LOYALTY DURING EMPLOYMENT. I agree that during the period of my employment by Company I will not, without Company’s express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.

 

5.      NO SOLICITATION OF EMPLOYEES, CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR POTENTIAL CUSTOMERS. I agree that during the period of my  employment and for the one (1) year period after the date my employment ends for any

 

15


 

reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any  other capacity, either directly or through others, except on behalf of Company:

 

5.1 solicit, induce, encourage, or participate in soliciting, inducing or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company, even if I did not initiate the discussion or seek out the contact;

 

5.2 solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company to render services to me or any other person or entity that researches, develops, markets, sells, performs or provides or is preparing to develop, market, sell, perform or provide Conflicting Services (as defined in Section 6 below);

 

5.3 hire, employ, or engage in a business venture with as partners or owners or other joint capacity, or attempt to hire, employ, or engage in a business venture as partners or owners or other joint capacity, with any person then employed by Company or who has left the employment of Company within the preceding three (3) months to research, develop, market, sell, perform or provide Conflicting Services;

 

5.4 solicit, induce or attempt to induce any Customer or Potential Customer (as defined below), to terminate, diminish, or materially alter in a manner harmful to Company its relationship with Company;

 

5.5 solicit or assist in the solicitation of any Customer or Potential Customer to induce or attempt to induce such Customer or Potential Customer to purchase or contract for any Conflicting Services; or

 

5.6 perform, provide or attempt to perform or provide any Conflicting Services for a Customer or Potential Customer.

 

The parties agree that for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year period prior to my contact with such person or entity as described in Sections 5.4 5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one (1) year period prior to the date my employment with  Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.

 

6.      NON COMPETE PROVISION. I agree that for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit,

 

16


 

perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory (as defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.

 

The parties agree that for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than Company that directly competes with a product, service, or process, including the research and development thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information during my employment by Company.

 

The parties agree that for purposes of this Agreement, “Restricted Territory” means the one hundred (100) mile radius of any of the following locations: (i) any Company  business location at which I have worked on a regular or occasional basis during the preceding year; (ii) my home if I work from home on a regular or occasional basis; (iii)  any potential business location of Company under active consideration by Company to which I have traveled in connection with the consideration of that location; (iv) the primary business location of a Customer or Potential  Customer; or (v) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom I have been in contact in the preceding year are based.

 

7.      REASONABLENESS OF RESTRICTIONS.

 

7.1 I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company’s legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.

 

7.2 In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.

 

7.3 If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I and Company agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

7.4 Furthermore, the parties agree that the market for Company’s products is the entire United States. If, however, after applying the provisions of subsections 7.2  and 7.3, a court still decides that this Agreement or any of its restrictions is unenforceable for lack of reasonable geographic limitation and the Agreement or restriction(s)  cannot otherwise be enforced, the parties hereby agree that the fifty (50) mile radius from any location at which I  worked for Company on either a regular or occasional basis during the one (1) year immediately preceding termination of my employment with Company shall be the geographic limitation relevant to the contested restriction.

 

8.      NO CONFLICTING AGREEMENT OR OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of Company

 

17


 

does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.

 

9.      RETURN OF COMPANY PROPERTY. When I leave the employ of Company, I will deliver to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or e mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company’s personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company’s termination statement if required to do so by Company.

 

10.    LEGAL AND EQUITABLE REMEDIES.

 

10.1              I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.

 

10.2              I agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will be entitled to payment of all costs, including reasonable attorneys’ fees, from me.

 

10.3              In the event Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.

 

11.    NOTICES. Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, labeled “Attention Chief Executive Officer,” and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.

 

18


 

12.    PUBLICATION OF THIS AGREEMENT TO SUBSEQUENT EMPLOYER OR BUSINESS ASSOCIATES OF EMPLOYEE.

 

12.1              If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the restrictions described in Sections 5 and 6 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and also agree to provide such person or persons with a copy  of this Agreement.

 

12.2              I agree to inform Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and 6 of this Agreement are in effect and I also authorize Company to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations under this Agreement.

 

13.    GENERAL PROVISIONS.

 

13.1              Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the State of Texas as such laws are applied to agreements entered into and to be performed entirely within Houston between Houston residents. I hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in Houston for any lawsuit filed there against me by Company arising from or related to this Agreement.

 

13.2              Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.

 

13.3              Successors and Assigns. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.

 

13.4              Survival. The provisions of this Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.

 

13.5              Employment terms with the company will be in accordance with the attached Exhibits A-F below.

 

13.6              Waiver. No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.

 

13.7              Export. I agree not to export, re-export, or transfer, directly or indirectly,

 

19


 

any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.

 

13.8              Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.

 

13.9              Entire Agreement. The obligations pursuant  to Sections 1 and 2 (except Subsections 2.4 and 2.7(a)) of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs nondisclosure and assignment of Inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

 

20


 

This Agreement will be effective as of the Company’s IPO date.

 

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.

 

 

 

ACCEPTED AND AGREED TO:

 

 

KIROMIC BIOPHARMA INC.

 

 

 

 

/s/ Gianluca Rotino

 

By:

/s/ Tony Tontat

(Signature)

 

Name:

Tony Tontat

 

 

Title:

CFO, COO

 

 

 

 

 

 

Gianluca Rotino

 

 

 

21



EX-10.21 8 a2241635zex-10_21.htm EX-10.21

Exhibit 10.21

 

Execution

 

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of the Company’s IPO date and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Maurizio Chiriva-Internati (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”

 

W I T N E S S E T H:

 

WHEREAS, the Company wishes to employ the Executive, and the Executive desires to accept employment with the Company, upon the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 hereof, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

 

1.             Employment.  As of the Effective Date, the Company hereby employs the Executive and the Executive hereby accepts employment as the Chief Executive Officer (“CEO”) of the Company upon the terms and conditions of this Agreement.  The Executive shall report to the Chairman of the Board of Kiromic.

 

2.             Duties.

 

(a)           The Executive shall faithfully perform all duties of the Company related to the position held by the Executive, including but not limited to all duties set forth in this Agreement and all additional duties that are prescribed from time to time by the Board, the CEO and in all cases such duties shall be consistent with the position of a Chief Executive Officer of a publicly traded company having similar characteristics to the Company.  The Executive shall devote substantially all of the Executive’s business time to the performance of the Executive’s duties and responsibilities on behalf of the Company.  Executive, subject to the Executive’s obligations hereunder, shall also be permitted to make personal investments, perform reasonable volunteer services and, with the written prior consent of the Company, serve on outside boards of directors for non-profit or for profit corporations.  The Executive shall comply in all material respects with all applicable written Company policies, standards, rules and regulations (the “Company Policies”) and all government laws, rules and regulations applicable to the Company’s business that are now or hereafter in effect.  The Executive

 


 

acknowledges receipt of copies of all written Company Policies that are in effect as of the date of this Agreement.

 

(b)           Executive shall work remotely from his residence in Arkansas and Houston Texas (The company’s headquarters), subject to reasonable business travel.

 

3.             Term.  The term of this Agreement shall continue until terminated by either party as set forth in Section 5 of this Agreement (the “Term”).

 

4.             Compensation.  During the Term, as compensation for the services rendered by the Executive under this Agreement, the Executive shall be entitled to receive the following (all payments are subject to applicable tax withholdings):

 

(a)           Base Salary.  Executive shall be paid a gross base annual salary in the amount of $504,000 which shall be payable in accordance with the then-current payroll schedule of the Company (the “Base Salary”).  The payment to the Executive will be net of the Executive’s personal applicable tax withholdings.  The Executive’s Base Salary will be reviewed periodically and may be increased from time to time by the Company at its discretion.   See Exhibit A for more details.

 

(b)           Target Performance Bonus.  Executive shall be eligible to receive a bonus in stock options in accordance with Exhibit A:  “Schedule of Stock Option Vesting” (less applicable tax withholdings) if the IPO is completed in 2020 (the “Target Event”).  Executive will be paid the bonus within thirty (30) days following the occurrence of the Target Event.

 

(c)           Annual Performance Bonuses.  Executive shall be eligible to participate in any bonus or similar incentive plan adopted by the Company as approved by the Board of Directors (“Board”) for executives at Executive’s level, based on a target of 40% to 50% of Executive’s Base Salary.  The amount awarded, if any, to the Executive under any bonus or incentive plan shall be in the discretion of the Board or any committee administering such plan.  Executive’s bonus, if any, shall be subject to the terms and conditions of any plan or program adopted or approved by the Board and applicable to executives at Executive’s level.  Any bonus earned hereunder shall be paid no later than 2.5 months after the end of the calendar year in which it is earned.  For calendar year 2020, Executive’s bonus shall be prorated to reflect the portion of such year that Executive was actually retained by the Company (including, without limitation, as a consultant).  Except as provided in Section 5(c)(ii), Executive must be employed as of December 31 of any calendar year to be eligible for a bonus under this Section 4(c).

 

(d)           Equity. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company for executives at the Executive’s level.  The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board, and the applicable award agreement.  On or promptly after the Effective Date, the Company will make an initial grant to Executive of          options to purchase shares of common stock of the Company, priced at fair market value at the time of grant.  Such grant will be effective when made and shall be subject to terms and conditions to be imposed by the Board under the Company’s plans, programs or applicable award agreement, to include, among other things, vesting on a monthly basis over a three

 


 

(3) year period conditioned upon continued employment with the Company, with 100% of such grant vesting as of the effective date of such grant.

 

(e)           Benefits. The Executive shall be entitled to receive those benefits provided from time to time to other executive employees of the Company, in accordance with the terms and conditions of the applicable plan documents; provided that the Executive meets the eligibility requirements thereof.  All such benefits are subject to amendment or termination from time to time by the Company without the consent of the Executive or any other employee of the Company.

 

(f)            Paid Time Off.  The Executive shall be entitled to four weeks of paid time off (“PTO”) to be taken in accordance with the Company’s standard PTO policies.

 

(g)           Business ExpensesThe Company will reimburse Executive for reasonable travel, entertainment, and other expenses incurred by Executive in the furtherance of the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy for senior executives as in effect from time to time. Provided, however, that the Company will make the reimbursement only if the corresponding expense is incurred during the term of this Agreement and the reimbursement is made on or before the last day of the calendar year following the calendar year in which the expense is incurred, the amount of expenses eligible for such reimbursement during a calendar year will not affect the amount of expenses eligible for such reimbursement in another calendar year, and the right to such reimbursement is not subject to liquidation or exchange for another benefit from the Company.

 

(h)           Reimbursement of Attorneys’ Fees.  The Company will reimburse Executive for his reasonable attorneys’ fees incurred in connection with this Agreement of amount of Ten Thousand and 00/100 Dollars ($10,000).  Such amount will be paid within thirty (30) days of Executive’ submission of acceptable documentation of such fees, but in no event later than August 31, 2020. Executive shall be solely responsible for all taxes, if any, associated with this reimbursement.

 

5.             Termination.  This Agreement and the Executive’s employment by the Company shall or may be terminated, as the case may be, as follows:

 

(a)           Termination by the Executive.  The Executive may terminate this Agreement and Executive’s employment by the Company:

 

(i)            for “Good Reason” (as defined herein).  For purposes of this Agreement, “Good Reason” shall mean, the existence, without the consent of the Executive, of any of the following events: (A) the Executive’s duties and responsibilities are substantially reduced or diminished; (B) the Executive’s base salary is materially reduced from the level prior to such reduction, except for an across-the-board reduction in base salary for all executive officers, (C) the Company materially breaches its obligations under this Agreement; or (D) the Executive’s place of employment is relocated outside of the Company’s Houston headquarters.  In addition to any requirements set forth above, in order for any of the above events to constitute “Good Reason”, the Executive must (X) inform the Company of the existence of the event within 90 days of the initial existence of the event, after which date the Company shall have no less than 30 days to cure

 


 

the event which otherwise would constitute “Good Reason” hereunder and (Y) the Executive must terminate employment with the Company for such “Good Reason” no later than two years after the initial existence of the event which prompted the Executive’s termination.

 

(ii)           Other than for Good Reason 90-120 days after notice to the Company.

 

(b)           Termination by the Company.  The Company may terminate this Agreement and the Executive’s employment by the Company upon notice to the Executive (or personal representative):

 

(i)            at any time and for any reason;

 

(ii)           upon the death of the Executive, in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive’s spouse or beneficiaries which are fully vested as of the date of death;

 

(iii)          if the Executive is “permanently disabled” (as defined herein), in which case this Agreement shall terminate immediately; provided that, such termination shall not prejudice any benefits payable to the Executive, the Executive’s spouse or beneficiaries which are fully vested as of the date of the termination of this Agreement.  For purposes of this Agreement, the Executive shall be considered “permanently disabled” when a qualified medical doctor mutually acceptable to the Company and the Executive or the Executive’s personal representative shall have certified in writing that:  (A) the Executive is unable, because of a medically determinable physical or mental disability, to perform substantially all of the Executive’s duties, with or without a reasonable accommodation, for more than 180 calendar days measured from the last full day of work; or (B) by reason of mental or physical disability, it is unlikely that the Executive will be able, within 180 calendar days, to resume substantially all business duties and responsibilities in which the Executive was previously engaged and otherwise discharge the Executive’s duties under this Agreement; or

 

(iv)          “for cause” (as defined herein).  “For cause” shall be determined by the Company and shall mean:

 

A.          Any material breach of the terms of this Agreement by the Executive or the material and deliberate failure of the Executive to diligently perform the Executive’s duties for the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(A) and a period of ten (10) business days in which to cure such grounds;

 

B.          The Executive’s unauthorized use of the Company’s tangible or intangible property (excluding incidental use) that results (or would be reasonably likely to result) in material harm to the Company, or Executive’s material breach of the Proprietary Information Agreement (as defined herein) or any other similar written agreement between Executive and the Company regarding confidentiality, intellectual property rights, non-competition or non-solicitation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(B) and a period of ten (10) business days in which to cure such grounds;

 


 

C.          Any material failure to comply with applicable material Company Policies, government laws, rules and regulations applicable to the Company’s business and/or directives of the Board consistent with Executive’s position; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(C) and a period of ten (10) business days in which to cure such grounds;

 

D.          The Executive’s use of illegal drugs or any illegal substance, or the Executive’s use of alcohol, in any case,  in any manner that materially interferes with the performance of the Executive’s duties under this Agreement; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(D) and a period of ten (10) business days in which to cure such grounds;

 

E.          Any action taken by the Executive in bad faith which is materially detrimental to the interest and well-being of the Company, including, without limitation, material harm to its reputation; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(E) and a period of ten (10) business days in which to cure such grounds; or

 

F.           The Executive’s failure to fully disclose any material conflict of interest that the Executive may have with the Company in a transaction between the Company and any third party which is materially detrimental to the interest and well-being of the Company; provided, however, that the Company must first provide Executive with written notice of the grounds under this Section 5(b)(iv)(F) and a period of ten (10) business days in which to cure such grounds.

 

(c)           Obligations of the Company Upon Termination.

 

(i)            Upon the termination of this Agreement: (A) by the Executive pursuant to paragraph 5(a)(ii); or (B) by the Company pursuant to paragraph 5(b)(ii), (iii), or (iv) the Company shall have no further obligations hereunder other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus under Section 4(b), all of which shall be paid on or before the Company’s next regularly scheduled payday unless such amount is not then-calculable, in which case payment shall be made on the first regularly scheduled payday after the amount is calculable (provided that in the case of a termination by the Company pursuant to paragraph 5(b)(ii) or (iii), then (1) Executive (or his estate, as applicable) shall be entitled to receive payment of any bonus earned in the year prior to the year of termination but that is unpaid as of the termination date, to be paid at the same time such bonus would have been paid if no such termination had occurred (the “Earned But Unpaid Bonus”) and (2) All unvested stock options will all vest upon the Termination Date and the time for the Executive to exercise all options granted and vested shall be equal to the term of the option (the “Termination Options”).

 

(ii)           Upon termination of this Agreement:  (A) by the Executive pursuant to paragraph 5(a)(i); or (B) by the Company pursuant to paragraph 5(b)(i) and provided that the Executive first executes and does not revoke a release agreement within the time period then-specified by the Company but in any event no later than twenty (20) days after the date of termination (the “Release”):  (1) the Company shall pay the Executive an amount equal to twelve

 


 

(24) months of Executive’s then-current Base Salary (less all applicable tax withholdings) payable in installments during the one year period immediately following the termination date in accordance with the then-current generally applicable payroll schedule of the Company commencing on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked the Release (with the first payment to include a catchup for any amounts that would have been paid had the Release been effective on the termination date); (2) conditioned on Executive’s proper and timely election to continue the Company’s health insurance benefits under COBRA, or under applicable state law, reimbursement of the additional costs incurred by Executive for continuing such benefits at the same level in which Executive participated prior to the date Executive’s employment terminated  for the shorter of (a) twelve (12) months from the date of termination or (b) until the Executive obtains reasonably comparable coverage, with such reimbursements to begin at the same time as severance pay set forth in Section 5(c)(ii)(A); (3) the Earned But Unpaid Bonus (if any), to be paid at the same time such bonus would have been paid if no such termination had occurred; (4) all stock options, restricted stock unit and other stock-based awards granted to Executive that were scheduled to vest during the 12 month period immediately following Executive’s termination of employment shall become immediately vested and exercisable (if applicable) and with respect to restricted stock units and similar awards, including the RSUs described in Section 4(d) herein, shall be settled within 30 days after the termination date; and (5) Executive shall be entitled to receive his annual bonus for the year of termination as determined by the Board, pro-rated based on the number of days that Executive was employed by the Company during the year in which such termination of employment occurred (to be paid at the same time such bonus would have been paid if no such termination had occurred).

 

(d)           Resignation as Officer and Director. Upon termination of this Agreement and the Executive’s employment hereunder for any reason by either party, the Executive shall be deemed to have resigned from all offices and positions the Executive may hold with the Company at such time including without limitation Board membership and/or positions as an officer of the Company.

 

6.             Proprietary Information Agreement.  The terms of the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement by and between the Company and the Executive, entered into simultaneously herewith (the “Proprietary Information Agreement”) and any other similar agreement regarding confidentiality, intellectual property rights, non-competition or non-solicitation between the Company and the Executive, are hereby incorporated by reference and are a material part of this Agreement.

 

7.             Representations and Warranties.

 

(a)           The Executive represents and warrants to the Company that the Executive’s performance of this Agreement and as an employee of the Company does not and will not breach any noncompetition agreement or any agreement to keep in confidence proprietary information acquired by the Executive in confidence or in trust prior to the Executive’s employment by the Company.  The Executive represents and warrants to the Company that the Executive has not entered into, and agrees not to enter into, any agreement that conflicts with or violates this Agreement.

 


 

(b)           The Executive represents and warrants to the Company that the Executive has not brought and shall not bring with the Executive to the Company, or use in the performance of the Executive’s responsibilities for the Company, any materials or documents of a former employer which are not generally available to the public or which did not belong to the Executive prior to the Executive’s employment with the Company, unless the Executive has obtained written authorization from the former employer or other owner for their possession and use and provided the Company with a copy thereof.

 

8.             Indemnification.  The Company will indemnify and hold harmless the Executive from any liabilities and expenses arising from Executive’s actions as an officer, director or employee of the Company to the fullest extent permitted by law, excepting any unauthorized acts or illegal conduct which breaches the terms of this or any other agreement or Company policy, including but not limited to the Proprietary Information Agreement.  Executive will be entitled to indemnification under the Company’s Directors and Officers insurance policy during his employment with the Company and for the six (6) year period thereafter on terms no less favorable than any other officer of the Company.

 

9.               Notices.  All notices, requests, consents, approvals, and other communications to, upon, and between the parties shall be in writing and shall be deemed to have been given, delivered, made, and received when:  (a) personally delivered; (b) deposited for next day delivery by Federal Express, or other similar overnight courier services; (c) transmitted via telefacsimile or other similar device to the attention of the Company President with receipt acknowledged; or (d) three days after being sent or mailed by certified mail, postage prepaid and return receipt requested, addressed

 

If to the Company,

 

Kiromic Biopharma, Inc.

7707 Fannin Street, Suite 140

Houston, TX 77054

Attn: CFO, COO

Email: ttontat@kiromic.com

 

If to Executive:

 

Maurizio Chiriva-Internati

8030 Mason Road

Manvel, Texas 77578

Email: mchiriva@gmail.com

 

10.            Effect.  This Agreement may be assigned by the Company to its successors in interests.  This Agreement shall be binding on and inure to the respective benefit of the Company and its successors and assigns and the Executive and Executive’s personal representatives.

 

11.            Entire Agreement.  This Agreement and the Proprietary Information Agreement and any other similar agreement regarding confidentiality, intellectual property rights, non-competition or

 


 

non-solicitation constitute the entire agreement between the parties with respect to the matters set forth herein and supersede all prior agreements and understandings between the parties with respect to the same.

 

12.            Severability.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision.

 

13.            Amendment and WaiverA waiver of any breach of this Agreement shall not constitute a waiver of any other provision of this Agreement or any subsequent breach of this Agreement. No provision of this Agreement may be amended, modified, deleted, or waived in any manner except by a written agreement executed by the parties.

 

14.            Section 409A Matters.  This Agreement is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended and the Treasury Regulations and other applicable guidance thereunder (“Section 409A”).  To the extent that there is any ambiguity as to whether this Agreement (or any of its provisions) contravenes one or more requirements of Section 409A, such provision shall be interpreted and applied in a matter that does not result in a Section 409A violation.  Without limiting the generality of the above:

 

(a)           For clarity, the severance benefits specified in this Agreement (the “Severance Benefits”) are only payable upon a “separation from service” as defined in Section 409A.  The Severance Benefits shall be deemed to be series of separate payments, with each installment being treated as a separate payment.  The time and form of payment of any compensation may not be deferred or accelerated to the extent it would result in an impermissible acceleration or deferral under Section 409A.

 

(b)           To the extent this Agreement contains payments which are subject to Section 409A (as opposed to exempt from Section 409A), the Executive’s rights to such payments are not subject to anticipation, alienation, sale, transfer, pledge, encumbrance, attachment or garnishment and, where applicable, may only be transferred by will or the laws of descent and distribution.

 

(c)           To the extent the Severance Benefits are intended to be exempt from Section 409A as a result of an “involuntary separation from service” under Section 409A, if all conditions necessary to establish the Executive’s entitlement to such Severance Benefits have been satisfied, all Severance Benefits shall be paid or provided in full no later than December 31st of the first calendar year following the calendar year in which the Executive’s employment terminated unless another time period is applicable.  To the extent required by Section 409A, any portion of the severance benefits payable to Executive under Section 5(c)(ii) that are contingent on the Executive’s execution and non-revocation of the Release and that could be paid in the calendar year in which Executive terminates employment or in the immediately following calendar year, depending on when the Release becomes effective shall be paid on the first payroll date in such immediately following calendar year or such later date required by Section 5(c)(ii) (with all remaining payments of such severance benefits to be paid as if no such delay had occurred).

 

(d)           If the Executive is a “specified employee” (as defined in Section 409A) on the termination date and a delayed payment is required by Section 409A to avoid a prohibited distribution

 


 

under Section 409A, then no Severance Benefits that constitute “non-qualified deferred compensation” under Section 409A shall be paid until the earlier of (i) the first day of the 7th month following the date of Employee’s “separation from service” as defined in Section 409A, or (ii) the date of Employee’s death.  Upon the expiration of the applicable deferral period, all payments deferred under this clause shall be paid in a lump sum and any remaining severance benefits shall be paid per the schedule specified in this Agreement.

 

(e)           The Company makes no representation that this Agreement will be exempt from or compliant with Section 409A and makes no affirmative undertaking to preclude Section 409A from applying.

 

15.          Governing LawThis Agreement shall be construed, interpreted, and governed in accordance with and by Texas law and the applicable provisions of federal law (“Applicable Federal Law”).  Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of Texas, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any Texas conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in Texas have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.

 

16.          Consent to Jurisdiction and Venue.  Each of the parties agrees that any suit, action, or proceeding arising out of this Agreement may be instituted against it in the state or federal courts located in Texas.  Each of the parties hereby waives any objection that it may have to the venue of any such suit, action, or proceeding, and each of the parties hereby irrevocably consents to the personal jurisdiction of any such court in any such suit, action, or proceeding.

 

17.          Counterparts.  This Agreement may be executed in more than one counterpart, each of which shall be deemed an original, and all of which shall be deemed a single agreement.

 

18.          Headings.  The headings herein are for convenience only and shall not affect the interpretation of this Agreement.

 

[The remainder of this page is intentionally left blank.]

 


 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.   The Executive must furnish all legal proofs of eligibility to work in the Company.

 

 

ACCEPTED AND AGREED TO:

 

KIROMIC BIOPHARMA INC.

 

 

/s/ Maurizio Chiriva-Internati

 

By:

/s/ Tony Tontat

(Signature)

 

Name: Tony Tontat

 

 

Title: CFO, COO

 

 

 

 

 

Maurizio Chiriva-Internati

 

 


 

CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND
NON-COMPETITION AGREEMENT

 

In consideration of my employment by Kiromic Biopharma Inc., and its subsidiaries, parents, affiliates, successors and assigns (together, “Kiromic” or the “Company”) and the compensation now and later paid to me, I hereby enter into this Employee Confidential Information, Inventions, Non Solicitation and Non-Competition Agreement (the “Agreement”) and agree as follows:

 

1.      CONFIDENTIAL INFORMATION PROTECTIONS.

 

1.1 Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company’s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon or publish any of Company’s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and/or incorporates any Confidential Information. I hereby assign to Kiromic any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Kiromic and its assigns. I will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

1.2 Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, “Confidential Information” includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, “Inventions”); (b)  information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing  policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of Company, including customer lists, names,

 


 

representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non public information relating to customers and potential customers; (d) information regarding any of Company’s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other non public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding  the foregoing, it is understood that, at all such times, I am free to use information which was known to me prior to employment with Company or which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to “whistleblower” statutes or other similar provisions that protect such disclosure.

 

1.3 Third Party Information. I understand, in addition, that Company has received and in the future will receive from third parties their confidential and/or proprietary knowledge, data or information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my  employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such  information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.

 

1.4 Term of Nondisclosure Restrictions. I understand that Confidential Information and Third Party Information is never to be used or disclosed by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two (2) year period after the date my employment ends will be the temporal limitation relevant to the contested restriction, provided, however, that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.

 

1.5 No Improper Use of Information of Prior Employers and Others. During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of

 

12


 

Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 

2.      ASSIGNMENTS OF INVENTIONS

 

2.1 Definitions. As used in this Agreement, the term “Intellectual Property Rights” means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term “Copyright” means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term “Moral Rights” means all  paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.

 

2.2 Excluded Inventions and Other Inventions. Attached hereto as Exhibit A is a list describing all existing Inventions, if any, that may relate to Company’s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (“Excluded Inventions”). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company’s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, “Other Inventions” means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company  under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non exclusive, perpetual, transferable, fully paid and royalty free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.

 

2.3 Assignment of Company Inventions. Inventions assigned to Kiromic, or to a third party as directed by Kiromic pursuant to Section 2.6, are referred to in this Agreement as “Company Inventions.” Subject to Section 2.4 (Unassigned or Nonassignable Inventions)  and except for Excluded Inventions set forth in Exhibit A and Other Inventions, I hereby assign to Kiromic all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the

 

13


 

period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Kiromic and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company’s customers, with respect to such rights. I further acknowledge and agree that neither my successors in interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).

 

2.4 Unassigned or Nonassignable Inventions. I  recognize that this Agreement will not be deemed to require assignment of any Invention  that I developed entirely on my own time without using Company’s equipment, supplies, facilities, trade secrets or Confidential Information, except for those Inventions that either (i) relate to Company’s actual or anticipated business, research or development, or (ii) result from or are connected with work performed by me for Company. In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to Company under any specifically applicable state law, regulation, rule or public policy (“Specific Inventions Law”).

 

2.5 Obligation to Keep Company Informed. During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I  believe fully qualify for protection under the provisions of any applicable Specific Inventions Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep  in confidence and will not use for any purpose or disclose to third parties without my consent any Confidential Information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully  for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.

 

2.6 Government or Third Party. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.

 

2.7 Ownership of Work Product.

 

(a)    I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).

 

(b)    I agree that Kiromic will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I  hereby irrevocably and unconditionally assign to Kiromic all right, title, and interest

 

14


 

worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.

 

2.8 Enforcement of Intellectual Property Rights and Assistance. I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Kiromic or its designee, including the United States or any third party designated by Kiromic. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company’s request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Kiromic.

 

2.9 Incorporation of Software Code. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with Company’s policies regarding the use of such software.

 

3.      RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all  Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.

 

4.      DUTY OF LOYALTY DURING EMPLOYMENT. I agree that during the period of my employment by Company I will not, without Company’s express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.

 

5.      NO SOLICITATION OF EMPLOYEES, CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR POTENTIAL CUSTOMERS. I agree that during the period of my  employment and for the one (1) year period after the date my employment ends for any

 

15


 

reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any  other capacity, either directly or through others, except on behalf of Company:

 

5.1 solicit, induce, encourage, or participate in soliciting, inducing or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company, even if I did not initiate the discussion or seek out the contact;

 

5.2 solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company to render services to me or any other person or entity that researches, develops, markets, sells, performs or provides or is preparing to develop, market, sell, perform or provide Conflicting Services (as defined in Section 6 below);

 

5.3 hire, employ, or engage in a business venture with as partners or owners or other joint capacity, or attempt to hire, employ, or engage in a business venture as partners or owners or other joint capacity, with any person then employed by Company or who has left the employment of Company within the preceding three (3) months to research, develop, market, sell, perform or provide Conflicting Services;

 

5.4 solicit, induce or attempt to induce any Customer or Potential Customer (as defined below), to terminate, diminish, or materially alter in a manner harmful to Company its relationship with Company;

 

5.5 solicit or assist in the solicitation of any Customer or Potential Customer to induce or attempt to induce such Customer or Potential Customer to purchase or contract for any Conflicting Services; or

 

5.6 perform, provide or attempt to perform or provide any Conflicting Services for a Customer or Potential Customer.

 

The parties agree that for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year period prior to my contact with such person or entity as described in Sections 5.4 5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one (1) year period prior to the date my employment with  Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.

 

6.      NON COMPETE PROVISION. I agree that for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit,

 

16


 

perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory (as defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.

 

The parties agree that for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than Company that directly competes with a product, service, or process, including the research and development thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information during my employment by Company.

 

The parties agree that for purposes of this Agreement, “Restricted Territory” means the one hundred (100) mile radius of any of the following locations: (i) any Company  business location at which I have worked on a regular or occasional basis during the preceding year; (ii) my home if I work from home on a regular or occasional basis; (iii)  any potential business location of Company under active consideration by Company to which I have traveled in connection with the consideration of that location; (iv) the primary business location of a Customer or Potential  Customer; or (v) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom I have been in contact in the preceding year are based.

 

7.      REASONABLENESS OF RESTRICTIONS.

 

7.1 I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company’s legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.

 

7.2 In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.

 

7.3 If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I and Company agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

7.4 Furthermore, the parties agree that the market for Company’s products is the entire United States. If, however, after applying the provisions of subsections 7.2  and 7.3, a court still decides that this Agreement or any of its restrictions is unenforceable for lack of reasonable geographic limitation and the Agreement or restriction(s)  cannot otherwise be enforced, the parties hereby agree that the fifty (50) mile radius from any location at which I  worked for Company on either a regular or occasional basis during the one (1) year immediately preceding termination of my employment with Company shall be the geographic limitation relevant to the contested restriction.

 

8.      NO CONFLICTING AGREEMENT OR OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of Company

 

17


 

does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.

 

9.      RETURN OF COMPANY PROPERTY. When I leave the employ of Company, I will deliver to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or e mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company’s personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company’s termination statement if required to do so by Company.

 

10.    LEGAL AND EQUITABLE REMEDIES.

 

10.1              I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.

 

10.2              I agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will be entitled to payment of all costs, including reasonable attorneys’ fees, from me.

 

10.3              In the event Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.

 

11.    NOTICES. Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, labeled “Attention Chief Executive Officer,” and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.

 

18


 

12.    PUBLICATION OF THIS AGREEMENT TO SUBSEQUENT EMPLOYER OR BUSINESS ASSOCIATES OF EMPLOYEE.

 

12.1              If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the restrictions described in Sections 5 and 6 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and also agree to provide such person or persons with a copy  of this Agreement.

 

12.2              I agree to inform Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and 6 of this Agreement are in effect and I also authorize Company to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations under this Agreement.

 

13.    GENERAL PROVISIONS.

 

13.1              Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the State of Texas as such laws are applied to agreements entered into and to be performed entirely within Houston between Houston residents. I hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in Houston for any lawsuit filed there against me by Company arising from or related to this Agreement.

 

13.2              Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.

 

13.3              Successors and Assigns. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.

 

13.4              Survival. The provisions of this Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.

 

13.5              Employment At Will. I agree and understand that my employment with the company will be executed in accordance with terms of my employment agreement as shown on Exhibit C and Section 02 (“Duties”).

 

13.6              Waiver. No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.

 

 

19


 

13.7              Export. I agree not to export, re-export, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.

 

13.8              Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.

 

13.9              Entire Agreement. The obligations pursuant  to Sections 1 and 2 (except Subsections 2.4 and 2.7(a)) of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs nondisclosure and assignment of Inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

 

20


 

This Agreement will be effective as of the Company’s IPO Date.

 

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.

 

 

 

ACCEPTED AND AGREED TO:

 

 

KIROMIC BIOPHARMA INC.

 

 

 

/s/ Maurizio Chiriva-Internati

 

By:

/s/ Tony Tontat

(Signature)

 

 

Name: Tony Tontat

 

 

 

Title: CFO, COO

 

 

 

Maurizio Chiriva-Internati

 

 

 

21



EX-10.24 9 a2241635zex-10_24.htm EX-10.24

Exhibit 10.24

 

 

KIROMIC BIOPHARMA, INC.


DIRECTOR SERVICES AGREEMENT

 

This Director Services Agreement (this “Agreement”), dated as of             , 2020, is entered into between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”) with a place of business at 7707 Fannin St., Suite 140, Houston, TX 77054, and                        , an individual (“Director”) with an address of                                                                      (email: [                       ]).

 

RECITALS

 

WHEREAS, the Company desires to retain the services of Director as a member of the Company’s Board of Directors (the “Board”) for the benefit of the Company and its stockholders; and

 

WHEREAS, Director desires to serve on the Board for the period of time and subject to the terms and conditions set forth herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and as set forth herein, the parties hereto agree as follows:

 

AGREEMENT

 

1.                                      Board Duties.

 

(a)                                        Effectiveness of Agreement. Director agrees to provide services to the Company as a member of the Board from and after the later of (i)                     and (ii) the date on which Director is elected to the Board (the “Effective Date”), provided that this Agreement shall be effective only upon, and subject to, the Director’s election to the Board in accordance with the Company’s certificate of incorporation and bylaws.  In the event Director is not so elected to the Board on or before                      , this Agreement shall terminate and be of no force or effect and neither the Company nor Director shall have any obligations hereunder.

 

(b)                                        Director Services. Director shall, for so long as he remains a member of the Board, meet with the other members of the Board and/or the Company’s executive officers upon request in accordance with Exhibit A “Director Meeting Obligations” below. Director acknowledges and agrees that the Company may rely upon Director’s expertise in business disciplines where Director has significant experience with respect to the Company’s business operations and that such requests may require substantial additional time and efforts in addition to Director’s customary service as a member of the Board. Additional meetings to be determined relative to the various board committees on which the Director may serve.

 


 

Exhibit A

 

Director Meeting Obligations

 

Meeting Venue

Zoom, MS Team, or other teleconferencing facilities

 

 

Meeting Time

10 AM Central Time (Houston) on the day of the meeting

 

 

Meeting Agenda Distribution

Meeting Agendas will be distributed by email 48 hours prior to the meeting

 

 

Meeting Invite

Emailed invite will come from Executive Assistant (Ms. Trish Faulkner)

 

 

Corporate Board Meetings

6 (six) bi-monthly corporate meetings 60-90 mins duration

 

 

Ad-Hoc Project Approval Meetings

6 (six) bi-monthly Ad-Hoc project approval meetings 60-90 mins duration

 

 

Quarterly Meetings Finance and Audit Committee

4 (four) Quarterly Finance and Audit Committee Members only 30 mins review with corporate auditors

 

 

On-demand Meetings Pricing Committee

Pricing Committee Members only 60 mins review with underwriters

 

 

Annual Meeting Compensation Committee

1 (one) meeting Compensation Committee Members only 60 mins review to review, adjust corporate compensations

 

 

Annual Meeting Nomination Committee

1 (one) meeting Nomination Committee Members only 60 mins review with review, recommend, vote on officers and board members

 

(c)                                         Fiduciary Obligations and Conduct. Director understands that as a member of the Board he is bound by fiduciary duties applicable to directors of corporations organized pursuant to the General Corporation Law of the State of Delaware, including the duties of care, loyalty and good faith. As such, among other things, Director may not use Director’s position of trust and confidence to further Director’s private interests, Director must inform himself of the material information reasonably available before voting on a transaction and Director may act as a member of the Board only for the purpose of advancing the best interests of the Company and all of its stockholders, may not intentionally violate the law and may not consciously disregard or violate Director’s duties to the Company (including any subsidiary) and its stockholders. Membership on the Board shall require adherence to any board member conduct policies adopted by the Board from time to time and enforced equally upon all directors.

 


 

2.                                             Compensation. The Director will be compensated for his services and expenses in accordance to Exhibit B “Director Compensation” as shown below. In the event of termination without cause, prior to the Quarterly distribution dates and quarterly vesting period dates as set forth in Exhibit B “Director Compensation”, Director shall be entitled to his proportionate share of cash and stock compensation for the number of days he served as Director during the relevant quarterly period. By way of example, the Director would be compensated for the number of days served on the board during the relevant quarter, divided by the number of days in the relevant quarter, multiplied by $6,250 (cash) or $12,500 (value of NQSO).

 

Exhibit B

 

Director Compensation

 

Cash Compensation

$25,000 Annual cash compensation

4 Quarterly distributions (3/31, 7/31, 9/30, 12/30)

 

 

Stock Option Compensation

Non-Qualified Stock Option (NQSO)

 

$50,000 NQSO Annual compensation

4 Quarterly vesting periods (3/31, 7/31, 9/30, 12/30)

 

 

Special Committee Meeting Compensation

$750 per meeting

 

 

Travel Compensation

$2,500 per day Travel to and from specific meeting site or the company headquarters (Houston) Travel only at the request of the board or the CEO

 

 

Travel Expenses

The company covers travel expenses including (shuttle, taxi, UBER, air fares, hotel, lodging, and meals)

 

3.                                             Non-Disparagement. Director agrees to forbear from making, causing to be made, publishing, ratifying or endorsing any and all disparaging remarks, derogatory statements or comments to any third party with respect to the Company and its affiliates, including, without limitation, the Company’s parent, subsidiaries, officers, directors and employees (collectively, “Company Parties”) . Further, Director hereby agrees to forbear from making any public or non-confidential statement with respect to any of the Company Parties.

 

4.                                             Confidentiality. Director agrees that Director will have access to and become acquainted with confidential proprietary information of the Company and its subsidiaries (“Confidential Information”) which is owned by the Company and its subsidiaries and is regularly used in the operation of the Company’s and its subsidiaries’ businesses. As used in this Agreement, the term “Confidential Information” shall mean proprietary and non-public information relating to the Company (including its subsidiaries) or its business. Director agrees that the term “Confidential Information” as used in this Agreement is to be broadly interpreted and includes (i) information that has, or could have, commercial value for the business in which the Company or any of its subsidiaries is engaged, or in which the Company or its subsidiaries may engage at a later time, and (ii) information that, if disclosed without authorization, could be detrimental to the economic interests of the Company or any of its subsidiaries. Director agrees that the term “Confidential Information” includes, without limitation, any patent, patent application, copyright, trademark, trade name, service mark, service name, “know-how,” negative “know-how,” trade secrets, customer and supplier

 


 

identities, characteristics and terms of agreement, details of customer or consultant contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisitions plans, science or technical information, ideas, discoveries, designs, computer programs (including source codes), financial forecasts, unpublished financial information, budgets, processes, procedures, formulae, improvements or other proprietary or intellectual property of the Company, whether or not in written or tangible form, and whether or not registered, and including all memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof. Director acknowledges that all Confidential Information, whether prepared by Director or otherwise acquired by Director in any other way, shall remain the exclusive property of the Company. Director covenants and agrees that Director shall not misuse, misappropriate, or disclose in any way to any person or entity any of the Company’s Confidential Information, either directly or indirectly, nor will Director use the Confidential Information in any way or at any time except as required in the course of Director’s business relationship with the Company. Director agrees that the sale or unauthorized use or disclosure of any of the Company’s Confidential Information constitutes unfair competition. Director promises and agrees not to engage in any unfair competition with the Company and will take measures that are appropriate to prevent its agents and representatives from engaging in unfair competition with the Company. Director further agrees that, at any time, upon the request of the Company and without further compensation, but at no expense to Director, Director shall perform any lawful acts, including the execution of papers and oaths and the giving of testimony, that in the opinion of the Company, its successors or assigns, may be necessary or desirable in order to obtain, sustain, reissue and renew, and in order to enforce, perfect, record and maintain, patent applications and United States and foreign patents on the Company’s or its subsidiaries’ inventions, and copyright registrations on the Company’s and its subsidiaries’ inventions.

 

5.                                             Term. Except as otherwise provided herein, the term of this Agreement and the duties and obligations of Director and the Company under it shall continue until the date that Director ceases to be a member of the Board for any reason. Without limiting the foregoing, Director may voluntarily resign Director’s position on the Board at any time and such resignation shall not be considered a breach of this Agreement.

 

6.                                             Cooperation. Director will notify the Company promptly if Director is subpoenaed or otherwise served with legal process in any matter involving the Company or any subsidiary and will cooperate in the review, defense or prosecution of any such matter. Director will notify the Company if any attorney who is not representing the Company directly or indirectly contacts or attempts to contact Director (other than Director’s own legal counsel) to obtain information that in any way relates to the Company or any subsidiary, and Director will not discuss any of these matters with any such attorney without first so notifying the Company and providing the Company with an opportunity to have its attorney present during any meeting or conversation with any such attorney. In the event of any claim or litigation against the Company or Director based upon any alleged conduct, acts or omissions of Director during Director’s tenure as a director of the Company, Director will provide to the Company such information and documents as are necessary and reasonably requested by the Company or its counsel, subject to restrictions imposed by federal or state securities laws or court order or injunction.

 

7.                                             Entire Agreement. This Agreement represents the entire agreement among the parties with respect to the subject matter herein.

 

8.                                             Governing Law. This Agreement, and any dispute or controversy arising in connection with this Agreement, shall be construed, interpreted and enforced in accordance with the laws of the State of Delaware without regard to principles of conflicts of law that would result in the application of the law of any other jurisdiction. Each of the parties irrevocably submits to the jurisdiction of the state courts of the State of Texas located in Harris County, Texas, and the United States District Court for the Southern District of Texas for the purpose of any suit, action or other proceeding arising out of or based upon this

 


 

Agreement and agrees not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the State of Texas located in Harris County and the United States District Court for the Southern District of Texas.

 

9.                                             Injunctive Relief. It is agreed that the rights and benefits of the Company pursuant to Sections 1, 3, 4 and 6 of this Agreement are unique and that no adequate remedy exists at law if Director shall fail to perform, or breaches, any of Director’s obligations thereunder, that it would not be possible to determine the amount of damages resulting therefrom, and that any such breach would cause irreparable injury to the Company. Therefore, the Company shall be entitled to injunctive relief to prevent or restrain any such breach of this Agreement by Director in addition to any other remedies that may be available to the Company at law.

 

10.                                      Notices. All notices required or permitted under this Agreement shall be in writing (including by email) and shall be deemed effective upon personal delivery, upon confirmed receipt of email message, or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10.

 

11.                                      Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.

 

12.                                      Survival. The provisions of Sections 3—17 shall survive termination of this Agreement, together with any other provision that by its nature is intended to survive termination.

 

13.                                      Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and Director.

 

14.                                      Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Director are personal and shall not be assigned without the prior written consent of the Company.

 

15.                                      Interpretation. If any restriction set forth in this Agreement, including but not limited to Section 3 or Section 4 hereof, is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

 

16.                                      Indemnification. The Company will indemnify and hold harmless the Executive from any liabilities and expenses arising from Executive’s actions as an officer, director or employee of the Company to the fullest extent permitted by law, excepting any unauthorized acts or illegal conduct which breaches the terms of this or any other agreement or Company policy, including but not limited to the Proprietary Information Agreement. Executive will be entitled to indemnification under the Company’s Directors and Officers insurance policy during his employment with the Company and for the six (6) year period thereafter on terms no less favorable than any other officer of the Company.

 

17.                                      Miscellaneous. No delay or omission by a party in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by a party on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any

 


 

right on any other occasion. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. In the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same agreement. Facsimile or electronically transmitted copies of executed signature pages shall be deemed binding originals.

 

IN WITNESS WHEREOF, the parties hereto enter into this Agreement as of the date first set forth above.

 

 

ACCEPTED AND AGREED TO:

KIROMIC BIOPHARMA INC.

 

 

 

 

 

 

By:

 

(Signature)

 

 

Name: Tony Tontat

 

 

 

Title: CFO, COO

 

 

 

 

 

 

Board Member (First, Last Name)

 

 

 



EX-10.25 10 a2241635zex-10_25.htm EX-10.25

Exhibit 10.25

 

KIROMIC BIOPHARMA, INC.

 

DIRECTOR INDEMNIFICATION AGREEMENT

 

This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of           , 2020 by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and                              (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

 

RECITALS

 

WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company from certain liabilities. The By-Laws (the “By-Laws”) of the Company and the Certificate of Incorporation of the Company (“the Certificate of Incorporation”) require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The By-Laws and the Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the By-Laws and the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;

 

1


 

WHEREAS, Indemnitee does not regard the protection available under the By-Laws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and

 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

Section 1. Services to the Company. Indemnitee agrees to continue to serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to keep Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company, if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company, other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the By-Laws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a director of the Company.

 

Section 2. Definitions. As used in this Agreement:

 

(a)   References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other Enterprise at the request of, for the convenience of, or to represent the interests of the Company.

 

(b)   A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i)        Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing more than fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities;

 

(ii)       Change in Board. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

 

(iii)      Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 51% of the combined voting power of the voting

 

2


 

securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;

 

(iv)      Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

(v)       Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

For purposes of this Section 2(b), the following terms shall have the following meanings:

 

(A)  “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

 

(B)  “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(C)  “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.

 

(c)   “Corporate Status” describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

 

(d)   “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(e)   “Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary.

 

(f)    “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed

 

3


 

conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(g)   “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

(h)   The term “Proceeding” shall include any threatened, pending or completed action, suit, appeal, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him or of any action on his part while acting as director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company, including prior to the date of this Agreement, as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.

 

(i)    Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the

 

4


 

Certificate of Incorporation, the By-Laws, vote of the Company’s stockholders or disinterested directors or applicable law.

 

Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.

 

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

Section 6. Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

Section 7. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, actually and reasonably incurred by Indemnitee in the investigation, defense, settlement of a Proceeding, but is precluded by applicable law or the specific terms of this Agreement to indemnification for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 

Section 8. Additional Indemnification.

 

(a)   Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the Proceeding.

 

(b)   For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to:

 

5


 

(i)        to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and

 

(ii)       to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.

 

Section 9. Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

(a)   for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)   for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or

 

(c)   except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, or (ii) Indemnitee’s participation is required by applicable law, or (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, or except (iv) with respect to Proceedings brought to establish or enforce a right to indemnification under this Agreement or under any other agreement, provision in the By-laws or Certificate of Incorporation or applicable law.

 

Section 10. Advances of Expenses. In accordance with Section 3 of Article XI of the By-Laws, and notwithstanding any provision of this Agreement to the contrary, the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The right to advances under this Section shall continue until the final disposition of any Proceeding, including any appeal therein. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.

 

Section 11. Procedure for Notification and Defense of Claim.

 

(a)   Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably

 

6


 

practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such action, suit or proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.

 

(b)         The Company will be entitled to participate in the Proceeding at its own expense.

 

Section 12. Procedure Upon Application for Indemnification.

 

(a)   Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made a by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

(b)   The Independent Counsel shall be selected by Indemnitee, unless Indemnitee shall request that such selection be made by the Board, and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such

 

7


 

objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

Section 13. Presumptions and Effect of Certain Proceedings.

 

(a)   In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(b)   If the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefore, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.

 

(c)   The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to

 

8


 

indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

(d)   Reliance as Safe Harbor. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(e)   Actions of Others. The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

Section 14. Remedies of Indemnitee.

 

(a)   In the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, 6 or 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

(b)   In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

 

(c)   If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by

 

9


 

Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)   The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company if Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification and advancement shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.

 

Section 15. Non-exclusivity; Survival of Rights; Insurance; Subrogation.

 

(a)   The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-Laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the By-Laws, the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

(b)   The Company shall use its best efforts to maintain an insurance policy or policies providing liability insurance for directors and officers in effect at all times. To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the

 

10


 

commencement of a proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 

(c)   In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

(d)   The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)   The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

Section 16. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as an officer of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and administrators.

 

Section 17. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

Section 18. Enforcement.

 

(a)   The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.

 

(b)   This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the By-Laws and

 

11


 

applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

 

Section 19. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

Section 20. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.

 

Section 21. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

 

(i)        If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.

 

(ii)                      If to the Company to

 

Kiromic Biopharma, Inc.
7707 Fannin, Suite 140

Houston, TX 77054

Attention: Chief Executive Officer
Email: mchiriva@kiromic.com

 

or to any other address as may have been furnished to Indemnitee by the Company.

 

Section 22. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (a) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (b) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

Section 23. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the

 

12


 

“Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (c) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably The Corporation Service Company, 2711 Centerville Road, City of Wilmington, County of New Castle, Delaware 19808 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (d) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (e) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

 

Section 24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

Section 25. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.

 

 

 

ACCEPTED AND AGREED TO:
KIROMIC BIOPHARMA INC.

 

 

 

 

 

 

 

 

 

By:

 

(Signature)

 

 

Name: Tony Tontat

 

 

 

Title: CFO, COO

 

 

 

 

 

 

Director / Board Member (First, Last Name)

 

 

 

13



EX-23.2 11 a2241635zex-23_2.htm EX-23.2

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the use in this Registration Statement (No. 333-238153) on Form S-1 of our report dated April 6, 2020, (June 25, 2020 as to the effects of the reverse stock split described in Notes 2 and 12) relating to the financial statements of Kiromic BioPharma, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

 

/s/ Deloitte & Touche LLP

 

 

Houston, Texas

June 25, 2020

 



GRAPHIC 12 g945773.jpg G945773.JPG begin 644 g945773.jpg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g115292.jpg G115292.JPG begin 644 g115292.jpg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�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

S7IQ:IFELH;B8IYY>JIK0QUW: MB^MQ/LE*ABUZ,V"LR[8M$!%L7'+:^S/N!<>RT%HG4N.%T)4TY+E.%K:(HD?YXEI)I$!3@4R@)[5.6YRF M&6T/:4I60EJK:4E.@Z5HA#I2E?\ SE4-F%J\]12DAQ1Q#:2XDK\S'Z2_:-QY M1R-86MB;)U*)XRG"#+6L@1<&B:.6[N#("+%F+MT)7K/PTTJ"ZP.9-8#CI&W$ M??AH]0D6UR)=-\UL^%@D' 1]/"9*SI2"F6A2E5ACIFC"D,.'QB&FRC@P2O: MI@F+1G %154L;&,)'B=IJE+B<1MIX2X5J[>RMO:A>.Y*:EFDBZ/3LW/L)-2' M@XH#LTV,5-N#G?S+T)4J$$F$64C[8K#A-L=!6CX(:J9U&F>\MTK\-Z3J6$JR MC)^HZ3J^7B[C15*UC19+K7F)2IHI5"4+*.1&7YLJ5J>4@ M)0EP%=:DJ]IQGV0$O*(=FJ;="'"A2O,&F5*0%07IGC XHJ.HF#MU3=ZZOC*% MIN%DJ;AZ:+]ANHUI3\LR7C'<,<7\.[=O(Q%@X60CFC]RZ2AP,16(!BN@W51Q M.$XA;V03JSDA"7#?M'-@(R0AK.N&\?3:P4/%RJ1D)!I'@O#KHR:;M$YDE#SY M)98" 4B:I"D*!9W5/P>4V[N9?RZ%S[G4%8RU]+<4#JS]'!3]M)F2I^K*^+*( MRBM-P=$0DT_>491;%B!"/'CIY,(,4UG?9*HV9*@IN^_W N6]_&%Q.NZ;.>VE ML;;/;10?@[;6GDJ[DG%25A0%,.THZ"H"CE84C:-9('6GS70Z IW_ "&D&A2M'F!"5%"%M$Z$JQ6! M1?%9Q)V\A)VF:/N_4\-3M0RDW.24(9O 2T868J1P[=S\E$M9Z%EDZ>>S#I\[ MUL.<@(@/03>T'F%+<#;8>):6%_B44!?M!)40="J8KVDLBK#L?YJ&4 M./!SRPVL-NI2CS"6TA:-.R0HIE.H"0R+M![AR/:''<+AD!# AW2@"./B/XX# MSD=?X91G?):0@7,FC.)1=N7L6[CN]2EDY,](P:C,['P@'7.\!44P;=R!U5S" M4AB'$YB&T2NB)D%@#("9!" M?P%CYYO)K,WS&+<,0I"E3.'+:63;&;^&1705(JZ0,H#95-8IP[21PURU#H%2 MP3"O^:5T!7\YUT9T0;F0)@6@&<8LMJ++@ (!J:,E0CV4Z:A.J1) 3(N=C$7. M-!7.GKBUA,(S%Q23*+\L>1C%MY*'?0+!C'MRB8S2$BW+9LU:-U7*JC]\5BGA MQ(NUWCD157R%A=-L#NZ]LDU*0JA/T1LXW3$H'(H<%N'YRIV3*& "@!E)4Y,> M[DQ$<#L(GT7Q9RT1*MJ)<,*E0F$DUJC*HB%90=3HL3K(QRPBD,>U9.&8K\E" MNRB"HHE[HB?8,)Y X@XK]!*IDKE4W0RL!0-AB,FU24O5-:'J9>=LE-1[IA$1 M%(RD1,H/XQ!LD_:/&;YDLT71:.6JI52'.;HJM[SJ*D4&ON^MBM;2RTA:P@E; M+24I0RVI1),2$),2=5I([6G8+=54 N>:4NTCBG7%(3(2%.*)6XH)$"TJ4"2( M%RD&K2H1;N*BJ)0CEN<5*AGE!["R1A$5)E\G7'7YY#;;KJXVL9FVC:'3EGMN[E5:O(B95G-2%(T]8"C'Z1Q*J MM((/K[S=72,B"XF%0I6D4[*4%"G!4QC!J)-37&M5'IIJJV\I"5?+RJJ8PL3( MVIK$C&)19IB5S*5"TL;#QRLBYDE#H),8J2<=AJD=RLZ(/= OV-)F[SX2$4+U MH1=UL&4]6UA+B!;=Q"!QTG2?RU#2B35HD^U"6U:0%:?YP5(4;C\"U&+QN<0G M\$;(@(& -]_ASSD #YY#YZ/"&$,9'&=M_NP)0^.<#U\M3CF*JL;'0=,R%1V3 M@(MY5#%U,M8Y&E2%?MJ8*HBVB*G=*0%S*#2!K4;A.64ADRM4C.HZ*^UP_P!0 MDF!E/E5%,<-4,NQ;22CJ$EY&GX>HCPPTW@E3E6R2I1,#&0N_(' M2?Z,V)=@/AYN/;"(Y /[QZVB3!N/[%24#>YXS<.KETY5,G*556UJ4K8TW3<-!PM+4U+G.J,@_?K/W3 M+NFQ2CX@R"!#K:U,TJ%55$ZPVS4I6X D!Q 3N-HUE1),1 ,F_?&Q0,>14H=4 MXR0B\H7KV@\I @ &22+"3TQ7*@R,"#;<1$&[?.1YB"1,] #F&-\CK[@S]!Y[ MY-Z!R\OEG.^G4J'9 H9$0* %#'D AN7GZ]<\N?IG7 M>%SNK>)N!]=OECJ@E5O9B!U'&F9OWYO'KAF\&(ASY9WV ?PZ>N?+(:/"&[(A MDW/J(!Y;8S@0SR'.^GGN1'KCX[_00QRZAT'2 @/7IRY!_/\ AIYF]U;#J.E_ MG[][\S2KH;[F4\Z8( W($1 L>><,W@S>>0W'8=\[],#\,#C'+TUS!H8 Z_[V M/PVT[=QYYY\P' ?$=OEC?IG&0T=R(?75UD[%1VVGZ]>??@$J@2 M.EY'^F/C\HWVAX%( '&_IRW^&WKTW^_2"GC8<^FP!]_73X+<0V$G0 YAOY ( MY#S_ (\ASH!OCFF'/; /U][^@^6VM$K5/2_$1Q?^\^G?L0F($#8=.@CX3^Q ML<,G=@/+(_(!V'GMCK^>6@$L[!\N6WX!U#;F&GP&^X93# ?[/X=KEGGY\]'A MQV#L9\P$0QCRR!OEC;;[VM5K\#I^EL-/,0-I'N])]/7B<,8I '4?(>7/&1#K MH[K;&!^@?RS_ T^>&$.9//D("(?+(?=TYZ/#CR[L/A[OP\^?KS]>6FH]?JW M;F/H;@G:W86].GN-ATC#'W0CY_<'Y]1T D4=L>0YR'GC/D/EM\.>GOP^V0(' MR$/NP/F'X#I1;[X[!<#UR 9ZB(AG.WST"S-S-]K=NUKQMVQ-/;H?@ =IVB/S MBQPQ@D <@'U# ?RT"F',0'Z '\/3EI[!N(Y#LO\ O>77T$=+X8=\$WZ< MOGGWO\_EIJ/7:.FX@]/?^^+IF+>E]C MO'3T/?#)@0DL15-I&SZYYVKSRXQ1OLY^FJG&D*M-1#)^F9J#A:73)(RL6NDFM4\*"--LU%Z3:+/%(J6BB.%*E/) M,$V:#F+<*KG59RO'Z["EB-*I5'E. U( 4A(6L:E?=4N3!6?-+NJ5 M2 !O*842C24(\M6M!#,$*4I"?9'G%!39,IT:8!D2;ZB9WNMZ=5(P\/U)30$ M.D<6J[:)<-W I& QDEBL:=(X4;K=GL.4TU2BJF94I#)"("73LHA,.:OFZAMW M1=74$PDI-=_$0=-%J=96#:NC=M.-:S#%@P>N&J*O? R[92=TW[MH3O ;@<\V MVK-V847CB5KZ05:"Z?QD-&O*@F(ZH6ZC%)%LTJ5X>O6+9B-:QS@Z3YC*. 8N^\DWCF594A<^!CY1Q *U :#J MQ?.>XC@K"G%'3Z$JJC)91]&+*]B6@IMJHVD)FGIJ,F&B+?-FIIZM+J6Z/ M+E582"TE2&M#A,:A*VFU**$RK3*=9!0I;0'FF.,.L%LJJ:S[N50LI4L% $ > MRE:T@*,"844@A02L^QADK*@>+"I6DJRJYY7]:-XLHO):GS5ZC52R!&A".0=& MI9K4+I5\5F55-<%8R+D ;B('(8#$$2Q9[O8!'/0,[?3ES#D(#N&,#@0QJQVL MZZM'6C6 N+159TA3]W64 RBEG5S8"9IN1IR5CESE2JF*9TW$U-1;RIE(]8I5 M*CI=I&MUY=@69:TY3"DB:,CXJ7L>4S-7)FIBDI)M.,I..I=Y,3#)D[CHV3K5 M2E80M?OXAK(,HQZ6)?UF2;>L%W4>Q6=D<&>&:H@N!=;N75-0K_*=IDTXT*)2 MW3.4Z4NMJ0E8A16E2'-04RX"@N)0L>7 "SKUC#:4A;;RGB5) UNMNJ4A4E)E M.@I4DI_S$$*"2M/MS*!HSL /+.1] '^'X8TO=XW'M>_P M -\ACN\#Y@!?EN(@.?QUVNHW,C<=/=Q?CY8Z^-H';CM[ M^GPZC#'W>//'38/QP(#^'71W8 !<".<#D.R'01QCY==\8]-/@MML]C(]0V^N MQASH\..!'L@'Q'?Y^\&_E]!#36>HXZ3-K[<["?G&*!]6 M YZ6]+<89!3Y\\ M]0P&WETQ\PY>>^N(I#D-QSZ8'/EC(#M]?+3Z#;;<@!O@.6,XV_:Y_ !T>&$- MNP&XCL(AM\L\\>61TU$G>(CI;;T['^V)IWD21U'I[AQO\;W8Q3Y9S\P#?.XY M' "(\^N@$^8;B._0,@ _+[]/?AQ 0]S'PQN [<\^G+/QT"W''_)ACRR'X /Y MYCIJ5U'R^K_,XNF(L+;6ZP;=[WYYPQ]UU'.0WR.,X$?@'PR'STHIAMD!# B/ M0,^@X ,Z>_##R F,;\PQGT][?U'Y;<])X;?OUTH)\Q#M;<^0!UR ACEMRV_AI\\./(I M.8;AD.?PSR\P'Y\M MAV]P!VSS -QY@ =K&,ATT*CUY&Y'NX',1L-][XD#IM M'Z?L,,?X\QWW';U]-/?AC=4PY=1#/U$W+\YP.CPPY . M[#(B &0R(CL !ON(CL ==-2HWYY([?*WI>^*!T'RZ1_;BT>F&/NPP.XAD-L M8R.X@(YZ=>FXZ7N]NHAY[#]X!MZ\M9"C%2DB\81$2VCU9N8E(>"AT)F52I^* M5EY^590D426FW*+E&%C#2$@V!_*K-G"<>T[UT9!8$NZ/W:@I.L:&JRL;?W!A M(V!K>@*E>TE54;"U(QJZ%;S3!G'O72494<>DU;R2;8DDBT> +5JX82K>1BG2 M!7#%81UU5K":M%$78JEL*J$-:5&64+#:UZ@DMB%D#25!1F0" 3CD##GE%[1_ ME!Q+17[( 6I.H)B9NE,[0(N=AC$03 1R(9YCV=_N_AS]0TG=@. WY[6GSPYN?8 0\\AN&?0WER#.X^@:/#CT)MOML'S'?KGS'EZ:V-1$#Y6X/I\.E ML<6D#@?#BQ'))QGT.E_Q&7$]T1_XTK1CL 9#_M7N]SZ>6!Y["&,ZTW(.6T6P M?R;U4R32-9.Y!TH0AE3IM63=5TX.5)(#JJG*BB<2))$,HJ?LIID,NZ?K^!=4+536 MFZ=J=S U"YB1>,8JKH%A4%..G*\8\E(T3/6$FS1610OW"\53>5A]N6?J"QCR-@+;Q%3TE M&S,=3=WJE.$C/W&IU!9R[AS/Z5IAF@SA9"C) L/*55/^/GGLNK301R5_=%W> MM#(/$]I*4%0F MP\BUP^#2^'#S#4K45\*.1AK4*,Z>4E;CT!6,-5]+GA5"1:(LHB:8M6TY%3U2 ME=LH.C7L]1<;$&GIN)$B&LB\9-3-V3R7+'12&Z5K+E5/<^R%+25: MP\=4\?;2C*XHY*FUI,D_31F=5T0^;33V7,M3$J8Z5)'G%G<='5LB5\HX*,"D MPF%_/#<6PMW.%N^=Q_[LK1S3Z,M?!N;F1E7UA2J-V(.A[63-.(OYN-6+4#1M M;I5Y1T16)Z-J)PX;W"KAA',&;N+FTV2IIA]V.1^,JFI==%8E"ZLTS;=&%U#6 M7T1"7#YAJ0\ORTU"U*1"VD/.%I 0RPB75.:F99"U3I:53%?D%Q1=/E*J*A)* M!I#?EIE382E1A10 HRXXH% 1$VE4P-25TC%P8#4Q2ABF+V3 )1N-29BF*8ON MB!BB4Q3!L8H@)1$!SKG;1,/TI,.0_P"]:X@!L XS;FJPSRZ>77Y#GZ6^I]E3 MUO:]@HU%5..B:.I&.8IKN%'2A&K6XE*$02,X6.910$R!V4\CV4TB)HI 1%-, MA76VZ!BU2(F* !^BUP@'/K;JJ]LYQGET#; CMKZ&5K\FK*P$K(E:0O4$K-(P M5 +A)4 92#I1/0;#S:4^W3P+ I(M!@/J@VF =[$D?/&IBI (%_V2CR* _JAZ M>70-*9,2@8W9.;LE,/8* "8P@&0 N>R':$=BY$ R(9$ W#,8&F)NI7P15/Q2 MTK(EC)B8.V059(=U$TY$.YV.9:JG-)RK^%FBMI.#0%1_*JS,>^.FP-FX*D[>WJMZ%M:5/5C!@U MJ^BZ/N,0T($Y4=(5)4=(OH>(BZ537CWDQ3M'HR24FB6+;UY4$HJ5ZUA(]D4[ MC1_#7QHW.X7D:F:4E TW.0E11Z;0(*0!\Q3@%U6HDFIVE9I%U(3\/4$ZX9PS MR1,JI+Q,H]CFKE]'D4B83PV-<1?%#T_ MJ61.$=,L5 MV+&-=5#.*2\>1Y.55, Q5=*5*JC$BT;/1:PD' K@X?O_ ):SDGB$>(Q42ZAA M;CCA=^]);3]V#+2$M%3:E*2IIIU%(GRFU)0H+^[J+30<1ZYRORPY2&@E!>0A M*= 9U'SBX5*)F6T=4;$5E4FTK1\ZL ME%53&O2)'(#A!2(Y?+1Z G=KL&%7KUQR^'S'<- M)V"[<]M^G/Z?=O\ ?I\%L;F! Z#_ #_:W'/EU^.=+X?,,<^GGN.GOPXY .Q ML'E@?ACW@W^&= -\CN0!\QR X^/O=/7X>F@63<';>X^I]![MY:>W0BPML!'R M[^Z,,?=YVR(8\L!CGSR&,^HX'7R70,=NY3+DQE6SA,@& NYE$3D( #@ #)C! MN.P!N(@ ".LB\-Y)\NN0 ?\ SH?SG68V^MO6%U*SI^W]!0#BHJNJA]]GPT0U M.V1,X6*BHY756*.*?5E&2IF"I$14*Z!,PJ;YN!P5M[?<+- M'U%,%HQ:]=3<31K8(U5#W7B)>W_Z*N*>E#ILI&:2E"4?!+15013QK.R$JFP? MPRK)TA(J$;=@3ZSHS@:N%-W!LO3U05-;=I05YJG>4["W1HZX=*UG3"SF%$%* M@AHIZU=)(/JT0;@J2%IE7I!X=:I?9*"AAUTAYYT_>' MET2'2IQI;2PI2 VI\I;:"$K27069UC'=/?Q=;P)"@IQ");0@!M J%-Z4.)6G M2%%26PI3FHI(1#@ 3C<4]QT0EN:)X66EJ*+L_7U>6NX,:N:"@JPJ!A+&K**FE*M3K2=AQDVDFBW-$U1+ LC,JI,T'ZD>Y4;E6 M,=)JL@_U3P<5*TO1<.TU+5_9MX%(5:WIJ&D*KN_15.O*B6FGTDWIR#;M5%BB MYK<21XMZEIU@U.6F9=9*-DG""KAL"FR[?\%4Y5%E>(%G*TS&0%];3WPH&AW+ MVKZ\BZ2IFE:>>Q1'M4A,23Z82I1TW/_A9UP@!:-*' M&TA*(;)9;05MI]E>MQ7W9)25$JU(&E24I&G7D=QVW"1=7;"H+<6BKZGKJW35 MO4C1U?T_*5%3E 7..8G8J:CD!EFB_>IE1;=MK+JNDG!FR)E#D35?)/'5S[0& MY$K<&\E95);FUU5P=\@HES6EN9YM4ZM+MYJ@(1G 0-10$@PGH^HHB7\"T[+Q M0D@J@X*J"0(IIH-Q3P)UP>7=B+CU':JJW%L*#J^F@IH%$:\NG2=+1T\-8@X- M3(4C(/G)AJG[6\,L1,(ML<62Q ;RH,%S$3'Y,>#N]BTQR#QW(/5Q(F057C]RJ[=KBFD1-)/OG"ZJHII$32()^RF0A *4)2T'PC7HN M13,955-1-* RJ9Y5$=0,;-5U3,#4ET7]%)KJU2UMC3DB\2D:P/#)MEQ<*-4V M[=4Q!3:K.%,D"-HMC%$2F2,40$0,0Q1*!HYI<=@W>-FQ>Z[IF2F%ZG6;QYQ%=(J44Z;,US**E1(S[P>QK"K&RT M13,U5TLO5,=1%6IT))M+;5/,M9)Q#Q-8/YJGVSMP^6B8:?=QZIZ,&JVD:_\ MLU5 CYVD@X5;)N!73DI%7!LC;*BJGF&,O!O[HUBG'-'D59J.DV\ MQ=1U/#M:5MXXFGJJ*"\O%TE4M0Q\9B=;,*JHU^2U2(J+H2D. MTSCZ%+<*+DI6AMME"2=3I*SJ2I*@T %JV*2G:*?,0TH(2;!/LK4 MMPD A'L )(4%+,I3&V7OQQ(TG,RE.5/5M0Q\_"NUHV9A*OI*DEY6->MQ$%F4 MDSJ"E5G:"R8^\9-P 9 Q52B9-0AS-TI+!TW-/Q+- MG+YU1-=PTC)HQ+RKWU-O C6[=E&(-!IX!""8?9J30!5)V=@3,E9JJ MSK2E7UC3=2&G'?O"U65&585(HR49/5RU&Z+$MCKIE=2C-1-!=0%5SLRF M-& J@F98K=)TX.07ZF9Q0S:[EN5M)P8%D)*-1:I2;*BQ;1"#9NA(/HBI90:9 M*S4GZB:N5UX=U'+M6C2.8>.?LT4BO'1\G:D>PM(<;\I'DMC[PD:&T:/9;5]U MU(_$"I87J6E"4K*AH08VPKVDD-K"E!Q1+!E2C$%8#\'8PDI]E2BI("@HBMJ0 M;L49&00BWX2D^D*G8$-L:Z@E M$0#WAWZ=>8AZ9#;;RY8Y:F?>6DXFIJ?:U? E;KO$$'SOOV;6%;^*;LQ4<3\" MY"%8,$I):,8(FJVDI@A'!)FGF==@R?2L-%T](+1+\..=R!C/,,"/41R(#OZ? M@(XUW=+4_>&0O9224K22DJ2I)&\)3,QN !,B 4G'7/,%E<6*2 M) @%)B )F M(M8$\&X.&(4P$,;[;[@'QSRSR]=*"8#@,CO\ Y?+/YQTT]^',/['J(9]1WW, M'E]?O/##OD@<_,/O][G^<:V L]1/N'3M\;]#QCAT@186ZP"#[[^_#'W8!MOM M\/X!H!+(#S''/D&WSSI\[@P#GL8S\Q^F?F':SGERT>'';_1A@>@B'/EY] _. M TUGK^4VB>/K:^ 3T Z>ID<\G8^Z<,?=[9WQY]/PTO=@/+M#^?AI[\.([]C? M.W+(\@P.1SCIR$.?+0+;'_IOG\!].GJ Z!9)WW@[C:PG8V]/7K@4^AV'':>> M)'PGC#T".! -AV .7IC8!\PQU^6@4>OIG)0,(_/U\QWWT] V >>W\?A@=OS\ MCPVX9'EGX>F6M77W /-AMTN!]#:Q&-C2)N2+3O'(@6&T;;[D[G# M+X?'3/+H(COZ8.?ZA M%@+#:Q!,#UN+">N)I2.O;VC8P!.P[BW?B,,??U#?TY_+?2 U /VLYYARVST'\_/3S"(&H? =NVWOMWOBZ M1;VCWDF]A%@/CW[89!0#&P'QD0'[_KG/]- YM[0Z 1S]=1[[X1W/8 G>WUOO)Z2TMS* M-7#=P@)"+-7#=RB8Y .4J[58BZ(G3-[JA2JID$R9A IR@)3" &'4I)N[U65R MZ<3L1>QW10,8N1$O^I('$ MPB4N,B.N@ZK1LS;)^.NS>&NI,5#BX8P\S-T;39 *.4S&G)R2E)]^!Q$>T1*C MXD4]Q3^]L8>8H[E,'C0@@;7@H^(!$QP8.'E62H!0!-_=3&$4 $@!6] M6*-S&VSVDER*+F+YE*]3/R %0$,BV3TVO.A&M@CX:#B8-DHQA8*!8_9\7'(K MKBZ>+=DZCEY(2LDYPXEIN5>/9:453;@Z=&0:-$&_Q%N.^!'?X#SY\QZ_P^J> M&^?Y^(:Y$I2E04%$E-TE;CCFDD02D.K6 2"H$@!4**9N<8DDB-02" "$I2B8 M@B="!(D203$C:8(901$!P ;_ /.]!\OS\M(*._(//]K'X8^6GP6XCYYR CRZ MD23:0?A80WZ=7P6^V Y9Y".X_0? MXZ.X'&.GR^_?D.^WUSU!<1=,[<6].@WWMQBP(N53'"OEM$\DQ>^TV9!0*'+; MEL/:SCGG&/D(8$?+1W(8YARQRW$//("&VPYY\M\:>A;9YXSTP(XQOMC; _'T MTGAO3[_ZZGF;>U/J)O:^V\>EYL3,32+75W]HS:.P%X-^^&;N0SOMUW#R\@#< M \_GG;2=P&1Y" ;YWZ],0' /PSS\\:/#[B.0WV'F&0V]?E_#4\SG4/AZ<1V'7L; M' =5?\ $9FVQTVV^9N,,O<<]@Z<@$VXAN&>F/+.=<>Y]!^8&QMTZAMCEZX3SOB:?]2I'^ MHWOZ<>H/?C'0@(-C/5=&1%17!I^U5)FA:GD'M9S\#-5$@ZJ=HP31H.B"-XIN M=K3S2L*F=MFLW6]1NHZ"I:";/G1W17AVPE>J.I>I)"Z5*6Z$684^+:4EIMHTIF.6FS^C;AIX.7W"=3=JWSRZ4'3T=!4J@\OS)2!B"I M5U5B+_[*H>*J.969Q=,V0H^9J>2"D:9,S,K&&CHQ*GPA5JDJE>3\#G_B'^'K MJDTE8G,#6)71NT15H&6N,I2TMU#C1;<3K"E:FU*#BG!YC;Z4M^6?0Y9E2JOR M2ZTNG#)2^'X)-0AQ6I""EW4A0&F4K2"@)E*VUD@XJHK?V>]]%[Q+W+:\/]KK M+60?7*M;*,[;!=>,EWD?3#%:CY&JHXM*(M)5DI,2 Q]1(RU+0T\,0LHV=O'-U%$'D>W*507$@L1P9I&FCSE<.S/A9(*"D\4(>*4P_LSQA6AJ)I M4Q*PM!;^SK]5M<6EI=W248W9P V]9SD6\^W:.FZ@1I&8I: EXRH:5J&G*BA* M]M=5L2!C-8]\@@1QY3+O%-?E[[*EI8JTMT:*1"'92\6$++IAX;$K(*E+2L*2 M@)"0$B.\J\CIZA#@0MQE:WB_(TEO6H)206P$C2E(.D)4D@J43JN#Y7)>$6@Y M-"-4FH*;64@(N0G&T.WF$'-#5HGZ8-P'?<>8=0W^.X@ >>!^8ZW96]@J\MK7=PK;)QQ)N)MQ*K ML(>X$A-T51-#U;1*T:2?H6J&M7U-.4_1?VA4%*N&!96 A'[Z4BZM0EX8(1$Q M6*#C751PB-,UD]I9C7EO+GQZ%&V[JQ"MK6OGDG1ZCNN(1U)RE*D?/E!<.)>D MW+0K=VJNWBW;IB_C'[V!@EG0,"_3314PS)-=5U+2GM26TA0.DOJ2ZE MA);I="5:$M.K"]* E2G%ZEJ\A4T3R"\Z:=3#+;@;A2R$@@A T%9"G=2@5*6@ M%(,D!*2E(RV)1'^Y*X ;[W.M1N #TIJ[0M,S,0YDX]5JR?C&/._8.VKP[1"2035K44M'2D.J^ZL$-E2P4)UD!) M*O9$R1%LT"24R\X=5A)C> ??RQXD'M(-^(V@RQ]4W,N M55CZ"N70C-])5/,DK>K$8%>G:FIZ8KQTC4AHR802AX*IGWB@D)4(-W*398YP MWCE1&\RW]JZ*@X=:M:,MU$VOKNLZ32,^$T>U<2]-NIA(T\K NRI+N6)4(>HW MIUY&*BCI1#N0:&4!)4"H&+X[)"L:P<5\TN3$SJ=NJL;UDUFZ=EK9Q*]+0%H$ MY6;:DD5[G;D M6SO!;2G[ITFDPG*:B[K67JNI[9.JRA6\5W)JB7HVM86(D:=4D3 HX,>#J9%$ MKHKEJRC21)$'+OY1G>0Y@K,/.8H@HU3"JLT=*@J:H2%(;4S]Y+;;2U$E*H8@ MB5@-!M"''?8Y;FE*BE\MY\A+"PTEYTC4_JU+"RV"MQ 3!&I4IC1*]:BA-H]N MJ9XOJCW]>,[BP)CSEP)Z,JF<=4"8D8_K8#/X9FUB'T@_GS33"BT7 M:+!PPI1XS2=?8\@Q8-6/GQXQK@U=?N_/$#=JAW:P491=OF5'73&V]S&SJ.BK M?6Q C&N!KINUEZ>?51;9]73J3!J]:0U1TO4I(Y!)D\?/&CYDAN2O_:"7-E(% MAP\1M*KV456,K)PE.T+)2R3O[;@48U M_,R*<4JT8M:MAU%?#)5HNZ=A'R#F/&*5"GR2#PL)#S#IM(O&-.-YH'M,Q,T[ MC6L7&R[J-8L8,9/NH].(>S$:F[(S7!LU<#L>&LBKTO)J7&DH"J-E^E->RBLH M'TNN PXI#J%H?" %M D)*7' DA"5\.;YE3+;#"'%D)?4AX,K4R^A3:+:=39 M"FM2BE9,:HTI!$J&94RB/Z,7/S@1_1RF>UD!R A<2EQ$1R',1Z8#J(ZY6Y0 M*H' Y :8N"&<". &WM4@)L;Y$ Y@&1V$ Y@(.],MO^U>Y>% M2YA,..0B("(^8COSTMO6_P#VS@;/*F:^Z^=OJJ#'ESQTYXP/E]/6N&ZT3;VK M$2#_ ,V9 O\ #'E$@:J>YV3?G_IE\3$G:1%H-L3K]GSPS6LN3:FL[Y78IV9J M^;A:LJ6AX6@Z?!S+JP\9#0D2>H'K6'C%0=5)4-6Q%5> , )J&C*5470B&Q', MZ^6'%O:'V M':.4M75%KZ.:6X?W;@)EM5M!)QRA8NGUZ53I&4:U)3K".=?HQ M2%;.%7[JE:V^R!U%LJS5A5E>W)J69K M*Y=:3%<55.OF;M]+20H,$ 1B4'+. 8,H&&28T]&L(%F\>MXMI'QK=)O]H2"P M *[URHKX9&09POQ$JOJ'_,I!4:_,XQOC 9Z@. M SSP'+;8 W#IOH!#KOCU < (COL(\Q'SR.<^NGL6^>>1],X\\>@8YS50[#U#T'6J3M4U2'(J00H3(-0[-SUOU^-LN/KOG6;4I1%>7"GGE+VSMY75S:CC8)2IY>'H6$2EG,13 MY'8L$Y235=OHMBU(^?E580[ 'IY>-NO3=0;^8\]A#RQC'7TW !#.V_EN^88G4..!(%CQ-[?&,:L"-R>(U&0/A M\QUVW&&0$-MP$-_(1#R#/7F/W\A'&D[D,ACF'3'X\QV^&?/3YX;<=]A#'/. M\OX\O3;2 VQR'?S$=L;= W'KS -->UT_ ;V^OATP(N+F!T41>W4?/\SLR]QC MX#TW$=O\.!'J(A@0Z#G?=.X M0W4-.L/:5LO-K:=0;%2'$Z%#4"%"4F)!!'!!VS;4IIQ#J%D+;6E:#,PI"@I) M 4"+$<@S>9Q8U&\7G#A1%%T!;^A+%5K,T90W$D>]R\!NNZ[MR>/&EJ@:V24IZ#NS44K M9GB2->M%]=BHJ4D74_3Y4G1F]-D>4K',&E/"S,]/&0\2RA'4=#Q35HH:3DW2 MBZ9*V ;!U#X;_CORTOA]L9V .F0SGIG/X[JNAXNXSI\+IO)U7;6H9YW S M9(RUTK, \>(-Z<56G%6SQPR=JH'5!V1GK/BXL#E?F)+X<*6T^8*AT. LJIUMJ#FK6 ME254S2@=6X(V)&!S*I*0A1:4@*6=!:;TPXEP+&G1I@AY8,@[@\2;,F?'_1!Z MBN9*+VTKJD$I2FK5TC:V>MY5=,M[CTY1]J2*IMJ*G:QJFGIE5O#U@=PX1Q"W.4I& MNC;U]0$E7,A0+VP\[04=%N8^KZADJECZ7J5I<&DJB<1D?2;F1-'1R8"4 MI$Z4A-@A*9@&VY))+-W&/0?(0-S#IOY"'/YZ3N,B(FY;;B [?# ;?73X"&,@ M(B/J @(= Z[].>_II!;YYCG?S''TS^'GMK=+G,B_83N(G;;IO\,:T=S[R3M& M\^D6CG':B:A"*C'\+*0\!45.R#IM(N8RH6ZO99R;1(S=&6A9=HNREJ?DSM3F M8NW,<]31E&'=LI5H^01;$0[J,O;TI>TA:Z*<9 0 ZE=U6JCD,"8 (P!B(?NX M[\QB@(=HPCGM;ZX36 KWI9=E>(:N&UN[UOX]_.E9FB8B5CK/5L^B)IZ:1:OV M3=*%DF[:3!ZNS9TG%7,N+#SM96[M;>NX=S;AV:@ M85\N]IFFE:2D:)I9^_-!TM UW6"" U64TVDF1NS0F(&/?5 Z38NP1ZNHK$,U M*FU-N% ;0ZXXPX^"G6E\!2F64A*DS3!LK\P+*W&T)0HWQNLL*<9"@XD'7Y;: M%I;*;%F1YCA*A_TI5H"=(2E:M0W,+4:N@VAC!&VZI-D)0 3=B>N4HH41#)>V M9&NVO,.0F3*(X[1 >,DPV%2F[CW2@G11'?*9WM5U$Q X#R[V- M5+C;L]=25C+0P-Q:1M?!0LQ4*:E307%6_M'#OXZCFTDM4- U'%S161C*A3CVM.'CX9RX9K-L7P]4>U?4ZTG_ -/YHC:S%(7/ MNFYIZHK:49#6]DK@2(R--0TO5-Q10@XPJ%"NHAZI'NE74[,U3*%C&*+)BU>* MM\#644+#A<"TJ=!;+KVK0AYQG65+6A("G&BW).GS"&TJ4"%JS#%02G24E)"" M%:&XE2&UZ1I2HR$+"["='ME*+@:?0J_Q+5%2%O7=>DI %3 :*J]_4RX6NNBW3( M&P?*'D7Z42M"OFS1@J+MEO1PKT M[:ZD:X>-ZFE/TEMQ-0,(]/-5G:"0A[@*O)0*?J@:.I:D:ED*_IQS3:ZEIGSF&'/,2I%,M"T>REW2?O30_S M"I8DJ6D(0M2*V I"E* ]E,I4RYSD"E #J B.,9'&^1'3YX? "&< MY'//ER^>V//.D\-@<@.1'/4!'Y[@&_3;7:LMML%91I"G"DJ4$-H!T_A 2VA" M0!J5!(F2K4I6-%QQ3I2%*.E((2-2E :M,G4O6N3 F3I$" (+("(9W'T#.1_ M. QY[?>H(9W ,YW'(#MTV#?Z;!G[GKPVV/GSQ@?F;<>7+[]+X?E@>7J.V.74 M/7SV'&VMCS#_ %"(D"!:/JU@>V.+2+23-MB;"!(,P#)O(C#(" ?';F(;8WW_ M #Y8#2=R&X_+8!QC//T'[^F?)]% <#[V?N_SS\L:X^&Y\@\MQ^_\^>GFI4=K6L ;89.X#]GWM\;=H=P''3(?3YZ.X\@S_O?=I[\./+ M< #E@?7EC/WY_AKEW AL @ !RT\S_581 @<1'$V_?I9I%H*I'^H_M^1Z]L/( M)Y ![(?D/7F'D._UTO=9_9#ZX_ =.G<". [(9 ,X#KG<-A\]_+??1W ]2AVM M^@?0?7\X'6J5]OF/7KZ_(;FW-H!(,F+=#T[7CG>>O5K[KT#;YY_/KH[OKV0^ M[\,XTZ=P.WN@ ^8=G^@YWQUT=P/D&!Y\@ZAZ[_/XZFOM\QVG^W7XQ?+3?VOD M;V].O/RYPU]UG]D ^@?AOI.Z_P /W_UTZBW'&Q0Y\\!].H:!0'<1 /H C^.^ MWYZ:H6.GS';X[F +R,3RQ_5TX])&]^>@MO>S7W6_(/X?S^[^.D[K<<@ ".-L MA]V/OTZ=P;H!?AMC_/F ?'/IH! 1Z%SRZ#OY#OS].N@4.?S':^W<]-N,/+3R MH\;#T]>I^&&SNL9]T/KG/P#1W>_(/NW^ >?RZ:<_#FWV QMM_?#7W?^$/N^_1W0CN!8[<\8_.W71W'3 9SSP&,;_+RZ_3EJ:^QMOMV_?W M^^U#:=RKY$=)&Q[[=L-7=?X?O_KI>[_PAO\ #\AIT\/Z!] ^?7?F&@$/,H#T MV -O7GCES^@;Z:^W3D?77Y3$VGEC^KY;;?N>FVYPU=U_A^_^N@$O\(;>OX[^ MNG7N!ZE#GY;"&W\^@[=?0\..?U0#SV#;[]_KIKV$<#D"Q VF.NWT'EI_JOUB MW''Q^'?#5W>_ZH@% ?(G6WI?F+Y:8_%)].;?WMSU&&ON_\ "&_P_/TT MG=?X?O\ YC_73MW @.X?< "'+U^(??KCW \\%^& W^\,9^[37V^8[3[K[\_& M ;3RHSZ;;;[SSSTOAK[H V[//UYX#X^7\/32]UMCLA]0S])L\M/]73@]IWCO\L-? M=8_9#YCG\1T=UTP ^NP?RTZ"W\@#Y@&?SS\NGK@[CEMD!Y8 .?W\_+'3Y::Q MT]?E\;V^=^(6P.3\^8CCZZ]6ONA'H4/B'3Y37M;?N.WU\.MGEIX5(]/38\S>+#]VONQ_=#[OQ M'2 F(9]T.GE^(C_E\].O<#@?= ?+8OSZ_P = MQZ 'W!]X::Q:VYC?;;Y7/P M^%\L;:N\Q;B!UZS[MHPU]U_A#Z_RVT E_A#;SP/\].G<6-M7 MO(@;C??:\[\1TQL>Q2L=$7\X>928>O6].Q'$;9R;;,C/STS4)F#@7$744:Q51\J M\O)4R_+2[NAK;KVTE&M TM&U!.U+5*UV*W)<@(A9O6=44&YJ5W/4+0#)Q*+$ M5IUW'4O)54DX8H3,?)4>84XA/T$>SCXL;5W?HV"HVH&=/4EQ#4O LJ-FE5XI MA3ZMY(JGFQG!:]MH_7$CZO8-V A(UDPC57ZU&5J[FF;Q(S!2,EY'Y5XI:=?7 M39B+2*E;H4X\7'66I#:W M7M*<6O_+E>@J0#[+(W$-!VD^\! M]P%+@6C6IH)TI1H0XL)/LD)@:4IN0@J@D;KJ:'MQPA<,\9;6J*8J2]U)5'-U M#1[JDSQ=)N350O<-[5E9SD,>(FY&#I"'I-NR"=;L80[L4R-$(^$CTY29D$C. M=I41%<.JUF:2M_3T935.VWO53#QG3U'.'3:'D*M:553ZCZ?8HIGDSS4W40Q1 MW*\Z[;2$I,MS-%'BTB8K1%R7J7I6H>Y-94SP]W$M=5E2T[5Y6U0M:RB*E;4P MVIV8I]*;FVC]A+0%94U M&:@Z'JBJDW5/U=1=)O+:V HJ@I=%E<*80.,$Y_1:WU/2K]./<)-5::@G\Y5D MF1%A2,3%K3DW4<:S0656\DEM:G EE(<)T,H;TJ*U*)2 A @E2E P$B95 B2< M=\M24)*E%*4($J4H@)"1$R3Q'AF:L^-RV'#;(<:;:@ZCO&E8^-I+A]H]I M+U'/4(WJZ-[RFXNO*BA2&K^8J1-T[KV?9O&@R-/R\>O-U=4PAII[+WFPU_#WR7%K0DE*2XES7*'/:2I*92XM* MD:/"YJ4ON^:&6VPZIQQ#Z%%?WAN4I05"2$E(200((42%)!%\YBD_^)FO P&] MRK6CC 8_[W+K!C/+H XS\>88UCW8_NA]VMQ12 _W-5V _P#N2;7" !C& IVZ M8CZ!SP._EMGDSVVM?6%VZWB:%HIBJ]FILYTF1? NG#-$&+&1F9=Q(N&IN^23 M9PD8N[9LFA#/9)1!VU35:G,U7#NW*QFD;JZA]12TTZ%.* *BE/D4XG2!) !D MD38;6QHBG4\JG:;NM;<)!@ GS7(%XN=A>Y(ZC&L@(0QCD 2&.GV04("A3'3[ M8=HG>$ PF)VB^\3M@':+[QWE4J6I8^GBUG#1)8QW(PTE3IY MY&GZA;QKRF8.H'D/)$JYZP@Z>2VC@AA50!9HL54OAW"G=J]G1RKQ!0YOYB&-8<02%-J M2=005K"%*(D)EM*5*)(0%K#:'%J!(YJO*WZ(I+L:5!,+201J]G4(L3"B0 )4 M4C6H)!LDW-U55T_,5=6\ZVJ*J9]=@M*RC*EZ8HMBJ$5"Q=/QY4*', )BX ?U1[. ,'42B. MP_$,AZCI/#CY!] ^6-]_7YAKMV&VJ=EMAEL-M,H2AM 5(2A( 2 5'48'))FU MS,XU' 75J<6X5+6HJ6HB2HD@DDB+DDD]2#C(*;2_[6KDY -Z=IOEC'_?_2X[ M]>@\M]O72V_2_P"V;D'_ 'M5[RZ_]H-4!\NF^.7PV0Y&@:H#?8/,?EN.VN-:CHJ^OM$ M7Z4S5N\3-NF,T(&NFORCC_YR^@]._K-M:$2]P@=G/NE\L\@\AW_CKBH*:!!4 M6,1,A 3&,8 H&,! $PCC83"!0$=NUL [#K(8V)B',K6U45W0G M4.F>7/2=UG]G[P#\!U9/?[@T/3%7LHBEZ?I>F:?EE:@J&@T*?B9!S7-41<1! M?;U24I-$)4M8NVTD'N6T574FBJ*:)EVKIHJH M@W74:/6;I@]; Z;).TDW3%\BW>M%@062,=!VW1<$ P=ZF0PXUR9-X@I$I<0E< @#4A M4B H$RGVO:3<"RHSZM4O^T&R>W_L+U[_ .?4J@>8^7+8=_7&VK%S(MT%G+A1 M%NW;I*.'"ZZA$4$$$2&467764$J22**93*+*J'*FFF4QSF I1'6X:Y(5&WUF ME3@;L(TG6A3*+A*E!2E%*5$) -P =(-MP\%TS?SN+MR=I:( MN13$3Q V4KM+AXNR@M!TRI65[[!4M6-;4D2E(6?1?24[051QE3S,26=EH)"G M)2?;P;B'?)G )%/1(\,'&C1UH::O0XM51EXK62=(-*N?O[(59.S5S8%DY0\9 M,*3UM*WC8:IYB=B)$\BWJZ-AS2$TRFV4PFL@HLW6'7J^5BJ<0D(-ZJQB4).( M8R$-31^Y:MEXY@];,OM*,I]J0$B-6ZK"(8IN&<4@0$HR/2;@FE'H'3#Y4S4L M!4Z,RM3CTKQ*GZLJ*D995!-=MX2J:8?^#J%D4YR(J*+L)(QD5GB.4UG155$5 MU<"J;Y:C/LP:KG\P86AE^J4%/A#:"A0$0@A05"=B;DD@J)*H./:JH*1RE:I' M&?-982$HUK7K28(U!:"F%$;& E-PE(28QY#*#M)>.92 MK QU6<@V2=MCJI*-U126*!@*LW7 BS==,>TDX;JD*JW<)JHJ%!1,P!*KV@5I MRV:XMJBI2WE1U=0EM.*VW"U\ZUHVC)AO!PKNZE&5@A2572G<%C5W+!A5K!U3 MLO)1<4Y8QTE*HR"DDB\;.2MDXV1\2VBV+2.9)"FU9($;H$,'LSS+,T.U=6*5-&L!#"&0L/(=;@/:RHJ M24F2H $D2D#G'DLWH*"B+3%/]X\[_I'%N%)06E_A A*94E7LV2 =*B9)&.MW M6/V?O ?Q'2BEOR#ZCC^'W!IS[@>H!\ /YAR'GZ=0TO<9Z 'Q[/3GR'SQUVU MZ0+F+;D#<A'3U_+B+3.&ONAR/NA]"[8^_ZZ 2] #X[_P ] M.G<#Y &,[X#EUZ[?'KY8W%>XV'W!Z &P=>6.0#GF/EIK[?/T]WSXO& ;'*O@ M#V[>OKVPU=UC? "/W?0=L:3NL?L_?G^(Z=?#CG< ^@?S_/EY@(#Y!] #^.FL M=/GOMM\_A\)Y8_J.TW21TXOQ/O\ FU]U_A#[OPY:.[S^R'W?PWTZ=P(B/N@& MX\\#\.OQZYY;;Z 0'?(!TY '/?Z[?3/U:QT^8[?W[]M\/+3U/U'-^_'NX+7W M6/V0^H?Q'^N@4O\ "&/,,!_(=.G<>0!\P#^F@4/(-MNA1^?,--8Z?7U/PO$X M>6.5=+@3O%HGB;F>,-?=C^Z'W:.Z#R ?@/+X\OXCIT!N(B(8#Z%#Z;[_ #0 M+<<\@ ,=0 1S\-OSTU=0Y_,=O[])@03.'EIM[1O_ *8(V[G@GWX:P2_P@'QW M_GC1W6/V0'[_ ,=.H(>90'Z?/KH%#R# _+_/4UCITYZQ^5_A\'EI'\T^X]NQ MYGW8:NYS^SZCOR^_II.ZW_5^_P#F/XZ=A0';;F'4 SO]-AWTG<"&!QMON ;] M>7/ZZ!>]NG\T;D=1Z^F*6T_U$^[TZQWOZ6PYTA5%,51-4B-0C"J-T MQJ>C:AH.6%RW*Z%2GJG0:MY9) 3*$%N\,DT1!L]*)CMC 8Q2&$VS<*!MA[(B M&=M@ -^>6Q=NO[V_EMY>6L"&U%14VDE82E1('M)0HE M5.X25J(F "3&YQD!I"0'%#0HD0# 4H)"E 6L0 %7N$B>F,PBKGUI!EME]DR# M=BK:*>F*DHAR@S2!TQEIZ<85#)*OE3B8LDBK(1K8I6RQ"I%9F<,S HDN<0RE MO?RX:NGU-R\5 R2:C2(>4L=ZY:T M^" F:,XQ4T6X:O6 ]QK4O<#G]4.?D'+KY_R]<[:.X'J 8^ .<[?(//KK!3% M.N=;#1)F92F2"ZFHW@'_ *8![?\ Z0!8]J2,PMP !+S@@)Y@ AORK #AOV.Z M/8N-]KR]^KB3Y+LI38TQ+H7IEHVHJU0D:6C'":540S1RQBJKI;(E5I.HX]J^ M?(MI&*5*5--ZX(#?L]P"#77-W*BN(R43JBG+;+SSQ6/7EJ\CK>T_$7$GUXTA MDTG$[5C B3B0=NRF TT^!JB]GE")K3+EXL43CKWPYOW0VY\A#T\OQTH(>8 / MR /XZB6*="DJ2PVA2""DI"4E,(:;$$<:&FDQL4MH_H&F%;J@0IY:@H*"@22( M*E*,@S)U+<5UE2H(*C+5W7^$/J'\]'=?X0V]0_GO\].GA^>WU N,>7,!SZ_= MH[@?W0Y;#MSY_3IY[\NNN?6/H^G[GM;'%Y8Y5R...>?AZ7&&ONL] ^O\MOSO MH[H1_9#[@_ =.G<&SN780#? 8ZX^/+Z>6D[@<_JACX!N.V.O+<=]^735UCMQ MR.WY2?A\'EI@>T9YMZ=_7DSVVPV=V(?LA\\#^(Z04A']G'PP&G3PYN@!] WW MY==OOZ:7N-N09SS "XY\A#?X9R&_TTUB1S>#!].H];]O@\L!>V MUN+_ "ZX!M(-U$CL#V[S&_>TX?1:AY0#C8>?0!#'E\^6N((\_=^.0-C&>889_# (!L(\]\ /7RZ;\\]?GI ;AC M(9#GOV%#; =>I0'ZAY?3X[: M>1;^0"/UQ\0QG\\M)W >0CMT*(A]0Z_'[M-?I\^W:^VQ$;1SB^6.EQ'0&;7\M-8YCW3O8=/>=^PPT ;"">H'$=5"?E._&&?PQ>@" ^8! MOOY[CM]-_AC2>&+@-A =]P#GGTQY?Q\]/7<>@_,!^>-QWY<\!ZZS>@;:U74B8XRH*.42IM2NC.E^T8R2) MB)*F)BMY#:"MQ2$(2)6M:@E*0(DDJL!<[F+;SBI9*U!*4*42 $C42;0!?W6 MN<:O\, 9 "[8WR': 1^'+X &0#?;1X8H;8^I0'ESQTQ_/GRU(QEPT7;D6+*1 M:Q%*BT?TRYJ]LHKE,X3*6)&2[IFP.PB*6[HU)A6X%_O,MJ"XTZ) 4!P+8U6@N#[LCC[&%,LP!_]&+(# M^[K@&84FQJJ;>#_G-[R)&YY&T\$;S/)]T>@'R'HM?RU?A/,\VW%Q'.(X"V > M@^0"(!S$.F>G/U 0Y\LGA@'<0$1ZY* _38!V_.V0U(Q]PTW=C4G:SF#ITY&- M.M*J6!G<6W,@<\._=*LVAFR;*JESO9!5PB8@PS4%95,!344:D(JB8_6>\-=\ MX\\P5[;*H&YH!.-6F ,X@3"Q2F%#(QBAP1FE.](\5(6UG6QX5S$,Y0JK MVG0\$YGE4D8=%02SI@.:05713;BCWI ,H'>F2 #"'7/PZ7Q*L_0+:BM'!XR? M;4L_%E%A((-:D>ILE6D(=U'N730T@NG),#)(I+J%'Q:!14 YQ* 5U(9/WJE. MT$/MD?RD7!(N%)OSJ%H4)GW5T;L/ F1!;7M\R#((L-P8.\:$\* ;X''^R'3& M>@_+;'3H(Z7PX9 <=>A>R.-^6"_7/P#KK>JO#W>](BQSVCN"(-I\E*K@C3,@ MY43J50J)TX$4&I%ES2QR.$#E:$344,19,P#V1SKX!8*]QCI)%L[= ZCB2=PZ M"9:#J M;,[+1X.!D$ M6ABPYBN5F ,W8O4D.\4:^%<"N5,4%>PQFHBKR($&*/[(A_S1W\N8;#YAOS MUD2L8\;E3,X8O6X+)]ZB*[)VB59';*J(JHD!9(.T4>]2$Z89+[_O%UU#)D(/ M9.)$S;>ZH84S>\&2B!3B!A 0')1Y&#<,AK,.@[%)%X@R.!M'QL3:3C'R^"DS M;^6PLGJ>WP%XOAH!N7D ;X$!]W(_'T$/NTOAPP&P@(_M8'M??MR_P\@TZ "( MX %D#"(X "K$$1'J4 XB80VR4-PSR#._P!"H=H,E #%Y]HHB8,;[Y 3-Q ?U1 >N0,'SQT#EC7'N/0FX<\%#'/H&_GR ?72 V*&)^K]YH']/Q]VX),1(FYM/>6;PX! MN!>7D4?X9'Z:7PQ>6.?^$,]!Z<_GG&GCN0#F YQ^Z;'+SY?/H//2]QG; ^NQ MNFW/K\,A]VFL>_O[NQF_K;>-L7RQ:PX[]._IOU[F6;PQ M?3(?B>&+D0[(Y'_ &!^. P(\LA*P\>V[#=X=VNY>K=@4/(,!G&_:#^0!\=P^.E[C.V $ M// C_'D.V_X (YX'F*:H4RM]EIU3"EEDK3J+9<2$+TRG9:8"@1! %B0(S05M MI4A"U(#ND+2D^RL(4E:0KV@#! *9V5<&2<;"CKD\44-0D!5]/7BO\C0]-715 ML\E5IZM>U&$,=W:69JMQ2*5=U(>?JV++]I*TJ($7?&47>BSC49DJQ#1XZN26 M2+ W/B):F(FNJDNBI2QE;MW&JBNJRN=1"<(^4>3JM*2$_)R_?S53&0B#(SS^ M4:N8!PQ5/X6<9!%QL8W)4G&-Y)>414FDCNIEKRGGP4,>4L.*"P M5*!#I2%*4((4 DD!0%P01C'7,0P>.&CMTP9+N8]=1S'N%F;=9>/75(9-19@X M52.NS6,F%+Y"&0V QL X^/TY?+3QW/IZG7IH[G? 'W@/T#7H N#: 9DF8G8#BYL-QL/AH: 1$'C<;?A_U CX=M.@]*?N< [ .>N>0[]=:W%OL&,9Y8R8!#F/3?SWY\OEH5##='&SS>EH^#H^FH-K)T;1/Z0DJ.3JN2=U;!)0 M3FEXYL2548GF)NE1J.0K>,G%(G#>-0&32J)M_0%17CN+3- 0SN11F*I*0BTU M(F3FA@6,1#(+3DT_!P1!,L*QD#%91$4CWRS-.3@8HJS\Y'"RV. T("@K8.!S M%*4<*+F(8"CL841/W/> ]D5P2[\R>$3JF1*1,L_/9\6V&K:QNQ4/VJ_IQ:* MA:8H^-J&!=.&U2-Q+*WUK+77<2M?:V%<1S6W MU(0T36$J\?2DG*5/6L\H>JW\C.2,@2A8\IX[NV+(B[V-0;LTFR;- MM&GPQ=\%QOT =OAOSW_#?IJ2W%%'5!_P@;S3,U!3D4A-W,J%U&N)5@9%)VV< M(,GC))!VU.ZCE13C3I"W12>&TE:U)4"2JWM"9QUF9)4:ZHU(\O2O0E( M0$@MM@-MJ2"4^RI* H0"DS[.-V6F;V=&VU]37#/4*-6,Z5A'%!M(>509MJHD M%:@8(MH9^@NRH:SVW5PZMM34*]445(!&R[FGZBIA9?NA634BJGBUHN03 M$@B @JD"B3UDN!@,UD&31R4# F9,^VXAQ+=8IE>MVH&I"'EK+2"&D-:$@ :4 MJT%2B"?:/*4@8UT%LJ8\Q!2ED^T6TI"U#S/,*C),E.H 6$I'!)5C&:";NX&X M,7-!&-GTA21P7:(R$:O4<=%5"I,QM/I3!X",727F74U&OJ)CR4=)DII_XB.K&$J"H)&>E819![7NOMM6L'<%#JT\S2JB)192$9!Z[@Y)5WXAW".X]%= A MV0K.,N-4U7)@X81E0NUXAU!FIX[^1AFR$HTBRN$"F:TRBX>R 4RTD8]LC%2R M23-#[7B4DTGC!D BQ!D9QS9BT:L6B14&K)LW9MD""<01;M42(()%[0B<2I)) MD( F,S.V.S35<"42YR _WGU*/,.6!W#'(0VY:?.#2\$!PZ\8=OEJE(RA;?WWHN M9L,XG1*A'1%-7 DGT&ZYHGNC^DS M9A%9D]:TK5(-0ZV6TEQ>MJJ6ZE"4B"=93I,&!.HBV.HR]98S"G4 "E09;7J4 M$ITN,(;U%1($H"M0$W(@;G'IA>M+;\2]'R$%/@((,JTJH]*R=/5">#K:,=VL MN*^I>.N;0-1Q:I)ZG'"%34ZJDRJ"),5JLHF\AG9I",=NV#G):9I2B>'JVR\1 M3L?5\A!Q;V8J6J)V2<&4EJBJ":F9)Q*3LY)+MF3-N M!UW2\5!QA 9^<^&XA>*JWU95?5/#;5M VKMK5!::A:.LQ="T["M_[O+9VZAO MT1M?2S:>8R[>=9/6E,(_;E3Q7VD[9*5Q4-2R"RKJ2>/WSO5%[+Q<9?$"M&T! M?NZLE65M9V2IUS,4/::D8>V%HY&*9RRR]4Q5T/"O35M.MR1B+):G&*LPXBIA M\LJR?1X@V4!3YR/#^:@-*52+2AU3("B0K3YQ2 5MH*G$A)7_ )DH!1"M40<> MK%?1$K0*MLZ XI2/:!46A*@E2DI;48$(A>E=BDD1C?7$O5\)?RYLCQ1VXK]2 MZ5E8ITTL^V:/8]>GJUL#5UQ:F&07IRIZ>E11=3UN;C55 MBVVN#2ZLY3;=VE M(TXL_503;2(:[@1#/+80^>!#XY#?755HFEW#V"DEJ?C#/Z:;I-8%R1 ML*(Q+5$,-VS1%N=-OX5IDQX]NJBJA'+"9PP(V<',L.1=QC; ]-@ P_<'SQ_# M7TS):)W+*4T;CS3S:'%*84A!;44K"5*\S<%7F%<*D^P$21L/'YC4M5SZ7T-N M-J4V$K"E!=T$A!01I@%.DJL@:RJQ,E3/X8HY]W_HXQCR]1#X^>,[Z3PI>0@ MY !P(!_/J/0>O+3SW'D4?F!@_AH[@?W0\OVNG\O\]=P' +VFW<\=1Z\XT/+' M0_ ;6O(/UUWPS^'+N(E#YEP ?# AG[_NT>&*(8WP&X #Y;8Z8#3QW&.F1$. M6^?X8Y;8^>-'<@&^/+GG&>>.?EORWTUBQYM8S'';8?/@8F@3 %K1(',=XZ<] M.N&?PQ?+/_-_B'Q]>F@6Q>@;8P&V1ZWZ7^.&@'<=.(_I_P!7?\N^&;PH .X;? ,_^HZ>@0Y^[GTP81\^6 M,A\>8!T\E\.;;)1 .6>R;81_'F'J&=NFFL>[K?MV^@#Z%HN($I1$?]GGD>?+GGKN'F&VG-XF3I.^HV$\#X20&L6P8Q@0 .>V0^?3Z :/# M!U 1Y#RWV_CL/U^&GDB * !D@[T!$0#N@,H F !,)E QR (Y.4! MQ\U(W*0 >2(XG<7(Y!VB1BALF\=#8=@/ZMM@..HG&*>&+^[Y\P\]MN7ICF.W M72>&+M[OICLCN/Y^[<0UL5M;JO7@I TH.MW0KM',@B#>CZG6[Z/9$(H]?H]U M%F[]DT3.0[IVEVVS!O?&0 M8400&U\;()W@Q(CXD^O3&I?#%P&V0WSML/3H(" _/IMH%J'4H!C A@ '/4,@ M/]?IC6ZGEB+T1R4@O(6CN4Q0B8I&=E%WE$5(V1C85P+D&\L_56CR$:1JPLW@ M)O5Q(W.+5S@X]R?#HYX;[\M/%BZL]<63;PY7(=K*0R; MA5-%EV@PLH< VWQ@:VEF/O-->(E]%_P@ 7N?:2+;2.HFBF=_]RZ3:8:5;\^A MWC8C<'&@/#!Z\^A0#?\ IS#RR.E%N4=\;;?L]>@^H^N_WZD ;AOODF:1(XM9 M5;)6(DXJ&DT)%&.BW#&4FP8C$LUVTE),UP/(!),!;JD2,V$'20J+IAVQ+]@X M9K["LY;_ -V%0]\SF&M/N2>)@ [F9>M6[UI'F-]N=@55VKMLL50ASMR@L0AU MRJY3"??J3FJI0+7^\-?S!-_Q7'M)O,7!&^'W9T7\A[G_ -6O^4B)Z;'T@CKB M/(-@VVY9YE#??X<_3TQUT"V+^Z(? N?AS 1^.^/IJ0C3AMO2Z7;H&H-U'D\]\1 ML\,'D(=-B\^N1R']/GKD+8!#8,!Y8R&/@(CGZ>O+4EH_A%N\4B6$.SA MZ25+4;!_)1 FNE:]#OFL<#87?B 6K G@'! =H=TT>^'H"/SQD,#\-@^>D%L'(2[#UP.1V'\["'\-/:C4R1SIJ !5$E%$E"]K/94 M2.9,Y0$HB!@*^@&Y>0@(\^G+//'USN'Q# MIIX% >H?B'\/SC2]QYEY>0&SCUY;;$GJ/3WXF@=!Q\+' MJ..;\S:89?#%QRSGKV0'KTZ>GUUR!J'0 YC^R4?QR.G?N =M_@!A+]>7/GG MU^&E! !Z#]#?SU0L=1O;?MN2/[<=9>6.AX]\Q_J[\]MIP_ T#;( ?#/,,AO MSP'0<;]<T >7E] SIY[DX@'N .W^'^(\M+W2@ .W_G(XSD,! MC/(//[\:Z_6+][3/=-[CU^!QMA(@>T!M]&)-NL<890:^0 AR$Z/R[/X>GON3C^R 9'S+ZY'K\-_/1W)QS[OWAG;?S^?UT#FUHZPK?;J+6-[Q( M[8:$B/:'R[?MWXZ89/"Y'D'GY (]>@YW\Q$!T"TVZ;^@_?@-OK\]/8(G#D7; MXASV]1'Y\OAOH[DXX.'[ 9Y8]W._P#/.D% _/L],;"7Z" [;8_KIK'3C@@?T[_'XB>N M&A/!2!ML.QM)/KO8X81CD!R/<-Q-GM]HS=,3"8, !A$4PR8 R #D1WV$.>D^ MS4!P(MVOZW;'_5T\]K.1-CNP]_(9[6YA'KI_[DX#D"XSY" !],X#[M9 ML]V @;'[61'ID0UR"/1#&&[<,@')NAD P @B0 M0#.<[]G.^1R&-^0Y =_L1N*90(F(IE <]E(3I)]H-\@4G9+G(;&[(" [@(" M#IW[DPX'L^@9$ ]>60_#??7(43CS*'U+_/4UBUAW]JVXZ;Q/4"W8X:1_4/E^ M^&M('**A%D'+E!8AP5*LBY<(K%5 , H15(Y3E5 -@5 Y5 #;M &N\G)SJ"B: MZ$[.(K(+FYC$GB,>JC6U2F\$A("!GZ+5!>16:I)/ M3 !W294@*NJ4JRA15(4X8=W)PS[O/GN ]?+.D[@W+L>O, ^_/W9]<:Q*65"% M,M*F =24D1 !D$0095(BX)[XH*@;.J%Y$*,S:#OO;Y#&SH[B!OQ%N&#IC=RN M4W$7!.J7C#K3!GH1]./3,#NH9H210=IH,ESQ<<)R$)VP%DV["I03 ![I^(V^ MBK<&CBX<@\2)22U"E,^A:4D%RTFOV 4A@=O*>7="B)4DB%YQ0Z ?S=A\!TQN!SQ%75?)R2$BXH22;RM/M:9<-WEJ;:F21C&17 MQ&AV*;>EVP,)) LB\ LL@(/3]I'O%#BU:BCU)"],E,+2[F:MC8>3)AX=/&JNY/R[ ?4O\]+W M)PP %VSMN'7SP(CC04]*![+#2#:"@!&Q01)0$FVD3UTWVQ0ZYR\I0O(4K4/< M%$B;G>UR8Z['<7)IQ\,B9[8FRX&D)",>%/#L*]IS[-:QXLN_B8A*,KL&[)E+ M%:+%DEED7+U0TB]4;KMS^&%OWOTTLV[*N,EP^LF2KFH(Y^<]*77KZ-194ZU2 M:$?4]%-)T*F CF4.@Y65G9%S(.&AGZQ6;-(K=J*>J10/L/9#8=L"'\^6E[I3 M]W[R_P ]4,LV@O)V_#55*/Z.$N@6"1N.%6N<8ZU3W^ C M<"4GPRO'38[ZV5Y(-L:9=NGI8"Z5,S!TH)1!X1E%QPS]%-S&>MW L%W,B].< M[E--ZB1,@+(&2ZR<)PUO? D_2N^%.&4D)PLBN[HFA:G0;Q?B7!Z:6;(Q]6P; ME9YX/PB$ZB(BGXKQ3B/,5+N4@U1W)PR(%Y\]P_G^>NCN3\^R&?B&>7IR\LC@ M/76(: _ ]4(@0-3ZG8MT?#PYD3.P"K#%U)/XD,*YD("#-O\ W918@08CGKC8 MC2@[0/B18%OEI[[3/)$. MZ$JW?&.0![,=9>&EHU@^CKX61(X7IYW.O(>>J*HZ4DXM=GW(*4^X^VJ629NI MU7+'4-_GZ?+?6 M12[_ "U3O_;33J'P2P@Q<"-6R!<'42!:V+3>PV+@-M(!)+BA-IF/YCQ$;5+P MXU\X:>-BY*V("029M7!FSD MA3.5$C LW72,4JJ*A"Z]%H41R+=(PY WO$2-[P; ;)SGVB5RV8%;(IH-E.TW[HIDE$SI*K$.Y.[ZUU,/Y62JF)MO63R-XMHC+,H]RT0E"^(,Z*=5VY45@=J1 M 4TPL0+I?T=,TL;I<4(X+22( .Y#@),:?Y.2)]D3 M'OPF,[8ZB(YWZX#)=N8;8S^&D%KD-@#EU 0W#KRW^ ?#&I (U_;^0=G4JNQ= M&JH.ZB+,NU:"G:OH)ZC&&;)-UZ:B4 EY^#9QHJ)>+055BUGK5RLX$JYTE02+ MW3EX;IA- I6=ZJ!=K3CP[IP5Q1MQX6.ITY7JC%NT8*%HZ*:N% M"$; NOU'%A+J=Q&.8JF/TO0EH-[4C8U!2T372B4+'*LTGSV0:4P[D'T7X0[] MCWZ+YL@L4'28E(;LK C164\@*6$&/PO:F";G8/)03^%9D6( 5L;ON[AV3J2( MN@A8&V_EE0&XB2+VW! FFEY).,J5 MM$MF@D_U15"90J)9\1TH!^&>>JU*2ZI2PX''?,0( T(#;2 W8#5I*5$*)DI@3()Q5Z%!M M(2E!;1I5>ZCJ*M4$^S,B1L") OAC\)S' 8Z (8';Y;]=O\]3Q]G[5C)I55SK M9(R4/25:3T=&U93%1H0A'@9ZYZ?A]VFB6IB(GDBMYJ'92:1%"KI@[1*8Z*I2F M*55! MTA)$A25* L2G\0$@C&S05*:-[S2-:%-E"DITA4'2923M!2"4V"ME'G$FN,^9 MH^JN(VHY&D7S"2,QHN@8.K'\6D"<>M6T%^E<=)E15)DCM9"&M %#) (- MS+'4[X C!X/ <9!-(N M"D 1 !,4A0 3B8X@)SF,;N&;J;Y(.^P#YCRYX'&^V_SUSY=3_<:*GI%+#A:1 M"U@!(42K5($$V"M()N0F#SCBJW4U-0X\(2E924I5"B $I2)]8)(V!/PPJ8+* ME-&1U.QTA-U).R 1D#3\-3\Y5LY.28LWCU&*B*;ILBDR_(6D7]4=Y!2U*+=YNSVC3YBK; M6B[;3TT[G+LDO/#UM2\Y!,$8V6HBSAY]RVJ!S+RS=NR1\ [@74=1\W*-8DL; M+STE L)-,CI%C(/O.5>?UM/G":4,%-.MRG:#;X25D*6-;K2T+T)#@41*E. ! M*2="M2,=LQE=*[0AQ2@IQ(>6'&IT@A/LH6E2=4(TR0D(45*/X@4J-;H-,YSV M?+<#!\!W#?77 &1 ,)^R'; HE[8 /:$HB!A)VNSGL"8 ,)1'LB8 -@1 M!T_@@J ;IB ;["'R$, &<@.P[9#&^^@4%?W!'X8W^77Z;Z]B%CI.VY'5,\>L M^G;'0Z0+:DCX B(ZX8P:]<8]1R([;_N_3(AORZZ46H(ZS> M('%A;I(._2,72G^H$=+;6WXOM<'N,935J!1HNT)0$#=FFZUP 8$0_P",NHP- MD '(8-[HYY#M@!UKOPV QC&<;X$>?G@/NQ].>I&7'NV:N[:V?H<(1E'.K>1, MNUJ&918QS5Q4\@+Y9O3[URZ:ID<. C:9[+9QXLP=]*.Y!\8IU%>_-K:F*!K: MM'K2/HZD*DJA\^%P#-O 0DA)BZ\*0%'0HK-6YVQRM4S%.Z/WX$;D,4RQB%,4 M1UV7=+:E/)2S_FODZG! 27UE*M6E*0%(.H6F#*@#8D!J.V0Y"/F ;[#G PQ/NZ@!J MA'364-F(!$)4I*MC-A?IM.B_#=,!U\^R&X[\OID/QW!:#G. #<0*;?(;[\ ML8ZC@ U(M_+<.S%I)H05N+J3SY>)8)14E6%Q86*0C9T@N1DWCB)I&G2_:$8M MEF5JR-()N$P([[QRF91$Y.FO=2*;C(EINREFJ?2>KPZ[4[RG9FM9")^R3HJB MFQ?UI4H.M9SQ3\8IL:*I.HGZ:\H"2RXQR*K:-.DH M_!!NX5,T[?B2)H*F%, 3,(;=3XB;Q,T73:!GHBCVCN=85(=K1%%4-222,Q%I M-$(]TS-$4^BNT(U39-^PW07*W4."BBZ2JBZYE,&F[D7,J0'03U?5K*IO)5>< M=(O*IF#-5YITBBW<2IVB3U)H#]9!LW1.Y(@4XI()D 0*7 @Y5&VAAL'DNNN6 M(&Z RT.O_K-@+B3%T4XOK6J=P$-H!-I$ZU@_\/-^)=8OAMO/*GC@&@)*';RL MU)T\UD*K>0](QI)J%)('E8YX\J*2CBQ[AB,7(H*^-(@47C15BD=1YV4#=Y#A MVGBJPZ@J683@2SBT>1X=NNG&JJ)G2>*I@ MGWB!UD"JZB61.X.=1P7Q*BAC'4.Y,#@YSF,)C'.98RACG.<1.0X -@P '3 8VU#]Y,_\X:2#L$TYU#< RNH6DD: MDFZ1)2JP!A(>0/Y"3()U.I(,$I&Y11(1,I"QXG5_T M>O.Z4V#L\N63 /+ES'ITT=R<<9+RW#H9HHS%H\%-R;QI/#ZI[DX\RA\Q M#U]?SG0")\YP ;8^7/;R^. \M0,I)E;M0J=_^<.(FZ#_ .J+8$D7@;%0/LE0 M+6-DI9!)_P#=(5:XCVPNX!(%_F)&S)*N+8"\EE*?L!2K!B]"&/&-:BKZY54K M0+B.-VY &[A&7@$9-C/=DJ;]C*-%Q01%5-BZ;BJ!TT6NC# +P&5B[%,4G4NP METB'IBKI91B#$8\QHA@YEZX>+)PD@9@<9)@N9QXD)&23*LDDND5OK3N3\^R& M?B&?G]-'6?7(;_>&J&61$^8H"![=54+-M%_;<4#^$$S7O&"[6H8"-7BZD?59'.(NW5NH] MPTFY%&2;N5B+H4H*JC,$)9ZBWC'!EHYJ11$4&Y#M&IT=/]TH'[/WEQY^?U\_ MKD!$X;X ,CU$!W^6=AT-/2$7IF5$P)6A*S&D W4#:"01>1(VP\UT;/J M^%9 M!WD;$;'GC&X!XEK_ *1*J-T9YB>#F9BH(LT6RIZ+!G-SQ9,DQ)%)'P38BR[ M].8DT5 *(H)I)D2*FQ-+[7S8I,DF-W;ALDHU&5;1J;.IY)L$>WFUB M.9=!GW)BBU0?KD36730,F!3II"W[GNB 77G=*?N_>7^>CN3[>Z'/S#;/7[]\ M9'??KB"GI0(%+3#T9:YDG^2\^8N9ZKO"E2\UT[U#AV_]8KB-CJ_TB+<"UA#Z M:X=RS-D&9KCW ,T;1Z\2W:C7-4^';Q3D41X%LW,X9)D*V7%N@ M*J9^Z3[#2XJ*K'3<[1S5E4.6JC-*/4:N:FGW+51@@8QT6*C=9^=%1BB8YS), MCIBU2,8PIHE[0Y^'7G@!]!\]@^/IGIR@-"(; M;%P3"4B_LF3;>23)&X/NPDD?]*?>H[6M!/&/@=_,+%436F)=8BR145BK2\HH M19$O:[*"Q%')B*HE[1^RBJ!DB]LX 0.V?+<*"@]H>V?)L 8>\6$3 7]3M>][ MW8QDG:$>Q^R 9T\BD?\ 5$H"'GL(;[[CZ>NX:!1.("'9Y\]P_'/X?PVS"DIV M &U@0/Z>P_M&]L2#RH;\WZH M?ST\SW&!LK_J]AUZP(CC$*0?YD_ ?OAB"/0'FW;X$,#E%,P8Z%$!+^KML&, M.-M 1R 9 6[8?= ,]PG@0Y 0/_6 M R*0]H0Y"/\ H]\=.UG'0=+]FMA[66S;WAR;*"8]H0SN;M)^\.XX'.0R(@// M3[W!QV[ ?4O\]+W)]MN0[;AOL(=,_?C5"^\;<\VCX=>(Q-">J8[ =N_//[;, M8-.88+@.08$-@$-@P'EY;#T'7(&F!V -]PW-MZ"//RV]1Z:>>X, C@O/;.0Q MZ[9^['UTO?UYZA6"=@-N;WB9^)._!Q="3>4\< ;1'-MNV&4&N/ MW<]1#M;[^@8^6= M '; 8STSGD./3;ES^O5Z[H_+LAMRW+_ ?IGEH!(X"(=G M&(,]CMZX9>YWZX^6X?'D AZYSO@=MSN!\PWSS#E\=]Q^6-/7<#^[\ MLC]/+UY]-'0!CF'T^//2B@/0?EU_EG\/73SW(Y'W1YX\N>!P'+7+N<"'NY'.!YCC/+.? M/X??IK&\'Y#:!^OO^)PTCGM!*3Q!-HOMU]>S)W&^!WQOG& _COS$-^6CN!#F M.?0-OQ_/\'H4,?L[YY!G?UWQUQ]V@4,@&0W#IVZ;[6V^._%L,O<&Z#GY?S'1W ^>.7,!W\Q ?NQOOG?3T"(@ 8)D,>61 M^>WYY>FD[H1R $'(?'GY9_/GC36)_+;MO)_2_N.+H @[6O[/0#MMW/;H<,PH M#R 0'S#G@-]Q]-'ST$.NX=?0>6>?3TT"@(!^J(^GO;?G\ M=M77]>SV[F\;G\HM D&UNWLGM_IX&QG>#;#**'/V,Z!0WSL/ MTS\QZ[_'E\-/7X'8>R(^7I],<^H[_+36!,SQPGH/2.MO?VH W)!V&WIM;?:1!G MF.&7N1P&/OZ?'E_'D.D[@<\P'UQZAYC\_P [/?<_X?(>H[[@ ?'F'EH!(1_8 MQ\0^7+X[8QSU?, X]?PGX3Z]N>F "0+&.OLR-AV^'NPR=P(_ ?/ ^6X^?Y^: M^'';< ^7+/YWT\]P.1V'KSVSCX!MSSC;1W([X*(;@/(-A^?/.-P'._KH'/A[ MNW&_KUCF\6!MWD>R3_3V'OCJ+G#-X<>73J.V^P8V#ED/CTYAI/#B/D(CRV#[ M_C^(Y$=/8H"(@/9]<8Y"'\_3[M\IW(@/+.P^73/GC<,?#IC4U]M_2VWRY!,? MGC'2-IWDSI,D6BT=NN&;N1_@(;9_D'PYZ0$!VY?, '&.74?EY:>Q0''ZHAG< M1WV^.?( ^7D/5>XQG;;?H8?NQM\0Y::P+0>-XV,&>WUMAI%A:#$V,G;;V?AV M@<89 0$>8^8;ACY]Q1STWZ"'KC;Z!GETVWT=P M/4!VZ_SQCSR(CR#TP&A6/RZ<1WY^._3#2.(V _">-/\ IM/8WM[V7N1SSS]W MTY_P^/+)W ]1]0].G//IT# CY:>@0''ZN1$.H9' _$,8_//2=Q[P[<^08P&V M/+<-AY;@&-MN3S!T/%H$S:XZ=!?EF[@1_KR^[//H M'H.CP_D(>NW\>OTVT]@AUQORQ@1#YCYAO\-<>X'<0(;< WQ^'GM\?+37VXO8 M=C/IW(OMM. $;1Q;22(M'&\"-ML,HMQ]!QZ!_$='<Y$,AV1'ES#??RQOCXXZ]-7S+B1L!_3VCI/OXW[6!( MD;#H;[?Z!;KOQAE[@>>0SRY=//.>6>GW#I!0'X^7+;Y#G?'ER'KI[!$>>,=< M#GI^GKN1_<'S\_/S^?YQH[@0Y%'<> M6^WGT_CSZZ:QP#>!%AR/V]_.+I%HX%P0>TQ;YQ(F9OAF[D0QOGGD _K]_/.E M0(HU4%9JHHU7$#$,LU.=JL)5"B4Y3+-SD5,4Q1$IRF/@Q#"40$#"&GCN!_=$ M.?GT^>CN!_<$/K_#.A6(VWB1;8P>M[&W]CB!,<](("K$Q&PZ<8V8A?6YJD]J)_0<_CS'\XUJN4M*Y;0MJQ_\G==I MI) $J##C:5* %BL&(/4XYD/.IY2X+1YK8=V,P"XA12+FR2+WW@BSYU%<+4A% M$J*A^'6B*RIM82]U(LJOK9N\:&."1S1LW#F74>0TTU35PZCW G3.+=PLQ%_>ZH. >TE+P!(WU(B3_(,;B:AI<2AE"K C MR&=)4")@J0=(V,*-KPHWQNL9CAJQVT^$BEUTP P=M*X=:CE0I 64+W98XQ\( M(@MWGZQ>VW4#M%*(#KJ'GN&XF$S\(E-D6$R!3%-75?&*4%%N[%3(QA1$FY!) M^J8XF'L@8O9,?$U&+:4[A=@_8NFH-T@*N1V$C'@0I154)XE-4RB!EE>^(#$R M:A$UG1$"*G* 'TU#%E,83/6*BCLH@X< HFS;&.@V%-4#F57,].=0W<+"!3)= MGNQ)GM .!P2TV9ERJFVH??*P$;&+O@3UBW7BN,PZL#0GRPG4%% 9:"280 M)*?+TS ]1 QM$)?AK('^GX1J91-W9B$*>X=:@8SLH)=I Y#QY#ICVU@3[2F/ M? V_9#M"J3_AQ0F#=A1:O*T #Y$QDAQDAR@=))4XAW9C@8R),8, MGDW:R#&LD-JJUJMM6583$\DOP! &Y'5.]\"M*;K2PDTEV41PN,X5:J*YX=:'H^FF8 9=\[K*M%G[Q8G:4-%P,0=RW=3.7+ <&\"K&%.8&RLWT,2?$1 ,_'/IK;9R]*25/OU3BC$(165 M:4(B+"'PM1(B28%@$I!!)UW*H'2&VV$CDJIV@I6W_P O2!O $GJ3;&\:CO!; MT74+*6TX>+>6[FHB2)(FDI&2FKCMG0)-';=)F>GJI*6GBH]\[*^.NNP>.!>L M8U1(R/AC KK:I[GW'K-NU8U)64X^C(]U+.XV&1 M-;K;-.WITH*E)_"MU2GG!O,..J6L"%*@!0$$@0,:RG%JW7 ,2E"0V@FQG0A* M4DV!F 28).&,K8I?QY]P.VX?0,[[[> MOKG?EG&GKNAZ$SUV#/Y^?EZ:7N!V]T?7 #M_/U'GY:V/,_(;A-Q;Z]W&,# & MXV&Z1VYCH=M^IPR=P.^X /ECT^//IH[@<Y,(;%$/+; _A^/WCIK!X/N@].GZQ>>9P@$6MQL;[02=(O%O MAWEE[@=]PQ\.?S]/4/@&CN!#;D',.7(>6P=?Y8VT]=P(!L [>7UR.0 .GEOO MI.X$<#V1VY>8@([<@#'W>6^- Y<\?\/4'8VW^7R@ &Q''!@[6VM%NLR,,O<" M/W<\>?H/3GR#^:]P/F&_7 ].GWZ>@0$=^R/PW_ESVY>HYY:.YS^SZ8.G3IUO?]?TP 3N2/AWFY([=]N@C#+W Y' [^@9'UY;CRY '4/+2= MP(;Y#KR#?X_/ZZ?!0$.11'/H.W^?GGTVT@H9']7ECX#RYAC;?ERSSU=8_(_R M]NI^/O[X0D >X[6XO^'8V D1ZX9>X'H/3<, (^OD&P?=UT"@( .!VZ!C?\^@ M??C3T* B&Y=\[;!D?A@-PW'GR^>CN.08QZAGH.1VZC^8;? M].>=]*"!OW1^>=OI^?75#FPB9-K#8.GY=OCZ<_E-( ,$<'J!L!_+\K=P8.&3N1ZC^'//+GUZ?+0" M_+'( Y>.>X[;Z>Q1';W0WY8V_@'RWW^6D[D?W!'Z_G\[Z:[C?Y=KF\ M<]AZ\73M!M;^4BUMK'Z]<,HH;?PV'H/P_CG.CN1_KD,?S]?ZZ>^Y'?)/N_(! MC'ICII.X$-@*([<]]A'._3/T#KSTUCH?E^^)I3M/NTD2;1P?UBT##** ^88^ MN/P^X-** ASSR'IY<^@YS]P<]/((B(; /KD!SD.8#D! -_AGX:7N1#?L_+&W MWAS_ #STUCH;^GYDB/7IZXL) WB>Q[1>!VX%C'0X8^X$.6,>@!_32@@'+?;R M -Q] _.?73SW(CGW!'GSSC(!\Q\P^>-'<\MA-D-P$0Y_=\.O737_ &%HXY[7 MW]\8FD6,B_$*OMS'/UQAG!OL'0/ESY@ <@SU_EI.X$>@_/'GSQMUY#]-/8(# MO@N,\PP/QYX'<>OIC0"(@/ZH\PWP(_/??;36.]O0].OOM&U[8H2.OR)Z=1!& MYM<3>1?#)W _O!C/ET\\9^[(Z!0\N?3K_ //S#KIZ\..O0,[Z3N/AS\@QY M#ZYZ_#UVT^=P/[O/; Y_B&D[C'GC?SZCZ<]-=MB8[ = >=]MAT] M<6 18S'8Q-AT@_F9O.&4$,;?>& #\,Z!;YZE^89_@'^>^GL$!V'L[^N?X9#\ M_/2=P/0HC]?CCI^?737 %CP>.Q_+M\+X@ ML3W!ZB..;;VP\ E@!VW'.?>'J M.<7RY?3ET]'DK00#UZ8[(9R8=@R.V!W$!$/GKD+,W4 M!'T]T?XXUPZAU$;7@="/D;G?C'/Y9W$BVT^FW [#I(/=D[L<#MY]1STY>@]= MP^&^@$Q$ R ;;<\#CD._E]?@.GOP9MAW'K^S_//(>GW;AH!H(YV$?CV0$!WQ M^UC/SZ],Z:Q N.FP['D<N]P;<[B8(M_<,O=!MMC ?O#USU / MKS^6CL#Y8\MP#&?/'/Z?#3SX0P=!+YXQ@=OCMTY@'D :/!B([@.?@4!S\1$- M_+<-4+MQ\$FUKDP1:;WVOB>6>Y_[1[=]_P!.;QAE[L0 73H&GH&@AMOOO@>SG[S9$<\MM]PZ;@M!YX,.V.GS# CCG\] MM2=N^WR'%N>O>\G#03[[[^FU]KWXZ<89>ZW 0 Y=?+'3U_'TYN+"$EY8ZA8 MF'EI4R(%%<(J-?R1D0/VNR=;P+=<42G[)@*)P*!Q*;&1*.NT+01#("R"IP.0A MP(H8@&.4< ]PJCWC(K@I3"\=&7QN*L#1=57 M4N@MN8HN KN=NC%TJ>4?++D1%C#1BL0^DZUK 'IECG;X919D4R- MDSE6;N$]:0S9"?,#S826@XE8;4E>I;;P:/E*7Y06DCVA9*[+&F4G'*:(D)T+ M)"RD@JE.E*FPL:M)44FX'*3(),&U9@I9YXV]1_/7KOI02P.VWU$-_B.0Y!O@ M1_'5@$7P]6GIB)O%*7!4K">;VKO;"4&W-3CUM%O9Z"F0C6#5%VDL8&;)8'DT MUD'[YKET"3!9DQ!('15"9!7W#19>$#B"I*GEJ^&MK14@A<9E.2LE'*P"T6^0 M4E&]+IQK=(J[L6L<0C1>7>=T\7=K@Y2P1N=NKR?Q6FUA(2Z9*?;#8TC46 #, M@A(^\LZK C6(22"!!1ND3*1O;609&LD0+7\M<7_EO C%;PI"&1V#US@1'SSC M;?;IUSG.R@F(8VV\LC]/+?5C\1PQ6C)/6VL[-K5LO'=BJ6%V51R@S;IMD$VK"-*E,9H](W>))*F:N2IF,W7*3NEP*84S& HCJ:J]@+7VYI"Z]:W+-6 M=71-+7=?VBIR-I&0CX%^7PP@<]1RCITBNV.X,W<))MV!P3:*NT2I=VL:02!O MU>.EJ0;T1?<]^*);84,1,S@I2+BF7[9 @KI@/9(MV<"J0N2E.)@ V"B$!1D!14)5Q? MRS$$R+D#$&^['TYAU'??SQOCU#;IMH[K([AD Z9$ 'ZN=PY #M MO@!][;YYZ[;['A!Z=KUV#G]=;VH6V%IO;>.8O;ZN<:Y;/S_J//O^N!AE[K'( M #IS$=O/EY<^7+KU3NO,.N1 3#OGKUW]?7ZO?@C<@SC [AV=OED!Y\^7+2BS M/G/O#ZCV_M&+P!/6\]1'KAC[H>H@ M.,]1Z_SZ^?PVTHI9QUV\QZ\_E]XA]-/?@S;<\?\ -SZ#CM;8^FWQUQ\(;8<" M(9VV+Y[#CM9#[]4*&W7KW@Q^7Z3?#03>>G-N.^V_P[X913'D 9#ID>7SV_ 1 MW\LZ7NQP 8#GRR/+X0P8WUY<_P\]/G@QV$<^@;#CT'?( /GGXZX^$/_B^ @ ??G >HZH7MML.F M]K;23>Y^)Z0-P=SO<%1V]G:3;?8P>UXPR@E@3#CH.-QR(_'?&?/8?OT=WD!# ML\AP&1$,9YXWW^/T\P?/!CU <[#^R.1Y;X-Z@&WRTGA#;X P &/+&/0!,'S_ M '8- K;;X B;".G(C@=L"W/)O$0J)V)Y C\_?.&0$L= ^&1\N7PZ#Y_#?2@ MGG8=@^(CCICGY?+&GKP@XR.>F!P =,CC<=A'\/J@M!$!SVL"&,X#'RP(#@=@ M'. 'IG&FJX^'&]K1UO<&]C8XNC:Y[ *VN(.\R;WGI)C9E!(0 =OH8<#\A^\! M^_JO=#R' @'+CUX,1'/9$>?,"[A]>N=@#2"T';G@?VO=''P][ M#D.G/KZ-0D38VXM,3'?CUD8>6=OC>_'?]1\[LO=;[]<[]H>70!'&>@ &PX'Z MZ.Z'/( R/+.W\?,_"&QG?'3]7E\A'\\] ,S9QN ? H"&?+([^73//; MEIJ!Z6_*W(L3V!/Q)Q V9W(&^Y@[6@WZ[^F&3NQR.P8'?KO\>ORQL.^@$@QO MSQC0[.V^/WO MCYCC(\M-8$?L+3%S/NOZ\S@$$W)@#:^]QT-]N3>8YLR=URVSCS$<;<@P.-OJ M'P#0*>1S@//.<8'RY],!CO0^U?9,Q)CL"+["V.@Q=OXI?Q46\LE9%DDV7>,$GC15^S0> IX-=VR(L9VU0=@BJ+19PBDDZ[I4& MYU.[.!5=JL8XK<\@^9,".W3=@U.^>-61';]V;L-&+?ERT]^#-CD.X[[9'^&WRVY>6@6@X'GGH.-]\DWB:"3.HF (5J)F(MO^GPPR]T(#,(X'.>NP#T_V@\_/8!T S'E@P;^1?KCM?_\ M.WPU=0/(L!/U:?SG>^)Y9[^Y4[1-B8['OZSAD[H?+. Q^L._Y_RTO=CYA]1^ M'R^(8'UYZ>1:;X'.<].R/H/[7H "'7RQMI0:P-Z;%''D X-]X;Z:K3 X, M0!TV) %N>.N^+H/7:V]C,6-YZQ/:V&;NQW_5'T'.,^?+^GII.[$,8Q]1V^O\ M ^FGH&8YQ[V>NQ=@'EL)]AWW ,]='A!]0#.1P 9^>^.7F'STU?F +6O;I'?O MOSB:#UXZ\VMN;[";;^APS"F/3 >>!'<>0CT^/7TZ:3N@R&"@'GN(_C\?PY:> MO!CG(=K_ '2Y'T$<[>G/( &1#0#,V^-Q'I[H"'^UOT].7ER#34.(X[$3$';W M_P"YP\N>HC_68FUC7E^>7UT@I9QL'+?<>?T#X_'.?5[\& M;U'?_"&/CDV_Q#Z: 9F\C!\BA^(A\_PU-0ZB;<]8OQP9PT0>?CW Y/>T[].C M+W6PA_Z$/+EY?+/EMRT=UCE@!QC81W^0AS]/+'/.-^6]"QV&VX':X!XZGMSB^7ZV,[^EM_6QMMM.&0$Q#ICIS MW^.0^_'ICEH%(1Y@'UW^?\=Q'E\GOP@@.-PVP& 1VST[7+Z=<:/!B(?MG7&^^FH7VBUXZP-XZ]#P>^)H,[[WWW].?TZVC#*"8CD.7KD0S@ M/,-Q]!Y>>E%/._9 =N0".1'RZ9Z[=H SCGIY!F/0# /P /OSSTO@S#T'YXW^ MHXTUCMO.VWK;:\7/;K#RR>2.@U'L"=XZ?1NR=UOR ,?XC (>GIUSS^>1T@I< ML [^8A@,[YY9'X!Y>6-/8M!\C8\\!O\0R/ECX>>CP9L#D!' 8\L; M[=!VU=8WZ"=K\1:+S\/6^,?+,[FW^HQQO)^NFV&7NQ\@Y8YC@>FX"(]/NP'/ M2=S@_QVT]"T,.0#M#T'8NWQS].0_ ='A!QR,;<<[%\^7/GC;Y M::O3@[^G4;7]]N=KH[D[ $JYL(C_ (M^D<1AF[K.>FWF(C\\?3/IRQKO,(66 MEE%$XJ)DY51("G53C(Y])J)D$3 0RI&2"YTR&$! #'*4!$IL"( ..X+/& P( M"&X &-^>^PCO^?+4U>%:4EZ7MIQ5SL%)NH:9B[8Q#V-E6:I473!ZW7J0Z#I! M0P&(15(P]HAC%$ ]0$=:]54*884ZE 4K4TD)4=()==;;!) 40D:Y,#C3N<Q[MPPD6CI@_9K&;O&+]LX9O&C ME(<*-W+1RFDX;+ICLHBJF10N0[10SJSVF'4Q>"R=N:RNJ[>.*VAN(>AJ5M]< M "(1%6R-/2<[!$E&S&69MT!D$V??RRR$@"3@J;J,(X]YPT45.V#8FD*GO)>- M[<./J&2IM"[+&D&E>3USXVCVOVC*,(L0BTRK1+V3JZKW#AZB$?'-$FD>#;PS M(ZR*H !M(9JE"G$O-A*F?,2L-J2X%+0ZTB&BL-A0*7 8("]04D))$GF-$3I* M5J.O04E0*82I*B=805004FXE,$$D VK+%+8 P XSC<=+W0\@P /F._GRW^N M.G/&]@1.'NTU&Q_$=*5X6L:ACK*5[3$7%C3LFUBY68@YM)HL1@Z*N 1Y')QD MFB3N1*F15,K=P=D5$ZI"ERFJ^&.RC.6NI0M/N*_"L8&U3F\]-34G(,#T_&PZ M1$U$:2=,40%Y*N3 0XN)=V":HE=E(@)5&(G=\AS6FF-+Q!TG6&@4P4L+U3JD M!*:AI2I /M6!((Q/N;L E2!O;60H^TH09%R2VN)D2.^*U.[^H_XAQZ^Z/,-_ M/0*0;;!C;;M#OCKL'4/G\.EB5+\-MHTWMG+<5>I6[^OKWT0M6D?5T#)L&M/4 M<#B+5DHV." 606&>*B5!1.2=K+X[1DE !JDNEW74I>Q%E8.@[?U!.J[1O/T2F4F,>ZU(->XI@!3". />$1'!0 R(FVV #(CG !N/+3U.4O45-.&K2I(" M7IYT^CVTJR;S,>[C5WD8\[0M)%LD\33469.@(?N':9116 AA34-V1$)P3'#A M;.V$5>^K[CKU=5],V_KQK;VGX2EI%C R;H9J.B)9O-3,JY241048Q\ZV:]R! M$F;E\@J<2* X;MR=+CB:-1N-;L&0NP9IV6HI)IXXA"/0;%=S@(>,(F/=D==U MW?B")^X1;O +[N,Y-YBV^^RVRDJ;6EPETI@$H;9<"4C\1(#J=6I,7A)/M052 M*0A:EJ(4DI 2E6X4I23JXB4'3"IL28G$$P3'Y M6?B([["/PT]"T$/,,_[/RS[WRWQL&D\(/,.T(YY !0P'/F)O/??J.M_5/8?V M$2>)GW\WMC@\LB\] ;D[D6@VZ;WZ$89N[';8!#X[!TY;;8\OQT=T ( 4NX_ MO"&V?@/7?S$/73R#0>6!^&PB !M@0R(8STVQI1:"'/M?0/+X_?Y;Z:KQ:UK@ M3QQ'PZ\;G#03:3[E;7$S!!.U][Q?#)W>!P >F0$<"'//00^>^VWD""D(CR ? MK_,/PT^>$'<<\N>Y<]?(?QZ9QH\-CI^1W\PU"OB)(Z#T[7%[3^1PT7%XB#,W MF18WOO\ EM.,B%N8,AC;(AR# _'?;[]+X01P'ZIASY (!\> M6!VQS0D?R@V%S/0?7?BV&? MPY_(=N6W]=M)X<_4OPV_KIZ!$0QDIASY^[RSR#?TW''X:.ZY8 PYZ;[?'!?( M!$ #YZFI7]1O'![=['Y_ RTIX0#MP8O'H=YYPR]P8<[#Y#D.F_/?ESYXT W/ MD=@^(8$=]]\#U^.GD4#;[#CK@,?'F&!SSV#K\M*"&_9 IO0 0#'G@2Y_(XU M=1O<\==OC_M[KW2D[ =Q!, 1VGY[>Z6;N#^0_0.8C\>8Z/#G\A^G]=//<#D0 MP8=NFP?>&_P#^ Z3NO,#H]9]<32G^E( MYV-A;]^_;B6;PY@VQC/H 9^6=];.MY=FO+6MJA94<]BF[.JDV*4ZSEJ?B)]J M_3CO%&9E.VEFSI$I4A=KF$ +V%!.7O"G[M/LX7W&^!*;T'ES#D B 8'RQOG8 M0'I(RR]M:#J:A[P5Q7+.JI%&V\; 2#&)I>6:Q#J0^U%I))PD=PZCI IE %JW M[C!"%+_I0,!Q,7L<%2XTEE2GD>:V5M)*"D*U*4ZA##@734Z)TQCZ=8M6L.B0PH(@N7PHF7(DFDJ M4JMS6IO%TO3D@$;4SY457TG _:$K&/BB#-"0>^+PXAI!0G78%"OPC62( A1- MB9D\Q34)41#DDW4DN*DZ1)!3))TB;R0!$6C&&2EX;BR["LHU_*,E6=?5;&UO M5!"0\>B9]4D2JQ78O$%")]MBBDK&M#'9-Q*W6[LX'+A50#=R1OC<^6F:^GWL MPQ5E+FTVVI2LEBPD:F20@VK;P:+9NV(D"4'>/&P/4EG2D@\1;?9@-#$='E".#LP;G34 M255*H03? ]3R]&EI%4U0PU/DJA5B21CC$D()5TFS1?PCTC@6#5*1- M2(B:L58'GH]D*:::94T7P+(IIID072*DEV&)O=NX+1C;6.2E&P,[1RCF9H4A MXEBH>,D7COQKA=VJ=,RLL"CGWQ3D#+% ,EW 1'6QY:S1L>H%-A -3K/9.0=KR38Z,BQ*LCWRZ:)5P!NNV79Y3A M\NC#MD'365I0'8N$<+3!&R2 J%! MR=$P@ Q+F7DDQ2IU.JO#(\Q90 5)*29E#Q3< GS%"(7[4(?$#_-("$@C_,)2 M =K[$%$P) TC^DPVQ/$#=Z#>5D\C:E03/7DTK4=1M74!!24:M/K"F)IIA&R3 M%VTBI$G=(]VLS3(0!;MC'3.=NB8F$U]7E87.G$:CK21++3*$3'PA7I639F=1 MA&=_X0%R-2D(LXRY6.LY.'>K'4$3C@"@&][H\,\Y05;1E(PTW!SBHZ6IL&YV;5-Q,FDD7LNFG$1S87#<(UT^<=J7 5Q9"X%!7LX8'#]=$:MCJ*) M3[=:=F:>=U5# UG(=Y%S4"S3[U=_$3+-VXC7X=G )HHK LHD8UEX7GOI[[@=P[)L]-N?SP! M>7F&^>8:3N#?NFY9Z?AS'Y!KFU':3]1OWV^B<8Z1/X1Z0>8CB>>OIQ++X _GM\-/'<] *8,CN.-\]<[>GEG :.Y-^Z?U MV'\<;:A6?ZCQU[=/SVDWPTC^@7X@]N]Q.U_TPS]P??F'R^X-^>D\.;J'F&X M'QYC_GIZ!$0Z&^/SWQD!WZ;6X@4/ M3(&#;GY_#II00$/V1'X_D _GTR&H%$_S3(^.W>W?X>MA(_E3\QT,G](@3?@8 M9?#G\A^G]=)XH9TGG/^N@6 MK^KIP>W?XGO?F4)VTI]"%<@=.OT=L,WAS_NC_NATY=?IH% VP8$<\MML!\_I MIZ[D=O=-OMG&_GM\O0 ^F=)W [['STVYX\@_' #H%'?4>VY''NY_3@X!*=]* M3'J)V$@^I^>VV&?PY_(?I_72>'/OD!\AV' _#H/TSIZ! ?(V?78=AY \]A M1VY?#1W [>Z;?K\?/;E\M-2C_,>.H_7L?UN#+2F0 E)V&QW//'T><,HH&#F M\AWP'TY_=\='<&';&=L\@$-P\\X_CIZ[D?(WP /(<#N #]^,#\='<#^Z??X; M;!L.VWY'&=ANHQ^([3.W3ZWZW-Y0F/PIV[WO'R@['GMAE\.8>F>70/EG?1X< MW0/AMYH@UGK M\>T3OQWVZSA"?Z1'O[3L.!O:-N@EF\.<>8?#(9_CI/#FSC&_/'9#ZAO^&GL$ M>?NCG'(=\\L"&V<[\]@QUT@H"./=$,#S'G\OCMRV^HZFI0W5_?;N>>#_ +R$ M_P!*?>#T[==]N<,OAS;;6_IH\.;'ZHX^ =-L\^6WTT\]R(!^J8!$ M=Q ,CTV$0#D.P@'/EL&VE[@0Q[I]^@!O\]MM74>I^)CCZ'ZP<72F-A>TD0-Q MVX@[^I&PQJ.[J!RVFNH8,AV;97#$! ,8Q1LV.V! <[ 8W#ICF$>/9\)&-P6 M\/)NR( %#N0+C< *6J:C*4I>79*4H 4I0P4 P!0QC4G[OH_\4EU_=,.+87$$ M-P$ Q1DYOD P._KC8>NHZ>SP1[7!/PZC@V]#NMPSOBJZD#.0#IC?Y:[MM4>& MZHE7_P!>9=?<_P#D&9^\VO'?OCSK@'^+*(1(_P .9F2F#'_G/)K_ /6,V/KP M1C5-H4Q'VCG& 3 @/]S5BQ-N.,%;0_8SD=^SVS@4-^SVC]D $QA'K^T<1,2C MN&H<"7/%]9H2B&2CVRFFQ(8,#LK_P#0[Q,1,C/\\ -Y'_C.X+'H!,;[7VQ8 M2NW,"[C #@'#CH'_ *F/Y#C'W8U\>X/Y" ;[XVP'4=]O,/,/II__Y#EE% P^H?\ NXQ\,_'0*)CVCQUCC??ZZWPA/*!Z7'3UZB-ORPR]P?R$ M?@&?+'7K^>N%\.?GC?X;_'\>NGD6_+)3@.,"._4=N0?# 8Z_/0"(CD>R< #R M#UP.,A\="HB/:/)-O3N9 [B/CA">$CYR8CG:Y[?I+*#<_D/S+Y?,0WP& ^>C MPY]MA#X@ ;B \\CL//J&GKN!\C>G+/7I^/7[] H"&.T4V.>V!Y#MR^74/YP+ M.\^GH8^.XOQ;IA )_"DGN"2=KV^HGMAE! _0!QN.0#F.?O\ KD?+2^'./0?F M']=/''.(?JCCIDO\!';1X?9/O MZ"/W;?B&?OTO<"&![)_781S\L;!^1'EIJ)Y(V'(Z1SN9^/OB:0+:0;]#V].P MZ_+#-X<_E\! .8?'.<>G\])X8#M]=/0H[9[)LY$,8''Q ,!CE MC?._J(Z.Y =NR6_/?TZ>7SA69N3\_3T^N^+I3!]D<7@P-I!M\?EQAE\ M.;;(8SL " ?3G]P:7N#^0_3^NGKN1SL4?+&P^@YP ;_' [Y .N@4#;!V1#IM MZ^8[_4=@U2HVO\?4?V]_6^'L[:4WWWCCCMSOVPR>',/[([^90^_(YT>'-Y#T MZ>7+KTT]=P/+!LXST^?(!^7G]V@$1'(=DV<=0Z[\^6/0!Y_#4U'^JQN-YX[S M[^)]90F/PI-KV.U@!Q^WRPS>'/Y#]/ZZ3PYN>!WW'W=_GOST\]SL B!\;#RV MY^F!'IL.,Y]-'-P8XZ\_EWOAI3RE/P-HB0;'\M MS8\89_#GY8'Y!CECJ Z/#G\A^G]=//7WZXF1,4AS8-D"& M$,AMD"B(9#80#(=1Y[:FHV.K>-Y(W$=?G/'OD)_I'78\Q]3S;WL_AS#T 0Z[ M!S^&?3GK9-N[HUS:P9X*->1S9*IV;1A.-96!B9YG(-&2CE5NBJVE6[E$I"'= MN!, $[*H' JH' I "7E5\.EJD'5P*4I\+@1E14):EKI7#:I&93U94I*PE"KTW3[U)O4Z;=LT+.0B3Z/=%@I' MPS-LEW\<"1BBD59(4W.5A^U1\/UTJ53C5Y:GVPM9*>:TN5[&3\)-LHZHGKA! MHVA9US%/G2<*^4<.44A)(=T0IS=GO>W@HN-1\-%XZ5AJBG)BDRI,:53.YG"M M9R$?OVD>05.U+A%-7JDBK$""2QTWQ6P$420<+)D,@@HH6$Y:4MIFB*#[#22& M2D_YB5%*!M_TFDD#^XD]A:YV!Z3C"9J\5QJ@8W$ MCI649+M+J245,5LF2&CVYI)_"$:IQRK95-,#1A4B,6P*)LA(182&%0!%0^7! MQ?6Z3JHYBK%IED,Y/T*:W$HY""BRI+TD8H$%@FV!$$6[@2E /M!(I78"'ZX! ML&<1'#A<9HZHN;J2CE7U)5#,40DD$?4D,Q<3;:LG!!C(Z.>JJG!F^>(;.%5D M@)%@LB=T=,52G)T'EB:SGJPKMC2=,%AH6FJP=TT!:FJRGV36-D57&(ZF?TBD MGS5C-SADE$B$3CSN3K=M(3J&$Y55@ M+$Y#)SJ@I?9[E1,Y1/K]A8ZXDM3IJGBHN*E&2<&%2JQL=5=-/:G3I\0 1EU* M5:R:DZDT(0P'4[UH1PF&1,W 3+,2T9"LX!L]!BT9*GCF*KE9 '(,TTB.7(JNEU%G:A>^6,?W\ 4H!G MY; 7/&E8RMS035.DI:/@I)E.KS<6@R%M4ND3+H&()F;0 M3O78IH$,.NM*6+N/".*^;RT*@Q&V3*,?U@NXE6)6C%O,I%5BBLW0&,E*.'Y3 ME!LV9"HJ09^F^CPYQSDN?EG;GOO\ M]/(HCR[)N?D/,.8<@\A >>E[@,8[)^F ,!C/,>>!'[M;NLR 2?<#V'U)]=\ M<(2!_*.LP;"U[<>G/NEE%N;]T1R/[H#\^?+1XCN#?NF^[^ M6KK/"OUZ?VCU[G !'*4CW$_KA_\ #".0 .6V1[.<<@V'KMU^F^D% W(>O38< M_?\ =TY=-/8(@/0!SYYSOT$/4>?GSQTTH(!R >@8$?CMD,#\-]<&LG@ F^ MU^.L]NL8Y;QL.!;?@&;$?+;TPR>&VR&,@.X8#;?;?;?\ART>'-G'/XAY[#US MSVY>FGD6X="@.^ V';[]_,0#&/7GH[@ Y@7/+D(=/GT_EIJN=O0QV[>G$;6P MC>W(X&UI_+]MAAG%OM@!$0'D'9YXZ<\?RT@-S="CY ( ?D,[\P =/7ARXY! MG?H(AMOSS]= ( '[H<^@YYAMS#'J/W:D^A]1P(^/ O\ K@1M$3SM<6GH3WO> M;\89?#&$?U=^6X!C\<:3N#!D?O #/(>HA]_X:>A1#F(!CD&0-]0].G+<>N@ M$ \@QY" \P'UZ==PZZNKL+=AO8W_ +1OB =AWL!OO>(/.WOWLR]P;;'RP #S M^ CCUU(RR]V&]K:%O&Q9R<\/4%TJGN+/U%+3E86QFJ3BY8Q7,D^&6;,=9PN[ MBI)HNHDJS=$4<* TE 46 A3(* **KP5DJJ'V6A(!!4"ZM$D$1>9XMW)75+7F94YFJJ,K)D:B48A,QVZ8(',H8413,N?N M#K%02AHDN\3:+,TGCI%D[%)1VR2=.B,W1TL&2.Y:)J@W<'2$"BD=9%0Z8@ D M,7 8^/< (!G [XV[6-O+/GT#RZZTDY>P-84I905)\E"50EM(98:O(*E+*68E M1C2;)"KXW#4.>S^'5'MJB2HZU+[ )E5@!,W)(L-\4#=B%HZS9*:.F[?U@PO' M2=Q&K%=LL:-?QU/GA%UTG,J(*II+K*1JR8%,4ZP"9-8"J?JAFEW;VTU6%+5H MC2M1S#):OE8UQ,T6ZMC1\:@)DGC9VX0EJZ8))RTP+%1(YXY\<7+Q8WN+*=VL MN;'7'D M6<^I(2EN34T\^U*3BYUI0-4,&C9&%J"+BGG>-JH.F9611-WI3HML-ETD@\2N M1!]:<15ND[BVDJE>3J=ZRHJW=8TM.2#RF&[&4=2LL:.+'NR1D*5.-33=@S5< M*)192LH[O"-P'W1$L%O#E\BX^ C\>H7%K^JZS=&7$)V8=+L4E\F.TB$3^&AF)0,!1*1K&(M M4N[[/N'[8#N(Z:$W#Q!J[8HNW:+%\9 SYDBZMW/P^IM;#;"45+M22DEQ"&T) @)2D)U*,DRM92@*("04 M-MB)$XXRLE"&^ 2HDQ),V@01"9, S=2C-\,G<9Y!\,@&_+8.7G^1T>''R#Z! M\?/KN/UT]B@ ]," B'O /IN&^^WJ&@$ #& +D=AV'[MQUM:^D<=QQ'?IST]_ M'!BT#J($';G3>W: =N<,?AS#TSMRP _Q'E]-F^ S]1$<_CH%N 8$/7&P!\_(GTTO M< ([E#8 SL([#RWR&, &1YY#4"KVCO':+$"WKZ][ ./B0 (VXB-]IN)MUPR@ MV, 8Q\ \\_/IOG(_AI ;FYX]1QCUWR B ]?/3T*(!RQCJ ^6^!_IOI00+_ M (0QR#!L=?+/X;YQ\;KC@38;>A'$VL1QS<1$@[VF>1OM?8F+?K,0,,HH#CSS M\,?# CO]>N@&YOUL;?\ -],]=LX\ONSEY% HYV+G(]!Q^(?@&E% O+W<=/=' M_K!^&FN.@L9/P]P@1;\\6-HMSL"!M,6L?D;X9/#&'?&<9\A^OO>O(?EMH!N( M\\XP&XAR#IS'K]^V=L:>P;AD1P4,>0#D!]1Z=>FD%#_9Q@,[&'?;UY?#/UY MYQ8\VCB"."/E?"#/!@CIM8P?9XXVZX9?#F'IGSV ?KOH%N/QVP.P;;\N?Y'3 MWW( '[(;9Y&\OD(?#?/WZ0$ $-P*.=PV-O\ 7/YVTU0#M'>(GO;X1'OY &_3 M;\(F+#@ 09_+X /W<<@V'EY@.?3< QGST"N('][;^L3\#B01&W>!;C_3 M\1;L8&&7PYBAC&.O3'ET'G^<: ;9Y]>7N@.1Z]=_73T"!<@. SY[Y^_^?+1W M "(; (_/^O0 WZZ:K6@;&T7[G^T8L=AUM$38;&?B(YM.&3N!#X@(@ !@,=,\ M\8Y[;#\]<@;]<[]1[.;# B# !M-AVMMTGZB&7PY@$<;]1' !]8[@./3[M/8H!OL&_F \QW#.!QYCZ]-(*09#;ID1 !Y=0#<-LX -\ M (\M"K:P^ OM/T(Q((Z&QX$2=/8=_=O-AC3]XV^+07:$PGPQR'J^TN2,2B^&/&+#_P ,;>A$3VV)$GR MU8/_ !-\3_\ Y?SO8 S_ .,SG:>!OZQ;%C+I 00+*;[#O\ +;YZ^(H%\B]. M@_AM^.^O!:K"/4&!M;J-]NGRQ],(OTYV%C;J+&UM_D,,H(#OR#;/(-QZNV_+/+EGRYZ>P0#_#Y[ ?IZ#C?R$?CH[@,<@W^.!W\^H;C MGR'YZ:^.D#\K&!L1 /IO$C R?EN!?;?V;;$'FP)PR@V'F(8#SP&V.N '/3T^ M.D\./3'I@ Y_#//R_P ]/0(AC(@&^W[09 ,@(;^0_GS/#@'0O3&P]>OJ'TU= M9G8;6'POUZ?+?.P#CX[Y#?ERTI6X[[#MZ M8]< (YVZAT$1#&GGN0 ,@ 9Y#L8/I@1$?C]WD"C\/H8?AUZ<\CCY8SIJ])]! MQ'O_ -Q$6Q(,6B;<=(_T]08VPRBB;?GL&X<\>?(0ZCSP&CN!Y8'. W\^8Y'/ M/ =<_P!7L$ $=@#(\_U@W^\1#UT=R'[0<_(!QRZ[[9#XYTU"P@6[^F]K\?48 M1U V%[6B-AI^&_NPR=P(=,[#TZ?7EGD'+ICIH[@>@!CX!_,/+3UW!>6 V#]T M< (_/EGGCSZ=5! O,0#.>>!Z?'\XZZ:P+0/?[M["9MTO&]L4)]!!M8=O]/SM MTOAD\,;RQGD& R/+IG/KY;:!;F_='[AY9WW$,8SOSQYCIZ[@,ND\.;];'H([!R],].HXSMST\]P& V+Y; (\_3^N@$"AN \MP'G MSZ9VY=<;[B&J%6X/T(B(Z#GIA!&Q''':-X_(0#VDEF\.;.0#GN&P"/EGF X' MX!H[@0YYR G/Z: M:CV]P';L>!]0,2X^0L-@8!XCU'(O:,,GAS". #F(CTYC\]]A'/YP>',.V.73 M8,;8_>#H.GH$ #]T!] 'E]'#H!?H//RQGS]>O+S:SVG_ &OTG:/6V+!F MQ MO GCL!%OKAE[@P;8'X &/+'(?,0^(:/#CL 8'.^,!S'Y\_P#(.6GL40#8 M,!T#8WW[[?GX: 0 -P[.<^1@'YYR _4.PFV)!@V' XB; M7_#[^>@OLR^'' [8\@P&^_+F ;?B.N!VQA(< *&1(F0Z?GGJZ_3K;W6M[N^TXH!M,3(V'H.EN/> M-XL-_P!_+\3MP)%W"4C5E1(V[=4W!1Z\ HE]D-W,BUCP1DR/$@2(]=-3NR)' M!)PY49K=GM D)0UE-1W^@$KO6>N% -Y2;BJ H>%IZ5BWB2D>H=Z1K*L)@T:D M[.9OWQ6T@DLU>=DB;A9N1(ZI"!WI8K=R&-P#UV, #Y" B._+^NVCPY?(NV((-YQREUTDJ) M]HE)Y5I*5:DZ0K9()-KP .^);)7)MO&,W-"VZ6JNH#71O+2U9SLC5$M64E">M6B=),4I2$C$SS)9),_?.T$F0MU6K%RF99N[!V@B4J#L7!(($3, MD8BB1A243.51-1,QTSIG(8#$.0Y!*7/8-(*&XB %QYB _4= M_CCK\]9*H*9:4).O_+3I1[221_FE[5!1I)U*B%)*-)@I,@XQ#[@,^S<@FQ'\ MJ41,@BPM>9VYB436\%&5-'7YIJX,U5#AM<]_3TC$5A&TM$(R+DU*IMT8PDK3 MS,Q6+%=T2/9"L=#O$MG JJHK&(N,8 MW^@?+6E[HU_,416G#W3<8SBW#*[-W'U U J]3=&4MU2BRV5@:%O:-2$-Q34A*RD%!2%!A@% M( D*2D(T:C/"]7_=$!YV- <88!"%$ZJJJ;9;!A4E)>>2%2;!1*I@'$Q+FUW$ MU;;RQM(PCJ5,^H2D'$)4#8Z#EHV"87/&)MSLA,H#=\)0;K%3=$+E/M%*!P[P MX!('B1K%U'VKI"CYV/"'NE74?2E]O\ 3/'7I$;X9@;B("(@&0$-\!GXN-0*_ZIN-Q83'3J(VWQ(Z1OL0.TG8> M\@]M]GWPH#S$>GGN!#D&V_4H>NVW7IRST MSH[@<9\^F0SY;["'3Z:UO,V&H1Z#CZYC&01M95H$B>G:.#VW[X9?"AYC]0_Z MNCPH;;CUSY^@ ..7Q#X<]/8H"'7/P$/S]WS'H@(#OL(<]\@'^8_CIY@ZCU@3 MN-[3WV,Q?%T\P;[7,?M[L,WA0YY$?B//S']7?UZ>>D%J _M?A^ %#3UW(^H? M,/I_GI10$/CGH(#M^'TY"/7&FL'=0/K!V]T#Y3WQ-!'\JNO/;J>WRPR>%#J8 M1^?7_=S]^@&H;[B/EOR^[&?7&VGL$?P\PY^G]=ONT=P.,X''Q#?X?GH.FNQN M(Y'LQP/V_P!\-,<*$^L_GO\ 4X9/"A^\./EGZ]G^&E\*'GGY_P BAIZ!'GSY M=1#^'7X[:.X' [_#<-_AL&?7X:%?&H=+1SQ^_'NQ=)Z*^*O3KAE\,&^1SGX? MP*&H<\6;<"U5P6>1N-2V8#UP T-<_P!//IOGX:G!W ]1#Z@.^P\\8VU2U[2; MBRG+#7BX>:?J6TCR>IJDKI47?^A:E@*F007K=.E(*K:3JN@7T4\BW/V-/,*@ MJ6)48R;=9\V=P[ULJ:,\2H3M]_X9HZG,=2@FNIE@N>2APH M00V4A:P$%PH;!\QQM*KB2-0[!=Q_5+C?EM_LX^//2^%#S'ZA_P!737;]]5,[ M0U'S=;TZVI"L)FFX>5J6DV;]630IB8D623QW3X2*Z#95\O#&6+'O71FS<%GS M=R9)!)$4TRY<* _0?,HY^'YVZZZ-:BVM;:EI*D*4DE"DK05(5I.E:"4*22"4 MJ22E0@@D*!/I&R'&VW$AP)<0E:0M*VU@*2% *;7I6A0!]I"DA2""E20H1AE\ M*'F/U#_JZ46H#^T/U#_J_GER#3UW _7U+_D&CN1]?J'\>7SUAK&^H<7(GMN1 M-N8]>9.>CF#ZRK;UG#)X4.@CZ;AG_P YVW\A_'&E\( !OGXY^[]7'W:>>Y'U M^H:.Y'U^H:OF?ZA\OG-Y_;%T'HK_ +WU[N<,OA0\Q#Y__&CH\*'F/U#_ *NG MSP_J'(/V@_E_EI 0'XXYY';G\ '/7'RSJ>9M[7R].8N=I&_7#3_UOBKG;GG# M+X4-MQ#'D._S]WG]/NT>%P',V-PSGX\Q[.1^&1^& T]@W$>H?[P?+;&D[C^' M7^GUSMIK Y YVZP>D=#VCC$T3P;1UD;QZ;X9/"ACF/3RSUSOV?AMH\*'F/U# M[_=T]BW'S <[?K%^_P#/IH[@0#._/H(<^?P^F?73S._,W$7CN.GY][V#T-X/ M/;^W62>^&3PI?WAS\0Q\>7W:/"AT$?J _P#H.GL$!'^H@&CN-N?RR'T^G7EO MUP.KYDS[0^7;M<=0/?W:;[&1ZVF^WSPR^%#; B/ERR/QP7?SZ^N=)X4/WA^H M?]73UW(^O(>H?R]/7[AT"@.WKZ@. ^7+[_AJ:Q_4-ATO$1[QWO8X:3T5\5?O MAE\*&^X^7/\ ^-]- M0\\!Y?UQGZY^FVGL4!#^AB_GZ: 0$<["/ID,_+'/&F MN8.H&!:8]>>>^^)IMS .\G\_K>V^&46H#U'ET'TY_J^74/CI/"E_>'Z__&Z> MA1' CL&V<"M%W+Z#EA2SIPHX53_; M@) 81 2 ,X[ ^'Z]N#45&44IF"FHSO*$NC\/XF45KCPXD%L&Q@&^.L'B?+G M3II:;.ZV1J"Z;(,[4R18C34.4+=.2>-+IF)D)OBPOPH9SVAW'S_ ,8^F/XZ M:E$0 #"(CT T=XH'PJ&$7;>C(JD M* CU"&]XR;9"&="=N &$P)F.9;LIX*"88WXTY=0-JBI\0Y6W!@IIV,TJU 0+ M@MY>FG4+ #34$'<&)..16;9DXD&D\,9PY[ 4E534910HN!"5)D((X[0L5)$7NXY /]6$<@(!RU#A'V3UAI0>]N1=3B@NR ML8>TL-:7MDRH+CCW@,VBXQN<"G.(G$I788#!0' 9#<=)^S>X(:.2;DCN&^W\ MHN@ +^KR2]92"YB@ JY6J.6?(KJF'WC&%J4!,': @#D1Y/*\,LD%S-+7P?*R;**"4V579S552PJUBQ198$';< M5@Z7%\8C4WM)^!6E>V5YQ&TA+*DV%O2D;5=5*F-N&$SPU/+MCB AL .<#S*( ME$1U@*'M/;&5**Z-J+7\3UZ':8#W2= 60FE&JH_^FP.^E'K7PR:FP@JJU'LE M'M=@1]W4]Z:L?9RC2D)2-H[84T"8 "8P=O:/CE" "59M#$7R 9[S.W/ M?6S4T123*BD(HHE .RBB8$D0P&Q023["8 &VP% H?+&J:SPTT/\ +RS-:I4S MJJ\VIVFU1&[5)EB5CO%4"!SBBB\6/'_-SC)Z,:1**'):I]Q*K7#];FRVR!:) MH\58FXON,>I]K=>S:NNFBILB^NE<2G*)2QD/](LU7BF:I"=D0,( Z[0;AD0# M(*:J_:QU7G[*LKPFVG04')5*MN#.5F^;E' ^^A!2K]%00Y=GPF , AVV>F>09Y[Y'&?+;2]R/K]0_/YY:G\;H6X%-X=R1N"/:?5F=:LQ$ M2*C,E,DV_P#('=0@IIAE.7MI(BZ#2Y6FI$F\&I5%H( M(O5//\*_'Y=Z+?P=V^-JE**I:I8U>&JFD;)6@;,B.H9^F=K*QK:H9=6+DP^T M&2JS198RPI*)J&*JBHB99%2P&UMK*5L[;JC+6T0V694I0E/L:<@T72_BGAFC M,#G4=/G(ID\1(2#Q9S(/G!4TB*.W2PI)))=VD3;/<"([ /R$,??OKB"(]0^\ M!#ZA_#6G6YS5US+=.O[HQ2MN>%,RI8"UM4R66U MK"5*02E.FKJRS?/M/N-8@B( 6QU@!VVR M8/?K\@QL&!QOG4I^)OALIKBWD_.35)O8^H(:LZ-K*G!2--T?6E-G<*0LZR1<"FB[(D#IPW>,C+M#N&RYA; MOF+M)N[1C79-+_YJ/QND#/NV+X?!'T 6D%@1R'+'UQUU9GW _P .8>OD'+X9 MUV6<5C]'F.5U5,\6:AC)/#SK3J8E*QE%$084"DBPU)4"E224J24J(/4Y%14] M?E6) M[52E2_\ H]X9.&VZ*26>VI;^[+RF';@";CW#:HYG!#G#($*+3 &']7L]DH6F M=S\1^8?Q -'<>>_S# _+GC7#_B$N$_>LHR&K43=1RX42C,")RIW+QQN!-S)Q ML?X8#9'W3//$M&$C2A S5=>A-YDC.&LR*C>P42!:!:]6J7&EQ-4T) N?[.'B M$C&Y#8=R5MJ@@;CMDB%R*BJ#5C&(G-5E3=D P(J%0$IBCVBY -[00;@7 E M'?\ 5P!L>N V#;/YV^;EFD]2%!\BD^0$!*9!\FB\0, \RB@Z*LF8H\A*)!*( M8 0P&G\4R)T@OY!Y(V/\.S6KIR)@R$Y@C-0 (ML#R1A_"O$;0(IO$WGD :?X MKDM'47_UG+',F49_TZ>L6Q!.F?:'\#M5@F$9Q+V[9JJ"4"H5(M.4HL43"( 5 M3](X.-13-@-^TOV2Y]XP:DE2%T[3W 3[V@[H6\K,@ 4QOT7K>F9Q0I5!]P3H MQ\DNY()\"!"J)%,(@."CKC4_#I8.M 4"KK(6AJ050'O#RUMZ-I**D$C".0%(T1 M, S(!1W @L1(&X=GLCV=-?A=T0ES/J$F+J1EV9(2) DZ596M4;?RVWG"/&#- MU-^'*]('X0YFN5..*F;%2,Y0C@C\4D$6!G$V@CUA+W@).13Y@H"*O=B7H('! M/L#@,8$#8QN& '7Q\,4/=$X=K/[P /PQC^NJWC>RKM;"G%:V/$!Q;6H43'M( M$IB]#IZS;B&!3*5H_C$S&3)R AW8B)1')^6,C8\%_$]2R2/Z$>T?OX95N8#$ M:W)H>B+BQ*P$P!$G2$E().U$1)[JH Y 5/U@[ AJ&BR50!8\2-()V36Y77,1 M_P!;[FC,DC;@D3M,X)S+/T$A_P *OJ2D?BH,YRVHU'V;)36KRI4DF1K")Z", M3_\ "AYC]0Z?\W2@U#S$<^O7Y%YZ@G(4A[3JDDTS4W=SA)O&4AA!1M6EKZQM M;(*IAD 'QU)S,E' L?F(]A,@&#]8"8+K&Y&\/M/:9%(7_!?8VO44@,#D]O;^ M"T<.3 ..VT;5*Y!9#/ZQ4E6RY^R.!$I@'6*,F<=C[OFN1/A1M.9L41M$>SF: M:!8F!$I ZP"<9K\0(9G[UDWB*GTA))&4U%>F#!)"LI5F*%:>=*B;6Q8?X4 W MR/PR&/H)<9]=+X8!P(CN'J'+RQV]G1Q/4O'H@)I"9H M)2&NTLFA',(PRZ0"4PY^T"B! [8B(;#L*S_M&.&B\=?P5JV#RXE!7 M$J=95G3M+W6MY+T2M-2*21U31%$:AAE"G'7J)ZES!I#2$E2UK6-_+E_#GG3V"&>6^0R&X;]=MOQTG^X_.0_E]>F@$!$,Y#Z@'X_ST\S;VATB!;8\".GPP M*2.%?%7[X9?#!OOSZYS^)?OY^ND!J&-QSOSS_3;(=,^H;Z>P1WY#\Q#'ST"@ M.<8$/F&/C\/70+YU"#Z<>Z;=!MP, FX@':POM;CW?1PR>$#S'Z_P[./NT>%# MS'ZA_P!73UW([^?Q#?YAD-'O,-/7@%HOL(.&DV ML;;;X9?"ACF(\LCMS]/=^8_G)X4N.8Y]1Y?0 T] @.^X?#(9^N<9#R].6E[@ M<9^[(9_#IG3S(YM(Z< =+QQ[C/=IVL8M%R/<+]OJ^&7P@8Z^@YY_]''T#^H+ M4-MQ#GOGG]0\^?X:>NY''(>?/(>7+Y== H#@<;XQUVSRSR^/\.>GF7WO/;M? MI&V_2U\-/8[]][1^D?+#)X4/,?J&_P#T='A0Q^M\\]/+EI\\..PY -LX$0SZ M?G?2 CL/\]^8!\/XZ:X_FC;](]T1?8C$TG_5P)DWV_/W$^_#)X8-M^7/U]>7 MGT'(8$=13XB&^+K<$N!$.UQ+S ;;X_X@;O#Y ., /GY &^IC"B.^/EOM\.6? MK]=4L^T#XT):P/$78FDYVSLE4R- 5FPO50$K!5.BR+<./G[=5]:]S2;EL^AW M9X2>B*VGRHJ/6IY-J\BB-U"QZ#QTD53OO#=#59GF1IJ)M+SWW',E!OS&6E*! MH7V1I+RVTJ.MY$@**DIUN$!#:U)\WXLS&BRG*4U5>ZJGIQF.4I+OE/NA!3F= M*\=09;<6D%ME<$I@JTMI/F.(2JXLK4.R&X\@Z\MO0H@&?GZ:4&H#D,CG;EC? MX>[D/A_+2TU]NNJ=@7-41[*'J5S"Q3FH8B.=*O&$3..&#=:5B6CQPFFN\0BW MYUV!'BJ21W16X.!22!0$R/7<".=P#XF+_#71J7I4I)4DE)*93I4)"H]DB0H2 M+$2"(4+0<>B3"D)5"X4D*A04E0D PI*H*5"1*3!2;&#AD\*'01SYY_\ C>7Y MSI0:@'7/S_AV?QSIZ% 0_H(#_#^NCN/SD/Y?C@?3EK$KZD==A,^D3]7QGI)X M5_WL,OA #J/S'RY_L_71X4-]QW]>6?+W?IIY[@?A\1 ?P#^.N7AQ'KRWYA_+ M3S.]XWB3'J!M<7^>^)I[*^*O3KZ#Y89/"@(\Q'..H!RY] #'PW^ND\*'[P_4 M _\ 0=/8(#@1^[(9#GPCC#2(V/Q,<$ M?O\ ##P+!_IZSSSVQCOAS?N#ZYQMR\^0 M_3?(!N&R>','[)ONV^[\=9%X4=]R_P"X4/IO\-PZXZZ!;&Y]K[@Z?\[35Q(O M'3M'?@>N'L]#[D_ND_1QCPMS;;&Y;[AYC_#&CPQ^79-GEC)?S_/60^&$1_6Z M /ZH!MR_>_KU'1X4?,//]4N_7?WM_GG34!R+^GY;8>ST_P"[_;&/>',/(IOJ M'7[Q^6CPY\_JF#X]G'4.H?G'QUD MA#F8/F4!_$1T W$=P,&W^$-L^@CC35S M(X$VXB/R&)[$Q%^FG^WUWQC_ (8W/L&Y]>R&^<]>6X?72E;*'.5,A#G4,."D M(';.<1Z%(4!,8?0H".1^&M0<5ETIBP?#-?Z]U/QT7-3UI+1UO<"&B9LKT8:0 ME:;AEGS%M+%C'+61/&F<%(=ZDP=-7BS8BB+=RV44*NGM:.]DQ6%WFL:\XPN. M6_MRHI9)L\>6CX746G!19:00?-D57$5./+?2M5\0-8Q8I'\."4_?%!-0IUUP M9-E%^[3TZJN;I=(6E2UJ3*0D)@@&/:4=A:-E'L1..=ICS9("0 8)(O[A%_EB M/%\N+3AHX;'4?$WLO/1=#U1,J"A3] &>.ZFNC4KH!2(5G35JJ,8U'<:<=JJ+ MH(H(L*85!9==!(A^TH75:''[=^1G'7!W<"L> GB61M[$<27VO15>WT5MYPS( M5BXI>V=7W-FJ8C[?W$D)^[YX.9@:!^W17K"@:!:O9*GHB%9*NI&;;MM>LCA^ MX-^%/A39G:\.7#S:.SKAR@#>3GZ+HJ'95K/@!A,*]4W"=H/:^JMZH8PF6?5) M4TH[6.)C*K&,8PC4][>010;^S)?F.8$$/:&-Q> 0YB++)*\,]]5#AW@"4!SX MTZD.-J96 I0T^TVM:#[$@*, M&;XM1E-%6TZZ6M915,.*;4XTXD!M9:=0\W*4P3I=;0L>U^)(XMB %/\ M7[7 M2DJ6#J"Q-_8&?4.8JT7&/.'^LI %PR=P4D.POG$5:J=,1$QDQI--V)-ZZXH*(X<:OEDYNW,W0JRL74LC;27E']S&%SZD97&9 MO*=J"74F_EJ2D&ML[-U/(U M""D=4;)*V].M8]*2-00U2P=Q#6,!5%!)6>,M'/5D$".G2"2:2+A Y4#M]1.= M5:8U!I=A=2")_#/X5) X$D6C>3;=%$RJ8U S&P,W'5*K[VF_, QC=5'>T"X% MK@2#:(I/B^X>'\V[,)6\#(W2IJDIY4X% QDP@ZU,\*LEZ/9B<#EGJ3CZJ6HE)TI,.HP[ELC1UC:AJJ' M4J2@G-?LB-)A2 +<9NWBF*2T:5>IJ@@7\PFD2H(15VP*J>,T )A*K\#0#.W,@1UY_/%G:S!R@ @X:NFXXW!P@='TY+$+@< MY ?(?IKX@@)MR[@&WNF*(!].0?=RU1T;@LM]2DL8;<\57%[:>%\,W?I.:7O5 M?V/29 _$3-!1I*.O@[IAO%D1*5,QRLTT6H$(V2C$T )G:E 6FXE\OD&!\_IY:JOIVOO:/?9C@\-='A>NC,1 MY#%2X+N'VZ3J(.0DTTM;?B[U)2\>5<@'8NUXZI[(7"B"MI4 <&CCMJI?9(P M?B\\&!&_?\Z,VHE?^L*;Q[39.\= KJ/HWX31NB/8![@HCKSV^4^N+4 ;&Y MASZE]1\L?G?2^'/^Z8.7EM\1'EG59L=[3-[&R25.7,X,^(FC*H*(HO8VGZ@L MG6#-)P0A#JE:.*KKZTDF]3( B;MFA&ZO8* &2*N86ZB:L@Y:9I& KR".:/))S<5*0\]1]40<_"3\#-RL3), M7Q#(N04(=,NTW5T[QTMO(4J)T[*BW! -H'%K]\<:V5(&I39 F)@$3MN._P"V M-L^&-G]4V?B7D..OEUTOAC;Y(.PY$/=WSOOY_+?;61>'V#EOC<0Y_(3!@<_, M-)X4W[WW!_UM<^H=1\OKC\^IQQ^ST_[OI_I^IQCP-S?NF^H7/2 W M'(^Z(9Z[?CR_SUD7A1\PQ_LE^[?8?7GH!L(YP;T'8!Q_TOO#34.H^78?1_?# MV>A'HD]9Z8QX6QNI3!\P#R'< _$?F//0#[N M @'N%SZ[Y_CH\-C&<"([ (E =^G7EZ"._P!=-7<2?2_7UVO[^IPE/3U]D\Q MVQCWAS_NF#Z8'IS';J'+D/EH!L;?!! 0W$=@S\?R&LA\,.1#( // %#8,]/> MV#T#1X8=MPR.=Q*41V\ASD,?'X::NXM'2;;=]OEA[-[?]TVVL;7_ +C&I+HH MJI6PN:J3O2'3MK<)5-0IA(9,Y*+G3D4*RK8I, M^ 3AW48H$9"_IVI'KX[),C07KQ:NZJ36=NS(%3,Z_761>%'F(@//F0H\_G]/+IH\*/^'_<)_/7G]0ZCY=A^@QZ7V>A]=)O?GV>< M8\+8PX]P<@..G/Y_=C&>FCN#=2F\L; /X?+?/PUD'A\B(=H!$!QCLEQG'0!' M'+RT W$1P!@VZ 4 #[C '735W ]('3I[OHX#1TD=@?\ Z)XG&/\ AS". (;Z MAY>NW3IC1X8^WNC]2[Y'X_A\]9#X4>@X#G^J7/S'(9T"V'("(ESY]@OWCGZ9 M^6FK:".VW$?L,/9''Q2;^OLQOQC'O#F_=-]WP\N?W_/0#'' AVN0[^Z&<[]6?SYZ/#FV]T?J'W^7W:R'PH^89]2E$?J)LAH\*/ MF'^Z'W^]OIJ'4?+M^U^O.'L]/^Z?V.,>\.?]TWS$ S\,Z06QA_8$1#?.P[!] M0_CK(/#YV 0W\B &?C@0^_7(6P]3!OM^J&_QP;[QTU1:1Z&/38^GU?$!3Z\? MA]+6'7YXJELBB/\ V4[CA)VHXT@MS?NCGS#&<9Y9WR'W^NLC\+M MC!<^?8+^&= -AY#@0WV #GYX'A2AGXB Z!;8'?LX$>78 M*/RSG/S'0*'!$^HP]D&,.?=$]]<:0&N0R ACEGL@&WKN&?GIJ'46CI]<3 M\>IP]GI[M)]_'IC'O#F'H;?U /OV$/KC[](+81W[([_[(^7H(_7S^&,B\*(! MG( '^R'_ %O78>FE\((UF1[%G>'KEG_AG\/X#@ #]9Y4. V';EG(?/7H?"J_\ QARJXO4* M3;D%IP%/LWTD&XVC?'F?&(2?#.;B! 8;-TV!%0R0;C<&".1N,69NVH@Z=AV! M >.@#]7;_6%-@#D !TZ!MTQKX^'-T(/GM@<_''GUY:RAVV,+MX.0#_7'>P M'_JPI_B^?GD1SKX>%-G.=_\ 9#_K:\Z% !-Q8#IV_;'IU:958[D?A/7TXC&/ M>&-G(E'ZER&?CD0]<_/1X<_[IOCMCZ\OOUD/AAV#.,] * !M\!P&@6P[B(A_ MN%_#/^6_KJZNX^5^ .XM\>^)[-[?]VP_[OYGX8QT&X\^P8<>>.OKS^0?AI?# MG'?LF^79_ .7+61>&R.=L8R =D,G!_E]+[%'<1$!YC^J7'TR(?+&@&HCC.!#R[)0^F^WKCGUTU#J/EV^O\ ?%]G:/\ MNGWG;TQCW<&W]P?+&0VQY;]H/KZ:06YA_8'SZ#T^?+ZAU'61>%-YAY;E ?Q- MH*U.<0(3WC&,5,I0(7WCG,!2E#(XR)A \L]--0/(.W0[0!^GTTLM7 GG!IFRO$E<2-@ MZCJJE!JB#HRVE*T=,3%%U3+4341J=F;F7D$3'?UXVO:)X4VP 4V^X?J^H^6/NS\]+X8PV[XAG[I^UIV"EILL>RK!X]7CHY<$E =BD1QP*S>D3("EJC^E [?U%)X$] M><*M:8IUL>+8J>KJ0IIQ*W@:,[KJ-'=7.6Z0O&;R_%1W M9>.6D8F===\W28-55W B@W0!8ZP&UU9XVDPAE1VN5(3S;9*^Q].N.1- H@$J M2.L)GD3)('7C;I,#%A-P>(WASM,V7>71X@+'VZ;MQ JYZTN[;RG54S]LB8$, MTDJB1>]OO#D)V ;"8#G N $0Q&YY[4'@%15!M#<1T%7[HQP33;6EH:[EWU5U M3&[!4T5+9V[J=FJVD'TY',2!R)H$0)43_ %0D)/'4*ZXQ MNK_:860I)@$F-L.)U]'F%,J,A,6>B[4QZXK=D$.Z7OS7]IG E7[102,+$.V8 M03 H*&(0\$KP\7%,\35Y^$&9I/@DKRXU5T?Q TI$T%'S]Z.'JE92LY.X+@M+ MP]-1P#.5C24K'-:W>495*R;^M8>.CI.-C3RLG&LY([W5O'#14UK&=:1D/-Q= MGJ1B$Z=F#&%*(MG3+]W+*6SJ^4@72LY/OH=NX47GXZ,03/-RD?$.YP8]C(NR M(/GYE]8\9FFW&!8H956(E(22APN DOP]NJA,!Z3>OJ- M1GTWBG=U2C23M>,+))HIKG.!6>LJ?Q#F=,Z'Z5X4SH0ZTEQE.E80^TIAY(*B MHPMIQ;9-C"K!)@CAJ;;<2#:4 M@*D$C'8F>.RR=LZABJ,XHHN['!77$X8Q8B"XO+:S%J(&<4(KX=0:;O(R6JNP ME4)^)[:15H>ZJYU3D,84"%$NIE,%6DM&-)F+=-92'D$RJL)F,=M9*'?(J% R M:S"68JN(YZDH4P&35:N5DE""!B&, @(W'S-/P54P3NG*FA8BHZ=E6PMI.GZ@ MBV$Y R3=4N%$9"%EFSR+>I* .#D=-%2F#80QJKJXWL9N#.>FUJRL.WNMP,U\ MNL#A>IN".XKRR%.2C@JAUQ4J>R/@*BX?:M%PN@DFCW63 M.&.'[(_'(?7G_ M $]-)X<^?U3>?3&/CR$/B/IJ,Z27$/P]\;4+P=W:O)2/$9258<*M8\2%*70& MS<79>Z$"ZHZ\M'VJ6HZLF%%59*6VK%M)(55]L(5'3M(4"[;N&GA7,0LDH54T MN?"F\P^/9+GZYS]^NY8J4/MAULD))(A0"2"#!!%Q8[$$CD&^-1:/+5I4!(O[ M(D7B^T_$#&/"W-^Z(=-A+_'(XVSOM\M'AS?NF'TZ]=^6W,/0=N>LA\,(]0$ MY")"CS\A[0_/0#?(XR7U*! QMSZX^>N75W'?;81\K#''[/3W:=^^W]NV,>%N M?]TP8VVQM\>8_,?PQI01,&W8$?C@?OUD'A1]/]TN/IG'4>G/?SR@M1ZX^1 _ M@.--6UQVV[?L,7V>0?''H80V]!^0#C(>?\AUP ]" +$?+MU']\ M%'&YL_+'RW_R'IG3WW @. ' ?'(#MY#N' MRT WY;X'J.T81\^W^.V?7&,#I0;&QD3#CS ^0'TQVO,?OQUT U SV@#;.0#&0 M^&X_73WX;GG8?/M"/PR E#(!M@!SH\-R]<9]X0#Y;<@WQY8^B3$3;IOM'7CM MB:#M(O' ML-S>(]-N^(*^T::_P#S/[C9$5!)V>%F]JO> #V>XH66< ;':WP M*74>O(>0^AVGU@<4]3S@#=L%Z=I]<#X[/:!:%8*]K&"X[7;[6.R&,X$ $!U0 M7[0QB=QP#<;B!%$R&-PE\0@@HJ(BF7NK65.N)C@ "(D*"63$?(8VZ8$)5,?BX]/08RT,;YSRVQYY#GZ8SJ@OV]O91IKV;S]1(CA-C[0R M.44:GV(Y(IPN\164CF$IR 411]X#IG <@/9' ZOSU05[?M,1M[[/5P =L6WM M#($ 1P;"X+\+?$T IB)#%. ""0@/8R80$>R)1 !'J3^HY[B?D-L;.-[W4FH5 M*P=>5G"3D5-5I#4(283D9F:4DEG=QW=V:IAZICWTF[N0YD'4L[BDV#>0HI]2 M+"-IUD=*19RQN^4BHNN:!N[4BYD8@*4MS4SF-F8&*G'=6T1 5,XD!DJ#AJC1 M=Q$E,L99"1#!R*HIE&R^YT,P<6PKNX9HJ$JJHWM&(7 M:RU4VVBYYA(5S4M\9^BI!!6:?TLI1JC3[.(T3:4U'*HU+"B4)A\=S%+HF&NE M"\;AY-56V_NRLV\=4VG E3DW%F:(06?,WE$QDY)D,\0I@%DFS607! QRI$>DD6)%Q!@653<4Y=H'@+NT6$>3PZ18O4;JRK9G5%N9IDVH^WE,-XVL:6$9*EJ M7CX-VF=&B*EF'S==5DU3=)D1:SC@%&I@7;NRD8O2(%722,$EN("C8&+B*6JR M!I:;K)U6,_3ZC>%=W2O/2="4FE<.EZQK6.6@*-B:H"FZ9;)K,%86.+ A).UX MU;_7E(--NW8'H'H1\=R)D#FW$WDDX" J]HCKT%IM8=R))VVF/,JO:,K.*-&Q M-=F4D8)1)%LK(TLO&"U=.9A9LA.@WAWKEXE%N4I8%#@F]<&4.[1,FZ,4_8V? MP;!4TA6?$0PIE_)1TY'7/?ID(J@C-HN*-;W(>I00/2PJU(O'#9C-KIFD)1V5 MG398!VX3JR(4(5)HEK:GIJ@(8M%E9T'69G$VBV=ED'MPJJGG<69W-2S4J+9" MNY":5)RH%:D78II%4,+44TG) /L3A B)28)0 M-MX\R+%>2IYH]A A0(V?13V>A78(+MU(V*27;.VL>+]>49(PK9P]8BW5C!&D MH,L5*K*M*L3IV.49,L1194UVJS&968LX@[U'Q*41W! M69P.J1.;0EEY=F[!BX@CCW\= )._XA-M@?7&2H(!WXDQUV@=HB>8WB<1(IVE M[E2?LX:3C%&3ZVE*?9[ABY=-'#E9S%,ZI[Y MQ($\.@W9+@X.(-E'*JJ2RJQI)'.BV*51NF[72:'+X4BIS(''78Y42*M!&^AP;D@#0.NYM$G< F M9%]>L$M?]I,6&TIW-@=Q;T$8YQT$0_$ _G\1T>'''ZV?3(AGYXVWS^ [!KTTGJ!SP!P>G8=IYB3CJ]*IW M'N ['IVV_OR&QLR U'/ MZW(>8@'ET]X1#\[:7PH=3;!UQY?GF. ]=PT]^&ZB([CVL@. $0SD0 VQR'D M.P:/#CT$1QYGP(_Q\N@ &^^FHB+BVUA%^EAOZ3@4FUQ\!VVM?8#CIAD!KUSG M.=\!N'GN(X^&>>^.>CPH\Q-Y]-P^\>?H&GOPVPX,(#_M#M]P9 .GWZ/#C^\( M=/ULY]=R[#\- HSN.GH+<18;[=,-"@201\ .G$1\,:ENPV[-J+JCVAVM?W[/#AB$!QFD:C']8 P(7#K$.H#C M(=0Z].>O0,D_X6KXM_XP91>T?^;LZW^$S%HWOCS3J3_C'+Q;_P!&LXZ<9ID' M'H??SOB? -?,V_\ G\<$#GG?Y M(0X$,;_723:_]HB.. MP^&U\ @]1\!?;Y6Y^%\,GA1S^L/PP'USR^7/TUUW@),FCQ\N8_<,FCIZOW9 M.H*+-NHY5[LF2]LX)I&[!1$.T; (9SK(O##^]C(!R$ W]0*',.8[^F,::*B M;B%.5$(#VA+3T\.,B.P1#X< 4 QSY &>>WEK@JWEL4M0\@IULT[SB-0]G4AL MJ3JVD2D3>3$ C?&W04R:FNHJ=T_Y;]53LN:8"M#KS:%Z200%:5&"08,&#,8T M+3G$';>I'=/MDQJN%1JU0&]-2U2TL]AH&;>"**E,@BDJLD4 MZY11!0#B4!V]&.G[Y]-M'5/R40C%/R-&+YXO'+-ZA;&0%523CDF3I=RU:HJ9 M;*)2:;1UWI3'*B9+!QK[@:ABZZL#9VS-)&?3=Q$JIIV1?1+6-DB(4\QB:AE9 M5_)RLFY:HQK)NE'.$C]ZFZ44,544P#M9(?,:[E4(B*XK5GT;)2S%[>VBHI4C M28EX%LV;/HPAA>RLC$$5DTH% 4@&1:LB%%[VT&BJA"JF WYLR/[9LV&5T69Y ML_EFDS9_,,I;.7Y>UF#O@;//$>:>',P6VQXA=549+5Y72H?=H/NU92C M,J85E(Z6'*>L_:WBK_DTY"K/\PR+(*7.O#68)\1YED%+D_B!Q.;YP]E%/]JG MA+P1X?\ &N4H>JO!K#5)XFR_/Z]ZD8S?[[EM>YDE<1\<,[4*C M=.LCQYC?I H*DD<7TF0YE5""].Y*DHX<"1(H*B4.SI?MTS&O13*R[PG05!7 M)56,I=R>O6O,$*<:9Q/GP@]H"Y-G?( 41,&/,-L8'GI/"XP':Z"(@& P (B M.!'D4H")AY &1$0 ,ZJ:XF+^7KM+8JP-3,+5W)N?1U0Q-M8U]/VWGXXE0-:S MDJNCHA-O6,:\C'LRG''9KQ;F)E&8KL'Q49YJ\\+,-XTKV10LZON3,<)K6]5' M2M*S-5M[C%JJBW]0-G$RVB3))*0T=5LI1JC**";=PZ,8ZJ.-BG"K-H_6<12[ METX0>]KW]9XZSFGR&C\0,^$73EV;(\&C)JJLSS*F*:MJ_%F9Y3EIIGT4?\2S M2B&6G-V7UONY4XFH2R\@)866 _\ (*\P\(57VB4HS7('?M*5XDH M19_G?WRE7F7\$R+-%YTGP]4TC-(UG[2Z-U^F<4NI;35&E MFR+< **G:#L=D#B?).QV1Q@XJ=KL=@0Q@V1*.V!'EK!:.K:.K.7KV'9,7[)> MW]4&I225>&;&1?/"MA<^*8@@4"U M$5Q&5W#5B JRJC=I3C$2&@VDBHS,+\L.5PH^-@HBGVS*"E_K I9R."NU27#Y M8WC8OC%)K*TA:Q:HJUI9LJE)J+2@1M).!HJ-;HR9/M5T,U/.(2,9)N0,Y72> MHE'M=LHCX_PW]K.8>+?%O@[):3+Z/*:;-6@]F-*[F3=7F=2:KP?4YXR*6E5E MM.M.54M<&J1&/HWC3_ )/>4_9]]GGVD^):_-\Q\0UV M0/FER/,*?)',MR*B30?:/0>%*G[_ )@C.:MM7B&NRLU&8.>&W*1]&7Y=74-> MUFE2IQ.+!O#@ 9,< P(Y$P@4,@(@("(C@! 0P("(" [#@=+X;_%OSP&W7Z!C MESUY)X!.^EB.##CQX9;]4W>:CZPK^R_#_P 7-+$NRYB7$[-5U/WEM=1'%4\I M)]2U45.W+2J]SG$%-0K-T\CIX(V0<.I:&8F5.4_KV4;8.H #@0.< 'M#C &' M'(,;^F0^N-?H:MHS2:2'D/)6XM"%H2-"DMM4S@6DA2@02^6R!8*:5=4P/Q_0 M5IKM8+*F%(::6M"S[:%+>JFO+4G0DI*13!P&Q4EU,I3$EA\+Y&'8-\AD>O7U M#RSOS\M'A0P'O?7IZ[_YZ>_#\\"._/<<_(>8?+R#1X8 Y?>8?F/(1_GYZT9Z M?D.8G]CU]#CL=!ZBT18?/X=_SPR>%ZYSSP( '+XYZ_+/EH!KMC^0?=G&GL&P MCRVSR][M .V!R AC8 Q^&D\/G/ZV/4_40';K\OX!IJ,;B)VL+R/=OQUW&+I/ M]0^ D$0(Z<#G<;89?"[;[[]\6W%KSAC\* \C M#S'(8Y=,Y'E\,;Y\\ZJK]K:@)+.<.O7/&IP^!D0W#M/*B^N^P[@&^-6W^&$0 MW-RY9'?.P9 <"/KC8/ASU5'[79$269X'HH9$!R(NZB'?F.!QRZ8#; M.=>A\*$_XBRFX_\ *"-O_E.6V]WZ\X\QXR0?\,9O<6ID/,#R>.^6,?]T*9QR'^NNN#41R/:$/00WS]0V_CZ;AD;MO_ *X^P;;Q MKL W';#E7S_#ETY;:Z_AQQG(B.'/0, (^N_3;U_EI/"[X[60^74.N^X<]L?AG M3WXY1#KGG@?+?Z:LGJ/@(,D=O3?$TJ MMM\!VZBY_;>^&3PO+WOH&,?Y?$?30+0-@[60YB&-@YX^.?( '?3YX;'(1SZF M\^O0-\^?J&_- ;CG?X9[8Y^X,<_7ⅅ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end GRAPHIC 15 g324368.jpg G324368.JPG begin 644 g324368.jpg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end GRAPHIC 16 g804073.jpg G804073.JPG begin 644 g804073.jpg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g869396.jpg G869396.JPG begin 644 g869396.jpg M_]C_X 02D9)1@ ! 0$!F@&: #__@ ^1$E32S$S,SI;,C!:0THR+C(P6D-* M-#8P,#(N3U544%5473$Y-#8P7S)?1$E!34].1%\T0U]02%0N15!3_]L 0P ! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\ M$0@"X0*: P$B (1 0,1 ?_$ !\ 0 " @(# 0$ ("0<* 08" M! 4#"__$ '$0 ' (! @0"! <�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g175335.jpg G175335.JPG begin 644 g175335.jpg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g568731.jpg G568731.JPG begin 644 g568731.jpg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end GRAPHIC 20 g766016.jpg G766016.JPG begin 644 g766016.jpg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g490658.jpg G490658.JPG begin 644 g490658.jpg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end GRAPHIC 22 g609357.jpg G609357.JPG begin 644 g609357.jpg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

P^OU#Z>P'ZA] M!#[@/\/7[_>>)E"%*8QCE I0$PC\0>@*'W,(B/H"A]S&$0*4 $3" (XIZ]? M:O/&:XV[/TF?B36FT+EKG6^L>C.DX_7KUW'6W96E*;7I+7C9U'.G#.14BI>= MLT4\EX=DY:N6X68(]E6Y)5LX4A9219I_BS7K\^[KK?1ND=4;ZI\59(.I;BH% M6V/5XNXQS>(L[2 MT4A,Q))F.:/I)HV>G8N4%C$:R#QN=-5-5%PHFH4:6VES_$K !.@.",Y!PT?TV#?VRC)4A M-1QVU/P?ZAA6"N4SB1_^2?/_ %F, &1%_P#+^%3\*7!MIQWO.[3O=TVIU>H& MZVC&\K4C.,C09)SH#6:E)3N[QQOJ2A/'52N TX9ZG \:N"QE9'C]\EL!WU=> MG:9"\_;PTNKS5?FM(?2FV()O&,;B=W(V:,(M%_AO8Q4NV4JZ[Z1K;U1P\91, MK!OS.E"OC)(V;?$7Z_4/H/H?J'T'^ _P'^61QM;2RVXG=6G!*20<;R0H:@D: MI(/'G1"TN)"D'*3D X(X$I/$ \01]QI7.,X]@ ^A$/?KWZ]A[]?Q]?P_G]LY M^_VS"LJ8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8$0 M#ZB/H/XCC(2^1V(ZJG>'^E(GB21/%]1OM:22&HW;60B8B7&7%_&FFFE6F9U- M2&A+M)5$MBC:+.2GRV$+<7<')NEVR;47*2E39^@_N^W\0$/[O8!_>&=8M5*J M-YBW4)<:U!VB(>H*-G4=/1C.4:+MUB_"JB=)VDJ IJE$2J$ 0 Y1$I@$HB T M-A> M6$.Q8.M\Q=;U/H>AW#5S+9E2U?>J1/[&BZ'65Z)N77-@NE?+)5Y:ISE3MK*2 M:2=/MSYB62/'33&OG\AX>L50#R\.>N?S4G=B>#G@FPSTW>-.4NZ.M)G3%V6F9>M6*O0<:#O4;J]AKG7^E*S<-[O.BM@:D?=-=2P//6K%.5-%[<=:5J>^;SH-44*D;"?KUQ!U<[#9HNL1[M\,TZD<.OAICERZ9'AFJ"<\CP MXZXZ>/\ )UU-=_Y*\3$@A.:KWWY#=F*=:=$ZNJL#7]50+YB6&T+SA'Q$ P@2 M1.DM6-UEH:%E5F$>R2G[[*J3E_L[UL9U)VG\$+:(9W;H((MD4V[=)-%!%,B2 M**1"))(I)E B:22:92D333* %(F0I2$* 4 #Z91%&>:>8VM7N*V',O+"^X= MN]IM^LJY T>0WA4ZK3M7;3XVME-K6X8B\;5BZ[;8"6UHP:S-IL$+LVH,)8]K M81%/;5FJR;J_H_D,G^4>_P"]=7=);[UE6-2ZQKFJM![2VUI:VO9W?Z1.HH.W MZIDXR&;6VX\OEUT4*IJO:0;9C9&31L&!QR3H"2 M-3D]>&,G@.&NE#D] !P&@Z,XP%_BK.^ M96+?:-L5@>E]G384_H6OUZF11E/@28&WM/.3+I(K.2K6! /L '[>P^W\/Y#_ M ##[#F$.D]-,>A-$;4TN]E%J^?85+F8&(M+1O^)D:9:3(?C:;>HA(%4#!-4: MWLX.W0JI%D549:%9K(K(K$35)%S9G1>]*EM[7U"I5">[4BZ%KF1M'1'F+#+1;4[R;8-I"K-9!RWC%I!R.)4$ZDZ$C M',\AH/#CIXZ=<@DJT&,@$G) &!J-3S)T^@JQ//GR7MJ,A8[+MUK7W+XBKA*.):]?DJU G)",;-'I9EC5;99#I.TT4TURL7 MD?(/\&GO->M 0%/8;BL?0NQ):31NL%I3:R!,%/)&@R=<9P</#C0C)U..N-3CB3T& MG4BL&V6_VEYV#MJWZQM3&EQ6^-1N647/4)21>30;9X3VO(PKF#O;&6K[]"56 MONJ=L23HZ4!"O8U>G4]M(-'EG8PL9(/["JCV.C=HAP[KO/71[V9BY&4B+%7G M]!BJCI>8:Q<]S?T71=HRM4JBTI#:X@];[&L;S1^R5YQW'MV]NV%9([6>RX MA6=N=REWTU81I:CT&T-&&.T2E%9^?MRVJ4=+[ Z(F96(%^*2=:J5!D]$73*R/""@ZEV#)H_:-R,54XVPJ?.5(GU5IL;< M4LU4G=M;6DZK19*!?FC]=4FI3*FW7+A@_9E<-II&NZ_;7Z76?%="HU=ZO_5; M\!&%;UYRG)R"[VVFSS7*% :S82DE6XN=/(.6ZGXR27D;'M#9,Z@(D52B%K3< MYF7FWC8RR*1V\*23:UMLY_Z\.DS,+E]G6*-8-F6F8EY:?JCS750^<[C86"FU MHM3!6H@G>) MTU_Z5K4% 6;F[8[6#C9N4?N'%3L;Q/O:XFHYBXF)B9ZKIS\2W77 MNKN=5B&LLRPGWYN#;^HN*.HZY<-ASMDB9_E;9U-8N;;K"V(R+]S/4][3'$]/ M;"I,+L2K0\XZ&?23"+E'%(:2)VI7C!-15Q(RYK6BKS@+ T9ED ,)??X:4FHD M5!(8Q2_,$B:#ARF0QA*!S&^,OU#U['T&0/VKT:_O99_4]0@H]W'3))* E).: MKSVZ+S+M!BB\:L:[ /B(UV5=JSH1D?(0LVS<$@(H9.>EBLUXT69.FO%_@V1E MIZ:MS>>66XT9I)6])< 02VT%*2A/^20MQU;;:-\=XX :^IV3V0O>VUV9I5X,+ M[LJK4(:LSJBT#&ZNNECBEWU<; 1:QQ_2C!%"9HK5[%+(*S,/L>NZUNL0VBV9 MR0517%^ZF^C[>WX>KW;6=CC]AP5/C:!L!.4/+;&IV_JG6;\DYJ=@K*\0[W1> M:(?5SJ7=U>P2[FMP-AG5E9%\R;FJ]WKWS7YE1ITB\,S(]F)R9LTV=S$&U9*/ZZUJL.1XB>/KBL1&;,HJ4K$)&33Q.@ M6?2K=-($&3;E6VZ1+M&;FP75.LJ)1\06VXVZG=*V76UX4VXV5 *2=X'BDJ1A M5<':#9^Z[+W1ZSWB,F/+:2AP;CK4AF0PYGN9,=YHEI]AY*2I"][>QE+B4.)6 MA'LJ&ZMJ/8PESU[<]9]-5>RR#%J9&#<)4UO3';^8;-'3B'G:Y&6MM)52OQHR M+U[#6POZ[.CLDCQD[*$>@W3ZOOOL?;^LF$Q5JAIVMV39\@^@F>OU'VQ:E$52 M0_-D%'CM.T,+58Z9.0\LS9,912-CH]Y*Q\ZF2/_0-T+*, M95%87"Z+]\_CG95_F-VY&YTR!V!6H'&^<8\%<<J MAVJLM-IZ_WEK"7L$@&W=C6.,J]* M5DOZ)Y:*DH9A(U)C,;9FJS?FJS^WFI-GBVE1A&BDC:+"]38<==RBLN*8D26& MG$ICE0>6EHGWMQ;,9*%+*4+6\ZTXVA"2I96G!2"4A79L6:Y2X[2 VJI5FN=8,_3E*_;#TYY)V'7TPT;N)NK+Q*IE1YP=&F0=>8P0- 3P.= M"<<-.>,@5U91ID*2>@S@GAJ.6-<9SQ^6;",9%*!["U$%NA]8;)F6^I-NS4FK M$QM N2RR0SK@9!=A&NZC:DV2=7M<;."D16+6CY!)^!U@CY.,C95)9@25@" _ M4/\ U?W@/U#^W-@(/ @^1K @CB",\.A'4'@1XC2N<8QEJ5X*?[6?Z^OV3?M! M]RAZ'V;^P/K_ &9I*<80%#Z/_2;^UG_3)F-QL>HY72]IK2*:(&C9!1Q9V__ %\W_%!NW" " @(>P'Z" _80 M_@.:^/DF\&A>J.A(3M;DOH";Y%ZZB?RA64M\0RDW%:MTK M4XJ'M+A>M2419 MZKXH)*5%.N#J",XXLIMQ894VD.%IY+A;) WP,@X)(3O)SO)WM,CZWE;/GJ MO3J!>+Q9K=&Z\B*G2+9+2VQY'\N!&APC.'2[I+3L5 ;UY0\E_DEZ>DZ1LQ*)O=ZW=HN(H?%-Q7_ M +^2;PU8B7-BFG)#S;AE\DE&M-:B99Q7'+F18JUQ_'M4U=F+5GB[\F>QZWO MW5'D,\CC+?VD=V,K0L1C&S,T]J==9OYEE&6";?KN)-5DFT22YD P8REA^2 MP[EQH*'=+6T6B%;Q!7&4X5I40"@%I&#O%2BD8XTGWEX)[MIUO"%D'?2E8<&Z M4A6X^E(0=3O?&K0I"4E6OZ?*'W)W4Z[4\3\#R3OB=T8_[%YUU;*C1W3W\TU( MC?MWVX8!I/7*K.6DBC8DJDUM9%67XE-T90\%%F60=F1 A_9RSNGR#<*^;[7G MCWZ$[-O79FL=WTM*0>2^Q"NDOP)9R@WRYUZPUN)DY&==4F=@[%0I&&E(R)G' M5?GJ_(D.HR0>),BQM@6Z/#5M[:W2WBIWRANS7$2Q\?NMM"4F]P#BHVMP]V._ MU%:X6P2LA47J$DFV@&*O8VQ_,?H_R8 M,-LTB.H&J:= UF2U<\K5C7N,NXB*9M2LJNV-B0?IP#9)5SL!B[33YW?Y*&P\=S>W0,@Y&[G ^$ DYI]TMN/R/\ G [,ZQC])=Q7;A?E M?F.RJUJKL-3QQB6:70D;)9Z[3#SC1C-UJ;L,[96U(FK1:)>8LQH2M@NUKD! M&!47*?7_ "<^0'H3F#>?+'C-E>W-\:XI.J](T&Q=;]CZVU^I;NE=MVN;C9V3 M9N*TQ;/I.2C6KYK#LBJA'O$#-I*RKO+(^F86LIL9":NP/!9UQH_KO;747B^[ M>AN86F])":FKUKN\TIU8XN-=V6<=66:A8HS1C/P$Y5$K$\>3568SE7;3=04> MN8Z.FUX\ !7*/3WA?Z;W5)PA9<@ MV:2KT>5)_"2QV]@G8AXFZC)^ GZU*KP$O7"M&K$R.8?@]ZTK?8]V#.ZTUW&Z MXQ([H#??48[G>#O-[XSWP"E!8;5NDUAW4KNG!NN]\7C;+/>1?EY+IO?W1>IH'CGH;>7+G2.YZ6^H^]J; M9=>T5G(+$F9%TF#]'X7,Z5..1>.Y$C6:JI)N!)&QL^XB&V7/!FZ\HWD C=2= M)[B[2GI3E32%EVMINY:PF9R>>7S?TM9Z7*RUJB*4;"Q[ALO)R]PFB^0/)_(T+JZG]P=N:HWLSW?SK:].:SKM"TTE0ZU MK:UV:$LL(O>GZD;&P#V8([:3C9"4C"-CK*IQZ9VKIN<3%4[=XC?'7L;QP<86 MOF>T[6J=\M\WL[8%^C+Q3ZW-Q$1%!;:I4X"-25AIZ16?.GD0^KJD@O\ "]00 M=)JHH)F1.513-3\F,&90;3&#RU1T)*$=X"GNEH>=0I4=D(400%;K:?C*E(R< M&MC;#V^P5J=[M(=4H*44X47$*;0M(><*DC!QE2OAPE6F4G7 K&N/*+^C?/=V M66D:DUKU3P99[?!35ONX^F0A5TV9DXN3B_C=L#I,9 I2]]NOA1\Q^V=+L%$M4Y<)^N,'[=\FQE5I$X3TNB"[5NY_*)?9SR-<+-VZ+Y5V MQ2!OD5_TA#DW77&WCR\9O*FMGLTZINN-Y6VNDGYM=!2RSTG8Z5-S%LM4FHW* MBT2EINPSLO- U9II,8X[A"/9%39M$1#EMJBR)<0N+CR)2GE!U;+;H;=9$=6Z MI]#J$I[W? R$)Q@'.N,<=:7VF'PA+K3"6T=VEQ:"M#I=2<-J;45=V$DC*B3G M&-KH:9)^13]TU_6J6 M9V]BVE6-7)QVC0KG54*C.04^9^ESV)0/?PJZB44* AZ M_P DMR#6SD P"(^C"F< .'V]_3[9F=OX'.O>DMVZ"L7D)[__ -DMSCSB=@OK M&@Q5)>5:Z6""9.HB181-O?)"V@8^1L*4-!LM@VU)2TVV?BXL(EE+1Y%@=H3K MC_%5LAEYJ97RBGVU2%->R%/4K*>J2UJQA=4UE-*Q>K0='L@OQKPHED&!Y;Y0 M,0.# Z;4# Y**F:%28H0H%QE3RK?+9<<994TVXIQ;1CMA(;;&\A"5 G< Q@% M1(-;0R\5 [KJ6Q*CN(0XX'%I2A)[U1.^K12B#NA1UU TJG+QJ>4'IB@ZC\V MG0&[MJ[!Z&3Y358O].TS9EH>2D#!2S_8F[*M7(%E^&20=Q=?D)5M4F4V+10' M/Y-%)IHKHJ-TE2YC\9&A?*AY!ZAJ[R![E\INVM:TNX[?;6B,YZUO%_A:5;-; M4+89(BU5Q_&PEBKE?I;&U# 35?BHI.#L\@QAU4)2BMG53:^M>^2JQR\70(2QU*=I\*ZG]I3"JAY.==R+=6>8&OD4[AGS-N" M#26@Q4SAJXU^B\]>2^I)X8*_R^L;3JY\ZGIZLMK3 M&S-KKZ;1TSL$75Y&[Q#-Q&6-Q3[%"0SV1>N)I.+:O%EC'KS\-1E^[N1F7%+8 M*''(^\A3*8[:7&VAW+@;67@2H[B2KDK&HC;4E(CAY+KB$I7OA#NZH.EU10M? M]Q)6GIWMV[]ZPXAU'K2QV:@\MZYY2U)-6Y"PN M(&8G8=M:=U35>4:2*@/',$VE9B.W\,6#?;!A6=>K5KK-DEF2;*-;FGT(NR!!33YLP;$E MW4267<))OWSQ,L;;CX8^T.>^K-U]&>+;MRKD+;LW36U=<&O=+2LI= M=[VA>C=W$L-OEY_9]>IJ%%B7D9-SJ\C7X!G -DVZ*:%8C%B0K=T1HS_%-6J! MSMBJ 3]52LT9+QC1] /6J5CA7S1O*J24;(MI%DU.&6< M8IZZ_FJ3K/XCIKI$.K[QVOOR+V'NWIW2&J>>XJQ:'U.EI[7>D-=:.V8^W=K, M:90KO=MQOKI;&FZ72&P+%.[)LTXPED8]A3F$'#UP'R+[\%T\7&^=VOIQZ\/S5!(_UPX:CQTXU 3R&AH@\O!E?C8]=V6\4.0:GF&:81]K6=&, ML=BDBI'?5T]J^][(?6\?34*0T(1BY?7-_:#N3NW\JP= <5>NUG@3:4QWG2>U=U;8TI.2.G M(7=M5UJ&F^<%M0;7O%.V^FA&0]1Z2VL]VK>PVE6-3UYL@A3*_!5>G1CBXIDO MCQ)L\(6)"U'&,>)^OKUYFF>/CI]\Z?.F,8RU*8QC%*8QC%*8QC%*8QC%*8QC M%*8QC%*?;[YA#86X#0:LI5]?P3F_;#18+"A&,CMV]9KK]=-9*-7O]K>.F437 M&/XLGS5XM)T^MSUD@X/#5U^?Y7Q9OS%]P;BG)IG#]DBK8AB>@^@&*8Z:@@'O MT!C "?Q&] )@ @#[^$/6#BBE.1@:@:C/$U1C.O#Y_IK]QYU#B&K6U'\/.6KK M7;T,Z_+F;,C9EJN2A1,['I=GD:K1Z50[9.T&QJ2%Q#7DUKY>F:A+1&TN^?SEQ?:W>P:>Q M=OVUPU5D+.X;[%+!:W8R;=M8I*MJ2(5YC)V+VRDP3.:7VY,EOMXEZ%&SE@J5 M2+//)&!AI!*&,FLYI- ;_@*^K=7+-NY80]AF4IJPQZDK(IPLC'FD%"C!N=N- MCW/L=XHJ2\2%L@HRT1T! 0T#2 M;P3Z&D9&W,PCD85WZ^0VDO@M3+;#)6JY3B&H@&[\&2 MT%Q*T+6VCO%-L[JR MXM(2I*$**T^C]G^QR]II2EE4V-9[#HUH!Y4:S:DK3,UB/;3;@',!&5ELV8SC]^G& UB8- MLTB&Y$ 8F%1HP05?QK16/6FE4GNR$A)H2,E/H1TK=FSZSQ%N?1->5A:?&P:TVG&6V3!K$_FLS'P)(@ M%W+=^T;V(2SR'@%!6?K0D8Z.NDD*L]*Q4$[E*%.N.!6XVI"R5[KBT M%UO^VM%OH6VA* MXPAT1I!]X9=-88V#9Z_%Z[ ^YZ1*VNM787=5LM>;19KG3R1\LX1:QS"VLG,= M$-6L58A42;&?24,M%H.@%LZ>E*=JJZB33G-=N?16O5VU!J5=AI=1:=E*60Z, MJ@I8WM;F9X=C*P,H9Y'PU:R_I M-IUY'L;C;[A+1B9ZZZU37;786<#-M9=FDG,/MB-8A'7],M[^118NGX$CU(/ZMB]H2VWZW-5I]7 1C&@6*V25YL"U/M-CC72J_ZO0U7395 MJQIO$ECQS>.NTLT6:RL9#)K0D0U16F%)-K\_M)/O3>T5BMD-3YC27XSZR;)O;!;9;075N*BY6Z M#=;:7YHDS1'5,:XPK,Y9TXMQ"/I) ME79!_#2'YG=0U],3+^>N;C8>S[LY_*I@+),3LI"D83$;%0,7$?J/"4V>JE0H M\@X)$MWR3BJ0K"3%R:6?JR[TLHJ#ST'>1U*CDCX>)^1(SP)T!\#C->&AI1&2 M"-W.3N9T) ''',_<8SG2:]CL)J+7WDPPI,_8WZ3AJB6*J[8\Q(OUG"IDTW2C MDA5WH,4%1*+YT[0 622GQF*'[(&I3;WF13"Y.8)&#JT$^O4\B>D1[MSJL^TM$3^3#5%HJ1DWFNU9"#/73RD2N]@9(&P,)!^:>B"2)0\;+HUW5?I;V=I]N:>VHMLJTJ?*X$.YO7!MR3*==$*X1F8UO8M2 M2IAV9F;(F17V4^_I4PZ(Y3A2V[-.3:'=(*AK7&Z-%V-TOS2LJ?EJS=J8D;3X M&$;QU.;I1$<5JBSD'C(32,R8ZYQD'ATG@)MOJF:1T@T?%0%TL]>MQ-Z!-1Q) M(L&XB/U*"2+2.<)+?$40$A#?B%# )0 QO?O(*TZ/A31+M[6*U?)'7DJHW8Q- M9:72SJU@?P:IFDH[I\9+2S9V9C.E9N6\FXD5U:\M(048ZC")M9QRI(<2%.>0 M*<&ZUY([3U.G)JQK%] T6:56B$C(6-Y,%8FAI-G,-("&>14U)+2:]?95@$G_ M .&BR?A/RE)RZ] LT6+;[7"B1'E28[;"2W*4M#JI7>GOURE.((0X9+CBGRM& MA*R1D'->%;67.X7W:.\72Z146Z=(FK0];4,+CM6T1@B*U;4,.*4ZRBWL,-0T MM.96@,!*SO9-3"EZ8UOL8>'N["F7:O.!=F/$VFK1EM8J"HW&.=G-&S4>#!4Y MVCO\"[57:G*9%V#57:58TB6;L-7V'^L8M M7C2"EG=TO[VX.X3V\;LX.&G6UN-+QS*Q=N!!:5(^=Q3259] MV%4B6@K)K9^B=R1U/C7RZ#REW=K6[DU5>.4A> WEI^1A4+F>'% &K9I#S$Y) M$3T[DV M!-,KQ289;:%C8ZH@(*Q2-KV LD[B)J2BI7+M*LOU8M%FN1 M']H3DQ:0<*W?M+=\XE7:,4ABDHA",<1D.WK#-!']]ZT[ U^8:/XIW).:PG&L MH2MOXA$@5.4<3*S[>>L%UG4@K)7+&#@6T&WA@B6+>6(DV<"V9BG\J:& M9G=>W.,@&ZA+2Z)85I*NI%2_#6B]V,D8TIT9'K1M<=R44,A()J%F4(IY#-B! M,H/K#'MH!:1>1GY]VAG79=WG(D*1&N"'2\RXPX^]W;B666U,0URVXH1%;+*5 M)!8*7T=_('O;7N[*?W=L%:-E6-EK%(MZ';C8WV$Q)C,YB%#2^TJ9(D,S[K'M MLFX]YQTWK+9%_8Z[L%0?JMPAW3%2>DC/JB M[1=520CU&, ];9:IFR:/+.8"A1DF:A7 8=JU;:XNU2&I.I=>/AVKN86ID0Y; MLZ_:$HP#*'E7&NW\Y&,B^UUTVK=5,ZN6RP$BR2$J$](E<)$,=-JLDC^$.R$*"GHH&#X! H9^AF>\2TSWH!=[MOO%()"5N!"0L@%1.%*R1 MG) R"2PL,1Q6W?\ 3/1[U9FMN<-W2:\A3PEJ,O"MTXLY&B$< MWLT_7AEFSQW'R4]"D.,HAVSG7Z:T6?K,9@MBV:9XOKC9$%\ M%>N%,K$G9)6T;"=0SB7CG$PO5[_6JG,:Z<'7CC-5H>5B'[J6KEK('9*"U(C$ MO#I+E;3S!NU=D;*KMCMTG+B)D04 @-Q5^-5!4';(KA/XG2:C8%1+@NTQ3MA; M&4V_H6PXJ\.7[%%KN31M?C9-M,P:""JDHWVS5'LF]:JLXR,C2,W<5:8:]A)& M_(3ZKEG$^DTK$9O23J>>=,>.#C&.O#>R,ZC05H"LIQA.- !E1QDCEO9QDC.# MD=,9%3MI=P3MK ZBT5(0$RQ*U)-04D5-5>,=N415!-&29&7B)ED?X5 ;2L.\ M=LG/RSD$R#A)9LEW+,;ZI<*/*:P>?K-'6]FY5<'C9Z.9MF1G;1)46RA91-BX M5CCS*$@@]0DC1[2'0273_"*PD:\;.D R1G+224@GB0#]?F?S6H\?]_KK]:8Q MC+4IC&,4IC&,4IC&,4K@?^D/](AE3'B7WAMG>$3Y#E]LWJ1P#AT4JZGSG2PB A;./V_M+_B& M4A^$+_<3RG?\];Y#O];:7BE7>YA?A>B&-?C-[Z;UCN*.J_>=^R/O1B]S9T5S(5* M;CJHBP^&A./ @\OOX50,D#J1Z_UKTKIVPMG:\U+7R6O9=S@:17E71&+.0G7 MOX8TI(J"()1=>CT".)>SS:QDS A"5J.EIE82F,DQ,1,YBU6[3O>RE)U78L#, MWPE84F6$A:YA_H^:UW4YZ;.*;*BN:B6YD8W"7BH"""UJVB=LD(P@B/9^%C&K MMRM^*,M(BJU"O0D^O:X&'GK;LFOZOZ_[&F$XDYHATW;61-))G2&] MN#:EV+5\>$3=MCVITFR2JM09N;M M?)9@Z?1R,Z\&BLZA*OZU%1Y 8E>.Y=]6X>N-Y4\FE.$>HI.3_&;6P3/LTKN4 M3ES([+CL 0%/*?$S=06E)88>92Z5;I945J4$LO/8_P R:])[+[R+)M;:_>%V M9NVSI4:+>E7Q$),0VI2\2DJE2HDM44-!29:5,)0XY)BQLG*$@8JBF^O7.U(: MMMV[>D$8[-=[#1FZC=+O&2D,VA(&RQDLV7FHB8.5)=<$22C#\#&- BZ^H2O" M^D&TXZ?!("F4'1LFNE*TC1U)<2C4SYL[NEL;0MNNZS]]"K@Y"0LEHC9JYRDT M[=?A&KEU-2\J:1BUS&HV-]8'].<7& EZ4HZ5F7$J\82[6(G).,KUGDF!)5T2OM+#M;W-BJ+=-VC)IU9Y694[2K6EFR8Q4(Y81E?=1 M!7CERW?.#L_D?'["R[DTZY#_ *=_PTBZ2DS78L5240)2$%IMIYUI0AE.(V\M M;(6$I>::WDX:#OJ_;/:+'+:8NG_B(FX0-G;4JU1KC<-]V]07W&Y#\F+%D(5< MD.!5Q4TVQ*4RMU421*4EP&4N-T"V6NC5N'-JNV7FHM/Q["/K<1K&"K@SSIB! M6;AN5LKK"D0]BL48DD_79N&+_P#(V#% Q3-&1F[LL:Z0BUIU+:$#:C:X5UF] ME)&5M;"@#5+HVE-?FD))C'1[Q6UM7,U"34NVK<56[&UM4NF+$PNBR@+#')6: M1;K-K88G9W'W..F*3>J[+ZUUQIZXIM&-$E:K%J)M[HZ66W MV!U$0MFL2S!-G)SSAO%S\JZ24,RDET^Q6GI76ETWMJUP591E;/JOJ=_H2YS$E6 M+(^K6O:0[OL#ZW!.5.I.E+59ZM1]5W2MV6?0@Y.,4D#INI20F:M"(2DC%1T_ MI@\A;?B?BBR:^J$C*;7#74^=?"E2SPW M>.,@ \ ,:G/\\#4TPX^;"S*V=]#=).3%EV,HH^+=:1#OE6K-=9=:"_$5_6<. M+6$D?F@D_08@U?"@DFDTD68?,%2)V[/'9/+627M^E[4)W]VMK=W84+NX<2:L M"UDCMFKF=3DY5^JZF(VO,$544ZJ!VY)!BJ#1H5JN5VXD++=OUR[7'3^T*EKR MU!0MCVG6]VKM&NY/GJ%I5VG*O*1E9M9002,X5+6YYTQER@DD98#DFL5:K5*LP>S-NM4JC",(-H]D+5%SQY M=".9E9M5)QC8*[)QSH3 0BBB#%O&I^O3=(R2)$RE[3+\Y0\JT000V!LB $>>PH"ZMD_HY-IP(?)_*D(BV4&W5"0C!;)@=HYCYN+M5]1EB'< M"2T<[A8KY"/PKM)'XR';K=:U+LCM(=I=<.MM4N*3UWKUO=E].5"'J=@7F;0G M%S,^XU4]I%L:13>"N#:[:[CHQ[?H92PV.TP6RY5.';1]*BR%A'$KN?97;4[I M76E@WHWKS#;5BI\%8;S#5:KS=0A:U.S\>WEW-3;P5CM%OFTEZD+T*[(O9";, MO*R$6[E/RZ$*[+#,7?+PK#?4#G*?_ &4\QU !TTY\1X52 MON/7V_64W=%=T:M@T*S%OY"#H$OK66D&$-7&+9K"R[216D)\R2]KKKA(P.;I M;5:Y5PKSCY=4@81S+L'+V44*[KS!HY?HGNF871U MV/M&+=Z7DH6QQNW*(\T'LR:JL5 2G;=2=9W27DI]]&PEC@KO$S-EG:_LZL5V"K MB+&O2C^(F&M^KO6^R'BEI MELRO$+5;?4KO7;#7["ZKZ\E-P[Y"+6C;CJ:)E[#$IE=%6(__ %AK:\K+6=B@W3(RE2/X M(EC3_!R:[!TP;+0IWLGDB@;&H&SX9U-:\ML+<(J->.(R3-$N3G>U^29+G9N( MJPPKU!G8:O)(.$Q3-&66,BW_ *^6=) [=9!12#EM8Q]+<1Z)KU-<^VZP2+R- MCX39S/\ !QKNR.DSN5XA*8<.0IEA=N5D&WR#QMQLD=(-6X+Q1WIS)'-V6I4R MRW[:L"UO]$B8*Z0;A@]K^[:0XFZ=-H*N&K(JY&=C:F_,IM.99,S,)R#?/G5= MD68IQ#N#>M5_B3P2HYW5)^)1P, <\ M@SRSG@8 'A6BF,8RTIC&,4IC&,4IC&,4K@?M_:7_ !#*0_"%_N)Y3O\ GK?( M=_K;2\N\'[?VE_Q#*0_"%](3RG!_#S6^0[_6VEXI5WN,8Q2F,8Q2F,8Q2F,8 MQ2F,8Q2F,_,[>-6+==T\<(-6S5!1RY<.%DT$&[9$AE%G#A94Q$D$$B%,=194 MY$DRE$3G RL&[^6OG +5*ZXYFJNY>]-H0;TT98*IQC12;4K=.>@Y.Q^&_;J MDY:K:)II4)%,S-^VDMD*3+$Y3G5B#$3.(;V8S\@D,-+6I*?&M+TAB. 7G4HWCA"2>LY1THF3_, M(?Y"!SE#XCE*;WZW&&$Z.S(32N@=7(_]Z&U);_\ ?K1[X5:M0YKJ>O=(C_\ MNS'8SG_N5:+C*N1U!Y=:NV.K!]L\9;,=I%,=!CL?AK8E/0>* 7T"#F6UUUBY\13H'RN::9MG>Y.%]']*0SC7<1<6D M:V(991W&:2Z:J-#3F'IB ":,+$[ED)!PX]I-_F>R"=[EO?\ )EPWC_V]\8YX M9T]\1&!Z8!))T )I[[N_\Z)-9'4L!\<<:^YKDD=2>"D$C"T'DI)*2-02*Y#+[,A.^RZAU(."4*!W3_VJ U2H6,8S36VF,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F M,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F?"L\8K,UV=B4$VBRTE#R;%)!^90C!=5VS60 M21?&11<+%9J*'*1T9%!94&YE!23.?X2C]W&.-*B'4.5RD.J^V1?K+8DWD?+,9FWAH%RE;K.[2$7";BQ72XR\A+"LHJNR8IJ?@TI%4K7 ME'US"A7J+58*J0OSUG:D?!1S>/0@^(YA$QC>O9C")C")A$1]@A[_P ?[0^H?Z<8S*I44Z[R51(NE5^BS4I. M6")H_1UDZ0UZK^)-#O:A/S.U[=M>*JZ#E@H8\C5Z^\NT]5$&3OT$A37(0;PH M(@(CE*%T9J>"B-50C6CP;ECI!@WC=3#,(*6![0VK6);P3;]7Y.<4D)%HX0AV MK:-0>_B3/46:"2*;@H$ O0"'OUZ^P_7W]0_CGEC+2F,8Q2 MF,8Q2N *4!$P "/KV( 'L?7V]C]Q]?N]_;.1#V @/V'Z#C&*5T)QJO6;N6M M\^YU]25Y[8-?)4[W.*U6"/,W.KI-5V25=MO4NH[*UGLME'L;&_D7T?U&N1:D,[?J*%K40QK[9ZWCFZ2))(XR$ \15R>O3[I+LGK9<@B59!T@JDJ41 Y# .8SJFC-=T>7>#]O[2_P"(92'X0O\ XQC%*8QC% M*8QC%*8QC%*9"/KGN37G++BEZ^95JW;OZ6W 220T3S#J9!G)[1V<[C0 CZ8< M*/EVT#KO6< JHDI=-M7V0AJ96&8+"+N2E 0B'/7NW.QI[0WZA:/T!3HKD))5A78V-B@(%RWGN>48?,D*EH;4[==%_;YE%,LI9)=>(H=3*O8 M9PBC'Z7&G#U:YA1N6Q[M;)'>W6>[%FLST3TYBQFMM1UQ9*OUF':-57GYK/J/IASS6F6FFTR90*DKS[O'22E<@I)!6M0U M;C(4"E2T_&\L*:9*2'7F.(XZXXX8\?X5)']Z00%(8S@A" 00Y(4D[R4'*&TX M6[D*0VY&"*X#W?V/^&NGE*V6TMU7>+)R45P-HJ>L%>Y.J21#G5C6>WK(D$+L M#J>TL2F1/*+V]U ZH"2(H2'UPY:H(2#BUNC4"CZQJ<'0],N+6K)K8S':9RI*27%#"W5G?=7SPIQ7Q;H M/^*!A"."$I IC&,X];Z8$ $/0@ @/W ?J _V8QBE86WOSGHKIZ@26K>@]44 M3<% E!!1Q6+]7F%ACD'90^%&2C!>)B[A)=K_ )S*9A'4=*LC^E&CU!0 ,%:; MSG_M+Q] E8..;7;.R.88HQ?SWBK>UY_,MU:^K#?X#*CR9T9:UC2=@5BFQ3%B M]+;^E9>+D6Z2<76-DUM8K1DK*DIR%-.8T#K*FW0,@+ )!XST5MU0<&6GTC"7V\)= S MG=)QAQ'5MP+;)U*"0"(S\L=<:1[%UTKL;2UE=R"$1-OJA>Z=98=_4=E:JV!# MB4D_KC:E!G$FU@H]Y@%C?*D(65; FX2^7)0SV5AW+22<29RL7KKC.]J[(;=L M<22,/KOM.GPR$;8H&3'368R*! B[57'D/:X)5Q#S#50*^PV6_>8Q46"H)<;60IV,XK@ MAPI2D+;7@]T\$I"\%*DH6DI)IU84&)&Z'L$H6@%+;Z$XRM ))2I.1WC1)*MZ;:Z51;; M>ZC6+CLA272U]6K#88J%FKNXKJ;%Q/-*DPDW35>QOH=K),7DE'Q!7;YJS4RV;8O\ 3];UH_FZ\@$8G.7>QQ-8CEY23O-#CXR* M:N)AVT![*R23M%@D!&,+",4_:LE8 MK)*K,*[6XI #.)2>E(]@@0RK@H9FG*@.G6C;L?R#\\\=?,-(Z;Y/B83NOJ&/ M2*FYA[)?D9MY6.-]0V3X#J(J-%[;'7O>DS799FY;2+;6U.7,1,'#=;.3$92\ M[_D%.A#+8RH))! 6X=UELD$=ZX@$:UQY3RF6O@ +KBT,LI.H+KAP" M1D$I;3O/. :]VVLCA62?'GSML>+1O':/5D"W8=G=8MXF9O, L8KTO.FGHTZC MO4O)],>']BS@M;Q+HDKL-PR!N%TV_*VBQ20.2MH@&EFV< 'H #_V$1^HC_6( M_4?YCG.8/O*D.J=6 G. E"M-7LZ2[ MV5+M+;!:^!>NIP=PF(=DTA[D<,7CENI&/;]&YVTE3I>UO-;0=CD%W4=&U#7\I,/7L M7,VJP.W5?KU=J]>L3Z6K=51F9>Q.TG"\)!,X]J\DWTZZ0.]^:XSGQ41'.[;< M;E.2%NI&ZT6PA2"I.$)*E)W%JU!<6%H0#G2\PPV22RHD.-=PG.L]:UXUQ/*1UN;LJ1: M'-8F))2/A$6@_E:,JZL$XD1U8F[YM"P;&&?R!?S=E%S%J8%;.]?P]P1D&!G. M?++86L%7G\T94@@DQ558% 2B=Z\.@<\>U;D,(?-7=K?+(BGZ^H&$QP*F10Q: M_8N:X>295Z)L:$;!SUM3H"LC6)FUW=0T WD4WUEAF\D>5L8M8&FO':OYK;(9 M19G%2$M/1 ["@U9Z::H+2J>.B6B].%2G"5B:RBR_+8I$!%G(*JG.=PJW5(I\ MMPZ04;*JN&P 9-=DG& ":C=N^;O.IVC?1;HT=$9F2U*FNJC,+DI"4;Q:"C(0 M$J674,I0ZZ4ME2G26VVM7$[O8R[+#:=CJ3;[Q"88;2KN_@;RW4F;YA6*^TE!*:51AHXLL%]X,_*#JJ,?#K9^C5M? M^2:@P:9UT;CH:.6+%5#J%A!-DS*OMH\P.GY'-BD&J:TG:-%.+)"NPRQ+">KMBB)."GH.5;(O8R9A)ABO&RT1(M'!3H.F$G'.G+ M%XW6(9)9LNHFZ#N.((<9 MQ:FB^@/'E?9-])V+@O8L?3M52TLH=Q)VWCK9\8O=>5[(Y?"1-L^<5JLI633$ MDHT%8R4CJE0L@J6046(-LV22S[N^XUO;Z4E*FW ,!QEQ*7&70.0=:6AP Z@* MP=12,]W[*'=W<4!+;J5H)&A*W@CH6$Z2FXO1$;HY*"KNJYZ_3^MF,E)SFXMWZG35E36BNO&QHB+;R"Y MD7#)9-0Y3N0:Y Y'\A6D>O;3LG5D%7=NZ3Z#TVC$O]L1W(LUY%@BYA#! ?I'NSC& 1+_U M%_48#^R)@_W[.RO?L ?KZ !^WV 1^P?2*W>V[)!GY2;7MOD5LUO.[?'QX@. M\+GT(G68*%FDX!J_E&T>5&55 M/G'.AXYX_J/H!$I@ ?J ?0P@ #]_I M]?K^[W]NM%Z#GZ] M@1;-FCE!;$KFS6>I-E6:AVLDP5.=H]0.9%RDHG^R$RQS5$ZAZ W+P9MKRR<>TRX3LYLSO"+U+O'QI, MY&YRWY]';B[(ND5QKMFGT=:6=/T8AGI7<#NO[P;P<(>/9P-7EGLH2,:-OC>G MQ38-+;WM,<%<8\./6/#T#J,5N M(B_93%#ZA[^@B /\ M_7OU]A]#FH'=-$]CS5H\!?%':^W-G5.Y7>\>1+66^7^L]ZV:0MFS] 4C4SVY MT&B7_:M3>5N2L5EL>J(&KT.[;#8'CKHFLXL4]!S$38I=V^-FSJ[>#;P==3[@ MOT2^GW/,74W 4LWYYUE8KK=K?'P?<'%=;BJGKG5-5;629M+\CO?VN;G52NG8 M+I3=DFZ5)R;\T^_:O7*-Y^&NOTQ]=?IXU./GG&/IPZ\<8'0UM'_$'KXOKZ^O M_!-['U_ OKXA_EZ ?8?4/89R)@ 'Z_40 /0"(^Q_B (AZ_?[ /7[_65GKM-["MW.LU5-Y;)>7.PR]U4V_MZ"DYC:EHB[DI*H6$JD!? M[1+*4]RVE&:\/%0L*RCSLT&:*9*7.5=Z;E[2G_%CX]-A6RTH;;X;O&[=E^25 MW%W.;:V&8?\ CZM3_FO15?CIR^O6MM/XR@/[_ +^O?PF$O_E>OA]!]A'WZ ?H M/H?ID+M-=D16X.R>T.06M%DX.5XX@N9IJ7N[B;9OXZ]%Z2I-JND@] MA!JJ-768/E'KZ0"55=IKMB,TT3IJ:IVG-;^0;N_GVZ==:EYPLDAWC8.@]MS= M [!G_(U+4U'GVS:FZ*FH6*T&KRG'QR-2J^JJE1Z>WUG=-16)C(#?&$Q*W:?7 M=25CC9!C/>@<7ZI[5\R/F*@>CPO[ZGUS5'C/,\UG0MM;+UC4I.\6715W_#W. M:>ZRM-/G+-+Z_2B91A0&\Q)NZY#J6.7GE(-W8"0\C$WB#IY:D!G MKUK6PCMK>Y]57O0]&3TWO/91=Y[ D*&K22H[*[?[+E=F[0Z MFCNQ^@:P>A&WGNVDP'&@:$V[(U/7&@ZCK_7%_IU1KQH6JUJMVZSO9.O.)J_+ M6]V>VO)ID\705F?OP!TQU\?L=?#AEC09TY]=#C'HXX\\5VL&K6,CSP3-=*[(QB<.X6E'!5&!W M1GX@Y!JWF>!@-]O8?3W^T4Q?I_+X@#WZ_?Z^WL/?KWFE1O/>&Y=(ZH\RB&EW MT[7'^ZO/3IGGJ_7RMWMIJF;H.JMPZ^YY@+W,Q^W9)H_CM1.;&Q(WUNWVB\;& M"@K7I*RLCH24U5+? \PJ<>\:VW05HK6T]-ONWI_K.*L^_ M8NWP,MK;;E8C+:W7EJ=9S556X5.]R49)(-;DV7B9&Q-GLQ&MGYG7SZYUT\]/ MICIBICCKZZ=?IGZ:UL#XQC+4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4I MC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4I MC&<"/H/[@#^L1]![_E['ZXI7.,UAJY^D9QDSY!8_E%[SJSC-#SG55IY8@>F1 MV8NK'25CKTBE649Q.$5J+>$,W=6B1KH.HY*T'780%DB90RZIW":2DT?,OY4+ MSXQ*3H*;H&F*UN*?WEL"R49!E:+E*5)A!K0<''2C98IHF'E%I%62=R*;#Y9U MV"+7X?GG64*(E)S/<)0=99+6')"=]H%;8"DX))*M[=24@'>2HA0Q@C)&>/[T MQN..!>4-*W5D)7D$XQ@;N5 Y&%)!20<@XR:NF.7XB^OW@(&#^'LH@( /KZ_" M(AZ, ?,C3_C1KW2L!JDK99'H7I_9>^%%2-#(+5NHV)RDWUSJM MNY6.H[>06M8 CIG&GO>O\ 2''7DM M71TDQA]67NE[0C=A5=:2EGIH2("401([9NHM>R*,8&9?0]I6DZL[E(MQ*U]1 M@^2=%Z7L_P T?>EB[RZR#Q%/>F<9WEY*^[W.Z=[S?W0O=+>YOYW?BU&,#CI6SKC-?'G'SLQ MV_>,NW=\/>=YG6^_.%*S)2VSM#6:VF4C)9\S0ET6Q8NWI5]O*QB1YVMV.OSD M;+5?6X:S\7W,?D-9GG=2BSK^CE-4[)6$9IH%E%2E<*"T(*\]PE[_ '?=?%WR M6,;[?_-6V74ISOX(+8*@L$HQ_P!62 7O3&[O=Y\/=J=SNK_P2H(4<;N6AK9&4_(3F]).V3,M"5IFTI*0KX'& MW1@YXJ;4M(.ARDG(T.,$$[6W$N)WD[V,X^)"VSG .@<2DD:C4#!U&<@TQC&: MJSKQ/_FB'L0]_L@(![$!,/P@/K^0B Y4WXJT&FT&W8_;"JJTG(=?=?[:4JDZ MY:E:+JZ&YIFG7,^CX=!("$/^5I1FN[+:V@G$PG>7*1<>SBX,JI8IN^^*:MTU MMC9:2::JFO=9W^\D35#VF<]0J,S8DR'#V7V0YXTI3![#]D1^H?00B/XFZFI2 M_&?PG#N$ODOG?+.FK3*D$/1C3=YIT==YQ93Z )EG$O8GJZYQ]F.LH*'' TVMPMM)WW5[B2K<;1D;RU8PA.1O*(&1F MLC9^5\\;Q[-T_=K$;M6;9=VY74$031;MD3KKK*" &$")))G4.)2F$"E$0*;U MZR%U6E.FE7[4"HSB]+&V:_2:O+_$U^+V2YIB^R99O9W+^,KC5."3>A4RH!)F M>I1W 7U)9SWBVTJZA=^B,PU3)*'XB!A+:)3? M=+>=4EY26F0%*#BU!E91NDI6DH*5'>P,QR7D"TV?5LI:Y%+851FY MMC:U4D MX%D_ODFX@HZOO!D(06I9^G-!48W"N2H9A'L MDW\A-HL6%0L\:A*IMH\MMUV:A-'E =3=ELJK+6QZ= Q=W?5BF,I1O)3:<].P M]VU[9#FK4-#F382FLYIU,0,K7I.!J-4;561@I"+G)DMU_+G&L3+A,LSP\M%%0@GE2?-(V/&'0!5*'@ MYSYCL_Q6P/:-,V%U]R#'"IS$Q"4!M(4@NA"I3BWDKCK#"4ML MMN-J<>0IEWZSL5[36+?M:MF[VUB1;G8"P]+0TVU.M*Q,)+/=?VN?FD*M9 MK&R?(VM4).(/#/*Y'?*LM3C*TFK!04U4HV#0>JP$-LD:6K:<;4VSAXI(23T[ MT%224W^6*R;A:/CT8,\BHK%,F$8+AZ#=R*R\6Q9,7'QG4;-TD5"ES$NMN7*Y M3GLZ_9U>HT@]J>LU[>I2F@M96Y_E3UQ(1+B??E @?B&KM^Z.3Y1U0;I%:HMR ME%HT6;] 8;EW->7CQ'6L&PAZ_KZ9EHNQ(0T0XFT4"QCRDD_5UP1[!NQL,Q 1 M\G.B[BJ6_AALA&BSB#GT5V0-G';[4;7L2[G;9DFU7*+#9;DHM-L4PU(N4R8I M32I0I;RF ME*E^Y;57!/:%WT+9L6^V6RV*2].G3YP: MCL(GE3B&WWFT.)4Y,G-EA"(+!8=<2PZZEJ1+?0FP'&0X<;$Z)8,P:$HSB6FH M_P#5B<[]^AMQ9:?2IM"F5I'OQC& M=K71U4GT(#G2/E=XP'^(#E5OEC)'0>LN4-KOR%*. ME?(SPS=DG@%#Y[!I:-W0VFK(H@?Z"'XNJ;0FH]+2N,](*/['=K$[0 K=Y8; M=+SW^,E[50*( MCUIS0XO&UE':&L*>AO75ZMGV,NPG)*KOD:+ DM)I2U*-;/"S-<63A6STY)Z( MDX;T,BP=-DN!IG@,YZ<]-?QK7.U\?]_OC[5'[5WB*\>>E-V1706I^>6VO]C0 M%MFKU7D:OLS.G]4MU(_M+Z%BK,\<1U;DMR[ M0I6LV5@?LTTUGC*$<7*;ADY5TR053NF-3V;)P4-K:T/+M66]=5E"Q5KD;%&LGDA!,X)V_<2 MS%HZ=L4UF[=91-@=!ZT_BF3U/K4_O]ZZ9LOE?G[<6V]$[VV9J^OV_;?,TK;I MS1EVDSR19+7TI>HA"#M+N-;M'[:,D#24MF\K$)L)9!)\3$O M4_CIXW[1FZ?:NB]-M[A=* R>Q=/V!6[KL?4VR82#D517?UI'8^G[?0KNYJCM MR=1VM59">>5XSY11^6-(].9<["H2:<);'VG-GTK M9C.LS"Q%%48NP.:9-S*4._<)(K*MFT@9NHY2244;@J5,XE[[8]E:[I]DH]-M ME\IM8MVS9*5A]<5>PV>%A;#?Y>#BE9Z:BJ5#23UM(VF2B(-!:9DV$&W?.V,2 MBM(N44F:2BQ6GAQ\./[\*FO+T*P+5^'N6Z:KRTXK^J635UQ6PND;S&]2&T9]*K-&37]7FTJ5O+CJGIZ)TIK?;;!#?FB#HZBB';[#U;SQ MKM!NUV_O?1&K[2C$ZV?V&NV7<=(CU(5QMAZ[A=?I%6FY&#>/6%ZLT5-U_7TF MI%L@O#Z&?I0355PU=M6K3AZT]#3]*NO'7]<]?74=14B ( $^ ?V@$! PCZ]F M^+W\0B ?41$1^GKZ_;, ZYY8Y]U)N3>?06N-65JI;DZ6<4MUO&^Q1'Q9?8 M3C7L0X@ZBK*)+O5XUD>+CG;DJHPC&+"5>+JRDR$A*&%YGX(GL3DN?W&]YV@N MG>?9K?\ '/)..D-(1.Y==R.VF,E"$45F8UWKMG8UK8A)1"**KB5CE(HK^.;I MG6>MD$R&,&#^;.KK[N3M;R.\VV.#J4?3./;AS#7]=S$*UET;-/L]V<]0VV[* MKQCMQ'3\BLP@S0L7"IHQ!$TGR;]X!GAFG#3R\OVTIC\9^^*ZW?O$9X M]-E;PDNC+/STW0VS/6V"OMHF:=LSAP^E2 MH95#Q[\=T-EHZ.J.E8F%9>Y=]J].7SG2-<;L?3E7L\_;JOL M#;.NFESL=+>,Y"L3^PZ=KJ^U2C[%FHIW'L3DE+O6YYZ[29M6TBL];MTTBV08 MQ@<,:=*N3U.G#PJ+J/%G+:5?Z2J2^F*E+U7KVXR]_P"D:Q92R5KKVV+=/5R# MJ49,VTO\Q^?''*?C8XVXFM$_<^;= M6SE(LEDJ[>D2,E/;CWAM+Y-0:2:$PUK4(SVWLB\Q]9AD))LW=$95QI%D^)!$ MAA,DF5,)TXR8'05,GKZX?C2F,8RTIC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC M&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC M&,4ID-/(9T6ER9Q+TUT*#E=I)ZUU':I&K+-DTUE@OBM\0?BCU"HUX MNWO7&%$ZBD^NV'>,D#!35]@D[XTC=;0\2]>H0Q\LXF'3-[:(< MZQ6I6TH@8EU/Z01O5CU=PMX?^@:](_(#=-MLW%N@K;Q^;AF:K#Y;GH=00FD25U&:?-II M&DUV+CHR&%"RHB632GV'Y2QDD+ 4_P"8%F4"R?Q?B1]Y!78W@FX7V?S5I/E& MQAO)'4_/=POEUU8E'[EG36.O2.Q55%[%'C.RC*35>07XA=PO%13AN*,.JNJ+ M R13 4.[3=(ZWF'G&UMJ8E2'!N K!9?;(.=]PX6' #N)P@ G= KK3">2VXVE M:5)<8:0=X[N'&EC'^*1E)05?$?CR!GEC7CZEI&[?'!Y?_'[LWKGH)#R9/[U( MPM=HSG9$4XI6Q]+)2E]AZ(C:JGKVL6)U4(F1BYRX_GU*E'#-[$6E\PLK=_$M M[#&15A8^O5_/O072?GP\JM'YOZZN/&=W81UXFY'9%+ID5,EUF\ C.122RQ827"^B=\[1Z+NLCT9";"W%8'%DOA*%O*;J$#+/7;2/9/&Q&#"+.Z:13 MQ",: O%HR'X,3D%8B9%1^,(FXQ@2G>7GW,Q^^,9K<*O>$.I_X0.%E*$I"@0# M\:B5%(."7NCVAPC'O'?=WWSF\ 6MQ7]\(#A45:ZY"4C )X#6PX1V$TI/ 'GE MXXEJI1;#L75VM-AW&Z=,T>?G+(;>3I.PW"@J+V&7G'\B251CY.*D):GRT3^5 M(OXZBW3PN<.W[D/47$-AKFR5M# M:1ODYL>B1;3:EG969M9["XN+F16E+8B8)679&4O-@^2P=F%! JS8I ],T?3^ MIQN_[W=="??69!R$DJ2B,IE9QOX25+.\E )2E)P% "H8+I:" I&1&=9&IP" MMYMQ.N[J$I1@J(*E'4@DDF,/CPYL\C.NMMZ;OF_?*G4.B-'EH3E-USTQHM1K M\E)GG-?D1IR:,G')IR FIKM9E(J 0WS'Z<>!&@-<]A"D(PI.ZLP3-[3*V<:?IYTB$$1]B4A1^ !'Z_3Z_7WDF;?7&%PJEEJOC;WG7833*;I'->EY5QL PN(T;_M6QU:(U;2_F 1)* MTOEHB3DCS\Y;)0WPU;ELJES9 M:D@%(AHMQFLR"[D!.X_ALZ22P4JW?I=FS6]#]D5C0.T.X=@4K4>]Y9,FM=6< MI56O,=IU^L&.H+I+:S]8R%HK]<5!M(%2V3%2EB:O4&;Y5[5(MDR<*ESVIX:> M8(V.;.-7W+:^OI>2@H^"M,DO;UYYW?47,V68EINY.%TXR:F;3)LRH1D8"\J2 MGU\S24@IQ/*TN+N5DVTS9[1[FZ_P!C.P6NEXK55>K04&U?J(-T M(B/ML_\ @*I3:FU61;-0>O7\2BHR;M4Q;1$,R8Q#.YZ-U/T_L-PWNU^V3$Z= ME(4I).@ZRUV@WM<+'S:*B*S-?;=CEVC0]U:*MDU(>6J531@V+5!V^=1USD7R M<._COJ>T:V-?T>+L7,N3$&R-VZ-%O;*(S=EC;1W&,M#C+5!1\]JG_ &0JM8KY M;;5:_;G=;>TM\JM;5K#9'T:J]L52=6IG8(Z2B)"-?&@VD*@SBSK.0^I-&9Y**9I,$(5!RQB)1*10BRPL MPLU@G2:+]=JW5^SJKGYFRT16=9[ICZW>9US(V"\[!! KQW6W^Q[S:K%>;<^A MS/4V4@I%I6*URR$*J^10>?E96I72)5@,4OWK3R_HJXNY:2GM=0+N6FE))P^E M116_&JO)9%9%X^-\:ZC19TH*I7(BZ:.$#O&L>Z5056CF)F_ADJU,VN;,8V=9 MM;$!$A3;!2RZGWAIM:T]]O-E)"7@$.-)((0%;B0A"4HKVFTP7X=OB^[18<)U MUAIZ1'6TH+:=>"WG8ZE-*QNQW'.Z;2"4I2C<3NH2D5\HG7G.YDB+*;':,T1F M8NNKJR5?N$6E'3TU,RU?C8:94DJZT)!R;F8@Y1B#*8%BX25:"9=-))5!17[= M-Z5T->;% 5&G['KLQ8[:RE)BOP[4K]!W+LXMU-MY!TV*Z8-2&,"M;L*J)%3D M5?3)YF6 MD?Q#7\:Y(_D%E$$#H@Q0(FU33:@#5 4^\53GG2]'LT0;CE'>>YA!W.\">^*N(*PG)W2GNM>"8>*(F'Q*GD'7:. MCSH%2+_PE/A14$I?7U^OOZ9:Z3[#_P =3_2H8RF!!0>*G)D@==QPL, ^6_%6!X@UPF2%39JQP0B M+'/3?0EU\CS")39/@1UJG"LIFK_GEW&6PH 1?9_BWT*XU@_743 '\=J+J7<+ M;;$+%?$?YJBT)(;/US+S2"1/22$[$N5/95/9-=:!YVT3_P#6OG:.ZB:GU^EN M!7:/5>SPVHE6(5/8C:_:L[>M4+KJQQUV!J-CC'E1A8AK#P:<;)M6K6,=2S)- M 49R6*]W--G\S:UVIN'0.^Y@)Z$VOS?,7)YKVW5>33BWKBM['KH5O86N+4BN MS?-;'KRYH-8&6EX!RBDLA9JE5+'$2,9*PJ+@^6R4:F$K;JGEJ=:"J/A>"]K? MY!#A /#2#L\@_,ZA09!%N#/GZJCUX*S0XNG:AW*_S%CF./ QKGURU^6/K7.! MUUX?SG7K_KI6N%4=JP%FU2;VUWM^11FMH5F+<)SDO5WD(Y69.8DBOQ542M!K]R\=&J: MTC51#AO='Z3;0%.-:7+QR\/59/AS8FV7T?%LZ3 NDF3J%U%=K&ZVB[IT4#9B M1U4IPZK-$(N4;**[PUQUEKG81OH/R]TS3078@ T41 R8.,9Z:\],9//6F=0?'ARP M=, >6GTZ5KWV353'6OG?:T#F%&B\Y3.X?#/MX'4K4]:P"]-3O6O^FJ36M37N MV:PA75/A;T\UQ&2[N*AVCZ2BG:U=*%9)-LHPB14/K>1/E?LZ%XOL70MXZ"J7 M3W2'"FY=;]U\[O*5H&*YQ69QFADW#[8==11=J113 M\OB3PTF!TU"[ !H"#/-HV4\/%&L3>,6AD)TTGZ'[XZ\JTXMX*?[);Q8>=GR MB2R4@M&=FT*R4'E]65;N6(,.).8T6]!U!(1L+)))R%=-L_8,CM79TLS,()2G MYW!R92%^)(I)@Z[T+IO<_GOGIK:^OJKL9;5WB,Y*M%$CKG$1UFK]=N,CNS8D M4C=&E>EV[R)&X0T6+J/K-D4:GE*XUFILL.X:'EW*A]CT:=4QK(4L:Q7AJ 1Q M8@*L,)%C7 BB !2QH00M!B0CRE*4I60,_P *4 "I ?K0KL UEU9]M"1" M$XO%M81:91C&*4JM#L5E'#**5DDVY7JD:T7657;,#KF:-UE5%442'. M''QX?G&*9_3KR]?M6B!TOV;%=.4'06^VFT^/>=KO&^7W6(:_X9UGI"&:]EZL MG*?UTWH>P-I[_P!N$O*-II>P[LV4E;'LIVVU97Z?/L+O U&0MEEF+(8ZVQKP M6/ORM>= ?B ?_A2X$#[@(A\/%=9#T(!]0 /L'Q 'OU]/89:Z&HM4FF;!8@UM MK\;!:5XUQ:)P*76!F+$YAGR,I$+3\I^5"^F%XJ1;MY".4DG#E1B]11=M3).4 MDU2]R9PD/'R$M+,8J-9RD\HS6FY%HP:-G\NK'M2L6*LH\013'' TIG0^6/N#K]/0KZF,8RU*8QC%*8QC%*8 MQC%*8QC%*8Q[#[>_J/V#^/K[XQ2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,9 MB7>F\-:\XZGO&ZMN65C5*!KZ"=3T_*O%$RG,DB $:1<6V.HD>4L$X].A$5V# M:F%]-S3QG&,B'<." "G'A7?[)9:Y38";M=NGX6K5:M13^>L5DL4HRA(& @XI MLH]E)F:F))=M'Q<5<573^1?.$&C-LDHNX632(8P4+];_I,'BIYA:GC*ENT MG66QUW"C.,UWRPFQV09PX(=%+Y\CL59_$ZKAXY)1;XEW![@^> @BX6;QKD$3 M .O/UEV_Y!?*_?\ K*O+[@4X*XIYLI%;L5BYVAK>@\V7T?K2ZRJ*97ULN-"% MH[LB-DHLP@ZN&JX&Z$J\8@_"JI/IR6!*>+F"\\LZ'I\CI#ASD:\2,<<9L.E?TC MSH>+MS6G&\/N[5I>8?UJ-KD(3J?0[JZ33NXLF\K62)4^'B99X1&3B73=^9ZB MY>1\>FY;?F3MHFNFL,E-/_I">IG=[EZ!V'R[OOAMQ6K7 T>_7/:3NF7'76F[ M5;GLS'T6.WO.5*0;V#4D1LEU"/"ZYO\ /U)QK*R%24.K=(PH)&6JAKG66A$= MCP.GN@]W<9UUQ()V".9OMB<9GVL;8\\\I\79*'O%>9H>VJ;J?9,?O.!"S6/6 M6ZBUA6[1]KK4O1MCUNJ[692<#)9"&?M&DI2?UGM;6VB.CN/Y]]L"IM+LQA:S MNJEZ[=;01-&KS4M'V>MJ;.U&]L%F,V5M>G[Q2IS25FK$;&HPR4JM*Q\I+3>7 MS '3Q&AYGY>/GH+W:2,)X]2=#D\1P'#EQU&G.MQ6#ME7LZ2R];L4'/HMOD_B M%H27CY9)O^(*8[?YZL>Y0ACH?-,0%B%,9+XRE,(=@S1\Y#J7*^EN-66 M]^!"3<>9CLBMU^KU2TM:Q6\PK.A^O+7@ M/ ^'4<:P4DI^FN=#G SIS'CTXXJT3&,9E6%,8QBE,8QBE,8QBE,8QBE,8QBE M,8QBE,8QBE,8QBE!^G^C_2/K(S\S]6ZPZN:[Q=ZP1M"*?/O26W.6+Z%HA4(4 MZFS=+/XV.N*L"5"2D_S.L'<2K;\GF%18KOTP5,K&M!(!327'[?VE_P 0RD/P MA?[B>4[_ )ZWR'?ZVTO%*N]QC&*4QC&*4QC&*5P/L0'U]_0^A^GT']P_7Z?0 M?XYKV;%@]R-.T-X\NZI"1D;,,&;J&I0\K*UFO$F-3;7MKMG.O:NZDWD>B^84 M7;2EDJTZT*\0DH)M)U1T+9TVFF9C;"F52>3FI736:.D/(;J.'E)Z_<-V2PV# M:%/@$5W$UM7CC8;&/BNG-?1[! /@EIVOP\+7-TTUL\*N9.QZP(UC$ROI;XC? M1;,W=^SW!;C#41Y:ELVEU38E"L,5;:1>*]#VRH6F#=$>P]C MK5@8(2D)-QCM/]A=C)QSIN[;G#Z_ J!3 4Y3%#MF:5W+:$I'=M1DLLA2EN!'>.N+7\Z-BHN%8MXR(C6, M7&M" FUCXUDW9,6Q 'V!$&;-))NB4!^H FD4 '^O/H 8!_?^_P!?7Z#['[!Z M'T/O^65F^0B]72?D-*>Y)K9>A7%2NKN1=;*TM/3&MKL>9=KO M9EPI&*NCPC]^Z6^-5=P9B4\4NNLLLLJ]A7*BBJBAA,/BS6W\"3MS*V+]VD=\ MS$=<1=UK2J'*NT>/"N$RS-X!69L:V7&)<'"I>"TMU. IE6?TG)[';S"[)K?V MI>_0C%E7&.RYLXAMQ-T@[.SIMULUJVJ?SAL6F??['=+*SNIWDR6HRRHMRVL3 M^^(/X&_\DW_JSGV'KW_T#[_N^_O^7KWFLMH2R:&LM%M$MT+V?O;66Q&EOLK6 M%@(39-N,DK76J#16(DR1WY5-F=N%Y)20;D;DDFWX@K1)N5)N(@L:6U0O^YY' MQ=[IM]ONEGD'K-S,I:QN[N:=(7A[1VMHK;6.D)"58O!DVZYG)I-NT%T_-*IL M!_"NE#MR-SJ?$V3MKB7B.])%D0E"=F+YM.AN#?K;=)##-C9;>=B7B-&2F19G MI7>):BKE-*2X[\ &0:]5VL]E>Z;,38T$[4N+6YM_LEL X_=]C[[L]"F3-K9, MB-'N.S$^>M<+:F+;S&<>N"+?(0XQ'+;N\4+!J[+X@_\ GO\ R3?Z?I]/[?\ MHSGX@^@_40'[>@$?\ 'T'\Q]!FL_+6K0\3S^QN55[:W\;I,E1@I$M :[(MC] MF%\-2_B(XKEP[(@3Y1S ;.+ MVTQ'K?=9RK*V[_3+;8KH?Z5?[=>(Q9OMWCVAJ)+EPT'^GW-EQ_WA4"0R7%L- M.D%)36FY>RYUUA0-H=D+YLO-D=FI6TLFY6VW7-85 M>K!*:C"$W>(4@,LRY$=*T*#@JY_XP^O^=]/_ )TWK^P?7H?[/?K.0$!^WO\ MM*8/\0#-?79=CUU)]O=(US?_ $IM;2]"B#0JU/&I; L<&T6G%8:L?B8M%DU9 M3C1)N#%9R^%%!BS]KB985C&,8AK$>*(G0 .=@S&B^C-F;Z232KT594[WJA\\%46B9%/EBF3XN\V=[2D[17^196+?:X MXC7>]6ESO=J;9_6%&RORV'9*-GNZ3<%,O*BEQ&#\,=1?*E-H)/R>VG88[L5L M;!VJEW;:"89^S&R>TK)C]G]_&S*$;5PK7.CP'MM%/*LSTB6XY!#QS\T6CF?FZ,8;3>-)GHGA-Q/DK%> MTV:Q$T$U(*EHA$:VJ0)MFY$JG3(8GR2G^9[G?G)FN(4\&VE!;,9M$9I0_P 5 MAO)<=1SW'WU//I!U = /"N/"0M+1<=24/27%274G_)!:A:)7EU!3?6.928MG:Z#ME"$EY!FY:)=6I?E9X-O_-NWNNJWOF,<<\Z M/V"IJV_[&>5.^1C9M?BMZ:JVJD!7']91N-NL$D\OU5@(B$K5>DYB4MNCNL.6.>-3T79_.6H+3OFU::V+HJU[ M0I[72*.B^M]=K&V"WR%M,-:T(]:KK66(19SCV-*WH(C7-3@*C#6Z-U:U>4KE"_4'HR\/9#;&KGW)^O'6W=\ZQW;HG;&HMTTC5:<)-6..V(34UUK M$;<;)49Z&KTPYA)BJL)I!XY8+PZH-9L@QV=;TYY?N&MZ[MH.BZ#L*Z+36X6\ MT.C;_8M-;8IVD-\2=7C5Y:V5[2NZK34HK7>RIVML&SE60:UJ;=M7:C5TU@WL MPY0.D%.?/)SNG2NQ_*UT[T$Y\5O1_,\0MV7H2V:ZCG\9>X"WVN'U MCK>)>\Q:'D[ULUM>XHBI8N&+:W$2G.F;(&$9EN3)"]%Z3VB\YK_1R8&LZJO* MTII/LGQ]2^S8>%I'@<9Y:_/7^*>&..,?/\^'GQ-6+[T\M'&7/.R;GK>_6K8[\ MVI7D PW]L/7VC=P;-TUS6ZMC5F\J[?H/;M&ITW1=6N99I(,7JS.;EC/:_%O& MDS:FT##.4'ZED#&08R;%G)QSQK(1T@T;OF+]BX2=LGC)VB1RU=M';-^A'0T!*5OI/OJBP&D=6:*U[5-F>8P1P/G@_:K@8!X<>.=3@'D-./XK MW[[\LG&O.6S+GK"_6G8\H\U)^KJG05SUOHW;^T]5\SMK>S0D*JYZ)VA0:A.T MW5)9I@Y;R@-9V3&1B(-=O8+"RAH)RWDE>]=,^1GF;EJ>UO1[E+[!V'L_;==? M7:@ZFYVU%LCHW9\YKB)5;IS>T I6GJ]:I9EK>)_%) K;Y C2+DE?FM(!28?( M+MDM;Z8T4YT1N7R8Z1[%V3Y;]74?K/KGH[53F#>UC@-KP<.1YK"]U*\6&KM4(F(K;JL"$\>_'_+^E=N:\TW?NA]EZOM'*Z5FAQU1N2I:OJTA>X.=V?#34'9&UB0K M*%9EK@P=QLB,:\;*D8LX)SPSIX9Q@8\=='RZ_OQX#ECCJ:ZYS+Y( MKYM;F?M+H W:;6E45IYM'VA- ;5N>CI?;<;_ +'>SVO1K"AZ4@Z%'15=L-?+ M<4;C)5N/LUH8DEZ%(2SIW8UH]5BJO&SFUYY<*[:/)]T3P%,:QVFRA-5Q^CX" MDW:'Y^Z)F%9?8^PY.Z,KHK?K A15*50M51@P402B;2G%HFAWA%67E(&YSC-O M\+:DPFD^C;=PYV@_?\M[SUY:]O?I&^MNFJ_J6;UW++WJ,U!;=R\U75.W/XJM MMI5BXBH>#3?.[I.P;R5K5=EXVRL7DXJ>"DG1;+WJTUOTA*;:8; J^PKS5(B4@]8R<ZX3W(UUY9;?3;=ST+!7>&M=[ZSO>@=GZM MB9J+>S]=L]RHNUH6M3454K%7XYY-1-E,D>)49-G /'#)T@LU3U\N?^>=V,M& M^!Z&L.D-G-GVK_+!VKL/8\7,:YLR;G7E3F=D=ISE/N]U:.XCXZG7Y,LY5Y2N M62<(PCW9Y> =1KPZLA&G6D;VSR!OOI'R!>2VEZRKUHJ[7H#P5UO1=&VB]A9J M)US.;@D-U[9_#T5W>?PB<&>;7AWC%E.LROG$M#5B;+(NFI(]1(56O(YX <^. M-=#TR?OPIC.=!GZ8X#P'/7].<]*MYQ?'M:IBGL$=@;2@83:U]J&M]"[ N?.. M^J7K+H^S7.ZPNOH]+G[8-EH$=6-J,F-FGX\DR\@'XECH'\;J%,IE+J$7-VNXW"US MSMK$0%+RI[6 M#=&F76L=:ZAMNOMBU6HI5'6]WG5TX/&EMBUJ<7L&OMWTT-.P M=FO%;=:ZL,:A(!:F=;L$=%KN6R$Q#24>^6;& \=<\/+7H>?'3Y=)_;P M/CUUY:5]NG>33F>S#H9I8$-W:@G>C-SV?GG7-7WQSKN?35A-NBK55&ZKT*R, M;U4(M.M/YRMK"]ILI).25RYN6TA$5N9D)B,D6#7[.Y/)1Q]H&S;ZJ>U=HKUR M6YGUUJO9VYOP](O<^TJL'O&S.*?IZ%;.:[7I4+)?MD6%LI'5+7=93E[E*G,B MNG$%;.$5CT>*4#L3KCQ%]83>[+=L]]L;D;I"P]-^,OI7H[6T=SSO:X4GE1C6 M=KZ=VCM:GO(:J$J$G9%6FR-7OKA9:K1YJPTF6<6.?AHMPZ&07^OI'7NH=\>- M?I3M_NW4&_GK'R@]!U7J%[$Z JNT=E= :"U/ R51RE.>.?TXXTX>>.!R<4ZV4-*QO;O#/:.QEZ[ M")T.WFF*19'3MK5[Q;S15 A9MW;72T$G+B[>3OF.A:NU7LF:;;X4E=ZV6YU' M2FC6G,N^O]E!M"3"5_A6%YWHG5%AW4E6]*WW;CC0:%@L-+OD--U'=3!O:E9G5VS*0^KB- MUUO=H-U3)Z(DX"W0$<^)-IQD4T2>.K! %D\)-_.;P6ZC+DW1D^@QVK19M**G M.:5.3NB4.ITXUS7G-R;7A'GU?7Z>Q/Z-#TIHM;'6Q7<6SJ41%"V0G)2+F9"- MB7E5-YY0J$CI7DC9'-3/N[?+'MM0SM8V4X2H[)W2;AN-]K\= M,:A>UG5)(>MUIPYND]1HR-8UQIC49QIQYZ\M..=*8''CJ<\LXQX=3_HUT[R#>2.PZFXIT/Y6>,[2TWS MS+!S+.0V?KQJR0BX3;^H]RM'>MZE86TA.PS:[TV[ZNWFI0DQCD"QJX1DI?JY M;(1=VE'N(5E.^ZFEXT;^C>[1T;9M4["C-Q[H[=WM1=1Z?>TJ=C+A8%O]GU?> MAT%HFH/V+654@E-.ZRMEYC7S-@=BZ@6Z$LT.I'NB.C,$<->.-=-=0,Z@^!TZ M#F:@QSR/VT\.F:W7,8QF52F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2@_;_V^_[OWA_B M&:5W9]DV#Y+^_._ZO8=K15]XQ\2*^FI:.XZ?WB-TC!;OWO+F8)VL^PKI&PS^ MTV&LQ#V'N\'6HM_)BA9KS#1=.BF$3%V1\O*;IY_\T?X_8/ZQ^@>OJ'U]B'KZ MA]?7U#[YI#^2[7&HKC&TN5UXUK-;FNW/,-M2/VX6JBM7:?N^'U'+2W.E8AYV M/D0=0]PD3.:/:+S7I*74A(R8V3%[9MFOYV%MK^)?Y@LZ?H.)U'\\3X\LC-L9 M5R^?\:Z^'E@Y JC^T=Y=Q]HW'83/53VT0EYNS&PZ0IVC*>E(Z_HJ%-UVHNZJ M&AD-/O9:TU:OS$55VD3<-9W.FLH*P6:;UC8:98P6E62,K)R-TYXN_-=8](;# MYYNVM=KNWRE,96S5MPG;.S8_DVRM#/7,I3J?,/K(>2:Q4/9I&G25#B_P4Q&P MEJCDX68,]B&]N>N+3O[\[<+\G\LGEY+2.BM=TBU6=K6F]OO#&$&2OEM/46)6 M,&I8[W8W,W=)P8T?GN61Y>P/G"3QTZ?*N%I!TY=*RS!,@>O10^GV_?Z]!Z_? M_+Z?U>@^P!C=/EJ#IQTQST'73&-3X8R[S7AG3&I(' #./EIS^=:4/+GZ,/?+ MA*H=$=87M.E[NO%%9V64KR,A&WV9U[M*U7"7MUEC)"6A$FL5(*U)!S Q=?G: M[9W*R!ZZDS7E9^(DGZ!94;E_1B8&TT[UHOL7;&@;H^H;FFRL7&-GEGUZ**UB M@IJ&:I)FF8>ROHR@Q[.3K52_.UY)R,,6N)(%@/U;AR1VUSC*4@\2?#PX:"L2 MXKP'@!QX<>?+/GFM$&5\'OD:XHI^IJ^RW91NC=,2FZ;OO;H9U'T5]%1>NK96 MY9A::!:7$.Q?-;S;(.SNXV.4O*-9A7@P[&+LT,TB'"UI8/EJJ?()T#8:WTW% M=&.-NLM;[-B-X4ZZ5!TC8F<=N"3FZZRA9F%Z&GH&M2#AB+^[5N5M%87_IX7&LQMSJ=GJ,PB1Q$VFNSE;DT% .8BT=/1;J*? M)'!)9NI\"K5VJ0_RUT3_ F'X5DA_P H7^47(ZB8I66.UA8ZG5]-;8TW==LZ M[U/L:.L"H7*4?UK8!976[*2;V&R?J6-8+'NW:KFIR\>^/-/:\T7UM:E(UY$T M!UK4,'P/YP,^6?+ER &=C9R".)&!S\-3KKP(QD$DCPK^GIQ9OPG37,>J=R*2 M,-+R\_%2\%;92N-WK.N2-]U[9YO76P'];8R0!),JV_NE4G'U=:R'MXC".H\B MYCG 3FE)E;/B$28?]3EY M7>#]O[2_XAE(GA"_W$\I_P"[_P"+7>0[Z?P_[;J7BE7>8QC%*8QC%*8QC%*9 MZ7""+I%5NX237073.DLBLF55)5)4ADU$U4C@)%$U"&,11,X"10AC$. E,(#[ ML8I5*.EY8_BTZ :\G7@BL5P=T??I!WQ!L1X\$:QSUN&XNWT]:.*;G).3 C7* MI;IM64MW*\C(*)1ZQ7=@U F[_,8RL,W-U@& P>RC[^OK["'H0'T(" ^A 0'Z M& ?J @("'L/68FWIHK5'2FJ;II/=M*A]@ZRV#$FAK559M-46K]J"J;IHY;.F MJK>0B9B)?H-96!GHETSF8&99LI:)>-7[1%8M5M)Z'W!XRIFO:+[OM4]L[DY[ M)-:MH#R%RR:SYQ46;IT1G6=4=WN6S8K:EVF,15:P57Z54!+7^R6[=J-^/< MR26G-<1LG):=_P"UC)/FB[R@Z?R#5YQLW:1'#5VT'[_ /V_PSQECLGL<>9$O")UT_\ $4;: M61M*[>C*?*I4F9)>7,B.6WOOZ8U%D0'C:E=Q%;D"$VRGOBM!4K]'S/:*VLG6 MRX[-.VK9_P#\%3=@X.P,;9A%MBI1;[?:X,-NUW!F^)CB_2)\*]0T[2I$NX/P MG+N_)6J(&G0A% /,$IL_0= L-(N?C[VEM>3E;W8;*WGGE'C2$+'2;>-:-X8X MS=6UU,UV5W/.HV'7FC8 M4AIB6KS,D^R<+D;1#(5S-'#ILNBT28%$CS\MKJ#I^U;'4(BG>=CT'V]?3^&= M7 [&846)%@RMI+K.BVVQWVQVEHP++#,-F_VYVV3'GI$*WLR[BM$9Y19;FR76 M4NA#JD*6A)'T-X]I^[7"XW&[0-A]G;1<+[M;LEM=M%(%UVJN:;G+V.O<>_VV M+&AW2]2;;9F7I\9L2GK7"8E+C*E7U/X[Z4^JMGN5AUKM%W,WHM?9K6)I0H:1LT!,,8V3DF(KM48^ CA-'_BTU M1CTQ8.4F!S,FZ(C>6( /W#W@0 ?N ?3,SV.0Y##[=QVCNDYU=GM]BBO)@66W MB+;K?>+9>4I4U;K?&$Q]R1:HS9?FK?6VTI[N]UQU2ZT__29ND25%=LFQ&SUH MC(VEO6UL^,J[[5WA5QO=YV9OVRRW4OWN]SS;(D>%M#.?$.UM1&Y$E$7WA3C, M9IH4@S[39>J.V.C]F/.1-C;XIEW1A(FNK1E2;OX<%6D;6EUIAB^EHB39N"^V M;F..+0A5"J%4(IZT0CWD:[ ],Q M)%HA&PD2#A\Q;JJ//:QUA3;'4 A2@8PC,OT']_WSHNRMGZ[TW1K-LS:UVJVN M]?4V,6F+5<[G.1]B6VZ;"VIF[V[9;9G9B/M(SM)MK9-[6;-V1*1CM(2.=8TEFI*5#F ')"*S#Y>S;>(B MF@YIRX?"4:;5\P0Q!FN1>/0GH!T2/L^H M^/7BR*3Q6,D31]_Z CA(@_85[7KT22UUD'"1%:A8FNU^+C8.!@8UC#0D)#,& ML7#P\1%M4F,9%148R2191T;',4$&;!@T12:LVJ"3=NF1),A0]4.("%HR#-<2 MIM>,$0VU#"T%0)!E.)*D+ TCMJ6A1[]2@QX/K-4A6"(B%!:01@R5I.4**2/^ M0A6%H/%U:4J']H N_4 *'H ]!_ZQ]C_ 'C]1SG&,Z^N=4'.I^+I_I2UUJX5 MCM#M'EA]!5IW4I**YGV72*Y5;=#O9-234=V"K["UGLB(2M;4ZJC2+N<"A#6. M/8F!H1\=%) J>5N5^5]0\4LMDD9:W627NMXNETNL\]M5W MOM\N=@<.IJU7.X661?3<]-/U@,LZ7*@T09L&S1HA(W&3&N?7TX_?T#U]Q^H?P'Z_4!_> ^P']_O/+&6E>'RR> M_8!\/OZC\(B3W]/7[0%$ -]/I^U[^F>8!Z#T'V#Z!C&*5X?+)[$?0@(C['X3 M&+\0^O7LWPB'Q?3Z?7WG(D+]/IZ]!Z#X1$H^OOZ]E$!]?R'Z#^\,\L8I7@"9 M #X0#T !Z $0] '_!#T/T+]/\T/0?RP*9!'W\/KV'H0 1 !#T(!\0 ( ;T M_3V ^OW9YXQ2O'X"_3Z?;^8_7U]O?U^H!^X!]@'[OL&?)GX9.P0LO"+/9..2 MF(N1BEGT-(NHF69HR3)PR4=1J-O5FY4'55Z:13Z%BM@HP=,UW M07&PMA5^-DGK>MW3:\C=IN"66&5CUDIOXI,]L D*/[OM] $!$#?3_P"> 0-_ MI^O[\\L8X4J'_9'&&N^X*#5M2;>N.U(G4;"\QMMV/K?75T6I=?WS 1U7)2;F/G)ZLP\M N)QY!QS-])'BE'S)S+&-BHV'CV,3$L&<7%Q MC-M'1L=&MD6#".CV2";9FQ8-&I$F[-FS;))-FK5NFF@W;I)H(D(D0I0_?C&/ M7E2O#Y9/0A\/OXO7Q>Q$1$0]>A$1$1$0]!Z$1]AZ#T/T#./E$^GT^H>_1OB- M\8>_H/H_OXP]A]!_:^WTSV8Q2O'X"_P'^8B(B(_\81'V8!] @81 0 'V ! MCX"_]Z'K^ _4OT_?\(_3W_/U[_GGEC%*QO8M1ZXMNP-=[3LM/@IS8&I$;BCK M2URC$KV7HX; BV4'2?HH_CE(G\3&)N4F+Y^@Y9DC&, M8_-*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*\#^OA#W] ^-/[_ ,?F%]?N'[CZ M /Y_7V'WS1O\C%[I<'S;P,>BL(.2A/\ 9F;AE*3!1U>=5"PSUR8]L;-7+<*G M?*MC9^+'#.,'QSI M]S_NMY5$3F23,H42J"0HJ%$"E$IQ !.42E57*7X3"(?"594I?7HJJA0 YO;E M(7:7D7Z7T/IO3%SY]?7[4VO+P^ZG[!Z3H7/^E*HK'#GTY\N7'GRSTK#!(R!IUY#AQ/ <1STYXK:LQD;MN=*U366@"[VB8>>V M&G8X*K+:GH5:0187;;USV,2.;ZLUW4V$^:.1962^S,S$QB*\^>.B:NV7D+#; M7D/7X";D&6KYU-Y0_)AJ2Z*Q>Y>L^#.++7+&E)&)T#7-,RG1BU"BFZ[!)>K; M!Z.V;MG3&NKOLBHK.T8RZ#JF$>5"#EG!F$BZ9./DHI-X#CIIG^#X\=/"@!/# MUP_>MNVZO)..I]ID(1DYDIAC79MY%QS-4J#M_(-HQTLS9-5CQLR1)TZ<$31; M*'B9,A'!TA/'O" 9LI_*OZ%T;:7&HKG,;>ZBO<]#TW==WGM VS9A5BV)SKUS M;]=R.[:3)5FK_FKA-U5"WYY?7M(0&DP[::J5IG]8,++7+#$+Q_\ 1!\;&Z^J MMZZFE9SI.>YQV=#K,HA>A[4T;"[.UG,6=C*,E'#V(VKH;9C"1"B3R#%6-E8J MPTC9%THM]A)A*6K8,8LC"2FM0_R1TRVU;N6S!&#J M..>H.AQH<9R3IUX'&QOB1X9)&.'CK@ZXQXUNO>/"KJ4W@_CJNKOW$DY8\T:5 M6=NW,D,P<[R4U_ S#M)*7.SCU91HUE2<YZ%=1LMK.4/#+2&LK73IJ4H]UUH\4X3& _ZM9Y#C M>_?T^$+;2A$PC]@*'L/9A$"A[#V(>\4J[_&/O]L8I3&,8I3&,8I3&,8I3/BV M&N0%LA9:MVB$B;'7I^->0T[ STNJ-L^/6^K.#QRC[?,,:9TM.Q9BN$OP:EIE:'8%S&%)Q6VB_I(;9,^9+PL1/QKV'G(N/F8B10.V MD(N59-I&-?ME/7S$'L>]279NT3@'HR3A%4AOWESF^]H>TFL>\*/&0VON99_\ M[NZXV^3Q4M]EQY6@#R0 *X0BJ9(]T>+"1QCK3WT;'/<05(<9TT2EEU#0)*BR MHFNK:^VEK7;5=:V[5FP:3LNJ/DTE65FU_:H*Z0#M)2BDQ1!'Y41#]Y;OEF""8_0J*(721M3HB:8 )C^+%0H!\ M/S!+[ 1;MZM42I+?_JNQ$$#J.\:DJ*L=>Z1GH*O>3TCXHT=S@,M2EI)ZDH0[:K AO:D/<^]>AVD0Z( ^P1=,*/:*8FJC]_:7Q%*;V/Q?$(B.9AU1XN? M'UI:P_KC1>3M/C=P3(F2^W6OJ[5V F":A5BF2O6U7EUM:2OS2%.99&635.8/ M9CC]L=W;DZJDRG2/^AJ*VVE7#3O7))*>>O<+X<-:G>3UXQ'C- \5.25K4GAC M^VW' 5ST[Y'G6 I#R6,9P:YM,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE M,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE<"'L!#^("']^:HO ME,CM:NI?M+DK;W).Z5"U:COG^R/:5>;K;59:(NDIK M[6NUZ'$ZOM+EK^L%EU=I6X4MVK;7T,E#[7>56]U5S5^JM\<\=J[1-5*_2]70 M=MUI;=B7E.22HNMY&PW#7][UK?;[.1B:IZA6HMW4=A41C;WK=Q$PMQVK6$IH MB;JD7D28P,!1Z#.N >F?*KD@D#J0.HSI@'EFNV[ @Z&UM.AF\_%2+Y9#;L] M)4<_QFDF43?GNL=K2 2DB9^5XZ;MR0#FY,X;\.JW:Q;^18M&Y4&96[8M9G0O MA-Y1Z N1YJ[Z=T-L2FI7)UL6$J.PJ=M".LE=N,Y$U^'MY&FS-6;FH3Z?U[;$ M*G7I":U;=ZK9ZY(6-!]8I)Q(/Y%P&2>C?(MS99H'G68@-YZ$=O-[WNLUF)AT MMCI.)1=G9%9.*:&A(>2CJ];"3:EC-6H [&Q5:%.QE9=U$R*"+MH?,^\^;X:; MEI9+6\/$,6TWL;;E5UX_;JJQS;9-3UU>;#7(V[UB)F5@F5HV8B8<)'YB17;1 MZV14LL,YEH2R M,*?78>M*W>YSNQ[BRK:U@)6WEWLOX8)V6@X2=FII*LM)$K%FJI!PAV,,D[*N MZ08)+NG"BNK[U2\HM?\ *7U[UA-UG88V:DQU X3TA>5'\O!U376\X[D:3[83 MN\(YKRC&0![=']7UOI-%65<$C+(A/VZKK/ABI-Q6[)MO*&])G. ^_1#& 0^O MOT41 0]?]&:MO;SC771-/ZC8-MF0;[:Y_(^ASA2=3Q]Q:.;9_2T[I^E=:ZXF MZQKZ'4;23G9\4$&SDGEIM:[Z/USS<3=%HK$.VFI5U,JB. &=.8UQIC\'AQYC MAK4G74\<9SG7!!Q]OE5\?#S:H!S'KN?H:%@;5/8[[8FZ8I*SK,EY@!WKM*[[ MD?J*GCTD&I&BTE>GBT2@1(BC:(48-G'Q.4EC#++.CZSHT/K'7-#UM72B2OZ] MIM8H\$02_!\,/4H1C7XST7YBPE S..1/Z%50P?%^TH0K"F,8RT MIC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4J@O\ 2*=4]!ON#Y;JWD796P=4 M=+\02ZF\ZI9M;V"6A)N5UC^'1BMW5"0:L$G;"PP#BID979]7IUB]AY%:AH)/ M&ZB9S)GTR? /=^ZO)]WJQT%LK?VP''*$;NG8GD.Z_HU9,QI-1V]?)6?K[Y^R MOS>DLJU^M$7M/:!*0Q?425>K4UI -; ^A:RB=JL4_P#43L$%$6>#EZW8(QC- MP,_&/X6;AI-LD\CI>'E6BS"5BW[1P4Z#EE(L'#AD[06(9)9NNHFJYJ^O\ KS=?&MU<1B"?O62K+K_<6D=:/)5FDHDE&UY&Q'UE7Y!4Y2(1 M$);HZ9$",6:GQ8+B_)W4^-6>O:GT?IGKC?/=/7%@WML*SZ9YAYXG]IVB#;Z6 MO4I0W%"JD4-BCX]+6^IJE%0T96'D--R:5HAS/-V2:;=39QI>9D5)0T=PUTEM M(-J1D3/\+=T;JJ^PF5CF6,,\@^:NT;4XJE?7KE^;/T/F(:KZ6MU8J-MU]L!P MLO'T/HPTG6[">)0V-3)).9.X-,:C[2U33)UB_B'"S<6E]U!L]"MPL_)U>1D& M@IJ.X]&=:E?-&,TT$\/;8EB_K&@ M-99!XY&>)_7ZYT&.7$BJ@ZMY1H:I!6+:;QI>>">N41.[7F96*)P/9(92U+[5 MGW4ZNG;FA+R2IR[&H)J,HBC)A+.%J^PCTTVJ22:[@@][I/E9YW[EV;8.,]R< M=>0SDRV,M37#?#RZ]':78:46U'3:2RDU4MO,[W ;!GK=JB?CSM) :'=!BF"2 MDXS5B4'ZH+J-'F6DO&/O\KWYJO:3P\5\WY@0*=,+#8YTKI^Y= #CARYD:X &#Y]=/$ M=6G'/D ,8&<^770<\:XKZG&-PVK;>3] 6K?CMF?;\UI^B6;8;G\+'P[E9_-1 M)'Z8(R&EY2,!"1L3*.3;Q#">/,-(U%NS:$;H5+^"S7_-N\-9;L[@CM M3ZBL^Y-@]]>0*?KG12NOJ8_VRZI-AZ(N*=;91NT31"MP)7AI;B.BV+%M-E8I MPHA'-TRL#F1/DKI;;]RV308WFCG!(:KV)Y(J[-22,ZQ(_&2Y5XP9()TQ]TIL M",<2LFA5W=.U;,Q\#K.KL%H!I=^C;Z5K7V)R1EXEV&;/$GI_7W/.JNDM!ZGK MS.IZTTUVAO+7]'K;$H%1B:Y"Q&N31Q%3 "XD'R;G\UEWZH%<2DL_?2CGXW# MQ50U&NN>OWP1]OS4Z^/EQT/R]?*UO&,9:E,8QBE,8QBE,8QBE,8QBE,8QBE, M8QBE,8SINQ+Q ZRH5UV1:G)V=6U_4[)=[,\(G\T[6O5*$?6":<%3^(OQF1CH MYRTM=:U/:GJL95RW^\5>F&LDD@+8%HZ "R M2L8,R^1%XS^:TCOQ+A/\6V^-,OXA'X_YOFM]A[NU'L7FKSHV21LL?7MY>2G= M4?1EFL$77DF>*D)8C0#E,D>#D:U-;EJ"@&4403<:]9MD4$CI+*&O4_2D M74;,.?%;(M%&-W+-T.G'#1XV6]'3.DY;*(KI*ICZ.0Y# M(AZSM3:]V3'8+X4EX/!2TH_Y;L<+[UO!4=[=*0-[(T5G=&->")N\TZXEO"D* M:W4J5_DAXI#;F< @*"CI@X*2,GEM\8RECK[R\2.G.H%^).2N3]D]P]15^G$V M!L>G4:SP=&J6M*RX:MY-NG9+E,,Y<#V)>,?Q#TL0C&)-4BS\ R/*'F)9K%CA M)IYZXRW\*;%[2U1R7?[Q)\\;(_HXZNT#*WV&J>PM%"=J)D[R+\:Y.,+90D9+ MX6$E)@S@)6&32EWLM$-4JS82L>&F%)4E"@WHX4!.5M@_W20T5)*PI"7",(4L M)2LXW2?Z$U'7-R[&LA[NQIT-S379%RM^L;#9"1JW M8%W\W1VS%Q^>L(\[45IF0J< S,H[M;,[>%'C]ZJX7YMZ)\XVZJQI3G*24>UL\Y:9%LXLC*%-9 M64#&&*&0A/A+F^VXE:4MJ0@!)*N\>2R-X;X6@%1(1\"BH@:!)WJQ]Y;*D;JD M%*E+2I1*AC<;+AW?A*58&JLJ2 ,ZDC%;7^,I#\>?E>Z![RO]/<#XY]L:CYBV M1"7B!*5)R, M@@+"20000H#!&H)%,8QFJLZ8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8Q MC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*8Q MC%*8QC%*8QC%*8QC%*8QC%*8QC%*8QC%*KV\K%3C[?X]>J&TM'L):*K6M#[+ MDXJ4;-GD;)QVH;'7]KO8Z09O4UFCQB]:TI5LZ:.DE6SI!0Z#A%5)0Q#82U]M MW7_C3O$MH/?-P4H'(NT[=8MC.K M]97AB[M<.0'\:V5US=86-!G/0#>>J6QFTG1KS#3T$,;8H.[MC6"5AG5(@ED\ M2<'EP^@SK]=.>.?+7+B /$_/08\/]^-270Z;YQ=1))YMOW2CB#4*4Z@ M*Q1R&)\PIBR*=B,S,4Q! X&*L("7]H!$/KE4_?/;%B8?J(F7FKT->RPM=@FCRZOF=42LTR$! %9JCG&--=/#4@=?'Q_FOTUZ> M!\].'&NY\3\2P/*<3LN]6BR/]J]+]!3C:Y]";OL"HN96RR4M2BG;[/HES<*N[596!M6K[7+&E&.H0SF M30MSFYF-K4%*6";>HQ\1 QCZ9EY!R<"H,HR*:*R$D\74,)0*DW9MEUE%#" M4@G,/T$HVN(UHZTW8D:]+QDW%S32S[*HML:WBB#9()^X$8Z'CYC S\\#[YJ#7 M)SY^.3KS'3/RY5L/XS7/W?Y4NL>?;]+\G42D_7J9I)[+0-2SUF'%7 MD?YW[5AF<;5)Q2A;O:5UA8;CSOL(#5O:T#%/6Z*S:Y5Z"EDH]SLO3T^54C^B M;KH+>:UW=()TPD6$NV=K.8ME00?73&?IFA!'$<>'B*L Q@! 0]@("'\0^H8R MU*8QC%*8QC%*8QC%*8QC%*8QC%*93[YTGV^7WCCW5K'FW4FU-Q;2W>:OZD1@ MM1UJ;L]CA:?8I).0O]B>-(-JX60B0J,/)UY55=1NDL\L3-J0RIU?E&N"QFQE MSNG6G=U*^[<0YN*SNJ*%!0"L:X)&OA6#B=]"T;Q3OI*=Y.,C(P2,Z9Z=*T;- MR_HY4Y">+6,V-3;OUA=NJX;4- V<_P"4WEB:R^M4KW,_E.'?YDY1S]7=.E>Z>JN$?"FC(\H='RNZ-%WJ=J& M_:Y_1#9TK+44: YUI3(>Z6>*(S!>/@K97JLA/1TVNF1M)$!\J4YE6SCUO$>@ M]>O0>OX>OI_=CT'\ _NSL$W:1O(4X$.K;===0I>04]ZTII3?PD?!A6\!QW@- M<9%<7W%D A!4@*0VA03C![M86E1SGXM-T\L'05H\>3[QP[JUYY.]R=73G'W2 MO:_+71T;$2Y&G).S[?KC:=!O36M5:">1L[^H0R5A="]97G^A5AI3=OZW=$6)U7(R@O MBGW_ &R+E:\S:PM-CV=^ML"WKD\@O?[ M_7\/?W]8^$OU^@?7[_0/K_,?XC_,R7KL[QU'3<[68Z1DF,5 MK.WJHQUE_:*QMM1FG%M_#KN*8W*GWSD#GGH+2>X//OL+;7 ^X=X4#;LQ=%=> MZ>FZA)5]AU#7)G=VUE7U?U[-R,:[;S!']:L#2>:R40V>.D&:C&3C4SN3LS9N M0>@#[ ?V!@2E'Z" " ?8! !]?WY'+DXZ7%+:;*WD,H=6"M!7W#J74*^%0W5 M$)""4E.$@$?%K1$-#80$+6$MJ<4VD[JMTN-EM0^))R 5%8!S\1.7DI"LV-NPA:DVEV,(YN)SVT M:0\KSQPPL5UA%8R8E9NT-8-=*-/NY![]![^H^@]_U_OQ\(>P'T B'V$?J(?U M"/U#.)C%(43&$"E#[B/\ ,?0?WB( M ?O'Z9'WH_JKG_DJ@_TD=!;0K6MZXZ?I0E=1EEW#RS7JT.@_['TK6M)AT)&Y M;+O-V%XW^09'X57:,BJTC? M(7NR%.7XBL@;L%Y2N<3U&8(H)7;DSV[]'NXT#(MDM&3QBND7W]>OTIZ]?7E4 M,?-?Y(J1"EU?P!IZ4-<-@]!="ZEU'TA:*]^/<5/0NGD[93KQMBH7.W,TCUV, MVS?=7%<-6FLGKT;/':UF9Z[S\;$0B\"_D+:H72T'5]K=-TJ F+;7(#IMA#[I M4".^(C.I[;;D:ZPV!:Z=.)OTW\9)3;" U'8G->(DC%LK,QE[0@HN[M,PV3BU MU]XN-97/G#4.K^;]:T:LJW-+ZJJ-GU_''?QJ\C4ZG?MAO)F2ME"=+UNNNXZQZ]W/M&IS#.+B%H"YN4T M012P.^I>LRS9 MVN8LBG8MH'VCJ_F"F1HE 150M&P(EPG\U+Y/XM)0Z:G>JKXR58N[/K4\\5_] M)QW[ T:FMTIY"ZG*G,BH'HSZ5B:UK+9;J%E51 #N3Q%MLZK&NO'0\@>?X.:F!G.<#7&FN.',C.03CRZ\)P=1^7#@%]KBPP3J=CB3M4@]F1KFN:PKSV[197=0:V=QL1#\D+,KRS4B MJS,ATZY=L[X[(\A%WG=12.N]H:ZH,.V0;R_'FA73B1V(V*](NXB6W56QW$]I MZK45Q8()$TK6Z1MS:.G-5I,CI*AIWM6O*LEVMGFF?'/?%!C#[3F]4<]42"15 M:U71O$5>DZE.1,4[<@L_A[KV-<6R>_[4WD&AC1T@CJ.-YX9+MBJ(KC(-U?EA M9IJ/2^J=#4IAKO3NOZKKFF1SAR^1@*G$-8IDM*OS K)SDB9$HNIBQ3#@/Q)QD#/[:YQQ\.>E,@<-3RR.' _4<.>HR-.-0O& M?B#I5&:EMW1L!!.22JE.EV?,%>L"EITY!OJ1\Q>EO]PRR%=HL#O^WU1ZY>3D M#58W6FLN6-9V>1UU4IO3^VW*9BKJF4VCI"@6-]^RO.;/DWQE7*_=JCY0]7P]JKNN.N]1[ MOX)V+:)EM5JX3INLPS73-RMCKY16M>H74NN9^\ MKTTU>Q,PP<%^BK20:+HG] /P?$ "#'C^O\_?'A33F/I\OD?USQKMA%"*%^(@ M^P_M 0$0 0]@/U#V @(?Q 0$/8" YYY1A>K\/A,5;66[W2PVWQ:6:=K]1CVM MCEWEPV1P7<+',)1L+'5MU,R3R^;=Y/G578MTJA''N&SN>'#)JE5HFU:H?+LM M>W/Z_P!@T7:]*K.Q]97&L;!H%TAV=AJ-UI<[&V:JV:"D4_FL9>!GH=R[C)6- M=I_M(.V;E5$_HQ?B Y#E*!^1Z>N/R^=2NX8QGSY63CX:,D)>6?-(R*BV;J1D MY)^X2:,8^.8H*.G[YXZ7,1%LU9M$EG+A=8Y$D4DCJ*&*0HB%I5*76/G%T7R7 MY'M#^/.VZ[L\^]VX.JH^Y[NC+!$M*+I2S;OL%HK^KZU>(YRQ5=B^L2E>:R9U M#2D65K#ST>_(FZ3*I[NZ*?V0#&]%^G[7L0]%-[]&*(^Q#V!O91]"(>P] (_? M/YJ^Q^QO'OV#RGYE-Y[2ZTHVNNX^M.IX_;_)4!,15N-;ZMK/BIPP;":6F$?R\M,_0GSJGEICAYGQU/XTK9C^(OH1]AZ#[C[#T'\A'[ /\ +./B+_WP M??X?N'^=_P![[^WQ?R^_\LU+-W5#N;GKPW]G>0_9/?\ T/<.F]\\CZMV?$5B MO6,*AJ#F)U,6>I6R(@^?X.*(C+U^7BZG;$Z5:;BZ?GE[DLR<3#SY*[K,#]RU M_P C7%WCCUAYC">2?HZX=/5A+FS9.U.=Y2:AQXBL-.W-/4*O*:?@=+L8N.6LLQ:;9\FQ_9?\ C!Z'V'W#T/T^FQ /8@ >Q /8C]@#W^\?W! MFG=Y$:GWUXON?]#^4(OD=Z:WCN.,W1I)MU5S_>9^ 3Y OM2V[+$96&D:FTS$ MPC)KK.&K+Y^A7Z[(?F4Y/+1B@V)239SS9)4T\>U]L=/=@^4S5?BMT!T#L/DS M3=)YA<=C=;;ET\O%0^\[G5YJZ&U_1-/ZON$FTF!H*BDDJRDY^S,F!WID9,ZR M9EBP:<9*LY]>O6*8_37UT.E;$ " B( (>P]>P_>'O[>P^X>_W>_OCXB^_0& M1]B'H! 1]AZ]AZ#]X>P]_P /WYK$(63IGQ.>5'B/F69ZMWSU?PWY$VFR=>5V M'ZGNB6V-QZ)WOK>'9SC1]7-I*0\39)FFVI2;K44$+-'=-FJ,M,J+D%S#136]#2->ZYL22-KV*\:7LDQ#:>M]KET' M;B,YRIM-IS6'#6L.F1"PO+O-KNET/P+8YF>(Y@O'Z].=;?8F M* B'L/8![$/?U /XB'[@^GW'Z?SQ[ 0]@(>O7OW[^GK[^_?V]>OK[S19BO*+ MSOV]MCJ+9?87E)[MXTK-7WSL74W)O/O$U1Z-J]=J.K]<2)8."W-M:[:GT+L* M/V;L*^ROXZ9>5":L#F+K#5F>,7C3-'\6TC,MT;S2=FNO#).RU=EGUS[0EN^H M7QB<]]&W;7KJD-]F.-CO&LSK#I*:HUIAXK\+..-9.'B!F\E7T6Q+PUB9:QPK MA09F+59]<,_7Z>>E!KDYX'!\/IGUXFMDWRD=?6O@S@?I#K>B56N7FVZ5J,+8 MH2JVMS)M*[,+RMYJE452DW$,NVDRH(-K"L[(#-PBHHNW12,J1,YS!,35UM=7 MS6VO[N^:-V#RX4BI6EVR:G54:LW-BKL;-.&K=1;VL=!NL^.BB=414,D0IE!^ M,1S3N\T7C?ZBY;\2?2VSF'DL[!Z3F I%1C.I:)TY=XB^Z>VG6YC9%':2RC\5(KA3%^WU P")?M]AP,\]/GFI5>/:7E_U?S+NUIR/I+26ZNX>TWE=;VY MUS;S?"-9*2HE5=D269VC<=[E#EK.L8-VBX9+(_CR2DR1M*PTB[B&<5+QSYUV MCBSNCL?H3;&>73AI]M>>O(U?EZ]:_3YTK>6;S8Z<\ M4-BT'5+OJVX[CGMS'LT]/1U&F8Z,7U7JRHR]8@9K9]L*]C),RL*:8LY(^+;$ M*R+(.8F73&1;G;%*I:_?=I0=*T]'DU0_'E51(@T;%&U MWQ%]?(]=?H_LTYE+(VLNQ>?><=]\P[+'^M*^1K;S^=8[ YI@ M^Y$/"_T'*<22<78+2]W/K+I;1NRKTRHU0E9B&MMM0T4G&UN\.8ZNOJ].EDCO MEH=FV;1;B27D48KX7P[ W-G1&JNLM$ZMZ-TC8#V?5FX*A'72FS"S!U%O%HQ^ M*J*K22BWI".HR8B9!L]AYF-7 RC"58/&HG5!(%3Z,G(GDJ[CY/\ T>[4<'2/ M');G&D$M9[*UXQ[OL&T*=<-1T>#V;N+8L%8MO6O1&N8VS;P_5K73FR2\>\:R M$0Q9NY.&1=+.EH]^R8R&X3XM>;:5R-X\N3]!ZZV*TVU3Z5IV$D(?:4:S5CXG M8 WQ9]L9_-/7G MG!UUTT/KET;O/RKZ X4M.O\ 3W69R J6"QOVPOD8F<4@8^:&"ERLX_Z,\FW?5[W!J^B[O\*74F M@];;/MD55TMQM=RZBVS'T1"75.5.T[0J-;:P\Q2ZO&()F=3S]V[5=W>6R8Y.;W9JS;NC] :Y>S:YGDI0M#I4RQ*Q\35$7 M)SA!P=X4J<#+R16*2*+YPS^,YC&=O1'=S5RI;2\;^XC:&O/1NM M>;]<]/M]SZ90I=SLVSE4$X:384ENK*WZ,;%21L"YFTO&L_C)7W)%7K0[MJ M M>O'PST\L?//TTH.F,G.FNGKR(K]W3OETWUK?O"T^/_E#QT7KL[;5)TK3]ZVN M0BNB=5:-A(BEVYX$:FY,OL>(79J#'R3B-CUBC*)NG#F0)^&9&12.KGGI'S90 M3C?VON5.\>1=_P#CAWWN&1-":92W8I6[QI#;UE(LDW&H:^WY1%1JDE:!7AK]HJQ-6Z/ZPUS:X;6KE>8.J MP[^ SIG(R%;FK''N3LA!4[$RIC (($.DSQ\#CZX_&?I]VFFG$=>>P+Z$!$?^]]#Z$!$?IZ'U\(_YWKT.:S_ $/Y\NI>6X1M;=U^ M%OK2C4N6V/7]65RUS>WM1(1U@N%QEW4/3(E@DU8/G8.[,X:B# BB/R$Q.4KA MTF E4/-O87F&YQY?7J&JNA8+IM[MQIJG5ELNBVO.3]Y[-K(REQHD/8G8)6JB MTV6K:SXKIRZ"28H/15C'WS63HB2Z*B9(=?I$-KA[_P"/#E.]5]"0;P=U[MX+ MMD.E,0[Z F$XFR69[,QI)>#E$&LG#R9&;]$K^)D6Z#^-=_.9O$4G"*I"LC., MY/0?+\9_/2F,8R!KPS_!_-6)<1]Q=4=.;)M-*WOXTN@>+*U TMS9(G8FVKWK MVUP%HGV\_$1!:5&M:@4':,LNPD'TXD[6.=F+*&>)B **MS'L]STI$('Q' A0 M,*BWLP% ##[6/[]F]>_K^_ZY[L#3]*E,8QEI3&,8I3&,8I3&,8I3&,8I3&,8 MI3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8 MI3&,8I3&,8I7YW3ILQ;KNWBZ+5JV257<.'"J:"""""9EEEEEE3$21112(=55 M50Y$TDR'44,4A3&"IJ3[3Z&[!?.JGXT*-47FL2R;R#G_ "#[V92R_.;$\>Z, MRF%.;=7P\A7[SUW*L%DGS1M:HR=UWH$LHV*9MM.WD;NXHV'>V=P6#K;KS3WC M:J;=ZTYEE-GI5GOF]LWSR,=74K/0=VZ0@N-JPY:%;O31E^IU9JLMTE,QS11:,FB*39LDFBF0@/7KUSIZ]=?7E4$^:?'?JC1EX M5WWL:SW7JGKN79+-)_JGH-S&6;8D8T?E5/*5/3< P8,*'SKK!5R[>_AMR!]?K] ^_P!?OGLQEI7C\!1^X>_J ^C")@ 0^P@41$"^OY &>6,8 MI3&,8I3&,8I01 $1^@ 'L1_@ 971M?K+95OOEYU%RW"TF-8:JE4JUOSKK>3 MAU'<\:.M#IJTL2O0^WHM*0CAL=-@K;1-?49U),8F];386TQZ2>= M-Y>RK6L3"%;F*]"W"2CY",I+NT@LM!_KD[C7HUHDBQ:.V4A*,RR:2+A[%1KA M.1?L&[M!H8B@_,)5_HWFC3FXK=&J6BKQ.TN?.4%EJ1J9YL-N>S5?:G5[FWRE MIZ5Z?5A)UU)5JU66.V&\2I=7OTU'OYV+V>EO%S6WK9B[82LK">77]QG7@,?7 MAC!Q5 YGA]_T^6O(]*Q+LC:7/_+4[ ;"7IFX_(;V/,6&6I].OLG47]C?(7-) M@U?V*H:9?MZHXUQJ&OH1*BKA[4>3W( M&XH\Q2_./CJ\A&S('784.RW>K+V;47<%S92SVJ;?#351&0AM'T+JE:/3H]PI M[&RV)XXV^WK-WLT10;/:I^-G[O\ 3-(O$-&2]EVU-DGMBVVQV">>M&CY20K- M#@I!P@TKFNZ.*L?%F0@J_6HJ#;S<@+%!W<;829M,K\P[UF@R@9YLHQ%3QV[1 MLZ:)PD]6;.Y7W'!.VYA2<1/'/&KH=.N-2=1^F!Y<.G*V$H_$4#>A#V #Z$/0A[_<(#]0 M$/L(#]0'Z#D"O)_KOI37WUMW64KJVGN+38FE5A(J/V LVJUV MF7$X\;.R,G<90Y.RKQ IMU%U)@6!412, JISS3]_"/O_ +]7^[YI_7^CUGGF M58\*AYQ9R32^2N.^=^6F,/7Y1EIO2]+US-.2Q#$[.S3C""1)>IMP@NV,"I;C M9WEAF9 BY3BX-+N! M(J'8):FM^W:/L*7I-K; S.-%7K1*@YD&Z#L7;:2EI]^FT4:(@4QMN'&/7GXF MGKU^/*J@NX^-=U[W\-&P^)M?L:VYWE8N4=::DC&,I8F\76#W&JQFOFTH@K9% MFYFR,>"MU,QJ;G>CS7G*E;29 MV"T(056"2U'=-3SMP*>RJLW"((),:?,&CEA:>I!8K9(A4A7 27CXR8T Z8^V M/V_-*I7\V?#V^.ZO'([YGT*QJKW9[G8>@+$#>UV="L098O7=MBYFRG&97:.T MOG),V:OX-'Y/Q.S^@3_:]$/T[NOAGKN$[=TKY0_'FYUI/[]I.FW?->_^=]Q6 MB:H]%Z&T2ZFUK3%M(F^13242IU\J=D03R.UO4.@J=QK5;M%\L/%9 MQ)O3DO=7E*O&X8^KLH#K#O"\]!:A/7K,A8'3K7D\D^"-7L#5%HU-!2_Q.$07 MB5S*JI"*A?FG(F556YO&/GZT]>9J5K5ZLY<\IWBSVITA3.&=*\\=E<5;\W;= M>C-=Z^V+O%WSGM;G>];/<-WM]HJ$PZK%HK-IUHD]9MEZPBR:?F29?B<.ACWJ MT@F]DKV1P]U+Y0?&X&L>A6^KN6>TJSLV)WSI&0U5>K'L_7^J]J:LLTF_U,XE MK:_@H>7DSRM6?.Z][_&7UZ]O7K]*U.NU. M>?/MY*^'MI1]26#ZX7/7>ZI6\S/2]SJ,Q"S-8I%9@G3-E!Z0H5 MBL<>G:+K-62;LLF5I$,:Y#1R24D\4;;/.FJO+TW4.KJ?82-TYVKZYHM;FB,U MP"JD1$R16KHI2 N@1\S7!!P4I053 BI2E^( #)F,4K6\V?X[?('P_V9 MN_L_Q,V'25[UWUC96MTZ@X;Z&DY>CTZ2V40KH'^UM-;!KZ1T*M9)U5T\VA:Y*RSR MR.DZT1K\YA!6^7L\]-/;&@JHQ J$,F9C\]-= M1+80QC'K3P_:F?7D,#Z52;X_/'/?-;^$BF>-OIN/K32[R>@=^Z:V*W@)M*RU M]F7;=LV@^8N(^<:-TB/#,XRXQ+\ZR#47Q7[%U;5^AKS2H/7?3G-N]T)EEHSIV ML5TD>S@IYY8:J9.4JNQH*+BXMBSE'"/RESQ,8^:3D*(V..MD5^O^=_-3Y.TN M8-3;MY'Y%Y:UYI3KW2/3%IV,PZOF-JRTNVU.ZF4W<1 U2#U^9P49*.GGZK9) M^Y*=1ZBP;K/V2!G3HFUCC'KUZYU0@.=?)KI#S&[E\@?(W+.G>E MM=[8Y$UMSP$1?NE(;2$C#R=>L;&S3$J*3JMV1XX^0YA6;)! 67X9T@].Y3>D M50%#/W2WCZ\AODSW?I*_>526T/I/E#G39$/N"B<-\V66T;)<;5V;6TTS5RP= M"[?GV<&PDH:O.CO2L:W4XH[*1C'S^+<-8U9XXF5=D#&3'YSR]?K3/VX>&N:] M8)% /7LWOZB(@QRHGS/\;;I[;YFU/JW1#&MOK7 M4.ON:]RS*5GL*%:8DI6L[8_E;4X;/G"#@CF319N4CLXXI2K/3?&5(PJ% A[> ML9:E>! $I1 ?WF.;^PQS&#]P?N'ZA^[[9YXQBE,8QBE,8QBE,8QBE,8QBE,8 MQBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8 MQBE,8QBE,8QBE,X, B'KZ?40]@(>P$OL/B 0_F7V']N(O* MH.N8B04C(MR^N;:<"]7>3;UBXWDR$&LSCG$I3]+?K76]4C^/9N8N[;)F+8_> M-T*Q&,IGOMITFS6J.HM94(K.B:VUY>-VG6SY9NB\K*$T155P]=E26D#C)@<>O'Q'3R_/.KDZ>&HK@ ] "/L M0 $1^X^OW_VY$GO#GF?ZNY Z YXJ.:RD.?RLFZ28Q MT:S=2#]XN;X46C%B@HZ>.E1 #>DV[9%58X_"/HI!^@_;%*_?C/YQVSOTCGRD MR6P=E;5U7LFN1'.#?=LO$T>O.-):SDFS.I.7\S9:71GUCD8):QN)B9UW!+.G M;YQ)&E"*JNUDW:2J3?X=_J.VG#;5YM8[HH4DN->V+I5/9=/E&ZIV[LL3:J$: MT03M-1,2JMG:"#UL?V E6;N$A ?A53'USI5O?AAHO%&'L@;BBHH4 DE+@*1N MJ 6#@9S@X.E<5B6U(+@;WO[>"=X ;R22 I.IRDD'73ED5G8! ?\ W"'^./?O M^/\ <(?XAFEE^BZ]5=.=![MZJB=\]#[JW1%US2.MY2 CMI;*M5X90DH_M\TU M?244UL$D]28OG;9%)NY=MRIK*HIIIG.)"@ >O]&OZLZ>WQV_UI4MW]$[KW!5 MJSIJ1DZ[7-E;*M5T@X*23W>RB"2$1&3TD\:,'I(HQHTKINDFL#$QFWQ?*,8H M['K:XRJ8DNH/N:&5KP%#?[X @)T_Z[SDG7 M4'&F.NN*W4L9\R4FHB#9J2$S*1\2P1$I57TF]:Q[-,QA$"D4=O%4&Y#F]#Z( M94##^X,][&182;5!['/6K]FZ3^:U=LG"+IJY3'V'S&[EN=1!=;7,K]F,_!(RD;$-%G\J_91K%L4IW#Q^Z09-&Y3& A3+NG*B2"(&.(%* M*BA0,8?A+['Z9Z0G84S=J[++1@M7R15F3D'[3\.\1,!1*LT7^=\IRD8#E$JJ M!U$S?$'HP^PQ2OJXSQ$Q2_<0^WOU]Q$/WB ![$0#]X@'H ^H_3/CQ=DK\V=T MG#S<1+'8J D])&2;&0,S5$3 ";LK-PN+8XB0P 5<$Q$2F ]@(8Z^''P\Z5] MK&?A<2<23P?CGMS6H M;N=;%J1I]TWM-4I%LE-:D0E_UABJ+<+JNVKL%8#RIH!\[77>1S]W76,TQB)) MO(.$DUY&\$QW3<+Q]H.-[*L,59^EF-$0;[9G(I_!2C9Y.IR, O+A;W%@! 7WA [LY)&Z%9SO#&2,<#G-2_QGP7]IK46^;QDG8(2.DG@ M%%I'OY:/9/G(',)""W9NG*3E8#G 2D%-(P'$! OL<^]FJL_TIC&,4IC&,4IC M&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC M&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IFN,;M[3W-GG7[1K_476= MT9JIQP_R>ZU[7]Y;QA-=T!Q;G-NN"MD<4V%O%EBJ\M95X[\*M-*PC4TLK'E* MN]$S4ASEV.Z_P!( [K1W7I376V:_&<%<>N:\3:6M:S?8:.DE;I> M6SU>&"W0DLP9OUFZ(-W2C($W"J*0I*B8B(@13Z\1G'F/MUKX&R.[M*]'>;_Q M+U'D_K[7>[M>'U)W^?<54T%O:#V#35))OJB!D*$;8\#0K-)0JD@@M'S+^I#9 M69G2*C20=Q $%)54);;7\SM I]EW:IIWDGL+K#2W+=CFJCTQT;SW2*%-:JUK M::HF56_5FM!;MAU*V[CGM6I"+C:375M>GV5,;%4.YD72R"Z"44N@><=0:8\[ MWAT6T7H_6^H8B3TSY&CV][J;5U7HL>\.&AI!ZE$#*F M.9(SETDR^ SE8JM,G(+;G+A2F;9X[\E/DD\C_!6]:#O'>*_ZHU.ZSM4T3T)0 MKY>):RP.Y=(NXOG[9R%R:WN)FDS6IN%I>V +(=V59BV.L9DRGS'CYZ>//]15 M'XX_C/+AY_;-;;6V/(!'P>I- ;;YFYMZ,[GA.F:T%RU>XYJKE/-7&=15K\/9 MF%EV7>-J7+7=8UI&S$;,HMH5I870S\C-M9&%3A2/(U^#>OSJ?OC6G=GAK\L% MAI%-VQI[8FD>2/#/;N:MHW4W1U:=7J@; M:V)LB9GB7S56E=L[@KNLVFQ=/1"\':'DH6!BJ_1;%*HO35=^FV-#JN(O!7/< M95#<7_I3;/5%[0GD=@" MT6LM54#GS!!\]1IH<<]1C/ M#K4N=B>3'HGD^D?H_P#I?5&D.I;?1]F:W,^B*V/);-ZUTCJ MZ[71@):&W_5T(HS:\2(+R$.'GU;V(RUKYP/'MT)8]%=*K M6&^>+'+,^#\?6MXAN;^C(K3%8U1$UZ9V-L>P=#.8YOKRM MU^%L-HK,+^>J _66FH]_8F:T46*ED# L]9BV/!C3M.C)[SW>2R*L592E*C=? M'KR' 6-G(QAEH2S1\G.WN#F(I]\Y(&43:NH:\Q>WB5Z7\>D=)2*C4[AQ9J=! M[)V?:EFHMF8(?DJK1H_Q;;9:/9J<^G9)?\]J:,?#E>0ZJS&/?1BGR5DI[^<%!5;Q%^0U!NDJNJ M?E/:I$TDB*++*&&')]"D(!CG,/U$?0"/W,/H $<@#H?SX<$4_CW0^N-"V38O M8O3=0YZU-3HOF7FW3NVKOL*9V)7=95N$4K'_ #%1D%XV;_T)Y#YEO7]P MO-S.INW[4;S,"J$%$-F$,A8QL4 MF0E+I'4K;@,E$55-9WO\CFB.'D9$D<*SVOER[LYXUVQ-=9:/:;-DYAE;8BAP,4VF"6V>U!7EZE(R\:Q_,F; M:4;6I\PDGD/%_CU)']F]?Z*\R6Y_&KSUX[UYO?DEI_O'1O8N^=XQ.OK]7J/S M)J_2",Y*S\1>+=;*M7D8+95]+)##0]*1=&E7,A&DCGR15WL<4\'+7@-<\F.<=R[1\=WFF8Z=U3.;%GM4 M_I">Y>DD]+1$,]"6VWK;3^Q].76U5>IP16GQ61:3@V;?73F^:5A.BN/^T.,-8]/6:' MIO.&^NDMG4=">Z643U?I763.Z.K)3MNP?ZR26T6#YC M/JF@]::DBU(]OM"T6]A )1TY/UZ&K[>P*R"[AA3UY0^Z^?/,US;JK@CQ^$N^ MZ.C]Y= :%L%T8AJG8U=<\75BAW9O;+[L/?TW/UV*B=;2E3182-/58?FC]]*' M=32,"#X%HT9"P_E.N*)_I WE7L3N)#8J(L+I@N0JS9Q#6)689LI!1( M$E"N'<3&K2""*IO:[% 5B_&@'PS.,:\P,Z:CP\-0/"LA@YTX#KTQGQZ_IPJ_ M8!]_N$/J(?7^0B'O^H?7L/Y#G.,9E6-,8QBE,J.\YG2"G,?C'Z9MD8_5CK;L M"JH:,HRS=U^#>$LFY'9*8N]8+E$%0=058>V2Q@5O_EQ1B%3%,D4IE26XYJA? MI,>C.WNLT>9=$4I2([I0E2EE)2@)!*MY7P@@ $_#G>/@#6MM3M@\*-?"'LW0B>C:[K\E"OKTCU&C*L=7UNIGN257-2XXC_4TG;)P#C8RHD>O"L7?RGAP M1':R_1\NFC[U\2<[K69ED'UNY<#:&FG;<[A=>4+1UJZ^N6L7KWYXF^!L6NS[ MFLQ@)B")6M4! A0% P9)+6/@1\=49S/2-8WWEW5DSM5OIB&I]RVTI&K.+J[V M$O3DXZQ7MO/$YM*T.'DS&/@:!^',@T^6G\")"Y3'X$.3?(+Q5NSK74&\> M9=QU+4.Y]*6F)87-[%0*]+?;8U:ZF&-/DR232<RR_& M?8*PDH6P6%%M*SN!("DETG(WBLX*A@'70"L*?HBO_=\[#'U]]!ZL_P!-VG_[ MO_R9\/\ 1=9EC7.X^Z;#**F1C(#G:RSJ$2( F4.1JW5, M1,H?$

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end GRAPHIC 23 g454383.jpg G454383.JPG begin 644 g454383.jpg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end GRAPHIC 24 g570734.jpg G570734.JPG begin 644 g570734.jpg M_]C_X 02D9)1@ ! 0$ V #8 #__@ ]1$E32S$S,SI;,C!:0THR+C(P6D-* M-#8P,#(N3U544%5473$Y-#8P7S)?3$E.14%27S1#7U!(5"Y%4%/_VP!# $! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1 M" ,V 8,# 2( A$! Q$!_\0 'P ! (" @,! 0 @)!@<%"@$" M! ,+_\0 3! 00" @$"!0($! ,$!@8+!0,$!@.&T_\0 '0$! (# M 0$! 0 $" P0%!@<("?_$ $,1 (" 00! P($ P8$!0,#!0$" M Q$$ 42(3$&$R)!40<4,F$C0G$54H&1H? SL<'A"!9#8M$D<$B%L89QM_K-#$4TC3O MZU"?+MRQ%L7B,D:[NU![W<:]49:?%%I)ZNM473G3;C;;H?L^V[5D^PE&?PH5 MT=UV)@Z2,_*&L9QIII[BJFPP6.USKOA5NT^37^I[:YU^-\5OG&<8Q\-H]?\ MM)=R?6X[8>:G1EU66Z3E4KUC)4RQ#;1/!B'NQ&!";P<_N M2F7=RT!MKW54M?\ 7ES8I>I\I$MWP^7:L&N8NW&MR18P92="OBMWG_.M6H40 M)V).BJWS7P\8V;ZI*C5?L=2AI7MV>L">3>H MYM6XN,V?&H>I-P V*3\/.HO+1J:*/N'MI4.;ILAY;1TZ:)*)K:KH:)KJ;[[Z M*M%45-;Q7OG)T[=@-8VA6,)CFMAFL1IFZ@ETQ6SBL5/N7*#-B/F8L"CA,0I\ MZY08.]%7::VJVZB[/1XFU=)IX[674JR%HW;HPU4'7&@#LKK _"8G+Z;6E+J0 MI%)#LEH1P2R]>O&K.,/VK5N@[38;ZF$MBZVNF<;[(I;N]%5L:9 M]^4M=L:?S9QS==(]?9[7_:/L?U$J0;)NO 'U'CK_ %(K]M44J'2J M %FR>Z[_P C]/\ 8JWG]MFYG2E(57/--FUH=>^U,,K:7(+:ZIN'HP6D7'1L MW\/1-/&VJC8>J(77QIG#AP-T?>_;4BEGECD[[?39:WYC2_7ZF-[?D=;BUB<\ M)/Y:UB(DOJMG9PZVQRTHZZ]BJCOZS;LZTJ5M(FER--DY)&[#>$ACB.FEE4WJID>Y9I; M(D6J11-4FW;[KI[^7[L>Y9.44VCI&H#"QW0(['D@5_L]?U/G5R48#Q9#&F) M#$KU8JAT:[K7N9]1(1KUU&WE'H"HY*M+.%5G.8(7._)O8R_=CGY-RZ:/V@YS ML334:M$E!.'#$=EWLLJW=X9.FBZ6,QK#N3,#]ZB*6MFD"E0.9I&"$N@3\E)6 M1=R]#M&;\NAL>;(-D&8Y5<0,(9NG3U7"31 MOHW0UE18-!3>4]NZ+NMG^GMX+7T"D,8D[=Z17T,+.R[&4M4]&(OZ;KLFK_ *_U/6JD1T:K^?NS8( X@=]B MR0"1V!_76=V5V2B8BLY],J?/5]<,E@D-=#1!10%DT[; M),6"R[I)39ELDY71T:?$TW7TVYHY;O"Z,".J.(-!A9Z5=E'2[=X&=21TU;0E M$20;!I&]4<-P[EV3;BB>"VNFZK)BFY;!G:F%-=\ZZJL-^:[$RH88K[R> M?822:-)P$G6L2EZD:$.F#H,N3T9:+;(:NG.C\>JZ:)-E5F^,+ZM5-D M73>!R 'F@#T +N_WOZ&_'?T_>QX$CP2646230"K^_BP03]!?>N5IWN2M=$AM M*H)9$HW&Y:"KXU)QA.#6&'LV&G16@]!%Z@VD0=!!M@BRV*M%-TD=G26=/FD' M&S-VSRBO@_ID@6$IZ?2:,%M5MA7CX <\U07T_G06RV<* MX26UQ[D]\ZJ8QYUQCGK3?5.ZXW>QJV)3&:1A0214N:@Z,/JA9^,#QLJ^:#4& M+1,>L&2T(;[J#U'!@[AYMLX7=XT2152:I[;2!Z-45..O%*K0"P% *A[>:'CV MNT=(N"@_Y DR"H-L9],*Z^M6DFQ7ABK7,H>-]Y0_4,Y+ M-ATG62W2-;8^:2;_ !1#/.S?&/A[8PKCQC"F=<245[B:T^QE5>4A4S*953UJ M2;0B0R"56N%CDD(; /B(%$(B$(MG1.5X%IM72.[[3RH[61PK\OHDHC\:0!OK M_/7_ 'DAW89NI'_T "K-W$GJ:I-SK(^- M?C9PCG*>,;Q(FG1*QXO9]@R"#59USN^)V!*'\H$?QC_4(^0U^X)NW1!V,;+B M7C7#P5AZ_5WSA!=PJZ2;-]\H,'7QLN(HBZ%?(]U?75??K_#K4@JU!VNE'1-" M[-V;'=>+/U^_F0EA]ZG00_1(VM:N=V4VOV!.)-$6NA] >P?64V:"H^Z;NVJ MPIN@F^SKH?)K$]-!C9N^<()/,(:84U.AZBEK/XU/7 SK$_<2BGGQ':WVZLV: MHQV'!F;M4>BMA[]-V+ORVS]H43?CVPM9)@Q&+E4W3UKMMJVV?(NJ4V7N3I_- M(R&KV,Q&CH_AE,8^")E&@\<0=;*.GS:%,'@UPX>A]'[ASLR^IO6CO"&^GQ\[ MK>_;/ QKJ5:PD=WO:N5(EE7L8N;4KOX)QYOHEJ0=S19O^H\[!M,BLZZ'F'Q/ ME<$_;G5QC&=OA:94?+[GQ]O_ &@_;ZF_\?'VU'\*AT":![+7VP!!(('2V>AY M_;K64V-WNTBD)ZUS^*UF1F0J_P#8BA@$@6U;2<4388%-, Q+?1DX8FBBIM^L M*3^,Y'ME,M]7&F^=%,IZ^85VVE\KG\WH"YZ>GY-&VZ4E;2L<8'( W M;Q=#9^U:-6WQ_DM7#ALY8*OF:VPXHS<;,WK/X*D/;WJRPZK@OIU55DG'QEG1 MZQY"+&EDE'!B-L9(\E$>?A7BVVS1HY?#4%GC+9^EJS36V2PX33TVVUUVVE37 MW7/L%-+U.]ANP;^OQ?V[^G> MC^CMAR^L.D;Z4PR'@Y@23N60LG:$FG06NHX$%KB0BKN0FY.=QLR;,&6S=%KE M#7_F7#E\WU1QMXVQG=<([NS"T8A?X !7(5"Y*KBBT@#C(O8P"5Q"1"EU-&3D MT&FJ37 E=6.:K_4E4=$G;0AMHV9MU_FE'+5"/6.@E\-.MT"@7S5?%I3 [I-V M2^@Q X3<0F:B2(Z/,F3(B1R,98PY:*#'J2C1TST05'$GVB+]NZW2VSOGK_U- MM>%V_= M./QQS+K#IQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQ MQIIQQQQIIQQR+?8SLHM14BHB$!*QE%JSGL+8LAKB#@(Z=B,;;MR<7JZ;6V7( M'#4Q*C&#,Y6GIN%PBQ8XWAAT'(BP&1A03MHNCKMEAVVZP% M#EJ1MCV!IUP4:A1L D4:HAA8(/):()!Y"CV-0'0]AA]O-&^[!![!%&P1 M8H_;4A^.16CO>/IW+3D7C,9[.48=D$UFI*N8F&%V9%7I&0SH3JEN\BHIH@2W M6=FLZ.6FS)FGK[BNKUCD5E]\ZU^-[RGNQU7B;NYP[R]:Q?RSK]!Y785L081- MHT^F<2C4)&[$I*Y(@/JB3E%<3ILT9DFZFVFXHB3$L2_T]U)=>V]^:X MMXOC?CQRZO[]>=.:?WU\U^H>:O[_ &[U*;CD4(EWBZIRUE0RB-Z5@&-]E8;& M9Q3T/.SN)LY9+@\L1Q](3&BD3#K#EZN4T>QM-%LX63>R<65 "UGY-@Y;Z;7A M-[TO94QFM?5]:D!FTVK=31"?1>*RD0>-0UUL7, -F4F8C73A4,00-@#(EV/? MX1>LR YTU=MT%M,:[0R.OZD85]U(ZY<;\>.75^+ZT#J:IE-^.Q9ZOQ_3O^FM ML<<<>N]@6;'VR#J2C6H\5&M7:.KADW.2$DV#L2 M#Q#=1/#AN+RZ4([-G]S]6>H=B]+[-$DV[>HMWV[9-LBE MD$,3YVZ9<.%BK+,P*Q1&>=/=0FDH= 8J0V#7?>\JA]8QUQ$2!1NJ)*$W0Y:7&8 M^0TT;$]&0Y+RP:O=_E'J*)9LZWPDOIMKKY+_ ,[9&+LN\;UO?IG==FBVW;L? M\W8]PGQMN_P#+K;6T4FY;SN&/NN!B2S>G(=O;)W2' M=,8L\N)MV?\ F,3"F@6*2??/'G']_P#;/_PY7YT&M*8R.O[&I^T3A W;77RP M)-!).2+O'C\L7$;OB#F-G7)%\JJ[?ZK_ 23!N[4WWW49CF*N^^ELZ+;0Y]38&[Y@AW#>=JV1=MFV.3!@W+;LK M*W2:#%;.@R\Q\7V4E!:7%FKXCD/6[+_X<]ZW/>/Q!VK(WPQCT'O'IK:SD[-Z M8]1^JGWW%]70[MF[#OFW[?L.)E;@FSYFV;9%N(RY,9@N/N.&"ID<*>R;QR&_ M0N?VI9G6>$2NW\OG4H=.3S5H;*,,#2NVGSFC5M M@BDW2?Y34V<;.7$R.?1-BW:#?MFVK>\:')Q\?=MOQ-Q@@RXQ%DQ19D$>0D<\ M89U615D"OQ=T)!*.RD,?B7JWTYE^C_5'J'TIG9.#F9OIO>MRV3+R]MF.1@9. M1MF7+AS38/HZ[;:OI6;9B]WF MVNVNORXM@JIDD9>;;;:ZI,1+-Z\6VSC1)#?;.,V'1")857V:IE6(+%W'/]_=LJA@>G]LC?>>0+Z%K=BH]$;&J7M-9+.V[>K>9"7!&:CVC=JR4$6'"H_. M6,>;J-Q@?ZFA%B)(R&;%]Q0WYQJB@FDP:MVJ&G)ZS/#)'*GNPQN%8!D!ZUWMFW+^U]LQ-Q.'E;>^0 MC>]@9PA7,PLB*1XMASVNZ4N^>6%9S)6522)G'($UUUMNN .L9>1;=D5#H*U1'#0WV65QHM,IS)0<1B8%KEX9DBWM;GPD,, M"Y-,4HX10\.ASB5"HJ;<([:[[1U))1%57M[9MV[[DKRX<"/% P1LK+R<;"QE ME_B.(CEY^1C8S3LLTC"'W6E9#S"4.0X.[;YLFS,D>X9;1S3J7CQ,7&R\_+>( M&-#*,+;\?*RQ KI&IG,(B5R%:0%N)U]+NEL\)6??4X"AZ[3;6+=?IF3R.Y4= MX9OE(QTXL:#RV:,"V$8\IADX8C@AU.",DE7C=PZ>ZI?&":.UE--#L.A/8U_% M:VH0H%IX+!>OTK[H3:+7BSEQ=[+[C<=D8%V#A<5CQ^!?HG1U!TB"W8#:37<^ M/MBNLAT<1B9FG:?L$+?(N9'U<#$X[OC;YIM6-]Q^43MC_@YW M25UC\ZAE5QDFCNKX1538S75XCG.%4VKK3SC&5L^U4L:Y20. MS:C!SEQC;3W?R),;,,:I[:;9QIOJLIIG&WN]OO\ ;XSM-L.^1*"8\!EI6Y+N M^SR!2(Q "3'N# ,$%<6\!N9%%2-"/U;Z:GL)D9RD%AQDV;>HF/S]TT)=N4LO M/L%;L@J#88:JU0].7LN\9+ )/$XW)(]NT*A-;RL M,^CD A;0G;L5PV@C>T:P) I%7AS2<2$N#.-XV/QN?=VM=-*)DU"0ZXQ$N;QU M(K8G;7MK>35:/.(D6!M3K75-PBP?-=A[9^^: MM$'&^**=Z8O#2+5O>]7V31H!][M4+&/HQZ:5DQ7QLGIAK*Y971B2;P7W^_*F MI>8"@\6PBGOE60HJXREB5,SM6OH!7!NW)5*PXZNH_&MY<_E>KM)X+W ?*Z.V MKX.#KMZQ9B4GCEZV25T\[;=YQSC0Y.%*!FR*F&T & M3#F2@I$(L6?'>:#(E4F.-XH7:17*K(H-(F579&*+UL'CD!6O=N5R+5,I"NHO80Q&$T4EU MR4A7JR"&WZ;C5-9NI'8G(9_@D0T^6VWW=)FEXR\:.,:,MFF[G*VC?Z\]VC K M&'_) M-=<;9TSGTIOP/'\I"9/!A&X;:V2&_P#VSC+F'($O_P#I,7N_^S6DOK;TRPY# M<7]L]C(.W[FN*5Z_B#*;#&,8N_\ C"7VKOY]:G?QR":/=LL4VU:@^HG:A5XO MOG1JJ>#5!&!&N,><_,$";ZX%UAS?X>/?_B#EG?NVT0^4^/G9/7]$>XLY8[^R M2=/>P^NFZ^<:.H6\I^<-T66?&-'+]%&R@91LMKGW97:H#7FJ>GMV2=6'K3TXU<B>\TFL4K MN)R&=3<\.C41B@EZ=D)\HOA >+%#T=EW3MPIC&V^V--,>U-%'15PY6W2;-45 MG*R*6_GM[].29>/E^GMZVS),6[XDN#/@30S1R9F+GH^,R0A0LDBSJ[)%+CDE MF(,3\@#KUWI?UC_9.X;7ZP],;UBQYGIW% M'Q98HY9H,I>(4<9X^!(-9:NOJ12&O(M1#*OH?59,=N$CAOL>(L4,10Q&HYLS M22, (FBFL8;%2C-BDF\U69*:/L*.6N!H71XHJPY2WNJMR=@^S49=RB5SJ 55 M2M9CF$#M2,2",LIK*+'>[,%3\A8,F>7"L?>._=L@3>["!6-] Z:8OX:#O7&N MW=>X4TF:P[>E^LUDRD0[9.7ZDFM5\UHP,Y1RKJB)1C[,T+E$M*NR.NJSIQH3 MB\=;BV>&OS+K=\YV8(>SGL1VK:(X65Z?QW*FR6%,-M>QXQ-?.<:^Y1+XKJJ6 M[';?&?Y$]M7?P=L^,J*I:9]V/,R_@;/EXRX&^;QO>Z0_F=HE?"WSU5Z?PF_+ M[&V0^W[=-A0G:VAB3+E3-R<@P1;OEY&-B/E;A+#&L;?0(?\ Q41;=GONWI7T MQZ-]-Y@P?4N/'N?I?T/ZJW$+G>KDPHM[WK'W/.FWY9\F;;<:3:L/;_S4_IG; M,'<-RCV[8\;)R'R%TY5W52W^N7;,3-8@?F]QUE:D**Q^XYE.Y)'UY4'/-]]E MH^5(:++CGI]NUV8C&[)=FU?$FS1X7;K*:HX0T4P&EO3^(2#J5,:VMF%B(! MA9,KU7'Z;]0;'G94GX?S>HCZ=FW&>6+%V'VDPO44FT[C')@18,^T[3M./-#$ M(WPI40<-V,C*P*RHNLK'WA;(/&(J/"QJ;EZ<*D!X\:DX?MN+D93XT2"I\O);;L?+S5B:)LCV4]X\TEF7E* M'?Y=ZT]=[)/ZAW'=,S%VW8I][RY]U78?3.V[K/M^WKF32.5P-O@.[9>!MAF$ MRXB3S-!&$>#'<1PB..PKCE=K+LIVX4,9RYZYT_N*W6W3U$-+YE>DB01SG/L5 M6?.J7T"**8QXVV2T33TSG.VFJ_\ )[MN1?\ :SL4-QKAUU2 _&VWQK\-'L F MMKC7./J18\= MT=>37UWZ<*,[3;G&JL5)?T_Z@ ZKNQMC"C?0)#?=0=6 \<@CIVIO86W6?2;I MW+G8[&4%D'5:VU7,M4RSPDHJ\U>,)CFL"*)73.FJ3%DT:OV1!5733)5GG&^= M9,4W=$"O:$-)W "#IPPW>/@QH*78+AY9#I0(6RU.PZ:QIWC!*-2H$[UV0)"2 M">F_MV0?,E7@MZP?NM#-V/<\"'\SD01G'$B0M/BY>'G0QRR*S1Q328.1D)#) M(J.8TE*,_MR! 3&X7J;=ZDV;=)QBXF5)^::%ITQLO#S=OGEA1E1Y88=PQL62 M>.-GC$CPK(L?N1ERHEC+;6Y41ZG\1]0DFV 2;J?PQ M.XIV[?OIJ&-R+0>L9$MHTJI\['!TMBKYLN(PY9+$W)'31C:)/K%@M610M.;' MEL?@\0!ME79612DHT"B6:222BN<*.WZB*>ZRFJ6^$&J'Q7;I3&$6J"RVVJ>> ML!VE[77)ZKUB;=;.KZ)V$]4P1EOBQK"(-';!U86S5QJJBY,L\Y243 8QKEW$ M*X7WU?GG6C:1S=,S\I=YW;U'MT6X;'A8[ M(58''R.*9>Y$,#M^+ XR'R/;:TA$KCY]^,'J/9MN]-3[+/E[R^_;T$AV39_2 M^Z2[9O\ G9(D4H5R<8E\/;%(_P#ZCF3K^73%]U5YSM$AV?T6].+I7VC9-KYL M#L?8G=,WL^PU.MY0K*(0)8'4&+5PZ"24>>)$+,(KL4';551L\E300\;J(*89 MKLU===^Q= :\@-6149"ZWA\:@L0#I82&1R*AF (.TUQKKKLHDQ'HH(Y<+>S& MZ[I751VY4SLJX655VVWS KK]$*(Z35$.C^AT)%8_&PFV';XL_9Z$';K.LLCU%ZR MW/.EQ]QW?/\ 3V'D/'L\>ZRXV'CUV,;$PL+&BP-L.X3I2P8N!B+D3=(J2%2= M-_SX_P#1[XQ_OG7Q MX_OY\<^>^H%]K=\O%NS@#&VQS0 :3:\6#;I&%=$,^*Q!^MW]=?5/3;^]LN'E M@<5W(Y.[(/[L>[Y<^YQJ?L5CRU6OI5'O7MQSUQOKG/C^;'^>NVN/\O.V,8\_ MMCS]_P"G/;G&UW=....--....--....--....--....--....--....--... M.--.5W7KWOUJCM-"NIK6'Q<1+;%A8Z40JP+=G9."5Q)BQ,J4"M82">1V#3HB M[D^7PWX?PBJ8$A-_N]^B1))?6,1%J\?X M>GS?LO2.TXN7+E9FZ[?+F[:,;*P\9(II8LB;>98;V],...OS;P3-%+F12M%C M1XCDS3)/+AQS^#];[YE8$.)A;1N<6#NK96)FY+2PPS8\.QPS@;E)FR2\OR:3 MP"6+!EBCFRILQ (,>2&',EQYW-&/< DQVV=2[K?%7^VVNVNC* 6C/6J>FVN< M[)?,.['KU139+;QIA?Y)+#C7&5,MFN=L)XJA]2OMC?'4&,CV_P#QL@$;CDR& M'<5J*L>M$(27S((.=J(D'K#D MF?KC=;4%[D;.'94@G7\"?RJ$/?D,! EE21H_;"6-?PYN\VQ(]MW+A\S>.),< M&C&F B!DFW;?+"MEE>"Z3>FTT[&Y,]U?4*CVUD6S>1+2:QNK)$N12B$)B+I% M#>+8-QW1=O\ ..\B-6J,?B17981$HPF.:/1SB0O"JC;Z%LOI\^C\F7U!^(VT MP[=LN#)C##V0;!M&3G^H\_(B7(CP<9=TQI#'A8T%3;MDO(CXO*+%1X\O(0I\ MSWSU*WK;%C]-_AAN^3N._;A%EMF;\_J'>L;;?2^!BS?EI-PS#L^5"LF;E9'\ M#9\-(Y4RN,V7)$^)C2\Z9X-WRY5:Y04;-P,78N62^N5$GVZNJ:NEPT)3C MF'ZLM1R<;4K6'9$(M$T]4TTD6F ^-4?AXTTV352SHMIOIJIJKA37&V*H;/\ M0LJ*1SLA):GNB)$2Q@42$",:?^J"B^TBT' MJ;*:-'.C'"#!OWV_$#\,O4\Q3L9,IXSGJY&U;D9@@4Y1RL_)*9 M7$+\Y9M&IL:IHW1QG;;;97=-^MA M?*FN,[)IZ[8W4\>/'G/CFUX?V$C[=\KN^<*:H[:9W0RHDZRIKIK]_=WSF-HS,? MJ]9+YSA+5JCAN[3QA3PPVSE#/) ?2Y[MH+%6Q>ZZ::#E]$OELLC5E%_B[;:[ M>_3#?$4C[ECJEYQK[\DG>5\YSG5-'&OWULJ/\/T+JAC#P9^/.J' MB"GLR8[3%T)![C4U8);BS"F)C?B;A21(?1FY+/$[*_MY&W9,#, 3S]Z/)$(1 M@I[$C"^/$?)%:9,T[=P!N$*LWPU5YNLR=H"DE\,5522JZ*B.C7 K?*CI1%;. M?:NFKKG3=';?19/.NV<9I!$7QJ((PL:O%;!85FUE!J:TU!3I4\ZZX:2P"4=M MR,AJZ/FF3>/%48R7=.U&C(&7.Q*"E'#@A' H1UHBY1M"Y"V?S5HBHFZ=BY--I83=$14=);IX'%@T4"CB)4,JZ8K2=ND[7 M3S9E?/5ZI>P5+NJ-ED?:BHD@S'Z0U6--&8A[7!8"A\&+'8-JW0U:!'<;QHFB MQ9HM_I;D9\P"(,W09Z[9JZ&-ZL]">E([GG0MD8\6W1HCQ+/ MAP3HIR\I1/*SA/840>Y!%D!LJ18.U/Z&_$/U?B3[CN4F-Z?S,+&E3:MOG7&G MFW.1Y(IG@SLC&D9E5VBA.^XR(SRJ; !X77P MU(O#\WK TFEIOK\KLY"; ;%%)_%T]V[O48=3017\X:-/@;:Z)*J M9:I]29OPW+//#OVU)BRFXHBF479GJPT*Q?FH4)!ZR401@ -(20P\_%A?BFH3 M'E].[S)DP "242XHC58^(!CG:8XDST?_ /%D,9SCF;M>U$/88UV> ME'+UMG3X>[G<0JS6]NOC[^W7=77?7.WG'C&-?']?'YY#Q'TWNW)-XD@2WI0? MABUU7U=;VE."H!TYUVQKJR;,$JL;%D5W7POZ;G; MS?7=SKK0&-D,:?\ ):6G8FR[W?;;.,[-W.]2I,FB:'C7?;1V@OLOIG.B>4=] M/*G/DPO04E*_J';AV20F1%Q4/015D9G-#ZU(50]R!?(Z4,OXE0$R1>G-U[ M+XLO)C&!S9XU$:]@LHY1\I.O;)([S/LU;-16'"GKZ[#MV MTXG%C(2#GT/@47W.$J]8FF.^'FLRE?ZE'"G,TD MP]UA%O&&3\4C&8WJU4-H#'DB>MGX>5?:OJ7#NT<< ($3#^&3V#O"!&O[ %LV MQ9R!6,-T&IP.7!D%464FATD;M&2K_1FTY> M)LWLR[I@122,=\(20;5+-&MR;:K8TN8066-,O)PWQ95"%\>/,,4:R])O07KW M=]NS]Z.5%M&XY$<87TZ"T8W>*"6_;W5X\J'!4\#(V%C9B9<+%PF5)A+-*8H8 MPCM2PV:LW2^6:3/;1+PZ1S\PR:)8QG;3.FN/.N?JXE%937&WL< M#W*.FN^_\WPLJ::;Z[^,_P#M:8SC;[YQC^O-96UVJ43%NHWO&!\D7>,EV6^N MB6WTS+-XDHW7U(84TPW<,UD5%4G#5TFIAP@INW42434WUSI)AZ?';QEKE97^ M'[C&-$G#AHE<\A16=*>W/_+)**5BHVT42VQXW4WW11SKGW)[[[><7TSEN..D-Y0U$; MJZD\!B+ALDUVI[/H?$G7+FWO;,E(F]S^',"ZL.)!6/$9\J0?'I8HW8] \>]2 M$_$7+@_)0[#N^.TR^WQF@*QLIH,'DS%CQ8A9_5+(@7LJ"O>J\8;>H\184&KR M5SF4/ZYKN0H/Z^JLU9(^05S#)3'VCG6.)(BW+5>8*MX:FNY<1H";.F!\2619 MN!XUIJ$#[#+*!_:,,IGX2F<(KZ8QHX)#O@$A>$_'N3V;;M555=T""-Q>J3,]'70=)/Z-*PDA^"H1: MS88_23-HRE7=P1=&OC/B>S_#MZBYJ+=^EYV2B9@J,A\CJJ7Q[=TIL'E966RB MOSSEGG3.=-Y)%1L%E@EF6_"+UQ'3"@I^OC9^V$A4U?IJ.:'U+Z)]4^Z%DP"&-4$D;XN&#"LTGPW9^.-M]-D] M6I#.V<[8>9^81]WC.?Y-M%DM?=G'CQGQX_/.<<]AA,X]V<9UYES?TUNWS9O\ Q(^N3KV M;J[:JN)I;^JBF/O6; ] HX;_S'MJR MTI!$XGH,+_7"TD5_^VP5)^2CC6L<$OXE20F/_P L[JV/9^+8PQ^3 @?IF$,HY9+:8WVS]_;G?V^W?SC/W_ )\^ M,?;SXQXY3?V5[)"+6L'5IU_H$Y+.P98>Z8+R2L@_1T<^X8&2?4.\,JICX&-D9F-B2EFC]P[CDP1QPOAA.4C8Z2SO-*B M1<%5CDP[(],?B-ZVEQ=MW3';TWL<9#Y&?E0X>1F0B-&,8V[$FD>=,UGX1C(D MC@2")I)>4C*,:?J1B^CW?^W9@Q6N2A>UTS9,B"7TD;*22B0G*CITHKE#)N?S M3X$0$I>[&BKH4VRL@AMOHFZ99UU6VMXH/I#ZB X6QC(9I2W4Z!IY4;Y'(DT9 MI(A;)51+1P[8@X>F^'D3#M'W+JNR\];O'2Z6-B#_ "IG7..Q;[-/_P .O_NX M_P#ASVYS=]_'+U%O>.F(-E].86/$H]F%,/)R88'KN6+$RLN7 ,A))+S8DS=E M>7"T/H-@_P##[Z7V3)DS'WSU/N&1*Y::63.Q<26=#Q'M2Y6'AQ9XC 4*%@S( M5JF(,@YZKVJ'TY*=A3QE*+<,R7LG8#1UH12.VPJ@ZB@HEK[\?,QRLV?B),]M MR.Z&VR.VF4\YUS]G'/D^Y[SNF\3KD[EG3Y7#%QXPD&+%?8BQXHHP>PH.OL>T[#L^Q8S8FT[?C84+U[WMH6FR6 XB3+ MR)2^1ER\?B98VB<[ 7DR+R):/EK7>AB;<@PB4='NHV68OHLHP&) M,=@GR:KENM8):?5OK[=DC83"T:HB,RE8R/+Q)C)"C-QH;;QAR1R76C^I-@Z9 M/-A&Y7.27T]1;=MJ^S\UHGJO_/S9(FN8*#D>)@*BH1C*OT7'Z[VD:+%+!M2# MQ4@5*QR+*D]L;.U@H8F<,D![)57=-N\*/G&O^*Y4VVU3.3S;E(9)(^,A)[9^ M0)S9UT%A50JA(PD; QJ $0"@BKQ 0* H4U0 %#764ZH M;SE!KZ9QMH%NNH[!O*QAA\_VDLOMM8LQJJ\P47BQ*T2212D+P M_2I%K08@6BC,:\20?T]@ >% /0 'D$\JL@@'P#IQQQS7UETXXXXTTXXXXTTX MXXXTTXXXXTTXXXXTTXXYJ,K\OGU867:X@DBV9[1UM'ZMD]8 MQ0^S(.]WVC](N[(6K'UA*" YPT79LRZCIXT50:(O) )\"Z!)_H 23_@!>H) M[)KL#_$D #_$D#6W.,YQC&<_Y8Y7^_[TR!EV,2ZR:=.>S#Z>.H\2GS M FU-]7](L_JH38XRL7MG)/GG8MH3;@$SA@<^U OA+2?[A''SNL0RHFJWTQIA MZDT64'L)T;ZX]D(S0Q&ZW]%(]AW[&FBE:R%_6B7T_0D**'F8H4NN\;91!+U\0;"D .A+!KX@ ,26:C2@%C1H&CJGNI MV+/1(-HXJJNR5JA8L^!8LB]0#[]=P@Q;LI(*\?E$VD!ZS(#'CW+S"NPT;9A( M3H5+SPH&5327,$HW'BS&)U>VP@HDK("DL(#%73I8>NRK]K6"]D?6)MI4"P?& M:HZDUP4;ZGS&R.7*7S226N[7#Q)79-C.K=,MLZ.V[)SG:.5V+=Z.=DM<;-$Y M'V6^VW13KUW-C"HFUXMLWE#5BLSC-F191(-/XLI\3"J.S,MA!9L88-W.F%L1 M^3,S0#93*BFC!%QO\SKNZCJ2KKKM5\3J&K 2("&P\=JR8-]=MEGCYTIME+[[?R):(I)_;MM_$ST]Z<])X*^G-GEB]9X^.-O M@RL^.#)P=H!B5LW>\)C8R=PSLAG>%)L:-<-GD!]R)..9^?-U_"7U)ZI]:9TO MJC>X9O0^1D-N4^)MTF1B[AO)64K@;#FA:?#VW;X$C6=\?+D;.58ROM2N3A1= MC?IB]*XS48.F6E+ G<:#R^'SUT7)[JO9K)Y;"B.A$67ELPSA(P=T*->3[UUUUQC77&-=<8QC&,8\8QC'VQC&,?;&,8\8QC'VQ MC&,8QC&,8YYXY\-UW9_=^,DX@A$ MK+1<11AK"+7W/;-CV;94]O:-JV_;$_+XV*5P,/'Q V/A^[^5A801IRCQS/.8 ME:PAFE*@&1B7'''.=KJ:<<<<::[ Z]>("$.C8<_L:?V!8D(I^I:Z8$D M0.9K9MB%-AT>%DI.Z9D&<4C(UHV+2B8REP/)9 1&/FR3009(HLA#Z1W(R]JJ M )]@(%&6,3F6E>V?5MFP>[*AFCL1F1A0EC5Z]=+C$)5&]'PI>0PR3AB9^&3$ M2Q+ARJ\:D9)4*7&&$&#Q*\?#FGN?HY#EYJOWKOC_ 'N/RJ^/=:JW+B>/ZJZ\ M7_A?5UXOJ_/6H37[ZD%C],XI:V_:FCXHWFL=H.:7W3NU)6)*I] [:9P:51.% M2J"E"<@K"*3&OI+$SMCUN\,%G,/D,6=Q"3.I*S*-W$?, FVT.B/=^7=PI9?( ME_"(I%0-"F(37AW25VV33\7GY;K38O6^D@%;@)J^@$(:7"E0O,DO\0>3(7*J08ZX*U7:E[)>N7*AQ"#6$>\7!!/MBJ#!0Q M!!OD0#1!J@%)(XV02VLC8]_>IS\M(!&EI[-/H#UHSU-%8-9 :(RG1S::E8>TB5IQH);$KCD$E4KKDS)XW$3AD?I)BHIFX3>9_>S^[_7N!0"TI:SM M. /R-9RVTJK)-"I*4-@(NY*FJ9Q60)QZ/ MH.'B;$F0U;"G<&HAZ8ME)R>ZQ\GLZ%Q.K+<@'8&(S&*T^E9@>,VU)K8-,B-= MVI*:6E,L,T_35@U)AHX,.C-!CH^[LJ;&"9^0O!XW9,#C'D/28G6T4M9@:NF. MR.46UT?M"J9,2)18K@60[MWI%9;"KC[8+H[/W)1!&71,ZQC&8^B_5*(!42"6 M7657*>=1CPP?^,W1'7FP:^H05V"31)XE;XL&50;((_X:_P"=?XT6_H!]+![* MTQF%'_4CZ^O#M[Q^2N93'GM&6?7-1[IL*_M&5OK0F=DUG&[#!BZ?CP*OU9+9 M!)S@L;9L8[$1!J4.P<7>SUR&'0H@,+N,=<>J;U:&V"Y!EYAJA6KFEZJN2/VL M)C]A285D38%G6S5,DVL,4 @S]:F(]6U1H?UZ %]R"T(RK G$T=-'CU6/125/&8:?/A"#%5NYQ)=H([DC2+.<.6Z3" M1N1C]RMHW:J^:Z;8])&(M7Z^.K9MO5D-3($T#M=D CJ-60>02:-W3=LKC8A7'*D2LRLS *0#2*I4L M6-^74LJ4KTPLA1V<4AE##VU!4 \@2!R)L+0K^4@%K905/1)%:DA(?4HZ]LWU M1C8KM-940L_M+%>J)$0YK:TH=)*\F\MA!6P Q.:Q*5P(=*! 4U&VHUOXD)#3[N@MYRG M6I$H&0G*&SXNK&-9$[=L-GC8PB]T9/$+\<6HSR;]4?,7R-$%G!-* %L+R )N MR%/8%;GMA2U3\35"P5"GRQ)/R-6!]"1T=2EC?*[,&DU?-<1ZF;TDOZH;UB<>1VU?T#]!K4ABQ5ZE),'6;7:P M;)]Q6HY/!F:)A1&^CW,3S5WO8U%"8S>-Z=&^R=PMM -BE38.<]3 M5:(9R:#UL[4>C63F'SUA0L;)!)-*F^AZ-/BAP61 G6SE@7%;$J?H+-*]"]?A MA&?Q0HM3D0[\1TDLU"FD-2[KMY:#*>1=V,PX<[[LTH>/;J#)!JYSNJ3<*?%% M[(-_=IF/;Q@+,C$FJ56'0]KD03[1!/N@H/V(/CLN4Y-<0H_O%;_G"]#F/Y#R M[OP00-2*.]]>IL=DD1C#^WQBZ\S!UO)6)X+'YC(X$! W&JBA49:PK)C\=)0" MK65H+KHH5ZK9,DBN)@LLCH$^;^*EG?9]5]C:ANN3V/$ZRD9*3DJFDA:&3IZE M#)P,C N81Z0FXK)HFQF9J.#8C(9+%)!'R0N6 XV:+$HPXPRR;;L4B@Q1W5RI MZ8ERL:QG]!!+9K7-3=EJIZM0'L<7)Q*0J6!'R5!4_7='S A2VZ+KZ*JQLB!5 MH!0!(3;9%Q6TG6*2QOF4;/M0C:SKKA3Y*DH))8F4*CC#D[=O8FU$G0Q!VW00 M'71>M@VP($K_ #VZCAP0!"9@R"DWVVWPR#]@X>H:Z(+IZ:UD3'5+CD9W) O MJN*DL1[8JF+)QY7T&NNC*-*S4Z!5 ))^MWTOZC]"&)JO*U8O6_>...:^LVG' M''&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG('7Q$KJ"=LZ.[ 5K5'\ M68U$*!["U/)@["?0^%'!QNRIYU\E<:(M])DY8#R(O+.KI W(;MWV'3-TL.Q\ MJNBNKNC/'CETF#=FR\9'QN%?\$9ZI3PMS)1921 ;+D-VP2Q,1[=L*T78$V# *%* M)N)$.?J#E7[=)%MHHFY36Q!UCZ<5D1.L::GPL6G-;FJ+MK:EW2;K_.[EG<@Z M[6Y!YOV>L*=!EDX@9/.JT@MN5W"Y, M&H)@+AR#:,VF"5$'VSYN>(&65YO', MBY$BU5 **HT54.H4]W1#L#1!\$$$ ZH84-V"223?1(9N/R%BK!0$=5Y!!!K M7C'VQ]\?O_K]\_?_ #S^<_WS^<_GGGCCF#673CCCC33CCCC33CCCC33CCCC3 M3CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC3 M3CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCC.?&,Y_;[_;&<>?']\9Q_YXQYQ^V?QG'WQG..-->>..>OOU\^/O_G[=O;_[WCV_VQ]_OG[8 MXTU[<<<<::<<]?=CV^[[^/[:[9S_ .[C'N_\/Q]_Q]^>/?KXSG^;[?T]F_N_ M/C_N^WW9_P!,?W_'&FO?CGKC;&<><>?Z?;.NV,_?/C'VSC&?']_'C'WSG[8S MSQ\37SX\;^?/CSA-3./_ 'L:^WQ_?SX_KY\<::]^...--....--...>,YQC\ M^?Z_C&<_C[_TQG_3']<_;'G/VXTUYXYX\_C\_?[?C/[>?O\ ;[?YY^WG[?G[ M<\\::<<?OC'[^?'VSX^W]_P 8_P L_G[^/QGGGC33CCC&?.// M[_?[XSC/^N,_?'^6?OQIIQQQQIIQSQYQ^/V\?TSX^_G\9_&?Q]_'X_KXXQGS MCS]_]<9QG_;.,9_Z\_CC37GCGC.<8_?\XQ]L9S]\_OXQGQC^^?MC^N>>>--. M...--....--....--....--.1:[ROWHOI/W")CGSP60'=6NP3]@2'NG#%^.> MM*FESAJ^8O6BJ#IF\:+IIN&SILNBX;K)Z+(JIJ::[XE+SB3X '*@1J+R8.,D M,;D@DD D( VQ;% QP&89K#BP)K,R(PFP<.&3]B[15;.VJZK==/=)3?7- MD8*Z,185E8C[@$&O\=018('5@B_ZC73LJZ#RVAO2,N7M?+NI6\<)G>AU(E1M MIRGU$.T=TH]A-)H?K(\<,2&L!\M@CVAWQA1L(E^7%?S- R.J5V7CUYV@UCAKJW':VKCU+>OGITLZ'G828N.P=BHJ:DR<&A^:_>!TX:,6F+^5$5Q2XLO?,4INI3=7Z4D8K* E*=2C8N')58 M0B()[7B43!ILT0L:3AKEBI'] (E() MRIRT6>I.AS<@U#N=63?HC*@F:1LA:MI77D9)!3&#C&O(R%7*QN.1*J.5!D M&E[$D2H(C=!%;B%0V/<+.2H6UMU)';&B3R-DZMKGU.K8ETVZVPDB.IY$O;_J MA]U>EDH$,VYQ,V/JCK6*O1_&I$('K2]=TUFZV8%7^TO)OFST%LC)E/DP(GZP M'W0AA%O51]1*54GTHG) =0@V3>H$M:LDK?\ AMUYLFU-:DA'7Z%&RTA%%(B0 M[ 0I>S)I;)=N).M/DY=%&%5P0?,'66L_?,&RJ/8*$=/^J@&TRMX!NN%(#+D- MRU6>E+38UA#F]@.YJX$O@3J5[RU,1@XG('@@F28/BR+U)Z_;D'NKY9QNZ7WW M\S/J!U7L.I(_0LWZZ4I*:5B3AL[B=5&JTB3Z 19TT6L47"/Y;&A#>3Y!3,&X28.I-#!A&3NVV&Y(,TD+I_LT(HN-( M>BV\D'_ ZP:3"=RRQCPCLIW,BCF<3XYN,&CVJ239BQ9-T&S5!)-)!)/3377&&B*5J + @P=75^:<%; M-C0D7$ + : L4Z[//S4[#,FK%)L-EY=]*9*\)R-HFD6?NY :<.G2JQ-YNMKF M52DJ! BR2K(H !*!1(.%DEB/FH +D"B>R>\H1@R,6Y%8V1B21R),9Y4!Q!/$ MDD 'L#QXSLRN0:B23D2ST(E$&#Q8:/47T;)OGZ3951DR4-$-';K5)MNMO MG&J6JN=\YQC7SSKD%18*.^FA7O?R#SR9R;O@>VJZ>-;#=V),LR:>=I9C8T8B MLRZOD(8H>TC+V&+R-Q(: WH9.,X#QD*']PH*)E0%&1M>R1]L8\?;&,?;Q_3] ML8QC_P ,8_TY&*&]?>HLCG3+LY ZGH\Y/)#NX/#;GC$5B1(J6>O,N6KR5#I6 M.:K(N33]/9TR=2UFMDR_:;+-%RR[53=+9#*([)#5S1B%JG"\KB>Z^#WWY%#M M&ZXI$+T!7AAW=J3QIU\_):->.STP[N#TT]06S(Y'@!!@/K%P4)]X.[76QRQ7 M;%]]]8/UIJ'M+8<7(-VJQ#MMN.O].N;-DB[IV=G3JNXPO*23 MT@ )10H0<&%QN[O) S&#!..&R">^CPX#>+"B[A\RSA'79*M85JO'H7$EH##E MHM7+Z)DH!'%8T)4!PDA M4=(0^BHG9IEE'WR:)"@,10^Q-> 3YUUL MWA^;5GU![2=&)DGY1S^9QV13(\. MB^G8A"V8^L_:$GSJ-0"QXF";#'XQHPT(?7;T3D-;%.S76+2 Z5\,DDV]+F91 M3KQ%>S5H3VIRT9GW=)M6$Z/.;6-!0\_J8];Y#5. S&#AH,VBZ\*B0Z;AOUF< M,S!F%[%,_H^E[7W5WLVJ:ZL%1>..H@LK,8:!DBBL4?2"/RUW&U%2K!UOL#2K"MMODE#T:I02I)ZHW<-Y929 MKM91FZ9&I&@+L=Z1EC0JEH3=\ON:NX%"+.[=PR$2,X$L23)QN:1^1VU((M(6 ML\J,E%8]%VT>! 9& S*49Q+7B>UNG/75"T[%N.VI3U]AMA[BO43[BI)W))>T M-PB)L"%U]VKG;$#].JAC#"41=LX.B(9B(W&]IDQ%/QPI#5SJ)07W9XN+C'6[ MKU"@)"+Q&D:HC4=*R2-3$L%"5_%QHXK+8:4'FHA)R;9J+2U)'XN7$"B,;+O/ MF'P5Z+'N!:[95DWRGB9#J#U)WD!2?$>N]':25Y(G\[-2MQ7,20*.94Y);R(I M+B938\BZ<[N,[+<@Y2E64T-TW("N>K:.J"=4]4 M;F34_>=Z';!NF*%9@'*CJ4)UB-Q XV*'SNODF^SO%AJR6>RA8L^=1.&!?F1@ M5RN14)"*U$?4[[ESAE#Y/6=0QJ0LXAURZ8W)9@@!%8J[@TUD?9Z!-+!D0]2U MK$[)5:]I.&,1BSB/U>?Q!;6P9DK)VO(7:^J.8QRT'M%UD%=QX[6YJ.VA$V4= M8A9.^$*&:>I[L-7\F&6-'6+8-/P#"Q!)5H*E\;9:9(U]-XT83$KL3A=E(PDQ M!DF[1KDX'HMU3$QVAP1REX%81#K?7T%K6K9G9$4C\OFXJ.5T/9LXMJZD) 7A M4@['.V6A]IA9'Y4?)%G!T.R'/U?BZU23'2->:*[U1'$DJ0Q)9B>%\EI0 QX= ML"&%&S)*SGBQ5#1OEY'%12@6!Q(+7Q'*Z-@V(1O.Z?9V,2I>TI!I5<@I%'M] MVMZL-J=B$"E.MHE U&5_?K-3)FE,1HG#4*]5#.QQO+\>]0+ MZI-$\8ZK^H#VNDZC.4W704XFE?6#0$;O>(:515,%#S@>2DI^",FL5@4+#=I+ M>D]T5GL"G6"FUN.PU>; %XRX3D(S+J7"08*X!*L:T;?([(0*&H?2YT7M$=LE M&Q&F1]D'M#:9VP&>VK3&6LR+IR.0Z%9,EG0P^U.%]73Q3ZBZ^+IB@Z@ZBP64 M6R9ZZ5E3D0EK28.X);9*N(8" %V\I8L0LQ=1(XY&C6BR*;5O*@\CR#:[ZATG M1S4FFVU?NW"N:^["48>P+I0#7T#$]L""I[KD 2U!6!!U/MR K4I\DFSYZ4>" M"".C\>@.5BCUJNB5]_>UIGLE) 56TJ<1J6K[9ZUU?+XO.*[@\?*.VEX@Z959UZL$.(A]G3$1:K=]8JX]*._*V.J-C5 MHV9KMKTY-0?5B?78(L.6593,LOV "8Z>%R0Q&8J6L>-A\DB MR$+/;K.&ZQ=NU9F!)[2$F'J>^!90>;_3+IH\;$,Z>R747JRG-9;9&O7>E\SR M=)2="82Y6MHHI() C-Q*X.;HDR2HO9PLC-1+IRRF26-M$Y8BX6VD&I)17=3: MRSPK50T1'Q) %DF(H?D2?+-[G, .*X=@V*F*0DW)R'.Z)( IU;P!] "O$V+^ M5@]:JV@MNVR&NR2NI9((Y-XICN%$P-9QA\.GC#:H&+?T?"%^Y;1@@E:3ID:' M+N]$0CP'(P;P8\?%9C.ED?U6>$/8KP*??WN%!8'6,CL4IUY-F.S'6+K/=$&= MAJZF<9AO7Z57K>E#T@><3YR0M0H^L.K(.UO4?.'93+^!%U'4:>!73\<,.MB( M:UF;5MU3J5W*.P,X@-3PY^BQB;*4V44BPEN\T9AA!&K8AA\2T8JKX4'QN8I M!Y:/E?X/D2)7?5OQ$^Z@='!D#C=O(UQV3LL$LV>X^0.V2+E^)>N4$/;*RPJSCVQ(K-$5/MK5I&RN0IX MFG=K"@J/K5A:-'(P4ARA"N#\C8#.C#OY65"U9L^1=$ZA_CM)V'M!W:@(F $@%BQ M<+H82ER+F6#7\?BO7O<#NEU]ZZ4+'B9^A;(/3_H7U I\=WLHL;M1B5!76G*B$J2Q##6DL$/MDV"XHHW9#[;YA"NE ^45KV7FL M'I5K,9LZKRL*UM8W#1&D@-/[53;0ZMHN(++"?GOGY$S/)Q6.ZN$D7;047< D M'# 8]=--]X.J.IE\U LGE45R[9Q6+AH1&FKF&1Y=O'X;'3L:DP"*!45&&R8N M.A)'#8D>$AF>J(\>8C$?)-6Z3L.P50CW8E"@P_&UL%0.T%, ?+&S98D,;XFA MY&-R21)\@#1Y,>F([(% = T " >QYZK%<]I>UXZT/^$9[-JQH: M]T;N7LI_8N2U9:66U@BO5+!Y3>5I]=5)NAZI6>GV.P.T4S+MR"<6W;*?JC,< MUEBA#!G7%;8GN6.WZD3L%[)79Z:8>46%2G9@G1^IXTZ@LZM8+.86Y?LFS]8$ MF(@$XL&4)1AT#CSYC& B;,#+)%(!3H+'16-$B3 4SSG3?\6KCJ',Q\OJN(5W M1I\+!(>"IJ70L-"(D[!@X#*0PFSX_7CL8@)R*S$# B1")JP!-M5P[CZFV,ZI M_.*Y6Q8.B*K-CL RJ2> 57'7-U:A\7Y(. ' 4"/UD:CBS,0)00K$4')*_P!U M2+_4H#&S\C9!OC9@0R[5=K']YZ=+/XE4&.L\7<&,J7UMQH@PO#?$VW0/C=K.49K>7=@->QQ2E;:%XT=RAT5/UY$:^D-=W\P^1*C3/\ M#X58J[TFJFS'ND)T6MT*K.15I ZMIIG7-)PV"S0M-\0/>A*GM2JY68,@'X54 MO+Z_G0;?1Y*A3IRW/ 9L-/!Y,T)LMF95\;CQ F$=>M3]"H14Y#J!28/4T5,1^-ZD%+/G @U%I?;AV3LFB"^";^)222A14,C N-1$'B1$W#=FX M1;@604),;B"44GH\>)4EE#DL644HE?V[C!943D%(.G";E0+5XOG= E.AR[)1 M?<^1 8L5N_I@G;MS;[OM[TGB=.VE#:LD,I@7<'1T;GL=,SN/.6@:/TH33PTK ML5/*[;RF0H*IX<-%",B22 Q_>4$6Z*J^,8S7_GU4>XMBBFLLJ2CF#I*L*5I6 MQ[%"ZQ*(.(!9A^R7LW1*OV]PV)V1J9>EJ<-CX.Z6JV?8@UKZ/'9'=W(7;Q$+ MN!+74VM5O6?L2=7K&Y*YK6V3\#CXV5Z@9U#F$D=QZ78 MC,YBT@3D] ZU'8G>JSND2]$DHA)_XP1L/7$:M?NW5/TL[/+5HYA-E3$ MO.FO;>(BTIQ#!5AR"XW9J+#X:QQE2 FC ^?24@^U:IR\F:UP\=/]U5+$^C?: M_N!';JB?:6N[>D 68ENR\#@2E-UW#;1-I/*\5@XM1.XWL*BMGVW2,#%28B5 MAQ^I' _!J+C9C+3L5"1D-K/.(G>@YFG:^FL):]>B%)=AMZY',FXI5LHCIF+1Q\5..S-4?) M>#*$)0XJH(XD\5$A4E0:\ ^0-1 MNH'N)?,F[@EZDN7>'QV!3B5=CHW2K<%7#PW#9LC2$[1+T\9=#HI''MWX^.543?2^'=AY6O$SSALBM'MH=$SSGZ:U+[([: MS1KV']+!':*V]:UB]'#.V3*,Q^:7!M& <=96LUC5I/RNXJ1R11HT2((-YZ2C M3]R1(I[:.)$]&(.SZCI;Y!979AJ)4#9DXL..26%5U-9SK68"$62VD,-%&RC^ MIIL1DI,'"Y&\*"5DS4)-E0\F(:Q99T^%9?(OG;H>DLZU4<8.<0D!: \/:7DM M<:)(^:^:'$@*S$\B0QZ8*,@63C0D ;F:-EK%>#==V"2 + ^^J+I]V2[&S6 M65.417C]%V)-[V](8]86D?2LIT\)0F_[+[ $&M02X,^L@2.191Z-#8L-F&@< M8"<2Y^I+!D@PX9;@L U/7TK;RA2#+2')N*AWBY=>L"JYNN'#YWLUU=JN($8=.R4/7ROJO&WSITX$* M-%'*^5.6#4[4D?S#,@:S@07-;/XI\LQ2_3[R7[E MRNTE3TG -6@2 M@67.@,&<3=[)7,AR68AK, 8E4%V30!@)IBSL' O&SB?%4\(%YIOG9EJMK*##7&S(P$$*H[*KTPC5.5=E'C]HZ7WW[S4D:FE,1+1O6,6*PJ'M83(1M/AX. M+;L(J.$'V5=-;%%0"* DFPU@LLPK/9*3- D9;N$&,:9NG&B2+<6^T:9C!YO$ M[*AL4L*"'6$GA6Q*1BE-EAAZ.2!@@3#&!ZV^B>RK(BP[U1,G+=VU5QHNV717334UZU/ M4NMK0C%$QLTV@G<,FPZR^G*;5@-- 9E=-8/'O; 3:/9 %.P0AA+,Z,S-I-1" M(,7#TY #FD:&A34?/1**'QZD5SOV7]]]$]-E%-M=---=M]]]LXUUUUUQG;;; M;.?&,:ZZXSG.<_;&,9SG[<&Q19%.Q]@ NU.@FRNT3AK;) HYK%&*-;QD<885_$T0:S M(BA&A1=D4D"OK?$8[$02*R"&)E>TC6!U7V>[?@*2B)MEW8D 69U_D)11JFQX MR^NOAV179&9\".D)^TZU3.R8==%/OVCV> S(]C/D!Y!]AZ@S40W8CWSM/?=LS M&N(X$9S28B!; M4F^*@5F6JAXJ3VHZH^+4'8I#JRTLNJK*D,(<-Z%4D+V9/K>CUV"IDW8V1+)D4CKR'CMH6 M#P -56*R?8((:N6 MN?U'WBH:XH PN:/RF/@Z0(50,MC6U)A.ZWCP,6*?3&30MX.D8E>8JR"+.1!" M-[Y(%C@YE&\NGZ8%L9<20>9$CQG(0<(6(*HI+ <;*\%1+#%D)5F !!++R%<3 MI[8+]R@=FE4FR+!+,!QI@"JDD$!31L-JJ&]*N[1TX!ED;IB0=CW5?3.KNA,X MOB03 UV-N4AJ_=VK;T?[2'HXA%)6VMEC(C$2:5F]NJ#T)(HG*$X/JZ,18.(= M[YV=S1Z/Q2QI)TZO")S683NP@4HDEM ZF^O0:]JC(C*X+P(*+9Q>#/;YGDH[ M &88G+%I0Y@\XFY\5(=&I+87'M$HH!C)-W-A]VIZQC:]$6R2[#4@PJX_]1^A M6(]M6#-829V#K_+%M!,G6.Z!R"PIUY;$D63M9P/DQVL!>2!DX5B(J,-2BC'33K#&.N7PJ5[VV'*X_V&C^L[C78( M<,C:-+3OB)15QTSTJBU9! P3,&+D[(+$*?+63&H(YB\PC2(T/6B,-X^[DO8:C8\UEL;&S.* MN#MMP 0A)8@9V5U#RJ/JD9"V3,QLKL@M@:<';.1;W9%7#5TKLGOC7(V1*>A" M5)]Q0>)Y D $@A0>0(#M9/SMZ4L1JBQ1COW11X'S0*@BNBQ%-^D$ ?$@=D Z MZZI,^S:U_=S8K64DL72%I[C%)\ M9CT2JYC^HKZV_1LEK@6>?2QR1'M2#U+9][#;I"22=PZ55Y; UA:?:VWY>0G0 M+'<%I4KN3,^O73^/!F>D,ZCH"+8L8A*I/K8;JG'1R=P&JV#F#2Q,K)7DP2"- M1]\>DDZ^!RQ.[L2ZKQY"9"M*X)6.I+X\@U/CJ=>6/(%HEL<5+8&.MJ]=NK1) ME1R"F74?^7ERQ?5ND+(?)X^([?\ 4Z1$P 8%V9H$T8E#9M)$JN6DC?+YAA4(Q37?^Y^RUU0WV>-L*S^88OR6!B!RL L*8A;X ME1\0K*6HW9LMY(T]H <3(HN@+ /(#H MS KM'9WIM>GN*F:"^Y;%\!BI@=\*X(W4QH$5(Q6.G0UY MD6T@E)ZFR#V?'S!]_97T!2L<10/8IR4L"6RJ%)2](2.RCU,@+?K M$W;D5;;O)+5PF>Q4 MRV5A@.YN3G@<:"(OU"AXP-%-'+I*CSO(/;]NC(Z,/'@B,*%#+8%(.)5@/FX[ M#4++&J$2%["*P)[%=DL20U$V3R!!-A?JNNMY5*@LT,RW>*HW65/O:7UDX*MY/UPB-:@I$@P5,0IA)+2UQF6NY#;M1ES0>N8+)JTG-.E>FL0ZQP: M,FK"Q3,.0J(34:XUV#A1&&VL$D)*".@@+$8>Q@R#(&!LIBCL>.R;#I"I#%BI MO9!KM[U0C4+A]D2'LM08*OK"6(-X)-S%OP ;$IBN)E4,H M0JT:4W01+ M\"9 .(4L*XC^&U @,0R&[#'ZDFQV *#.MP?L=+XP)J_W]HR$4(]ANF6]F6L& M)=TJM>RF.E2EQ-KTBTS@E]D24\J.>[A1\56[)E:@M66TN2UD4>UCI"%'V6N2 M>5R2FNTU2Q4 >JDGW+(RPMCU::N)_4I]=TY7#53!89?^W2X..'G"I9(/L/.Q MVMG-,3O1OK/Y,5),<(S _N>PDYOA$HY -P)OD&BZ)/0HJ0XZ %+54*D0H%OW#0/$-7Z2L@!4? M4]KQ^I-GLWJC4_%;$F[E27LH'[L^GM-(BVV$WR7I]EU=B3+KX6D< MDD^J2*M*M!\9E6+,+VF7EV-+A$W(F0=D5TXQJ%WQV08C*QDS#[&Q#<\U9ZEY M"&RC)(Q(H@3^;C9XE'B"V TI%B"V1KA^,FS2##CKR1:0\T^!J M%PA!X.0<9#/6:I%!FOLHBGG8;M+UGD+*?$@782D3 ZJG*+2SB RUH(]8UVZ< MOU!3=";O&Y]1M%E'!1%88A@TJRU6(H+L$MMW:*J.F&=GDXJ8F0I70L@R19)ZR1!5[#JP;Z]6:[[-]D GEU=5XKNO*0=8[\N'MKWK9![AFM# MTY9L+Z\PLYN.J"(2?-EBW513&-3->%3B>-7H\25",BGT-PJ/$2!F()JM'+\> MX7WRUVB%=U82.@34ZI:'5A<#&BR=\4- (S-T'W:36!BH'4O0"IJ^AR<^TZKB MU;TM<,2DPM6,A&(0]$X=M9L9^-.Y>D18AH\7N^:=MNK+Z00&*,NR%$NY1:P\ M05K*.M[:@:QRP1A]19$"0A8G0]E])&9Q9LY1#+B4'2999JY2'9=*H*Z:8567 M=2D+?U<&H3)@;N !W_8,-*K )3BNQ >+&NNMD1ZM90B3%NI?^HU0II^=U/!) M8R%+QEK&L!B,G(@%)G"VQW(LTRT3&>"HB4![=%555[GUS,X,>JUU%2CF?Z).[ M-D>)DPKKK;ECW#!S=I$.W>@>R>\WJ'0>W&&;?OR*17?J\)-/EVRNKE#*G)2;L; M2T;HZ:]C-+#BDFIZ!1&630W-89(0O#B0LH))+BB1)+=BL-0'HO_ M (JQ?9$9_([5UTQ+9,AL"'@S,Z@@$$,]D(H %%2P8#MN5$F@H$"%!YDY"D;L M@@A.-LQ)-@A:)_2 30[-T>;)]K-*AI9I;JW;)Q4S.E?3U9]I%!&]M;60M"V$ MZ[G#;V62S$M4[*<2YPHTZX9[ NJ]3S:K^KLMWI7948JJOM+?K1 RC?I!W2"1 M:*7-H/G-D]VS-6#[;"SA&TI;%IHW.[PDGLTGR&E@%VDETU7RJ>9/6@_9XEJ@LMOP!>U)2FQI)3T9MZLI#;$/;JNY9 M682>1) WQ,?9MK\4"3]N^('9):R#JGBN$SMP5 MSZ1E5PJL+G$6#UA5I.R;OETWI&SZQ!U3$ZWZJ2RM+!@B\OLB+Q%(U+;(DLH' M5VUA<$5DC@HTP8,R1)C& ^Q%6+T$ZP7[UZK7TR L)J>?/Z3M&S^CMPWW!1T> M*;F.K/8BJX=J4N&PCD128;G0\%O *SSO8+%-HFA#[TC.32S;#JW2^K2^!YW% MZZB+DMVCY'9L5B4SHROJXLNQUY?(H[&@(&-VD4D0F.94+&#+7&'J#@ W4-MU MF[=,4A*H3E9?=65"DE,%CH>R'_9"/T-VQ^J-\N91V)1'R.](W66NW2S<(YC\+NR?5(NWQ_P 2 MNUK"YD)HR6PVXAM=%7&M=M;1DE#%'$V!F?X9D)>(*UZE(VNUI4<[/=;)>_E@ MJ)]@*3DQ*!1MQ,INP 6I!C#J'Q%GMG1Y*).B/.N-@4>9[8SJ]-$_EAS/.<:N MW*.V^NNWQ:=K^KRU9_QG3[%TV MRIIX#Y>X)9UWUW^6^'G&_*F:1I%8DC46&^0HA2025(%4HU(C0 M(5$O36Q)8=GCP8FB/CX) (IK)/>H%QX[V5.>E-)'<)AMU06Z6,2G0>.L5);- M)Y/#J3:3K-2:[<:ZP'5>8;D7#=BOLF[711WY0CV!H8/8HJGR MUT52,M@Z\W8!JS(6)$V=@E7^C! KLQ'P]P83D3MY]+<($M6:0_9PHP53>)); MM]L*:F'.O%7<4]0&L;=M3%11^^[$C? M6^S)),:_:JKGR,6OT#WVW<1N(1)MMGW[20/T@G+\[)32#UVZ90*"HQQQLW2' MH-51]UL0O2DY_-Y?6L%MVLYE8E?;*)SJ"1:>1B03"&[HN\,%M)3&A11V7!;( M/]M6*^";-OEN^SADO\)UGX/-K9QC/Y^_!R")"[1+VH'!P>(!)-J*! ,;,@\B MF+BB%XA$"H <]$TRU=@#H]D$AU#?_P#(4]7="HCU M$*QBT8L F\NB0_-QDAZ68J K3UWF-NWJBD(F?9Q=VVDLD)IN(@/F,LF J1DF M0^03%)_L3TZJ&L:@G?2EDII?K03./3R?;]@ MD2BQ3T6 W7"BO7)&OQ+F+RE MZYC562\$ D]HQ<5&8P-B_P ]& KI@_%$-HLDY974^/\ /\^?SG_KQ_;\9_KQ MX_Z_Z_\ /D-DLR<"HKB%/?1H. :\ \G+_;D :L7J1" W+D2>186!8OA8OR12 M<>_H3IQQQS6UFTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTU\KY%1PR=H( MYQA59LX23SMG.N,**([Z:9SMC&/6C3"RFF7+INC\1;2G.%^L-6PR@:>LZ[J_DL:F\PHI;L/:43C) M6KVC:J:G3D$K!-YVX3G=M@"C].1J@2- M?B>AW8>N[PHO-91>-QZ#17/3G,YD[N[,6I74BCG76-0Z*RMI8-17/5!R6E[N M"QR.DHO0]_U1(*ZD^S+6$&;"="'D;.#Y+@U->FUV)C]=$HE*P-7CBD>].+N1 MTEC;O67:ET#,UM6ZG,QKR:LU6\8PN%A4HC"R+J0:O$D9#'B22@QV")ZZ)/E) MY2'U+JP&S/:)Q:G.P5FL%K?$=?0TZ@,6@SZ$2.ZI55 *ZX/"09(W8P(FNQEU M=2!B;0L1X'8U?&/.[>=S*+J>WS\2OJ<5PX0BS:,T-V:FTM-UK<%JR6"1:#0E MU)JWC77VUB%+W2TF&Y&R18!W)H38 DH&9QJ%FI:3L#9EMM6:: Z 'FG&"S3GJ^@>A;(2% 6OU<;KNSW^VG*HZ MI7_5,X3BCRA^N%F0Z?67U N ];LRE"KHA5;OKM1E&U/( 8V&?H]([(IS&B=2 MF9%UYE(@NPCH-Y-%7\KT$*!WK&5QZ@_IX=G@M9U)DE#:G<2J@(9U9#-JZ)3_ M '<1>X2?5/M?&8%9_4&JNS.DVLJ9VY/8%6<(#> M^;DF; _+9-"V2^5XS$6C$I+GFJ3O"$_5HK3$E8S A$9($ZT*]/2?98E9!5L# MQ(AF7U#+RLD@!K;HK7XU!TR MMYSV/@_9:RH96D.;E.R/83L$3#Y9B6QB:DFXTG)MTWAHMR)WI!;Q'TQXMU*&E8Z(L^%.X <8L@TN?1^ M(ET:ROX=;8^"H3!"(EW4;&'(X$:1E@72AI5I&2*K!PJ!*"AJK)S+SK)W!K/M M$YLL#%&A.,SVGBT9%V/7YN05I+"\<1FP7>0PLQB2T[/K/KDT%DXMN0V8.P,U M)*LR ?0>WX-U]OZ[:;;7<&B;,!9#:@ MOI*,F7*0.*6:\N."C=]SHHL&:VM$*N>S2.+J$8JL[V2W1UH&R7D50@Y1-$RK M]!Q+O'5L2RU(6)!:T',D@%M6XP*A/(\9 X)^_(*K^ *-H!1JF/$ 6!K6M"=" M;>8WEU^OF?Q#0.O%.S-RWA8+*TK[VORS7.)!U &==8!*'9MC7L9A*$Z3*C<, MW@V'^]@PAK"/F7LI-2C9^/8XI#NF/:Z(0+KE1<[I^J+C&,HL):][ MJ[6LUA U*_MW2&D[F?\ 6X=?F8V _@R2O\0T?_4JT9N\2S:P,93/BB<(;SUS M 4*O=V Q(IB17NA0I#\^8#R4 >:A>77"Q'"%17N$$W9Z[_X7(GX\>)X)?7%K(L\JU"( MOU5EG8B\/4>@%?%(F=J$)5E[HU.&)KE58U$^[G>"H%(+V(BY&2;,R C*5>,8 MP_/DE@0S=^"(]J9^P*M%'NZS/,EYYT&GI2;]J)#%@56L1UIJ>F4E6J6SO(U< M:-Z=VD/ET^'D-6L:5^A-D 0]NWA"(]5ZF^T F[SMN0M M2K;:JJQ:0>Q =8,"L\5$6I5H]G,6VF$;U G8;-9I")6Q>A?A^XQ'9.^#H$MU M1"SW4D/*MF.C6WJ?]8'8]L];N)_NN\ZN1CM@V$[0[9 JO"Y=/D:N"035%P22 M;:7 XL%TQBJL"6=)JM2) ?LN3T:O$7&U?\8,+W?M<9$,WC]$AZDU/#K%)LK1WB=I9E$O)0K+9J[E,87E M9=4&""V(7*$M>_NIX]&.UW6C.=/OH#W M8:P"SQ\5;'D EB@EY-7TI8O83+IO&78F6! MV;_9)ID\C( 1,82"RD(#)L]V^T2^_:S.B6GBC8 1^^20706BP%*2-(S M$;16-,+H@"RRCPP'9"KX)-B^V .JIP_0*[DHW,B]<5'&**KT+;?4RZ:_Z1R' ML1)K1KR437KU9\GF5DO=#[H4>A5(C[.BC^%Q^*0V$BCD';2>MHW+I0'"N'*V M&?)7;U=[O6DBZ=QNHZ6J45;L,[(A91"J=L>'UU+8W,;E.AGK.27C=[RFYM+) MQ'I:("-']N1ZA$HKN6G"391_M/6+ 7(AF;0+U1[1-&X:YD/5NRB88[6O<^#E"K>6R>QF&1%>"3 ]05]8 MWF8]6+JJ*DX,2F_D3V*.QE&DY99"J\!C<$B,EJ1O*8M-)Y&K:*[F0$ M]AAF1.H!7$T&P ;)!SN8'%F)=G%*Q M[750(*ZD900!X"W9Y]? 4 #1"TJJ;('3:QKK!1UY]37YR42&&QN;*6)#_3KI M=0-#I6_4=@=ZTK=G3]O2U3XL240QS=;5L$+XP$T!TO,<$G M_MV7:$-PC9)@Z3?KN6$KKF[,1ZG+"IZK=X'8UA3:ZLS=W&QD"8139H&CM:?I M)>?RN6')G+X:$"A8R-F(TFIIJ_>F#":#H='Q90WNP&OJ_P"<^L;4*]2V],J9 MAM)#CA:M4Q5WP>NBD5$R64CAL;LXI.(()!IS2.RAX MV/5C.R M\->[&(Q&RZS5^R9XD.1)(DR("XX@-UQ(KVEL$U0"-WU^ER>E)%V]E4:)G(4D M]=V#8<]@79+#_-0.SWB$?Z.]B"UZ8A-2US"&7>'N1W&8=D8=-5B]@D!5_ MM+^C,,B:$)UC (P/L7(NV(_I-S;B5?IAM"(FVCXL@6,+MTPD?ZW]+SL&O6[. MO;&B[5^2K>F*/Z_BC]@]GWEIP29QF$=ANNUD3IO!:Q94U&FD1K@O%J5=&! ^ MPGQ.7C)200BC(:F)=G)@5LP*^H_7 8O9X9[3=_8=599$&HDGAO':\>[27L;9 M >MI!#J"A39C9[IW(9J1"6>%*/Y,F@VJ6-LAG7$EH6'0"RYM%)5(XS))1$G!,A5%D +8A1**G9 M)&)E7K60G0YY12.%F+:_NY2BP@%\7ZLGK^)S #\J(;Y=< " I(NO" D?.R+ M'?'NZ3B;7Z%17@V#Y -0L[-=2NX=J]@9N[C8Z)JU61O?JC<42>A;$A]5Q)>' MT;,*?/R2/VU#@]/&K5MVXT'D+EKJ"&9+9F*Q&@5X2-'-XL[CY!@8Q:9^G[V# MGL*OZ!+16LP[*01#U4J[A[M_,DW3";"^ZW::E[_K$N18L(LLXC@QM%X]*XA. M!1+5Z]%F0C'(_0V&+M7;.7@KU$8D[2:DAD"M^?$;%L.FJ]JVHHW6\:C=CLI# M;?5K?M$+!RDS+[=9PC936 BCAPT=)E(6)A[SX$,(ZDW[38X]Q^Z?4I$0!G;4 M5:5%:$'L4/3'9>P:<)VR&A+*+3^0==Z^D\S*-R$) V<[N>+QM[K']WX0W.H' M!0L[ )+/8@?VBQJO$*R]%?"!.9!862I/(@42&8=@D&6!N19R; M)![L?)@:NJ'86@3UT.KK4<>SU.&Z![4/>W!=2EQU=/\ L7U4,5]&K!*2"-P< MB5A/6+L31IM2:RX17DGBE)GH[^O0!*H;!FN,0MV>"CX,2-1H&7@8P)L42KE$#?UN70YKV01Y4C&HZ=6K\Z.D8J1 M@"SZ' GYF,/F1]./,DR#=GB;!#M0"@_6VM;IG(LG()1.P%*,1U>UJ/1)R>56 MA=+*.-HK"8H)*&635HJ;D)["+1[*) *!!0R#HY)) P##"!1&&<']5!HR7MP7 M;U6R@).Q_;>UJ'J*G6R]706>+PZI:CI2P)::G\LM"Z0%*(D@A*T-D,%PUI?1 MY>R+1!""LY L^4>+0#/+&%$8+1M& W*NH1Q50O0H+C72"W#%>W 9D$%K:*V;:UC>FQ/6 MQ)F9MW&F' M4AOUQ5FD=?R\5&]V^ZX,E7-CJP)P(259D,'&KO&(^N:(HL\1ZL=!+RJ3L5 G MEA8E,J@U*6WV4M6*6@[[-OEXJ8_CD9M!^,UC77QA6;L=GSMPT!-WQAIO$KWVH*/ZO,2% MY)P;D-=%V4K*1Y$(@F0AS_K_ %[)[:L:=R=H@3<*,:T95A'6,Y%R5##QV8"3 M>OM6H;ZG+6([2#)DA60I_P 2U(IN2\8U2O-BH^J8FP26!M3H$A)5@UE2"&M: M-N6[ZHV_U%=BE(HZC!V'Z=6[9O9JWI,(B<#.UC<8+TY7[H^?D;1LN')],^WY M:WI[&#,56!/WI;67P"3?/10FTQ*!0@G6U5E:TU/CI16$:I_>Q+%[$MVT8.Y2F5BV6]B"P M%"+C(Z_#ZC6X!G)6*>JSU_EHF3*-(G9K>8CX_54H@]8-MZIET^MD-=T[TK2L M-QQ%V6;[NZ=]D)IV-6[.JS.! MD:VWIOL[(:4C\2D UH-F(\$"JBH9EOM,\B)3,HT3.*2"='OE#<0//(H8C.L> M?AEWB2VY!XYY$0+%%'!0EL.^UA0$?+LA4C%CX>0?D=.,3FE=_D2QXFAT7-$U MT++$#SUUT-5MC?3%M9OUCZY5 6AM'2HU6G4WNG2MA1XI,99&8M*Y/?\ /ZIF MT3&I3*%QAI,AX1^YA!4B;EPANU-Q>3ZA3K42?52<);83O KJZT'J&O/L07A# M74#VBG)J"1?L=/03XDJ,E_512K"A2[.W=54@QKM6S@[B,+.*BEELQ4C(SM1;LJO*@ "-6]A114D$!*) /:<0I/@F@O@FK-UKJPUKT.[$VI0M MA5ZFNK<+A8.6]BNQ]F"WA$:?IF32LY0MCP:YQ#AX- M#AXU: 9K'H^\:Q1\Z,(:PRR:0]"I^JK/7 )K!M2!_OUT [""CC^0$7DA5J;J MO!^JL/E&A60$ 3HN[FC=K4]C-XRW?N7>YQ NU6*FAZLC+IMK><8\8\8_I_KG M_7.?OG/[YS]\_P!>.2^9*Q) 51R)KL]%T< V:/'@JV I('=GL!CH/))- 7T. MPI4D=6+LFB31/5#K5''1;H/>-$6[4.]JLC)R/];(I<,6B5C/NRI"3Q229M!T MTT5(5U13"M@CR))2MDT0-V0/L6:D] $M8,,Q-29[^^4(7C\<.4Y:>D0 81 MR "05\FAYR(5CO1)&:F*+Z^SR1EZ=!SJ:3*L&HK2PH3* \+LZKVT_D\=#67' MQF$Y"P?Z/9C#S906!;Z;ZYSC;7;5LKMKMKG'WQMK MMC&<9Q]\9QC./OSKW5AZA'9.+=5W%K"4ZZE->]+.N'2XS?["TOUF;O3L&=M^ MDZXM*=F(--$)@.$PUZ.C,Y&H0XC*HE8J]LV*U/A':D6:IHD=MK'$Y#F$@4T8 M((4V6)1/U C]3!:\6P8T%Y##+[=K[@)_51!(JJ9O!'T6S]:! NR#:RQZ7P9@ M?0/HRR7Y7;]M&/;G1OOK'\-_U@/H]I1*,5SA(0EMB*;1UFF84^'\,Q];VW^$ M02&^QCI#:1^GW=+3LJ+?4]=\VJ&I7U!]JH],;($#ZODDO(2SLSV^W[ &X4/C M\F".OH^ 0Z5RQ6"3PQ)5W#EB]XV0^H-V&@$G=6%,(A4Y:A<]I M>XW64=!8F'FFEP+Z=9ZMOVSX]8N\X?2MY%%%95O1)*'EX$G7NOR6YAG*1\M7 MV35C*>:TQW2[$#K M7L,K8D:#LI7H[1M,$#CJXZU9(0#JM!.I >/E:YL,&] RC8= 8",DT/Q>P'I4V-7W'$ M' 93X''I!U4Y@H&L7EMV05@["BIY1QUH7#5ZN7.H';^3[+5_.T7C&,C0@>65 M=:J#8D+&HQEY I,):-@R>\':*H;D['Z",MI\"LOLYU:HCKG# M'%06"9EU2(V-U45ON5FC]7K3Z#&IB0:1>+G,+5FV)P&1DK(+;K%Y#'00]0(C MN*%]SNX\Y=TQ$7-;5U5$I?@.W-*RDE0:$7N _)0QX*67ZGF M"0"2&,?_ $Y9AP-V0:!HDN%^AKY&C^Z^?! FYU7ZP*]G)R9%DG MRXFJ:GIN+!&@4;D:Q&QR&U5& C9'5WNH[,FB)\K(B3\Z_=KLW D7JS#M*_17 MHH5<@'DL>*W7-EQ9:HNPU),'D?K&C8A+G<4[%, [.2RBS)\)@F\RN.U1'T,> MH-GDX,.-'RNKIV9 /2Q$F4>:H5]0?ON/@Q>8F!'4U-P,]/6$^I"N''PZX5TV M\-**%DSO7M(FM9R.[Z3D&8G8D,NO9BQ'Q]XO]$7J&1MM-9!C?;GM'V.*=BIS MU]HT?4\8+'KT[0LG,\MO^+=I"PPJCZ*ZD34,NP@Z%E1C5MM)R]S.(\0CD7DD M4B8)NU_5XL0\.K'64C@+DQLQ$B O99EX<1[2@D_I^/%7H!!9L@ ]6Y0L%7@Y M"]*#RL\CT!\OE9 OD>NB:U(IOT,11M!B:VO&P]Z,#7Z4[2@^NVH6&)1H==Y= M^6D;A]F<:"?UNZKYM81TM:@ZNU'FC5I/7>JZAMS&&C2+HZZN?T^@6.O,%AT% M_6]C27K]U()];JOCFT]C=7F)/EO+>OT\CDTQ/E(9(!,]A0[K7Z MD-ODBQ&>GZ-[+>H(6A V:F3!,>W#U(\+F8;"DEMG6ST9$6&!:0QH,%*-T1HY M55,6$WC=85@QAZA M Z)HO5>IH>P+G5R;L!$XR9DSQLT26/20^L;D+D:,^9EZ8=&L9E'YBE(9UA2- M]N3?;%@&1<@&(79P5":),*7=-!@5C\U3$:G+03:@"-NMG!%G/ S!]N558X79 M*PUGOJ$=Z(8:4@(6I(9:UD5WU\K?L=9+6L*,LLW"Y5BY74\?P^FQ4J=7BPQ3 M28 '71\60OF;M)L%DI]RS)?PPB 42?;\WM(.[?8^/3V:S=['*=QU[K[NE4?4 M,I7J(N7N.P1C2Y0%-993=$^A,UX8'D<%F%Q"FA"MT8?(M9I%11&@M.W!B26!)!LNQ+7]"#8_ M:JJKS*<>EY!9>[+9;V[8849+JY[;5=.F20J'$'!V,=KNPC[LR3W'$'8K7($K M K(?*(QQYHU(I%8QKJ*D+1V^_P"UL3/@]"1V"7I?%\,#9QY(+^'5 -D05]]- MP$"ITZ#DH((H"^79HD?BE6\F=+%OJ3Q[K\9LV^1U:I_%T4I_JOU2.S,LA3ZW MIE3<=A%2V#UZGUT5M-)]7EC5W JM/LG40Q5$0ETX9S*R)9V0&6*SF+)BL:I2 MFXK)64W;CXH+A1!O,0I9CCSGO!W'LPX/JT::CE?S2N.]'3"$&Y@?Z\6U1^]A M5'>\=ED@? #-%S>V)).HMHR-1I9FN0?S=OK-XWLU4R&B*^COYV6ARFY*[KQ M(8V"*:1"UE5[(D$=C]5<2H,?>BRP"BJM=BNN["$+0)\%"U'QY!(;K5C=4]"H M_6D@E9AQ:,QDS(G%^T, B0AT&BHM&'P3M);HB[).(R\8,=GNX[ M6O8(# JS<'(C/IE7M?H0*S AMR/A$Y!@]G=<7FN>FM#=KX+K$I-'#,HGML1R[9%XYMLM=TF#2IPOHMD_7@B+1MW\02W4;KPHR!*R&0*2%LTI M5@[J.OC34S%BPZM20Q-$F]G@'"%@I-"R&'%2?O8L "O-$*P'8%J4THZ-SBX* MLN N1*X)U9#KAA0\ EHRV G!=S)P%*0*&L*M5"&5AZ=?L$QF&+UHEG4@0P]T M6VU%34U[I=4 M:8ENT%NJX:^&&ZSF5A$&$KC3R/PJ;@(]G0ZR,P0R12F8(-; G X%#/F1PP^0'C03Y"LA1>$I 8?I*)T4E4 !G<"^4U@VI M()'V&ID*\CR0&CYY/_-&2;"*37%*(HBP#^XL 7]/T.0A-F,B%QS_ %M:Q>Q- M:]M$+?#B8D)(PV_:RKVJX$+D,0'RR3A,/DFV MXER-Q.9>F%7=KU5)87;EJ63+)_8/8$-V'LNWP:<8@LDE)]E!1-,GX"R# !60 MT;JJ7]?ASJBY!%F.7)-[!3IQRXD;F3D-SF(NC.XW:*@PW5>(SJ-4&E]^O#7(%:,&JILJV*+/PN_#$2U M=,=#*H>P?KA-I9IV"[H4B>-/)'':SLJO9S7Q J27)E@49O>NT)H7@;M=?3=3 M#"+SX5,B$70W=+:"8C)@4=::-A0,8CBK?F(P6$@I0'#* +"M'& IXCH!>'J<=5ATI=2!5/1U@AI)&K/5!XD&U5'*0A"^ MC;6PXO(7#VZ)L[%DQ/9>/L\L:[ID1."PSL_!9["):1MFVD88XL:Z)A%F\]>N MH9)IDJF4!A=3=/3XN\:RW:GMA<5Y,[ M'ZX22H@%?;=V:5G:$84IXU'^PD0A\&;VO MF:T6L =0.42L@O']F$[2V5CZ+*21R4-WP0X#(E@_P62;A!=K&\QZ58LTFI+R MM^RB47F[N6R[E)V38-34O8,6(OK@KNJJXG$-5IZ219>&)0Y ;3<%*0K#==.4 MQ(L(3US)S IX9&E]>P;N_.1NIXU!818/92RJ$$ 9+9+VT+*@=> I'Z? M<=[:S@DX@S.:1= H?8M$G$-B$,AIJL@\J>[/9K*"6Q5@9V,:YM?M;W/J&7]C M;G;G.OQ]CU\Z/4#;-S5Z**6//ZRE4LCUY]M8Q.@E'D&LIBF*U/R^,PKW'I7* M0\_(1R11R/0(V!D3< YDF+(F2I($BJU*P#%2Q]PH@'(AOBS'CQ+<;7Y*+!-6 M:&B>!*]@E; '$%B?*_("B37+N@216I]./3_@CZO+*@!.Q)V_UM3K!676"32# M497P"B0Z52$K;A]4LQ'1YE$VJ3(4@& #]$W7S/,RKH M'2+!#SUK(A=>[B9&>$, 1$Y9PT\!A#9VM+!6@LP/1*(?7T,[.6K?25H M1F\-(R%LNOMH$5>PM*F[>Z_V!&@D[$F-V^LOK>TS<[&D@>TDC,H$0:TJUM*< M0JQ1X,DY^%�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�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

[MI9&WY%)I\990G7+D]!LSJ(T:OR;$@ZV M'GC<1IAF'*<(/S"F5C%+4X6<83W>55+H;PQJWN;2>NMF3=\6RKR+[4(AUX%# M""9$44J?\2TN+%?D&8CKK+.6\^5;C+:LJ\V%8QG&<8F+XENN=3M<21\NZEDL MVS7;($/JDWZ:5E#MA>APAGYACL,+ES2B&)K"J!)>95WT8%92I^2 MS$<04ME:8[2EY#[2.V#*79S6,]2LU4>7GS,V6WJ3D#LJI/9_6\D3ID;"!J>R;\R#LMF@M$@86 M("LUCGD(4F?@9">;9K(<>:V!PJ8V%4J("SIX98T*S&FR:H)C0AF5*D(2MV?4Z8F,5J M4)3?EEMR)]D2Z_,'LON*[EK5*A=O%%IM0O;;+]/LQ#3 RPQ9,E<6//B2!3R4 M#WY*'&W&62:[*;:<80U$"8L%0>6U,,ADHUJOX7NSND]I$_L MRKU9ST_-ROV-UWM(S/F*DHI3<"IU.*Y D0(^4*9-I1IEISRTL^*5K#6&F-DZ7*Z>KH6 M@V=@X6F1G M*CD2?L7(FC:&U5I#5=SW_BMA:T2O&T:^,/H DK*'CW,A6ZY"(*2/@113"%%3 M1@DN4EMU;HZ"+==;<<=R'.U7,U+1G*A5U[+K.9\N5K+M+ITZETFL5.GUES,S M#DJ'3XE';GMS7*NAEAU*&UU!F.MS\KJDAE3KVO8_ATR%F!WLKSAE"/G:5D#/ M.5,\YBKU)K^9-A"E2 MVV(MCNB^7&A.1;L^#JZ\,%C@N)\P(5LD/(@;"P.RZEG!%H86CQW)X]+BVVWI MHQR;&C./,-RW&''VDKQ1WFSQAK-JO=+L.U1@:R:UCDI%Q'$0UFB?+?E4D?$E M1XLQT,F$:(+DE8#,(8#D$2!);_\ ,$:3AE_+5*?'.L7_ %QXFE0KFP$T>#>% M$#_VIB:UAQ!]-:58M6$R3L,:.@PA\."IR/F$\2BQX49M)3#KWIY<7ZBLT-UQ M3-I>+'SN8BHQJA%B!PQ4.L37(K4Z1)@/M M//M)FQC(G)'=/(:4E3B5-;>H_P ,7953LW9G#N9,VRLCT_L!8[%"K,21%BR7:5/$"CJ4941R0@I8=3)N6T;S+X^CF*ML>^)BVO$>+,D5H()*6$N/ASD>I$DE6QD=V,*3):RE^,P0E1 MIDF.XW)CQG6%IIUMN[U%^(%%)RP/@M7'62Y!^%"C M>;*(HZ8\0FK1!9PF-%2_EN,VTTAI"%?RAXZ[_P!%\C-B'9Q,*VL5V$0%1T6.!9JA*E12&(5?;'K4/L8&1(D#A.&\O-04(EH5D*[4<_I MRQ6WDT6F2JWEG/4W*F8*E2Z=4JE3H5+@L]](KK5$;FLU!]+9(;6V)B4-H >< M".(MMX3?\/78NOM!RE$T?)="S%7*#0*Y5LQUB4(T/)TG-; MU(E4.$M] +S3QI;CKSI5$9[PM!]Z=/)?9>BN2_"VXV<;NA^D:S.F @5R_+J5 MKG18QX5:1>45\Y6&!C1\@-EEFXPXC\O:])"U(DLS%MQU]W1X=_HWUGQ%U[($ M;3@7+7=:"664Q%2_EQ?KH MQU6]MC>E%WGX:5\*TG7HG5CEF,YA2')0J,_C&51DYQ@2NT:/3LRRLVIA4JNR(_8I&K M2:M316(?M[KN98\006HDN<^Q"I8FO%]XO07*I&X'$N25);+!W%-[#9U/D!^HFKOU&FT>'+JV832&?9(WLE8:R[/ M[QAR/3T+>1+%KC/B:<-GK)BO8VF\TWE6$8L+]1MC%9\V5X0E2BKHE*F8V5Y[ M?'OQ&AZ48R^N4EC'J=29V7OK4VH:(.V9?KC"$44M,$P1EDA1"=B@$'SL=^4( M5#S6X95V1&GQX[KT>:TVJ(IO"3ZB/-4=>M*:$@>%8#NX^NU=JTHHE)NT* M\-1(7VGF[(+FA<0S#<.I1@E+S)G32E=D@W)+L2'$CX83#:R,:6S&*47L);PI M(<4VY(>&U[E##!U!4CSYPS6V\.3\Q(BU9^]"B'2AV.PE.[5LZ4--2BUR/EB=.?[-W.T*B2*2Q46H<7A-OPNIL/SW79+1U[N9'D1BOA2 M.$EZ[.LB?PX=E.;G:%/RE/[0*11X?;JSV*YKAYDF4-ZIU(+2%?V@R]+B4:-& M@R@+!^E3850#(<4X5I3&M+N*LWB.<0JL0"CYFTTD5F8(PFJ0!K-G,Q \ O%9 MFPGCKT,4K(N1F*^V[*%N(<+C^_ID($9W*6\S+K]A!VT$*LU9*P#H \.C%0Q@ M9):F#R0Z:RE^),B26E*;>8?:6E:%)S^.4JPE6%)Q0$?XYZ%D&V]$I EC9 MWRBO71Z\(:5FQ2BA2^LA9L5XBI:G/DS@F5F"V(1Y1[*6FI"&,3$YDYL \+*? M,FS*DO2&QEMV,-@(=7E28D!BW3G68C.,^R&&ER'5-MX[83EQ7;'OUTF1 M\_9NJF;8>7LT1* EBNY'A9WI+M$$Y"X4>5(CQO8)IFO."0[_ 'REJ=:0TE"D M63WB5V:X#M;[&>S7+O9K4\[=G]2SFY+R?VO57LDS+'S:JCN,U2; @29PK-(1 M28S)AQKL):1'E.R'7&W27.Y<9O(AR>V)L_4'BFA:81OUR):ZN]W%O#:G/LA* M37&Q.U:M+@QFFQ;[V8C<.$8*YB-FIJYT2*^AE4E.,*PD9.-8;RI2EY2RM MO&,)3C'4:H%)3O?3/B0[EMQ;RE-H1B4_B6[_O,^/Q@J MNGK;9JL6V:$J-^*TM_DARQXF"2CGQ8[1^HJM&G?$H4[A:M5-'RZ/ M45VQYO4LQD MI:NZ4X9;1W4E/;I=ZJ$A]O>*??8>ZX44\F)=]JX%5^QM?%#) MDRC,.0**(>'S,J9EPAU?BI+#Q3R'8LMR,B2N,]A:O/T=$[0ZX]4*CFFDAAZ; MVA9ORWDC+ZJN[*^>B6X(X1*G$"+\UN/ C2'T.MMTP\AP0C4GB M:ZV9T>.A 2,JSZ?GS@%<81"@Q3ML(.B;..;&P_38A,':LXW,)BF&F8ZD3W92 MHZ<2U*67#553W3XKUNUQ>8\F;435Q0&> B?PS]ESS3^SZI]@E0[; M(<(*HDG-](%%J%';JE'E*73V*?5X[T"=(-)EML4GVB26^]7W,9Q*;MBF M[OU3QIV70)5>.K62G*K0F@:9J8#MC8,.KFC^N*P4%BT"+">GOCV0PN'F6[%K@HL]#9?E MY5&A*F(8S/?9D-PL/KC/X;J\\6+7%'U5K_C50M?@(54IHJ;N!<$*.7)S%@Y+ M)K!$FMEF3XOV@&0YOU@QRZK\^)9C0FH, MZXCGVU0@%6L+@0)C5#DX4_EQ&0K]>2PQ5''G%Q(5GFQB4YGYD\IZ#R!SE7W[-=,RY395'':'7:<,Z*;H4!LO19M.# MD2,A$G,M1BT^:U&[M+,2(X[/B\-]6VN4ND-'U>O6O9MQQ68ULA)GUH-+#FE6 MPNPJ,S*7EFI(@_/XGPK4AA)!1.% :&2'6XA%R+*7AG/ST%RGTOR7BG9&I;), M-NUG,#Y_#G #062-P45+2.RZHC#:AO\ Q?P,K*$PY4R&L@@L]-=CFJ_,D ML.R'XF%-IFHDN-QU_P"'?R?KNXCFR:*1TY3-2;6#1(!FTN4$(T !VZ('FNUM MU\@*4VB:)L%8SWF1OM._LG6V8-#HTAQQB M@F32*DZYFA+5/5(>DTZNM3OPR-(:DA)6:+S9G+#) MF3IBJ@L>$P 2J;2?L4I"9J6?FV4MQL?'(SEWS9DYRVK]YSVZFWT=:BK4&DUQ M5-558:)BJ/5(M9II6MY'LM3A%1BRT=TXV%K:XUV0YQM'B/$A6ENERYG#,F4D MUY&7:H[3$YGR_4,JUT--1G14*!5>Z_$*:Y[2R]W; =V\BYO& M/E5QE!PXRWA"L(4O&<18N'6K[MQSIO'&ZN%3H*BUX&(K=L1F&.M8DI7X.8$*R#9$= MAR%$(K84ZS,BYC/C)T1]^%+B/1W/*F6?1UB2LIY/(FTUM7$W$>8<<5'[M*OS!26DN7UX[@8V=/[2<]4FDY>HE+S+4*=3<0D)4AR0MDI*AW5E*!I\'>$;6W7A >X%-MYFGMM[4\YSJ!4E.K"N]=6%J!@7I?@%K;3^I=SZG38SUL@;L M@O#;$;-#PL4G!@?)) H?&'H'1VF%(&2YDLU%^)]3&2+Z\K3EKNG*BXD<*J5Q M+5=I8"T';D7NV <>66L4 /"E0!X-,U;8^&D0RRC+$N=/>GRLO>=:GTM81Y4( MQC,TNCJ[ R#D^ER*%*@4*)&D9:CRXM#=2I]2H#$Y3ZY2&^-Y0<+JY,A96^'5 MH6^ZIM25+43CUCMD[3:_"S?3JQF^I3H.?9M,J&;8SJ(:6ZS,HZ(;5->>#45L ML>S-4^"T&X9C-.-Q&&WD.(:0!QG'?';]F?X\9[X_X<=5O5WPU]9UOD8SR#A7 M6T*D1=C%MD0Z.H97TUV,3)ND9C<%N5B-DI\' )D%$8RLNYD8?89QE>,8SGJR M+HZV%;RO0,QN4MVMTUBH.4:BNB0R]W14AUU"7 MX_=26DNN!IY'&J]>_*GP]:'REOP_8)F\VFF%8M2C5.8S71H&6R38A3B4R'/D MN%8[SR)<=LF]$0EI6&P]1KTI;PJ"E&57Q->9B)5\' M+'L@HT9@,0$RXV$K&%13D./*'S(N$YCOMXQA"V%.,K=[HZLQ\G98BS*_/9HT M,2LTH#>8''$K>15&PVXT6Y++RW&.[6AYT.H;;0E[C470LV(RYO:?G^H4O)E' MDYIJ9I_9ZZM_);3*VHKN7GUO1WP]!EQ6F9G?-.Q(ZH[KS[KD4-)3'4TBZ34- M&\)8")3+%USDOO"OU28[)4[7ADD="0XF5A2'LO.#7APU]]UO.$O2%AL./]N[ MN%>V.K4J76&J73ZM3V") M'JU<"UQ@H55'63(1P@Z.-8F$%Q6(T9RM:6TXSVZ4_1U9RYDC*V4G)+N7:4BFKEMMM/\$J<^A332E+;;0W*D MOMLMH4M12AA#:1Q$ 6TQE9Y[6NT+M*9@,9WS&[7FZ:\](B%Z!28CB9$AMMI] M]YZGP(CTIYUMEM*W93CRU<()5?7$'2W!^JEN6,'E@Y>K.S88)084146QX10! MQP;47*BAI4Q;'S;"'8SF9CBDO>?$C'IISAG.4Y\7*3@5K[DY<*Q?Y=KLNO+A M7AJ13YNH10ZY1F-"F(( 'IN2,=S+9"NR\R7!9!A6)"&Y.&',J:BQL-SOZ.K4 MC(.3Y4"K4R10XSL&NU=5>JC"W97^4UA:VG%3PX'P]'?*V6S_ ),XRCA"D!(0 MM:59$+ME[3:=6S*<*U(=+A=::6B!%_X)!ME;KU/O6T;3MTFVZP&ZVB.M,!ZZU"M<[79F0;P M6*]V5OPI-@F27%$V1JVXT?*E9@H9QG"4YCE3PBJW*BU4*U'[W9ZF_0X,V#$B M 1X28P01.,#C"W):RK#SK:D.#FV488SA.6W%J5C*\)ZF_P!'4/Y RC*B5B%( MHS3T:OS8M1K#;DF]#C:V&E$MK0%J3=P*)5=#[9>TNGU+* M]6@YIDQ:ADNE3Z)E=]F#24)HU)J;:=4TASA94V$HX M8?@5\W'MR_;YF5IV&L2'MJ<,AG&Q;GK"(AC, MXG8"Y,6.D8Q):"-E(0=]W&$3(4B,IZ.[:=T=6:EV<9(J]9_'ZEEZ'+JIFPFWT09SK"0$M.3(SZTH 0%< "1ET'MT[6LLY7&3*%G>JT[ M+J&)T6-#9;@KDT^-4U%50C4FJO1':O2(\Q94X^S2Y\1MQU2G2GO%%6(QCY@D8<]2)2$X0K*X\5 MQ.>[.$Y:@MP"UN4XL@.+OVFL4837[&W;HUU:AAE6-^Q9,D2LPA(BN1_E:L3( MQ26(6RAI*6Q_HH0K*F4YS/3HZS9^2,JU2?4JG/HL63/K%(70:E)6IX+ETEPM MJ5$6$.I2D$M-V=;2A](;0D.@(2!JJ-VL]HN7J-0,OT;-51@4;*^9VLY4& TF M*IFG9D90ZANI-*=CK<64I??O%>6["47WE+C*4ZLJCKQKXXU?C5JE&JZZ6)GX MCI@^;)G2C$*"5*33S^/.Y(P*;880J$/:B#(BV\8<3&AL9RKSX]F2XH<":?Q4 MOEXO0.]V6V2;2*76Q0\K!'CV ==<,L&U1YCL);CAXM\5$BM8+.I@-H8;>R@> MF1,DOJGOT=5(R7E=M>6G$4B.E63VW6LMD+D 4M#T=N*Z&TA[A>XV6FTDR0^> M-(>!#P[S%MWM4[0'FL^,NYGFN-]IS\:3GM*FH9_M"]$FO5",N0KV;BB]U*D/ M+2FGF(@MN*CJ28Q[G!U&_D9Q6U)R>K\(-L85*:)!E/N5RW 'VAUIKSDG&/B6 MX)!R/*8D#Y:D-+FB"46:,E.,LOKC)DLM/HDAT=;FITNG5J#(IE6A1JC3Y:.[ MDPY;2'F'D7"@%MK!%TJ"5H4+*;<2EQ"DK2E0Y>@9@KF5:Q!S!ENJSJ)6J8]W M\"ITV0Y%F17>%2%%MYI25!+C:EM/-F[;S*W&74+:<6A5-2/!UH[:%P&]^[/; MK[CWKK"($UQ#*E]^^'%H1E(Q;^,_>R_D3E>5?>]E=NTJB? V@/\ %AOBL*N= MR'5A%DCVG-HE(!D[$X419/M/(PMG(^$)Q#D3.["6&HC:F(V<80ZIW'JYG7T= M<93>RGL^I*:@FGY:BQQ5*;)H\X^TU!U3U,FJ5S^(SMJS(Y1'*UGRH3590NV"5:9=]5%>C0@4(:A?J*=RMJ#*<*BF7 M%34>1.?DNQVU()0I+"VPI!*% ITQJ\Z]N?:SVATQ5%S?G>JU M6CN2$RWZ4VB#3*=+E(4EQ$B;"I$2!&G/-N)#K;DMIY3;H#B"E8"L'40>77$. MN;?0%*96VX.%UIM8*%I-T M@$VN#Q&5B.J2U*9?CKXX\AYH MAQI8 62 %!*@FZ;6V:;4:M48TIZ;'JU,)QC'22W'IVA;WH)G6^QA&"]<,89=[M.JBDA1*(K+@XV% M(-XR\.+CGLYBJA/0Y" M\P]%4WW*F'6W.(.-J:_(I*^+B3>]\8,6LU6#5V*_!J$N%6HM0158M4AO+BS8 MU1;?$EN9'?8+:V'VY #K:VB@H6 46L,5)U#PH*O1[0'-U_D%MN$*#68+:&0+ M# "*U,( B4,E#427$0P-F*4N$TRZ\X$P]EKOA&4=D>5XN1'ASZIWM?5;4%6> MVZHV%+6R^7.4A4%,8Q/C-(CQCB'FXR$1G2P<@.?G,H1F>F2^C#^;" MNCKBF>RKL^8I8[&6_.=")<4.B/(BNNRUOPG64O/(0N$['(0 MZXC^5:@?5Y'\17;3*S! S2]GVI_CU-I\RE,3VHE(CJ>IL]4= M/(=G1ULH>0LI0#1E M1*.VVK+ZZF[1U*E3G5PW*PT&:DM*WI3BWE2VTA*S(4]PVNWP*UQH:IVQ=I-9 M1FINHYG??;SJSE^/F=I$"DQFJJSE:095 ;6U%@,-QDTV0I3C(A)C<9-G^]2 MD0UXB\-ZUQ'C7J-7;I8[AB]/UU^6NPP0T+,!5=8)L,IBX$,LIC M8CO)*.+<7A&'DJ:1A"L84KO)+HZRV,H94Z MX_(;+JGC(LZZZXLD/!0*B$E( ULOM,SS.SVWVF2\P2'L\M3H-2;S"J/!3)3 M-IL:/#@R/9T14P2J/&BL-)28O H-@K2I14HTTX\&[724^5.\MGI3C&4X2D54 MTI3C.,X[)2F-A*<>_P!,8QC\NW3];/\ #KK6VX>F:_;=MWYVE:7IE:I@BH1( M0)H>88$HB,G2Y-]QMU]HU;(<*..(3(6&?@1[3<<(TU3;-;+*9(1U*CR8 M0AB( D,QEHC3PT.+$D-Y2VKSUH\O->BMK>)C6]966?.C#+K U?7R9$,XS!)Q ML2:F3Z/1<2XC.<];&73?3M3:O*7*)L0EKJD3[ M[ 7#<@W295@TFU0UCV7(\%<8^]#6385#8=<9BJ:DIRPTXMMO*4JSC.KSEV34 M;,,5$>E1H-+]MS?1LS9A0L2EQJLBG)E-26?94.]PS(F,R5H<=:::#MR7RLA) M'0]EO\2.:.K/"UHE2V6)V7LS:UVW7-K\Z$2"B;9$C-0G9(I6' M0OVEE2B!LD>CB7TMRHHYN4-%+D,M_$PWHWGC*7')'P[ZIO;:D7>L7Z.M MXCLLR"BCOT)&7(PILFH-55]'M,\RW*DP%)9FFI*EFI!]I*EH:6F6GNVW'6T< M*'7$JY!S^(;MF=S/$S@O/50-=@T21ER(Z(-&13V:%+4AD-KIBN^?8CON%3T=E:*U]5>&Q2=4;HIF[!FU]DV"QUAYX@3:M60QA=J-$!! M,4:*%BSD9)1MPDDEE[#++R\1LQFD)=>\[RUN)6^#M5K?*XIRM8OEHDV$F4LA M1RI/CP:0+3ECK*ZR\TW,:8P5RB*POXIE2GO,M_'E=SEO/;JPM#V?(UG#>.W32[.\-2'L.[[ MD;D=N>L#-E6(K8K141TJ L#*>,*3B7" M;AL.CH3L!+"&XC+)$?/5F(TTS(7)\F5*L^Z.J9G9ODJ>U-9E4-MQNHU>57IJ M43:DP7ZM-:[B5+4IB8TL%]HEMQI*DL%)4.ZL3>NE=NO:M19%*E4[-KS+U$RQ M3\FTI3M+H(.',-M M1&DN86ZM= N'.LHW&(9Q:MCQ*ZTP6R1^&-D$0QMCBD9=@)V*"<&R1K26!A@/ M,)*3!E1VE(6RVIB8S)C2I<=Z6W1UFL9&RE&=[YF@P$'^S_\ 94MAM1C*R^7> M_-+5$4LQ5L*=NM94R77"5<;B@H@ZJ5VN=I4V/[-)SC674_VU_P"44/EY"9R< M[",(:,PHJ2&TU!N:U&2EEE*)*8[*4H[IA!0@IIW9\(H#E+%=(AHAC([+,Y:E>K.:4N;)K<&&M]C\?:W MQQ!3B6N:-53%?+"55R/!GSDK N3GU8DJ,(?;F22\J?(G%R4CSS9DUUV2XXIQ MU6>IA='6MIW9AD2E1:I#@Y=C-,5F$:;40N1.D.OTY6\!$B3*=D1H=[$1HKK+ M(*4*" 4(*=[6OX@>V',-1R]5:OGB?)F96JR:]0U-0J1"CQ*XG:L.P8%.BP9] M3MQ),^HQY="XAD.(M=(<38G$YRXV!NNQ D FW(@B,GULB;&S8 MVI.8:F&XY82;A-YA;0UMN+AN,XYEIE24X6M&,9<[J]^I ='6\B95R_!J,*K1:< MVS4:=1&MB$EN9FR4PN-(K*W&XR'T/N,.+;+++K<0!1*8X58B, MW*CC)6>5.OAM"LAXM6$"+4.M8\V#B#99%B5!@DAST3#9-EV/F).B$WFY..V% M^9IA:<]V^V<-I?B-2=-Z M?'Z&9+V,#=<77[1&BT4:P3FJN@[ B2OX>$TB"C M, 8U#BQ/WO/F^#;<=SE2E=2RZ.HNL MW+4]M\,>UA;:B74LF08P>/?=SWMEX@1Q.X#4?BE;K%W&=8*SAS:61IJ;"4] FQC\**AN$DR&+C)O'3P\->Z.OSFVK/=+7N/:"?B'(%GN264,"B$QA< M68;B0LR",V8?>AKS";+FS!21"C*<1 3%6[ES"M&\)*L-Y:3.6:+S9W;%,G3Y MRZ@N $Q7T*GTINE+;3,2Q\VREN*WBCJN+V?9-A0J; M3XM"C-1*36F$N379'$D)0H%*$!-JH=M7:C M5:K7JU4,X5"34EE[*,ONS(R_$A(AI@TNG.*:2L,TJ-"[MQ3 MCK10X\ZI<,N7?#.L\NHE(B6.[62G)I&;-F(NO00TU4[-FCBX\CXKYNP]AO$5 M(MM3/H83Y\NK]7OA*>R2Y%>'[K?D,QK>02M%CJ%FUW6X=2;M-S$ M*:*RXZY)XIOX0$BFJ)2^GN%Q4H2EMR-W+A3<+4H*5>W0>V3M-RQ'RG$H&;JA M3(V1E5Y65F8[,'@I7]IU+57D .1%F8U4E+4IYF>932%<*F4-J0@IK@V=X?A/ M9AFKVR7R@W8$NH&A5_7Y"QAGQPY=@'5Q\@[&)$8PET4\DL1R06^8<1/,=M]IC-FLM%Q34^1*G3'6 MG7F1'>?:1+E/LMR7F1P.R4-ID.@JXW%%1)KJG;/VF5C*KN2)N:7_ .RLA+#< MBC0J?1Z9'D1XLDS(L.0Y3*?#DOP8LH]_&@.O+AL+"2TP@(0$G1T='78X\OP= M'1T=,,'1T='3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T=,,'1T='3#!T= M'1TPP='1T=,,'1T='3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T=,,'1T= M'3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T= M,,'1T='3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T9]L9_']6/KTPP='4" MJAR>VD?Y4=$?1 M3I[4-27!M$M$V0E+T\?'S)V"/VW*'PYJ]@4E.9,.-*4A&KRZO+EYA#JDIQ^D MS*LXQE6<8QVSGMC'?.<^_69/@R*:\TQ)2WWCT.'.1W+S3R>XG1F9;'$IM:@A MT-/)#K*K.-.!2%I! OCQ93,QMQQDJX6Y$B,KC;<;/>QGEL.V"T@J0%MJX5IN ME:;%).P=CHZ:[ K;.5.8SL.DXPC/USK JG';"$JRKNK9F,*3CS>ZD94G'T4K M"L*QCXHA[/<>^%Y]LX^]_!SC/6# MQ$_Z*OBG_P";U;RQDV\1\_MZMY7=?HZ:O _:F75,XV%3,NI7EOM^BPQA.5I; M2ZI.%YV7A"O(A:M"7K8SC" M>V$);V?)Y<*2I6,YQAQ>!^*>=O\ :\<+#J/G]L.QT=- S&VV MMO*WKW3FS*LY<7A.5HQG"DXZ[YB;92\G MOL"B.1'75M]Y*Y+3+3&%K<5]DG M_P!GP_VNAOY7Z86'4?/[8=SHZ:[2EW([(U10;T7;@M%+/6X!6>@9%FP1_P 4 M^E:7EPX1%^3.AQW%MY<;BRY,B1'2OT77W5(RXI46Z=;!XE_"IZ.F,%7#:4VV!:T: TZL2"="DVB;&8FV&U)&F!] M@&A9@ELVW"K8LC#<8*,38\IMF,00I#C,D8EG+4QQR/0N_P#IA5O]Z3'_ $YU M2%7_ -%7PMTZG3?$V\1Z-N5_'X>5U7T=)3T+M_IA5O\ >DQ_T[T>A=_],*M_ MO28_ZG@24$I'2A:_-$E-+5E*E>7"I]"[_Z85;_>DQ_T MYTXO _+P\?'Y'IA;Q'+KSMX>/R/A=5]'24]"[_Z85;_>DQ_TY^W_ S[908@ MXC+WSB0*?QGR?#_+(DR+E';S>IZWQ<^;Y_-]SR>GZ?E[*\WF[I[2#?D1YV^^ M%O$>K??Y'&7Z.FNOV[],ZI%03VT-M:RUN#*69JE##-^OU3IPDC/4H! M*QEQL.99I$AAYAD!'?<++>:<:Q$\Z%)Q&GE=OG=VIMJ<5:MIW7#6S!NW+?L< M#=!J2 D9*CQ0VO9)9)N\\AAONX,-^<\"XX4H2M3,=P-)4H!;A0BX*@<8TF2W$:#SH M64%Z.S_=H4XKCDR&HS9X$@J*0X\DK(!X4!2K&UL3GZ.HQU>W[GMFS-I4I\MK MZLQ*#%UL[$7&J-@LBIDBXU1\N:962EW*O8G1QA>'(C#2#(<5\7!6WB4/8F,O M]W1^2[:_JA4K^Q@4_OF=8(5?9)Z?Z/\ \U_Z>5\FUN8V!Y\P"-AXXK'PNMXCY M_;U;RNYG1U'V^FMLT0,R9699MC3D]J"]!I6ER!PG$;1*EPT_#Y:<<=99P9R%O10G#%-C]DQI#\N /F.RN)U[3!$$)>'E2 MH)2>SLR1$;D!DMQU%,PWIK.,3X:8#L]2W4L07 #8@@^/#X:#\VIUQ(22+@CY M_;Z8G+T=-DD/ME6,*3L*E=L_AG6!7&<>W?MG&=F8SC/;MWQGWQGVSC&>^, & M?=8-P^SEG-5\]%EUJ0;BR1%9FUM^'(A%H0]UEY,FSV)N8S(:GI<3E.(JV'(^ M<9R\E[LU-_ @'G^6VMK;$]?0Q%M[$&WGM\/'#F]'1T=58C!T='1TPP='1T=, M,'1T='3#!T='1TPP='1T=,,'1T='3#!T='1TPP='1T=,,'1T='3#!T='75>% M9Q]W/96,XSC\L]LXSVS[9]E8]L]O?MGV]^F&#*TXQC.58[9SA.,]\>ZLY[8Q MC\\YS[=L>_?J.&G>7G'#?]OMU&TYM>N7^PTI$M\PT!:-.#),$>=>JY$K6K'+ M$Q*U=@HVRQWJ^1-TDQ8A$ VVL7,G,S<>CFD:[&M=H;^XIT&=<-U;3X/V M+DCS.G6$K6LRGMZ5J?&G=4ZTZX M.P;WKD%58<>/Q]HN][EL39U9QQ8\@X56SM+F6.K QA()LF69IOKT\^IMX^-C MXD'JV]\6T _$2X"V:TBZ/7.;'$\]=#AV'6 U1#<@]5$[,5L9 C M@1 C@4.TO$YAB:5S@9$'1XKDN1/_F-II()=]%;YYBV?ASKC6^G="[%T#4:SL>@Z M6QR),W:Y7@=M>WE;K> Q&5L"#KTS7J1K=6L*Z0B0@V+6LW9QA.5;ZO*'U>O? M@?#P^=OI>WGBY$J7& QI(P7FQQXP1 F%"N:R^SLSG1KG?_ M !PL_+'7_(7^8W^.-A?U$=\8\Z>^?ICS8[Y]^WMCOW^OM^WI&4 M#8U&VG7$V[7EH$6^M+.6^M)-!)6)FHD52'1Q_Q)55=%%QV<9[?M[9]OX^M.W5_-CGM<>-?(3DB_R*H@.\B."7/?96Z= M6RN4&N[CL34VZ]9:WLI?77M>O5C8CNJ-J!-P:?H&Q M=H:RJ52JE=S'J%?UKM2U;#G:K>8.5K,[7(14&&EN0>9, ;WM?3[ Z/&92I;LA]]IEAI"<=U*<><6EMM*<>^5+4G M&,?CU]DN(4GS)6G*<8[Y5A6,XQC\\Y[]L8_;UI^\W=CD[7J'FQH[2?.#:O++ MBM5^'6@N2EXW.G86O]G&-1;7;Y05.,W7I&\:#48M:BT[;FDH!S;=CU@1'NO4 M0=0$VX*NKTVT-C'9NDU]ZS:]M<2"QF ZJ(TOJ?7A]? MKJ-B5CZ\K_KKC8G\Z.^,>=/?/TQYL=\_A[8[]\^^,XZ3-7N],N\,F0IEMK-M M@!;'9*<8FUDZ+.Q!-MIIF57;=5B<@7*E-0;%5C\&:#L824MHD$,1)0TE&C3& M'64ZM4/F3M=3G(RZC.=]Q/\ *S2/BXWCBMH;A<]9]8M!]HZC1RDJ-$$ZGL^I M$U=J^W?[2ZH/W*PL;H9*,2==PJRV9B%X ND6EDC(.C;*WYO7>FBM"8Y&[/U; M1ME\M?&_K5]):@10:K<3]/XX=K\NGGT]^%O+GSZ8V.,J3C&,Y4G&%=NV_T[9SGW[_A MVZ[8SC/OC/?'YXZU1]*\V]N[29XP53EYS2N/&G5$#1/,0D&Y 3FM]5&N37( MKB_S;V/QR@URX6@Q4"5:*V2GZ/H55VF=U!3Q()O:UEOY?$'<>V+3.N^R-E:.IUQNEL)#H8>:?L!MF1+GDI <;::0IQUU:6VT)!*EN+4$H0D#4J4H@ #4D@8(; G,L_"CIA"'# M8KLV?,>\B5K]*+$8>?<\B%+RAM6$I4KMC-/<_P 3F[;8JA"QZ!U?6]54Z"40 MF7O;E]<:Y3]?Q:\H0D_%(!=84ZV2MNW(K8Q,L1*KXV .@QFX9B+-GRENM.C, MIL7XE\VX[4O?%#=6L!BB=PJUDK(2Q\5K18.0B8-G)5TE\WH!4XVMG5ODQI90W2Z:]2Z"5 MC;+VI4ZC'?&4,@FC6H;EL80RJAR9B8HD.N,REQ8R'N)Z*EN2Q MWG>HZW+N5&G%2TUEE;3C2(8]E>#JUO<+3S:%@A"1Q+6M#6JG6'$<8% M^7 OQ!8'*\A:M86ZOP@&Y: ,?-EYE/R3(:NO=59/HKC-UHA(LE)P3&ED'XF7 MZI:&6RT%F;&D1)Y>*I]V+9AUJ6\%-F5[3/+ K^AC7^VMJ60EKZVZMK L^4I% M%%7F[E;O42TT:6N$ P?H(2K:VK]=>EE"T)3.F6+-@",0P)(Q5 M]O+(A$![LB+):SGV\[3BL)S]U?E5C*<9[&<9^G^'ZOV_JZ]S;<0ZA#C:TN-N M)2MMQ"@I"T* 4E:%))"DJ!!2H$@@@@VQQBDJ2HI4DI4DD*2H$*20;$$&Q!!T M(.H.#HZ.CJO$8.CHZ.F&(%R8!0GO[FQ""G)=;)OZ'XTJCFAX0;8YL3#&.0K\ MA$8$7C3!Q1V;$:?@8B28SOGQ*SEI.'TM9Q-@>XXV"&O,^GC#8V"XK"\N91AE M,5C+G;RX4XI:6L*4UCRK\Z\)0KRX5E:8=#UX;Y'\TE_OWFQH3CGA.(\YH9)4 MXN%R,0TB*2?=99@27%J0B/,==;1'>4AU2TX3WQ+-SCTVW,HRO/E[XSLZR/\N9'6DT&VV_X-3OVOX: MXU],TBN'_O&K_P#%9A_7'J5,RW%]>2YB,AG+679#F$NNMJDO*]1*_*I2&(R< M+84E")3CS&$H;?0MM.,N^!F8[)C*]''D]%R2B1 EQFE-04)BQE)@.P8R6I+^ M6?71E"V$NH3A3N5J4CT>F].6F$*"$+ 405.BX#L=J0+H@1RX%Y$2:25&BDV@ MX9F;B0AV/Z\0O&A0YST>-#;E-KRO&%==*=>0IL*.L28=LC(E+(CA;%AU_;*6 M5S+@SE?%)P(-"HQI HXM+/R:9+=DQ+ W'1,A29;3.9.-;87*?](:@#IIJ-#M M:YVMIC8V-KV-KVOROAQG9^,1I\.2Y)=G-XD2&6X+K3\[&$8;:DY&MJ2AQS [ M,A+C/Q+:GG&W6GO(XK..W=N2WZ+3",+>5Z>68JFX:L]D/>6-CT9+LB*K"GV\ MIENXR]B2ZAN0XVK.$IPG$LN8Q":'/2&IF'6D99PT/2,>F/,2<8FM0V\R66L( M\F,,=X[JFV(ZHZT-.QV9*G?5(95E45,IY^) PV]ASU4-*80IV4CRMKD1W%0\ M-H0IR&N3)92^M'F<;D(<<2ZESZZ^.OEL;'UKB,?5F0^B0Y&9B^DE#$>-$DQ\ M,-IG-1O24_+;94I^0EEAQ3[2VIF5MO,I;6RZZ[(PA7OBM,83'SF.B(EN0WZ< M5#OG:[K=:4SZ*FV<*PWA]"WVD)4E"&I"W'$J0\XTC"N$<1RT*#$0^TMY;LK+ M)):<^9#,Q$,EE"U9D2,MLYDQ)'9*FHR''F5L*SAMYEC,1WXSD^.AI[*LRV)/ MHKB+\T5Z!$E-I9PI;*E,1GFLNN-M+0M,N0EIQ+GE]'#;$6]VE^OG?7I>^X!Y M:88:;BFW(:XZZ@:EQ<093=*&(D0TI2A,5Y*G\.1TH0I2$X:7C*,)2K*<8QVQ MG..G;N1PQ6ZT4- :D7O):"W'7$JH*8$@%BRG9D:.ZW#EV(B)#,KC1WGISF9I M&,A;$5UMI2Y"V6G&OXQL.Q=!:JC/N.NNL5& RX[(6A;SBVW)":Z+T>5C1$AR/+ER4ZMIYZWVUZ_E&OOQ M4J^EQ;3:UK6)TU)P==5Y[)5G\DYS_)C.>NW7"L=TJQ^:EC6U*SG/EPE",YQA*<8 MG#U!WC>'4(VGLLBZC.)%L.;N<7E7?OF-6>4NV&X.<9S]<*9M"NWMV2E*,)SE M.<=3BZI3M\?GK?8;WO[]=<5*O?7HGY #],'7&?IGZY[>^,8^N_9*59]NW?VQG/MW]N_P"7?V[]58IQJ;\A>/0+2G(C M99BP6*WT %),\BJ;2S/B3<)@7*?@)4M:827J6>67++3UMYI[ MDHFU*Y3N1HEG>&P]#:VUQR[\46M:.XWZZN^JZK3+E<#^_>'8NB!*.,X[LQI9 M:+KJY7ACDCM79-B!NC'Z@!&7,&1%WJ7.RUJGG?#6L!J?JD%78$6XI1(U)(:Q MII*9'%6R1Q@[4*FVF<3:+-=6Q UI"AQ_B281P)%@0U2'VHV-I1?\8^3<#\(S M!8W&G^8JAKSOU)-]AUQ@U&_L[6E[U"E>))-3A]#?][XD)IPM.G;UY%C3$&/& M. H6BX)>4.)-S0Q&9*U^0)O2!<9QADH*CM/S)$9, PN1-6RS'GX>RQ-;0B4W M48]/6>M6S<6]B=>)HEN9&:3R8&/QI XV G3J04,Q!=C#3XL0H$-9#$QLN2** MLM$(27T1Y3,=]MR.U)SK4IVZZJ_]X^NAY8V"M_\ PI^:0<'2!V$;*A!@=0=Y MF-++V^HUQ3*^Z:O: M_90ZG)\^4YSM'6:L>7.,*SY+>.5G'OW^ZK&/(OVS]U2L8RG.<*Q)V]XV\QTU MQ W'F/KA6C1AV,_EPA9EDFLM*2EA0<;#PAW*D*2[AV/CU,Y1C"D^3/W%87YL MX]D])>JZCH=(,3K#5P<888GBV \Z1EI7ERE6.R6\X7VFY\II2VI#;* ME1\,N90ZD$C0GEU))OIJ-3:W/KK:^MUS\=[: ^8&$[JFTF;0,M>3;D1Z37MC MWRHQY,6-\)F2-K9Z0/&ORV<.NM?'*B);3*=8PRR\XC+J(['GRWC(/?ST1W^P M(S_QE!=(_1?_ &/V7^?Z;]M=_P _>U2,X_X,X[?GCMGW^O2P>_GHCO\ 8$9_ MXR@NH'\H_P##\B,!_I>7ZC"GL=DKM/ F;5;3P:KUBNC)IJP6.Q%((0""##8Z MY9$L9,$WXHX6,@16G),V?.DL1(K#:WGWFVTJ5C$T?85#V;61]TUM=*IL&G%E M2TBK;1[$(MM9)Y@2WX$[ \_7YA$5,S#G1I$.4F/+<5&EL/1G\-OM.-I1G(73 MT#D#HW;6D2AN?6H&U=?VBB2;",B02! (BR"WQV"L. 30X.G/P%NIDMPYR%1) M66_0D8])Q6>M??E-X=FNZ(Z>M:LP('K.TSM5[&#ULFJ7KT:1I%;-6\^/C6J[6:>)(UTM\^=[>0Y<^N M -M3>_2_2WAN>OD,;("[W26[DSKIRWUAO8$BN.W%BC+/B47%ZI1R"!+]H:JZ MIF#KE=8*N-C'CB!^1;1!:(2Y29*DM95?50O&_B7H*Q\J8_('7=DW'")\3@$' MC!-I%SIF*T$DWJAZI8ULW8H%G-"V[390*=861AV0$%E9=$*V8R-NV7I-@AIR MW;UU5U^7P'ZWQ&#H^GUZ.L%:(Y"76S\42=Q6"LD*5CC;(J)$GIK\]X?(:A'% M09_\PS$B)*VB2HLSO%D8C99D8RTM>.GR\]![SRQ(%R!MU@J M,E3)@^-/A2)X_P!+X^$Q*CO2X7KI\[/QD9MQ;\7#J/OMYD-MX6G[R>^/?K(8 MSC/OC/?'YXZT/>)&UI)S;H"AGKMLFB[TA6,T[;-DKOUM)2CYE,J=FV7&TM6, MVI3-HFREMOAL0(L%4N$6@DX)8!#?PL?L-UGFSR*T*RT(W!3H^\Z-#@J;8VE5 M'LB+&-4R\TW&A)A(<7+/,B9#C*_142*$%9FE.N(A9S;>:1+ETZ0 MW37D*=9J4 N5-AM*5*"FYK#+")D=U%@%+:CRHI-S[2$\-_8,T=CE8R_)9AQ: MC$J3^ M]26(,Y#\)F0V,XSCOC_AQG&?X\9[9QG\\9QC./QQUU<&H0JG&;F4^4Q,C.BZ M'H[B74'JDE)/"M)_*M"K+0H%*TA0('E,Z!.IDIV%48DB#+844/1I3*V'FU#D MIMQ*5 '<&UE @@D$''/1T='69C$P='1T=,,'1T='3#!T='1TPP='1T=,,'1U M";EMR$VQI2PZ<$:IHP>_2;G+V--M ,N&V Y)DU^BT])^./JEDJ(XJ%'WNSV! M\13Z?5K)!>?MQ$Z[-$^G!J=B=3"F#S;YLYLC$R%Q^@VH*6(T.H"S$L=L#7>H MB^6#VS7SMRKA.VT_&RJ_)V;$C5VB5B->!TT%7K%4WSD]+H:WUI1RDJ TYW \ MK\\5!)/EU/F!^OUZ8M#K6BJE5][;6Y!CYAQRZ;@U_I[6]H@2)L=5>C M)E-I M%ZC*$0FH+4R,6DR=N69!J3)(2VI4>,(;B,0LQ9"I;B@*74*H\6D5FL5VNOGR M*S!UX$$%AG319>%863+N#(D190@O"E85-GYD2E84K&7<^97>F0-S:YP)O&RR M+.A5VFJ("0#HJO?8/<==B:X: 5>PS+16GYA+7\0]>-A03QD"U=V03A,')AT, M] UM (6,S!&N+DIS(YBSH,5<;CVX\!DD*O46+11PFR8%B/F)RYEA=V16@5]H M9*&)U2O'$6/3D"-AI M>P^?W\<6^I@043GB:(<5)&1&8A/STQV<3'HD5UYZ/%=E81B0Y'CO2)#K+"W% M-,N/O.-H2MUQ2L#9:12[BX*=MU4K-G_F//E?%Q2M>T-RT.7==,J;ES>A*&NV MU=<"KL[@Y;"HJX#EA5!R8G]6 MF;PF:BZ%M<4,G;DDA[8DBFSD*D&F6#$\6S&AM#IN##TW$N W$C(AR/4C(CLI M:PTAS^IQ3B+O'3B'I[C,+.0J,*=*E3FT-Y[5=M]KC 2=S@E^06UK3N*\@1MC MB!!L^'4V+7;BC(0,VO/PPI$5B?((RFW);LC, 0B684? @9A@<1=+P&L#X>&X M15YR6Z\2B(PQY8Q!UV?-<=G,8;E.+F2EK>4J2]ES+='2UOI\,,(I.M]?(.&K M.BCU!-DL0WAUN%EQEES,-"TQLK:;7EK M*FT93D.CI8=/0V^&&$B&H-(K@F\-_DK-;F 1>Q@;7R MKESO@.IFV L MB$IV2SF6QH9$AUY$3&&R,TB[W>S(YD"%CR&94<2-8DQWR4EB0S B-/L2#+N' MRS[+S;*7&GBCR4ND76UIEB]4ZVTOK@6H+0=4T:K:[IHMR4].D0JU3PL,"'9F$9.52R<_X M*"TL@4F+N.ZCSRTBQI/&/?RY--#;!^7Z@V"9C4RPPG20:Q$0-:('18^ M:/CI5*F(R3&Q'VH\++%+2@+X7>Z6FZ02W(2 M6'"A2ORH<2EPJ;42 %@<1";XU%'N.%\B;=#ZF/6*$"L-L(6QS$L$6$GK/+I- M4CMS"%WA5X04E/.Q2K+K6 (XBC,IQQDCED5*;#X: 0)Q!!:,]%%B9JYPIR7'C M/M8A(D_?4^N- !N-J!(F@"9):V56I[@K/)^LNQ %LK9NH5);QZWOW14 MO#Z-G(^*?U-NGEY;"9JEH0@/!_,S+4*M M9L0[0*'/I4ZEF/3I.=ZE)@5&FR($6--J;LZB-1G7GFI3DZ/$1(7$B=_,;E0& M784Z%W%4>I_N4^9_>-/2$NI6RZMB(R"R6Y2W$-($HI3WBVDH*U,!;KC*6BM: M%)4MU@8^''6E;ZAT&LXKHT+4ZWJW>&X;(]$H-BL!K;'Z6TP3>I8_VW=E#*]( MJPFB463+%4T3'@N'Y<8O]I"*Q+9I,-3C[;):PD=2;Q.:FLUQLXG=^T+V#=WHB?947YZ-I$WCY# M*KV!X>5A2WF@:!PM4B(VW)'R)'6.RS.JE4H.8JUFZIT6@%->I MN6(4)F@26X!>B4UUB>XFGH?3PPVF:O#5+C.R6VPZZVU!DQ3;1_?+EL-1 MF52REDR%.!+2'A,7=U:WP9!LTE+[W<.H0\OA"4( =2IO4KCY*%7_1.N-E\A94 MDM7;62HDD)FNR(HX(&;$6=O$,W&%AWW"QYT 3+PX;\2U72?*K=NAM?UU/* 3 MK\GK@!7(Q@K:ZMMYC86[Z#0C,R"FH6'9M&;'MD;77J]%.5VM62]@I*GHD$)BH4\Q=I%RM7N5UN>Q==-$9H:M-:AJ%6M4*TP5W:J31A"@3 M=<5 M-6H0$+1Y-CLI"='<:E@I9X2\^N&3RUB%YCC,F;>+-BAF-9[&GW>08@:JU9J@ MJ0OUC+J*N0OA'9<*%&FRR%L-8BUL:@;C#TJ1!9QGO7ZOF',465494#+16S';36"3# 9E07*+4:I(@KDO-R&*_CLL.M-J4'I3C+[;O"V7DK;C MH1C<6&$QYH:/,"ID<@+*PHA(=/B.I>BS8$Z.W*AS(SR,Y0['E1GFGV74YREQ MIQ*L>V>O=UC L-H<'%0(\&*,8@C8,-D="\OP(,FC7-"\;G948R.0 M7%J3&8Y%26W)PQQ*DSF([S+4C,?&,+6IE.6LH=PA>&^\3+DQ%XI\(K9M)0MD MX?=:IM7HHQ]\BCXJ_'IP]->?PD5"FS\L!&XQ*U$YS#>/DH@ 0-N9[0$XZ7>" M;%T9QF^'!U58)NPSE/YY"QE9%JLQ<""Q(BH>7-5@@6B-Y9 MC.8:^(D>C%?I:_Q0#=)5GI>N-2QALXFUKR#JC8L$:/G/1G;);-G%;O48[*6F M76)2\A:#0+Y$A):PAQPM=!\A[TQX\DEWMJ1 C53.V6:?.5P1)?\ 9=J4KC0V M!&-+IBGB7%J2AM(:2HK<60E";K42$D8YB9/6:Y46^'O( S'+;X]4\;4Z> MM'$.8"DC3GH/'"@XF>(UH_DVL]HV[H*-WXU.@93J6WV69EBPQ(#,:RP)FG+% M69=-E6D=&FQX:X(Q]H%;B+5@67E")HQZ2V[<[&LL$5"&A \%RO5HQ//388V9 M&G2"9-N?*R=N1*(NR/D\69J5+(2<+0RTU#:D2E-8(#V,CR$G0UTM:"&G )N/ ML*K0&&3I,C!4RMM&VJ41V'0#-K"T&J66_SB4>XT0A3 )#(N M2=E(FJ.BK;Q_ <82\XZ MM]GOY6$^=.4.>@A.4N-N27DXDJ6\IUS"5.8PXC+F&D>(RTH:>4A*^,H)2I=P M1=(2FP(_F (-CLK15K&Q[])ND'47 -B+'4#E_2VUK@XPL81#:RA2V2KR,34N M8?=;:0IN6/4[EN3*9QA*UIDR%Y=C.)84WZN&G5,Q\(;=RJ<(RXXP\E64>EYD M.LY4A?E6XIE2DKRC"DX?:4G*.1K5/J0+(.57CD^N$H\Z'8(Q!I>"XJ:/)QX3F(:HY1F%+8;EZ[+CPA_Q1%UJ PRPTJ2Y*D,QFX_?"$YP](5(RPWY7%8;RKXE2,JSC"75 MXSA2FFX[XQ^A+6V.V.WV9B>WX?YM(Z<.X4VI[ K9:GWFM K?5#L=,0U7+*+A MF0A6,A]F4A@@,GM/Q);2),=B0A#S2TH?9:=3C"VT*Q0@:)/^PD#W"_CO?7RQ M-]AR!)O;76WCX:"_77#>)DPYNZP$N!.;EQG=363+7PDJ1)A*;^V]2QA]M3)% MT6I:U)6UZK8Y,M>&E)7/=9;1'8>CJ-X&ATBD[R L4^MUNLH;TH6#I@@A%<%J M0'%7ZMNBXV?@A[)Q0^$Z0GI@QGYS@:(I^3\##8EO2W79(=2GG>VXVU&PZX&V MENG/S.#KA6>V._ZTX_E5C'_+USU\9#B&F7'G5I;:9QAYU:L]DH;9SAUQ6>_X M)0A2L_EC'?JK$8A;IRP8-;.UY/BM9^!L^L.19Q3R4Y2A4R'R(J;CJO?&.ZY* MSTB0K'UQC&58[8SWZFQU7KIM4JL*X.M)=9?:N&L=Q_$3D)QA4ENU"JIM" C" ML9__ $[<#,M>,>9/G:5E.<=_>9VS;.1IM&L5E$)KRR0F#B1#1:B[@&OJ?5)C M1T)*&&8\MP?'5E_"/7Q'.F>U%L"R7IBQ_:4= M28$D&2B0&U4NZ/6^.^IV"B1)202^"#*$2HLC#C*(^'B2);.$R4/L]LM*>%:? M,A2>_;S)4G&?VXSC^/M]>I!! (YXI((-COZZ8H'.[XLU5M'._7UTXN;\Y@WF MR[SV= T)L?C%K?6NR*7%!%:/3ZS4M+S-I1)PV%QOV;IBSMS6MBHWDBNH&FIC MNSQECLXXXF$-F-$!7NL2O"TKN])(@CM"M5NRC-LSH^!N0DG8(+B)8&+K/AYC M-,"<0OM'$)2&),-B+ 4C'Q,-B)%6VRTCZ9X5E39N'(JZWG?/*2 1W?R0VINR M"(T5RSY-:$IP )?L $#@CU(USLX!5%V* @.XHQ9!XF*^:D/-RI+CKS6%)S7. M#2;E^'<;^.0$V9PB\4ODMH^':+192YZS11EKXB[#U_*M)>UF\F#EBM(T,1EG MG"AJ3((68]%2@N6C.%)1:/MJ+_BWR03:D5\D;_\ 450TM;7]^F,"I?\ ,-6Y MSZ3KMK^)P[DG3;KT&)%:KV'KZ$NK1A.4(7G&5^=O",+4XA*M=/C_X;M#(/44]!+VW5@02%$ZTVO=4(5N/5+?N0.E]G[?KDH'6KHQ48\I@S 3WE%LIF1C Y<1EPLS%;A+C-QW MXPUT@.;02;DQG)L>"X*EI1/7KHZ$..H0ZZ&6U$\3A23P G_5!NH@FUK@7U)2 M 2,YQ1 )">(A*;)! O9(&YT'7Z7YN'=.1.KZ689!6&T!QCK[/K+D22T*.W": M9DQ6)A&;\0MAN.%'.S8JIYAV0F S'00?1%$XD/"(U7#@\*)U9CH[BQ1=-TT-58D-N3\K?DXF3,IFNN2\O9C-0E)6\I[*FFH, /%P MX^N5(BH%P$YFX=;E(7LY#-)9CH+4EZ5*[Q-P$!,4IB2%Y7GXB/E#D? MH4U=[_Y3AN>_?OW=(9[YSW[YSWF^^<]\]\_7/X]+. $;&MYQ%7(SY%I<:\TI MU?J);2ZAJ(YA]3W=AM"\-HRI;BLJPAY>?59;5UG\=^V/-C&,]O?&/?&,_EWZ MU"@@DV2 +FP(!MMSL!TO8 7'AC.XE=3YW/WPGZS5*Y31F0U6#0 8Q4V>26X\^\M2W%JSTGWOYZ([_8$9_P",H+IP M>F^>_GHCO]@1G_C*"Z@[#S3]1@/]+R_48<#/?MGM]>V>W[?P_/\ M9ZH=Y!\ MC=1XY!6Z;L?B/<+8:L[%ZTQ4[-,O,^JU[8C/&>P6-P>- NXJP60VF]7?:*]; M756#I6C':N;&5>P2[6/@V&L1+XLX[XSC/XXSC^7K&/!!,AZ+)?'07Y$)BKGHRU.5&=<94Y'5-:SEN8IE2,RF\Y1(RXGVZ$$\[? ZZ6W& (%[B] MQ;>UOEBN#BER]H6WMDVZM:TU9 UY M]\M]L.'+O?8X.R[-FMURHQF+]KFBO! M9\NZL%XT!ADRW$+@H5:K8RO6!:YKEG9'QK,L>^,9_/&.L4H$'7(A2UC8*Y8U M;[H^4N%$5)@.RHWP MO5\#X"V#IFM^' 8O5ML$&GGT9NP,W1Q4:&TMZ;-)V0&3AX1&0A2,I1"@_'ER M$I;C3(\4.G3GWFVX^-:O*G*NW?MV]N_;OWSC'US[8^OUSVQC\LB^Y+2?:HU&UZS8"T0^5DS69JM> " B5:+L"A1"(M$(U>2 -S7]$8- MJFLV0$:2E4#T;6S!D<_FBI"FT::ZCA5)=86S&:42"XZ]9E 2 "2HK=2E M93 MBD))2%%0WF6Z8[5:S BH;<<2J4R7 TGB7PI5QD #6Y2E6@NH@*X I0"3IT[< M9^-\4Z_UD4,0R,K1F.[8&G$NPQSAF+JZKRRDV6F-W5F.AU,25'PMM4?UXS;C MR/*A"567ZSY)[.M@8+0PD&9:K$4*"ZA41\4HB(?+V0\0:$U\$V0>[LM-DI\E MB.[-E)[1!ZI)%U*VX;B<]]GKP->*CMHM=NY7W&+)6$HA$E M0-2QI#7^1Y&^NCLP=B75K*Y"7I"Z0*F_HX"/_#JB1SIC8R67WI0]K$/A\OTU MUB'2J1#64*#*427$*"@TPTAOVB00H*NI2@4-$@W?>;*@E%SC[_[1:G2LMY)= MJV9X;$Z92:=1:=0(CZ;F17EMR.)AE86VI,9AL^U22CAXHL1Y*>\>*09V.>$U MKN10*N\SLN_T?D5!"Q"/C+G(G+E2G/E5[1XA?$L.H!L&I0^26LZNVX@/?].C7+;;4AW7G7<_:G3I M4O7]A)P&BQD1HB]>FK# A,RT14 "2(:)DFY%<9IS';*<8_5C'W?_ !?I_)V_ M;U33X@?*[9-:Y#\<^(O'6T'*ALJR3_TV;7N@>GC+C%KNH:6^\ANEN0K!#G!2 MA+9Y+S %@$)9.-YG5-^'/#/'!DY[L9N5*4XI4J$J30YY2E)J5&>$.2L(X>$2 MD%#D6RJ2 G$E- >)1QPWFTD5&ML0'>!RGHMIJ4Q@E%+UJ? M%>9C/LG*Z6@C+G7U8DN^@^T;K49L;*;D1)LW*HKKW4^19@4 M'8I$9+8GP)+>>V<.,3(BW8SJ,XSC.%-NJQVSWZUI]SV\%S;\0>J<;'=8ZR,F MP[,VHCFX> YFT79OAC1=?7/2W)^_VT!=;798J=7;5B9L1D4&! GS9VYB[J$( MUV23'@9$FM IN3\5P^4)6@$[@A(:B2HJM=)J.9LNQ),NHI@9AI\1H.N2F#^# MU1MI-N)3\9TO0)+EM0([L0N*-DLI)2E704+*&6.T*M4N@Y3EU#+N8:U(3%AT M:N)75J6_)<22AJ)7*9'3):02%$JJ=)CLQFAQ/3EI2MT;0^,XS[XSC./SQGOU MSUK3>'?XFN[>0.VJ'1[)<,$PEE+^C.CF!0UY^(VMV)%FLD7T0TV&)B6N=$CU M,J/+J#(-Y;@&8$F.0;=:V6$]\I3W^OEQW_;VZVV6\S0\SQI,B)'EQ51))BR& M)B6 XEWNFW@I"XS\AEQI2'4\+B7-5!:; I..=S_V?Y@[-J[_ &>S&(8GF,W+ M28,@R65,.K<0@\9;:4E?$VH*;6A*TZ$C48YZ.CHZZ/'#X.CKC.<8]\Y[?_CG MZ8Q^><_AC'OG/TZB?L?F3JC7&PEZR=%[-O%G&HK;UO3J[6=KV$+H#5P)-BZL MFZ%P,-V",(')"\OPP,)TI8D#$*,S!$82IJ:YBRYL. RJ1-DL1&$A14[(<2TV MD)25K*EK( 2A"5.+)-D-I4M1"$J(S8--GU-U;%/B/RW6VE/N(8;*^[90I*%. MN$?E;1QK;;"EE(4ZXVTDEQQ"52QZ.HPG.8O'NMC; 4,WI<.-4)XX=N9#/P8<-^6-*MY<'&1SHXD6A28$E27(S["YC)83.;7!-C!TKR-+TT M;-^59DZ)38>8Z)+J$]*U0H<6IPY#\D-LKD+++;+RRNS#3KP U4VR\M(*67"F M5TRHML.27(,IN.T4AQYQAQ#:"LI2FZEI U*T#PXT7MQIO([.,9^O]O/;/[$XQ]W"\J\OX=O;J->1]:>( M]'$W'3I]??Y?H<,QQLO]AVMH?56Q;8NI.62X4P.<-.44I&+5=1"6TK+^1#(V6SEX (&)CXE$"920B)$BLJ<;81EQQSMG+CTAUF-&8;2N1 M+EOL0XK3TI]EE9&+[,63(!+$=]\!022RRXX I1 2DE"56420 -R2+#7$GNC MJ-&D^6FFM_'S-;UZ8+2"@L4Q8X*# D$CVBHRLC_ (>WU*7-;PP< .8+AW'' MFU,3X;!D-(GCXL^<>^>VTVNX'(KQ,91M>58M=K@\"B26HI"QR X=I6!==@/.9:>,F)0Z')E-K M&#%D"V4#U:[N^MT6/8FZ+G9=SU$X$DW)%7D:;J-TVC-U5:-2ZH=;8(T6^ZF( MTVT':P?.V4U+;?V:)P"8M]A%6NY;*VQ"N$3;&QMVTTL; MJ>MH]OV6%UY>;73;*"U'-M=-*A=I!*:PX6HA4/:8+I@G)!QQU%F[%D7$2ZQ+ M)0#N8/R_F/\ B:ID1C,;="H50F2*148U.@S"P[*C5!;CT]#ZF84<-SG76&J> MN8(\=,A:J:XJ?JF)*CH[^'D1Q2H*YDUM#4AGOGDH *F@4L$!*D*<+@27E(62 MAJ[K8;;*D.!]-\4GQ!- XJYBU",;)LD>I/D6]AA@FK+C]JM8LBIR($N5L2LE MX0@I5T.N+Q(%0Y+3Q>P0$/3@(TE&8><;;"B^)]J&_P"PJ]7P]3M*-<6\Y)K5 M:VP^5IZH^2C=I'4B"0M>MF#KFSZ%4CMM*CP06S6NN#VUR)L.65@!QDE,U%8T M'512#J"=RH??UW;Z3R-V33+%0*?L@_M*H[#O=YK2) ;5I1%/U)$/UV\VK8Y6 M"9M O5:QX%-+$CJ_@A<&I#1[ )L-2<>WP,7><.^ (^OMB4NML7#?]V:V56;+ M)E5*][(EW1H7H'7548?:5L2VG*U%URS]I+,@'KVV)PPF99B#D:-,Y9?;7VU+ MG99B.Y(IE,=JS&7ZBXVY)IP3(I\F'^)5J6ZB1653*738M/8F/..3(\:=%<9_ M(U*2P^E>,=QYA*KFZ' MM@)2E+:"ZZS)<0WQ)2M#G&A(9)= M2M&UQCWQCO\ 7\?V_CC\?IUSU5IK3Q!C$_?%1TUM*OZH&N["7#R+=UILDU<9 M]"E'UD6:L(OKQ:I 0!&67*PV*Y-75"CDD(=,U=,D1('6!$P?:4G/F3C/T[XQ MGM^.._X9[]L]\?3/?&,_JZ^J\K9PR[G. [4LMU%-0B,251'E]Q)C.-2$M,O\ M#C$MEAY'$Q(9=0HMA*T. I)(4$^?5"F3:6ZVS-9+*W6@\W^9"TK;)4D*2IM2 MDD<25 ZWTO\ RE)//1T='72XP,'5/7,K=%AV+M*\<=7[K,U)HS7PBOR]TW>N M371E]L*IM,.;7. Z^6RF3\($!4(!'>RI^E+%QUY6B MMF_8ZPW_ (\E=PU\+L:GVK7U?361UOI)4.:=?CPL!&FD3H\QR*J(Z\\RIF1' M6SEKQCMT>S:UDQE&3X$JK3':Y3!5J/3Y2(M1JV7D*=75*="67&GU+E@,,/)B M.-R517'PEUI!6ZCJLAMY1M;MMXI>J)MPW*.LRJE49X)] M(LF&3LY@83B6^O5^>4CX:EEY$:OO0@\J7-4TXA6]];,VYJP!R<52QQOD-=MH MTBF[?$W2C"+-$VT!"6M2HT:0)BN9MH&=)(T9F'9IT>/8*O7 1NI"V69ZVWY( MAM 6BB5,S523E^I&ATK+]/A3TA]B9'+TVG1U1('X>B((TBH-<$QV5)DP0R(AC3:DK MV1LL+?@O0 B2PVU)"9;DU$U0XW6BA06Y[2J4[WB'6PXV^A+" XVM1LVE+':( MX[0I?(FF:ZU3"U9REMNNHEXN^W8]UER)W$;7E7,"FH ^!(F.,&H[]_Q=68%I M/*!P1+\GY/'&/+[N&9T=W^7>G-BU)Z?LVI$='P]8*2HWO,#Q#OFSQ,%8D@8' M0SAR?32QBT54;)2#^-RS%"@(8R5'8E2"< EEEF*\I>.I76%VUQ::UJB_!<%: MYHTK,+[TNH5B-%=0^8%0:(=I+,>FA;0JT M1*E0U"H/MI:EQVV(L@HF/5&EMIUZ ?&U1(V9-9%#HD-G#L2UF]\J_P! PZ=J6MV[ M0^N!E>)CY,#!VW:\'%ET%\2S##U-ZD'R&%KJXS*TQXX2C1;85RK$=#TRP!VIH2 M9:300%90%:0!^;1HLB$[!0W&=?>MD:9IJL0];:JU'KFONUTT8R6OEGIH2^[' MN!%,N6,^,,%KB,+? *F!FH8XA!ALNJ?\DAF/(C1)"(;=$2M56E9KJ-1G3I79 MC7H]-JT20S1$,L5*B M1$8F,QFT1&Y[0<[P)D2P\RH\2_\ *77U+?4ZE!2IE""F0OB(XD )+@:\WK_C M#2-H:>V#LRCT.?7XFM-Z[+VC5*9!CMU:P#3I2N1-0R935!2ZW(<-[%L$,.#A MQ7E!%"T]H2KA<<39W M\U$1:*^^VI8]$)QWO.P%B1G7/.3*"IA%6IV5ZW5.T"3F)R*Y&G*0COHL5IRI M,N/*<1&K[2(E.IYE.1#!5,?65/*2AK69GEMT^B5%WO'5/RVD0&4+<48R4N%Y M*RQ'4>[[TMO2 MRSBNZ:;L4\/YK(TXSA*<9^N$XQG]N,>_7;HZ.OU(QX5@Z. MCHZ88@U&^&_=$>/G'K$I9*6Z/&IC?+>1_K*(3V,X?A0L-^;XJ6S MG#T=C"W6_O(QU1QXO!]^M;X#NEU)3 QKC4=A:?0W,DR60C(3:->'QX$&)A2B M1*1:91Y7P;C,J''B9^/>::RA%7S%KY)\PZX!MN\P)LD(B#G9?C8?AK:(PGVL-R5N-X0^VTXCV[8X0:DWO8*I;MQ!J MW>;/40@D&*./!SX:=%B YDDF+^ P#O,!F,Z.*D3! =(=9F3H3I20VS,2C*L. M9^884&HNFGU1#SM+GT*E0*DU'46Y+U.FY>A1)S,=X.M&/(>AO/MQY-UIBOJ1 M)7'EI:,5[G'X#U4H4^!'E)AO29]1")*V$24L]W7G7RHL.?W;MTM%'=N70KB M6DH*@=,E_2][WL)BU";#N58U\U;HCIG8FQ,M5K*F5X62,G";EK*<)4QT4J+5)TAZ;(J)0J>_59K[W>352BA"5QT-QH M#:6D)CPF4BQNPLN4V-,F566VQ5:U49?M\VJRH%/CK,OAX0Y#A08L6GTY*!<( M1"C-!(4JY423A:0!\0;%8A0F4,18K:6(S*.^4,1V\>5IAOS9SE+32.R&T8SY M4(QA&/;'7MZ:Z,%VFMT]\5?JRF*[,C9JV8U#7B3"@8$CT346#+UL<8+3'#J2 MLF(\,2%88$/CH#\>3.B2B4W**"WK+CRDW@;AI3*4QVU4V,I;4C&7_.ZZ[@\G M#[2L*C82PEIA:,LO9S(7B0C$; )/0GG>X^^-_P"\?/[87O757TQ_KD?_ $T] M-C@/M#!:#G-ZKRP:!$QHFS]A,H+R#^90OY=,@3/M2J#$"MPDFTSQTF#-GO2Y M IZ.4CQX,V,0R306]IQ&R]>!3JF\8S*\M,9:;D+3A.<9:3BPK7&;RO&;&.H%1C4.F5R MG1)\DHQ7AC U!"8B.U)F>EYEJ?>:BMMQVE.+<4K#3*$H;3Y4)[]O-E7YQW^F M>WOC/\F<9SC^/&.V?U9Z)%D@'D #[A;#8Z (=%-W0UZ>DB, M);/E&FH."S#L6)!D*DMTP*-=[ M/'70;886Q@9<0^+ )7]M=0.57$HC@TQC65Z:L:H:P[^!.11$5$(I;><@7%]#U^ 38;D7Y;VN#B38V-QMKH=_<,/CT@]I% MH8'6M_-$"+(F"*I=IGRRG/-'P] R0;2Y VPSAMYQA)3X1Y3#[3+JQV) M##Z&I7Q"3VOJ_;^QA$0)B^ZYP#8*OE25:,:PL_]1;XX\V % M* 8Z[GXBFE*GK$1/S%=3G)(GJ2P4R*RM./-F&DE,@Q(_P"_9QA$A;#& M;&>L5YN$CDM8:?0Y\8/.%U5%&U*\ I T#7L,V65(L-PK)PC.C MF9D=VQ3Y!&5$A!T)6PPWB.AU]7>[ZYVQL.EP:T?M^OX$UR+5BLXF#I5QCR@U M[KTB(>CV&I3%;!;>AM";<.'DPK!6*0PY CO"SK12/.EMK0\/2F_['"#0]P;Q MIMZ@ I3[\BM!],N5.I75Z 7:DU(:+T4+$LPX3*99NLC20JHE[(F--4+P' MAM!E1<\@JQ(Z#H-K@@<_C?30R+:?F'O!-AOIH=;W^^^,PQK'9EGJZRM)Y2(*U!->Z",BY6",).!Q^(^/HK48Q&6WB,^R_&GIQ+CH;PQ+;3Z;K;YV M0C.AVK7\2-*=9BE"E@CD&4^7R2V8U4*SH[;OF2I79J7':?1Y%(5E;>/-E2>Z M0%?+G8I"05B."V!JM&U/<4N^4\S<;=KDE5*Z*/2)0ZN4.U5^P2+82@ M,"8PT(V^5B>MN@'RWP-NH M._(CZ#]K^_#Z]0\WMGMR7X19S],7_=_?VSGVQQXO>?ICOG/[,8SG/X=3#Z@S MRAK;=LW]PI!R"ID1$E[$W+\:\#EM0IDN$SH*Z/S!3LER-)<;@&(K3PLDJ'\, M0P/F2?ETX?/^&G1]S1;^UR+"_P#FBO\ _ ZA_3&NJ/\ AVKZ?Y?2O'_K2'TP M\VOY[DK>V_8JLO>F/@Z>:9PXA]#>$R*S8):O0R[(<;<;RM[/G6PQ&1A[#C;B M77FUN9D!TP=8TJF@V.V':+;IPYBTA:,(P$/#V+#%"Q]>UUVL5V,(GORH!=T< ML8M"R.#DTZ6F$4NS/GC?KN1^L&>K7*Q4FDYK&X=,QXK=@@KV2W8=%V@A)(53 M J2;E#V,)0C,F-YF',1',3%]]#IY M>&F_CB+>(^?VPXW1TU X'MILK(R5V'5I87Y5"1&:A:[='%4G$SR*B,IZ4_Q?ZH(7OAKRY[T1K/[]ZTE27,] MK1C][Q'7$:RU_"R['??P]A$IMB*OX'Y??U;RNMXCSU^.U_E?PPXW3?/?ST1W M^P(S_P 9076&@@MNM')BB6Q:G+K:QS.!\:)KIV ;CE_F4MNA =+%J$ M*@QF8K0J%-03:F3ES5Q)+(^-FPE7-1K)FQGK.P:D( )!0XL,$P%9:]8@V1(R MGE)(DG)*Y#L6&W%82J.B&RW(]14Q>O!6#'A"4Q0+;KOV4IPF*D("><45DN%S3<(C M!OA\0[_$V-4V):[;N7AKN;/8R)&QF=2W65*.:SG&2#JY4Y54/1H\FVT5$ MV8X]*6-FQ[B&1(D2EQQZ,W"?I=0!KZ4,K=CUM MQJ//3,"6N\,=G@;2\@/66R6GIJ&2E+C2FW$DI5?'UNSV^Z5#7] CIE62WVH! M2:$+<3E]E^VW$Q! "I+T?&6U.LIGRF299I&4.*%#YZD=LHRKK]+OCC0]>:&T MQKC2M 5&;K&N*N.K4-_"E^N6EQTK>-66>Z^XZ_+*VP\^4LYB=)6N3-*EYDN2 MXX\\M>?S>_"[WEH_3W+B@;)W?=44ZF5@)<9=7L$L2^7K4/8Q<2BLUJ=;)D!B M=)K0,6+-64G%MC<-\>,/Q1'S:4*'NO%8F\]1]TMSAXDR(+PC Q%9FB#8:*/1D(DLTBDTQ,EA:V5M1YM1J M"@N8_&=*0U*;CQT1(_&E2^YDB6V2E2E7LGVAMK7FF];W3;6R[2/J.O->UZ?: M[E9R&)+D,)7Q3?KD)[S4!B5.?PTUCRML0HTF8^ZMMF+'??<;:75B%TC>J17- M^\W:;8!',3:&UHA';&HR&ID/.B3X)<%J#HD/2:S9KN:JTX+10)5JUD206T?$ MW=T'%AC1WK-!Q;,!_$DVU;N4NP=%F-2B4P% )09K9 IKHA(D8AR,19MYW%V "H5!C!12)HL.1-GS&=VSR*MP2O'$$:-1,S]0T\= F.R!4J-7R#J[S9%):4VS\ M4>N[9"-B2UWRH/5*LF++>;E(]/:D\37E>]Q>XO6 [6BK8J_[!D/4&D3T/83, M!+FBIQ*T7."UAQI2Y-.JD(D2&X4XVS]H7@+*_54\B+(_.#L#SI M-24-4="N%O\ +.J+A_*CNFR51F5*N!8K;+[FJ>[1':N1WJ$(1*=;0:K4 M?\B8T-T0FE<*PM4V4;#V96-TO_$]>FZ& M7X[_ *972 ^X&/M>4EQFYL>'B92;A(BMBC EF$R^^IAH(.%05AB4W&)DR;8; M"5'LC84F*V]LFXQVQVQ],>V.M:/_ !/O:M<5NC%-/R'8U=V:(A6J)\D9<^&S M8R(.V)([-7:8CTEQZ'LVJ33=1'*!,(6 >UBFJW&DDS(L]8(U9V7.MODF*S&H M#'=1V8Y?D3)#G.*6^9*R,;NOPZ!]%A3&+/(B%&$*;9JF"ZWVG\FJ=R54"--H^PJTS8ZV M'KRX]!7;H2&DZ^)%(8O6Q:P':WLBBU*RQI*;4/&1W+ !2]/,52; 8(88FERL MUG6Z;N2^%(\RP[H:.7JE[OL6IY>MZ%,J8'9]LB"=2:L [3W<4GM6:#K.Y21+ M O&K:_6+ >)U2,0AEGHM0F_%NP=!,W*/;JD5H\]J^ZU 0"V*1K/8VH#J!8:4 M2==S:Z[JL'N*R$HU<.4W$=58UG8;? VD.P=FXK67( UBDM=@RE:#[4HMV9J0X MCLFR$ZLJQBJ>3UVZY%Q-,/#18(0$H1XJWA*04K0> WBFU6^:PVCHX^_;M>2* M$Y%UG++.Q9HMV&T"8NUTF@#LV[HRP+Y-5N_*O"*>"S#HP"DQT?&65I;53E5: MX-QN\J\@:\*%%H()^PU?=ME';&K9\H%K+3^HC>O(U*I\8X3VV\'#*#"Z90!B MA1V),AH#N5F1B8^N/VQ+* =MM<@3JWFUVVIRX[033#"#"JP2>^SS##-LLH%R M!.K-7)6<+*%V4W6HM@M:E-,RHA:T@WI"Y6/%JQ(I=!CT+-G9Q[!&[NE2:+'F M.-I@YAA5>@LTCV_,!?13)++A>+, /JC-)=6^]?2*UN_%DZ]HDF#(F2X1.PVZ^W\8\RI#D MKTWGD8?4O"'7$XPK*UZ_3:CMOLTFEM2IBZC):IT)N1/<0AMR<^B,TEZ8M#9+ M:%R7 I]2$$H2IPI02D#'@LHH5)D*;:#+:GWBAE))2T@N**6@5?F(;39 *M2! MKK@Z.CHZV.+&#JNKG;R@-ZK8$Z1H4IBM[#V_1;Q+@;-*%IH41JJ!!D@ZN/LC M;L&I6^3./%++:!P $XT-6/K)27"L=ARLX)NPKIM;9.MSVR=?TS8.L9VGY@#?\ /H%;"Z^(8IU4MVJX5'"2QI]_:&\; M&4-5 Q8)\<@(2*,!9D>PB8P5(_'#]HSU99R?6C0:BQ2*C[(XI-6ELOO0Z=&8 M29$Z1*,=#CT=LPF7VDRVT*5%==;D H+86GJ,I4Z%4:L$SWF&V([)?2R\^PPN M6^IUF.PPP)#K+;SB77TR%L!2W'8[#R6V)"^%AR$U7BKL4_64=5>KU&COW2ZSXUOBU^ M$J!>SP^WG9>06E1%ZN58>JMK8+FZX?A? .#QTDB%?9\\P0TZ2+JS'PS,9'DD M)(RD0;(//"DN?S!Y4ZO^UK+7268$"R0#30('M0O8I6O#MM#&-@;B=3?+.1 V MJ0Z3KMK--*)TT\.UN@Q=[L+9+2 ,Q Z/.;C0Y+.T=PW<'/<5] ."8OR^ O55 M06P)^ 4.P$RH8UZP#$9QEA_. +_JAL29+?Q4[$'$Z4MV3)==7Z9_#=/KPS'7 MG5R0="N^7!FMRUR)(JQBFW8TF8&(3$0Y4:4EES$G^NJ\]D_P :<9^N,]LJ MQC/;MVSW[9SV[>_?MV]^L*I4Z%5Z?-I=1CHEP*C%?A38SE^[?C26U-/-+L0> M%;:E))201>X(-CB]'D/17V9+"RV\PXAUI8L2E:%!238@@V(U!!!%P002,4[< M9.)=%XY[-$;#Y'W+10&]U:NN -)TR-LXK8&J;&)RYZ[!9!QC:J@!F4IX8L=5 M:."@ D0*#5HA*,P3,&+"8*.I+D5HD-I+8(@O6-E5H?*MMDOEHTJ*@:8N>[.2 M]&.WHQD_=86F@==MXFL&ZHBR'2MC$6+9@EX%K298'VI$@I 2+CLP7L!QXU?^ M0YR^?N1B-KM^V=KT?D%/Y%$*^X8UH,U&6'"!)B& M7R860MB8)GEBLE>&KE&M)2EU$)F_[+I92]ZV,JX_$4DI0IW8'%&-M&_ 3.L* MA%MQ6NA'2CE4=H>U8(*?889N0&L AV(1'@)C4(?^?]8[0>SV+EO,.4X?9B^Y M2NS&M_B,.=*F5:6NFSWLPNT&15:T\PN#44O269+DE3:Y[K3D%UKC4Y$8"FO7 MFJ54ESHU2E5X!VJ,)9?;2PUW;C7LO?AIA*^^1W+:DKXU=R2MLN.V"7U!5B(H M#J#;=5T[Q"U:[LS6.RN,X1=OK.N>0M-LM.@;;J#M8E4BYFYMBK+JXKQYYJ^R MCD"U4LK\^HML(ME\5IX0X_$S73MK5.-08VL(16[P#A![*1U:[7=)VZUW,AC9 M0RM4+?0J]7:\% H$W87G[<3I3H9\@"P J$>@2)BJ[9[!8XQ&#E^&FL;R(Y:: M3H!2;L [#I.V['=ZC%>;,:Z=$UJITXB,VS>9(:UHP?'U.0=LM HQ@./DOCKV M41+&Y7-'Q&IN?CSQOXR9NRW;N>UP(LL.SV>\Z@!![TJP9J5=-\?#$.F.W2RZ M['DA,"U;//(9L;@]^Y-/LAM?L4Q+0R0XQ(CJU.;:G2<[9(H':5*::RWFA>:1 MDFG2*:[7$TFNY:I]$J4U,5-+,MB(S(8A.N4^5)"%*48\JEOWC276!GT^)(IU M=7169"I\)R#^)N(=+/>(FNR0;EPV4>\4VY( <2IQLE7"IQ025O[XV]X MU2\[E#52"\JOW#:(*'4M6!]4F+);=;W.J5^#;-B2!Z,2[B%D$KO*L%>3 C@P M[MY K+%F3$L<*5%V+\8QC&,8^F/;\_\ AS[Y_;GWSUKQ>$_3+AKWD*?>/9'P M(FSM1W=^13PL=J>'I4R@7#5I48$'JQ(F_8#,=.T#:"M!$R8X>'.Q';F05$XK M.8.P]U]/_P ,<6EL=E,!VF"&I,JM9@36-AW/<^QB MMP"J2=K-?'V(N/#475U#FV@>,;G3AX*WV)(9#*<1(SD7,=7Q[VO9?[9IW:.I M[*-/GRJ),IE/33ZE!FQ8\>FJB!?MS%0&/<8>9DR+(OX0A:W2[[N9 MM3CE9ZVVXZV;39K7NS]/!^3&CK)QO5O38A2ZAY58VQ,'T601R,K(.A@CE=%Q MBS=%M%'/%"):R6:6Q.N#[UX@I(00PU#F<_/(K6=Z]4JSFC,.7TTRI9=BL,U& MI9AH$ZKJ$EA]YIPU& Y)F,+?4XZW+IT1A$>A)>H[49$20^CV9[KX[$&+%1"C M/K#,RZHC##T6.IME(2^L0W&5LO.-+0D=Z^AQ^00ZIU3R5*4ZAS-6:KH-_P"8 MU'%:1Y'US3FQ+B3V*3;ME*U^8&:[J^O"M:G2(-1H.-M+$8V4Y.LV!P&H/#W' M(QH&T=+^5QP'#1AU^4/Z4CO,JNUBUP3KK-5" M;9L'E-F!"[D+(2[&/K-8 ,R'S@_ *%(-I\SSGMV1QQ?K^N=X2-@1[!F9.JQP MQ9=F[ +R+E9+%:A$'T:P2DVL],5.(R0BHZ9P-F#)@L5V(-\T6..3A]+C(:]. MC]RF=(HO>GM34#4.EI-#B;%'5.@(K-D^6&JJL:*V'L6T2H\0Y9JZYLF&%<-? M'/*9K9:P02RX[P_SDXW)(KO9_554(PBME\LO1LH,RS+9E"0AR&W'2W(C!IASA=2VL( M6F2L>T.EQQ;0[O@ 4&N-:P5E+J?O5:WQ5]EU'DGL6Q&!]K*6T+?PFQ]Q4+9^ MLA5HF!6HB"$&86/:Y8""H 8@83&C?*2#+@N)A:4Q$SE8V[J^UB:_O"Y MLV/CM(*):L4P?LRA7*RTDEA3ODK]FK=^"!&*58AA12(ZHJ6RL6?(+-LCR . M84J!,0VP0EO%2J?.I5)#9-AIZ+$@TXQAINMB!;J$M2"\2,Q M$F/-,8*D,OON$9BH[.9"X-:!#UNXXUOI(?3M^6S<$095QAK0LR\AM1Z=-VW6 M_J$Y5FMK)R='<**Q"0.EV 4NN(LTJ)%?G(:GD)3LN1S,]NA9XJ<^52(6?JVX MY(9I-"J;/X4Y6ZO4:E$1*E,3XYC2J<]'E5%3RBT79$B(\I!1.7,R"-2 V@\$I)%U3OWWF'T-X8NC:O4X4[>E;@[=V29(SK;;F"A@]+U@+M1V M3)E%X51HOQ ZOK$M,O1A2IIH3-G%F!S3RT08SR1K-E8@0+ "QP0(/AB0XB#$ M&"Q8Z,S#'CAT!AN+"@P8<=#;$6'$C--L1X[+:&F6FTH0G&,=??O8#V/YG[/' MC4ZU*ID*"[EMJE0Z$M3:LJ1(=96N.DLMMJ[AI26F MD)QY3F[,--J;0@T],EU+4[V@RG[!L\#"V"(R>\4H-/%0<)*&;E 44*4JZ.!A,*^#Y&(CYD& MI2VHXM+DE;+*)KKB4L.N(7CNK"4Y>/6>F=23=9T*1+UAK]R7*HM3&NJ??4XI3BWGL.*=:;>Q$RTXIU;:,-I]3R9Q*S5CB4ZMUR MI>59PJATW'FPA6,]U5L7C&MG6#>:S_NFA_P#! M:>W33WXP[>E=-KSEQS5&M?082E;$C[(5O.'L M99REQUS"1J&TIQYU)QYE+0KMES"6\X3VZMZ2T\[)5ES4>O6T1EKQ'5FG5AUJ M0E]I&4X<0XG+:ZP23E'77F'$,( M9D-/8RYAI^.$-C2.G, M*5E6JM<*PK./*G[$5K'DQA.,93C.!O=7=6%*[JSG./-G&/;&.O@K3.FE.*9; MU7K;#B496O&:17,KPA6%)2M"92VW,:CKTW^&YY]3LN M>I]?T'PPW,;3.G7D*\^IM<)<;6XTO":57LI4IM64^9"EB6O.E6/+GNE'DPO* MD)4O"/-GHK3>HL.Q\M:BUNXPZM.1*6M;DA2E.Q%9RJ,YG. M?OL*SYFE=T9]TYZ=^VU"L7RO$JI<08ZQUPNB.V3#%6,2H$Y$67'GQTR&%9QA M>&9D6-);[YQY7F6UX]TXZN.BSC@ LM8";Z"RCI?A3H-K\"?_P!HVQ"3< D[ M@$GA.<->1.),] M6@-[@7OY\ASL+^%^6F*R=K$[>7G]-=]>>&VQJ/7^/; )7^_!_P#Z5ZX_1#K[ M_2%7^_!__I;IRNCJ>%/0? 8BYZGXG#:XU%K['O\ (5?[\'_^E>A6H]?_ .D* MOKC_ /6Y_P#'/;W[%<=^G*Z^,AU###S[N>S;#:WEYQ[Y\C* MG"GH/@,+GJ?B<1BTI#UWN.AXN[=&D5Y&;IM.H8&OV0W.=_ZFNT;EK;YCE]L@ MQC"#F*FDXS&RWYH3!)J&MQ];"GW%4Y5 =3VMKS%?C2!R"(38;4]I!0N^Q+1' MC55Z/B1&E3WX[V8[OF<86XTI;"ENY94WZSWJ,WP'L$PYI26S.8;COCKC.FN- MM_13NP*M3-OR7LX^N%R)FQY3ZL*SE7=SWS[]2&LW\]?5_P#WHV1_YE5>J/\ M12;6-T7ZZJ3?7GBHW"BFY( 5N;W%C:_*_EI?;#K]01Y6U==SWAPTK"3QNMLE M[]NB-/)UV0W",+%*T!=_FPN*0RT[)%X,C?BA;I44N&=%MRU3P1,86CQ)S$S; M3;*U2 G#.LR2985 ,WK=L0C)"28\,A)%N\>KRDD*3+?BS,Q8IF M$I\;-E04QBT:+)OZ7M?_,=1Y^-CC75#1AH[6J%* M-[7M:J0S>W.V]L+37VG-:2=G\A73&OZ,8D?J6"^-V M/R#B.S"$R.B\TU8W!&4W,7#'.:IIF6H$1U++3J!\>1B5F.S-5)G8=%..*4M:$8PE/;S+3YLIQG MS8KIY3\RM1TD%7D$P!FRDX=OB$XE<+56?@1.^4UTG.7%A2IKJ6(<9R0ZM24I0VF]U*( N?Y4ZD:J(%[8QI M,N-#95(ER&XS#8NMUU80A(T NHD#>P',FP )L,/M?-5:]-AW%:J&Z+$%ADGTS* [>#L2I<45 G0T$O\C%P M&4M3WL%)?E^&EP&,37,^,\4(H/MH2-L#6H>+2#KL*.S-$2#A \VP70IF/))! M,U1V)%>'.NC\EV91T>\3@S9R0PM:5_!<:>9@.-.H5CZ+0M25?7&>OC4:E5:AL2SPZI6P59B2 MZ94)4N* %01$:5*;.W=EN3(8@,1VGY"&<892^ZA3R6<):PO#:<)PSG!F?$*\ M>Q) IICX%.$Q%,-J M9RAN0D/^>:?_ -@M2_XPW?K(((-B+*22"-BDC0BVXUTMIC8?ZVMQ;3XI_3"\ MZ.F-Y,;E_<\J_G=<^VS],F0&[M/P*1H MBSO"+EM83LI$FBEB.M<5H;:[ZV=E40?F."USL\=A,T[294&;%Q>WA?U\_@<+ M$["_[?UQ>1T=08J?+^RWKD=IW3%:T]G%.VIQE5R:*W,S?6AE[UA6YDX4&K(: M_:K:IY 5%FW0^7P'K#@G:A*5,=K5^DNB&8E0==(3GZD:XC!TWE\U71=DC)8J MV@()*/,CO1G5N,-X>4T\VIMQ"G/+YEH4A:DJ;_&JQXAO\ B?#6VQ&2VPN/HINH6O.%S',U&#$' MNN.I[JRLA765QA)=.,)1C#L=J(11V\Z)J/OX7K>5H%XC/AK6N;]@Y!&96X4] M[YS0F&YY^AV&+&<=4M1G6I%4%R&^]EU[.2-3=@V>,^XZZT8RI>'%_ITYQC.. MV<=\=1=W[Q%TWR#$RXMPJX[YNZRM$<]&CH8),.9QGRKS(:PE3F<*]_WWSXQ^ M7X]:B32&%J+K(4R[K^9E1;5R/*Z5BX_,%@E0_+Q #'I%#[3\P4V%^#U+V3, M5#4?S4NOQTU*.A-K684Z1(C%(U:++J4LK 6VWQW)TH.'OB%<3[MN'85^W38= MB:&VOMFR5LG?1.R2[NP](+2!RB-&KM"L[((5<=45Z1+0.F2JEL"$7KT>4&#? MY8$P ;7J[8NM;ZP3A"B8@E"+ABC,=X.2#3HA$249>2C,=8DF.>DC9["T+;4P M[#D/L+;6UE"\I6CO1)S:\$Z4/D3C@@%#N@Y/Q&8DYAIX99HS/EPI*634#+6[:HN0LYN(;HU4_L/5'U633\PO.3LMNNJ("6XM;9:5- MI^QTJ41Y"ED--OH%KRK\:OG(5WER,L%0K!5Z1K'3D4UI>JHBRY'PAZQQB"'M MJVAMK*DMM8GVL>S7FWTH:>6&H@3SYSA[SO4G:#+;(1NFF_H5CD9>S1I2-/JC M@>4Y',C209#T]T]$(M86X)0/C-ORB9!]*H#<)+S1%+T1UR&]FZ$&*[TVKK[7 MDH@0BMVRW0*X1EX^(FEX>2Q-#1LC)S,P^^X09;S,E39,_#F3^^OS3!N1$R9+EC;^<_4;L2RSEO)]"I[53DM4528@=0RF$_P 2'$/U2HH4EPRTU*>Y(DO1 M $)?;+S1>9;#7>ZX^FN5^>+FVP/).^\815SY*TRC9IJY VDW.OB9(;(=P-)O M2;1I622U[,L7V>E2:VX;L_'ZLVMD5,FQW2Y#$ETQQ-\230O*2#31L,E%H MNQ[<,'28^N"QT.<+MDWX4^23 8?!OOO0S(3(R5\>*LPZN%4Q519;<%U#Z\,2 M.VQQ YDZ(YA\;8A+.:[:A4E.^$*?=85GW M6RKKC5O'RN:WEKF2Y,&[38)605JU@LU1JBKK7'98W(>4K-SAC&C9>=($9P*? M,3W_ )K(&X^!E2GX^G'O4AMGNW9 _7H^O1T=7, MCU:%:-.7>M@:W#NS=H,W:R#3$DE\ )J\TF49M=:W$2H@0;AK@&A@\M <6TXN M$3A12$1;C*\.,N*C3&GV%+:7C"VUY;RI"L84G.,XQGJ%VQ>-'#@;//$"Z:GI M67(%?:*^XH][9TBU8J]/,OCOG-[A5\M7H1 ;(L19V''L<^*Q*29F*@QC*9$E M49SYWSAV3YRF5_,F;,N9DHL^I52(W3*-2LST>.[#H=-E^SMUN-&GNQZS9$IM MN2MMMNDM)=%1J#,M;@D*=5V]&S%2(D"%2YE-DMQV)*YDE^GRW6G9\T^^(VF& MNOS#6M)!5:HZ]FYFH W\[*%/6W8U]7$NM>B"A#9?!&'.@C7Y@<9^'FP=W2XF M[+2.IFK8G:32*]9JL=+'K59J14#CX'N]6< P541"90#76Z-9B)*=.*4Z&",V M>NF),..W.F/4> ^G0+@L]9]U[8VEHVIU\M+UGK/8=SK!#6^O0-B@L.D9(R] MZ\ OMDJB C$-L,/N=_L%<&P&8TY3EQH[V7<@%Q<6<)#/ML<&G1N. MD9L]DAO"GIEFJ32&YE3GR79+G<,JM'[AKO1'2_W 0TZI4^3] MPB $"P0J.F(+"CH0D;$0I:T11XV,U#A1TK<4MQ26(K#36%+4I:L([KSE6)WMJRCZV]ID6&LA:L6*FHM-\':Y=&HVL> ?.20 MZ(W59I@689J8*N6(2#G6VZ@J_:;@(<+UU("$$6MTZW;7TV6R],ZIW' ACMHZ M\I]\C#5NN"LV@# *R1#KZF%2'@\]]KY@(>D9C1\2'1DN(Y(0RVV\IQ",)QQ^ M?*%6LRY6J=%R_6FZ#4IR6&T3WH@F,F,F0TN;#>9"D+2U4(:7X+CS2N\91(4X MA+A3W:MG1YD6!48TN7&,MAE966DKX%!8![MQ!N 5M+LM() XD@W! (UN:UNO M2=-T.2=W$"W+MO==K%6.O$2UEVP%I%@K-?&[HEPZ?;=.AY$9L:%VB4M-)9M\ MU5< DTQK+KB2NZW.,(9$09^>VC0]0@J'I_5EMH_;F%VS"KE78NE%@=/U M[$RN;" [@(Z2 S+"8O%C,689HB&BI"*K&S/M=L::@,RCQVPN7#[BX":DV60 ME*V5+ZCE!:97-=XA4JNZ],5F53::2+&:4/14+]3K=7A!*FF39.?6[ !A#"L9 M4^5&FND(KJ6F^&=!\3+/K_4NC@M['R953JQ=O6QBK[4&)VH5"9*/9NY>,9%3 MW2-FAGK*#E$KDKY;/".6<1F&4VB/:NM G8%KK MS\ 39ZC1Y(HE:6-DW56OQVJ]=U#7PN0_,AU0+%%)G26F&)$]]O*WII!V-$[1 M(JY\YZ3,^#B8Q%AX?Q%CXPRRCKRTNNZYU"$K6N*ZZ*KL7.2*@0F>61DP=(2I MRR)\LITK*67L9TJ7*/%+"8=7-($"A)V80>4_+QE3E]>G]F7910^SU$JI,QXY MS-6XL5%=EQ%S!3DO(O(DQJ/#E2'_ ,/IBZB[)E-QVN[2GO&VT-,1V(T:/SN8 M\QKK:H[+:'VH4-*@TB2^F1(><*EW?>=2TT >!26VVK.*:0FSC\AU2WEG1T=' M7K&.8P='1T=,,'4!O$$N=OKNM*A5ZS89E0A[2N)&A&K"-.(JY.2Y(H%S.U>B MCK;EZ*_3)&S+6%%4Y=L@3(!@?%FR85?)"3I,<5A3YZ2USI%.V+72%0OM5KET MJQ9+2"=Z=;[UB#0VGQ\C4M4UD:O=E/2(%N<)S+];]>2J_%L&=EP'GG"2 M3$801E/2B8[$Y[-S^(/3MQ%-<5+?O'OCON'12AP.Z6>D5Z9:K%:-'8FH5&D$ M6-@RQX*K%;;3:$6S,LPRK"1=?"R&IXEBZNRAZ5)NX"<&^+E2K]_K]-U+7*>Q MLG7UBUA92(#)!HRFDVB ^/, @Q.?.(20 ^2A_#ZX@94**[*CQ'I##^8K&$5T MG/#5EL&ZW4MH=O'S/_P GW;1DRB4.@Y;DT7,B*E7ILW,[W^21H,=A MY=/3&87$K*)#LFF=TQ+=?887Q,NOJ;98 M5WRE)[]3CK:XZWE(?2IU"4*6Z%*#;94YP%U RVTS.G> %M!5K1,030HF\]@";OR*NK='BM?LXSTYKX:7)SDH[9EMSCEJ3E6&"7:K[%G@IJ@$BJ#MDZDFT M*S#['3&RRI>:>;B6&OWJB7&N";#&<)B(T\7*EUL\W+E")P]^22;DN/QTU3K? M5E/GQ*#:I.PYYPRLK>ME&3HBS6N\VML?!@9)64N"9B"&GAX>.,%B@0<<)"5\ M-'A0!(F&QE2I'85'LLS'F3.4BD9CC95>[%H[/M%,RW#;>BS&IR8$)F(J*U%8 MC+H\V%4?Q*;^+4RH,O.M2$L!([UX)T;>8(46EID153/[2K*4.SG5]X0E+_>E MQ;BPH/H6T$M!MT+#9;84A+:F2XXA.,'%$=Q_4:/EK"Q;;JV,?CG/MCZYSC'4$ @@[$$'EH?$:X V-^FN-1W3X+D17-=V3 M6/'3<5EJ^Y-/[?W )WG0&2<:A;'O94R2E)AY1- M1-JL M++\MJD0JCKJ"8CD#L4LV@O"G10TM3LCY2/:O6Y0\?^!?(W:[MUC 22D_,;%F).]9=)S%8,O-2;8(E0V(,4G+%R(K$*0^S MFN#NK> M9S=+AP]V%K3=EA>0,K]]V?6MVB^0MQC0I+6"02L&KK&LUIF A,AF M-\R'UYMX9#FX8^/^%DXCM.M?&*?X;L\+S>AJ3V@!WLY:K;E913_\O56@R_-5 M47:.SWLARFLQW9!#;CXCJ=,57=I<*TW'J9SY!1 4MJGA%5<;"5'V6.$ET 6< M5,2M+BV0JZD([@.) [H+2+.8J.Y9Z7I^F-Q6BHDI?(/E+IZB:_U^8-Z_([4 M^NB;6^*[QKN=K5VG.-)KFPAVM#IQ^?',FA ME$DR#3]OW;:$X/:5-%")*$AT1>)+B@Z)!;3*2+I( M6I*5JI:V_I1=;VONXMQFUUJ0GNRC[YO#A>OS:;6YMSH%1,MU.PZY*ZQJMD0B MIQFH\*#)DP"L(4])@H*SODOISF9"D>'@WI"\M\Z,]I4:KR\TT>;D*)F^1F^+3'&) MZ:LTMVJJJ[=*2VE8@=TS)4VPB3?O!!8;CZH2&L6UYWA&A/0T1I":D]3Q!6Z6 MVB+]QW!7[7WW>%H&[R6O9P0L\!4JZG3+;&.V,8Q^&,8_DZYZQ4PX&'2Q,">5 M'P9QZ8^/!PYDR-%E&9T:!+*R(8F.^ZV\3E,#($TB]'@HD.M0(ONAF#4U: MXO(MKR#7;"3#!426DK5(3D@2BL^5E6$J==RVPY)>D/Q(^FZ*[/E9A1&M>51] M^:M[++;"(M7&RE+DN-Y2M3"L,91(90A?Q+2G&,M+0XI/4=X"O+R.YJ*_F;[N M@..^?YLRK$3V'5NLO64"T!WK\W,("I%7DMF?GK^!,6?,2A*9L"*U*6XV+FR/ MB6Y^(C[4=U2)4W*,JZBVQL64 J8[ 7%9E(E,C/A6D" Y'UQF<6N#$BXG62EJLT%B0G:I*?4Q MUXBUYV)$AAZI91P<9!KQ6.;-E D1: M:XA&%0S84X_?"&78?R]M"<16,.$'G^\1$AM#B6WG7/C7E,O-1$+2\Y)RE>&\ MJRYYEUT?IMD3Y\:-8T5L42I[TM\WKS$\'#S"BLRQY%UXE/?F)V0ZZF0 M^SB$.HDL96XE]$?R)6U0::J28R[ ^<8E,H\\6$\E, M*(6SAV3'5'(/M#WI3F(S:E$/5EMY3+]05,BRE1%.RUN6)CSVG(R_A=PU7'\PU5N,U#L%KD0XS%?U\X9L4H3$DO0H\<4U/G%7Q\"(R_,>8888? M<8BQ6'Y+B$8:89==4E"G/,[!A0]??I%K@.S7\;("BCX@N MAQ9>>";==7"GMD%L3)L)UN(V_P"9/Q#>(ZVLT97WC_&.DUJ9(4&?+Z^=#RI( M9Y4G(]4]N=#DK'2"#&''?22ZXEAZ0RV]E/9?[T[Y5H?.KUV%5*V J\#*UCZ\ M$$ 87K8QES,,,/CCHOJ=N^,K]",WYLX_T7OWSGWS2HDK)_+8DFZ;!.IY *(X M>EB1:UB1KB= .=[['IX[&_P]V&/K]EFV;=P":_6KM68[VE2\U$*U#0XYI$B9 M>ZUZ\3R0B1$@V;@HCM))Q9"\06H[P]R&[(6_(6F1_3)R&XZ>08=:4,8DYT[8 MD+5B>YE_X=-^JJFD9%YSZ+3.'%NY1/3C#CZ\KC*SE,9OL]G5*01>YN;[]=!\ M/5M+8E7+2WY1^N#HZ.CJK%.#INMOSYHK5&S2@UWT" W7MU(07NW?T9D.L%9$ M5WMWQW].0VVOMW]^W;]?3B],AR0,2 FC=FR8L*21DRZI.",0H<9^9)DN61V- M6TMLQHR''G%YR7QG[B,X1C&7%]D)4K$'0$]!B1N/,?7&,X_TV#1H5Z#048:; M58:9)RTG&$I;^%T;J&M82A.,8\J.U;^[C..^/=/^AZ5=F_GKZO\ ^]&R/_,J MKTD];3)R=V/F:GF"7'F7DQ78\_7R8DC$1]:$M/Y:EAW4R<,K7Z2 M\HPYY5KQCI66;^>OJ_\ [T;(_P#,JKU2?Y0/]M/_ /T'TVQ//_P__!A*!,+97#6R'*Y^Y,;NX;*U_"#SK<]?=V0PV#\AQD- >G: O,11PBTPMJ03B M 6WLF) .++'RSK4-8J,4%ORD3F'9Y8X6UJ=LEA3JT"=A:IFKAQ40VR)!3VPP M N+#%EB!ZNP*Z1S.)1)$6P3)[L0]^_?_ )>MQ0]9TFQL?P>NWY7_ ,QU*VO,;Z&^OAC J7^%9-@1^(TS M0WU(J<$ZZ^6UMM<./J5PTO8.]VS\<4U/BVVDQ4OAY0R@4@5)Q&OM5BFU"GH3V6K''UA44D8Y M7$)2E-&68WR_$IJ=A,],?,++B?AU1251TI3+-<#J7FV*O!E.M1X[:WGGG4M M--H'$M:W%\"$@##(PY'C*DR6)"(L_$+ M,6&XVNB#E_JPI/($A(V"&3+KPH5%=8^'55L\3C9-R;#,5NM-:X7+%3'&2%U:!&#D0\ZB M2-CS( \668"3X"EE!LT)*%%X$V=&8A+ELLP21MM32ZJ,$_FAO2OT MJ2$V&J56F6J>:Q"!G1ZX=,8O<:JPK,00:C1[$+5;)I,7#A2&71Z)TP@6,E9# MR;*J3-GD&8\ZV+C%Q.L@R,*M6WP.PGI@Z6*=@T5="80-!21#\J0B4X;9L"(I MB!-01R2E-#<81F1%B."24/EUEEIMO.?2<9^O9AEW#+33V4X3G#><\Y77,KS*Y,K](RM18-:GO MF1-S":=%-73XC[SC;SCK,4J#7>=XV%!0;;;"@E89"VVU(83BS6#5*U(P&M8 M:=7#4G9&^+0D24<97,CA[IO;8]LK3LC$29.BQW2%9-AIZ('Q2Y$1,G,=]IJ6 MS*;0Z0YYI_9)UUEQ#K2J+4_*XVK"DJ[6.\ISV5C.<9[*2I.?RSC.,^^.L"^@ MKDT/F>>3\+(DI(2!;\=I]Q;:([C#L2(Y'7'0F3!DN-+3)E../.(;;BQ8,B3C MSM>^MKRY>2+N8WPOK:[ICWH?ON%,Y?L%W=RTM#[;3Z'&\+QZB7D(=2YE:'$( M4G.,Z8\M02;7WWOKRWYZ7 Z[X[7KXC]1AP28P<:'3A!>!"*"B<21 (C2,6/. M@3X,MI3$J'-A2VWHLN+)96MI^-(:=8>;4IMUM:%93FJGE>.LUDL-DXZTOA_K M>^4P!1-8%I!J77XI(2>U38[:59)Z5A 1H@&H)]K"U#MM7*KB&"%,IPP_4[=> M 1"IE[)#A6B_:BMN6%^H-V *Y:XPID_(K#92 Y860+LOX)LP\$1(R4:$O2TJ MAMDG(J8+DKO'3(R[C*.JIIFE?$*;DM 7>6%#K-%?MS[Y;XUZ6?O)*P%+[7"X M2K-W$S%02K==)UB$T+AU:L--&2$6QGA$90-9.O&0%)Z6)!!U !VM86/7UUQ* M1KK;WW_:_OWQ.30<';2+#O&;M=@&IJ+M8G5]3D1E)&5.;-TR%" B-6R0FPBQ M9^P^BO2-FWIJ;&KX%M$RK MY76Z&)+V^PTZ-!GOEAS)R!7*<-@%"I6;\-@H'882-"BZN[''RR#%M=L5B>'$ M8QC"E9[]L=^Z58SW_/..WX_7]?UQ[9QU-_=YX@^8/E\.@MMCZ]'1T=3B,-KM M#;^N-,AQ)_9ML&5 .;L$*KC2!7XOX=\S.C39Z&%JAQ9:HL>,-&$BQ,G,3'$A MA X@7,3X R%)EM,Z.YP<3R@8M88N^=;I" @FS+,6)S#V!D2%6-.AP]CV39G% MDX\-2JY5:X?"V*8>:0X)E@"<,T)F$1CN)6'0VQI*@;K^P+.PP[5A%Z\O\TXV5%QHUGF3<#7V%*ES-CGQ0"(H8C/=@F7T#"?P,WS,)AGR M$XM<*]IK"N6JT50<[;2@(6'D#3,*=Z\VSC+&8KRFYPEV3\!!,#:E9IHPH14R M&E- B.6IRE1G$]+[8>A:3IKCV(UW8K1L.^ZL';GXPC:=523E&S,K)(CR+UW M"17BV:A'=L]3=N9Z"4M :SI)S)M69(5D80B8DQY#"4B^%WJ:-#K4;.T-QYET MV&TFL&XQ6F#SXPGFN-5:;.Q*23%PCY%B05@6L M+.A-369R'>KD!)0'/Q,A!"(N;@%+R%(1ADV)*^43XS+2U"YK,5YU0^8PPZPM M4&2EF0TTXTI324+1G-9T'PH-$B8 ^*)N6R(<@5*?)0Y;B=>D6EEB%8H5-*3B M8@M0YX,ZV]7->B( T:<'$8 !U^1-#-19$43D?*KCAQ/UCQM5G\QK)'C MLD_GT^*3E27(MTV-=6)TN>R.A32A7$K994.X5*NS2#X(/7(3KZG![KT@VVEN MX2@)!-R;W.HN;F]R2HDD\R3YXN/R'9"DK>><>4E"&TJ<45$(;0AMM"2=D(;2 ME"$[)0A*0 D#$GNCIOZKM?65Y+EP%,V%1[8=KZEH/!JS<*W8"H1;;V8SB3 T M,4G31:D2,9CKQ.8CY0_CT5=G>R.OF/VWJXM*A016Q**3FD;08I(^(.N-:G2I MUQKT)9(]58<>*5>>EV4*/0J>7K\9#I@9"QF7/A1X^,N8N[XQ\.)UB#YL=609 MFQ%W5L"@(HB:)/-M./N,CQ4)\A-=0PRE3KRVXT=U:6FDJ<<4G"$)RI6,=8\7 M=*B;"+LH>SUXI76Y,V&X>''!4\*B6-(/"2,99:),>')D#RC#XVK52QVA2V_/5J>,,!:[7'O2FM^N"'"+ :%X%/^I"E#BL(!+8> MQL39TB%8![,>*9BS6H["6Z2"=[7&UB?#P\#XVTZG%5P-B1KX'8Z'EK\?/$#- MQU+BCO@Z8(N(N,J% 4!@16 M2LN#&:@0#DQ-@&RF@>6F".!_QA-V#&&P)N<\<8DAH]M?D M?K*O(-&9!$%2V..\416S0ZKA<3$1P5*M48.(>B506TQ!:D" T@LU,> U_(J9 MI;A;Q;.%91PMI:GS3$MJ2PLDZV3Q+8CSS,L^5CCWFR2%"XYLJ1*2#\<;F(R? M;,&H9I$^"9*1I M>4;DQ(#B&WY<5+S8Z_X"\7Z$'$07->-WW%F.HDP8#926\VJ78H(\>+L3Y89 B0V8U\+>_U[ MN6]SMB?R_P"UOX;:?/?Y;8C%OC>G%G?H=NALJEQG5Y\^"5 M"N,>XTL(>%NQG2TL]4!EN$.1A;LB:%L**\2A1W#[%?0\QVN1'".K4>3387): M'7B='HO*/CTU=$0!.J#-/7?#HVQ;$_1UB2$'2:8QK$E3GHM3B 5IK44@1)-C MU%2!2(UU/?/##C%ZN9*-15YF;F!D5\QCS+!&)_*T.3I X;\SCF6I^!]=F$'2 M-0A8DXC4LK%$E:FT%(@PLJ!ZB'#WC.5*3#933U2)%B1HO8BL\@V1F22YLXXB M42(F%R2#GS:0Z3;0>CY)8E(@6;"K0/1%L2U$\Q8WY?'[ 7/Z"UA@6B<7J)O09MJS\G[S;S%0U8 MM5MF51BA.LT(&MJR0Q<,D 'L&(M6PB!8&WS+XO*CP7\[NU^TP1FBQ@]R4:S$ M3-GEC)JNQX<7,F,SZ\F.8(\4>.Y8X-L9'4] M6F&!%4M5('27FIV6XM7N\:S0K8*1"3.3 4V>A7*SPR,ER,N:]#,RXN)2&,M- MM^07Q$XWAB;!H?J6LM%8X]X8S/>45F24PY+-DCSDJCUOOCRP^8O&H@6EB(FW MZ:XZ/I1D$TE!(AIBQ3&(8+XG&&.&/$,:)-S[!J.EL LM2RMFD'"); =]C$Z0=L).QNE3N! M\EH[(5F5>IQ=3B+?%A0&+DZ8@"1S$/"0-(\(=G5R?/-0 S<4BYZM$UU%8A[+(+$76K*&, MTO,2-6X-YDR4FWHT>IJBUV.(BV5QYL K G,5F+M37]<+7IE) 972=H*DS%\G55EBLV M.GWD=KR;(;&0X.>K+[IH74&Q+"-MMSH80]9PREN!S\K$QLN)?6#-5O,D9/B2 MXT@?+0$L1L$#5V=40>IXSB- MAB["J\&N8R0V@JGXT';X53K:[57YV9(.Q$0T(R8'3##>9ZHU\/#7]O/%5QU. MHUT!\K:_/?$"+I5N)4ZLU2K@>9[^KP&NJ57:>TU6S@D'&:CT2RL[O<(0/@XH MB*">MH88:$W]@&E&;V&&0(+#T<[1?1P\O&2_<.^,=-F:WJ'(8%9@YBQJNB[* M>+B%P69MJ'4PD_T7A/QF:<8? MG:O&'940@0GP7[ 3/FE#FYTUV>V*'HG%7&8@,7(==?#!VV<01DR3/*,-?."I M8E/]+G"SBXZ[->"E0>;76# M&'I."PF;B5(]6 #X [:7.FGQVMY<^HD6L"JVYO;>X^W7?S.'JU[LFC;6K3%P MUW: ]OK,F82'L&@A:&WR$EJ.S(F.^HXXM:C-JI8L_1ZAQZM\F;$GCXT>?'Y![QM.D1,&.V^A;S4B MN$:N\=)NO8RU-@2V8EAK*[5U2MQ:IMP6[ MTX*8EJ/5P41JEH?$RJI<:]8R2*Y8*P<*"RR,L/I6B=G1TPQ1-QM\,+;'&'E^ M-Y277E;FW:PINF6*;;IUPD7I.P;M0P^DZO4EZCV?+-7*5K&5IW7NU@^Q.3M1 MM$D/-V ,N6SK-5I91FLL3")QJ+EI6C(X3[/XZZHYC:5H=VL?+?:O+,KD*5V% M2JAL+4&QM^6_DM T;M0QJJ13 M8FGPHQ*%,'3$*=B3XLB%*;2Z\PIR/*96P^A+T=QI]I2VG%IPZRZVZWG/G;<0 MO"58A?8=%\(-<2!%/LT#6M#FV>,Z+! #.RI-2(V%B4V''O11(^?=!I OE\L" M 6%W$)N2X[L0(#V I2M@B1]BCTVU&UAH-?+7;?\ ;$@[DW^^M]3N-MQK^NOO ML7AI+V'MNVFCOB(Z[V /OW+?0]BUO3E7+;%U;%*M8^UUVF:H3K7.;($'M:VQ MLH#1==[2KQ,:RYKU4U&SX(X\\I,M9[5UH9G[KX 4NITCN/6#]CAT?6-/V!6XQ\QL#7NO[I2I)K;M3LE ':QN]BDO.LD MFX<8C?X6TAQ J%AUR/*U/5E4LM96]9];C9!F#6RK+%&)L7HA-#"W#8^46#UL MV-@74W'5%(!H1@.)LYAA,\..G1&]E\3.$.R"5#9& :5+EMM9V;58-4OCV7;) M1WI1I,EB+%&V*4^9TP2)7*1DC7Q.$4">_(%CW6506V![@ V TW'U!^M]+6U\ M,3<'KH!L![_VWU^&*$ZYPANE75QYJ8GQ=(%3N6N-+PJ=L:U0-L[_ +ELP'NH M%:-U4C9]@U95S^RX=6L\;?5SO]/KERK.UZP7LM+':0 8U(P/@):D5EJZ7X>^ MTIVOB1T,'II6Q.#YR-T4G.^.JMO+%-_7KU\,=NCIO-3; C;5UM2=CPQTD3$NM;%V.,,F/, MR)4!DFQA]$5]^.E+#SK6,^53C2<(5GW3C&.G#Z@&X!&QU'ERPVP='1T=3AB# M$=IY_D3S4:C3)P]]6@N.>6Y@QF#((,+1#Y&.=XC!*).@.OKPG+26Y41YM6%Y MQC"5^1Q$?.;7*BN\:N+NDGY<4(3LIT)4BD 59)Z1M=CA*W383Q E8W&XLN:[ M!?+3@0$0)@+'SCMC)CH48K!9CSI++_?'01G(+FS.)2H$*#'X_<=,(<+8AMNRG6VN,O.-L-J=4A"@@7- MQ4SN3>_(?D97#@DN0,1JQ;,0$'151G(UIK$Q&/.O&)9&/3:/(BFK#@5.'!PL MN/V ?)!H(.)&4W)9>)RKR8$9FRWV9#T(B]1ZJ>(8?S/6PCX1MMQRQS6W@FZX M)DJG8.0W+<.96 (2)\NG:S)5Z#"?D+CL8@+Q<;%)<>8+#YF$.Y)C:6-==;9C MLPT#XZGH\C-RQV@=JSHD6;G/,3\5IM@!MZ?WYH+BYA M;2P91J+*4E)<3 ;9X4+\UK&4,Q566VY3ZM6B%-L][,JD:%0V&E$*XQ#@PZA5 MYJDL+6HH,A49UVX6K@^RUE^31(;;,RI/U22D *?6E2$$VWX%+=45 D@*4X;(X4I2G M6_WK 'Y'#=::&+8:F86[)B/OQ'76W&6EQ&(J6V,*A(@)C,,MPV&Y"LL-2,QY M.?3CXQTK6(<9CN^U'2T\_AG#J\XPIY24*QEIEQWNI3B(_FRAE.5J0TCNEKLC M/;I.8V'0LXQG%UJ6<*]TYQ9@><*QG&,]\9^/[9]LXS[=_;.,_CUU_2'0E^1* M+K4E9<6WA&$V8&K*NZT]O+A,_.5?7_0XSG/X=>?E6Y)^?(6%M3R.GP&.GL>A M]6_;Y817'?\ G*:Z_P!CK/\ YU*Z<*XP+.4K94?3+#!JMEE,M-"["2!ILL,6 MYF2PI^0Z#5/&((*S#3(:8:.+K4C1^M7V'6WV'JS&= M9>:6AUIUIR1)6VZTZWE2'&W$9PIMQ"E(6C.%)4K&<9R]><]L=_?/OC';'U[Y MSC&/^'/[,?7/MU2G^5(_V1].N^!T4?,^//H=,1;J(:\!][!F;O?'+I/SHN8P MZJ)0QU4!-E(5^!-E"\";%=GR\R#:7(2I5>E%Y[(C$)N7"]%LFM.92]1S$VZJ MVC>@8A7+&&-Q%:9.R6/KUBS9-@('*&).',QA0Z<3D8:3YW5,#XKLQ]+ M2?\ 1.*:86EO'TRO..^,_3.0P\TI.5I=;4C&,YRI*TY3C&._?.4:-)D=TR;3>7VZ[ ?PS'<^*>C M!8Q"592RXR%YA PY$D[C$:(\M,WTOX7P N0.IQ\..^T+/M2A-&KN %U>WQUB MU& 0B?+GPX<6RU@!>:TO"B#$:?'F.5>U!V3,&0AU,&P12\2-*EPV8\A;;8F0,LNX0\RYVZSY(B-TIM^99#+ZA>M-JU>O#"1^0A:@E7V/0W5! N39!ME> M1V-A4PM $Q)9%Q@0R4UY#'-O,E+ RU-PL>JZ_P!U[F$7L;2*L6IE'BFR[M_? MK[;+M\V67$/:\BQX$J6,CIM@6E4)!X?.-N+*BU$3@4.%FX?K15EBDV(*2;DZ M&VA\_AKTOIB1H>(7L-;Z[]/_ /+3]>>&QTAR5X]TQ)\/Q,*S8D4I(@L2BS<9$M+-G&=K: MO[9QG_(C9./;W]\0JMC./VXSC.,_EG';IMK34=8A=RT$<4UQ35#+_3KM6L$) M52KN8*S]6(5NXA 3JGX6$.R"(E=Q+#HS;:E*S7B4G"?-&]1#CV1:%;6U=Y5) MSC(C9.<=E8SW_F*JYSV[9]\^^,Y_'W[YZBUD\.ILM/3;B2>0'7IAJ3?JDGX) M(/72X/NPM[)5*];X<8?8Q<%*0ZAQ"LIZB%R7!1[%R%X0#9,PO :1M#;)3#X,M/"3E/AM&7 LQ'AR7FES?Z@MRBM<"H;^X6EYLRX08- M$^8'#D1F'R$J+&=DL>MA>-U10/;)%^=(KU M_'_,=1W\+7\/?C7U$GV=JQ.D^E$6OH?Q2'J.FV%7QFUX2UYLCF)DF:*F\[!Y M&)VA R8L)*S20XJSZDUJ-AU^/.)BA*X H:JO/J#UJ$V0&589)B@(!@DS ]1$ MG3%9&&T8:G->JUZ^)"V'.SL9Y>&TOLC'F7G[5U[LA/MCS*_R2^[COG&.^>V.^ MA)4J1+FZGHAB9,&_) MGY!JM"23+X:+E+P\*4CRF%Y+BXDS+T]F+,RZA!"9-F(]-V3GRO-7:?6ZQ#2. M"!88^(PRF*TAMO"_-%0E26H^7',K<5&CM*Q$BQUYPS$AM-0XS;<1IIO'C1LC M7RT9<1>*>IO&58RM-H J1C*NRMC4!/\ "N]0 M3CW]\V<%CMY>WF^I#'T[XQG\N^._UZONRI#R4H>D/.H3JA#CJUI20E*04I4H M@'A"1H+V &PQ:0TV@E3;2$%7\Q0A*2K6^I2 3J;Z\S?,8QC&,>V,8[8Q M^6,=>63&S(QC&'/)VRA6/N^;'=+B%9\V,*1E2%H3EM;><^FM*OWQ*\8\N4LC M8U <\WDN]07Y%>5?ELX%7E5VPKLKRD,^7/ESC/;/;/;.,]NV>N/TCZ_SCOB[ MT_./+A7?%H ]O*I/G2KO\P[>52/O8SGVRG'FQ[>_5C3K\_7ABNQ.POA2OPF5 M+]?#>5.8=0^I*?+G+SC:,MH]3U,]E81CRJ1CS-Y0MM"TKQE/NB0[/P^Q3C&, MO+0S1*BTAU]:7''$)L%VRE7GQGS*PGS9;[N)2YG*,YSA2?*M613L?7ZTY4B\ M4]2<8QG*DV@"I.,9QYL9SG!#.,8RG[V,Y]LXSWQ[=8"M&PIO8EC=#&QAQMBD MU%M]X81@D<,K=L%X=;0^N ZXVUE;2L*:2ORY<;QYD^;RJSTN!;7?Y^7RVZZC MF)UL?+]1^W7]<1\V1PWB;#VQ;MF)V?;ZHFX1=;+FCJFJ<"*,E=7QK(S7E_:4 M18!KTVO.RST8T2K! 5)C$#((2N;-DBFW1*VA.^&X.L@VM CG(/M=4F #$>]!ST>PP" "WG+ %R2L)=*B;ZH^1HFM*J\ 7E$ZS3HZ<( MZ>KW^OVVQ/$KKL+;#:P'3H!BK\EX;,^:3C%H?,'E4'D+M86TV)H;L@XU'MGR MHP'-.ABN%&E2!PJ7/@39V&*Q( Y9G3T8=^,#PDA)*#M?A"ZZNTL=/M6[]P6> M>-#Q!#1"TFIY\GE#;LD@1<^82SJ9/D+6 B:L3\5;CK$,B:G1QN(@I$ =#M\Z M.H*01;I;F>7CO; *(-P;$> ^WA@Z.CHZJQ3@Z.CHZ888GDCK*U;;U/.J-'.5 M^NW")=-27VMD[6+)F:U@OJ?;='VG#'G!P4D(+.C3+M-P'DNCB,:5#1/^,:]; M,?X=UJLPN?W?.?M)Q!]\YSC_ "E[S]N_X?=O^,>WX=L8QV_#'4R^CIAB&?P/ M/W^F3B#^O_*7O3^^![_\'3A:RB\J&[*I6XS&@I].P-D>1C6=(_P >>,O**F0-)$7^1#NGN'O/OBAMG0A] MPV[3/$/HLV?J[D5%E,W6(%:8W1MJBV/)C:8E(^=0K16\%X31,SAC$>#O3>FW M[_<1[X[9^ZGWQ^6?;WQ^WKG*$9^J$Y]NWNG&?;\OI]/U=4V(O8[^'/KOZ]V* MKCI\]>7.WA\\:_'.S@+!U[Q2\/#0FG^-%JY0<0^*&WQ+F^>)=5D5F?:MT:W1 MHG;%2!&S(2WV6GUO8I07O6V5C9UNC%S/Q3EBER[_ !XDF<"PIF8'"33W.S1W MA[<*-/6>VZOG\@M=:4J=:W;-W"NZWU<^G3 MX#>^NWSQ3B&?P//[^F3B#_67O3^[_KA4#GZI*D_:3B#CS8RGOBE[TSG'?';O MC_+_ /AU,WHZG"_JP] M]/[X'4S.CI^N%_6_CB&GP//W\;)Q"_K+WGG_ .\#'7'P//W^F3B#_67O3^^! MU,SHZ8F_E\!ZY?7J<0S^!Y^_TR<0?ZR]Z?WP.N?@>?G],G$+^LK>?]\'J9?1 MTPOY? >'V^O7$-/@>?G],G$+^LK>?]\'H^!Y^_C9.(7]9>\\_P#W@8ZF7T=/ M?]/MA?R^ ]]/[O\ H^!Y_?TR<0?ZR]Z?W?\ 4S.C MIA?R^ ]F?\ [P,='P//S^F3B%_65O/^^#U,OHZ8 M7\O@/7+Z]3BN'F;K3DKMKPUN=VI#PZB7G>&SN+7)>@:UK^H1]A"CCYBXZ;L% M>I8%MJ^'R,C%@(V6>J+F4LI%&>21![)84V^ZO7")\)>8%DU9M]?$_@I>.&P[ M?W!GB#X>-\IYR#K[6[FZMP'MP4Y&^.56S=;ZHM%CCUG6^F-"C=F:]+;*/QT[ M1OL38S<,97"8>#'>8W6LXQG&<9QC.,^V<9QWQG'Y9QGZ]<8;1CMV0C';.,X[ M)QCMG'TSCV^N/PS^'4$?+X[CY:?TUO T\M--.7N]?&^F92?"LY#'<\8=+;:T M$7JE7U/STW=Q5W*_J9<6;J7;?A,7P_(YQ:XUR2,V43%L5CT'1.0X:MZA%0BX MX?8A8IVTUM*8HNY3XZK;_%*X"T'G1NGA-J@UQ4IES!O;('VO?/*(O1:U.*Z@ MXYZ$)QMG1-!U2W3L,V &6Y&;,= 4? VNN/QH>N_TE2)[414P>MZ\3RI[]_*G MOW[]^V._?MV[]^W?OV]N_P!>WMUSE*5?VDQC3I?CV/I:!?O],G$'O\ ["]Z?V_T@?\ )U,SHZG" M_E\!B&?P//W^F3B#_67O3^^!T? \_?Z9.(/]9>]/[O\ J9G1TPOY? >N7UZG M$,_@>?O],G$'^LO>G]\#H^!Y^_TR<0?ZR]Z?WP.IF='3"_E\!ZY?7J<0T^!Y M^_TR<0OZR]Y_WP.F;MW%'D?M/.\+5L'8FDQ^P+W1N.5/H3=/I&P?L<'ER7DLLV7]'3PZBQ\O0Y8 D;?I MX'Z@'$-/@>?G=6<63B%C&5*5C'V*WE[84K*L8]K^G&>V,]LYPE.,]N^$IQGM MCCX'G]_3)Q!_K+WI_=_U,SHZ87\O@/MX>KG$,_@>?W],G$'^LO>G]W_7/P// MS^F3B%_65O/^^#U,OHZ87\O@/7+Z]3B*-7A\V464"JY'^+K]126A*LS-:J6X MXMB>"8=Q\P;!R2]WFBHY13'FQ#>(Q)4-#O;+[#B.Z>J7/%6XU7'9'/ #L4IX M?ULYW:JL?AF\B>-]8KPBI:BL=S/'YXE#=A76I MW6@;,;U'L\_L,I625M"ZS7\M&DY65,2[@/""X&GN+-XYMV38%8NT-5=WS9^, MG#>;L' 2;(JGAZ:\FYVMIVD:UGPHR2$37V=F[>V;C+,QUJ5/15ZO!G1L,505 MY+S_ "(]_NI]_K]W'O\ M]O?KG&,8[]L8QWSWSVQC'?/YY[?7/Z\]0!K>_+I M:^VOR&)TZ?/R_?X^&NLQ1_#PY5UK4GBE\>^,U*HFD*=O_P 2^'>!\7;-FOE4 M!;/XADM':-;W *HUTIP;8MM&S]P'Z[:=8E+'/%2'X@0Y>IC*FBS8O.9,^%#I MKQ!]&>&KPRU"=JFB-/7;7VK3%>NE!VB.V;9+*%D-[ M/E2Y\J%!?EX=7#BRITR2S&RVW(DONX6X MIU>CHZ@ #8"P\AAO@Z.CHZG#$/*,B KEMRNP43%6.QJ+BRY.Q.2PN'B,T] MR#==7*Q)QF/AAI*/4<4]CTT)1EQ6<83WP\#0_0S?P*F(6IFLCL9^6J9C49&8 M"5M8:5B#E#?\RX4SA+:O0\F%-XPC/=&,)ZA3N,P "7;Q"9%D(UT:.E<:>.XI M#MI*X#!I)$NSR('BASL[*5J^+(D7X\,;%;0MR<0>BPTISZ^>K)D"1>4(SD=! M[^5/?O!B)5W[8[^9.&NR5=^_F3CVQGOC'MCK9UFYF,VMI2J#OJ?^A:?T\K^> M,&EZ17#GV4NC\I%=^WRZ!W_P#[*+^K M_P#@_KQUS\H%_P"ET#_<47_V/6JL?]GER/WY:V_?387\5[#.XK'' M7#QR1D+IU;UF^"^T2W(-%=R?DJB:G5(E,)B29"HU&R_(BMKD.-Q7W5"L^9>4H[XPG*O,I. M,_3Y0+_TN@?[BB_^QZ6/1/AIY>/G\L1?S^/E]OITPSV*UQW24&FT"-0(+!PT MVO"B#<.C(E#@1&2(F3@\-Q*,?#CI4H $D/16DI:4Z*@*QC'PS?;WMC]#1VXZ M&H>I6&H+:T14HC49MN(UEOTUICI0VE,=&6L>126L(1E&/*K'EQVZ=+Y0+_TN M@?[BB_\ L>L)8Q(_-?/80.@-JR&+);6F''5G&5#I"<*RE+:,Y]U9QY,*QYL8 MSCS?>]EC9::+3DK5E.494I-:%X4K*,J7E/?.,Y\N5KRGOVRI7;OGU;! M*7H/6)L[754#7.TM.PTP@!^T+IPV4R[)0W-==/-A; J,Y%BY7(99^6.8ENH3 M'R]'PO+R*CI?F!IH#K;H!<^[%/KI]<)8_JC21"RYMEGH>NY-H?K[E64<- *[ M\TE5O!"$24'7+EQDORAS!&!"E-,.*=1$?:2J/Z/JO8=1B./W%ANQ![:SK#4+ M-B Y)Y$EV0U<:E1,&13P0HVG+?E:=:FC'W(KS3[3K7EREU*$OMMNH\-4A2KC MMX_G9U*ID0[$TWJZ4L$T=9OB!$DK9MCN%6\8)5@.W!:R2B/0HI"*E_%ABCFI M+Z(3D-,1#W9USK_/UHU.S^VL _\ W#JWJ=0E-MM1KH;:^MO=>K;0D["]MK&V ME[ZZ?089TGQYXJ&9C) GJS3DR='F#B#$MP%6DOLS1+P^0.DMN-8;4AV*Z*'9 M:4G./N1&FU^=OSI5ZCVA^+UGCS8I_6&G2K)%DVQ+^+K]46ZM%C1,;.^G)0TB M1&45;GS6IKD5UEQ]J4\TI?IKRGIV/T=:_P#Z1Z?_ %L _P#W#H_1UK_^D:G_ M -; /_W#I8_ZJ/AY>O=Y7FX_UE^O?Y^AJVKFFN.3T$8->HNL7X8<>/%CFGH0 M-W,: +'-"8$;#SCBGW&XXYEJ&G+SKJULI\KJW,Y5E74-I?C?7PT*OAZ'K"$' M&I-(@04P0;S,1JPF%GS#+.9*WG4,32Z_C5L>IZ+2TMMQT,L--M(1EIYWU%K6XXI6=H6DN/])MZKEKC7 MFNJY='YPM4!\G A2EI<1G]_8:PEQ*>Z%)+C MJ8H^^M+T3;DG3]3IJ[N.G%$5E\;6S<@2PP:*#(S$DE%$18S\MR+!9E2DL->E M&D2'8B'7TL8?=6]YSW[^W;MC\>IB=04Y558+=-Y<-:U8URL "5[W8 M@U'CSG8#1$4WQ\O+D\23=:6A3X,K&2Y!-0%K2Q/&OR(CZL-.KQG=T3_%R.?^ M:*_OI_U'4/7Z'&MJ-O9VK[>WTKE?_K2'RN/KB1UFBZ1MBST&VMZS//$!TZI6 M*.=74I\I\6ZS,AD:X4^.6Y,Q#RR0G1Y(J2I#;:9LI"F$9?=\S,%N-7!,Z;IU MD,:5XPDCNOW"SM,*S*3JYZ975G:M]B3&1SJH79&"51PBN3$.I>0\(;9AY3Y& M6O([VN:@*#V+;7N/!+'E(A=-ST_$JF]I@Z@RV.SO?*!?^ET#_<47_P!CUBR[M0K\3$\\]7 D'+S4?$TN ML6-B9D2%92PQB1,]%G+SZL92RUY_4TV(_U1M?0\K>/+6WD/X];7_7STPUXRJ\< D\L3#@-,BR![Y?\ZF#QU"A2"N134ID;D@N,TUF8N S M-EM17'_4<9:?=;2OR9\N!ZJ\;Y$94-^NZ4?B+8B1EQ71&O7(ZXT%G,>%'4RJ M-EO+$./G,>*SE/IQV,Y::2A&B:[V6/#%QC,V:^NC9UZ?(2F7 MA\N%&8?C'H!B QA$YZ/*'27&V&DE8\5$Q=-Q10YIVQRI"VPDI9:1.#CQKJ86!]/%8 M@$ ZC4 6'\MR3?2VPN-;8J )!/%TN.(A1O8:"QO]B,/B+I7&@)**3 U:TH*D MFX8D<7<'"J!#^9P ,:=#"PYJ([+;;"P]&>^'E,/Q7O3=5EJ0PZR MYY76UI3@1<6-%V58$1H\>.E5&J65889:9\V<6&\=O-Z2$85V[Y[=\9\O=7;M MYE=Z@#<&R;:[#J-QK[O+S-J>N^@Y_P#A'W^ PX?1T='56*<'1T='3#!T='1T MPP='1T=,,'1T='3#!T=)*+?J1-NA;6\2XU63L($ %6LS18]B#OW(35CLV<-" M64I5VIBCH\ 9(BRD 48F0&1Q&:-GQ8JK.P4*]4>FP#(4R>*R] MC'QD6,\\WW2COU\:1LW7^R57)%#N%?MJ]>WD[K2\( DXY%55O]99'R#]/.X8 M4KY?8!#!8:Z0&O=GXS.SRZ@5:,52WA1UAKQ=#,R&T2#E8R)<"8B,2C0IT?$B.XAS#,R)&DM]_(\PVY MA2,,,*GHZZ^=']&GZXQ_"Q]<_3'U^N?PQ^/X=&'$9SVPM&<]N_;"L9SVQ]<] ML9^GZ^F&.W1UT]1OMW\Z.V/KGS)[?G]>_;Z>_1EUO"^5)QCVQW M^O?M].F&._1TF@%QJEI>L$>M66OV!ZIV"74[0T$-#2SEI$+. C6FO0C\-M67!TDS7)D0V.:>QYI(V2S*1W;7C/ M7NK=SJ=P:*OU:S5ZR,@; ;J1QT <%FFPUKK4S(^Q5DJX,E2D#K" GI7!-!9B MF"8J8A4:?%COIRC##"FZ.D3C8]$5L%[5*;: SL>/38NPWZ5@E'^T;-(FG958 MAVIP7YO72#DV&#,#,D,X]%PC%?BISEQM6,?"N[0UY;+CL#7U;N5=-W?54RM# MMCU4:4CRSE)G7&N,6ZK1;) ;5EX6^?K$F.=%-R,)5,%O-RV\9;5WZ887O1UU M\Z.W?S)[=^W?S8[=_?';OW[=^^,X_BST86C/T4G/?/;'96,]\X^N/K]?;/\ M)TPQVZ.NOG1[??3[^V/O8]\]^W;'O[^_M^WVZ,+1GOC"TYSCZXPK'M^WW_5G M^3IACMT=>$B3'"1\TJ3GPAPP=#E$)Y"?+CPX,*#"87)F39DR2XU&BQ(D9IR1 M)DONML1V&W'GG$-H4K$?=9\O.-6X*#;MJ:]W/0S^M:$O*KG?%&IM M4RA,+8^PJE2Y9T->K$&CV,U$%ND@>LJTY<=@%8:)"TY?@TZK-.'[#(3]P:*0 MJ6_G#>/=9UBT5VZ5ROVZJ&AM@K-K!B;+7#@F4U,&&P!T?'*ABXV4UG+3& MRXTZ%);[H?C/M.ISY5XZG],,9[HZ0VP]ET'4U:7<=DV^OTBK-FZI6W#]E)," MA39V\V<12J>)7+D9PVF=9+:?"UT/'S]^<7*0H3.,NOHQTM\+1GWPI.?O93]< M?PL9SC*?K]<9QG&LDL"%DRFR1F+7F2PITY(&QI+0ALF.<(+C(FQE.J+"T9QG.%ISA/\ M+.%8SA/[<]_;^/IACMT=>.<1@#8,PF1G0X X=%D3I\^;*8B0H4.(RY)E2YDM M];<>+%C1VG'Y$A]Q#+++:W75I0A2L8^N6>N7"O@K95#X6S5>T"!M@K5DKQ: M; 6$"9B-3PYL&9&2)0TN(*P)#$X:3'R9$*?#?9DQ7W6'4+4]>OCAC.='7&5) MQGME6,9S[XQG.,9SC'US[_EWQTD(&P*,4/V>JC;E5"%FI3]>C7&NP;(%EG:G M(ML+!*JL68/'G.$0#UF'9Q/K[1:-$<-0LXE#$RF,X1L;Q"EQWID=['%O1/D>'P6B,Q&,BN1Z5^C#?:>:>PIO*T.Y6VKTF5./)[*; MPK%C+7^9-]NW;R)[=LYSCMVQV[9S[YQ^6<^^<=LY]\]5L;1ESH>PO$&>@0H4 MYS]S-Q]:?;G'\UIAJ$_"Y&LS97S7$*=E#T2,IQ^-$]%O!-]#8[,F+\3\0BR5 M"TH91E2L)QZ>,_?[-Y[)1YL]TJSCRYPG&FG+>?.CU,JSE..V/)YE MJ3CIJ*_N"I6&XRZ6TJRXMT;Y]!D19]#O8>OLL 926IKKY\@&S7$-S',Y<%2E M%,9-Q,82-0\IF4AO5$VL+BYVOSZ^^VV-A8F]@3;?P\\/(PK]Y]7LYVSYEI0X MVI#J$=\]FU(]U=TX]L=^^5>RL^^>_7HQGOC&?IWQWZ33D]V0UA^)Y)6(RV67 M1^%)8PX^MQA]"TR)'PZFG(K6,NNM*RM*&,.=V'G\):3[?CVF(SWF6[EQ+',=YQ&,HX\TWE"5K1A2\K2 MA.58\ZU(1EQ26T8[K<4E"5+4E"5*PA.59QVQG/2:MDA"J[9$>JEK$< 7=>4O MTU,X2L3.[(>^ZXZG"$^60O"6\9RWY,XRXE2V\XV:7"QF%LS)$=B'/:>QZK[J MQZG94AMMZ0^LEE^.N.IZ&^A/G9PUAIWSL8D)SEAKI/VTM!D@;0]"5$=7'!FV MUM*4GXE$?Y!-;S)=0^XIE4%S+\+'Q4?*UK96UEW#R4)934 ;I.MKCI;<:P*RAQM.4HRE"T]EH3E* M$)]\]-F!O(767&VO[#L+,_->I>G:Y9S: \+)&O[U4[YNNZD*?:0]H%MZAU+*2\%-MDXC39FR;.)P):8K, M5+,5LJ.=C28TY!"7@K';1CX:%B!A( MT;"+ALQ/=@>VRC$/#J/(E3^'5HEI8;:0RQ\%G+SO]4IVUM>YO;J#;U?7KB5; M^Y/T&#HZ.CJK$8.FWW'.F"]2;0)CW\QIX[75XGPI">\G*FUT@V-5C&,9SV-Q\ ^^,9]L MYQDEC.,?7/;MC.,]#L<2-QYCZX\7&X5&K6LF:?#0TU&IUINU<999QC#;3<*T MDWT(2G&,82G*):7$)QC&$H6C&,=NW2J/_P ];7?^Q?9?\?[]0>D-H.;(?+\@ M8+V<^4/R#N$)A'MV:CS*EKT\VA.,8QVPYDTM_P#:]G/?WQV7)_\ GKZ[_P!B MVR^_Z\^M0/?_ ).J1HE(Z<-K=+BV^NV)YDGF"?>4W^IPH[K>:QKP(NQV\JR& M"HG"ABIS[4R0G)$X2C" \)#$"+,ENOD"V,YSB(G*.K"K MIOOA17CB9;@F7LC<+\^)%F2(:"3$'0=VEN"">8RTYG@BN&LP#H=_SP3(M^2. MGLO1)#K2WQW_ !34^LU6 $PUA4S9^MT%'9$P##C,A8MFC$IZI&#KK#DQ+OP+ M+#<0!(9L^9#K,D(I3\9QIQA^5<6W$-X<,X-%+# %EG7[=D.&>+0LDV ;$KC[ M>V9IF*-RE48D6%15N3A XCV$SB##$0HM$)YY:=O1#>;*! (%'KVEKDWH=1)' M0Z#;XXU]1_PS)!L?Q&E:]+52$1R\3^V)%:GKJ:V;W/&::D,L$]L2; PA\X=. MX\IJB4.4\XRX>D2'1;+DSXI;8$6IH ([JCAV&(RLLH>7IGM4KLN2VW6K3.KI M&;%V:[%@2ZX/G#67 2*12' R##,\B2R[98T-[$8Y*A.QA[3IMC/._N'T M&/*_.BQEX:>>0AW+2WDM9[Y<6VWWRO+:,8RIS*<8RK*$84ORI4K"LQ@[%A4T-98(1 MEMEU4A)!J#*&E)-I!S#)*&\QG*",7&7W)PYQ?PZ)$!IOT)*&W_23Y5-.=Y,= M[#[*E/I2MJ5AE'D74GR2X;TC9$Z-8D5R-L E/:'I+3D20=>,3*U GR3+>%3R4!V..7B%B&S'D]%EK\ ]O!S"S)?AE "6XZ^"SA4F MRW#Q-*4A">(\'>-A1 2JZ5**=366JL_ =:HLMB%.4+-R9#'M*&Q8ZI:)X5*O M:Q6%)&I*56L8UL>()S0O4APQ2">H85=$,-N6^+"H-C-2AQ$>&%L$!MW(:N3Q-F-3P!,#,G,S;=46J@\,4, M9?D0(W8$Z2M3![-@1-@M?+ Y ZV)<9./M%(+CL!,1VM[]#^^*5:@U8UAJ;<= MG@S2DYQVL#YE(FP72YDO)@"TC;"@]#@@*9E$$C8"):98I$O =0N,*AR6P4D])A5ZOYUD!KXTS L#L<=+2++648?B%QN(06 M8/*S9<.0-9?F21JLMF(!#-&9DG^.@ E.$2J M[.G; W\0G@2F8F"@B7+Y$;95*@3?@GG(SLB-+:D(5^/A/=U")&0 M%>?99]792>]&JF.R\>57W;'>$]^WY9[=TY_%.<9_'IIN-E2EZMU%%K5N&P@1 ME5QW!9YHOYD*G*'C[IMF_P!W"L3ID*;)'YEYKIN$LDF),F18TQ,Y+TU_#;DM MYSP3[4F_EGF6TM-+U_3E(0A25MH2H[=5>1IQ'[VZVG*O(EQONVORY4WG*,XS MG1+*5+*DIX4*45)2"2$ W*4@J)40D&P))) NHWO?UA((%B;D) )TU((N=!;4 M]+#IA%.T];@6;1?->ZMNEOJ-?DA3ECC%CX$)*(#8[Y5J^)W?LN3O6I4C M:FD: >X_ZLLCKH'9P^G[3JEI<&F+AK\1<)H:BO[&?LMDNU>K@,&(CA]J4PPG M8&SC&?KW^F<>V&S*! /WUP=!A7K%'V'$ONT%[:[^(VOSZ6Q(MH+#?L;_89XX-1M:A=OM6@91K8=,$7;1/.5]>K19*LUZB22,XD MK-SK:&)[],)I&I[,K)7=4C8EI*V4?8=QGS>L&2AF*6^SVL)%?JJ0H*(W%@05 M#V6+#BV/_"S\D">&'H7Q!)]E$9IE^^@V^^GKQ\?AB#@Z.CHZG#!T='1TPP== M',YPC/;/;/MCS=N_E[YQCS9Q^2<9\V?IC&,9SG./KUWZ.F&-733D[D<.YF:T M\3_6YIJ'9Q.Q M9Y<=L8]_;/?ZY[]_UY[]\_K[Y[9Q[9]O;HRG&?S_ _T6D.8(G M2$^.^>:?+.OHI;'''D!R+WMR;MOAN\X-W;]T3MZHN9A4#FSJK]SA#33J9026 MK@JZL6U/)O&VF:QHFIY/!S0X#K\BX#MDNY#SMVW ,MI5C&,^;MC.,_PE9[]L MXSV5WSGS8SV[9QGO[9SC';&<]12U+P\U#IO9A;<, IMJ^[)GUHI21-LW+N/9 MFY2=*H9NP1+0;I="S?CYQFFUPT>&A9YUD.RQ,-_9ZLQ3!";!KH:-#BVU[:?J M0>O4<[D^=R9)\+===3UN;H>,[X;+NW2%\N"C0K8J0*( O:I-[]U!7L2<2+M!*N#]LU#11F M-4X9J]S:YMB\. $UREVN%3!U@F5,D^Q:JV2)R+*P*&UX(;&6"R3Q(26T04[F M5M8SG&?5[XQE/?"'^ZNV"+AQV1+V+/.UG&5=U=L8[]\)<_T/MVQVQ[Y]NV4I]\_CC/?'3:T M3;] V0?VS5:@8?*F](["CZNV3#4++1OD-UET*D[,8%-R)L1IDJVNF;"J97YB M*[Y;^&F%]_( _+[?IC5EY#';3OBC;AU1Q[Y7 M\G^3?$EE/AI; +;J.%&S5NJ?)6U<]M8A[)KZMWQW70);R9VG9D;;VS].KJ\L M;H2[5>GYQ!H8\Q-I+MF?B=[,W7I\OP\UT VJ4UEQ_LT'<83 \0M0-9%-RVNJCW)ECO0W5X9TA%F71F@5N.8NQ0*N<()BX+H8 0> M,&(,H,+8G%6EP^G$&EAY<>/*P5O+A$H4,A$<=AS83N8L^,U*C*D1ID>-+AN+ M8>:4Y%FL1Y+"\^E(8:>0I"7[?+W^?QY\P-K'H?'?3]OUQK=4CD;RW&;XXRTG M8_)2R;#TN;:X:BN9^\-*T!PEJ^I7\)&M#7) MHK'I*H&IS]EIHL&0UI Y!3VZ QO$CFYMT_4N.^Y8G)GDUR6WT39YI.\P.+04 M$$*PJMQZT=7N1$^C7*CZ^9H@H?1=EMWBG:-I6HKPX>DN;\,[#/#Y;%O@0VVZ M/MB]VU9\OW^^,ISWSAW&.Z%8SC'GSC&,Y[XQG*?-W7COG.,XSG/32Z,T;K+C M9JNKZ:U$"D5K7E.4>57PKY9)ZP%IB/B93V8R)& M(T?THK#+3<6 L1;S]XMM;?D=?&]\ =_O;X]1\^A&-8[1W)SEMLK!6B4_D7M# M.OKMR9\,6,&OE*N1+?A^D4[DS!W-$Y&T85O+9FE:S"L,R W2:VW:5P*I-J>G M-@3"XRNMUQ\S0=BY/[1GUOBMXA6\-:!*Y9]INZLY4:RW7&UC;'MF[BI]VV(XY2:63K\%GD/&K(G6ESO41U90K-V@\K M;PG*L^IVQCS9\R7>_;">_;"58[YSVQ[HQCOG/;S8[]NF#J?*+0USME[HXC8H M9BTZ]WHOC6=#'%2ZU+F;N;U4 W8YKZJI.MC\7,RC5MC'W)2:IDLPD2P9=R[A M0(RF%.@^_6VUS]]_EB;CI\]MMM^GSQ1GL#?NVFMUV2H;HW)LWC/PZL7/3EC6 M-F[SHT ?JHS5_LGQOXSVOCCK$_N$V\D>56KE4GPYM\4FYJ]Q=VC MLT&1UZ22BQ7S0=8UK<;UJF,/! ;F_9GV[+4&1ZV@C&T'YD9[=O-[Y[X[8<_+ M]6/X.<=NW^ASGMV[Y[==/4:Q[??_ "[>1[.>WMW7G'E[]O?W=S[=^^,J[XSV M6%_T]XU^6(O^W@=-?EBECDIR"VW-T!X<5MV+L>X\>M,;_E4*3S2WKK6*JJ6+ M6S=GXWE;M3:]-M[HPS*T70MA;U6%IULV:T-BSJFPZ+K+5DJ"[*L]$A5QP';9 MWCSY\.#;%OVWR'N=(IU&\6@+J'8-BC-59S;G'^@;RXR"M#779PU5!!,$)>VZ MH;)Q9MC4-JL[;U1UW0+W"CL_%%9Y[9CM5F"TRK6*Y6%^3&K]3 %[.;E0AI4U M,CA@(Z05)OQ1 .&2-EI+4&(^XR,$#YY0@XE,6!"ERW6F'/H L FR@PMC#O27 MA!X0.."Y$J 4&//#2\*.1@NR8):)"(09#D20RMV"2B12$-:E1Y<6/(;=90MS M-O.WEKOX>[3IJ^/CKZZ8UU.1(;=.OM^^)UR:U1M'=M'LVG][>'D7I]#I[4#] M&>U(Y;6>D*/?H.Q*](JA(GL<$1J%D-@9<",;C0ZK)@L6$+@3:1^2R/J7W;LS M.QP]:WCN[??'WC>6YL^)772^RM*4YVKER6PM<[7UK$XFZGL%PJFK;$1AURX5 M(CMX]76GH_K[QNU/K]*.F;0J:W5K9?GMC;U TI4,7O9!EX#6,VO7]*R02++$ MG,6/9][KNM:5"3#%Q)4WR%KC:@8MR6ECX2"B6J>0>CP(\F0TW')'2FN]PU=J M3L39>X-6U^DQK,8+V+5N^=DZ$:Q7I(9;-I1;3U$L=<:GU^,(A.S%22KZLUI3 M#QH-/#S$N3>H^&FGAJ1;WBPT\MKC$W'2VVNYT'+;ZZ7\!C62TC+Y*VZ3RAWM9*1"NL.709X9U,-\&-78M2P X MD4?B37@-D#RA+;$%+D4_?>\M0W?F[S_/S+56ZUK78'A9[]Y154)4)/PVU=(W M'P]J-2-[!0P22*?DS9.L3M]8VN(&@)D(A%-ZWS7I,ESXQX:_L::5-: HT"F\ M;=(MPA-R*[>ECI%1/)EIK4M*842U%;6J* MF.?-1<13,$F0S.ZM#:TY!BZ?7]IP#-AJE.V#6-E?8UH_8!-4ME@IDA9.JPMB MUP7*B0M@5,/8FQMK8I=L9)569: %?,$A4Y\1$2F1<"W46.W4&XTY$:::\\+@ MG4:::#W;:C>V*@.4FX.5?'OPP^/6R=L;HM^L-\;$Y-<1,[TN];&!REAUC2^2 MG*6KM[+UT #DJD3&OQ=5:LO4G7(AK[*3Y:<5)HFIDH1PZ[+;'7G+2T:AM-7M M:.3NQ]F>'I2?$+%ZNQRBVD03=(A[6UZX3;3G6.M6W;B*O!5<--43F2_KJK5' M;TME Z#9RWV(*WLL*KR/AKVMR:,UEOZNU:M;1!2; %INT=5;FK\5@N:".PMA MZ6O@79>NS:WPLR!+DH"7&O"2CPJ4XZ,+(CJ@%8_P!U/;&,X^F/?I;]#?K:V_P]6UCUZ^=QIC6WT?O;F%R% MW!H!D9LW><:JOZS\53D##ISM>;UXQM:T<=?$3%TKB+K+9[Y^HB['7:,4U19! MP4A58\ZHGKI26(;94DX/P5?F.KX16W.16X;,NP;:Y)5"_P LSQQK!S>^B2.V M[==]PZUY.S+7%18IY/6%AT!IY/%82*86->'86^?$ U3E+ MJ*MG;KLPUX>=,WG1-Q78KJX1L1[>8[D)=-3GN,EK?H<8>U"W#L/1/""Q['VY MLJFUN!@;:MB1*6"-!Y35OFUY4T?#!D5843WUH+0>WKIR8X'ZJI&C&M$[(V'. M7<4U"Z68)<\;2X[5._R@HF/L"@T*M!=67,8&;BR8>G2>R2NG1\D?7ZN#I%)M M)J&IZ!1+KMG85:$R(-JW?9*S;=C$'"):6V:/5&@UK6(&5&@3)#T(/\'3:B!& M+B"&(;,EV&HC)9=(29,EURL.-XSG'W^^>W?*D.^7';MC&,J4GRI[]_;&;./;[N48[8QW\N<8[]+ _KYZ'XBPM@#;Y M?(]=_@1C4HV9(VM?J5K2U>@UCQ?A>K[9JW9MGY',5/7A/@, ;"ZWN M.[2NJ]6E]DVT7?Y5O8"G"=8>*2:P2JE>FG[-8![;:$+IYFT0'@-DA0X8^^HL"ZPY" M.SA4:OG'IB:N:S+A "I2:#5&8P^,>RF_ M+YN^<8[XPI/?/NK'?OG.8M;8_+EIX^'CO@3?YGXZ^M^6-4[Q$=@V38MJY'T/ M9^\-U!-UTGGMP9"Z1XA55N3C5UOXC"]^\5KPWN9=+AU(@Y?!Y"8C9-MV%NA5 MJ6YK*R4N!1DOU2' DURT28'.%Y=V_CZBTROLED8'UE8*U^@:7JVUR)47%X>'Q80,P>G"[,PQL-]V_+Y\> M;"Z$^^.WOYNZ?;MW5]/;KA;>,>;'J8]^_E\CW?Z]O9OR]^V M<_3LGMG/TZDBXL?C;]_VO8VTP!M;2^M]?=]O@<:L4#;/,FD<(>*VXY.Y=UW[ M>>YO"_\ $*Y17:UW:J5XS8*=O@%Q6T09U>"I(B)1(6:&'K%GC39X*BPV&7;5 M8I9R9:&[//ENICNKO#8G,CC67Y&ZUI>]>3.SJ6:T-P%Y!WK:1VL!]D[3T/6= ML\G[WJWFS==##*_KA<*/BIZ'K+6P@VMH]9N4?6L^#.M%.J^8B%A9>R3A;><^ M7&5]^W;OV=QCW]NV7,XPGSXS[=LJ\Z5=\>RND+LJB!MHTFQ4,R8NU?'6*$B$ M^;U[VVM_:ITN2I0?CK=-MQ_GME5 M7#O$&H;#FY#GRU-KA79U:F7PX7F@+O8A]@D6R,M"$G+$.8C3)-=D/:_->UZ MV9LR)OKD)KXYQ8\)[PP^4VKJ5K^NUVLU"X\B+SK7;1G;PR]U5C7[C=TK]C51 M*^#LVHXB!X$(R4D2X040957YPG9.T#QRU=QM!VH7KQBV3RFP[C+V!L:[W^YV M_9>Q]@W66($5[[0W.\70D9L11^#7*^!K82"Y*C!J[70HL& &C!D-J-A_$J0K M*DI\_MCMG.<.)QGM^*5JQC"L^_WE(5G.<_PL]\=38"VVGZ]-=-;?3"_ASN?' M;[>6NV*KO$]388 MT3**#6 >^*G7]46 RB5%&CJKN6<9,QWHP3#\>HWD4)WI&3R!I'(G?VW U7XL M,WC?U(C!*5.S&FTVJQ-\;5/7.'KR2HQ6@M^,/W]) G$GBM=DQH1S*!- M<#2PZML;.,9^O[?;.^>_UZX\N/U_Q9SCMV_+MG';O^/;MW_' MOU'"-/#G\+GS-M3@#;UY$?,8UJKIL?DV%K^Z]LV7DOR($:;3XDZ^*-\N0+Y8 MJ#QUX*BF11;.Y*.P,H9!Z18[A?Y=6J%TY%FL'DZZU=?#)VOYJ\6JNVJ'9IX: MM^N5\HN]L2MD7K=FE:CR+N5.XO[NV4GXBW[.TT+JE%DSIZ[/@$#SLNKU3:\[ M8]#HVV7VY7';M[_ %[_ ,)7?^+/?OC]F,]OKCZ9 MST8QC'T_ESWSGW]_KGOG]F/PQ[8]L=2!;8Z=->EM[[>%C]E_M]+?2WEXW)YZ M.CHZG$8.CHZ.F&#HZ.CIABN'8;>'=C>(8WE49'FXN:)SYI@[)>/CRB>1ROOC MDNLYDYSV[-_OB<,NY1(SWPSY1>&4^@K&5) M4A7=WLVZMW][\B\J5W^F:\-K"LE]@^('&3+LL-3/&OCP02NI%?DQE[Y=%Y%3 M<1$S,NLI5 E^BJ.7AK=0B>*7,AJ[X?\ *K!^(AS?'\9P3(JNE:8Q91=>?MEI M(W)95VIU$;.;E0Z9"(C8!,''-V2\%H!1NJ5F>982] !%R/P)*8H$(-;J?'>F M56'%CM+>D2:?EZ.PRTDK<==;%LB02PE*FN,1C.CFX4);1B37\RU2(# YMY.2FGEL MCDWR"WJ4EFFSE@OU3(&D1\'-PG2\$,X)>%*B$8$/5@-=F+'\M3]LLRW+:4MU=I+HF:3.29E>8B!L89:Q$FCQR,1H^4N M5\(J-%C*C3IQ@M.'BX\9HJ](S\6UF.Q.S^EU)%&S%VGY.I=>*PRFA-S#5JJB M8LI2F$_#I7M#\:2'2&7V7D)?:4M"5,A1*1QU3[1Z3!9,B-#JE1BAPH5-BPW$ MP#PD_P#-S7PU&>*^%7=]VXH+"5*"N <6-[LWOZN"0Z7F9HDFJ>1+#H\89EJ" MZ[8H$Q+)T6R^*^;J^T['Q<@D\&D)A3I315AR)\P4X_TV-BY254BL3 9,!79Y M!MYV (8,)%QTI@PRDBQ$3)G!<6V@Q7S$4T-"SC44D$:NH-2 @XB-<9' MABL4;,APW0@J1&ZVBM;<,XM[:"8*OM#V7B"[6IL-(2,.O3#R84L^Y/<,L62? M/!SHXV&%B1$DXD?(T;#DMYDRI$6;UV5S_ (G57'3)9;E-!$5YISN7 MV XRIQE\-.HLM02IM8;>_(XI805MHQGY>S4YF9DRX$!UF*.)(7)4A)64N)'Y M> KL>$+U_.B_"05#BM)@7R&!VU@"\^IP0[+1ED*3E*CE*_9I,2>L=+' 5,3G MA1!44D_%E&BAUNOSYD68$:"PD3XKZ&W38D6*4U>II<79XQ!4 A(%$G\, M98>0$?8[8\T=;S;(U>&6B.&7%LS,QLJ6W'=3CSQ&E.1XZ\)\V5>^N@ MY<.ERC:Y2A5YT#6*+8&GDA;#K&IA#,2.YC"G1S]8$M3AZE3([^'(TIE+D*6U M)C+Q(B.O,O(QEQ796V:@-GJ*FBC;3<*8RU#"08UBIIB.)M<.*$D0'6VHA>2. M(ML_'L0$P"3F(7K2(,F6TR[%<>2^WZ=:(PWKNB(PE",(IE51A#?F]-.$U\=C M"4>;[WD3V[)\WOY<8[^_?KV70K9PE=($JA5L7,_'Q'^ KF3,&OX(*HVZY.7$WNN\KN-7C5"2UJ/43T M4.Q<1%I<2N>>V5(+9DQQP> \+7#)X>%-2GIY2"=9'HF#4C\L3&7I)=$[>%S; MEI?QU^-CX8'?W#Z#!T='1U5B,'3!\F:T6N.G+'5PL61,GG"E&'I8BLNONYBO M;%J'S%U3;*5+^'C#$S),QS./38B,O/O92RVXK#^9SVQG.?ICWSU!ODGOWC[/ M!F]8D=KZJ';"@;# 4F,!OAJS#H(B]N#8UGCL6.)5Y@@^T-Q5ICD_)1$QD S\ M5&7-GX\OI]0HV!ZV-AU/(>_$IW'F,2,US6 EJB/N(2U(0W(K3[3N6%+0T^E;2U8_GK:\_V+[*_^MH'43=/ M\C>-.LXUFK)K=NE8IG$NM'%0*?;;(6@K'6J6U4*[EA%C)&Y\HL1LL">/>AAU MY:1E8]Q^$R\^[)D2Q/9QG:VO.V?_ -F-EX_C2]0<9_DSWQU )*03O<:=/S;> M[%1%C_X="1:_Y?'#9\KNR-?U61F*T15%W1I%QH9(CCGF)[KNR@,5&%R)HTE+ M%*@9?^<,&PB89<3)&LS6Y\<>V10\E][9Q^Z5X1Y5_!QL#>659Q^&,<>;YW_P M_/VZE>7!!SR(39D;!)H'$8A> B?%8EIA%("U+A$8N'VUX8FQ5+7Z$EORNH2M MQ&%>1Q:50]Y' QA[D9P:@E8V9<:-M+;1AAO+TAG*"830]T*"Y65QW65KS&GQ MF7\LN*5'?\F6I+3S"UMJV]$!$V2>1H]=T\J'4?A9#AO- MNI:EQ9#3B<28TR%*B3XDR1%E->FY4N7&BMY7)5E*,84K&$MN/+7Z3:GUX;:9 M0XZZI#;:W,I;0I>$H4K&/;J-7&W4$#3Q?DC#@3USD;#Y(7';\EM,3+/&SLYW"94-R=Z;+\$5"S/R-!AA(:%!AMR<6WA>6\Y4XG+:_/CR+ MRC"L^1:/*YC'LXW]_*O(KNGSI0KMW3CK4C;X[;7OK;WXSU;^X?08AIN6^;&' MEFQ=!!C+"PF*U ME2)#)&83QZ#3D>,S*:8)@R9,5UR)%==:>PYA;R.[F$)CNL*PW[9PI6$+PCRJ MQY/26]C/^:*POT11[<97=&5-M)<<6S$;]),9G*\Y^^VAMEM260" "HJL@"]TA"0;DE2E63:WP?G*RM9 M_+PA%P$#6Y58"Y4; &ZB+#0 W):TOIJL39^24*(B!-4^XZA^$M^"J*_,88B2 MR"/@I$9+S[<6)&:@QW4?"#LI,YRVK/?R9^F.V,Y0M:G'5>7"&U8;[R/W MQM3Z,J;3YEJ0GI*#4-L[(.--IPA&*+4^V,8SY<9S8[QG.,=^_;'F5GMC&>R< M9[?3MV+<*^$:63HD%QK+*S"KV9SS_ *<)B2:E=FQ0]R5@B0]E18CB,X5FK'DE MQ.USL6\6K85SYB/TI6Q-DCHD$)$G-5L&.V! HQ;5FI1M>G52VUHXHY7 ^R&H MYXF^7FOD)\P5+A*ITO/G7.78?#[46T;T>O5Q;.$G[&U3G20'+X/Y'DU01]C% MU.R1G7J^_9(A M>R*NF\-0U$G)BKFQQUFV7204Y^&B?.%KELQ29V*^[&03&$ARWVT*:3.'S8:E M8D1)#;<3)_A6C9(11$4C,E'QV(-E1 ,PO++\*#AO+^%PY1B>4PQ\ 'A?K\]],-#J3KSL.6GK M;ESTQ9-T='1U5BG!T='1TPP='1T=,,'1T='3#!U3GXNM7O98'Q^M.N:UM+;5 MNU[=++9 '&ZNT#=UEU3R!,/Q*\)AU+86P-)& +^B+R%;E2K!IG;^R)L_558+ MQ[._<*Z4B^G.#W&==5(2K^%C&?;.,_KQG.,YQG\\>WTS[=#]OK^N)!L;_MC6 M/'\<=FZTY#$6*N[81M^KPIC=CK]>C_ %O"HHSE?B)Z:'X(;(M)+@&K=M,Y,RX>U&> M=MG-!Y&HFA7R942,AB-$??C2I M#4K9R])'T\N.W?OV[Y^OT[_7ZYQ[9S^/X]&4(S]4X]O\/^7JFW/G\>0!U.HV M(]]\+FUO$'X"WZ?7W:J^P"7.JI<5KQ3+%K/FI=-X\C/!*H6E-8RZ15-D68H" MYDT%K?HRVMW^Q 9'P.G]I2PE^UM8LWZY3:Q,N6*_/8''C%N#Q \IT]O:[WB* MC;XJMBX_7P_0.07/.JG[#L23JG>.WI]0K=?\,+CA6*U= VJM*;"UG=+G(O.\ MZN=T_&O=@MK&N]574?-M%\CONP(6P:6KVRA\#:DFVQ.:FL1.TV"U3NIBHD% MAZ5M4G4CU3>ITRVJ&HO=OQ,GU(L8OS!NXJ^UM>1HW6/'092]#M[$'76X"2+6GZ:/JUE#\B/W1U%VTR]<-J.VP5@ M .O#!6GMAME_TT=^_EQ],8_''?&/IC/;ZXQ^&,_3\.N/2;_H,?7&?VYQ],Y_ M/./PSGWQ^';J;:CRZ>(/CT_?"^EO&_Z6^_7PQKTUG2VT=(6[2_+DQ!W\(M@[ MQ&/$'M^OX=AI!FQR*>,T^.'5S1MBUHXH+YPQLA7I MP";'?/O)E2HYEW&T[YXT\.]O0-5\D9O':];.U9L_E3IG6\&Q,<@LNAX;5MKG=1G-SZYUP4.V4G6 YH6P/L@J*;"D;;'H[$AER.^RV\ MPZA;;K+J$N-.-N)4AQMQM>%(<;<0I2%H6E2%I4I*L93G.,]DM-I0E"4)2A'E M\B<8[83Y>WE\N/\ 0^7&,83V[=L8[8[= +? ?$>AA<:>=]^6EM?CKC6TY*%] MK437_*FE\:=#MY=GZ!W-9: \>,-N) MTG3ZWLXH65HV\^&3JC2\#; VN:\E-64[0X'(8+5Z]:K1 %$E5= >POFOA*E% MN"G-I'TT>_W<>_US[]\]L]\=\]^^>V??'O[9]\>_1Z:._?RX[]\Y[_CWSCMG MW_7CVS^KVZCAU%M /G8@C06 UO\ 'X/7T]?IC7=T](Y41]KZ@T-9M;\J%&M4 M>)1X@VTMN;"+5^^XTT3XY;=U]S.+\;W!>TYLMNL[ J1B3M'4PJO4ZM3#2M;6 M.OL"K0'IV.^ M,Y]^V._0"QOIH+#3Y[G[VMKU7_<7T/R%N?7?%;:=G6G;?"WEGKC7)7:6P=O: M(U/L;CA+VFY76Z58MN\AJQQO#33UEUX*!G)Q6"8;O]IC5TDB,]#=![6&VBL" M)4Q==^8.U4VS6G-$1L?:F-$ -O7;D/LCP]G (V][ J.\Z"1XH[FK'$G40FJ@ M-:[NN%L_]\+^'K3?X>&-7V5I385T8OL;B MOI+E50^,$L=X]FWZN5W.RZKY,[UY";OJ=#-6V/8ZB,XB2[%O6][1+43<%KV;6X9C8-&L>EZMK^E4(!=36M'2+C\( MF.?VCO31_0X^F,?Q8^F/];C\,?3'X8ZX])O^@Q[XSC^+.M=HD9='YC[/F<^M;ZN#;&L%& MEQ2U#GM.Q7N/FR]E;&!5S5VN>5M)\/JT<]=%2P&MKL2W1K8TSK85Q"Y+#^1] M@55;65#[FUQQJOFW9VF1*:=>' @T]?(=E,BZ]&!VB#();+GI-YQVRG&&AOBE^IA.06B?#KY>T01IS8>U2FN=P\KZ-H+55T* M;&/64GQOE;M*C-:X&DQ]@C[>V'5:GJ5/O[8^]]?U]<>FC'^AQ] MEZ=RXU#S@V]K"O:.YDZET$ I,K73]\:L&P]*\HQ^IM,0M!2>9&T0P M:D[Z/XU6 Q>!^SP&AA M%JKTJ[UUW9VLH37SH$&P;$WYNO&L*KRZ(\FJ=XM449I3:[>=SJX_:LXKUDMH M\KNFHV(K(,0]4U+64'5CVQZS;M)W>) V!9MFVL'(K-=F*CBB@':BRVC.,IRG M"L*QG&<*^]WPK^%W[]_KVQW_ &8Z254U]1Z*NSKIM4 UA=UMY>_VY0,;&'9L MEV/MPF35K-?#(1\P/%&AL!N<3D>>5)3$CX<<5AM/81?S!O\ M[QH>7.V%]][ MG]M-+::'KO;D+:JEEJG."_3^:]DH.D.0FDK+M?AKSE$6;7NOJ5O6M)KG(L+R M/U@GCA$$;KNFT;.-WANR?J^?L.Z5C9^CZE1-:QJ[8%UJMND6PB -=D_R2XJW M'7AKFAJRAE^2VNN-IZ'P3VU1) FFIWJD:YMCFZ+)K#: M(6J:C'*E8YW8XPTWCZ(QCV[?Q=^_;]G?W[?3OG.? MKG/7;*$YSC.<>^/IG'?&<=OV=NHX3UY_+2_EJ-M1X;67WYZ6^&WKXW&F-:FW M5?F39@1:S6[27(BBZ0*:S\)>;OCCMK.QW\_:8>KJQ Y)-4(+@)8.:W(\ MU1M;7NR[>HA +QCD<(18,<)V&&F'@VRZ5I:Z\LH-NM>I=8;,>@F1K) (E\*( M"SQ%?B[(7I-]NWD3VQG&<8[>V,XSWQG&/PSC/OC]>,9_#'7/D1[_ '<>_?O^ M>>_U[Y^N>_Z^I(V\+?(@_I\\+C737SV]<[WTT\<:Y'(?&]]-^!:0$70GR$!; M/H.^]?4$*_'NEI&='VB;8K+H/-3!UH^8L2)=B'%!4 MLN5>22D2EM-9>/6U]DWB-4- ZQYD4'@G1HKF MA9&@]V/C=RT;0EO-E].52T/S5U\!:+P.M5EK#+K9=-J*;+]]UU1-I5F13-C5 M&OW>IRBE<-R:[9Q<4P'?+U"QBK?5R3L&8AQAP"9"DY<@EAD&_P!W'NK*L_GE6?QSGZYS[_Q8]L>V,=-? ^?[WVY;F_,6OA?3G>]_ MI\_7EK8-ZJWU%Y!#1U3UORH#\SPWB'S3V-VSY&ROW+./#KA78A+!5EVVOF96 MDB6IU\;VP.LD:4@X;W*WON.];GP$8LB5L)]G!VO-X9X>H$C=0T0R O6Q= M(7?E'8[+K4KK"R;!U^/IPH1("3Q\P.+]FN''WDKS,+%-0\B=T4.X;7I*!^\5 MZ/W\!VN]<=M\D;O3\ZH/U*^F%T79^K-#UTV$N@;D+H\#4*%4N.& 0JWBIARN MXGEKPO31GOW3C/?MW[]\]^WOCOW^O;/O[_CT>FCOW\N._;M^/T^O;'Y8[YSG MMCVZ 6]?ITZ=.6APOX?'W=+=//?7'?&>_P">/?./?]6>W\F?KC]71T='4XC! MT='1TPP='1T=,,'1T='3#!T='1TPQ6?M@B*&7OQ"'C,H1#B2.-''R"APV\ZP M/=ESH?(B+!C.+CI4_P"M(E+::AH;3G+DM;*,]D95GJJ?Q0]+[(W3OF:0U#\L MM]9)QZ=?&Y,.;6K-1S)\53$T5#!^*-MT(E+-T]\0..0XTN&\(;05%/M.XE/> MO&NM#6H#2.3?,&WVF6H?7*WI?B\5-3DPR,_X0;&=Y!+DR%PQ,2>1D-M(SE;J M(L.0YAO"EY;RA*U8EZ,C+>&T)=72,(])_* MFDH3A6$/*4VE.%*4C'6XJ;I9J#2^[9>"Z)2XSC+Z5+:=9F9;B1'FU)2MM8XV M'W4\2%H<2HA3:T* 4-.U"CU*E3($MMQR+*FU5MY*'7&5*2*Q(<*0XRI*T_G; M3>RAQ(NE8*5%)U4=?>&QMO97D*3]CZ2H/S'L]#-[+L8P4@]!PC.7D#0$*]W: MRY3&@K62#6&'%@P7W9&/@<9#)6N18!KKP:>'"",0[OGF0^75H+L*H MZDHR)C)!*V!TJ+43TBSG'(RH3HZO#JX[0IT+2=?XXZ\9^-'0"TNOF:2V8E$(TR).C0#]DD$9-@*+=F2X;N MYHG)B>>4QF*/95*;4N5F=IZ6B,.8SLW6L:,%8[O=[O66F1L;TDRL9D9R62F, MSAAI$A*I&4HPRWAW&?33WPWD;?7'R'D@N&IV*LL2R9**C:FV"PHF74Q"C**D M%-41*IA%48PK5VQU)=3 MY/3\KN,T;*7,>3/D[+RK&$>W;R^W6>_*DRW5/2Y+LEY9NMU]UQYU9-M5..+4 MI1( %R3M:^-BVTVTA+;38;;2 $(;2E"$I%M$I2D) '*P VTPX3>X-/-R'8"- MI:U1+9B))/Q$7:K(?:A2)$EE$]V,DIZK<5^5'EM)E+1AEV0Q(1AQ3K3N$^$O MN#4KHJ:VUM'73CDL,2DQ4-W:LK7)CMPL*6^PE)/*GF4)E1E*=;PIM.)#&_'A!9\^E*D')0F,!DF4ZDV DM(!PILTG##/D<4/$UX5%)$2$^,.< M>5#8FSIDMIE#\E]QS(-\B-&>HUAJ:1]3"?09PWJ[9'GQAS*$X9;\M&\V$KRA MM/D3[*RE"?+G*4]K%S_K)'KS]?2NUM>%6ECK\>F'7USGO0*1_L0K'?&<9QG' M^0(_/;.,XQG'U_'&,_GCI8N.):;6ZO.$H;0I:U9^F$IQE2L^V,Y]L8SGMC&< MY^F,=^DY3;=6[[5PEQIY2*;K-C'L% I:'ZN(T^!(QG+3[:)#3$AKOE*D+9D, M,R&7$+:>:;<0I&%+E.%8SA6,9QGMWQGZ>V>^/Y,X[]5 6 '2V*<1;K.Z-3F] MQVJ4/V/2UM(U)JZ6\Q(M(.#.A-F['L(H+P2"3Y,,Z&?GC942=&09AP\S(DB. MY#:SA+RE/0G:>LU*RA.PZ,I>$Y7E&+?7$/)PK&*3J;5:"L0ZWK>C-F8#!"-#*M4X$T0C1RL9,,G':EMC4/I8(1$(C3& M:2\@OKFC%,2(TF$]\PIP&9EV),;D,RXR\OC'%*8DM2Y3;[6<^1U$F M0E>,X><\S\_^S\\/R?[7RPP50Y$"J#(FT[D9L[5@,\RQ , K]DZ"IM!N4 K' MS()! DLY87(R+%12F)88@,D2V"IBNXKER0.9P9(QAW$#86N-I[AK%GK%KHQ; M7&M I\ZSK1.)-9%62/6=EF%12M%J!.,O$3"V"-5#3F5X@*C+@^=N4/=0OX)<.(N+YDY^' M5%CJ:\F6&\IQHC46J0-<@4\/K>D#JH+9E1QE;BU$*V#'QII26:EQH0OY?F'% MC/EI\TBN,PRVQ\9)>?2VE:\YZBRK6_+IY\K6Z;873T-R+&UK#K;SZ:;Z;8:$ MK:-4"M\PS1B\5-.=A:KD5.,Q// E!Y\C6]J?M>8/K2)BHJR[0^]$2C,!S.)# MHN 2G1T.,CIBXRT7;ZG9=N42/7;-7CLB)5-DNRV QL65>C-*D4!"79#4"5(6 MRVIS/DPMQ*4Y7V1W\V<8RLX.KM9C,DLCM?4R#@Q-B$2J8M4#,MD9X\0@!!FS M&D0,-ORX@-"1$>0M'JM#4XA)7B/W;R!=6ZSK=HD76O4"G ;=+#/5Z790U8$B M34H'(+Y/OBI1*#"C27X#IM2BRXSSBVU$5KEYQZ[BUJ *YVW!-KG:QL+\M,#P M_P"U>PZ#D//]\+_J#'*&P+K>_.%Y.,',6(@U=]\?*J^!98<*G2J>-NQ'H :$ M]/?A!X,DI(83!CD#I(6$AR)$=TL2@0+UWQG]6>V._[.MU1+^V/VM_T17[^7X'4=OOR^8UU1_P[5]?\OI7A_P!: M0\*FC[AUR-/;HS9]C @3XR^.RYD.[SA5*FAA<"B5"-(\L4S\G=G5T;,&&(T> MW)1,$E5P"3D0U/CP5N,Y]WE3QB9D0HKW(S1#4HCF1@?&")K1QZHE)(EV=6W3-<0@ 6<#/PED0B4BIF7H*<,8T MX!',<^1W.O7S^6-A<'D;V'/I8=.GGCQ#=\:.,1'R K9:?]*9$]P,&>QV M=$CG/WQ3O[X/BK_?%]_,Y]]A7WU8SV4O^$K\.$ M)#W;ID@_-BP=M:RFR1JV&R,>)?:K)?@.2F52(R)K+!9QV*N1'2IYA,A#>7FD MY<:PM&,JZ^:MYZ40UZZ]P:N2SEEB1AU6P*EAK,>4SB1&?PYDOY,LOQ\X?9=\ MWD=9SAUM2F\X5TKU5.L_%R)[(,;$GS'A;\^=!A-P9I%03XCY2V2EPD1Y!"./ M3,F(C19KC\9MN7):]'+3[J%^Y00(M&6UB!BV\H;;RA0Z*I&4-)PEI&4Y8RG* M6TXPE">$# WII,HF4L9N'5I% M,%B-)F*@["J,M,2/-8=DPWY.8YAS$=F5&8>D1G7LH;?8:<=:4MMM:D^:IV:K M6O8MF(U6P@K+&8I%*B2IP L/,Q67735UGQHS\D;(D,-O.1)2)C#*UI<T-F$< 6"$4+'*R!Z8KI:$*CEB34 M<35+@14SI/I1D^JKI2,18L;&4QX[+&,^3.<,LH9PK*$):3GLA*<9REM"6\?7 M*6\)1[(QC'36^MK>%^FO/KYX&W*^W.QZ:[>!'D<>GHZ.CJ<1@Z.CHZ88.CHZ M.F&#HZ.CIA@Z.CHZ88.CHZ.F&#HZ.CIA@Z.CKJE>%9SC&%8[>V?,A:9,YX#33H.$VXX_AMT3&;6XU(?C/>FN$VA;C3T M=UM]AW",Y4AYEQ+[2\8<:<2XE*L07-_-\;JYV_(D"W"_[G'C[B$@V_)C"N^1 MW([#^9K\.+-DMMXC9?4A3461^_8;PMO+>5]IPP,^82)7&[ON0XL#NUB5Z&.R MH;*'$R,HPXAS+3#V9&&'$_>=2RK&49]-Q.TJ^LUD_P#=-"%]K?YEI^]S8:VU M/B1SQ@4W_"N?[QJ__%)>,$HFW-2DPY-,BAL4;-L,++7.BM/*RTU]W"\7XT4E9#XE6M.'?3G--(7F&](0A9EC@GI16IP_+;\V.- M7ZC?G;(Q94!;&G(>4TRE$M.75LIQ(CNO,R&HR/3;E+2\F0M;B(RHRX[N5CM/(:PF M0_F0[C*^[N$^CYL9<6I&,MH6I*GRIQD:LK$1'9?'L_,);+N$J]'>0N0 MA>5H;1EG"4)<])WS-NN*R[C+.<+PP_Y&\)RIW*74H=0IIM/J8ZOX2/JM7]&G\\]L M_LZQ;4S&,-/L)E/19LIY*G)32HBX:DY3%:8;AO18TM;+TIO.$+6A><8=S)R\ MJ(MI2?+@HB4L/NL\YSG.J!L/(8J5N?,_7$5V]8ZSON\-OO6>L!+'-@A=5H?S.6N8N%*?&6G* MT*CIF*3 ??@-#''6_0BNRF$0I#S;S>(S^5W^YPT;_4RJO\<)S/\ ;?Z^U11A M.Z-PJPC"?. U0M2L-H1ZBL0[HWYU+2\XIU6$H2WZCC;"TI0EK"%MMH=6\_4 M#>PO=7(7W.))/4[)YGH,,E^YPT;G/?\ 1E5?]Q._^WZ/W.&C>_?]&55[X_\ MY)W_ -XZ>WHZFPZ#X#$<2O\ 6/Q.&2_K1+TK95[A:\KR1@=4S"#DT#8;$B03RJ>RJ$)8'5J?B3.2E_+4AR&QAE M69.%(E9U$KD?9A%>M&LB!-E3ZZB@ILB*O'H]H61%_P!04*?+3ZN>R'LA-E&( MB7.V$IC2IF/,E>6\]9D",B5*;84VISO$O!*&RE*BX&7%-"Y! '>!'&2/Y;C> MV+;KBD-E07PV*22HFP3Q)XM+[E-[;#BM21' MO;]TQP@[ M_3](&[N^,_3M^YYO?UZF C^ G_6I_M8ZA_O7_MF.$'_A W=[_E_\'F]>^/P_ ME]NMS1/\7(_W17O^!U#&MJ7^';_]?I7_ !2'B!=K^3U$\P('737]>GQT%72^;^8?F735@*B B=@ 20<:N%%U(38F/B MXL9T]>[ T!C:E6%V^RU@D()ZZJE+8@2M-205,M&R216LEX-X#WI0N95USS]7 MN@*--&)M$:0_&?CET5@'#0OUY8Z%JM?M.J_F.PJI1BA]S8O(:OS7V0")XY+9 M3?VP(9,<.<-QY99H09?A0WYT&1(RQ)?;0N1YT,1UMO.SKBI9'HA,4VG,#6'6 M9D04FL"8;,8W#F0%L'&?YC?9CRVDA0ST3^8'G&GA(MS,IU$6.EG2-M[7X+$W MOPG4%2BI)UM_(I(3>Z4J!5;A*4HVJEIN-%Z)*390%R. H/\ *=BE7%S4"FQ! M2HK^&-,Z?\WD_1S2?/Y?4\F0(SSX1YO+YLIRSYO+A7WH,E='I8V"K8 IHH^L.-C1LP7 5F[HG.9:2WF"J0F.MU,C.8N7&VENX[M M)4C[WR1LP,@@6KTD?+Q %(TB7(3AZPM8BSE38D 8&A-362A@C!^'ES)>(<5 M3*G!V8PMUM]ST=6'FH9YQ&=Y!K=MBB[Y=T#FY1(,.H4HJL,J8+&U$M.LV9\R M3@6:RF61D1(%[069E4Y?H#1ZRPV7G8Z'9+@-T(6\T@)25N+0CA*N50H9EIIU0J:^+A$>"TIQS^4G MO'#:R&TV 4JRCJ ?S<.T>XOB&T_-B.NZ.3+%MSUDXBI52S)&H%2&H9)4YCU M'*R^EO#4M]B,K]_?90Y7WN6QTTKMYD!I?8^JQ]=MM=K(@=.$:RF MWR)7"&S1!FI4 K7@XBH$JQ:I,O9LROD#=Q=LCDJFP/A CM:FL_-$YI4U[7>. M5W0$3/CL+N!IFN? ZNVLV>LB0M?CSWPC8.#4R!4>-^)I2X&@F82R]VKE-#W?QMB[/V43NQVN'J0)=K6O8P6OZ8M2 -8O N3A@^8L34ZGRIU M/>,,38\R+G%H)UTG6(R+=/6*(36A,">NH&Z"]L2U&M:1PK-.M.HM,6H4]74, MM!R;94YMS+!9AN(KX1;TB$U%8L=7^;A[#TAG$MKS]8BI"1@+ M<-R#!1\(2(%Z@TY &BQL1B"/'PHMGW,S&AP845MJ-$BL-)2AF.PVAII&,)0G M&.LU[:]223H]71T='5S%K!T='1TPP='1T=,,'1T==;M]<=_PSG'MC.?;&??/?'7;HZ88I4V]XHE_P!, M6O<.M[1JRL&K]QVV7OR[;=K];*E<3I/!76G%BY>&QKVPZ$NVR^#V[8\0GM?9O%NH\CF>0>HMF[5 MD'[?KNWVZVT@E7-G64L;9D1M^ZPM1U\8#Y'4MFGS^0];^%OOV9H]CII0%"M* M1Q3HCW*#:_)HRR$L!/;7&_6G&@]5C%.!SH^:90;MMRY$6IAN7B1++A[GG:GR ML[4YD7 =QBM#WY.)ZGTM0U+H[BWH#C:P?8TAJRIZ[^TZ!<8U*"0Y+A*:*K[4 MIBKUQ18K+)%6:C4(TZ=$IE-BS8]3IT2=-B5<*(CRY+3L6ZZ@7&MB3M;$WZ>' MK?KK]L0%\-37TV)L+FG8C6W^26P7M4KA=9A:II6PAAZ M:M?[L? RS8LD8+JAV^= DVUN*3FP'33T-_+.*X=7[MYB:[TA9.JZB'A* M/6SM=(MV>79!J!^S#3M<4?7[UPD4RKA:T]?[F5V)=' \)N&NS7@W#%#RUI,* M1G.9AHA"!B8TJ8OLMUD?%1G&,-)ZQ@C3^L 6N26HA-"J!2N1-: M-)#KGS+ +>-P9EL^N^"7$;5,&% H>@M= D0#NL;,S,2(D$C#M@TK..D-1&)Q M\U.)G2A#6CUE,LT>24)3'*T/EI$B1'+7&5-CI\?N M#M<6VTO^L@CIRML/#6W7<_KSQ$;B/S@VOR'VL*TI9Z#1:U?]0T?>DHM$ZBGQ MDXO#] $=X7TU9(]^W1R5VM*VWNG8D:J#:7$.EH-="4&@UH#6X$PLZ&J.N=:5 M6LU$!$*'[":GR(IBS'3<\S89RT2LZ"_/UZ^_*V*3X>'TU^>#HZ.CJ<,'1T=' M3#!T='1TPP='1T=,,'1T='3#!T=04Y4\YZIQBO\ KG64RHMV>U[%K=IN$%1G M;FD-,5Z%7:D>JE9)+38=VWZCPSYM9:XB?1K]807GLP,/SR&82'(#RH#I6BN3DRXC1)-CL M@UAV4/K#0YTLM;:X+C2"2>(577&X]67VT"(62):M4W8-1L]A%0$NL,*F% 04Q-+#8R'I49AQ MZ=#CH;?D,L.90\ZA&7;ZG$8X5GMC.?R]\_7Z8^OTQG.<]N_;';WS[=4%;2\5 MF]TNF;6H^RM7P$;0T34^78SE$&UK9['5G*V_3+=K+6/%^V:XNLM!:92*]R-= MWK0;H(M%I&DR5"KX[8!U$(G^C,JN5?MGWQG'Y]1+KG$#7(S;/+?9EDAU^\C^ M88S58'9=(LE) 30I"NZQUK.UGBO6-V6F9]MPMA$$):Y8RP1%P83,B1 8CNL2 M7W%L2+<_6OVQ7SX>>D#>L1W)CP^MS8AP]DT*@\?;C:N0''79NY*"0V_3-K#+ M[6JU;YRWK''0IPBC\B M=@%]NHK%CFPR%BF#FYLXY890R%@8 M'58+**89AH7M4U]2Z,--AZC6@U=%V.S M6ZY&X B"U#C$[5?3<^R7,_-:;^Z^5LI\H0+F):L>>9/F2)#GWG5=4VU!L-!Y MVVMOTL>GUPOH1J;[?'6^O/W_ "QKU<+=S\E]%>'4#YL; IFU;&23QXXT[:N% M@Y$GEU"C6W)NHZ$.RKA\P$%1\M+&R+$]+C; M#I"8R:E>T3IS]K@EV96HPTZGX?O]L0YIWB]VG86Q.'=@ MIU*$EM);5YIFH;C-X_Z/OA;ECP^Y2[XXT:KUE8[ ML&MC.T^,I*H18NOK]9[D0D@3 G;XJ[C"@B0"'5J3030Z54)Q&XQR,6WQ;6YG M"3BE/VB/W/*T/K=S90DC038FRI (94)L6K135>U[:A0=A]JO#;=4:Q'BU$+; M(0ABR1:="@U#)1RLP8@EG+/<0^-KU3J-'1IVD0ZQ0*)?-9448+&O!\4RB;/P M)^WU9JLT3,A$@ VTJ!!G"F!G3Z M:[$7UMKH=]M,4Y&_$YM%057]Q2LP-J6@/PVY1&#U9&IW5QHH(W=&ON87&700 MR@[1T)M(U>"^J+;2;!MJ/#VA;K6FU6NF !Y]^F/$*I8V\$7'V/XB7+[3^TY? M%:QTKC7<^0&.0?"G60_8-<M+QF?;#(Z*1.2YLIO#F?C2>%7%G7@<*$ MJ>D:&/BU_95>W$+ERAD@V<:VA41MKV]W+:PVW-@--2<1I]/?M>^OTZX0_ [DI>^2>K]C/[6 M U,)M?1O(K>_&;9,C7^#+.OK1:M'W>36';I2!]DGEK($KUL$N"3+5>/%C!*O MSI$\.LT;8A1R\V;G2$HFLJ!K)JU,T"H *BW=[S:=EVY 5F[-T*-QIL9^M$Z1;Y=*G115CN,H!NG32W03T MU<.)"Q,EV5A@BWZR1<1:?C<,_P"$S5*O6-=1(Z.-_*S3NTHFI-3@=QWOD'>S MEZK&R=B5T=+$W?-&(D>0>YAZIXR\Q++)L#H\/4W%)GPX\I4E'.MJ-.D#'U<<- Y9GQ40' M)$938GD@[YD(*1Y4!6%X1EIS$EE2,-..92MES"'F_5OK8H"*L=48MVBC+7&! MLY>$0HGS&4.@3@@Z=#39VI!**[7:Q9<#RX1Z[0I(F*Q(<:$R",B0Q);C=&_' M7)J\9" 5 4BAJ79"UA*11*?^=8;2I02DE.O#:Y OW+N# M4.LQF0VTV[$\/-#JB1V,['.!802I&HAA@R/)V@A!'EH$*1;IDB$7KWRU)[UZV3CUT$LEM96ZG1\O')_VLEV4(NO8E5UQL6RF< 7/3VDGLRRV1CT:# M*9@>NP1Q,9GRTXA/2?GCX\"5);F@\W,0VY M(=D,,93ESX9\BXZB*_E+D1^@@WS=I^Q8];Q6]*W2YMB!1JRR7 -F)CI4([89 MWS2PONV\AK^(,.$9EC-"Y*T35@ISH]):,S5(5D BQTE,YYU2ZDY8J$$TO;-$ M2-D-LV.28^?XVM7(@BLQW29B.$KD8(U%!2K.EV?"@61R?"EC(T8/82,EN3F2 M]"QX.2,ZN3$0I,*.IQ#7M3C+U6IC=39BH;"G%II:2W+6RVXA9N&5$)5Q G^1 M-57S?V7N<2*?F)J)5 LQ6J=%I\V3 D/IFJ0%O5-RJ5!Q#RX:TN%,>,MGC8#* M6P5^T.7;F]D5<*3Y)(A&4T,4Q.AP1Q MC$F/!SCS0R,J/$D.,QEI6;=%(NB5QYYM3YL:S-2D[)P+3A ]42"1^6#2K[ZV M9;$B-!DD(LF/(6N/8(\^+,9RN6PB G' CL:Z4&L3HP&W5QU1HA8SI%AD@4(F M!T(Y9QLQ;QF;.EG"34ZR+AE(\9N4Q(1F!,@CHBX0F0_FQP1K]B))CDID^3/F MN0H"ILE]+C+LDNP6R:R27%S)DP$.((2IKD1K+#C@Y+V8T:1EC"L+QIS,6+_= M!WO">(A25!?$DZ@J0@<+9/Y24]ZLV2E)YJ38*7VW76GD!#C#BV74$DE+K:BA MQ(5H2 I)'\@'%?IAM>'49B'QHU%&C-K9CM5A:667'\R5LHR9+*2TJ3G.(DDDWO+AM'9P;4TJ4I3TAQ*WD#+;"1EMMUYUJ.G$:*PG+,5N,PI>%/ MK:5)>??>>SIEZ@AU&Z=QJ<<4M#H+4ZV$Y0E.&6L0+DVIM*DLMYN&SPJ_0 MRV)XU(+-XD)QE#;DO810JZI:L)4M#3J**UWSC';S,H7VRI&.TS1Y486B-3Q1 M&"3@O9=PS-'RF)L1[+#SD9_#4F,MUES+,EEZ.[A"\^F^TZTORN-K3B+VUQS# MQS=IJ*A#TS&@X]9=1A*U.+4V/VX>BMJ^[Z?I.J))PG&,^?*_-YL8QA&<[2D+ M#++R>)(2;<))XAS("5&P/(W /ZC$JV'$ M.LMNMY[H>3AY&?QREW'J)[X]^V?*K&<],SN/_KO4/_AGI_\ Z-LW3D5&9B?5 M:U.Q[_& LONGNI/\TC(CV.RL=\9QV4R'M,AU+2%9PIQ33#;C[F$85E#3:W%8PE.58UCB2E2D[E*^'S(5 M;%]%B4GK8_J,/8C^ G_6I_M8ZA_O;'?DQPA[?7](&[^W;ZXS^YXO?T^OO_%U M,!'\!/\ K4_VL=0_WMGMR8X09]OYX&[^W?Z?]KQ>_K^K\_U=;:B?XN1_NBO? M\#J&-?4O\.W_ .OTK_BD/UX;XQ&D.0NH@U**0)%A)H=:VGO1U2&Z'L;LWF1N M[83ZD+3]EGLMO(<<6B0TM>%H>2XE3;7^9(=W/)K32<9SFR%4IQ[YSFA[%PG& M/SRK[(]L8_//?V_'KIH:));UV298??;2O:^^T+1(]5I]E$C>^RGWGV5>1+N) M'D?3\+ZF/0PA#3J<92K+BWC4W/C0GU.S?0 MQYLN8PXM"LMI=PTZI3C3NG2#86*;FW(\P/IS^7CL38$BQT/7]C]3AD7^2>BI M;C3;]ADR'&)*)#*':#?WE-2H[:7,2&4JIZE(DQX[R7$NMY2ZVTZA6%H;=PK+ M'[(V]I&SSZG/?+.H/KNPN-F?,UI?R[(V.Y4+.RRVRB93HD8Y#<]5J:N)E.8C MTAQ3$E*\1O+T]C:3PV3+J0TX0?EX:(?-"X]?QD($Y/;;-#R1T(0F?-XS,QCM M#@M!)[C46%E+"_BY/Q*8Z8 1C0.%1QA("<%HA[;@/1&R1A\H_)'3*I<9"$QF MW7W<,R,34K4Y 4F)AF%+A^LXY(84WC-+2F6E.(?3Q7;"$@@%3:E \2@I8(2H M@'N^%2BFREE""GO* 05 <)MK^X(U)TB'L_1_!;9 ER!*JE9; M7-(,RY;C6J-@"2C+>&LX=0Q:*U3@9PCAN=A!AN(8FNCYQ5EXD*!19 VIU<$IET17:[J&[5BO@(K-?BBBS+D&2#BY M4&/\3%BR6H[TCUI\)3CRX_A?3'^C7_SNL22:<6M'DAS9?HLR936&2&8C&9,; M,9Z-%>3F8QAU&Y;BFW9)>+(I:Y MP^NJC267X)Z(AU9 S%4#;;9QG#TQHPTZTE65-KL'9 LXKL83;6Q[\*,W8\ MU5S)66.&2W6_+'CM'0\V)ER0Z,9)1EL1&GHY ZV8(076,#!DA[[ MZC+CKODU3J)/G=SC*U9Q:=S84I7EPE&%KSC"EX0A"._T2G';'6)*;;0F+P<' M$I'$YPW)"[$*2HE:QQ ] FR3:QM<7D&_>7XM_P I-K6NG8<(TY:DF]SB+7B$ ME/2MK[:7IBE 8-.T1N+>Q"3*N*:;=\?.C\+43 M]+JHMX2Q&FV:S"LR9[+#2VGV J_C5\5[/8H=&8J.]FM@_/N.]%L%.:UQ'G3J MEM+DU52%BUWJVQR6[&RR-N;1(%9J588$UN(D);ZT2&S%(0\/>E.;S2Y/VN@D M;-K.O:+$V^T5@3KG9U5NUT#S[CK,2(,6F2 ?/&(0FLDS 2UCS *Q5"OMBHY: M3 L=AUZ?FJ36C%A^0IR^GKL3N^Z=CE],5:5%T?"X][5TT_8],VQ^UUNV[- F M0=]O%V^RMDF.[++:(IY*V370%4%.6 ;F9+BC2$(HB&5L9[_ ,N>@-_+7^F'R59[XQV3G/?/TQVQW[Y_5C\>JL4XYS], M]OK^'59W)RI\WW+'L*5H0];G1A^S:S?H[42RZV@0*M+:U)M2OS9;T6S1X\O] M& G%5<[!+U8S*U4DW-!P;C*B,V MR8[YQ[]L^^?I^I6<8_CQC&._X=^_;VZC>X^.GQ&OA]=,38@ Z:[<]K?T^.*3 M(%/\546Q"NT.SFRGRHW-B$M0W OJR:2L4",+U:JUFXEFKA(4*P+M&Q86Q2FK M@N"-=-@-5.-""D^I&#+ D/,C7VV.2XSEXC1&Y7]'%:5<='[&W/1Y6M*OL$!: MZS]B=I:VI;-7MI*TWJT [7ZPC8[+CQH&"J*72@=V2R*C09[<*+.SJ#!__/)] M3?[2#D+_ /: XQ=+:[G8"U]-+?;WZWWP)OR \A;$Y^CHZ.IQ&#HZ.CIA@Z.C MZ?7KCS)[>;S8\OY]\=OY?ITPQST=?)QYIE"W75I;::1EQQUS.$--MIQE2G%N MKREM*$IQE2E95C"<8SG.<8QG/3 G>5?'JOS5"GMK58VQ>' 3@ M?P)W%R+U;O3=3](V9NVZ4RR4'7U5IZAK<1HY%1*4Q=*R"B323MJE;.V!5:UK MPD)I\NOU8G92%@3,$39&5SQ"[9*<>/;*XZ:H$$H76Y42+AMQ,CRN/)4WYA:5!)0I+ M<=P(4+W/>*2!8I)XP48MEPW' VMQ) (6A3/!PE-P05.I)!T X03<@VM%;CJ'#F;( MV9QN, P&ZZM69K\V512]C8G/"8DR8J,V+*^=8PE G2:].+Q!!F!,!%I$(Q&= MA)DYU$S0G&'AUHG96Y[GQTU/IW7.S-L$ADW=I'6L &,,V,B$?)?*U6D<'DJ0 M/5"ED2JV8R!XUG$R7,<6RJ2XXKJ6?6/=)N4'B3<@'3EO>Q(N#<'7%U2%MD)< M0I"N%*N%22DV4D*2;$ V4D@@\P0<'1T='3%.#HZ.CIA@Z.CHZ88.CHZ.F&*6 MO$AMYE[85'@UDF495FEOQ-Z5*NVX=+AW->W4O7I6M-GH.W&'2>7^T]>I MF*LU+A5BOGJ1Q7HMK0)OMS]6; NY,0S5+'64F @\L2"QB%?NC@MX9AQ M6L*=7AN,PCSON///.>5I&/.Z](RI]UU?;S..OJ4\XO*ENYRYE6>HYGW>CY\O M+XSR'6Y&_E:W3O7 MSY[XB_K;%;4O6.N==^)#QO50Z#2Z8Z3X<IV=!S\_T& M&.N5I3GMG/O^"<=\JS^Q..^<_P 6.C"DY^BL9_9G'XY[?V_;]OMU6KXE?AZ' M?$,T1==)#N66^.-T.XM4UMZ5K)^ORJ]A51M#5D4X6 *A ;0629])N(0CQ-C! M(2\PQ4AR'(1#?BSI8$A:F%:L^X2]9-6!2*N#AA5RD MRJ[4ZPI4@XJ)\T+NDW#$R02=6]DAGNOU)PPO:9M;66QI5@A:^V'1;S,JWNG\U?3'USG'5"R?#+Y.)K86"U==-!96O =GH ,12[EN6BQMT4FW; M2V-LY,W;=YI@2N72GE:+9;!1K=4@-0S:(,NRUJQ,DS[(ZU)^ 5%D\-OE>IB. ML'RG*'RA9@:1O$ZT;0WL'28VQ%SN4D4%(7&N0BY.YLPQQ!ZI#QLDDU-FV=J 8%3G*_& M8=+HADQTI<-+$Z(MZKK:OAM[CV#QDTII<9R03#MNM]RM[UO9C8%?-[FKVV-A M1MMB]D@3IAVZV1JS@ET-R%((T$0'F)KM>L38!, 1#%UH1B,R>NO"7WSK?? _ M:\GD!5=BQG]]6#:!.5+"%M9DF&;=L#CGL^[7<_5JLQ8JAM?8EW,:9LM>, K$ MJL4X:NS5G80:3'L5*"B1TW-@;=-.ER/#XX&USK?Q]'%^F,]\8S^>._Y_\/X] M'7&,=L8QG^WG/_#GWSV_//OGZYZYZG$8.CHZ.F&#HZQ!\@\)"%R<=I#[PX61 MG-,N*RAMUV%!D2FVW%I]T(<6RE"U8]TI5G..V<8Z@CX)X M22X;A%^$VW$6A3 MYE&JM>9$;\/HTBG19IU14A,01H;CJ94M%XKO?N1FG$1AW9?4V'6^* MP7HZ.CK*QI\'1T='3#!T='1TPQ#WDER2SL2W6NDG9%T9JF\-S;EV);"5$*76&:,5Z06-AI!6^O M4]EW!^J0IXV83:B!;+6X^JF).TJWL?C593VL*Z[N) M1G61/&OENO;32V(,4JC72)&.;+"AB$2RM5*6]:! ZVN59=*L<9?#1K%@UQ>- M@:NJ?(S5?(;6U2UW5$[NBZJ(L]A9V?JS6.N=) JH:UA0XU9CP% MM5/8H.7/8;%U]R-8"5H5?LIITN.MS?KL-@-^1/(:XGD?7/<]-#8?7?$BS0N& M9W7SM&D<2\PI7'+C[Z^(,TB/EY2P-Y&R4X8EB9HTBWGU64>9$:=%R^CSQW'/ M2=<2JLY-_M&R-QW0XR++$Y54DT)DG1F>.?'KUQ$*O$K7,G.8A\ MBZ#:J; $OC6IUNRRUP]V@ \8#G]['6EI2^9#,F M08;#22&/;\Q/ON@VX%M5%Q,=L )-U.J><4#I9#2[A8*AA([;W*6H:6GL@Y-D MN[M=46L$>!@&4DT<8#L#]?)@P%/- I;)&P$W9S90=#@3HY:Y_"I-CP!<&U*( MC:]P HEL063V3?R^;W7W2!,G3=7C7Q4&M0K,NU7&+9IB(TE^7'CS+B0LI>J(WR?,&6YWIPUWS#SW'VRU>NY*U'9V"\?#!I-N#\9]]N%9IV4AAP@> M;DEM-2XTILY&;CO/*DQ)GG3(D16'%-)P^XVT#77"&87-V\)JRX**'BK,Z3A$AKL DXJ"XU*^5069<*?\OBK3SN8JM(J6 M6:U0LOUNJ9(K=2C M,2X3J4AXQW&7'5OO5Y:VUW=]M*$5;5='"UFK-/LNVC:UF1B%J&ON2')) X)J M3L"2,7F7.W,C'!(; M:^ ^*JFK0U?-OC!FH1,>0IO(HO&8A1I>1\5[5D8%77$-^G+D1 @\7:1V?P9$;+##[-0JK'!F'-E6F*K6>..9BJ)0FZBNJB!$D3P^X]#9CT]%,R_1@7.)MFB M4-+\E"6HX"41I,YU^"LU435!4 $&A08 40*'A0PR%#2PP,&0 M(S;"83+JW'I+T=:T>MVDO..>HI2G7'G5+=5G([/PT6/'_>^S#;#.,,LICLX2 MWY$)2TPC*D,MI3C&$-(SE*$XPE.>V,=,'GD_JM,S _,/<'QRHGQZ8O[G+D/E M[,+UT1LR<(QJ[.?2Q(<;8RK\'581GW[XQ]%\F-88E0X*H&X$2I[KC<-E?'/D M*E>N,M7&M16 MKB4I1*E*5=2E%1N5%1N22=22;DZG'PXH?]K[K/\ [RS/_3QCJ1'4;^(LC$SC MCJB:F.0BMS*VY,:CEA1,&39:E&"LAI$\,:B0"XN7AIQ'KP"<&).BN94S)C,O M)6VF2'4#8>0Q"MSYGZX92G>K^FS<_J)9PC 74V(^6U+4XIGY;;\Y5)PJ,RE# MV)&7TI2V]+1F.EA67T.*7%8>OJ/D8F=KNW=HD,T:[&!9,)K1@:4$#13HZ6X/ MA6[)!F+(G&QRGW(+LIAN6A+?FCNR&DJ[I>;SE9P=DS9R)ZDZSV=&6/^,^_M[9]_?VZ;A^_D6>V/T;; M%=SEU3>,LC:VYC[KZV,+SG[5IQAM7D]5*\YQC+*T.9\N,YQCI#V)-FPHLUO6 M^R6D27)+6&)@8)!F,9C.S&5JDPY=E:?8;<'B/CB+']-QX?<>7/%5&X&1.I=G64:RFV_9VK["GV7(Z+68\>(5!6.OB+ M1@.)GM["# 715;,75]J*3)5V *B2FISFT8%LG$:R7>P*[;0:RJZZLM ?=.PS ML4C7"SMF$4:ICI(L)2;*6L9H6(7'*C=CSXINKQ"U7L0N[6JRFHE>'UP M8I68SG#F&!\Q[#$9]%4L#P*/%G6 MR',B1:WDNW7Q\&5$ARH@<*PF5%B2VW8:"(J> OA]IKB4VD-J/&I80@!:RCBN MA(4VA14M*0M:P4<0"[70^#9MQLK/ H\8LVD7CV:@-LRAL=<=F$O#L=#+;#3"<-Y M5'1\.IK.4G?-,:HI5HTM9J?KNG58]!V\!B1RU? 0!$U,0N!L\(E$<>A-,Y>C M2V,-86R[YV\.M-/)3AUMM:<]0]@7JN02H.W:JVQ+;AW27&KE@:B #RS-L175L:)0KJRT/VW M4R)$@_ $.01PU@19W'R,U< Y.?9@,.9CQ'Y/PZFV94R(TYY4O>HBMY*4NK2% M(7^<%*T$*2I)*5)4"";$I4"4D\25$H6 L* MH)/"=0DWT4;$6N+&]KV/, [ MC2V)"(_@)_UJ?[6.H?[U_P"V8X0?3^>!N_ZX[_\ Q>+W^'MW_EQU,!&>Z$_Z MW&,XS]<9[8[XSC\,X^F<9]\9ZA]O?VY+\(VVX>$/:L/TL/+U]%LDX@94AW(>VJFBFWJK,EPE/B'')<0JN6-CHF- MV*(@7*^TH,&],'1G(HOZ1W4?9+DBNJQ8"R3@G(O7#!FH\E,@2?V W7N)O9+D MI$S&C#+D4TQ]GPN DE$E:@L)1' =N->S(2>(E5N0MPJN0$J*CQ*!!4>)!MH!=0 MW"4V:RXYJ6Z2B*2X.4K5G.%(ML18'78ZDWT\+V%MAB@ MZ:CWJ'N\=/*^)>I^F/V8_M=,YO2^6C7-'=L=5I)>\R&9,C). %&GSDZ )@@3 MAMR6S7JF+,VD_(*3A ^ICQP(7,?05LL @00V#@E7VT7,OO*&,P\Y&X]:]GN- M-O*:CM\B7G&VT+D)R\XVVTZO"2V)!WGM"K MP %DT12&XS-@HUR85 Y"YCDQ)^EVD+<1"V9;FCYL;"X98.PQ-5'PXF5#S,C1 MI"<2$2,6U$VT)!NGD0;<0O:XUTY:7VN+W$IL#<@*%C^4JL";&UR% C6VHO;> MRMBE*GN_:9N:*L$CB)LVKRI6Q*1KIETU9:<_\'JJQ0Z'.E[&DQV3$PE\/6)E MK(-SPP *\RA=]JW-^./KW M^O?J!MHXOW*[6.PD#.@!,!=T-7.VEB 7DXP-2,/6J#2&YN8KT+1+)M,=96GC MK&)@Y=)C(UG08*SV\H+.1Y,HN.U3V/5BQF+>PJ($,)K?5= !%Y.SHVS[">=J MI#8Q,@_:"D>CT+X,K%@V@$E&VWOVSG';VZ[]<*SA*5*S]$XSG/[,8[Y_/\ #IABLBB[JV*_ MN7:1%K@0>(F(F][SJ4?O"H%] 4I=LHE<(@8C-GE-;%V;7-H&TPQ2')5B<%5U MR*9C5E#M>:+P6!V$O1S8M')JKT2CR^+@&4=N#NRAOVIB1P0@]Z](@5JT%) A M;95$IL=]J+'"KE<03^%A1&/F:F2URUN,>E7L%!#ESMO4TS?@C<%P)\P:32^* M>R7Z0Y;:,<^2Z4V'MHI5!]9SJV&W"O4$I2K5(>VW7V&+5?*B!IFVLQYNM:K8 MS1>8-AS[N\80YCOE.%8PI>/O8PKW2M2>^._?\<9[?EC/5(UO8Z7\MP#I;SOK MY'$GEM^_C>X^'77H*71FQ_%(@9@6ARGIL]6CFB0XW43=&KM3OLA$H5JFP6 C M"C@X!Z(U7:7T4<)*MID=?"?R.US'>I93>Q/Q,JHO<5+U=3 MQ".&&_5:[QK_ &):;R<( GN1''5;BK]#/:YHXJLGXL+ 9#D"L&+N+=G.ED-& MU1(D%^?:+Z;?;MY$=O?V\J>WO]?;M^/;'?\ 9U!JP?YY/J7W[?\ P(.0OM__ M - \8?\ \G\?4@6Z_$Z^)]?I@3MH!O[[^?3UK]#];[W.4 M3]'7 F#]XAZ*V%VO.T;$I%!JEC- M_$2\1YF;JUKF#L\D;&#%P!\ZU@BU!CV A!=+*KD14M_XI_KK.$W/>(EHY)%Q M]>\:Z_(VI<"A$I":%1=D6,27'4QDFU(9=BL8HFOD7*^%'"4B&X'D677AZ'A> M,_%1?:UM\SN6''C<=7A4^JE!8PBUOL@PDMK= TS!A$H3VNX$>7%>VF6=$SV9 MD29#D#]>C7'6U%+(5G19%5DWV8SKP4M*>%E"DI=D. I8:*KD<;EB.(@$I;0% M.N6(;0M5DXMK=0V0DFZU E+:;%Q8%M4IWL#:ZR0A-P5*2+G"3-:QXW:;)QR) M&I%-C[,M4#(<(*LA:S[IVE>$CHR:U5KHA-A*96 MJ+>-C+GT&FO+SB-EM8P8\.F[!/MJ;>>=8?8J@D/,S'RRW8&4OMR,%S&(MVXQ M)=(LI_@*I"A;4,-)XU1T'0%RY>4D:N--N+9QDL4Z7,2'5MA$<$?G=<0Q$2JX M #DAXMM.N7!(923<@\+;BD!8>201"B5P8,N<-@.RO+''Q)$J)%=E>3+3*&8< M=UQMBRE&;42< MB>3XI@14@;9*SF),;#C>7X@L1+DM)5A3C24^_4"N2'AEUGEWLG0>U]][FO96 MR:$LRK(!KU) T^IZ^FX?L%3L,P(H00&V6V114Z34HD>7)>O! \N-*?PR7C*9 MAXCV,UFEU&F1'(%1K "L0G7G9#L6OAQP=EZ0^I*GI#Z!T:/A^2\I*5/R'O4? MD+QYWG'%YRK.K;=G./24KC-QF4*;$9Y;P?6^E3:5.*<8;" R4.<3:1[0OC " M]+\(WTN'EJ'"I3L>L3*O/D-255:!'@*IL:G.MR7&XS<:J2R^N<'XH;DK6*6P M&5K5'_/P!U39R=H7DS*5"H&G[01:RXRE%EO\N)K.K^E(CN.)D-QB#9F_RL,. MI;;E,)H<9:4N=VG7%8RG'55.W/9\Q5V?:,"D0LQ&,S VJ*S 61^-2K*I#"KS ML%JRNR!KR%>AG(VD5HJG"4R(Y*(XI2$OGA*<9SG"<8SGZYQC&,Y_;VZYZO\ M6 -UF87H MZ5WUXH\:.0;6 MB"7&3P^M.<5=V\@M]4&R[-/W7DB28+7Y-\L(>P0F)C!HH= MPX)E,5XC50-;Z*&OS>G*)=W6A^VN3!8/8V M6=+M+UO2=X,Z_L\"7L^NV(+K6_5@HNMUX[KZ%3-V&;O+ M<%5'9-=J+5D WV\6"EU=6C?9V/ #OOA4."(\F$XL:-D28'K0DRH$-\:Z[$BR M'&OBHT>3"?>:0ZAM^.\O#J*1;6VNN_4@?3];XJ-[)OXV\C:WKRPH^CJG*1SZ MY!UZ/(=L^I@V3$WCH+MM=IT.F;+&FB.Y9FKM:WP>N-)D3"C)6GW Q:-G5X+K MD?'QL*O,Z*N4XQ8)KK\U@!AE\Z^4F7;#!Q4:$U%&6!RK1KLYI_;Y';F!&'%I\[>5K\O'3D>O M1PGRY:^M?=T\L2ZOW^>0\8O]I[S+_P#6WPQZG9U4]5MG;.V+XD>@D;"XZW_1 M; GAORP6$(76X:FL\6YY);3X>.D9#'J^=,AN/.ZE[ZU)0-H*I-DHBKM2:1; M\A+%&5A,;[85\>=5$%D\ICY-PQOQN8F2F8 [XE2&WSB6L MJ5V[84E"E9_+MA6,YS]/;VS]/U=)4A);4 A'=\2=5FV_>J-# M7EV+36LO=S7F:A(DRJ=OR]M [O9J.!UO+B:7C:HDTS9NR*^JD;:N]_V#?Z\\ MX?U_K:UGZO9WHU/F&[C42E18J?HEOFU;<6?XQ0"(SBA'\12P<]&^=4JNE<1SE=-E;(!-,?' M"I'I% =B.FCP@DWY98PT8)E83[$\C+D/Y6NG/KKST\//IT/AH,5>[H\4$S1> M,NE-\"=0%ZY+W?O(+40<:QBK?L<#7--#=VU^B6V_W$MJ, 6@5JV6NI3U_HNI M1-H:B7K.R:_V7M:F;./G&*S&?MEAL-BUT0J$1N2/=U81?+B2S%IMT/Z8 MUO6Q _8!;6]%J1,U!#@X-MEUJLUZ'CQYM&H;SR.V'R6L-VV];=Q3+3L!R0M51 G8Z84@&7>@O)AMQR:#WT,=K[;UAK* MV' MFCPV+%3[,("'1,M^*P5!FC2'"K57'C8X"X:J8^R]:J?&;7G&6OT<>,&Q MHGV=U];[';8EHL1YE*#%MM)"0?6V_.,X<6S+=L!G#[Y.VFG7)C='46^M_A;[ M88B#LSCSM@OM,SM/2?()>E2=OJE3J]Y'R]4UC:$0_P#8299WZH1A+LAL6L [ M"C6\Y$FQX3;S)+U8LAU33L;LXE?T$\V<9[IYX0$_GVXHZR[YQ[^W?[78_/./ M\,]YT='6Z;KU0;;;:X*6\&FT-(7*H5#F/]VT@-M(7)ETY^0X&VTI;;[QU90V MA#:2$)2D:M=(AK6M?'/:[Q:W%(C5:JQ6N-Q16XI+,:8TRCC65+7P(2%+6M9N MI1.(+YT7S8QC_M[X..WOE6>*6LNV<8^N/_SOQV_;G\NO*G3/,UQ*U-\]Q;B4 M9_?,M\6-7.I:QVQG]]4W<5);Q^/=U240^)_1G:?0^!Q'_?\ ,SUO)\+AC]^R_P"GAK[_ )>J%T<60M#X'LDV[4TX.@WN," MNM9$'"6L]@2HKX?-9S#/ _P]#Z?_ &9RWX6/_17/QOSWQ HL,C615N6GX[7- MA;6XJ'0$GKKUQ;^K2?-1/;"^>,#S9SA.._%'6>/O9S]UO&,V_'=Q6<9REM.< MN*QWRE&>V>WTSH_FLG*4JYX0,*7WRG'[E+6?=7T\V<8Q;\YSV[]U=N^<8]\^ MWOU5=HJS<4MQ[/,6'GQ0!>DQA747$8]P9TIR@)?9O6VN])'])TB09K^F/M4J MM 3>ZPN_(]Z#[!DM0V]RQ*Z-U8@B+ UJ>%@JEARMF>I_$CX@_(])0H MT=S6<[^GSQ'JPG/;.4\4M9*QWQGME/?%P[85C/?&<9]\9[XSVSC/7TQHOFQW MQWYVP^?ITU7A+L7V/QFV$UL_,!=^QS5Y M^*M#H:%8!U=D%'.8FXEO2:K"M,F:>C521YL/5IHC-F/)"KA8Q*D(PEU5GG4_ MVAG_ /9Z'X?_ %9RWX&__16OO\>N(_!88/\ SU6T_P"_JX1\ZCJ/K?$).&^E M.4VGA5H8Y'FWT='6!49[]4F/SI"(K;SZ@I:(<.+!C@@!(X(T-IEA!L 5 M*".-Q5W'5+<4I9S8D5J%';C,J?4VT"$JD2'Y3IN23Q/2'''"+G1/%PH%DH2E M "1&[9NI=W7"U.FJ'RFN^HP"AT&(BG@=8Z4M8]$Z-F1\66P7O5)/'U/D,.LX M=BKGYA1\1D?",M9<>\[?8X^\G\8_[?3:'?MV[_H,XQX_/W[?HQ_7^SJ:71UD MLUF6PTVRAFDJ0VD)27J%1'W2$@ =X^_3W'G56&JW'%K422I1.N++E.CN.+<4 M[/"EJ*B&ZI4VFP3:X2TU+0VA.FB4(2D7-@,0MSQ]Y/\ OG//3:/T]^^C>,7; MM]?ZF'?^7/;\>OAG0W)G'GSGGSL[&&DX4[A6CN,2?33VRK"W,JUCCTDY2G*\ M*<\J=UXP MIJ4A<5U3ML0*0RU*3F*Y(RRB3CT%.=406X-X>_#Z_=>R M;N
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end GRAPHIC 27 g818145.jpg G818145.JPG begin 644 g818145.jpg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end GRAPHIC 28 g479590.jpg G479590.JPG begin 644 g479590.jpg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

9W<,&+N&$? WBHQHH"S6/8MU0*8H*H,VR* M@%,'@Q0.DD4X%,'W !\#^?GG[.6;1Z0J;MJW=$*;WE(Y027(4_@2^X"JD.4# M>T1#W &\"(>? B _3QR"5+">02T!!S0$@).689CD,]HT9LPK"S,65I9EE1* M@V3*)<9G74[QQZ$3&-506;1S%NL4#%*J@S;(JE*< Q0422(< , !@ P 8 M !\ASI\ID^6S;Y63FLWH,Q)+*"JM(2E-K;]\JH(^144=NHQ5PH<1^HG.H8PC M]1'SS(''.,VCI)Z!+G4M-.EI5SI1-D2IB0IFY@E:5 *8 0E*4)"4)"4I 2E*0$I2D!@ M P L P&4>*I2EJ4M:E+6M14M:B5*4I1MDOE=SJHNK/4Z8WL M%H>_(1BMIO4^RJ]1@RK@FKY?S]@D643')"4 5=N4B&.0HB8,H@(&#R ^0\B' M]I1$I@_L$! ?ZN::/K'^L]U)[$]0X.@T6F]MHZ=8=J.H%W4<7GJ'N=#@C1% M["4FV3J"<]9*PSC#S"\7%N4H*'*X_$9Z5,VBHQNX=NB%+=CA'K6]1.P6PT7# MZ+2^W4?;]$L:U=@'M[Z?;M0JDW?"A(/P4GK=:*M'PT"R!%DJ4[V35;HI+&22 M5^&8_P!(^??:QZ?4^F,5OOF^P'B_]HP3ZQ7JH=QNBT1H$?U.Z,3NSI9=A[7? M]3[,:H]/7>L6:4\T_-PRU9*>,EX6P:1IZOX)\0:-"V"OR,9%*7CCN@0 ML?\ 3E['W3M]T8ZK]G=$B:U WC<\4I6D6F&IS:39U:-FK&P,Z>M(!I,RLY*M MXM%0 !JB_EY%T0GT5>+&_>Y%[UYO:/H]>H2< ^_6RX>!$/ ^#/(8?L/V\_3S M]A'P'G[!XY[T-_\ V(?T[?\ N4\J_P#^.;ANOKKUZANZ)%C&K:?2<4S+0-?T MJ>9U?/LOIMDO]VL4@<",X2JU*(=SD[)+>3%$X-8UDX431(/Q7"H)H) 910H# MJX9KZC/KQ]W<(N'J%=+>N73VC=3H9W;I?$>NVYFTFP=DNRF>4I_)Q\Y8VUDK M$S$U.NRK]:(DT*M$HJUQ.1EH]W',%K Q3C)RPV%?RD:?LE;]%'O=(58ZZ4@Z MH=#KS]5L03J%K-JV7.*Y;4S> 'VMW-"MEE1\E_I!,OTM82%K_IG M>GW$U]%%");]-.L"K8K8I2)G4=Y)3G[M;P7Z"=R^O/.[71^\>K?$?#6/G63UD.N6\^EI+^J'8$W>?T#.*-=97:Z&NZ3DK M%0]'SH"LK#ES)TZ2B6\Y.V":J37:2[]<8U-[+#HY;[#O65;-9W]7;*6 M& C8^.CE96#2++L:-("O'Q$KK?VRTW&N>B-ZZ>?U-9Z&7M/6!J\&U;MP4"-C MH"0T9H\D2-@3-\-L@ZD*7F[=P3P*1OBM$Q 3+%'G])_(ZQ4X[K%FM,8-625& MC\+IE98L44DD(Y&JM\VC(M!JDBF4J"3,L04$RID*5(B(@4I0*'&>X^'7Q&A$ M,O$>/U;IT[VB!:OK)=9$?2=1]6PR,P..KYF%J1H0O8I*ZJZ1^T)J ?%DEW"J M,>K:TM027IAY-,AHX[5NM;$6ZL*4"FJ:M_J'_P H$R+J_'>I_I76?I3)]4?P M&(U6]=/*D_U%+L[GO7>5/'2R%\>:$\?N*TXMC"IO4YZRM_P^01KL0J,U+41D M5I,PT+K+T-[(S7\FKR2@S#ER\SE_Z\<#07#1R=11B.=N\J3GW48'N-[ BE[( M^D)%1,@E2/(KKJB(JF,8/Z0O=N"@!Z*]MJRY9-&U7_P5-_@W# J"96+:!2QR MX,1:IH?NI$;-V"9$DTP]I2IIE /'M\@;X=>[-ODU[90\OKIZ\XR5UG["YUVP MZ_X_V1R607DLZVJ@5S0ZHL\0%K(MXVQ,$W9HN7:>3 SFX1X+J%FV8'4!I+1[ MQN!SE3 PUA>JGZG>I]5-+ZU]+NF62UC?>_O<&6DBY11;Q)2<7FF>4*O&6"Q: MSJ[F&T2E #D? 7>V7^5WJHV MT@BUS[TL3GS('!3 0$I*RM1E'3 #^2BHHYM]Z:K+( 43$171.(_".'+]?7K* M UZ7^(\\XR=2_4S]13HOW?ZS]0/5PJ76*SYQW8F'-,Z^=K.JK>^5RM0>N%7@ MF269Z15KXNHO\!W-V2O0$=,-V<*LU"PQ$\JYGHLL^2NR,]23U/=_R_M3A7IJ M^GEEN;[!WHW:N26B3K[+6T/F):D]7L8IE&.Z; MIE484ARRZ^.W*4>(D#V-UWA"'663_?64<+"Z>/AGMX_P![PZVS^3?- M]/A$C^MWJ6=Y^O'J$9OZ:OJOT[KXI:.Q].F;5U0[1]:B7""SG2Y:O*/U)?.; M75+FJZ8GU$XF-@G;,@"_+%S5HQ!.?02.7] M\&ZY$&B;I/P*9DSB*G@/OSOHLI%L?K7_ ,HEN=J03->HK=<3I,2X3W1GU,>X<#WZG_ $KO5"S7(*MV+D\V>:[UQW7K^G;VF0]D*)#$D%IU%C 6 MP[Z2@[7&L(>P2:_L<1K8IJQ8H5[ 1CQG%/[!?_*RT;!1ECD_3 MNA=/L=O]DH>1RW:]2_2FB=PYVEKHISAZPI59:(@,^K$@0R*<'IAIO8_6*^VZ\:%U:EK[2^X^=SC]99CCUNRV)<3 M5ME$WCTB3\:F]AF3R5C"R)3/XYRREZV]=/WT,K(/.H?R$JRUHH3YRQ9HF!BG)WG9+O7]%= "?[I5U*O,V('X@(!\L1158H$+X MX\S;[=P!\M>L,V'<+=2,[$_;NM%RV9>HSZZO?G'+EWTZ$]>^GE'ZD0TI;E<$ MP[L$&DV#L;VBJE%E)."L4NWF*C,Q53JLD_E(*595>'3S[J+ZR/7SL;Z8U@]2FY-'^3U#)*[>2]A:(_.:1G,VT;,F[7]J<_8+.TH@ M)^2FG4E7AHA%$V#J:3MM<9/T(^64?-6N9_2%@:_6_2O]/"+K*+9&)#IQUSD2 M@U(DFFK(36;UR;FG9P2*4IW+V;D9%X]6, J.'BZZZQCK**'-H03\]8*SZ2/\ MI9I54?/6V>QOJDYS%PS)H<_X:C%R_9E5C,IM@+Y2(D]CJM3$'@)@4#H-F0'$ M2B0.!HYS;T^5["S/V M"?3^[KYEZAW4?&NW.3M7\36-8K[IV[J\LN@YF*7;8"5>UNZTN5_-M']9ZO M#Z=/G&UB^P]S,'JVE66)[!9"XD8*/T3,]CK]OLMA@)M">C%362%?Q$3"+1%ZB M85ZU.VCD"-D!?3U<==G]9S+/[=WGZ>-CCTMM(N6H>FMT9U34;9,7&]7GJ?B% MRO-UL\@=_-6&Q3>?P\I.6"=E' @9P^?NUEWC]ZN8OO4.=10P>1'DTZ_>Z5;% MG;>KVVLV->/'VOT8"P0\TJQ$3>P >)Q;UV=KY/\ N!\P5,/>($_I" 3HBT]1/3'&9]6(KJEU'G] D$])MN:-[6>)HD(I'T&1>41RWN-KCKB MHJO'.Z'62N9RRI@!(M KQFDZ;:R/;?;?37ZKZ+TK[F>C!UV[C]8;I2NS>?U2 MRZP_RO<:/U;[&X5:P>FG:8YM.P66?;6*4LB,6V2BH\D3&*3]7D[))2K-S(P< M(\B#Y:N'VVOX/E%S[SZ]91N[=_/4LKW1?5^C&3O9K7E5603 M%(8UZ<644,Z<22SH$E4[J=I]/;TFNE7IQZ;UWTU=_P!9>A9M":ZSJ*!]\UZ# M"UR2<.[(@8\= QA9)8JY(Y?1M>EAD= M1KIG9\H6W/EW/M;-NZ^;Q<5 7RDVMT\95FW5BPO(_P#Z/:P5AAIERR\'^&/S MB$8^=K-0!3]P1<$3 #B!//N$ YVSG\S7O7N7IA]4VW6?NYZ*G7#M_P!<=0QS ML)2D5-Z+EF_4_JUO6,RS6;">H\Q;].8GB(I>T5QY:$I=L^ M,U8FC?Z7T>Z!ZQ9O"D%,KMJW=%3,(&%,KE$BY4Q$H% ?A@I[/( 'D"^>:B>O M./3\4COF567SK7YQ!'YA9H#A$722 ^!!=5L!_CI(B @8%E$RI>T0-[_ @(\- M7KM3[:H^2J]JKEC4C%@;R1("=B9HT>N(B (OBQ;QV+-41*8 3<@D<1 0 !'Z M+)F^UY%>)):-+;3;[/]=LLS&[VX<(-$5'#E4B*")#JK+*G*FDBDF43J M*K*'$I$DDR%$RBJABIIE 3',4 \\ZW7KQ3;;\U^RUKK=E!BH5%Z-?G8F;!DJ M<1 I'@Q3QW\J8QBB4 K=U&]) FAZ)F73$_6M'N M'VUK=%G'-6FMTA)B-=S57RNZG*]67 MD7B+UC_3(Q#T=.OU6]4+THX6Q]2MKZPZ+FS708"GZ'?[!0-JR:Z6F/J4G5=% MJ]]LMK0FD$IN0@A/>WKRB>O7K2-ACN?)^ MI0T[0=%6O31? $^N#W2YM/NNCJKQDWN;K/05(>RC\28@[_ \SMM\^"7S L_F$1=@W\B +BU*H*_PA\>!6 M!+X0" _O FNM7_'J'MOI MVFK^[R>7RZU;NEXQFMV/8[I;,JCK.R%*2KC'25:I#56R3,6NA)HU=Y,-FRI@ MK=76-(6)*]Q=5CLF;1TC0F3^TST$R5Z;N&$016 1<%CW/QY MEN"B(&UK?4PZ/8=Z%/;STONWOIJ15HP,NK]GZ]UJWO)4-&O]NSS6:#97,$Y7 M:SC&Z6*>EC&>0JMCCW[=>9S6-K]^V]H Y%M?MKXQN\M9./>M3O&CUHZ:IF4*HY;.4 M'"!3(_\ /0,LBHHD44P_>4 QP^&7ZG]H?7G"UZ[TZVG>)U:U5NR*1QP2?D@) MZ)FC,5!$2@F\+%O'8M3B8IB@5P"9A, @ "(>.:K'K5]$9KI!Z.3OKWZ8N9Z= M4>N[+L=!:%VUSO([IH5MUN>Z[V!.16UI.LSUFE[7;3P[ZJ2C$]/+9VZN;O1+S;T =)NZ?93TI:_&4S:JEECVE7VAO;YKT?IU;I]L>0H MN3Z/ENA7>PQLPX2DX5FQ3T"NEGZZ,DYY:T&R/?YCU MY=7 V8>...6)#CCCB$....(0XXXXA#CCCB$....(0XXXXA#CCCB$....(0XX MXXA#CCCB$....(0XXXXA#CCCB$....(0XXXXA#CCCB$....(0YX$/(" ^?K] M/H(@/]@@("']8" \\\<0BH+UL\=U+;.F==I6/4.VZ/:T>VO2^V.J[3XU[-RR M=6I?9&@V2V3JK-L)U"Q-<@V#N9EW9@!!@Q9JO7!DTD#*DMV23 $WD_D55C! MY4/[?!E3B'@ON]OM$! 0^GCQX\!S]Q !^X /]?UXY&SZE_@!](161ZS&7:)M M7I<]W\KR6F6'0]'O6"6F IU*JDF)T;RW4ZA/4'1J'UPS6L7.F6>/5C+#6;"PC?EW\1, M1R_M69OV:H@5PW5 JB0_0Y0'Z1DBW(N99C(-%".63HB3E Y54B&"PC M7+ZE;#M'KH8EZN&9;6A2*OTLL>HZ_P!.>J=@I=)E(FYS$%71GF[W6;%/3ELG MF=ED(5PZSQ_'H1O?I3]I-^[6X M57I/&>L?8'((>'M74Z]5%N=RQQVWW[4U5T8JK1E)C'3!HY8/4D7#Z!KL0WN9 MJ/-/)L6&TCU4ZJX=TLPRF==.NM,)1TOU^@?4?(A^0C^HA]A'^(_7Z! M^G(WPUU]'6$:R?7#T)IR-]"_:_3NVZW0ZG9'M6:X[KK-Y3<(R,!6>S]BDJU< M:4!Y6+C3KRU5TQV,G'>8LTOOSZQF;]'&'IRN?2? M[8V;U JGF'^#/6.Q[=A7'G4.2CFD%^PM;W:5W \JG63RT=4!;2[Q@O(%KDG: M&";B1L<.5ZZA&.XGSU]I?T#QY\^/R\^?/GQ]O/GZ^?'W^OWX9F:S>O[P]>O3 M1K VWT!U0] &(]+VOV2NN>P]08M]Q@]"2>.XJL/NUZ5A?WA\894&I'P5-TE+ M2V31$^^CTGK.L#%3SI@W69BV1C1J?>[U?.SW1R6]-Z"])SM?0.\.G9?_ (,V MP]AM&CH2#ZBUR!DX4*%INP0>R*2"L3.+V.H!*2$>R8.W+!A)SKAY7)F\J1D7 M$3^XOSQ[2_3Z!]/J ?D _J ?8!_B @9Z471?JETMA*- MJ?9>U:SD75',F=MI\W.UZ\Z3H:MEN>IW8U6@;!7);.#4AU%1DXQBY],EXVP=0\)WG9>NFZZM5 M'=MO752Q6NY8D1Y8)M"K5:Z6Z':P+ZX/*>S>H5ZRV2+C6B9:O*6-E)*U1Y[I M.!*QDQ!V63'M+X O@/ > /T\?;^[\A^_(WPR?P^-BQZPC4NSW9Z0 MRMVZ6]C.C?I\]'-79=C]"<]LX%CG^I[SM< M&N:53JQF:;MZ\4@8P(I2)7LR M+AQ#)5^R79>1DF$Y^SL!)YM]0SK]V]Z3>J;GWK%].,$O7:^A:!C9.N?>3KME M:K%WK3^HQ:L<%1TC-ZTLA\[:7D:2&J(KQ,:61?M9&ELT7B;&MV26G(#9V M1'Q]1^X_/AZ9MNT=C[(>-5).KYTD$A*5^J5]>+JCP)!T MHXB3MZ:FA$3SZ5LLJPKO*]G<<[;^ESZM&F>ISUCZQ:KW(ZI]ULSKE*[@XM@B M*-@VC/M2HS:+85+3Z=0%'"+FU,7C6&;+)@T*NP9K3NB(6!]6PDJV]=[3P ? M8/J/W'\Q\?;R/W'Q_'@0 ?'D/M]A_,/R^@_V?J5>K-2?5,[1]7] Z>]:.H^2V3..F>);RQBH[<;O>[LE,,+1J-\I*:Z[V MDILF]@FW;5&021)\XWI+>MO9U".FY@THNK?;3[P>K7U8M<%0$_3WZW$< M]0XB5A*M*,M%T'4[C6#UG88R2NTC:9.&=-:4FPN[<8Z,IC)(S6R4YRY>F^$I M\_?<)"B'CQ^8&\A]_<40$HB/YB @ AY\A] \AX^G(R=5>G^#],:1;:'@M4>U MV,T'4+OM.@2TY9)ZXVN]:EHKY)_;[M;+59WTC-3,U*J-VJ'Q'+H46C)HU9,T MD&Z)2";TY@_KUW9QJ]=(]U]2;T2,?O7ISZ-Z;';'N]6\NN^@.^CN\=9H!AF+U.0]-F_\ I6]I>SW8G!&5@R_JSV#Q:):VWJKI5*.>QKQ?9Q]I?K] ^OW#\A_+ZA]A^GZA^0?ISSR-E]+;>FA]8TY\D[Z>L!U[ MZ/0_IO//2;[9WCOAF.9?X-.8]A81C"S?4*=BHJ$&E4#9I_;7$JT@TE8*JFCW M[V.=2A(>6EH9NI,V:K*R,C%0]ZWHX]!77IK^GUAO5RP3$?8M%@V<]=-;GXDQ MU(F0U'0IIS9K4UB7*B:*TA#UHSEE3X>7<(MW$Q&5YK*JM&1GOR:%H'M+^@>/ M/GQ^7GSY\^/MY\_7SX^_U^_/;C7UT^T(UTO71Z3]M+[H72'U&^A%6C],[2>G MOH=DL08D_=LH]396#1<-I28K]ML"U;6<6B* MA8:8A'WY[?\ J6^JQT.WWK#UR]*;MOU@?V'+)B1W.[]HJ\TJX.(*KLD[4XQ7 MKK63M$K7LE_U>=AF=$BY?("'U^OT'[A]?/T'\P^P_GPWKZ>.N_E#UZUC2K[Y]"NZ=O]([T-)N MF=;[9L]B]/TG72_]G.E#UF[;WB\Q]5HE+83,0>D+>5+',U=S7)NKR5:;LI2> M397A^Y8PDHP;334>G^L1IGJ(^K1U=QV ZZ^E+V^QO&<1[)9=J=W;;_38JI[G M=;/!)3%;AJ[DV'0,M.3[C/:K#669F[9H,J$=%&4+#144@B=M)%4WA/ > #P' M@/'@/T\?;Q^GC\O'V_+G@2%'[E ?ZP ?/C[>?/GSX\CX_3AO738>OZ4%M,K_ M !'VC6W_ )0K@_:&YQ7IT]N.L.$6SLA.=$NY-,[!WO%:,B=QH-CI+0U'L'6^WWJI=".IO9W%.E' M8^!/UM[EM->U7H'O56)2]@U[.:$K^&_BHT,SIR6Q-E/AOV<- LVLO.3-/ "'@?J'\?K_ )_^(<-]#8-DWPL/ MOM(T<_6:TCU$/5[Z)L,SZP^E%VYQ',\IU'-]%OS3L138ND;!=IV#6=5*MYY@ M6)P!1N,C;K=?GZ$%!QT)56\8T12>KG:'W?/U\^/MY M\^?MY'Q^GD?UYYY?7KRA&B[VHTCM/CO\JDTK5>IN((]D[70^BM)F]/PMM9(^ MJ7'0L./ T^,O;3,9:6.2+6TJ!?/ZW;*O!O 5_:8\"[KS1NX?R;1(V?>ZQ+'MB]8D)U*I5^ONWLQ<)6O3'T:$];J_^J4OI%*7S6X=2V/7AKF*< M=/A>&L\V-2A4GW,B=L%=-$&_99?VHI.C/1!VD4R!134,-T'@//GQ]?MY'ZCX M_3R/U\?0/IQ"-8/U/>E';'KGZ@G5GU@O3YQ+_")E\9RY?KYV=ZO0?J'V'^SCP'GSX^H?81^HAY^X M>1^OC^')Z[\OC"-:+U+.FNL27J#?R>YS@&,7VV89T_U*\0U_LM=AWDY Y)G\ M7%8C!TUU=YE/W)Q;9:(J+Q))\\$I'1XUT8IA4 I#?;K/6;L%,?RG#JSVCB\> MOS[KM4^A]RS^R[.VK[I7/82ZNVFT%:UB1L1?]"-9EP>?AB(L5!*LH:1:_#*8 M#F$FR@( (@(@ B'V$0^H?U?IQX#SY\!Y_7P'G^_[\IO\/@7BO9O68^T:SO\ M*/\ K#V&[*QGIJ)8#C>@:\IF/?K/M"T).A5YY/FIU(CF2";ZT3X-"F_#H5J< MIBKOG'L03$!]YR_3SZ_RA;KYVFGKIZ8?=_K!AEM[*N^@':QWJ.CXQG+-28T: MR4BQS&;RJDE58%JFXDIDK17/%(1^G#,9>2C%++&SRT6I!1DT\8[,@E*;^D # MX^H>0 ? _K]>! !^_P#7_4/ZA^G(V?7/X#Z0?+I?UY13/9O5(WUEU2S'M15? M2H[WVE"T:S:*5HW7U>FPT!V>S6@0;"9+':FCE+QRJ\M=2[=NQ02?U.]3L-VONEZXN5>IAF_I_;AZQ09WMQ6+(-W3*D-#R,XC.)PD4AM]>T!\>0\^! M\@/Y@/Z@/W\^/I]_M]/MP B/CZC]Q^X_3\O(_7Q_#CQV]=T3UZ^L 0 $ M?(@ (_J/YC_ &\\\</(@'GZ M!Y$ \C^@<\\K2[P7'4G&V]1<0S_09G.(76;+=E+G.5\[]O*J(P!*JVB&X.H> M5@I;Y, FICXC!.8:,'3Q9B]D4I!.)1CW$)8/W#Q)8?$Q4CF(#MG<] Y^ BRL M3 'W W]A#C_F*/'O ?R/_:F5\/O3UHUH,5Q>]/U:X.52@9PM)V9^N"B MIB_OF(C*/IA,I!_U*:Y70E#Z&.\GT\F]HC] WD@C_ % 8 $?N'V#\^>_*/O3XQQC< M*,T3KNC[5E+R%J5%LYQSS5+.6&>3+K2NPE1EQ>TR]+WJBOF[]"A0X*-E*J!2 MMV;1-!1,"K"K8HZIO;:KJR[NI[5F.E,3 48>M:WD[VJRP']Q/>#[2,KL;*.( M02@<1.GC[@1$2A["E 1$%$@'E(?NR[L_A I )','%K@C;)G^+91*WCD'9[MC M;2<="3*<(#HKZ3 D8W>/6_>)/O1TPB5#-WO:[KL#PH^TT>UV2@24B!_( "?X M?%SSUX*HC] 2! 5##]BCRA0U+'4&S>;1GE.S]U_B'B57'(HJ=U>OYR)*PDQH MEY1<%]S9SE^"[_JK-R'@?'P'^=Y?98]0/H/D0= 4O^J,'GGXH]O*S(?'-#8Y MV?=I( )C.9SKQHF:LQ*7[F!YK[#.VH!]A_QBQ!\" ^/'D02 P?4H M*0@''Z_N!X#STACZDA[/6K],9_4L%M\]0J%/:*]I$;W&S2TV)U6Z^XC&+]XE M_-14],BT44I*;@XQP[5E?DV+Z8CDW2Y"ND!5G.G?X'[11+42 PNVHU+;Q:CQ MS'60Z*SUW+,ZU*/BI"#8Z)2:S=&D-+':J2<4A9(AK*IQ[Y1BJLS5E$CFU7KMTO3*3 MNRM9J]LMKRBUZ9>JV+.6[AM)6QE7+>O"@E&JO7;9R2LS!E7;9%C\NF1X=PC; M;RJCN^[^0[I^FJK]03DM U.(5]H^W_&BODCMJ)A^ON#_ *(#V> ']XQ_=[0, M',K#IS:Z;ZAE ];QN664"P-E6+M=)%V8MW7$??>="]4XQV",5@6)04:\8.3B M[RK28;89UE(HO6/P$9Q/:9/K)#1;!:..Z,W7KZ-W<.'A#IO$8=%)LJ_\Q#_U M/YJDVU.RUOK) QYV$T@S-I+VT?M\ZCUX%87ZC^)QB4L^>LDV[Q1RV@P:6MY( M.V!4%Y5-H](;YBT1(?*28_JF0?[RASC9T@*0TL00\^^,D"^ ^_[S-T4+%AR( <:%[=22;ZWZL\:YV'6R08=9=Q/ R\M$JEH^!H) M*5Z:EJ[)J5]YZCO;*KRS5O/03Z-F&":1J5_H-,O2D 7KW7=,1ASVZMQ=C/%M)/L)=-C<.4F)Y'Y4K METQ*+LJ(+*M$C*>PE>O7EZ4G62X_O^4Y7%\& Y%!\?$^%ZH?<9P*GM,14A3$ M0:&3-]"AY$@"JF/M4#83ZDCYZL=;/H(?\P'&/H/GR'_,TJX^!\F./D//@?)S MC^IC?<<(#D/^Q)L6N[V:^1&?=E'282.9K'G(=GG;1Z?VB5U2>O_2W+'*)P$/ MI:B=98VQMS "!3)SOQ0 1_QHC]>9?C. MDM*9'(9WLW;*03*8#BU;]I-?J+$PAX$"A'YU/TIBDG]/^=MT$4Q 1\D'SR9H M@!O'D 'P("'D//U ?(#_ %@/@0'\A !#Z@'//.G*G;;?(=Y]"T<2M1U\@!\@ M(C0OU%PQ\V^4G(.X6YL=,$ET;WL&S7TKL@ 7R#T+AH,T1X B4#"#DBA?=]0* M \X=AT1Z61ZOS*?4_KNY=^[WB]E43F5^X^9C'E>R3*ZBB@WJF:T"L-VH>&R%>I=:A46X>1'P@E&Q;4 MB(>1$?"8%#S]>5/^J;:&].=S,L811;0?17LLLL"7A(B3>7[(='8M0"B4/8D9 M5 KA,! OCV>\# ) $!NCY0=ZU(BGFV[2(_$,E'=(K/%*%1 3'*:V]M>LK4G@ M"_O *A810/(?OM&Y5YB2=QGW@;C?>+D>O<V]H /U "_"]OC\O'.Z?:/,K+)\4_%0$;E_K&1LHWRLDF(Q=@-F]2W$+I P;_ %/K MI>'UR:J3D%1\GQ:Y,9N,J\>_A8.8F90;M+6N/81K";FXF(B@>7%W/W:>E&T' M6((\L[9Q09[RIIWQVC/XC1XOMKAQN%Z M\8#7:15L,\HW5FIV:E%IBQ6*?D 9-VK-%U,V*6E9,S1BU;,F M0.B,F2";=!(@8"5\;Y==P7\-XVI23+2P2%NQ'(,KWR;9M;G8-K?Y M%\2&ZKIB(&("^)]=Q'R"@^X9+U!>\4YY QA*82"1M\3R<#>""0WPU0$0#9$Z MMI@CUJZ^(@ "6'Y&F 3.ZT4 \>/ ?H !S7)0,1AUP8I$() M4'..]9%"^X *8H+=M/4$GT0*4Q ("1D6*BB(E,4_PTBF3,']/FR1UT0^6P'$ M&X@("AD&8HB ^?H*5%@$_P Q$?\ 4_F(CY^XCQ+.6Y0DGO89:M?6[Q9Q%P/W MJ;J+:9^<9FXXXYUCA#CCCB$.48^JN@UL$7V)JCE+Y@TIUYZL5E%(1 "^_1>[ M7X84OD?J7XRM80,;Q]!!MX\" ?NWG! I?(8F!TMO8/DY!'AF[].Z.LG_J WL4EQ MHRDG^D7SM$2-VR#=/^@W23;E^GC]U A40^GY?0G/HYZ$^P_[-3_*H8>>_-QR MAQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''' M'$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0A MQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"'''' M$(<<<<0AR"G<2/(OHG2>0 GE5CVHK:(' H")47=5LBJP"?Z"0AC,41,/GP8Q M2%$#?3Q.OD-NZ%,UBPU3)[=B]!::?=\AW*C::2@NKC"T-2U0D2TGHN9C&-EL M29X5@^*E+MW:?X@=!)5)NL5);Y@$D5LJ#@CNT?4'*-)+*&FF;9VN2P O=](Q MQZA/:BT=7*9G,O4+KGE-EK;9Y2,66T:C6"[1;J+BX,7SHS=*"N5)"*69N5F1 MUG;Z362417^$FU$0.LEE3JCL%OVWK-#:?>IBC62;FVUO.>5SR"?UVKO8]@[D M6T<+2'D[=>7[9P#1$B;[X\XH99R"BJ;-FDHF@%>/=^7["]@J54H*;Z7]JL]> M5*PNIM29SMKU[W@J[1W%+,'$?^ L-_HKIR/Q_DW2;EN9X8BC84P8K)K"NE\_ M5+M$CULP5/&[GUL]0:9F&,G$=5%I-"LQ*LY,M:ZAV%]1.GO[&:%:*@_E&$ M[GHF2EFD6$A+&8 [<,8M\L@9+DUH'U1V>!5BK9_N68U?-7-*KE6J3U:1O>M1 MQ_G(N'90R0*)7;K!1H]@9VLR.9%NZER" >X"*+%)[AAK0.F>EZC&YH_N77CN M<6 J?7*+SQC7J-J%*ZTL)&UK]@][T%\IH+?1;G7+BY90E3O-3] MEYYH1JJX(X!*5U$],ZEY0!KJWZV=+,6BZU#O)YWJ&XVK6NX-]BEV[4SI_8[< MUN:F34%%\S2(NHN\1M4DQ8G*#ALZ6 GM5PGV@"0FP"4 [N$I<9$:G4=]C'17 MLE$\Q)=:B EK.=?>YB[69)S\#("M^KC@5HBRS%=CH^Z1_P RV9*.J)OO59\F MB]>AY9L5DKQMVF, ?O>U-HCKP MUI5PA-2@:;EF,O\ .L@D[+"+#*5*H2 -TB%R;)..I'J'VZ"S#(J!0+KF\$K7]&[":!,8JXK;I>JM)DZU"R> D+O MGT+(/GNJV2 D'=IFH!^<\#GE-G8Q19O)7>$J'9R6CR_0! M, 3-9R6?A% ((^!42DCH&'_G:QP^H^T;WBZPR#CY9QI0UI8# 4Q+[2=(S@4S M>?'A8V@4VLD1\" ^?BF)X_/QYY"#MYD74=C?\OR*-PYO6WDG-0=^UR^X9DVG MEF,YRJMR_P")L(E1WUZK3M] 6';;-"A28TLJ2):+YO';!8#29#UUJ@^E;GO7 M7K)>:>$UB&DZR+MEO/X4DY;**).F"2+/592%8.6*_Q$',6M&HN M8]=(S99L@HD=(*Z[CW7M:_3KU\]\HSRH9VF,=6# ]3>VP9_KET.W757V$.?L MG@R'O'P5-WKM 8K"(^!#_$/K V6^H"'W3#].4F=[+G4-;[59CK6'DG4['$6*++^SNK=X-0?L5'T(]?M07(RA&[E1N94JH)G16\?".4YK83 M]*T#*$*;LMVE?,$S"(1-NO5!U*+.41#RFJTUS*KY\4@@'M-\14YE"B(*F. \ MZFY]/ZJO[KCEDD=,L*T%CFUP>_,*I$9I@E#1L^AU2G76FU9U:)C,LMI#^0CH MEE>YAV9F=,RKETFT(5TU;E626'F-B .N?CGW[[14*2@D@EVZ[@[#-FTSO%@A M?M_ 1$0_J$1$!_M\^>>>>I2@0I2AY$"E H"/W$"@ !Y_C].>W-QRAQQQQ"'' M''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0 MAQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<]!.4 \@(F^O MC]P!.(#_ !]H#X_B(^ #\^(1[\FHF4Y?S*'.YQTQ$S"!743)Q\HV, "5>->-GZ)@'[""K1 M59,0_B!A#D<;^K?>#':.2XYX P&^WG^THE'^XP /C^/V^_Z<\\L(<<<<0AQQ MQQ"''''$(<<<<0AQQQQ"''''$(<<<<0AQQQQ"''''$(<<<<0A]OOR#-_[GC_ M #PV'K]UWS7_ @M;HJ4>ZTF,3T6GYK5J(B_:E>BP>6&RF?2=HLT>T=PSN;K M5'K-B<5IM8:^>TOH)699(*3E$/(?VA_=Y#R']H>0Y1I/=;>VD+2[%FZ?5;&- M,GV?8/=M:I?8..[*-J5;7T;KN]W?5 2EHB1Q?]IZ8NZJ=O2IT^A6KK,N6#B, M1EX60<&0:M"X7SM[F;'9SE8$A0!V<$;MF.DL))]]FMGEGF;I) R("@IBXR,< MW+^KD^RO4H_--MZVW<55I#X%E<9"+F\W3.8\[(SL+#:\?D&47H,K4F()JGF; M/3VLPG&M4_G0BW2 F]EL+W9DM-%;7M)V*T"]IDC%H349. M1ZR!#JOT):/=M%(E!H@L]DUWC1FR;+/7*+<]6O4GTOK!4ZO*.NW%WKEU>WJP MFO\ I.,90WDX3(KU>7$L]FOQ3<;5))LKUV+95OYI"O4O/["A2\!K56C63,V* MSUE_$;K+>O;CL)(7:2U3/LB9VU![UW1!AF3EOU]W70LOM':N)C6,A7W$M9\L MR;1JRC7^N!)",EF,.Z26*.UJP#V6BDXW.T4I3*2I(]\N^5F/76[:9$]' C2@ MA2@$ C+F+VT!+-9CU(;4W,9AL?JIX+3K>G0[%G>]Q=N4DJI$?@/\W4$]D4). M\RDS"U1C((1E[>*0[N3EJ]-1CQI,%8.JV_CU6=M2@')T$EN-C.^_3KN+ R>. M/LXVS18"\U-S/2E)G.MFIOVD[3HJT_@3J8.WCX5Z*K**M\61L59JL5^W?M&D MDS*+4[-\K6G$239E5(VOR.8/*X>'(K$DDI'JUJ=L?KPC!L4[>2M+B M+G+*I/&D^62D5V,\Y>M'CV;463?K&]H3L98R3L)/SM5L<;&UUY9G5?B9OKQ- M*:2G8DJTE6ZW?T9JUL .)0'QC5W?/3XBI,'E7W^2 MP^Q%,W+*/ZEHFE9TYFTF!W8,FUPB[.@O!V9*,4>O@CALL.^6B1=O4F2S9-RY M34K]>ZQ*(J)-0L\C9,@BKF,E$4-NA1LYTV,)<85%S+6%%>*V4C6QA$HQ[F*F M@?V"'>-KQ,-)5NFO&BO'F^-U:9FP4^T1KO=G\5:H]A2F];@Q[/T%O'L)$L:5 MW-N(%4=(@%+J9@Z=!18Q^1\U!G4JBSG+3"SEALBUFY.L8]8C9&=I#C.K&WA(YFZGFBT"]&RU=96>D9]:KJ68Y9KG#XNIU\J>X0&QS MOJ ]=65Y*ZCD+*>L]G- M+K1:X@VD&B%.NC31-N=5&R1@)/@4AYBQ4V8F*TX M:E>51S".5E5PZ_-N80K#.YUGIK;29VOL6,:>EQ>H23=G>?P"ML([Y.\O+%=6 MAZRXW2Q38)WS6TM MDCEWU:K$>:1+&2%D3M,G!R< 2M4NJS<-/-:9*Q]'4N*MA0AD92ENJD_=R(7F M>^''''+$AQQQQ"'''' M$(<<<<0AQQQQ"''''$(<<<<0AQQSQ[B@(AY#R'CS]?MY^WG]//Y>?'G\N(1Y MXXXXA#CCCB$...!'Q]1XA#CGY'7223.JJ<$DTRB8ZBO^*(4H?<3'4]A0 /S$ M1 #ZB(!SHDCJ^81"AD971:)&JD,)#I/[C6F2A#AY\E,1S*)& P>!$2B'GZ# M]/IQ%8G($QD#CG$P\[#6%@A*04K'348Y*)F\E$OFLG'KE ? BB^8JN&BH!]/ M(D6-X\AY\>>0$!#]0'R']X<1(\\<<<0AQQQQ"''''$(<<<<0AQQQQ" M,<;#UEI6E42UVJ.C'RJZ#)\]@8-])M6KQ9J4SE-JJLV(5P9N M4R_P?B CX5$A@KF9=RNP#R$KRL+#4:_6=7.Y0^/Z<5,OCR!E M/V&GC$ 0_/R?L*0_8>84Y4 "P8WSN""+?4^'7HD#D4HAVLW>P=VLVF3]6:,E0O?34&_ MQ$+EB\(P!(L4Y! 0$0'ZN^MV.MGQS"87T-1H:N MO/RA?H1IOW9=<[7C MF/9>!>3Z(:-Z@?7[*&0-2E5IL)1Z_G-D;O! GN,XL_8*V6PRI$C@8IR#0(A0 MGD/BE3,'M#B-!SKKKH6-7.TQNVS7:5W!RM?F4968WT^DP$(^D[/#,411J- F M8G.&*)T%ER-6QZD5-0I#D("A/BD-*4W3?#&\8>)A6&BU)EY]Z:-(W3>AX& JM6K+ZZV.2 MMUG:PMCV7I=*MHIU:YY5S8YMC'672;&^B23DG*KL0EG#%HX(S%-L7!<#WN4V M-W.;7-\O0M:-I()]TD$50JSWOPT0@X8*FD'CLYC)D.3X9#B(^.J] M8>]<1MUJUS)-;RVT]7-_PVPYA!7W*-/M6>SS>0:[?&SLMCEFS?1*18I2G:) M:$A5K5'1*44NTLK2PUB?@I.NM7;),SC;Z>M/N(Q$]^.0C[M=S(?J)DXZ+'0$ M5IC93'STH9NPG7C \.RN)K4PC'\:T"Q-XX6J M#QH@Y&00X3MWWUSKKMTO[,]OLT=4GL)'];:?8[!,UFDZ1 .&,A.UMVR:O:E) MVBODM2-;ED_F_1J[YF) *JP\F^D<7Z9Q6RZEOE]XGOQR/6=[E(7*_;+5 M)W/W](K640N5S3#19:YT"1@+TWT*D.;C.'CX2'GW5NIK>@G;A$2[C1H2KEFC MJ?B];+(PB2KXN1L\U;,-;BWLYE>BT32H6.D5H=_,4"X5RYQ3*6;%(=S%NY&L MR21-'.)U&5E?>\ M0*TA64B]]QOEP(9#.).\>VKZ94,LMJ[O"ZXM M'9=8+C8D:VT7T\(J^24A3&$:Z.Y=RPRS%!XU91LDJ5JJ9HJ0+(/2C]3RJ^J; MB^K[)5/ >1\^?'M\?G[O %^HF\ ^+$CVXYKHZK_*5N MGM?U&^YKUSP3N;WK9Y&_>,M9TOJ!B'\X^74@8\P%D%3VQ]/PR4XT9&3=E_&( MUL2O/P:*+1,U),Q*[YL#T^TM+E4ZO;FL?,1#:U5V$L;6*L#$(V>CD)V*:2Z$ M?,1P+. 9R[)%V1O)LDUW(,WJ2[?XR@)_$-'!]=WW$([/QSU$Y0_40\>?(%,8 M/']8 (?Q^_T#Z_;@#E$ON ?(?D(?7SY^H>WQ_2 ?]2)?(&_U(CRPCV^_WY'> M9Z_IM;?:M RS0KGD=JNQ".+=G(4%"" B!O/@1*(!]1 P>/)1 /(@8/(>2B &#\P M#@%""'D!\A_#Z^?]CX\@;Z_0?;Y\#]!^OTX9XH)'K/OWB*\9D7945_=8.W4P MNV\>/A5O#\H@5O(E'Z@XFD;F3Z'$! !;#^X'L$1,/Q0YY]AM]E6Y$I#M1V 3 M4+]15A&F"U_W"/CR'^@,/%7QY#P'E8PE#S]1$?/)% 0$/(@ >0$/N ^*0>Y?KU]2NJ.^274ZDYUV0[E=H:\U0>7'$^H&6*: MI8Z(DJDBZ.WM\BI)Q42QEF[!PW?/86-6EY&)0<-@G$XE9TW14SRI&;^*E'YD MV^ B\Q)>S]$I'D /*+,H["+I$E5%GVA[ .U%"B $L),1L33ZB'D#-WV+$.) M1 / @FY1, >?:8HB(CBN:RK=H@ITYZH=:NS]?4-).GJ%JI+;'M 12( 'C&C5 MP$9J>>VV1.8#$5<2#'-F?DP&$Z8 8X=GZ1=OZ]W>P2%WBO9-MV)-I*P6JJO\ MZ[!4M M.KL$T9/MD]/J0H+I9/\ T2HCU,H^Z1S$X>1.HK.=>('7"(,1$0.1Y)-8OR53 MRLB@H"B:?6Y-QZ=%A.A#UOJ4-YFUUDS,XVA]$]*9+?,*%*1-1W:39#4JO! 3 M]U-1Y8K5#M6OU!=R@!#^VTP#$,;P']+P _80, #Y\"/T 0 ? @ CX P@( (B M @'@3)@/M$1'SY^@B8WN\??P B/O //[WM 0+_JO'CCE_P K6S2YT NX^47F M_P SVR40/D3\;16SA75"##Q+>K#97ST$Y"AY\_3QY\@ M ^WQ^ON\>T /J(B( ?4? !YYX^*GY /<'D?L _01^GD?'G[@ "!A$OD *( M&$0*("- ##Z#IHP\HR23GH&&98>+F/TXYZ&4(7[C^G]HC]@#]3#^1 \F-^1 M1Y[>X/'N#ZA^7C[B/V\?7Q]1'Z>!\?7Z#RQ(\\X[6?X$C32F+SL\GF2VQO;).8UF2SRLX2( M&KL4';F69),&"LV,J[^*91-B"*9U CCXM<;M]XK'X/:]O#;7:)0<J>! +."J$,'DI@$/'GR'U 0_4#!Y P?E^Z(^!^@_7Z33Y%DW$Z8+/%6C%9-JD*A .N9,HF M!Y2IT.P;6N[&#=?^_'8?N)VSC]#[ PE-[%0.1X1NPO5(D9F'6;N^]J/4N MMW5">HV :9UXI>MV++Z.ZMQ[7.X[FNT'NU-G&6MXZ M#FU6\3&I(0_#ZN&/AZTBCR.[GZ=1'#L?54CH3OW2>CNHTG(:W(Z[>]2SG,I# M/NU- V'7X:R9U5)70(A;?NOM=KL;8<5@-1HT-(35#DS6>WK,W81\#=65;D)1 M 2XIQ+UC[MIY^K>D7+IG/Y;U7[7=@)KJA1-Q>;C2;79&N^-[II-$JJ+S((FO M-9D,DO%GS&9BO[+JVQ) MTB4BBS)VL)&.7NI.H12:9/'[Q-K#MWI&)EGBJ",N^M@=K_I/GF//I%MTS;5P M-^_?.^3B%"]2>_:K)7W7Z)UK9(^GWD]HV2NWSN)?-KBZG-OHC /VOC=:T[-< M C:):;%<,NJMLI$]5D9.;N-.M=D69/)BO5-W#H-W+Z-N(>N]G>M6"NQKW/,S M8-=>Z];/V&P6*S[M?D^SZ4I&XOGZVJ2.>]F,ZHS$[OKCH-DSTA++$-V\MJ%< MC5T)NIV.>C+A"C#/I(YMZ:%QR=KJ>'57LJ,CT+V"X;18+/U+NF-0E@FH2J]A M1N4EKF2T/>XZ[5ZQ5_-+#:KU/6.-;RM-L=OK9G2T3%6LLX5ZJ9W4-P2K$]2BY]2I;0=@KUO!E=IZB58!9+O(:@ M48U[<&&0M9U'AU%#K]GT8;Q)?H?VAT;N-@M:["W3K MW+==JGI\13KSC4!9M!K5YMUPRJ[9_5+A"7FRL*LS2841U*2,Y*L(NHO)&4F_ MV?C8FP3?X'*3CJKPG>.X=BFZMUQU&7KDD\B)G\$81C.2CUW+1ZT_:"RP->LD8UY8&>9TB#I3:<=QS==TW8.99"$3?N&2#IRBU5<'02<+$3*H;'O= M,I#=;]"!0OO3]U,^(43&( IAH],%0!.00.F'L ?)RB!B!^\4?(!RG])[C\ND M$W4G_,/G$8JW:?0\FH D]0/26U?DJW19MM PV39SG;5:$ M&!9.FT$>W8^M0=4CFR:*[4"K5Z_Q"BXL4F\B,C'.';5?(^>].-TI3APHX[U[ MZ6/=M(IJM#12<5<&YW+-](+*29IGLHY[%61F\7;R!&1TJ])5Z-508M%9".D7 M:"3E/ M_P MW /=)P$A1-&> M*>!*BB=W8JT10=(@R0DX@J^18R<3?WJ[239I-'$>H MW=*.V67![I9RL195E1MQ^"@4QU%K-D5ES!'X9?(F4!781SL@)E !$3G,4H ' MGSXY]7^ IU'5<@[E<(HUF=&.*@N+BVD[LJ<_T$3*GM\I."H/D//E3W?7^(^1 MR?#=; 6 SCO MN2,NY[/<]+-ES)EO8*^%^MF;N'6(7VWU0LBKSH\>PK\8_>IF]BA9GLITMJ(I MG$1 "J1\IV1=6!-3S^[\$80SCSY#X/GZ<^9/U#)Z5BOQ"O9-6GIU_P#H(C/0 MM$TY-8/I]3*];^O.Y(&.'DO^*0=J (& 05\"7W63Q5=@8,@)0L+$Q"8!X!., MC&,>0 \>/ %9MT"@'@/L !SE_:'ZF_VQO^'AE?O_ -HZ=SZC338N"D?L'^H^ MN_QZ-4P\[P=@V418+=8\RP-NEW;5; MZ>X.M.Y)$,/U$#.(_NYBL"A1Y68,-;@H MN=18GHY.XBU7CCCFXYPXXXXA'0M2B_QO-= A_ F_%:1;HWV@'D3?/UR39^/' MY^?C^ #\Q^G*>_1:1>I993 D"@1W_@.=-6[@GCVB#J%TCN97W( 3P'M*3\.0 M*!?/DI1*7Z> #EWJQ$U4CI*D*HDJ44E"' !*MBD<#>[KS"5\/:/T\4+MYW/KXD /O_H<'141*/U3\ 40 ?H&"_.BV MBW.HR^;_ "CJG_I3,_U([B[V/DXBZ'CCCFXY0XXXXA#E"G8!M\IW:VT@ /LE M380L7P ^/>OV(]-9D!_'O$H^U101-_0.(%_HB'M'E]?*)=_4*?O=I;8P%,"= M9P=Z)1!,W@Y^SOIVE*?Q_3^@LBB03A[0,013-Y P!SF@,"=SW7!S+6[XZROU M'N'_ 'I'SC-OI;ZIEU/Z=UYG9]#HU8>(ZON[)RRL5RK,,Z;.T];N'L;*H24F MT63.HV;_ ##=(Z8*J-?:Y HHF*H:R&)V;(K ];QD%J.=34B]6(U9L(F\U62> MNG*H@5-!LT92Z[A=90Q@*1)%,ZAQ$ *41$ Y4)TAZB=;=6ZA2T]H?73*-7O, M1KW:4L9,SE-KX7*46A]IT0D#!_MH@T8V0C,Z)&40DV6F#-TVOPVY_<@DG[(8 M]%<(P7&(!Q3*HX."8$(!4R6XFM F:I=ZM$-*BDLB\>3MRJTU4HPJA#SC%=LI\(\0.]G0%+KWDN7 M]B*(7L)VGT^E>H_T+[<=LM/MH+:]V&O^/]<+K)0:J=5S[,ZA7()2(QZH7*5E M8#-!32A36R81BY:QOY%X_OFU;9,BPJHKW_;=2SG'J(T?,8UU=-2N]:SZ MJ-Y&24.E&L%K%:Y.)B2/I!5,Z3%F9V#AXH4R;=)4Q1 .*R#?\)["P+VT8-L^ M4;96(V0&)D+'DFC5#1X-A*@B5P,8^E:=,S#-C)%0.586+I9%T"1BJ?"]A@,- M:Y/K2WBT8C4T[=T_2.U47ZK^CT?JMV("7C>YV*([I5?5(U/H M!U2T_->M\]Z4[?KQ9*/ =4=#ZZ..PO:Y'<8^ZT,U#PB:SNAW2ZS^'9*I:*98 MKLRHAV[L]VCJ;'3$VE55$XS#>/KY#[\-W>73[CZ17\MAX/IJWG&I M9VBZ]]B[+JWJJSL%A^J7W(9?;O1:OVP9C 4>7/+]KNJN+YM%NNTF1YDF\"(: MZ9((0S,[:WT2#DGKJU,XF5RUTT7>VDD2[V!>D]PZJ72D6R3ZEXL^QJD)6=DU MGF3KJA>^IB4_8TZU$F*\;U+0,QRR7LPPL.:.K;FP-X1\P8N(PU<1DU#Q1VZ$ MD76I9XSTZ'QEU;H-'4K#2+#I,+1%'Q"V.2H=2G:Y6++;6<<(>Y2$@[!;JS$2 M+T#%*@_FXY$2B9P0>9 *'W'Q^HF$?\IA$?\O [QF7SU\;;_00)?R SV;[? M+://'''+$AQQQQ"''''$(<]% Q#@/GP)1^PB4?MY^@E$!#^P?X?;GOP(>0$ M!^P_0>(1JJ>A!Y'U3_Y1CY,;Z=VZSX #F /I<-\ !$H&\#X +]0_H^2?T1$ M.:?.;X*2M>BSVM]0NF;!N]%W[KGZGT;5,B3I6IV&MT&J(S33.4Y^PLZ;%KH1 M_P"VLX>SL_G[<)OQ@S&I5J(062BD9%K(?U4\]P#$,FMVG7_,,DSK/[OM4^C: MM=MU.J$)7K'IME;G>J(S]ZF(MFV?6B82/)2!TY"76=.B&>NA*H KJ>[$J70; MI*ADEIP-'J;UX2Q*[W$NA7')D\CI1<[M%Z(9B,CC%F7C1 M5\!F+0?C>6Z0ES?IT@T M*T8H7TY\3TOK[2=O[P6#T]L.P4@VZG1H0]3HE#K\75*C6XP%UW0LH2O MPK9G&1K<[MRY=K$:MT_CNW+ATL*CA=50^O7KX0?UULY\6R-HT]OY,_ZC7I\= M5_3B=]8>P>QY7U*[)87JNUO-^I.Y34?D=JM$T^MKEW'VE$MF&+6M,I%51Z$=9J=9H3,F+21)#FD)UQ)05F:O(R6)IAINLO+ R0;[Z M.T>G#T&[%WE'3-WZ;]:M3)$@2(5,L MPH_ B902* )![./3TZ*:7H+S5M"Z?];+KH\A2@SE]=+1C% F["[HY(4M; M1K#A^_@EE%8IO6REKC5(X"JSKQ2PC19"+*1J7+.UA:X&3',WO\KP![]/(-;> MS6(.FD:;$NSOWJ,=^/0#S'?=UW2,@>V/I%-+/V,=Y/IL_F,UJCEC4-6O$ZUG MGU97:II)7B6K3!MI?CN+;YM0UO MKWZL1NJ;#3BR\G,Z+E76=]'S,98"P-G061D:C'SMIJ]69+EK\A -F\;K]TP:C+9CBMKA\[K$?8LEZ-GL MNVCTWM2JBK.1?M5(&%6:1IV[QTB+?X:ZA3?54^J?6>B5_4ZG3U MW?X=+W?/?P@]FN>FF8SOL/[1HT]]PZE]*?2YK\GZ27:>QZE5NR_8?I]5._FK MP/:ZRVBZL,SE*EJD_$N=+L<4^MG<95X1ZH6(4JR]>DD&S^ MD?7*:=JN.=:O6M>Y#J_7&B=09_TX+?>:/UDZV>I>MWOE,;V6+-$,(G3(:Q/U M4] ID'H4>E>G+R2?G9E>RY&,29>1"+CDXG=!HG0GH)U\S[5J?0NJW6?+,PUU MO&I;+7HS+Z' 4O0&,4L["':W^/=1Q(:=CHMQ*O1B6DR15G'.7ZZC!)!PN)Q] M,G].WH!DE*T.H8[U!ZS4JC;?6RUW3XBFY)1F,)J%/DN9 M]T[7MFX[/N7<[$,??:4]U6[%LM7J] M563JJMWT*QM[ T?W]9G1;#&NHBQI6V$AI^;9L[.RN;62B4I!U /46&^+GF10[I]3>J&]TO]I^P?5_ M_EZHI!-*\ZV/,*U=W42UD;'&QJ[5C* M2#,)MFS!*6=N",6DH@R^;,5=1NIX.0\9@^PNUMG;RME 7/>6#_!W.7FW6-$' M:_5>]13L=Z.L;=-4[#2%TBY[U;W'6#;-@SH8+K]'O.N<#F-/ME?ITQH&/U1- M;/:/HUE>S;Z8NS>+DY-6):(Q"_[01"BT%*9./5]QQ/H[ZV'\U.K=F5Z[:O_.UG$*VL$)P>;(JE-XW#Y926.9SH*%;I*GG*4A"D MK\RY6*R9BH\DV+IZ=1HU4%Q\1NB=/%68^G9Z>^>YGH6;Y5U ZPUO*]MCHYEI M]6JN1T-*K:C#QCD7<2PN;=M%JM[;$QKSWNHUC**/&#)R=5=H@DJJJ_O+:;. Y):.GO?G^3<;;1.Q'8^XW_U%\&4D>UK MK4-CWOH/T MFU#8(KL!HW4[KQ>=MA5FKF.U6V9#1IZ]HNV 6.>JV*1A5W[U]& 4@1CZ04= MNX\$D@9KH@BE[*VX#^)V^V9R89Q'ZD6 +=+;Y-]NL:7,;E>G^I)ZL71G!^XN ML=AJ.7>_0XQ;4>R=1SC1K'DKVX:8-;L;U]^V4##&:,V'XE/_ (%<;/6$8Q@@ MO.1;:(?M4XE%U$FJ7+":G0/2$Q/U*8OL]V8DNTO5KU/FW4G$9B8V"S/J72,. MJE7E;:RJ,33%71F**HK5DB$*J3=9@)6'[*9$FW3+3]TT4TU,. M+#)QL^^3;.8TC]BH5ZR@$$JQM8]5=^UWJ=Z)]1[$]S-4S_8]-P?JU=M M.L4 MB_LM5IFL1-)3LSO(9N,TBO\ O;: ]O-1;4%@\M#1P[7LL_(.'R\B]>.UWR\\ M.PG1GISVP7KSOLMUAPO=7M31^6K,AJ>9U6Y2,$S$3F-'QDE,1SB0:QASJ'44 MC$W01QU3&5,U%4QCCD6;ZZX+9,6'KA.XWF4K@ UN)IP8J\I-?5RTM2@E&2T- M6"47Y M<) 1:LI"S:_M9!.E[S)+(.E,M_*NJY9-$O,M4Z9M?7S&^ MU6(S,UM5NIC30NR-ILU+MF;0,#,C8V1)Z#MJ\4Y;P60I2"]2L#U U=C(5VN= MO&'W4[1UMZ_W;%T.N=PQ;+K/@;6%KE<:XS.T>NRF8MJ_3UX]U585O27;!2 1 MBZXYB8QQ",DV)4(U=@T5:D3.@0P8^L?1;IO;I[";39NL.&3EDZQ-ZZSZ]3TC MFM7<2^,,:B\8R-5C\XD31_S=6CJU(QD?(0$?&JI,H=\R;.X]NW<)%4X]6-\\ MLLM]]H=S^M;'/;;3KWU\RZO=-QNN?Z?DW8'2M=Z>==M6D'F?UD+7EFU;78;!>H CI M,I3M!O))=W*15I DJT<23RE5DB>]9)]#>EDS0M2RV3ZJ=?WN=;;;N(NO#DEG=E--I. ^,B^34$3#QE=]//HC4F%FB MJOTYZRU^+NN9,\8N,;$8CGLL[LK)M )MIVH-GT>Q?I0DHDZ: M_9-7XE%XW27+"";L'#L^6EWZ-L/J3Z7:UK;-GW:^+/&L'_)E[G0LV[-]F^FE MJREH7MGG>(U"XZYVAR;N99^V& ]EXD+E'"VO9&KNUVRHT'2)<;Q!+NBUR00& M79,91A)UFD2T4^B9'="Y''KOU ZM=2(F=@^L?7O'L%B[.\1D+*TRC/ZW20L+ MQJ0Z;1>;6AU*F9)J*IL2OW"Z3(BJQ6B:(+*^^1W->O7H1/7E#CCCB$... M.(0Y@7M!K\E@F!Z?L$0WS5W)4&MGG6C;8=698?FBJA'S%H);AJ\C 6=E2(@" M.S&-,N8&23*Y*V:"@ N@53SURN+U<\7T[L/Z;W;K%L9J3R]:?HF4.J]3*DP= MQ+!Y.S"M@K[LC)!Y.2$7$MSBW:.%OB/I!J@!4C *ON$I3#D6A&;K]WIZ=97? MFF5Z1V:Q"DZ4ZNL/G(T>QZ/6HRR,[O886#GX&NRL6Z>I.H5Y.1MGK*L*K-IQ MK.56LM>8LG*TC-QK-S^M'[Q]/]*@]FLU"[*8O;*]UX2>.MOFX30:Z]B\OC&+ M!Y**SMQ>)O?@Q594CHV3>,[28RED6]WR[]L7N-8JJ]AM&] /7^G=6-7G-.@VM@WU:WR"^; MY.5NM,Q8IO&,'*2!:^_?(MJM"LGSQJE,L0<+(FEQJ#X'P>YUSZ;9Q;,]P>_4 M,]FZ[_UL_D?4]]/2*8:))ONY?71)GE,E$Q-]43U.L.E(%[.INE8DHMF;UP[E M6SY..EQ2D(%"6C2C!6$JKQ,U?F@8R;A-PQZRSM#K-U'/Y+5LVBH*V MP4P[OV90[BM-930:<6.?.26.F,5[E4DW-DB3NHE,UE@@%U_RS:?$J[HW329K M_J(]/]4)A=?B\=QSTJ;UUM=3S>*IRN?;KHW >E%J=UZF[#I@8IU2[M=4=:S#(G^73 M^C97/;-V.S?3\3DWL78-(K=>?9\]K69GKCV7A+.\9T0)"!<6 D;"@[H3[_1ZT MFQMZN1V!&I:6QJ(E?'6M,M2K4X;UF?A8!&1EV=A<(0OR*DDLFV-SDCW*ZJ16 M%5SLT\[!9*7 KB5B6GZNWN\(^IMN>RBCEO&PU4DV#IT-EL<@[9/F#2KPB+^R M+R+%]'$B1?,G;=&@?I'T/[2U*_\ HRV;:.O+JL%ZT67UD+GM364FZ'9VV/V/ MLMJR]KPU4DA&3CU.9?V&-DY D%/5)!^9F0%UY \*+HJ9NH6'H?VYHLMF^K1V M?=@(&CXIZI'JJ:ZYIW5^7P@=VB,3[73U@;8YN>/5/6&5HSJ990[![+$E::P: MQNK,JQHTX_IT>6=:OH9\<^@>GHCP>Q,1@2 '\QY=^8ZZ;1M 9?JN;;91:_IV M17NJ:5GMI;+.J]QEVR0S*-U>0N]\4A&MDL9ZWD MD;"T^IP%M7@$+,Q@2PL1-EDI.8E;%&,9J4>-R9([\)F5Z3]KP*/@Y.OVK+D' MP ^%&U/E'!! #?NB('2*( ;R7S]P$/(<9I+9D&_4C.^D5+!2=N8=[/TUCG\. MTBFU[KCUXD[G;:M5#3N)9<_;_M%8(>!(Y%2B5U=Q\K^+/60+D1,X(5040,"? MO(!_:)@ >^([SB+UV$@(-I-V1"2@:F]LQI\L2H=N5$^9O3EZL]7M4I=4M-PSVKV/]J(R%A*NM+R0?$-,T2R2-4NLC;<]6OM1BXR-G'E6?+-F M,;(EET.82M3A'*'Y07YCE;_";^6SO'4RT1,:7@G,6!0#\Q,+P"@'Y^?'([^FU7UXZ=]0N>7-\0+3ZC/89TV4\> %I M#M*=!$2#_7 BNR7()O\ 7")?]3R4?*4,!23C6O5T1'[>ZQ7.M09 M $/(>0$\@4!+]S /@ $1\

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end GRAPHIC 33 g24276.jpg G24276.JPG begin 644 g24276.jpg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end GRAPHIC 34 g405118.jpg G405118.JPG begin 644 g405118.jpg M_]C_X 02D9)1@ ! 0$!! $$ #__@!!35),3%]'4D%02$E#4SI;2TE23TU) M0U]"24]02$%234%?24Y#741)04U/3D1?0T%.0T527S1#7TQ/1T\N15!3_]L M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M_\ $0@ 7 $U P$B (1 0,1 ?_$ !\ , P # 0$! ("08' M"@$$!0,""__$ $<0 $$ @$# P("!0<)!@< 0! @,%!@<( D1$A,4%2$6 M,2(C.'>V%S(S-T%1M0H8)'%U>)&AMQDE-#:!L29#86AVLK/_Q = 0 !!0$ M P & 0%!P@# 0()_\0 .1$ @(" 0,# P," P4) @,! M! 4&!Q$2$P (%!4A(A8C,21!"3)A%Q@S-W9"0U%4<8&1L;+_V@ , P$ A$# M$0 _ ._CHZ.CI>EZ.CHZ.EZ7HZD%S<[@NVN-&[&:UPO$==W=,_"<=R53OX]?M'WCUJSV M;:/J?(/,JM>W/!U-@PI:QG+DX^[+Q1-JM-*$.ZUW(9WJ\A]OY]OY3UB?67+W MC>0#7>'Z_P!*>6K^DQ1/5[YG-C=/D-381);5]8URK))95I-P@D2JXH1L$4A2.UP M>QG'#N).@23*"D*(FUQ3/EG)J:^>:5SI"U5TDLH[Y'N55\JYSEI MI]U7BMA&OP<9WSKC'Z_%X[[)4Q78%/30Q TY5G9!%'4.2B50\;!:\XB2N.KK MIX;8!SY9:\R4?YORB"*QR"^9]1T^AR+5Y"C9Z@8[&9G)8#)8>LL!H7D5FM&' M";6/BM\B/.268]L)!EA;(((5-]X1_M7Y*Y.RW"&1X2+0,B_.9S5L!NF VN_8 M:69Q5JW6KFRJ]59%0LA\.8IKLJS:)N-33>B5M*R%[P3PK4 2SK"Q;"NL1!SJ M\\(B(L(X(R%A A@94#Y("12AY(YQR(9'Q312,DC>YCD58,\N>%G,C9_(+:N; MZU CFPO)#@)L=>NS*NB5T,&*T];-YJR#8I0O^\12D]+V-5W],B*DB*K#=HS; MMMF.F#J+%&QZ_IN1S>!PN5OI>B<(33MJS"JN3K6: M+#30NDRNDDWQADH4+"2HY()* *M.*="YHXJY_P"0]#XNP6I[EM6N8>W5M#MJ MZJL;8U>QDM=OTUDE(2.OJX2J4>X/DD+)5B1A@QR3.>1.K4;!$LLBIX=U&3 M%^G9(94Z*UU49%CX4L@H^8YZ;;!1WLS9?;8948U4*,9'5S>%<%)9V8U@;')% M,ZO#16Q/L_9]_P!0T+&8ZSL&5^(FVH QR82ZU?N I:NXUU:ZC=(K!BI8L_FJ&E:Y.3M8QYMS=F;-/'8C%L>YT I^0O6%5A8XU/ M^+56UUIZT.8E3%H<87*Z.N?_ 'O'Y[!>AP;2U)B9N/?(;#;$8$==5>0UX[O M'KG&J*Y57PV M=/8PHYB2P22.AFAGA>B2BFA%13@V 4S6SA'#$"SM;)"Y.O73.2].W[Y0:WE/ MDVJ0"RU1LUWT[JE$4!#O!8 ):B#(5FY!-6MA #" C""Z3F6=;C=;DA53870]:T)T91\%>*XQ@+%5DY' M^CQJJ.:O6%YYWD\\FR8Z+5NK\(@Q2$V5E9+G!UU8Y)8@0N]MI)H5%958%/.0 MB+,\.&:U<$V1L$I,TD;WO$7^X+BVO78\\Z\B5;.D54,7D?ERQ8B3&0@ZP%\< M>Z!^04BHS_;61L@ABR:?LM]PUV[7IJTVJ 6,8K*AD&;#@HQ@UWF0)2=T+[%_ M-9VD?P@@[*TQ#W+6DP,N@?HZD%@W=MUL=IO*OIP%$E_%DMD-+)C\?QI!G6\ED$.]6!>\GN5UPV>;5&JR M:%LD?NU8=ME4=JD/K\N8V^>9.,D[F>I(Y)M-K)EAIF;REUY93:+%L&:SA&ST"60F5D!DVPWLW]PN:M9ZH MG1IILUZZ6.M'E,QA\>B[;A";,#B+%BZ*>&\BM84.T,)>1'76JD!V-2>D;;3';ZO>V&VH+1L+Y(?E@3.8K)H7K : M',(>/^H*C1-LVMK6T=987-R>)5U-2"596EE8$1" U]># \DTXTJ=S(1A!1XI M)R)Y7MCBB8Y[W(B*O5L4LC1R-"ME*5I-G'7*J[M:XLXE#:KEPU;Q.>D0!+F" MF2Z=L=>[I,3$9RRF%RV$S%[7\MC[5'-8R^_%W\8]1#0+V!4$8:_X:M]2W53D=167]#8AV]+<@"6E3:UQ$98%C7' M0,)#-#)A-;GL/=QB\MCZN4QYVDD 6*-V7Q5 M>)?Q O\ C/E4%,$<)9(Q, 73Z?1TB'.KEKE'$[&=?7N,8A09=-F.2VU&7!?6 M5G6Q!PU](ZTCG&?60S/EEED3VGLE1&-C\N:JN\(J6N[P0X>GQ+LS7M&3N.UR M>\K1<1"O;*'%*;&JR.M>'D5];EC+9R%6DA90]?25P[I"?@DDSF@#PL^2&Y[E MO0]9S&1P.B7]77OS'[^IRFAI0%W3UK)%:9CY7%RL^L M^I:2#N[PNE5@ \B62!C#5$P!(9 Y Y@9AN5>#.2N%WXM6_8(,3Q]IE7Q_*K19I.:*;2(:HSKV!2TEL%JA8OJ62"7#^ M"/:*$GD'(B]S8.+Q2>W-$YDC/7&]['>')ZF.5J^454Z4GDYW7(]=9Y=8!I'# ML?S-<5.-J,@S3*C[%E!-=@3*,>!CM;32BDV8=81%.*5-J:BV+A--0Y3D(>*$XM>X24<71ED4^945Q8 75;:DE&U"R5H M!$P%@.?8BD$QJ'/"(Z6*9U:[]S3QX[#[IJE7/R>8/7]BQR&JJW/@GDOI=M:Z MJV^V]P16UU:V<4.N: M"2&*P/)+CBD?E3V.?&R>21&/5OZ*N:B.5OV5?"== G7/)V;OZW]R?NVQ[^+' M]=#?4G[=6,;Q5A3:PV'-[-=389&4],K:Z=2*9F>D?:/O]H^T>H'WP5J]3W$; M4BLA-9(XG4I%-=2TJ&2UG%D4BM8B$213)%,1'69F9^\^CHZD'WG^YX3VM.,> M*[?QG"L9V5L?8&UL?UOAF#Y3?6%#6%#255UDN77YD]/%/;N$H:&D6)JA02,2 MVN*>,QT0T[G.U5V0.[]:]UK -Z&YYKO"]4[-TMFN- %8IAN3V^0!6>"YI02F M8YD__P 0CB6L,KK^DRND,2.*0%KZ\-62-E(>Q=!1BKQ8XLK">M$&>(F]P]8+ MO$.O9U[Y'O* [HCIW3TZ_:?6.)RM$-LA R?\_Q$]L241/\ MQ$S'\3ZNCT=)?W#^3V0\,>%?(GE#BF+4N:Y%I?7I695.*Y$?85=+=E#VM57H M%8V%5%-8"CN98/D646-\OKC8U$]+G*B-=D;NE[%[I^GMV;*V-JK"=4G:NVQ7 M:\K:S"<@R'(1+4$S":?*7V)T^1##3CEL)LI!&PCL= L$3'J[W%7KF&/M,HNR M(A$U$.%#6=XQ(L/L[8[)GOF)[Q^\1,?SUG[>NAWZR[J<>9S%IZC>H.V9@EKG MH9=W\1TG[=)^_P!__7I;7HZ.CIEZ>>CHZ.CI>EZ.CHZ.EZ7HZ.CHZ7I>CHZ. MCI>EZ.N9/NR_M90?NGP?_%LMZZ;.N9/NS?M90?NGP?\ Q;+>L]^YK_EF7_4& M(_\ JUZVM[!?^?R/^C]C_P#UC_5N>"G[(?'W]VU+_P#N5TN_=L5J<4&HJHBN MVE@*-3RGE51UPY41/S7]%KG*B?=&M<[\FKU][AYR0T!A?%;25)E>Z-88_=T> MO*L:XIK;-L?"MJPD=Y2S"FULQR&CE1IX5PTD#9D1S51BHYJK-7N2\TL+W^N, MZNU18$6^!8C<$9-D.5NBE"J\ER*(,BNK(*: R" N:GHA"K$A]N0V""Q,.8H< M+A06&$,=TW/6L;P6K'MS&.;DLEI.(Q%/'5[E=]UENSBZ=<^M93#: 58(VV38 M(@L5R$EY36!RW$W%F^YSW=,S-;5\W7P>O\KY[9QXM )0IS5[I[,"+\SD2OC[?'U@GG^SSZ\X^W4_\ N(?M M?<@/]J5/_3_&NK/]K#15YJG1=OFV55A-3D&X+@+(Q #&.B+@PNJKE%Q.0H:1 MC)1)K-3;:[9!(GN(%8@/E1CW+&R,'<0_:^Y ?[4J?^G^-=4YO^*NX;VX\;TL M@DZ]HM@*Z26"0,6K)*V;(UH8!1! T^^GG++ M8:RJYCQTGZ4NTDQ:EUC 6>.\'?)+0D@8J,ACK0*:!$#%B+ (A*)]=,L. 4NT M^.-5KK(S;>OH,6ME733C%@X_?LH M0[ET9(SXY8&'#^FHGD1[44>QEC5?$GA91]N37''78.S%\9\]@X29H*.AM'D+91C>]!U M;#Z_JC=H;B*%VKM&WJT6239.PU"%)AL]XY[X3T,S MX?YDY$V?=>1ZO'E79R%F(IR,;21TWA M;281S+EB3/\ 7*-#,R'W/;D8QM4^TT>89Q-B')GDFAJMGYW7U\;W*YHH;R*F MR$1\[U1/NOF8/I<\&SL 81;2>0<>6=*QAK8YY(YR%@93+M(.:O%0UJ.159M MS-T>B+]VJX?&GHCO[E5CVN_U.1>A;C5U\_<5LDY*_A,A?/ VPO6]; TXBP\* MV"A@H6QCC\BC"%W(-A%\]-@R[9ZQ%B\ZU\.KV/:"&#PVV83#JW3'-Q&,WIR; M6S4Z;KVXDD[3TUJJOCV5NE^*E*%A&'L4EC)A/<<'L=HZK)N4M1C=Z''8T>0< MBDI;FNF61L)]5:;4E"L IEB?'(D)0LTL$OMO8]62.1KFK]^NC_FKIC6)O$O< M(L&$8M5IB&!6^28O)44-562T-IC$"6=9+5R B#O#8C@T%GBA=DD4 MBMZYU=?_ +8.(?[SU?\ ]7EZZ>^8O[*O(3]TF<_X*5UPX1HTK>FR@G=\UKA MM;JG6&=5./4U1D%?L-<6<=5U8->092W.,W!SP3)0QX7$P"F40A ;)UD05[B/ MC^VA$R.2/M4_M=U/[M]@_P#\Z3JC/>'_ &=\"_?+2_P=F?3#2*%)WMKWMS*E M[\9DNGVF8F>Y9R^5K>_3A^JC(WE58P M^#KQ6"TZ*\(OSLRKJH3W^* M!/:^(']WI$GUD8F,2[-=J=-J[^M8*Y_CPCG,]2_?RO6;GLI*V*,_&;.>L%I:> &28C,KJPB(# M@*K00T-UQV94\X'O5/[\[Q3_ %_^59_R_P#K_=U/;N7<3=L<#N8N ]T_3.9[ MGS/A]/EMC5<^N-0VQMC7M)A6M-K@VN"[2W)@6*3Y,4 /A@=1E"Y5=8S1UU)-6/=^']+PKL[8Q-=BWLMI4@'3G*M3,7BC7GO8P" MK4\B*QJOA405A$S4E@):P&9,]Q6\)XS]S_*^QUM7HYS(+945B+-JPQ ZOELG MJN&C]7TZJEDNYE\2U[;] [/>JI>[5?(.>[-Y BZLI<[EW5N!M<1J6U9'F% M5M]T467+))2_R(31["EF%EF'ECAE8*=+$L9;NK#MR<2]G\^.:N<=R[9>>[JQ M3@MA>1T^$\!./INR-B551M77>E*^NP'7>XLWQQN10"V.O+!,;,S6KJLA$M#- MH99?D7F1'6.,4HCLM+,1[=%:/:G.5>2,I8MNR$;,5AN-K3-HL@#$W\*SE/&#K.2X9UNCC*>N_H=%2ME8G@G(_'B\3I:ZAC MS/6E3D%V%5"0 SW(5]>43[%@8L<0T)!@ +3'0Q,^1,/\B9'D2RR/I/HG8= MIB':S!SMI17U;%](;&BJBXIG,*&(IK'*Z/'I(9O#G,=7^@!(7>%5C1F+^;?L MA_>*_:"UC^YR#^.,FZ>/CWA9FQ.U:/A5;%-/9Y%J+; %6.-<Y-HN1YD16B MPQ-5'22DFP00,8U?+G2(B>57QU%ZRIU/FWFBKAEC7=.HYUU-*!A8?/9.!V=YVZLS*L@O\;QZIO\ -[>J/_6B M6L^."C1U,5A$_P!33A%O["N,,$G]4!S!W0%I+!++%+9GN8:GUO)Q0S;+&85C M@N2825B)>,7=?5!UMC5/L,LI*$Z&$FOA&DD"*J[(H>:O(64%RK#.@Z$##RQ1 MA[?NX<8TGR:Q+*\LWUF(G#?%F]UJ>/TFW9N_K?W)^[;'OXL?UT- MJJ(BJOV1$\JO]R)USR=F[^M__BQ_5W-K;)Q/3>LM@[:SRRAI\*UGA> M3Y]EEI.YK8@<LI^^DH#W%[:1S P.'U(B*9^T1&KXN9F9_\ M"(B9F?7"3W^,MMNXCWGN*7;HP2X+=1:UL=?:MOV*4CJJKV!NNUJL_P!J9##% M'&Q%GQC3H.*1$/=+/(TJN-"'0=ZD-FQ7MV2 ]I'_ "C7:7$5K+0'3FZ,KR#C M_B$1LAQ$D&*[8CHMN<:[&9TZL^M$5MC]&U]+=R(_UNN+D]DK7.)8Z5G#'=_< M?V+SLVSW'^*'%W(.4>\8LTS_ "S(REU'F>V<3US>;SBO8*]TX&*7>/2U-Q78 M?]3QO#8Y[7VP:40ML0$C((GQ>QW0MD]T78^ZM6\W>9W$W(^*VQ\67#,$P/9- M5I7.=/T%]ENO[BZV)@*F%Y7D.2Q6&9T3V6$E=+":)++CU4@RC3Q5BO9M<,>8 M*3@"?5BG.%.HU7R5^>,HTA?-B$?YR@2_()_G\^O28B>OS?9DEFYN>A%N;@YD M;*G?'/X\XM/]/X9?/08@AGH4%/;^,?<2Z0'?[WV5\]HSG@OA4\Z*LE\*GA4\ MY)C/V5/[%_O3J-_^1]?LJ\O?]YNB_P"D&*=4 [C'(C&.6G^3U[YY(X>3&12; MCX?4^;(R/QYK;BRM,59D]"0U/T8SLYH;"!JJ@YM;/#]D:B)/_P#R/K[< M5.7J?_YX93OHZ'MFU7 [CC)P^QT?J..FPFU-?Y-NI^^COA1^6E M8K/_ !@S_'R=A=?R&>D=#70>1-QXPS\;1HV7^B9T:=G'C>^!CFJ>='09BN$N+L-=3D*6I5)M5S%B2NW,IDTK8$Q(,BKDKUNM+ *(( M#),D!1!!(S$3ZM/8?=A[A-HQ5K"Y;DK)_3[BC3:#%XW 8&PY#!D&(*_@L3CK M\):$D#5#9%;0(@8)C/3U_*-1K?2U$1$3PB(GV1$3PGV_N1/LB?DB?9/MU(WD M5VMI-];AV!M5N[4Q9,Y*$)2C_D^^L_3/BX_6T7H^H_BZN0SU_3_E>I0Q_3[O ML^%]OW'5TZ.BS:],UO=Z",7L^.^I4:UL;R4?+NT^RT"75Q9Y*-FLTNBK#@[" M.5SW]TCW",Q6_'7*.]<3YFUL&@9RZU4NLK^#,4D>R;RZ>4HW*]6W(=@,?46@W+4A3I8I"@"160=I'6A. MH<7P'&21DT\M5-10T,%O6PT=&,]H9E6$/9$M&) MA*(*<<8?*4QL.&W%BRXH85E6$$;&_'];?Y6S*P'?AC\-I3DRU(-78P-C^MW/ MRFF_3 R/<]8_LO8]OMO]:OZ<7HZ\X?C'1M?S%7/87 )QN4I4HQU>Q5MY!:XJ M0B*T@VK\N:EAAJB/+8L(;8:V(>UIOB&1XV?GWES<]9R&G[5N5O.Z_E,N6=N4 M\AC\,YQ9,K?SH2IHKKJ%*)CECW:@EHMPT^UOY= M$*2JV@/L?Z&NN?9]](,P_%7TA;'\82>UZT7X/SOAO5O_ (CXR^/9ZJ%N/7B[ M8U3L+6:6WT)<[Q&]Q;ZRH7U'Z9]:"E#^;\#Y(?S/C^[[GQ_E#^[Z?3[K//E- ME]'3K!GX MOP_/L_$7WO<_I(E9^DQW,;BZ[E?KN@P)N:I@WT/,P\M6T7'_ ,1_)^)3753\ M#X?U>G]KW/J_R/D_(D]/QTC]AWN^MC;]'7.AQUIV,UF_IU+$>'7,FQK;N.^? MDF>8WPB&S\MEP[J^Z*R?LJR$#V=1B)(NO?+\W\GY[?L/R?E=F^5O. 553BLWN^Y L?CT>A_P#.ZI35V5JR5=$UUP79 MWE!,(R*5KNTEQI3EC5%1PE1D#8F;D'MBWXF8QV#;R"SK MM4%6NDPYO+[877ID54)D3,_\ Q'VC[1_:/25\ MS^(C^6^/8-0LSY,#_!N06EZI2XU^)/J/U&G6J0;V?K5-\7V?4L_O>Y/Z_P"C M]MO\]/L\..++N)^ 9)@[LW3.OQ!F,^5I9_A[\.**D]+45/P5#2WN$F]*U?R/ MD_(C]7O^U[*>WZWMWT=!HZ3K [4>[#C>FS,KQ5/)?,O3U1%9=2%_$FS\&.B% M '=%:#^W=)=\R4V6SE??F\=IXH//26@U[TY).!^F8B("[-UV0EWU**$9/*+^2HO\ Z]>O]_K(=5JE8Q9TN*%4^,/J?\ 'ZS2U*GR-DTXC'KJ M(J'\'#LRJZM$E'6J'FVXX\N^N'A!9@^ZV75HFDXCID=8YGE;M MH)G:9;C5?CR IA_X;^ H%NZT^7\C\0W/R?=]7L>Q[4/H\>Y[KOYG6:]Q3B=E M?./B'MKBOBFVX-).W$!38WD>?282[/YQ<.@R"LN,FI0:!,HQ)BDY.!6?09+" M6U\ G&RL%(F=&C'U\V6')WVVF ML@GE)]K3,(Z]L# 1 Q4>_P"[[1RAGK^S;SE"S6.JE:N]*5F7;WF1',E,H.T3VM\=[5>@\YU %LY^YLEV)M2SV7D^P9 M<-;@GR6/Q^BQG'L>&QYN2Y7[ E#64LC_ )+KB5QI]I8$I *Q[84V)W3.WABO M^JP7.+VF28P5 MV[KG1PW2F)+(X5L$M&^CHF+(W"O?4B>4W?,-CS]JXGRC,2)=D!"ND=(CL[/' M(_C(R/6/0../IC1^FBF(I0F:_@[CF/%,3$CWR4LZ_>9@N_NB?O!1,1/J$VGN MS;F&MNTSNGM9Y!RJ9FM-L-F=5V!;;73RTL^N,O)6)H)=4>M$BVC7FI5.6N+Q5Y_[ MKM)DB<1'VB3@BB(&(*($8@Z.O'E$_-43_P!>CRG]Z?\ %.H[U)>O/1UX\I_> MG_'KSTO2]'1T>4_OZ.EZ7K ME[.P73^'VN>;&R,'%\7IV,<79'+*]7S3.]L8 M($,:./(8<0%IC4@Y ,$TS(BM(8B:A]G4LD8EYD)H+F&DNLGR5E="9$( M/6J8/*=)E3-A"U7ZD7 MZ*"55N8\K5H:!JNY>WD;R\=0&PK'A1=>%17EJI^\1OP8MDEYK?4EL UZ+.-7 MQY=0E>VW[O2(Y]]>Q1N]/E?5)7SM1/OZ%ZO7IW/3MHZMP'8UCC1&'E9OBU1D MZXV4='93U4-R*PT6"0Z(<1I'K$E@(:_XH[TCG8R2)DC7M34MWPGXG9!6RU=A MQ_U@P:81X2R5>,AT9\<,C?2Y1[2F0&Q&G1/YI4!3"&+_ #9$^_G+=V;>PWB] MI\W/;NDOCL6Q""CHQ*?%P8S36_*E'HZ07U%$BB!!).H@DU@:3&.*U\;GK(]S M(WV3I.'WS3!SF2Y%WRKGL%6QL65%*>R:!(DW7K=AQTE6(4JNN(6(6&@<&TB2 M!+7)4-RML_#W*1ZC@>$.'LAIVW7LX5&PL;9/C,#=&O4Q&-HUEY9]*;%F\YDN M8RC7:N55A7:8#[ AO;HZA#D/>@(:;[6,:$':&GV:[)]BM'L9OR5%4.HQHD>% M?/E/0TLGRGA?7]U:C1<:.Y[K+>>85&NLNQ2RU9F&02P@8Y(9;BW^+7]S,]61 M4HUQ&)6&5UH:[TMK![.MC&/G50H#E,<- 2]Q7-G&&:R:<10VFN=VRX*]8;%' M*4D/>PH!:@MW:5>M#&', H3:$M.1!7>1#$QFQ>T_W :KK]K9LUQW=5B:%5EZ M\=/+:_E;=2FD/(ZR['8O+7,AX4*@FV3"L8UD@;7RM8&0T\Z.M$BBFHQ+2"FG)9=WU?1I(P\D0Z&+XK[!I#F/'3?09DU(M*MBLJ*QMF3YMC7*F M$=*-H16RP#F&N%K63&*%@/J7"O*.]ZY9VW3]/R&P8"IF4:_8N8]^.8X,Q89C M%*ICCBN!DVS)9C'$;TTV5DJ>3G.6E%ABJV]'4+A.\XOX@5+'0$T6*NE5OK"V M!%/DL4"JJ)-\8G&Q:>>9$\.47YX\2JOH::B(DBV%U!MO"-XZ^Q_96OK-;/&\ M@'>^+WHT'L:TX:1P]C37 2OD>!;U9;)!3A7/>U'M;,/*0),.1+PU/DK2=WLV MJ>LYU.0MTPEKJI5[M*QX(,5S84F_6K&] F8 ;$B8J)BX;V2P()YR/P/RQQ-1 MQV3W[4+6$QN4;%:ID O8K*TIMRHW13?9P]_()J6S4MK%5[1I8\$O- L%#I#9 MG1TK/)CE[J+BY4"39U8%V657 TI6.8'CT<)>374$4BP/.6 *HIXR$6&2W MMR117RLE@"0TJ)XZ3&M.\Y:+8K]#X_"K4))X:MQL25EI+&BI^DYM=BDX,$CF MK_1LE)8Q?'ZQZ=--GY9X^T^].,SVQUZV1" EM*O7NY&Q7@X@@BR&/K6HK$02 M)BM\K80$!B$B8S,EH/MPYIY-Q(Y_3M&O9#",)@5\KY"L MHFA8Z=/7%V[+2,>OA^FRD!FK'*2.,^.$9\L[6,5%Z0+7A5N^0BPI*QR!G M9*N^:T.A+)&PW1U''37=]P#+L@JZ';.OR=:AVA314S.JR*/*<7KGSN2,>>[B M?5U5M75Z2+Z";(:*R&#;Y)+; *R::.G&XMI"ZHU#G.VHJM4_,?D@.3F9'8%WU=CU9B]/6AU-8_ZM:'6<#19 M9B/B1L;+,8\82&:CA$L["Z36;]NG,^MXW:\QGM'N8K%Z2J@W8 M[]G(X6:M+ZD-(ZBD.3DFKR3R7D*37HQ97'4UV4E<"O# Z_SRR[D.O..V0&Z\ MQ6BDV9LFOB1+H$:SCJL9Q,J:&.88*_N&CF$D6JPRQD34U0+-.)%)$VQ+ FE; M$DZ7=X7D0IRR)KW3;0_7Y0!0,R=-[?\ 8Q3_ ,5MV*;Z8V>(K0TJ*2_&LXV>CY MP]U+#91SJY3(VS/U+2U[MQ+G.5"I,)J$->X^%!RI59,C';ZU-J#2.M M-#8]:XMJS'(L8Q^WR*PRDJMA+--B;:64 8TZCS6$Y140D< T(@:SO@#A9[0 MZ,B\,2?.^.Z53:.V_G6IB=*W62SX1:B5DMX+F]76PV/RJ>LM_>BKYZ N8?VV M620>V\F57OA<]'-21&MT8&RJX^U'"/Y.V.O.2,XH7,LJG897N9!GR;"UJ3CL M<$B(54R,,*FB#\,DS]TY[L-LT1_-')6UU. M&O!@EK+,XO6K&3I)N8O!IG'T M7.L64D7S,-A$V6\:NZ3KOLG74608C=719#8 J9;!0:RPIK&P?)'$ E@"^N)(3XW MU*(F8:&?@GF/C6QFPUY.UT69)EB*J^BKD4669.%PA>4*M&-,R.8 )&U*S.8 M#(Y@9>VO;!SQ2U)F[6N.4I:NK70S&BQ M*1-S0!0$<,5STVGG>FN-&8Y_K>\7',MJK?#!@+5*^LM/8@M.3XAM;/URG'J[6%QD(=>N-XK3^ MU;BY+BP$!:E4E+7%R>V)9&1)#),Z!WO>M\3GQQ.8V?="_8WV#_M[7G\T#^TMFG[E\@_C#".JLWG/YVI[@]"PM3-96MA[F.QK+>*KY"VG'6C9;S@F=B MDMHUG$8I4)$Q920J7$S, /30W$FEZ?DO99S-M>1U77;^SXO/9M&,V*YA<;9S MF.2G%:8U2J.6=6._56MEJR:P186(%8>0Q$M9)-1W">=&\M$[@IM7ZK2FQ>O& MQ*GRFQOK?'1K\[(I[@ZRA06O99JH U37QUWQBGCCR'3GRS,^6*R&-DE"N(&Y MLCW[Q[P#:&6U$%/D-Z/:BVC 1YA:JQ*H[JPI7W-/!/,1+%66WP?F#0NGG2!S MY8(YYXXV2O27GERHT?KC:-'K3;?&&DW@16XH!E-1>7=E0PI5QY$99A$UXD%G M0614+56E9,0Z,IHY#GQ*L"20>M7OXL[4HMSZ)P+8>,X7#KR@MA+2OJ,-&(") M%H ,;N['&X QI*X*N!8-Z*I)AX!@AXAX96P(U5C5[C#4<@]_+6ZTSY$+.)54 ML2K3)IY-483P6L<;-*E/B>'5@^C MJ?7)GN,:8X[7I.$#B6FS-@U[TCNL;Q8D(4+&I'0MF8-D61'>L$2P>V2-75($ M%G9BL=ZSA1/5$V5'Q^\]<1GOE.X]!/IFJ]ZQ [()6V2%K?5^@XG#V@R3(B+X M:K8HY'>$];$^_1#G.9N-==R+<3E-GKA?KLE-E-2ID,'7V/7N/;[L/=0-FA:R.2P>#*_69'J!]N[)+CP#'(\:I\ANV7$G MRB*22W#$GCIGM CEELK5A9;*R$6L@GF..1(@XI/4G4CYLB1(R+.6=B/]$D+'M7J6VGDG2=," MH6QYVOCV7DC8JU?!;LW6URF(%\TZE=]E*9GJ(M>I2R,#7!2P#$1OCS@GE?E1 MF1#1=/NYM.)LE3R-_P"5C:&+KW CN*H.4R=VGC[-H0D6%7JV'N%3%.((4U9E M<;HZFWQ<[E&L.0V5!Z\R#'CM6YY:M;'CP-K;"7./90'+8,;)%7S%$Q^P^DGY_EU-:WM. V[&CEMI9RLUL@968$0KO7'VY\:9T];WG 7=>S H7:"M;E+56:K9 M,5VJ5VHVQ1OU28MJOD4[+TPY3D$<.4P!7KY?4DY^,VL]I;KR[DCCN M1\M^458-IKGR3_ -K+H$VW XU^ZZ3!Q>$SPY-:LMEJZ M;8T]?XNZ9+K;7'&WYNIQ7RO*IQ)LU7$:>S .LZY MKMVSCCR>[T*M\UVK>*?9:5FM:>@YL-=,*/L'M$0@=*\^]A[NU%D/'O"-2[*V M!,=A6L,YV!EDJWTD5OL2JUB[%BSB'%!!E@4CA8FN;'%[@>K9LAJVT;UD)9:O8[)V;^#P&/=8:Y ;'J^%UY>)QE M,&F1G4Y(ILQV@X7?] XBPPHQ^)S>OT,1M>YYNK1K5K; MM(W_ &OJ,#'CJ!:N-60M:Q\(XO\[T(]QU M[/<.:#J?DL(!1#PU]*7H[5-;4B1^61#UV*V&=48(\2?E[8PD4,#$1/#6,:GY M^>CJC\EN&5U')Y/6[FQYNQ:Q.3OUG6)OV#\Y3<8V'Q+7=\"T6BP _P JQF%A M$ (Q&L<%Q?K_ "7@L#O6*T?6*&/V/!86[5HJQ%!(4P#&5*LUNQ%:%D:#KRIC M?NQ[!)S2-K#*9C[)CMQM@9Y'E+"5O(,LOVY#&8CE+4^.Q(^I,(1WESIG/21' M>?TG*OW^Z]=I6&FU=EB.+V-(^*2F/QVC-J9(/"P/K"JH2 MI215AH+RG-+ 2SKZY)'I66@)BV P;&5Q !C(H"63/%.P8[B'D7>=6W-IXQ63 ML*&IE[@'X2^%9N-H/77R[)R,AL+Y4KJO!"09T5C'/5DA.0'U #/'I\*K M29?S3TH[[]*QW>LONLAQ;C8142$+KK*!LDRZ.2-?(IE_-48[-0J4L;GQN(%Q MZXM)@?OX]!9TD3G^ERLT#N/*NK5]*VO+Z_=PNWMQ%"J%K&U["K].1S5H,97C M(BDB!E,B<964P<$U*S3)+E@EZQ=QA[=^0[O*O&^L[IB=KXRK[/F,@W'YV]1L MX;*"6K8X\_=G"%:!;590%UTKH6I7((MO39$70@P]8+D7/7AGA]:5BFK>%F)W MF-^)PE,S"IP?&H+&)SG,2>2.2ERZ](4EJN>SZF8,;&U6(YK)45K)-9#D0,F5 M7>6X54KA5?\ 7SN"N)(AR#&TDL<$09CX897,'A5S& MN:JK4GMR["X:ZYQ/.KW>IV'5.THLA\5-EG%-]9:W#OI(DHL6'1/KK1L=@EI# M:);L"@9;$ODKHFND&=!&DZ^1&>4FS]Q;=V%C0$E7CF791?6U"!,/$)/!4*.T M*O6<2#S$+.2,)&7,*Q5^-*0^%SG/8]RXLW[(Y',:EJVPY+9]4L6KEJQ-#5== MQ&)H6]?J+!D$RS9HK5<4,,4A8TK4&'>P6+8QV[9%SJI+30Q^6:_$V#-%BZ^)#$/K5UVP">CG MG?:$9'V_K+HE(T1K$+L,JPH^;T-1/"-2>=_A/R]/A.H;\#M&X MER"Y&8_A.=Q3F8A64%_F-Y5#%3 R7D-$M? )32F#*PF $RPLQ'V7QI8")@8) MQH2('3^ZRV?,YR.[<&1/:OEKM=:;5J_WHZ]P/PO_ #3J7':8_:QF_=-F_P#B MN)=7+R;1J9GG/BRGE$+O5+N#UOY:'C#$VAG+Y=IK>!=1:II1T8LXD& 1 42) M3'K+7 &5R.K>T3W$9/7[;\3D<5MN[_3;E-A(LX]D:SJ5<'5'!,,KV$ L MA:AH@U9"P!*-B=T3B[J/1XFJLTU-B@>$P9-:7N*Y#25$I+:4F8&MBN*FU&!) ME(0,_P!MIX9SQY8X2X4">\?Y$,D\C"]FO(#YM>;RQTB=5J:/-L8O XW+]H", M@QLD:T1>?P<9UC?9C8V3'.1$;T M1S'W^NV/:OGPYCJ7*$>W[>%_2:JI]E_MZ5ED172(* 660&P8@,03NK)COF9],LQF\MM?^'BW+;/DKV>RE7/55+R> M6LNR&1[:_)5:FCON6C;88::5AE)1FPC"I,5X*%1 Q(K=&Q,DY"[VR[,S)9"+ M3/,W^E8\(1/+)#6U$ULRAQ"D@61SEA# <#&Z.-6L]^0LE$20B5SND76?;GX ML8-AM1C]YK'']A7PX4<=[F&7CSV5O=V;D1QA<;%)C$J1/?1S *^L@'A$%;&Q MSIR'$$S\V^\=:9)H#>&:8,:R<&RPS+Y;+&[!\$D;3J;ZFMSA^0A>ZUB3C%!H M'*DD?F-#!RQ?5[@TJ)?O5/=4XVY/A]>9LJYM=:YI ,V^HRL9R&[K9[1L34- MFQRUQ\"UC,K)I_7(*VP976,3'I$0(BQ^[(+\*VM,J[5O<ZW' MQC)/\+=R<9](7649CO/7>3[#REZ@!8-#7X]C.14./UZPSR7%G('D5S71,R$H ME1A1"FBD_#KX9?BS#S%$(^I'/B:KY7<)J'=6HHSKR@Q++79XY"P)Z^V7%Z9< MEPS*B_I^VG#))]$3Y!3W4E M>1C.="%Y5*S%IH8WP'5MQ4XO:!%3TU@Q\1T-H()9%AEPR0S#J&2R8;KR?

  •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end GRAPHIC 36 g446120.jpg G446120.JPG begin 644 g446120.jpg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

  •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end GRAPHIC 29 g509889.jpg G509889.JPG begin 644 g509889.jpg M_]C_X 02D9)1@ ! 0$!A0&% #__@ _1$E32S$S,SI;,C!:0THR+C(P6D-* M-#8P,#(N3U544%5473$Y-#8P7S)?4$E014Q)3D5?-$-?4$A4+D504__; $, M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_ M !$( 1T">0,!(@ "$0$#$0'_Q > $ @,! ,! !P@&"0H! M @,%!/_$ 'L0 % P$!!@P-"@P/#08' (#! 4& $'"!$)$A,A,5<4%A<8 M&4%15I*6E]<5-CAA<7B!L;?2U-76-U-WD:&VN,'1V"(C)S(U4EAGAY.4\"0E M)B@S0D-&1W-VAK73X31%5%5B8V5F:'65IK0I2'2$I+-R@H6BI*KJH25&@J:)!)H-INN;;M"GKQV[336>+2A-30:RU!(J3@* MF\[,6T7ZZ]T!R4=DIQP)IS='!AZ7WDN,R*6QU.0OE4HEQQA:0V+Q(5R%MT"% M$M/+;#U:$B[TZO83DB(Y"F2;YPKTNW,W6*VQH64P*XXLF9)73 ;$V^7N!V1P M*@VZ+,"2NNW%L2M_)N&YET:60F7-/#=,D5*5(BRC(QW/-(FF>MC%:V3%EK%! MSK.IB,"L-C-])$L8D3ZE4BL9:^U2F=C+KR!7M892I.6<'>C+M>W5Q?98-^W: MUMMN3M<=K]SM;:^/["V2=Z>'5I+:6VF\Z4A$[BI79V5P$<8:%D+IU#0D6E]# MNBAZYZ9"(N&=)/1H+Y;A[$1?K#Q\E3O]--+^D9]Z'T38717HHLS9-V_>V0EM MH+=6BG,F=S"86QB8R.F$O>0D=%!\ZB!!/7TLCHA;H/UB&=1KB#ERH-S"J2_T M4[GYK_GSWD!LP1GU[5R0V3JAM4'FSRG3I9$W20@)]PQ*4F%$)+N!3H(@Q*UK MU2<+NB>0 ;'$Q:%>2-#NY=95&&(\M,]R)B9U)I/1!2=U=VYN/,(N(0.& 2L4 MD&"*WX!@X0(;@WP1!V[X-[6Y5-3;>CA>O6> B=PE619VB;^C"FO;8F>G=SBT MC<"2K%;+ L6^."P-B@VMUK%[L<66+/^/\ ?EECOU'">,8 "OZ< M)1VQ6O?9VMG)MVWMR[;K)Z6K16+L5;AQ.DJM9&6"M7"6?AHF,C7CE]%0<;%1 MT($O8TNHQ\^]5?2Y\\AXLN8AVX+S4C>5Z:= M'4=;.-@)9*7,7"RN9RN52N:K,+*D1,KAH=,=#3F$AXAU#JAW*8J$?Q:7/21+ MQ+=&!SJUIVZ[P>XH"6FR8"R[F:L3%MUDA@0C JNM&:%+9,, P""?QUQA*N?9&H.N38VY8[%W,L&P M[@'8.VX1;-?>8PAON8#B&X0W#UK%@!?T+QIMN 0[;6<)A?9?>VMMV;+[-O=KW3$:3'SBW5A['"3NE M.[7R'Z9>1YC5A< KU*81?JZ(?U8IB$U@0CI%/G1H\*M3V0%?*DNT$0\=H?TL M:4C:9\Z>Z-+7N;+.I*)4A;N;I>S21R[UUY'_ $@E4$H"<*>] F$B@2X".E > M%2-YJ*6Q9R77:VZ2,"]R#<^PF]$\MJM<&Z6][*;72)U1BBUT]PWL?;@]I5[7 ML9O;VO7T,$XADJ6/#=%Y;&9&X1Y0!)($+"_-3PK8E1HC@%)GA.W*U)S:H,&F M4 +)6 ),$,@X-@W$4.P>1@ENR"XZG<@0[$QQJ*;Y!R/E+&K<"!.A=K&-J0]L+4%N:\-[B3M=UH[<=ZW_Z#-&/Z/\ 2[:&WL\3 M 0MB5PLH@IA,8*>SX3(/H2 Z"$?/9>[.(9Y$1,5$NT.XA#L+$,Z?N%J%' M@6/-=,WHUV,T.V3,XF.EAS,+33>12"<6/L<9"\A9C-T1TPA7$Z?QCYS&Q\/ M0,O@XAZ]@GS];I4Q?PD6Z=ZJG!=JF?6Z_/<9THYR?8X[+V-Z;H,K.;W9K4#2 M+T1PES>2(U,I+O891ER332[B#>U]X8*W;KG0TVZ9LT:OETX.AT]9FY3";,IS MNJF[[) FK!R$;I=&%$)K;7<8[@NTJ1*AJ;D!+WY/!V-N(=@=#.OGU'F?O\@E M7^DVNM"^A[67'-(IN3C)!"GR87GA<6"ALS.S.UV0&1P3[W"!5>C!> M\,3V,N38@S?E#WX-GKC3A]S<1I;L5!6TCXF"LHNSD0\F2W+^+=I=K#R=F&6D M0B'KU*WD8B$=*6[=%120E9" 5)]Y>B:BV\+Z-NE:;:+)'+YOI)=6[E\-(414 M#*XIX]<+%3QVE3Y02K,(AJ*U1Z"W;!DE75D*&IX M:0G7-"GOONA^E^7:F)'B>80;(^-6IJ1P]:WV8L@R848!T,^."=T*E#3L;UIJ MXE O6(_F98W2+4P8[1Z(";4SP%E8E-T!JA?'L> MP-H&(@]>^2(U,6F,7!(5+EI@.#).='A46@;$'!7+""P^Z^-"-FR3@IE3 L8E M9L.K6I((\(##;I6^0A2$7,%<%K7'][6V;*\)@YM31QI,3&.I MY:C1K!VDD<-9 S*9QDOBWSHS9X@IA8]Y#/W@AG#A$N>O88PO0H>*%(>&B'KT MI]K3&S)5IT]'_P"B(BR&CK3U,K#6MCM)@L_()7.I9!Q*;-.GSMY,))#S"$AC M'QL0\GL,ZCW,T:7&6(L;Q^5SEJ>AQZ'Q>.*)FN7HD M*"1+6YF3I;N"92H4 ),+763#.26X8PXU,$)@A#%88JS!PG$+:F(4H=);&&Z, MA%< Y$O?VA&Q '8P1-P"=U*PIOL*QH1%7#T1OK&!N"]M]:]JTU:PDQ1NY;Z= MQ#++%9,BP :6$0 W"&XX@I37W@=F]#^@/$'DV;V][6V54G1WHRE.L:!JE4JR M@YQ/%^+7%SBD+94#:G>Q@D#N,$L?S4C6M4)6M"DN<]$*%RX9:ATPUFK%"=QT;8^4S>5)5/$PR71?0R5J=1T1&N-5,+!PSE M\512X@OXI\ERYU4+?EXCY$E/HZ67GEB+2Z7+>:5A9*32G2?:*RUH%HL@\CWC M],+%!#N*E$%*XT*7'S.81L,A$M=P;N$E\&J+BB_>.X),.]Z48S,(G-&^[M#Y M/'I6UV.$GNY1MZ;7U!8\'&,BZQL4JB+' M>UQ%"'8P.WC#:LBO>UK;;WM:W= MOQ6[M_M6M>]^Y:U[WXK5R?Q!UR)H U>#C8GVYB>,2MB8YH! $],PSC'T@NVK M+JU32(9A?"^@CB6ZM]S;GJ6=[1;PA2:669T1>_=8M3$I:W./Z=X4]*FAK=(Z MGEF0U;:G/H>3=>DS1Y9*QEKH.T5CM)L@?6KD-MW\N?0:(2S\##PL9,XB M.EP?O%/'[B$F$L7!(1$.$3!],X)P],N6I_T&XM/F'$JM^M%DF3\>*I,)2)%: M.IIK&CGRZP%[A&DLU%N8EMU0!!%82:Q-S@WM?:"U[;*Q#5!>U]-V?-G,WDG[ MT77E[E2M/VCZ+X+,DT'U2-$PSDT-+4Z+HBF/:S6!_F.-DD,R1V3 M'HN'4F-3@H=%1BSH'?*B"NB=\FOMI0SM)\M: ]3L1F;DN?'W$>.9TP(WQQ/& MJ7+XF\P!X6QU,N5G",4+%;0)$YM@5:@P9QK>G;P&"&,D1@^DE>EZ+GT5-[(6 M@E$IET?,K)S>:2F(D5H8.T,(\2ZE\6]?2^.7!@IA8]RX2_]5@.+W>3 MW:FE?HLR(?KS'FD&:,:IX[?+Z:>!,O*2[Y#*3E'$WZ10Q:Z*R>ZVZ8%XF6,2 M_@+LAEE B+J]\B%"VXV?5BR_]C!A^^T%0(^%%=E#,'P1>^Z[QK%ON#!O]O3D MW\>^WM[[?7V[:].R.-E,'HDT4&;2A_-@\TBQ@@PYF\1*O5(I$SB=2(67#A^8 MA*0;G?\ 0/!3^BB'6LJOU!;.4VEFOI*>D@+-VFA+-*A]!< N:*BK-P=H_I.6 MJL_)P^E[E,7&0:8!X](2?6?]Z.H2>C2S*>PN)*7 M ._0)Y-*6-A/7 WU@7&C)=%Z4Q2"PKV#OR@C!OA!MOMM[5S_ &[%I2+:@,;* MAE$B$;B$H(A#* ,5K)9E(=[MN*U]MK<**]KT%M[/2"PB)T_L:@QD3&&*B-5;I,-! MPJWSU\.G> GH0[>?+-E?1Q\UF#J#<0BC!N"E8BU/X;I:3J"%1)2E,<4H3GE@.( M/(, :2<28&PRS232Q"+-*,#>P@& $( PWM<(KVO:]?F/LCC\7;3WF2OC/'FA M+LZ*=7QS1-+:FL*^RUSUS@>G2E;;[+6L,VU[[;;+7K3!N/>5Y(Y,F6<3O3FI M71R%EQZ614I6:,T# G?5#NCD+G0H4-NLC=.L"[L;9"T,#*$O9Q;.*B8"72B-F;B @X.)@(D0< MQ?Q\W?NTN74!"OU.BE^IVZ4^=/G2UIAP'RG/;97Z(DX>Z4=)EB9O:54/9G17 M+X&AWUP;=EMNRO)=&VDQ5MXNT$EF,O@Y=/;./(;UH2R M:N)U*8Z%BTJ4YBX"80X#M:4J1J/G57G1E;K^E+Q3URX\%TZ:!AHHEUB[526< MS.>60MU#QZI:\G]GHJRMHY5'RM;E$9+9S)(QZ\?.ED/DO(:( ="(#N((<)UKVOQ7M?CM>W;#?;:_$*VT-^*^VU[VV M7Y*^5*8XL;E4SQCG(FA+5>CF\=;SP,*.;*ISBU[4E'!8Y$PN"E0IW;;#)ABMN;R M6HMYN"W]"J9>6N,2":"CKWL)P3MIB\],&P@M)9X[E V@3> PK)4?5Q6?19BE M\=7;+J6>0-J9S0C'8(@@. 4H +@%)=A"X)4G$4I)VWN4:"][U5$C1RY9:&&B7CV31+X%*GDO6XAHI#TN4:KMTM]JAXY=0[J*A MHA4.'Z_N*,]('0AI6D=CUZ?[!6SF=M;%2QQ)G=H+%3"7N'-J9="J2M#B>.XV M.E[Z&#][TCZ(1"*6\=Q41&Q$!&0+N,5".M*FC+"\\U<:H#,NRM&>;$F7(!N3 M\C2.Q!Q30MD-G@3^UPYI-,$(!ZI6[ 2A/1%''#:8ZA.NL&4:XK_ (>1<9P++485PS)$59YA&%QI)ZAH>DW1"?HE,+?IE:8P RU* M):G%MN0M1'IU16^'8LX(1CL+F^\,[=Z-)W9!$X3$VCGT>XGD?/HET\2X?S:& M?(>NG2G22]?(@=0/G*EDOG_2Q3^-+M1*85/ /3"B'VGRR.D][98P-B+&R>+L ME)K&R^)38+7#Q27240L*7$!!RL/G:$+CUZ%9?N M@4%E^B)OT]-\3EZO+#ECEEQ>X%!;R+1Q.G9$J5&LD:)R)5'JG'AVAJLL(:2F MXI24H-/"K-*2(Q*SLWW&05NF+4#;9^O9\:C#?M7#Z(S"VVU^W^NM>VRVR]NW M6T?'FBK3%BU0Z+8=B6/HW!X:W1D6N3B>ZO[C9G>DIB%T;D:U[7KCVU,N1'') M%-FX24XY.:848<( Q6OG.*-..$L&J7=9B;';%!E+^E0(GDYFNOWS@E:S3SF\ MD^RQUPV?T6Z046TL1:^U<^L['&RLMB)0N#ES MJ,QKU]&O'R81V@)2ERE8( YK9^D%H77HJTL:,= M'%B[;29WI"GTMM.YF4]BY9%I5-S/I5-)JZB89S,'BI9+8:%E,/"REU#+F;YZ MI;Q<:]=GVEKJW&1D2=-Z)^B);V[B6B\ ']#O;'6MLM:UNU;9]JO.-$M@II8"5SV!FD7 1;V:6BC)PX7 +B%H=P\1 M#P;E#I\8B'AU!\E4.LJ"$K=T4FBR20/5'I(:8I#IEM#8V;V?ELWECBS=@Y39 M6+=SA$&AZ^C9?&S*)>Q$.(*,C$*A5HC7:4*>K=/2I*]9TD!)54#7SZCW/W^0 M2K_2;76K;0*>*L]AG4&B,RLV!QS=M#+(TS2&S?=6.8=%70V=T2NR2ZGH M=/T1T/P?#6))L9OK%@V;WYK"HMD6*O<)FK*DD,5D:(3<]LJ_ANA'%$,PLT2< M_@#2#MY:4K*6V6]E;V2R*41O(J(>OW,W0[6YPBW:%S!PLEZ_=J!=K*4DI1K=18K39*[)^CUI'T3.X M>?N+46PM/*YY*IW+EP[B7P4/!15F'K]U$Q*8YQ,73YZYDL8[ AX5Z[5T[I*U MA*GNI)+#&H[%4!;3&&%FCC44,1A38PM:%G;BS![-^8!"W$)DH1CV6WP[%6%? M9;;>N?S=D[7OF'$.RU[_ *F#WR6O?^^LSN5T/5!F5=-."\WNK6]Y6QLP39U9 M6XYI:UKOZ(<,B;E"FZPY(3T&O2 X(:J]SA;\ A[Z_$*UMEJ[GI2L5&6WL1&6 M6D[Z @'[^)EKURN+Z5S!NG<%&.8E:*0KA^M-4.REVE#DIUB 2D7CLGH\:5I7 MHCTM2G2'::%F\X@H*#GL/%.9;ZN_F;]]-I5%0+MZ%1\7"NEZKV(2\?*>1 64 M!12%JHDZO-7W%N6N +7Y?0W3[][ ZKUN>>N+%NFR"S?'F44X M\T"?@&FJV9M:5[0O0D'$JTAH+LR8] KL Y(INI.(4&(Q)P#47GW46.L<.T7, ML5CB!.SQZ.3S&;(R-:>XPI6YJ;"G)(@0I[G&&&<"F3$EDE\(:8/>@MOABOMO M4 ;FYITPKG[37*B,L0)EEQS/F.1%-#F<)4B>FLI1$84,XA"]-*E$YD)C30\( M-)=2-((S?&73\((0[^@YW++5PVG&12ZRLPE,):&7:.I>Y0\FKE^_E44(2&B( M>*@*>.7SM >)>(=A20DKI]BV3GNCN.]$2U\ZTAR:TDQL7.].LY MBGSBSL7!P5HY>J8/Y7&P$7"F++R7OG\.HI<1,,_>%RMP^?J=O"\0Z)H?+'5[ MUVZU;+XJP.B=#D"71M(F0&E@,61_'47*;&Y>^/9B6YJ9'9.R(%;HM'PQA)*Y M:2UD'JE(D_#V;W7/#\A8\JQ/,J5"J40R41-JARMQL2(:)EDD84K[H6YP.+O> MZ>SXU.!1S<8?P%E1Z) M70*>^TD#B]N2A8ZJRBA[3"TYBKH8LR_" )"/9>I-D<:CTO95\=E+(U2)A="! M)G%F>D"9R;%Q ^4I4B5EFD'!M?8,&_!<18PA,+$ 80BMY?#Z XF.L?:V M'/ M7#^UMKYTYM#%36#AUF7PNW'.; GS>:9& M62LT7G>.+ND,B\D:2BSTCJYNHFX(2U9BD@HD\(E"98G./ R M_!@G91NK+>#.LJ4'.26_ M *U)BFZHTNP;<-:X 7#W&R&C&U,L?Q?TW*=%D,D2*:2V"F5FI$^@ITN.C87U M-W&1$5ZDX=.7+R'>1+N+1#.T:X>JU7(3[#=@TF:>M'\_A):+)VD](J-6;72& M>360Z0+9PLXLF[E$KC_I)]+H*7B:1D1%1+J,AX%]+GTRB'IO>U[6ZF##QWM>UO3:"H'? B[* 9?>WV==VU\>R_?DWW]ZNB3%6F MG!>$'1T>\4XW8(2ZO3>0TNJUG]$.&6MJ93980D.Z,7*P<$6JM8X.\"$>_P"4 M6SBK\8[2/IQ49#%E@[$T9,R(*4%S2\K%Z*>B?304K N+>OV2Z&Z+ K++/ML3 MV)WX+;2M[Q5V1&@^TB;#V$LQ]*23URRUK8B?QK_I8_U:(A7T6]B$N857J/2F M("7@2H/G3IV% T>*%"?+W_I:6'>Z6M,6D!-GK5"5Z1=&4-8F4P9X._H MC8]*U75'+;HBN@UZ4O@KJE!Q_P"B (>_,%M%>VRUL\68S@SACP>*%L<;U&/! MQ@F&"BH[*/0V\73HBVTEFOO5%E5TA:$DM-:_1-CKE@MM-WWZ*O,X#1G.82UF ME*?O(V6*A;=2A[+Y8Y0N*,1"/7D(7 7'@PH=I=A9J3#O(A6K@DFYO5K&.I3/43#1#:03F>Q+QW "#F,.)HF/+J4J3'J?+?=&"@",XKU M?:;1=N.28"JY1[T^DF[V_:O8 Q;-G)?95"&V%PG N MHMY@&J& 25^B$?=7AG?&UAPMZA1<4=FL?/1+&T3XWG(PDJRDP5@$KBE M5J"@'67H[%6ZEL4Z<<)8/7O#GBC'3#"%S^D2(7E2SV7V,<$B$XY2D(/Z+7*@ M;P@]0<8#>! +:9>PA7MLM7].6-/F&,Y)D:?*V.HY,[MP3 -RUR2F%.[>6;OK MF%-[T@.1NR,D8Q7,$00L"0(S],N5^Y#*SV9 WQ_+3JN?7!L:2TB=;DM+= <[K$Z !CDJ=7MO M1)DR4Q38:LXI2?(9Z@925,4 9YXQG'"#]38[N>VC^,KB7)%A5@6K$R@ ME4F,?W*12(D@Y.8$TD9:-W>%2*]RS0A,#PBF4_3'O7[AT\?ZSQ3E;E*24.R'IH"H- M\_Z=-)=F+=_<["61M+IHG\NEAF3^.^^]:6&GJT1<5ZFB%7)H>"B8B'@TH8$O:B+P".N$G?2 MHXSJW][&V-A=C5/HT5U'7M>UA6O;"K@(-PBXPB"*SY<(@BMLN$0;WL*U[7#>]KVO3LW M.D+O3U(=WZB;EM_TW[]//GFW)T3R[V%7BHN.'DMN&I6GFV[1 M1QX^+;?9_3OM5[;=N=(5^/I4U(>11QXO9_IW1IT3SW%;-F>'-MPM*T]=FYTA M=ZFH_P BCC\]T[-SI"X_ZE-1_%^\HX_/>RG4>77W&O!G1O/<5GAP\0VX6E:> M>SI#C_>4.E#D>7GKR:]$\."%'J;<12M/79N-(7>IJ M0\BCCQ>S_3O9:G9N=(7>GJ0MQWMQX4<;E34AY%''Y[V\?+;UJ,Z-?NEMK\LAD M1G;5Z!3:+QZ7,O12==Z$R9G0/C;T8EW]TRKH%R(4)NB4]S!W).X/A"M^/>"# MOK[?JB$$A6/V\]I@L1C,-:U2P;BI;8LQMK @4+S"24YBTY(V)TQ!JLPA,G)& MH&"YHBB"2Q"N L%K:I;;MSI"O_>IJ/\ =PHX_/=>=FYTA=ZFI#R)N/SWVZZ8 MP<(8D1IA88Q@1T0BRX=>LAW?_1B(U.E"/:/L!>K>;KVZT1TU$"96(V.$L4^] M85+A%/\ U%3_ -G^F,('GJY?7)_I"[U[D^U<&W#4K3N/=O='Q=K7,B^HTNPA MEEA$9A=<6$1AHK ++"(;Z$(C#!W"666&]QF&"" %A"O:U?+LW.D*W]Z>I#R* M.-_O754//!NCZ)Y[BN7G,-N&I6GGLW.D+EZ4]2'D4<.[W+OFWU_] MO%7O9N=(7>GJ0\B;C]W^G?%W>/M6O4H#.B>>XK9LSP[VW"TK3UV;C2 M%R]*FI#R*./'['].Z7W;G2%;^]/4AR;>+"CC?N?]-]O;Q=JC3HWGN*OW'=XA MMPM*T]=FXTA=ZFI#R*.-_>>Z=FXTA=ZFH_R*..W[7HW1G1K]Q7+AXAMPM*T[ M@W;S1^:&XBXOJ-,#80P7$7A=<8&PRAW+,!<0'T0;#+,"(LP%[[XLP(@&6",- MPV^?9N-(7>IJ/\BCC\]U:'([.W#FSHU^Z6W"TK3UV;G2%WIZD/(HX?/E+;MS MI"O_ 'J:D/=PHX_/=2AR9T;SW%;-F>#;A:5IYONW.D+O4U(>11Q]_P!&]E>] MFXTA=ZFH_CXOJ*./SW_/;0"N#.C7[BL\.'B&W"TK3UV;C2%WJ:C_ "*./SW3 MLW.D*_\ >IJ0]W"CC\]TH>S[>:/R[6$9%]1A81# 6&YF%UP+7,-%8!18;B?;6$88.]@%EVO<9@[A M6$0Q6M>T.1Y%G1O/<5ROY=;;B*5IZONW.D*VW;%-2'%?9]11QO[SW7G9NM(7 M>GJ0\B;C^)[O48'3PWA"N3;AJ5IZ[-SI"[U-1_D5IJ/\ (HX_ M/=&=&OW5GJ0\BCC?WGN_\[>QM][-QI"V;>E/4AY% M'&WN\;W;BOR6OR;?=HUZ)Y[BK\+L6W"TK3UV;C2'VXGJ0M_ HX?/G\_M5YV; MG2%WIZD/(HX=W_OSW?8]?BHSHGGN*Y>NS_"&Q@;7$#?!M MMI0Y>?)#3HGGN'EYS'-MQ%*T\]FYTA=ZFI#R*.-O?>[;?<_)7O9N=(7>IJ/\ MBCA\]U:'(Y8;IJ/X_ MWE''[O\ 3O949T;SW%GJ0XOWE'#Y\_V>OLXZ=FYTA= MZFI#R)N/SWM^Y1KT3SW%11P];B_9SU_8]>O.S MB>>XKD MVR>E*4;C92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92 ME*,92E*,94)ZE?4ZYZ^POE3[PW_[7N5-E0GJ5]3KGK["^5/O#D%&J<1Q'>V= M0,DH4)A][EEWOTK1SCN %[[+,B"UK;;AOQ6M;9;N6XN396/9.RYC3#A,(4Y% M?"H\5D;)D(P_#AW:'1S]%\AY&QE\F@7I(A_^2T=_P!"H:J9KAPGD/-C7IA38\:T;H=C/6WI=S3+PK'9 TV0 MX^QA.C7R8.B82\TJS@L0MP@FIFE)PB]P'?@4A1AG%4!J 08?BZ%/F M09;=UZ6H\D"M<11B(2>>/8TXU:=%;T+B<%9)'*WTVQZLJYJ=D9G!0218Y6:6 M6E3J#B]/FB;05E;3IEC2WDH<'8HD^%XBUO1/5K)6F7-CD\3U]F^?8!/=+:>8 MGDKSU&0287%4\Z3PH\VR\C%;6X+HDU&,K6Y6;#*\YGW,O5#(H[K"Q[#T;0N@ M$#CF4VW<^V;IU:VT>_U?YN@.>,XE.5US@$S'ZO#:F'O&*\>N*T\0G2 S)\0- M1Z)N..0*I?2X;+A7<,\L,^9:@"M";JX[JT^>VZIV4;H)AN2,=9")DBJ$RB/R M=/#YK*L=28]G5$*BF2)IF$77F!L&Q+Q''( T+PDO>XD2DLPDR]A%#L'- M@"1F#& %B1&%BL$8+ !<98A!L,(3 [-\6(0+V&&P[!N,%[##:X;VO7.U$=RY MDR?)C-%W+33C)AQ$W;K%J'U49!I,EQW MD.<1*(O6*IRRB;!GH!.C6F>8ET4>5*F@?1?J-PUGC$,LGV+&'&+OC3"N=8)J MKU M>46J:O6Z&Y;GN1H<]P++DC:$!QLJ5&LI;!-,@">Z&@;P"G# WG+,5XF["FQA I6M^5W7M^?:V]?@2?K1?\6'M\O:[=5:Q( M6"^HS5A:Y8+ALYX0WMKA#>WZ'%95K<5[<6]MQ!V;-FV^SBO>K4U5C$?JCM67 M_>>$?@K)_+6F#!?ZH_B2UHN )^M%>M^E@XO8_0]JG DVMMN47LM;;_8P=JW+ MQ![7X_8K[:^!E[6 *]^3>WM]OB_'1LM4"^N;2\#.SAIR4S)Z;\D->16S#RI2 MZXKRFU8TZKSW &W*3+BA/FIPA*?#RK)+U 7=ODC-"D\X&_NZ51T*VHE3B6:B M!;.QS>*P-@DWZ:.Q9=K!*VF&<'H+/J*<:@4CF^7F>3U]X:N<\TX7?561G@&)4L8?&Q[C MY\;X#-54!(KS!OW"O'X!M4%PK3#>/A3X9MU)\"3?^Y%\?_(!?WPWKW@2?K1? M@!_)7EK\$6'A!W%>UK!N,5@VN,5N*X[V!:P;7'>UQ7M:UK6O?9:UK;+5]@16 M%;;;CMQ__=OMLKP!/UHO^+!V^W^M_GLJMNJ3THXT]LKIB^YG.#U9>@VC(BG4 6NP M<3W);ZN )V;."+Y=O]C!\7_;Z].!)V;."+V7V-&LMP)-O[D7X /R5Y<@F_P#:3H_AN M'9X*E6M,:S5; W M=R4L:">1DI8?0![ 2UR1.SJG!K OE1>:\;]P/=0\. MMK0C81MRVTKS[6M3P!/UHKB_YL'Y.U2Y)5ME[%%VO:X=E[ #:]N.W)?9Q>Y7 MVUY?D]T/OVJM&K?I<**OC9_VEEWV9SU,[-H \6S4/DP/%MMW+6M[%K6Y*L98 MDFW]R+XMO]S!V_8#5=M+?U-I!]G34U^$3DVK'5!>!P#56)XGO;ZKDDW_ +D7 M_%@_&&]. )^M%_Q8/B^Y[%0_J%SK!-,V%)I#',!2S488^B*VT-F<<<9 P/;VHL MU%KBU35("FI<*## #SYWL )PV7\FV&\"3]9*XN3]+!Q?-Q;4BI&$ MD(C;G\&$0K?D*.R!Q-=P( MF1]L8:47=G=#TCEOS"P="[X8;74%PY7Y4^7DM&D;@"?K17L<&#XM. )^M%?Q M8/B^O^2H%U':F,5:6,-R+.^5U\A*Q[&$5E[BLAL-D^07422Z50X#5IF2&MCN MX&-Z9M1K'1>[G%IV5L:TBAQ>4YP%!!*@N^TLXHLX%]E[;0&@"8" M^R]K7MM"*U]E[;;F'[F=H+> MH: 97CL(:C$<0UD+$$[/[$7Q_P#-@X_9MO?Q?=IP!/%^E%\7_-@^+[U?;2J M!AYV?!HWU6()M_\"3]:+\ /Y*H[J>W0+"NE";(X/D./Y@?UQ M6))=GR8.>,\6OF0F;&V%8%(&B-S+)<\4,A]E[9&XZO>DA[E9J;'UV*;"5[F! MK,1H5!@)#P%J[Q#J(5Y#;8:\$HG;'N4LI8R.9WAXC5G:2EXH>4#(]3Z+-K8] M."MSQ\Y*')& L$\!:#3!@+*<[HK(31B"$M0*X@VNH.[G=3X,; M*.!)^M%\FS^Q@_)7G $_6BOXL''_ /M]ZJL@UC8@!J+;=,CHER7')[)#I$V0 M9^E&)Y_'<89'D\.C@YC,(;C[)KLR)HE+)3&HD4KD:]M;5PRE36V/AK*K=38Z M_$MMJZ"FREW7D? \F4IWM]7 $_6B[<>W^Q@^+_MJL.+"P7U&ZHPW "]K=0S9 M:X [.+'[F&VRVS9Q6VVMLY+;;6V<=6CJK^*_5':I/X#?O +Y/F3'>#U>0L6.[\Z!CDB8H?+!)^M%_Q8 M/R>M6(*,BP%(_/464S6)IY+'&"TJD$>/DK(2^L48OOKVD3RSFKP.34P[ BOZ M,N"5,V[ WOT5LM>]?C/66H6VXQ=,N,ZY9/H8W,JM]2J<6-:[*#A)4R00R;)8 MTOP[./BTC\"3]9*_B MP?D]:U>\"3]:+\ /Y*@O3OJ,QQJ;@BR>8X,DJ4ADETGQ],(M-XF^P2=P.?PM M:!OE,*FT/D:5([,$B9CSDQAR8X!R96A6H'-M6+6UUD""6 -[:5-1>R]@!M>WZCHU4U%_ W-:Y@JK78.)[DMV84I2C1E*4HQE*4HQE*4HQE*4HQE*P M1QRCC5H7*FQUR#!VUQ0G"3K4#A+8\B6I#P6M<1*I(IU?Q]6+$O.?CSN^G>+\G=_9:I49AK0Y'D6D>E1QU8L2\Y^._'>+_.U. MK%B;G/QYX[Q?YUI49CGYS#*'(\BTCTJ..K%B7G/QWX[Q?YVIU8L2WY,GX\O_ M )[Q?YVI49CGYS'-E#D>1:1Z5''5BQ+SGX[\=XO\[4ZL6)N<_'GCO%_G6E1F M//VCFRAR/)I'I4<=6'$W.=CSQWB_SK3JQ8FY.J?CS;;EMT[Q?B__ )6E1F.; M*'(\BTCTJ..K%B;G/QYX[Q?YUIU8L2\Y^.^3;Z=XOR=W]EN2E1F.;*'(\BTC MTJ..K%B;G/QYX[Q?YVIU8L2\Y^.^3;Z=XOR=W]EN2E1F.890Y'D6D>E1QU8L M3+_.M.K%B;G/QYX[Q?YUI49CFRAR/(M(]0GJ5]3KGK["^5/O#D%9+ MU8L2\Y^.^W_?O%^UR_[[=KMU#>HK*^+U^G_.:)%D>!*E:K#N4$Z9*FF4;/4* M%!T&?BRB"""7,9IQQI@@@+*+ (8Q"L$-KWOLI49CFU2#47'$;#FW\F>)5F>" M:-YI/-/3,R2?,D#PZDG4%B$@:ESPW3EQAC$W2== 0(VUR:5A;I.V1J=8BP.1 M2X-F9_>6MW,3.!2$QN5Z5]26[*9(BV'Y?J!PL_8V<(PN'F?-V X,^P"/KD66 MM(^!G#&F+W7([YE*6ZC,.)FA+D;+[S+"HFDQI&,J9151]]@BV/8O?&EK>W=Z MWVPC+F*2(7$R3\EX^*,!&(\6869-8R6, [,J&P@" -T"((@WM>U[7M:]KVO6 M/.16DMY:XVQN]]/3JRPTE2GB30Y=2UP:XNG6I>@5B>.-RP)R-A(5H;]!J26D ME&6>EOT.:$95]Y6;J"BJ8;0,*5ZZ74O&%=C!4?FUZOD=WPI5N=IYU9Y#TR9V MU8S6*M09NLB>I/=:IVB9WF3Y#LR(C\:8*T"G,I[]'HY,VI@<(+$;3-TFDU&\ MQ]Z=HS$&*1.,(5Q9P7.:U?DK%K!R/BS4-KH5H=5^"\NY4GCKH*QEB[(N)<71 M9RQ9*GDC &IC+DDC@(UD76+"\40!R0PZ)OTO>I9)=1K:U*XJVMSX!=L?!6G*9,D0()&I-5V464&*']"U-B)\ M/&:(UW1MR!*XB4D(DQ96*IF71LC8119(VZ:4L:&I:5HX\F0XC(8AK&%4K6L: ML;.40!N$I9UJ] M-M-^>X-S\3;7=J$RMC299X=\M0=BB&5-S8W.C4I&]+R&\ICBJ.R7-FH-TA61 M97%,FP?,,2R$L8X\[MXC']X9TA*5U9GN"Q![[I]J BJO(LQ: MY1IY>DIDYW1O%;5I?(B[U;.N!0Z*\;Z@)="\X9L$#' M#KVUQO:W^Z>W<,MWG;4#0/J7U%97R/D[%NH=UQ))G1GTYZ.=347?\40.2X\2 M-;;JC:0\B&OG22^XC//8YF2M9CGYKD'0[E'T*IM"*66==,>8Y!*/L4;:Y9ERACL =KAOQVOLT",QU'L8 :+N/Y(&&2 MD>%6O *^RU[^QQ]JVV^R][\=N(/+?CMQ6O7.UF359DW4+C'/;@]Y>PQ#6* : MZ\.X/9]*[*Q+$>HV()<2;HKIX@B6>Y0F:S*%U(#Y^R %.>E)HQ.GBY@&J'5\WO]6+$W.?CSQWB_P [5'JM3I67R9PFBY5@%9,'5,VHW25*S\9J M9(XI&9:A?[S7)4)B+1C[03H;S2SXBCL3D>8X+$R\K M3Q;FM\=T+6S3#'\)2P'%F1)4W0!]F+B]/Y>Z8+]IJ#9R"%\PB&SRW/C0\!"Z M8\#9U:9,ZKWV1MCG8)UK+VY_>W5T=WM KLG9C?#L8N[,Z/+:W(FAN=G%J<;J4"YT0-3:WMB%Q5)SEJ M1N0HT"8\I(E()+E!A7#?MNH;C7"X7_, 1BD\CNSQOJ>G!FF<6G6+7S1ANE+ S2QBAD^0C*>DS##&JE=F%P)U%9 R9-F0QY?)( MSN4FDN&,0QCT0M&77&\JES. :A\Z:(K>XHU'Q"O<5[LC1>][WO>][W;4M[WO M>_'>][WO>][\M[[:@P0-)8G)[>!7T]7=Y(C4M\B=+]2V[B_-ZMG!'E:%Z77# M=6ZHU+"66R*4J\Y0G/: ;#2QH0A3VD,E\3QR!%D2"*QD:C--2PX"681Q0(I(CS;"U*M4 M8$ER,N!.E3%&J%!PK6+()+&:8()8!"#8SJQ8EYS\=^.\7^=JH(OO&.>X,H:" MXXG899U:-^,DN+54.3&1&"ZTXZZWEKXX,P!.&?M%>9]/\%$D M$@97@1Z8F=3]C/?S1V(&VQ\MP+_ #M3JPXF MYSL>>.\7^=:H4,01=?B& *& /+.X]C:#]0>Y*:@'ARSFEPD_8['CW+^B7.$4 M;H'+I<\LB&"ZNLS/NFI9D4Z*A;X@ZI&O$68#<&6R%+%]BE#FRY87R9^2Q]:D MG2PEJV:8JQ!J R%JK;-5FH:)XTQ.1C3"4YPAAS%N.\A/.57E05E^<0.<96GF M2INL@N.&/6\ZL6)N<_'GCO%_G: MG5BQ+SGX\[OIWB_)W?V6J>R/SL34BH\^;[KF'6.PX4P. \^;ZR/7E^3W0^_: MHYZL6)N<_'GCO%_G6O.K#B:^RULGX\VWN'^_>+WXM];CV6=;WV>Q:]6HS',- M*'(\BT2I3FVMN7MIUE"IX0(7-:V<"0F.,(6I4*D].I"2,LO?6L(-VB*M&287#-3V1,_ZDUFH*62+,4NR>M>=)>5N/R.&7@D9\6<9)"T# M#%S#F.*0Z-MJQ7&FY&M 82OV)=6+$O.?COQWB_SM7O5BQ-SGX\\=XO\ .U0Z MIH:B["\;CX-**PH>5^1WT[&YW8-N7>N./+-!$6=C\%=(NDM]T=/1#K&I2YXE4XZD;7%L2,S%E_%N.X[&CY)'WR&KUHQK9-] M).Y5:KV>$P1HB+5!(GC/#><)A*(%IJ397Q+)7=PA$_Q$O@KBKD&;YUHJE,.R M$X8UD;BYEXD)S=A3(65 P6738A^STC[:1?AMH,>IK[61V>]LZ[NKJHU+4IVI^=,=*(PSM3]D!KA4:"[,K$J4$M 'YLQ^Q$C96],:BBC M>2$IL*V'("3$Z%&0;O>%)2IBC-[??!WY1!98][>]@[0[X-]E]EMMME]EN2L# MZL6)><_'G=].\7Y.[^RU.K%B7G/QWX[Q?YVK0IL(V#9LX7;>UI11V'D?M:1Z MK7JA]*&-_;):8OAU@U2;U8L2\Y^._'>+_.U5UU,94QDMB6/ (\B056,C45IK M6' 32^.J!%)$>;H4J6*C DN0[EIDB8DU0I/'O2B""QG&B"6 8@Q1!&=XN&V\ M5 :I!J+CB-AS:Z-*CCJQ8FYS\>>.\7^=J=6+$W.?CSQWB_SM5J,QS#2AR/(M M0C4=H!2:H=8S%DK*1[DMT[VT=Y'P%-H7&S"BW2'5 MAJ4(R L3*35Y^ *2G5'&AQB.J (70U M+_ #M2[,;#6O#Y=C7VLCEAEA6Z M_K;FF9-R@UK%X\RTK?XWAQ;EV6S#31DW%A2;*N+R,9X_SCBK3OFG!LXR!+<8 M)]$Z3"DOQ?(D\W8HFHQ,3B"\B5XDNF/;LA-&1XHPK&VY&%-SAS="==J[.^3U MZ>81PC4'DO4?$XC'D:A7 6&-&ZK% M<"*@Z")2 MD;GI@!&K;D>K%B7G/QWR;?3O%^3N_LMR4ZL6)N<_'GCO%_G6H- M7,7;+J;+[MN_>UJKW3@1@K;3??A@;CM!:@(<9:MIYN@3!EO,&)<:K-/>%S); M']-"N-9U5%N\,',8>H8)UG>?8_48N)42_*,O;=_CB(Q=',FZ,8LQZ^RI66KE M+_ #K5J,^WAYZV MS0^Z>1:1ZK!BOU1VJ3U[8-^\!SM^*I8ZL6)><_'?CO%_G:JV8QREC-/J$U-+ MC\AP8E&MZB5D:HV7QXM,JX"!.03NACQN02C[$CO8!O!#%O!WV"V7I49CGYS' M-M)!HJXWINNQ]I+7:I?;VOY]W[E1QU8L2\?ZI^.^+E_JWB_%[/\ 3:G5BQ-S MGX\\=XO\[4J,QY^TH:6%C"T M8=JBW+75%*H-JVQ%@&/Z=X_A_4)F[4E/(M#TJZ(0-=#@97TB8%Q)!WE&ZONG MO+[?"XV'*D.RW(,JQ#%S'#\@2<]^ALH9LJ-N]E+&OW^]6+$O.?CODV^G>+\G M=_9;DIU8L2\Y^._'>+_.U0ZI%*@#<1F#\.]K[61Q)P.VGAL;0CG',^91Q2XZ:UPV%ID*S3:[3C!L"RG&L-2&! MYH89I(M1N)GDN\+>F+"(Q'S:SQ?S3)INRGI]TH9MC*#'1;_E3*^0\@9'<,:3 M/44PM\><_'?CO%_G:G5BQ+SGX[Y-OIWB_)W?V6Y*#5&!&W+;3P\:M?:(H0 M=FP[*#KPV]5&J3N=&G7)NF;"TQ@V14,9C*)^S;DK(>-\:1J?2++O4EQS,S65 M:WP5_P SS./1N:Y=E1LE3RJ:/TTEJ5>[$JIA:*%/S^U1EM=5-_:CCJQ8EYS\ M=\FWT[Q?D[O[+H/.,&$LHDDL9A@Q!"$-[WM7.)T*J_X*I_DYWQ* @X&K"" *BEY^#=5TTU M#PR'/@F 25:[*27'T$7.('F#1B/M\ANW!>>EH3]D"7Q!O=9,6RBN\K(Y&AOS MTV-5K+G1"C*,)L;7XC6J_J%PC;X4?6R)>BHB44LDI^18>UR%HL8,!2V-2278 M58\7*UB^P.$:$[WDR.,;H4,HU-*^#.*$.I&F+)\!9U^+,H:HGT@>0,4Q;,>' MIAE":FEMD0Q5EATFZ?*3NX2"S@F WP)ZR_C5U9U+-/GH3&6XI(<\PR[J-:[) M$;KMWB61\;Y'"[$P:=0Z;A95 $+Z"*2=DDEVE4<38TM$\ :%ZTQ H/('8P"5 MP 28>2.PPEC+%:]\)45@'6 J![-,P#?6^O"YMJ3J$@I)I^=4@=5-AV5V'@6^ M&-D [B/:GEN-'8I:WJ=A@+W M+/($H1*$BM1BTQU!8HA$A(A[I(U;M,E%E8@PR#QF5Y(EZ<*-"6XF&.49Q\QR M9X92!)#BCB5+XD;$IX# W).,M?BT8[I/AW&\M=0RC25JRR9IUG$#5/ LVQK3 M$.>)XD[- FI$TO[KD65XP(!$(&K@L03*5[PRREZ0V5,*:ZR/HFJ6HT)C_K4Q MIB;5;'<@33'T1U+0P[(4=>"GI[PEJRC6,\A8\G,#<6%L>V_(L+G3FN6&$IDB8H-KB,./, -N+;<5PVOQYZ@=/6N3%6-+R+4#/= M-\/A4Y>TD8@T"TAZ6\),^5\PREY.4$PN/PUSCR]L- !<(]H=S'=2Y.Y+;85A MI$2Q6T30@4! I6IIE7&E&W?O.MMP..5+,1V "\=FXGETY9S7!M&LR9D.6PUO9<9&K5BYSD$?!)+LX+1(Q M65HJN)"TD979C:#E6O-LZM:#HU).=]3A2XBEYRSN&P[/K7VVM?D]:_+:_;M? M9MX[7XK\=>U%&!RWHK"&'2I(NLYR(K%F/BG]R"8:<%Q>2HDT%N:\!I]@GF@6 MK G*@&'@ <8$VPS2RS!" &5ZV#4 Y@'FW&10D8T)%>#8XIB$46J#E:R-1]4J M4#N:>H4LC6>>>8+9M,..-2#--'?9;:,8Q"OLMMO7T=(T,[THSXOL_P BK7OJ M"W19JPEJ5DFG)-"&>1K&72SDW.893?(34B6!R5#XK-,AQ;#BF @;U$D$1*\; MXYFTS53E(<:B9"&MO:[MBU4\%G)/IA>ZR:0WF-KETIR(B8'V%X]BD_RPE;$# MO(F''[2N.Q^R9!?W%Z:T:@PN"XEF.2HM'LAS9>B0LD8 N/=W!39G8I2O8E1F M,:=;*'?]OC=RW-L/Z1H7WI1B_LQ]G_$BM7G2-#.]*,V_S?9_QHKU5:&:X,72 MG)\F20!R-C"WH%<+S;)CF=_CR-<\+&/'_2]DU[/0L+^86U 0<"R_?L(O MX4IVCR4R3V[V\87( PJYQ"W;'D#?7-0 IWC M+Y#8X_Q=\3EYS@77$YS+3%@O4'FW'C?"G[4L*.*<,XEPH[3?/4LDB.60\R:M MK:8"^-( M*D+0Q-9@:6U"AD8C[$8]N$P G.&60J+M_P!G.IIQ90]VW.A' M.[EN:\?2-#.].,^+[/\ (J]Z1H7WI1CQ?:/D5:S,F;J[A- K,8<)GM^498PY M3OCR;,Z]2X1L+&G1LN;R'QT1F60K5*T^/9%PJ[P!V1*4B"X%IHG-(-6T'LSB MZ27B'= HCEQCQ:X,S$&RQSEV#<,)YGO"J;)\/9X_=R:B39VF _ M/+[/\BKSI&A?>E&/%]GX^/;_ ,"][964VOMM:]N2]K7MMY>/CXZ]JMEL5Z1H M9WI1FW^;[/\ (J=(T,[THSXOL_R*LJI1K4YGS]@Y-BO2-"^U$HQ;V(^S\=^[ M?^@N6G2-#.]*,^+[/\BK*J4:5.?GR V*](T,[THS;_-]G_&BO3I&A?>E&;_Y MOL_R*LJI1K4YGS]@Y-BO2-#.].,^+[/\BJ&-1T,B*;3WG901%XX2<3AK*1A1 MI3$TEFE& @C^(!A9A:,(P# *UA!& 5A!O:U[7JR-0IJ4MMT[9ZM;EZB^5-EN M[?I#?Z-4UJ,<1WCP')OUX+"H>;"HB,R*1H8Q1>.W$,;"TB%>_H*@X[WNCO>] M^WQ^YQ<595TC0SO3C/B^S_(JK!"]:&E)'#XJE4Z@,7$GD1J/E'%#E**PRS"V M=$ 8!VV[0B .UPB#?8((K7"*UA6O:V3=>SI+_="8L\:D7Y:\>^ZZR@N-I[/ MBXCZ:EHH<*4]9J+]C>9#1QI$4 H6$MF00""+,3L@@T((/J-""*$'P:>>D:%] MZ48\7V?C_P#HNU3I&AG>E&?%]G^15 W7LZ2_W0F+/&I%^6G7LZ2_W0F+/&I% M^6I]U]D_K/9W^VI;_,[QS:_>WTB_4*VG]UYYN_Y'AY!:>>D:&=Z49\7V?Y%3 MI&AG>E&?%]G^15 W7LZ2_P!T)BSQJ1?EIU[&DO\ ="8L\:D7Y:?=?9/ZSV=_ MMJ6_S.\WTB_4.VG]UYYN_P"1XE*,>STOL^W_T6S[E5AQ1 M$HJ=J&U5)C8TP&$)G+"5B"3&1K&4386+"[WL46))^N*][[T(>.]]G%>]9 M)U[.DO\ ="8L\:D7Y:KGC'5MIF;,\:F7Q?G+&R5ID#CAP;*O.DR$"9S W8U+ M1+Q(Q[^_#V1JPW3*;@M>Q!^PHW>&7L&^DVLLLH+4FTMGU)=I"WA3.9<0[0I: M'86LB)(2DO'CMV%*H"MXA .LI(.3H[T@(*$/+#6Q0I^KHG"5V9G25/GH0I^7 M;H*@@5O XE;IZ[4IV\0H7A2%% M)V%O%8R#C)?%/X&80L3 QL*\4YB8.,N7B" %.WB$J2 M10@-BW2-"^]*,>+[/\BKSI&AG>E&?9Z7V?Y%L^Y654KF;IZG,^?L')L6Z1H7 MWI1CQ?9_D5>=(T,[THSXOL_R*LJI1E3F?/V#DU1=3L/B::)8W$GC$=)N;J0T MS$&7*8VLNXR3\WPHD\D5P) W$6<2884: 5[A&6,8!6N 0K7LATC0OO2C'L=+ M[/L_]%MJ$M4GI1QI[973%]W.<'JR]0;>/P#*F@OVG_M;%>D:&=Z49]CI?9_D M6W[M.D:%]Z48M[$?9_QHKUE5*K2IS;%ND:%]Z48\7VCY%3I&A?>C&/%]H^1U ME-*,J<_/D#DV+=(T+[41C%O8C[1\BKSI'AEME^E*,\5PW]+[/W;=Q%:_VKUE M5>7Y/=#[]J,J<_/D!JG:88;$E&.'\9\7CIPPYPU*E6&:Q-1@K%)]0>2B""[7 M&C%>Q9))8"B@6V!++ $L%@@"$-K$](\+[T8QXOM'R.H:TM_4VD'V=-37X1.3 M:L=4& V7!J2:F_:>_P"0;%>D:&=Z<9\7V?Y%7O2-"^]*,>STOL_R+9]RLII5 M94YGS]@Y-BO2-#.]*,^+[/\ (J]Z1X7WHQCQ?:/D=932C*G,^?L')L5Z1H9W MI1GQ?9_D5.D:&=Z49\7V?Y%654HRIS/G[!R;%ND:%]Z48\7V?B_^B]_;5<-3 MD.B:>(8[N1&(\3E*,WV]V/L_X MD5>](T+[T8Q;N_U/M''[/]!5E-*K2IS;%ND:%]Z48\7VCY%7G2-#.]*,^STO ML_R+9]RLJI1K4YGS]@Y-BW2-"]GI2C'L]+[/M_\ 1;/N5YTC0OO2C';X^E]G M[?;_ -Q?S[>VLJI1I4YMBO2-#.].,^+[/\BITC0SO3C/B^S_ "*LJI1E3GY\ M@E&+?YOL_XT5ZK/B^(Q4W41J?3FQJ/F$$=0ZY!(V1K&43M@#E87 M!%B27 7OMG'O0V];95P:J_BOU1^J3^ WX/W*C:231=_YH_B0T[=(T+[<2C%_ M9C[/^)%:O>D:%]Z,8\7VCY'64THV6Q7I&AG>G&?%]G^15[TC0OO2C'L]+[/\ MBV?+[1\BKSI&AG>G&?%]G^15E5*-*G/SY Y-2K79$8JAT3:PEB*- M1](J3:6-1)J=0F96L@\DT&')K<)A)Y*0!Q0PBM801EC"*U[6V7KFJZ(4?7SO MXT?QJZ=]>WJ'-9'M5-1?P-S6N8*E!DUJ:"_:?^UMM#]N6>HC+>:\A3W->K6. M)(7-%Y3ZKC>#L1'X\5R1\8FMW:(9TY@D,MF*%V8F9%)WU(Z-3@>^*G=O*;DR M)U9%0 N*+X0+XF4Y-CN3Y\Q291P$E4.2 ]8D MB\?E9\?3A9&!X;%!K(Q$/"\USB\N4LT;5(MY=*X^B14&E"#6XD7UK?U\]K(RW,#6ELE:TZ9W; ME:%0-06'?F+%*L:LQ0Y.*T2IRVVVS^=NY>WKVOQV]>M)6KC3\Y29EU*:;X?'44B2)FN.ZZ\*,:438\:MZHPBR5EZ=Q)5KIC]R.3&DH)#-)#9:?=$SI0%9?)UDTIL( &-:I M4*?^FEV>3:<+*5@UI[0)-=A]DXD"[6UCG2_ -6/1GZ*Y@UK,:><939,JXXTD M8]DV76=$GLYN*)CDKM&(;&H>0X>BJ4*%-(X+E!1FO'2C#9:X8FO.R$;+%'37_ )JCN$T M\-*E'AAF0Y"R%E:7(C78)3FU/2VLN M$T2+J7&N-?:U2*__ (A.VX&E206U$*]J[ %-+J4* 030&@)436X&HO ;CS1: MCW6+/B")9J-0SMG4LJ9UR.G0PZ0R3(C8],;K \>MYS3,4,3:&^&Q&5/,;F.- MV_*\O43*,DH8HX1=PC$9GO0KNOJEBZ*Y.R7J ;([IJF>.$3_ )\S3CLB5MTT M?87-L7O+W%1IGJ^8X)!\9O:UQG\@:@L%W06.YZ-6\KCE\E.7.#23T$ZJ968I4 MDR9R7H37AX3*#2%;D,N]P7R+3?H#T^:7WTN5P-).I#+DW:VNG1JW ZU+MQQ!%]#?B2+P *7!K;1% ]M44C+9)71 ^2-NC[,@?WIJ M:!,#6\/2-M3)G1U;F(:]U,9$#BN*/6)&@QTQ74X-TC:WLXXGW/<[(N1([F4V'ILQREID6LV8)U,L?$V5C81B[';;@63 M9!:S&I;TU)L=QR F%0)PCC$,$=-*>74KT%4N#VYGJ?X<3:4M ^8X#,VC&34; M,L./+_&H[.\<7D\\#B]\>X2AC4G-:I! WA2D:G9-(PJ(C(<@MJA&>QSY>04M ME"5S4JGZR^+]1NY[9>S9G+(^?$.:F!JD#T6Y8IAL'=(TRG1)MTY233A.\2RE MD?).1##XG M=CFZ8IGYHE*U)-BY1@MY3S?!,E592PC9&62DOE!_CF+WR!NPGDYF26:#XK98 M\/<-#.\K,?9 8S MY_%F)(S/4P1M#,^0>RLAW*#)I[C-WZ-Y=9K229IYE''272I[G,@G,DQ^X8PT MBQ>#Q2=3 #>D52F\=G>GJ8SM8>-M3(3I#/%DI;FI(_R6865JUP3=6M<[\:4% M=]33>#1F!'M5)H,[B+[ZD;2/) VGX6TN8*T\)7<>/(T8@NK(BZ,]UE4ED$U< MVB-8Y;G-KQ_$FEZFSJ]N##"LK3-,;0N;F)$6$QP6GGQ"Q8CT> MSG&^#--T'>S4C9B;&\#RY@$F$9%F<;R1"L?%('3'\.R+#YLV.J"8IVQX9W1[ MB)[HHC6# **H%HVRA!-/>;,,IS<7F3K-,O4LL^U#L"^2LV M5,K8[GF1W\60,CY(6J8\HXY!RTTJE+.1)$+<-N>HI% -T=8_Q= M7N@679TR"OF$$>\>,B%)A;"N.8.PRTIR4QV/2?#^>'/+#.^2R&6C4EBN3\?H MFE6E:5&*Y$C3(9(K(+4E2"&OC3&IBSKJ"X4NNI6M2!E?2FS&XY5@V7TJ<\*" MXX[^JA:Q8- VF(LA[;@Q![LPO.1194Z6.GN96CC1D!:BR*E>Y"P-?HUO,D(2&!2/+](5#R$US/D/)"V)QH38H%,XLM>7M4I1@.3*O MHP/H.R=C;*,OF[CEU/#/19?)%3],L.!.+R-J(6.^?7S+D?D.H(W)T=F3*)SA MD,7D8D;4K )Z<11U?(B(_+89#S(O XS7#'6Y/Y;@*QF7H,[1Q@.87U%/HP3% MV%S(M$,T9*FVR]KV MMMO:X16OQAOLP3(&4L>XL85\ER!+66+-#:QRN1GFN2L 51S-!HXXR^7+&UL* MX1S>+Q^,M#D]N25J2+%A"!$>=P%]YO;Z5(+N4.88=C[$T=9ON4;DW+'2"%-YR/3BPOJ=SRF7#XK'6>;*H#ATC)NB(>F.23?%KI)& MQWD[;.)EE!"U9FG*) M&/9B145WE,4A9Y,Q,TE8UH%[+(6ML>69<$!I(5S:\(B'!L4@*4%E'EV5HU)! MP"SBBS0!'O32P#",(<,Q[F3&F5;.O2#+$$C$QV(N[%I2EI!R"REVD+&G$I*6 MI4HP!4.L4D"4B]K"X6[:::']),(,-TP)MR(GC//<=*(SEA!%,*P>2P1_;L/8 M_7"A::)2MLQSIW9);FJ"O+YC;)2=ARNLFV'YF\EKF%GBDC?T63Y X'9,BSX^ MS/IF_?F>Y1SF?/I)DLF^.W^)IDV5#R(N[()4J:R9!,<;:E(Q$'HMK&0)N JB M.["^X8@$T)*MEPI?LJ,=YO MNPP.+;S:5@N+V&2Q7&V/XS,W\A$38Y3)S#E:@R1R-HC[,\?89RE]XC_45@>![FTC\M/ZR>\-QN"_?V[OEV;FZN[=V;OEV;F\ MI7NR_M7.Y%6O;2R M\6O:]K]6&:CV4I2C&K1JD]*.-/;*Z8?AT@]67JM&J3THXT]LKIB^[G.#U9 M>H,57Y/=#[]J]KR_)[H??M1C5RTM_4VD'V=-3 M7X1&3:L=5<=+?U-I!]G34U^$3DVK'4:JQ/$][*4I1HRE*48RE*48RJUZH?2A MC?VR6F+X=8-5E*K5JC])^-_;)Z8?AV@M94*BF9 YD-4XCB.]K*TI2M-&4I2C M&4I2C&4I2C&56#%=OZX[5)?U\&V^UC]R_+5GZK!BSU1VJ/V,&_>"YT;2<%_J MC^-+6?I2E&RRE*48RE*48RE*48U3->WJ'=9'M5-17P-S6N8*NGW7MZAS61[5 M347\#Y+=F%*4HT;P6W>BV,"%>^(9!&4.88_E3'#DF,;8N:RI\ZV? ME G]:S'6WN5HHW1' F:IOE1 ?!<0RV>Q9]R[AR:.;U$D9@WAH3Q/"6;H4^)V MMS3+D@6TA[6.D28W]6[ 5MY" X@D3_'?[MZRXUM6JL@ *4I2HI3A1M1!3K420;R200:E023A7;44J<-AJWM*4KG M;IV4I2C&Y^\_Y+U3-.IK78Q1ASRRFC;3)L#C@IT(?-0;ODMBP.KQGII4:BGC M3EAHJ%.VG&:O;6TK\P/#4^E.R[+:2?DR%+$6)?(F]H0J/O(R1E0O-ZTURE^K MDO2W0+%DI*BU!F97ZHUL.1P1,*%E'J23Z3;3 ^3+VC(YHB"3LRH"X MC;6-?OZN6"]]M[7OV]F^%O=O+MWNW>VOMX[7M;;:_':^WCKW>!V;./ MV=\+?>%MWWK)V-,!U-4 40!D/59K2F, F\,CF)Q)7-X)8LC*%+ @Z"#F MY">J2KCDB[#ALK6 TOI?U>':W.ME7/& ML5:3"\5'DY QW'&C.FFMX;EB;#^;YC+,X19-K];F3+(1Y?;7H#+A&*X9PU"F M*23@B7(U[+.8-/79<60SP @)8K5ZED;(>D><3#$4PTY M17,2.3R34&]O+6KB@)(WX_C2G(")\+QFJ;7_ Q"I\SMT$FKZOE"&0LLB=FY ML:DVWLQ.2< 99I83"S0"+-+'^B 8 8;@$ P MH3 "!>X! '80;AO<-[7#>]J M%)R"2BB"2@$DD@ 4443;@@%E%A" LH 2]Z$!8 !"$)8;6 $(;!L&UK6M2G#9 MF<*;Z^>-;K#+S=78I< ;]J_:Y+BMLVWV]NWCV[;]V^R]^.UJM#??<>S@01UCQ: TV"["X= MHVMH4BFLS=!'Z*,\@3PIJ>D,%73%WEMS-.>36ASSC%FK-V#(C&6**!,D28G' MKN\XXRI,W!9)6]NGC:I<\>FR"/-JR.$O(K[0=%\FQ#$LJ4J[@!=VO(L7,40=B7ZXCQ2)*J(?QJE8W.ZDVU( MB@#"(([7$$0;A$$0A"M<-[;+VO:][[;7M>]K]VU[VOQ7O:_UI$B5 E3(4*8A M&B1D$I4B1*26G3)4R;VY;87RI?\ \AO] M394)ZE?4ZYZ^POE3[PY!1JG$<1WM72&;GSHX6Q&+*U.#(X:H4QMA//,N[R^U MS#CFE$::.]@2,(;7&,0A7V!M;;>_=K)>QWZ,N8B-_P#C$Q^DE6E@7I(A_P#D MM'?]"H:RVO$S8.PQ))L990DFI)L[)R23>23ZF:DG$M[$&E_2TD!*=*.D5*4@ M!*4VWM,$@ "9@ "@%S4M['?HQYB(W_P",3'Z2T['?HQYB(WR[?V8F M/TEY/6Y*NE2GW!6%^I=D_P"[DG_DVOWX=+?Z4](_]^+3_P":;N_,M2WL=^C' MF(C?%_TQ,?I+Q^[3L=^C+F(C?_C$Q^DGK?SVWJZ5*?<%87ZEV3_NY)_Y-GWX M=+?Z4](_]^+3_P":;N_,M2WL=^C'F(C?+M_9B8_27D];DJN^--"VDYVSGJ1C MSAAB/*6>+.&(RV%")SE("VT#QCDMRYBLJMIL-8E"7B46.LLA+Y =O4IL_*4I>NP\=O@[> M0@"T!ZZ=/0E54AXZ=K UD)(PK2WI5>J=K>Z3=(3Q<,LOX9;RVEI%K[+'TY MJ0J7%42-V<"DI"Q;XKBDJE*\AA82%@8=S M!P4-#P<)#NTNH>%A7+N'AW#I-R7;EPY2ATZ=I%R4(2E(V -X1,)C,)M&Q4RF ML=&3.8QKY<1&S"81+Z-C8N(>&KQ_%142MX_B'RS>MZ]>+6HWJ42RE*5U#=&R ME*48U:-4GI1QI[973%\.<(]ZK+U6G5'Z4<:;?W2FF+XJ'TH8W] MLEIB^'6#592JUZHO2AC?VR6F+UO\.L%_GZ_)658'J[PU3B.([VLI2E*HP%E_"V;([%HVR(W&02N3NPR#BVB-1QLTN:QB?&Y I5.;&[H$D.!IB 3R^=&TD5*:@T* M@">L;>MI@Q)FQIRP>Z(B85.H(ZMK'&9/=JGC;'T*Q?'):<^IF1Y;SHU)94V' MI3ET:>D1Q)CB2X)ST03S4(4*YN6*YMK5?HZR;C/'>.WX<903N1*)%/U<4Q[C M2.M\IFTO;XO#XHP/0$):%U<%YD M7&>?L>91>7V)-:EZC>0HL06LDV,I]'7>#Y#9VP]1T(ED'2O($R52\PY>KL-$ MUSR+FOT'=EY"MO;9$J7(U:0&5_G U(S[DC'L80J2JB# M!DGISBCBQB ,(KFM3NY#P:%NEC4MSR8>\@,J_.!ITKZEN>/#OD!E7YP-32A> M&ES4.J1M=&]>K8EX&I\2HEB=4I9G0UN0.Y;<[$$&&&MR\QI=&QS D6 )4#;G M% M"7=,L3FF?4WO[$[+'MN:WAK<5\91H4*]*K6,#NJ:FU]3-;TF3FF'- M;BH9'EH>2$2X!"DUJ=6UQ+*$C7I#CC*\.0\&AOI8U+<\F'O(#*OS@:=+&I;M M9CP[;^ &5_G ^O7]S7J5T\/46G4Y:\Z8B6PG&#HI9Q/F9A/E.'\G8]RM&$KF>R MJI%C6:1N=L29Y2D)E2EH/>(LYNK<2Z)DJU&I/;S%(59*=6F.,)"4>4(9E3D/ M_2/!L'Z5]2W:S'AWR 2KU_\ M ^OVME>]+&I;GCP[[%L RO9R[?W0-29,,@0 M;'R1N7SJ7QJ'(GAULQM2N3/3>R)G)Y$VNCS9J0G.)ZZ4 M94[N0\&@/I8U+]O,F';V^P!*_P X*]>]+&I?GDP]Y 97^<#4]THRIW0&5_G U$&H..:B"<"YN-=,LXF7-I>(,FC7HT>#).@6*D880^W4I MDJ\W.R\I$H.)L(!*LU M+3FW <8C5 ).;=JH3U*>IVSSVOU%\J\@,J_.!J3H%Z2(A_DM'?]"H*RVJ MTJ=W(>#0)TL:EN>3#WD!E7YP-.E?4M;_ QX=\@,J]?_ +0/\^.I[I1E3NY# MP:!.EC4OSR8>\@,K_.!KSI7U+\?ZLF'?(!*^UR;?ZX'CV5/E*,J=W(>#0)TL M:E^>/#MO8P#*_P X'W//\ WSPCQ;.3 M]2PKM]O;3+SY^UJ":*PP]T>\G=W][97TL:E^>3#WD!E?YP-.EC4OSR8>\@,K M_.!J>Z4:5.[D/!H$Z5]2W/'AWR RK\X&EHQJ7M_ADP][F 97^<#4]THRIW0&5_G U/=*,J=W(>#:_\ 4C'M M0),4Q[=URKBE<6/4-IP*2 0X0DS<80Y&YHAY;8L.,.SDX@4(T:\:=4M;P$IS MG!*2:C(<6TPZRPNPO2QJ7YY,.^Y@&5VM^$#>OP]4GI1QIVOZY73%\.<(]_DJ MR]3&NX_ %K4T&&)V#).YH$Z6-2W/)A[R RK\X&G2QJ7YY,/>0&5_G U/=*K2 MIW0&5?G TZ6-2W/'A[R RK\X&I[I1E3NY#P:!.E?4MLV= M6/#NSN=0&5;/P@:=+&I;;;;F/#U[;X.VW4!E?)OK?]H*WOV]FW+4]UY?D]T/ MOVHRIWLBE.:H!Y.D/)0G+7$T@:X^?^EC4OV\R8=O\ P RO[7J@;\O;]BOS M-+?U-I!]G34U^$3DVK'5!> =W4U)O.&)V#/@T"=+&I;GDP]Y 95^<#3I8U+\ M\F'O(#*_S@:GNE5I4[N0\&@/I7U+<7ZL>'>+]X"5?G ^O7O2QJ7[69,.V_@! ME>S\(&I[I1E>'(>#0)TL:EN>3#WD!E7YP-.EC4OSR8>\@,K_ #@:GNE&5.[D M/!H$Z6-2_/)AWUOU 97^<#5>]2,=U!E13']W7*^*EI0]0FG I*!%A"2MQA#D M9FF&@;%AQIV<7()Z-&X"3*5J ))!S@F*,1D.+:8=967?^JUZH?2AC?VR6F+X M=8-4-PX4V[QYO:I)J,,1L&?!OV+1?4OQ;O>W;O@&5;?N:@>*O>EC4MSQ MX>\@,J_.!J>Z56E>'(>#0)TL:E^>3#WD!E?YP-.EC4MSR8>\@,J_.!J>Z494 M[N0\&@3I8U+6Y,QX>\@,J_.!ITL:E^>3#WD!E?YP-3W2C*G=R'@T"=+&I?GD MP]Y 97^<#3I8U+\\F'O(#*_S@:GNE&5.[D/!H$Z6-2_/)AWR 2O\X*JZ8VC^ M?QY]U*$H\I8I3.A743]%%IV$I0I2+-L"@4 \ M@,K_ #@:=+&I?GDP]Y 97^<#4]THV:G=R'@T"=+&I;GDP]Y 95^<#3I8U+<\ MF'O(#*OS@:GNE&5.[D/!H$Z6-2_/)A[R RO\X&G2QJ6YX\/>0&5^[_[P/;[= M3W2C*G=R'@T"=+&I?GDP]Y 97^<#3I8U+\\>'O(#*_S@?9J>Z494[N0\&URZ MVX]G]-HUU:J)!E3%;LQDZ8M01CNVMF%),S.2YM#B"976I6]W/S@\$-BT]/PA M:1>>TN9"11W+RBQHS^?OAFC_ ( X?^*)_FFNFO7MZAS61[5347\#6V1N*,Z]]>5IEKCN2@;B!J#K$DAO MPBI6=O0IT*,FPCUJTY.C("(X\%KY759=02\IVD>"<7]&K"!3?*[7('9&F2\* M0X13%B4Z;N:5P5"*&6E1*9.G@Z&]K#).5'+2TI1GZ8, H30$M *D#GPVM^7B M''^1Y+D-VSKFP=TSHH9D;5B3%O\ 2M6UX8C[ND"LDQPUZ9*6L=LERDL;.R3E M\6JEB5J''ET=A'0<77N"N1UQW05RC<02TB<:Q08458Q)*X$VGH#A@4'H N#L)&782Y0 [9YR6_G^*W;]:U:G=7V$ M%VJO/>FS'KPL2F0F'9/RG+9*;9+90L:X^SX?=X^F4QH85!(6^57D,P;D:"0G MW4@9E*H3A= X#2)T)F%G5 30J*R4C94T)O(PPIA0;;@VT'VP2=4"\TOHD8T! MQ.VFTX7M@>B;-<1D.8U)<',BLI9L@2N>MSB_Q)2G5-B=L08GP:\Q&4W+R+%N7 M(,8B(ET$>#2PIW).%.XIEC-)X?)D0?0V:0*3('*,2INX,*Y$!P1MCBAH-;13 M$]*6H[%\VP6TM43PE)H=,L;.L2&X.*I;"IDH<6*>L XVXO3FX.2Z*RFT1=S% M[,K.--CT@;$A[6INS.X&IEV]VY/=O]K;?9]SDJ.ZC60K\VE]<:@W[,J[CP:O M""I*T$T(NNH12X@]MV%,PU9-.F4,E24$DQIG5B:&'-.-P- I LC1"I-#,@1M M^"LM'242>,Y_ MPAD%/9L1G/X)3B22+E18KK%C))&V\ACS>C-N8 H)AW@30C%<"Q64FV& MJ;A,LY:^VVVW)?CM6TG$'%)IQ% 0>L'G5N,[#F.W ^=[*4I6FC:5]46BK4IE M[4!D_4-'2L9F.2J.R+3#!8ZO6*6^1K-+<\T\S-BFCBNFP5QC>T."K4/D($Z% M!C8NM"N;,91=68^E+E=DR6&F+1OND3/"\@0=AS#*8E.E,/QU$\2Y,:LN(P8D MQXL1/&*G&/S2V+BBUC\N68!C,*DL&/QHG;V['VD3YD" X M)%;R<=F'YN.'4;[KP:TIL5.P&X8WTI@,@=I&T8Y-/T$P+K/8\JX(E-TKVUQ= MNR!&'6=P^0ZDWZ90V.04K3=@:!SBTB4)[-TYRUD]+D2!SU=C.0.JQSB3L;*9 M ZY*BQ1DF3.D>P.783U8I,HL$9Q[+)_CA%E+5;JEB^69T@EC@UQ^'-YF'&[KAF>[6ZG),+ M8T<'9SAN&)HU-+5.E8%6'E.6IKJ$CJK'^H)1/E^,HW&IE"NHQ6=8]Q]I"R MU(RG1^'#I+C1]CJQ+J&E4"1O,=3.J1>=C\J2M:I0CEHDT074H*G+?AMN_5KB M*FMS7VKJT& &=+J7'*M>JIV-.VAK23JGQ2WN3=/YH5BJ#]-6.GR08F12%GS\ MT9-FS8QR:^HS(29]F;"F-Q;&-1^17EGR&GA\.3M2R-O30]/0VB.N,P=FVOZ& M;3%J*QCH6T38%E&6V..X[?XRZ1Z/9ACA#>:E+ M9YPNC$X5MJHY@;<@-<:41IU>V],MX!9(\)UNRB4:=,T9N<6G'Z67,$@=87CG M S4].(\F1W)3G.GW%.*\49HL[C2@8L@Y GQ<4)L@3L;4A:"G]6C3#DKYKDR4G2 M%TDD6.8U3'^Q"=T[G\KD>&&MNQ:P/I4S:<&%/$6 .2Q+*N1GW,$JRO"YDXX) MC;Q=XA;Y$-/CYC XR?R9QR$Y0B0L2QUE35D%AB:.#/V3X"U4ZP=QX,C9JEL?)Q.X M-'71T-9)'CIF-DZF'N.1F*5/C?DF,2V2Y Q6TEL4":I3>*M$,:)\\.V0&A>T M8-GW=-,^"@V6E&$V3&T?=FB.O\BC"Z0-,]<)YC2+X\R'I^0+\G9QQ<]L;7:* M8_S) ,HR61P0MU7,CQ$F=O87=R')E"R8IL;ZUA3SUW]8W7C?3.J=W/AXW_97 M?A:]K\E[7X[VXN[;EM[-NW7FVVW9MMM[FWC^U6@M)NB6HW"W5K(E>/R0@EB=SBDN5^AARJZ92HD@DIB IK#N[:;;QM9JFNSB>K=7;EC= MBW2!2JWZ8EN-Y:K94X!4&M+D>XM1+D\I$29X760K0O;/GFRE*48RH5U)6WVGC/%N[A MG*5OMP1_M4U5"NI+U/&=_L,Y2^\1_J' TR+:3^4G]8=[:/8WNP^3VV/,3>3A M> F%H65I1@,'*Y,$0PI&Y*GL,00M]K6N.Q6_O:VW9<6S:*]M]?\ :[,IE/F4 MQ_XV2?Y!6F-K_8UN_P#@4G_IRZ_NK\QHC3CI6=OWR$VRC0E+U:4CU&3&@"B M*_1M;@!ON#?OW!>B+Z.3V#A'KS1?+%/'D,X>+49S:H%2UND*4:"? "I-;@ - MF#;CNS*93YE,?^-DG^04[,IE/F4Q_P"-DG^05IQI7#]_/2Q]C?^BV5_VU:O\ S_<.3;CNS*93YE,?^-DG M^;ZNCN'?4D_ZF\JOD>;(PXN$TQHR&-+0M6."(!;%C-"04H"J7$D*!&*+' M7$87'H_Z2[I *RFBS5)(!'R5Z9V@31#HS MT205H;"V*@K/3E[;*3RQY'0\QGD4M4#$R^E'&GME=,7PYP?WJLO5:-4GI1QI[ M973#\.<'JR]0;>/P#78.)[DLI2E5HRE*48RO+\GNA]^U>UY?D]T/OVHQJY:6 M_J;2#[.FIK\(G)M6.JN.EOZFT@^SIJ:_")R;5CJ@P' ;VJL3Q/>RE*56C*4I M1C*4I1C*K7JA]*&-_;):8OAU@U64JM>J*VV(8W]LGIAO]K.T%O45AUCO#5.( MXCO:RE*4JM&4I2C&4I2C&4I2C&55_%?JC]4G\!OW@.56@JL&*_5':I/X#;_^ M0'*WXJ-I."_U1_&EK/TI2C992E*,92E*,92E*,:IFO;U#NLCVJFHKX&YK7,% M73[KV]0YK(]JIJ+^!N:US!4:[!Q/*<:M> M,)*PP5*H?)W#)0_+&',+IDV.8]3J0NN0XP>QJ\>PQ_2P-,ZY&:7D+:I:HQ(& M:SH6DVC"V[T6SEV7V>SLXJUWL"XI@R!F/*L@=G)JOBC4!/5 $!)K0FA[^8I4<"VD M8G.Z@VDDB[KPOPK7%L72:J0RY0F96;J^R)4JX,@U&SZ;]1*6R(9FS]*?UZG$ MS,A8S0"O8*D#VXH1)^.ZFQ80CN'/, I).ZZDIVLED971=#!<3L#5!DZ]P(,< M7HS($K7KL@/CXSI;K4#:,@<#A3+'. =E3B6G*DUGXA@ M"*JFEG)QF=YED/,+<0:.&.S#$6F&.@0D70G,1J^22!G9PF)UJTHQ^01YQ9)) M+2R3C"6MTG)$=-,+=F-X1(L)=I2M!UEK(KB0H $8[ME,^0:DU"KJ##';[(IL MK@=AH+FR[6;%93*,*WMCZS #)K'D?$+[C55)R%RE@3S(C)D8;T1+P2WK4*CT M*>6UT=HVYG6-&!$@>U*\1"BR3@1RGA":VGV-(](;)E:(PT@U&<@<34Y[FV*D M!MTJIF=34IAB4UV8E99S$ZG)CC4JAR;59Z4XU.868+Z\[DR6^,7]PAT=.E\G MC9[%,F6(I5Z=L6RQ9"Y"U2F\8;URL(D:=T?D[2>V-(UHB4-W12C+6*4RHKD:6M:A^G%Y8RDB/.8QP"3+'\4 MQ1.X$RU@>VI6P*T:ATWJ$703F:PVSM7KG;RBE.E\<@^)534\O;TZ,LA/ET=BQKC];>?V_=V_GTV>NXB6+M4EQ('R'D6]2[A'4 M Y]:@89X\1 MKM272#K%^H.7SP)6M]TT0@%XHO0A!==!T3M!#P-GU*4KZ);P-M7F=MTXQC@^ M8:M,>NN-9?()CIBC^$W] SH%\50@S.NS.E+<+1^!K75<0F1O<$0G-[K,RY#= M,6D9G%"\IAFI1CN7#\QW8[%$*)GKL\8F?W&/P>5/*)(ZQ*;062+TL,L>QT$? <6IO'),! M=*&H1#FO.%63LNB/3ZQXP;<0$Q0]?!T>4EV7G!O=UP7%1*)8XS&13E6"8+3D MO#2=C-?).Z6$R.O#)/0T1+5MZ")L6+-#6N5:;ZD'*ZZ[B*\= IV@XCE=7;Q^ M35STS9JTI&Y#U]+L>1)_:4NG:3,$:S'EV7S"2Y 3Y':8W!'R=K#XLLF.WI9D*)HF0@YOC9DD;9&Y," 2)<4M41(Z[KJS-LS>8"JT\2%#+&V0Q.,& MQEWR## RMD>GP_2@8_%SZ(-:1R?H6W-;=JIC[:TOIQ+LTOT\ASS"%JB/J72- MKW*VD-W/'3SC[';[BV(IIB@A\NA^!<>S9"YRI1*%$V@^ 7)Q6LS!*7"3I75: MZBG2-X>67*#X>=>13%L=EO#.B->(M:"1W;1[A)Y:LOM*QE=+ SCF:&9WR M( M>#B'1?.X"YXJ=XU=&XA)NI0L"-;AR&#''PC-0' +=BQ6"%V4U:8"[E3;44QP MPZZUJRJ=M3A>:[L=N=>0S;#(]KHT=3Q]51AHR0TN[PDDKP!.D40R6A [K(3% MIS/13&.JU\9+1R.*V8,23Y?%LCL:A?%7]?!WEJB[^X/#<%'?Q7N@^DTEI=G\ MV?/AL4CF0XOBZ43$.*>09[&9[+L_.[;L2FR>8+86F0.F-10)DQPY()2*-,'7)>AY1$K< M"%H>NK1Y"0Y;X9: NYAUEA&391Z 6$&UH\,U"-'8=V\FU\5>MSHTTO>1(;E5 M3'W>\YA+@SGMCPL6M4A*5L[/$,.0TJ,.33+6&1,YK*>@P1CIQ&H1H4$C1O;< MZ.+1(&R\@>"53VMQPNVX"M]:8UV8,]FNT,U4@FPW2+A:(A'WN7QIZ;X,JDCH@(EBM&X M-\="L=FQT1)(G8]T8QU(,J0F#&PXJ(1:=1+)\[!DS*4ZA^-V)ZQYBR<9:AK^ M\01#(Q=&9+KW+#CKFAXQHT/4H*<&2*J<[/4B>9LF2[&E._+&C^JAS;FEC"Y%D>2,@XNAC_ #9Y8L2.TM4(,<'E2J4Y6D+4 M1(&%K))6.ZZ'M^7I%%&IQ(>&P#DP-,1"_H'-PC;>M+'6W?#\WKS\T8-7;NV' M?6E",+L2V,/.Z68,5N<80X];E\Q9G5HGZN6F2!HEF*Y%"[QULQ*]14#C!LAP MEFDBABR?',LM$AALE&WIF"1,"4#BPJGM.H.&@D;#FMO&&==1\IP)C%H6/L?B M6&6[*5LG','LS3/X:,^&+G%IR= 9!)H4\@L)"V+3 M@)PJ3?PVCY*ZL26/8^B<>8W!P,2DE'- MD4C>,XVUL104A9W"'2)[>#WB22E_>5_]>-]S[QMAW*D/R9C*>Y:CQ,4;RH@7 M#5DXS2ZH--N%:[*;KKZ!H8;=U-A:O+3CBX['(&TI+E.8091 M*3,FPI>@C3#CC48ITZ3J7Y2:6P(W?%/"O"PULDJHF1M3A&7= M"38EBW0W2+((K))@CRMV3HE39[A\88U,NCH;XRA"HA< M^!52X2ME&8NE"X#P^E.=&L*5(.>?50;,^YAU=E1EMZS?V-.)>NK34^EQIUF0#X MTUO"QV2JTI']^EG5*VZDV-><=%%4%E37$\0SI9&5+L2_ '$,U8[;I[#'Y$Z) MT+?8:52?TTQ@]*L2)').[PYT-/2@1JVXT^.91NI5%JRDH5R(](I*+0G9E;T;GO&:[,N61E.3!GIP=XF22U%3 M%@'31$\ +9DMC[@NU6^E+\#AACA7==M:74W_9ALSQW<39.H5U);.MXS MQ>_%:V&.]N4!FTF:H# MVAJ/(T]Y?.(.;4!Q)Q4&>#"S2C4A)I9A8P%"", P#"((K7XPWM7Z76CZI?W. M^8_$1Z_U%==D"])$/_R6CO\ H5#66U\K//12LL]>+>&U%H 5K4L@.9;0%1J0 M/]VK3';6_&YOT1O\ 44ZT?5+^YWS'XB/7^HKL9I6/P3[*_6BT/[&6[O\ ME_->#1=]ATC(R/!UIS'(V\YK=2D:['#:8C4F(U%K&@ M)4@ ,1(Q6V#L$6SDO6X^JL8B]4=JR_[SPA\%95>>:.M!DDTEU:W3G8UU8V> M65LW)8.'G4%/$QS1<4I_!.(R%0Y(C(M^ZZ):8]XI9"-?60C5(!(:T]*4K MW@WR0RE*48RE*48U:=4?I1QI[933%\.<(JRU5IU1^E'&GME-,?PY0BK+5!BK MC\ UV#B>Y+*4I5:,I2E&,KR_)[H??M7M>7Y/=#[]J,:N6EOZFT@^SIJ:_")R M;5CJKCI;^IM(/LZ:FOPBJ+TH M8W]LEIB^'6#>]RU92JU:HO2AC?VR>F'[F=H+>HK#K'>&J<1Q'>UE:4I5:,I2 ME&,I2E&,I2E&,JK^*_5'ZI/X#?@_O;!OW@.=OQ4;2<%_JC M^-+6?I2E&RRE*48RE*48RE*48U3->WJ'-9'M5-1?P-S6N8*NGW7MZAS61[53 M47\#Y+=F%^.U[=VM=KH9D.&YPS PH,5(9+!%Z&/#=H M/(XW(\C61"%%Q:2Q5T*?6^5G6=ES$M:G>+1V7F+5#25L2KXWN M"W'>]N*VV]^T&UMM]M[\@;6X^.^RUN/CY:RI(4 "2*$$$8W,!(KO%#PJ#\&H M9BC09!HP6TJ,I2>69=3,;DG>XABR5.UG'!6*U:(P8V1K@,$6(A+WQLB!5TY, M26Y:?,A.4=5(R'*(@AI29G:&2^80!!;>@#8-NU:UMEK=N^RUN*VV^V]]G+>] M[\M[WKX@-+&&PP#"(-^0816$"_'LV6':]P7OMXMEA7OMXJ^RJ $B@ W>;SO MQ823>6\O:U[7M?CM>U[7MW;7XKU7F5Z4-/,Q?'65NF)XC#Q-(^TD1 M:7/#P%O-;"71\D,;"UN,@6D(C> +-D!KJ"Y0"BCBS2BBRPV'I721\O@)K!Q$ MOF<%"3& BG:G,3!1T.YBX2(=+%%NG\._0\=/7:A(*5)4" 04D$&]M2JW1EG_&#]*6K"G42G49GB54 MSMV2@8BG54N:"FA?@)X=TS5'HK,%[\:0 M.>)=H<*BK=!8=%(2S\+Z$0^-,46:N'%89WH;'FI(SH.&%:UK"-NE1E7-O:UK M7,N+9Q5D]*XY7*97)(-S+I/+X*5P$.G4<04OAG,)"N4U)(=0[A#MT[UE$J5J M(&LHE2JJ)+;BHN)C7RXB,B'T5$/#5X_B'BWSU9 "1K/'BE*- D 5- !04 " MG)2E=P;IV@N0ZD<119\=(Z]/SVG=F96-"X$)\?Y'UQ!:W*P6 ML,.PY&K4$"O>]@F7O85K?C==?@_ODD/DQRO]!JL7<-K\>T7N"%;[EK[*;VW= M%X8_C4O\CYM;LCS'@U=.NOP?WR2'R8Y7^@U.NOP?WR2'R8Y7^@U6+WMNZ+PQ M_&IO;=T7AC^-4OW8\&KIUU^#^^20^3'*_T&IUU^#^^20^3'*_T M&JQ>]MW1>&/XU-[;NB\,?QJ7[N7SX^1>NR/,>#5TZZ_!W?)(?)CE?Z#4ZZ_! MW?)(?)CE?Z#58O>V[HO#'\:F]MW1>&/XU6_R/FSVV[HO#'\:E_D?-EV1YCP:NG77X.[ MY)#Y,V[HO#'\:E_D?-EV1YC MP:NG77X.[Y)#Y,F+,4JH0^D$@,4JX60E3@$8,-AGJ3R2"0;3#3 "(5KT;VW=%X8_C5"FI M2VS3MGJ]KBV]1?*G]L*_]X;_ -V^S_;QTO\ (^?'SC4ZM1<<1M&?ZK1S"]4^ M%$D0BJ8^12 )Q$:CY1@;8TRF8&PP,R$(K!,+A RQAWUK[T8!""*VP0;WM>U9 M-UU^#^^20^3'*_T&J7X$&UX1#[WN+;TK1W^W%_Q*A_Y7+W;\M[\=^.LLWMNZ M+PQ_&HT]G(\Q_A:NG77X/[Y)#Y,V[HO#'\:F]MW1>&/XU2_=R^?'R+WLY'F/\+5TZZ_!W?)(?)CE?Z#57'&&I M+$#=GK4X\*GY] A>W'#(V\P&/,EG&&!28R+3'\,F(AQJI)>QH1<&%801<\NW M#$V&5^BK8SO;=T7AC^-56<1VVZC=6-KW%LLYX0M;]$+B_4K*]?;;;MVW[M^. M^V]6_P CY\?..DTHJXTU;[Q?[2=M+N3?M]=?@_ODD/DQRO\ 0:G77X/[Y)#Y M,]MW1>&/XU-[;NB\,?QJ7^1\^/D7YNR/,>#5TZZ_!W?)(?)CE?Z M#4ZZ_!_?)(?)CE?Z#58O>V[HO#'\:F]MW1>&/XU2_=R^?'R+UV1YCP:NG77X M.[Y)#Y,#:\M M1VI;#KU%G-U/L;CO)B2P435F6'N*X81JX2K*[VW=%X8_C5!MSK?R&_)K=07'$[1NW-73KK\']\DA\F.5_H M-3KK\']\DA\F.5_H-5B][;NB\,?QJ;VW=%X8_C4OWV[HO#'\:JR[(\QX-73K MK\'=\DA\F.5_H-Q^Y3KKL'WV6Z8Y#QW#R8QRMMY;?]1[>_:K%[VW=%X8_C5Y M<-N+C%RA_MA7[=N[>E_D?/CY%Z[(\QX-KYTWZF<.,V/7M*OD#Z4>=F?42X@" M5CK)JL%TCMGC(;HA'K&[VW=%X8_C4QP:F ME3<<3M&?!JZ==?@_ODD/DQRO]!J==?@_ODD/DQRO]!JL7O;=T7AC^-3>V[HO M#'\:I?NY?/CY%\NR/,>#5TZZ_!_?)(?)CE?Z#4ZZ_!_?)(?)CE?Z#58O>V[H MO#'\:F]MW1>&/XU+]W+Y\?(O>SD>8_PM73KK\']\DA\F.5_H-3KK\']\DA\F M.5_H-5B][;NB\,?QJ;VW=%X8_C4OW8\&KIUU^#N^20^3'*_P!! MJK]J-U+X=>8I 26^0/AAB/4#IS=3[&X[R8D"%"U9HAKBN, -7#2 &FEI$QPR MDI0C%2H8;$)23E RB3-AF]MW1>&/XU5LU0VV1#&^RXK;=26F+;^B%R=76#6O M;E[=KW]W9?EM:]HK\DUW8<>OXM4TJ+CB-HSX-_1;5A@Z_'TR2'R8Y7^@U.NO MP?WR2'R8Y7^@U6+WMNZ+PQ_&IO;=T7AC^-5\W@UV9GCY%\]G(\Q_A:NG77X/ M[Y)#Y,#5TZZ M_!_?)(?)CE?Z#4ZZ_!_?)(?)CE?Z#58O>V[HO#'\:F]MW1>&/XU2_=R^?'R+ MUV1YCP:NG77X/[Y)#Y,#5TZZ_!_?)(?)CE?Z#57;&^I/$"#/>I)X4OSZ! []1;H T..\EFF M&=!P-Q*/X5,3#C%:78,5N"Z+((Z(!M,(X0NUQ5L4WMNZ+PQ_&JL&++;=1VJ2 MU[WV6ZANS]$*W^#]R[=K[>/M]WMTO\Y>?-U^A2B[C^3G_P 2=S?J==?@[ODD M/DQRO]!J==?@_ODD/DQRO]!JL7O;=T7AC^-3>V[HO#'\:E_D?/CY%^;LCS'@ MU=.NOP=WR2'R8Y7^@U.NOP?WR2'R8Y7^@U6+WMNZ+PQ_&IO;=T7AC^-1EV1Y MCP:NG77X/[Y)#Y,NR/,>#5TZZ_!W?)(?)CE?Z#4ZZ_!_?)(?)CE?Z#58O>V[HO#'\:F] MMW1>&/XU6_R/FR[(\QX-K7UL:E,0271MJU8&A^?5#H\Z8M0+:WD&X\R6A*-5 MK,0S(@@!JUPAR1 D+$88'A%*Q4G2D WQIYQ90!#MH,]"%_UD'\J0_*JZ:=>M MK6T.ZR+VN+U*FHO^V%?_ -S7M7O>W^WCKF#IU^>UAI04&TXFN6X-V6F#L6 M0Q7V!#:]Q"OR!#:VT0K^L$-KBVY+ ME96E#25%)U)X!AO%6$\?(4,O*D.55# [LS1+YPX0^S5,2\RINQA MC%D98M9U4.'1%>VVVSU[7MR\MK[;D)YFB)S8Y7AO)\:;5R1_%@QQ1/ZM$SS(A8Q MM;7"6N-M3WD+'DT@I5SJ!OK>H=W)*->[IQ'#7E7:TMZA,@R6;9(TT:A MFYH;-0V%TK6ZJ)'&VQ6Q0?..,7I0:@CV88$RN*QQ5LF^TR=G3(]#\=SL\93QQ*\,RS7%AB8X*R*T%QJ33E3-I'DR3WBB01PW]8 MUPU? T#'$Y0XIF]4%ND#[FMO88N\(FN2+54F,(,:'W;YID?C-3NJQSU>0B.. MK-@:(Z=5&GO'DWD*=42NSD\R+(L>GSLO?96NW4;J6R?$GO'[\XKCFPE_;F=]'S:XK3*XFZE:@4J30F M^^F&VC< 0:5J!6\"^IWW"@W5()N(%""VVZE>6OMM;;Q7[=N79?MVV\6W9?M[ M..O:VV&4I2C&TU:I-T?EV)=5T\T^PT['EXO&]..11&NSHR2U1-&G5@+#60-0 M.+XUZ+B$#&PXD;BK'QJIVBCF>5-GB0S&'B; ELYAP5_Y$6W7^,-N&I1E2:XH MR6^PG#V,8O,*)Y9!$,?.:B%; MTU.*=F2)24YB9A&;DUK<>^[\G#9=COJ1FVA3:FX &M_B,>0V#%OYH=KW<%F2 M(9 9QC8^*VR#E>,8X+D2N01XJ$8]>9;IVPUF>-0%UGZ!Q?6&>Y*F#CE$YKA3 M8T%1-MEQ#*^I(RM>7%D; R_#GO=*$N.)!*T^18.XK&B09-SI$L)@BPD(7&0$ M::F]\W.M@ M"I>6I_T?,Q6 GEG2N#DWR/#:(G#\@(*18ZCJ=T4)W$LF"O"4N'-T(CQ2\3:N M1WC"./--B1L9:1)A\X+T2,61 3B\U@[GD[!&2I%JF7P**Y A4AEK#)LE8T3X M"DDQ50AT>E+C%8Z^1W([8Y.)S3>*MBV5/::3J%:IPDR\$@"M*U!ON-:BFW*M M+_@P7G\G+#JV[ <[\>!:&]'^L'+&9(]D*(9%DZACS+*W7'>0<2/3;A)7/\:L MF&=1J&53'3V\+4>,'I,K-F$C\%1=+CIW6&YJ:L5G05 M!TDOK0@6#5EY&:X>()L?=6UJ:%P0(7],E6(F]N4)DZ4DE*:27">1LJ:+6&&Z M0<-Y)QPP)(5J2D43BVGO%[MB1,MCL;=446*DD2$YQU*V*V7%R=E*_-/G9C>"RZM:&EPW<+O&M*WWU:GV5-U%ED@0 M@'A:"2&(H&?/CIBY5-II&S7>-RPF(,.I*+SUB;E)C<@9VJ2LF6,*;]N2)'M\ M5O,'**?S0LYRUT8&B6L&:^9QD9!A] _15,QOA#CI,9,FEO*2Z=[R4S:F\.J' M!ORSC"/M]RR6/&J7+8TC:TR=0JD*!\1QW(T=4MT7>(X P'R!J8W/LE=+5J3! MYBUA;TS9E'*\U;M/)3G$X2-3E'..GU@FD[NC0*'!*K7S#'69&Q1*6YA= ,L7 M&\RJ:.K'&7E6YFR5@:0:8LNRNS%-;RP(#'U$MA@54B3%719!.=<+@,Z7G<*UV5O M& :W7W$ #=6MU;]M]=GLU&YMC ;[X-AF5MSBE3K$AY0RCR0## M<-I%K>+892E*,92E*,92E*,94*ZD@B'IWSR$-KB%?#&4[!#:VVXA7@C_ &M: MUK;=M[WO:UK=ODJ:JA_4+]0/-WV(4^4:@T(.1JV$0O4AI^1Q"*I%6;<4 M)U*>-,!)Y!T_C!9I)Q3.B :4:6)RL(LTHP(BS"QVL,L81 &$(PB#;)NN9T[< M^>)/*#%_G*N,\PHJYINTLN_Z<=_:!^NC]:OAP)7UHOP _DKX??\ I76@]K6M;(,8O>][WM:U MN)RY;WO:UO7O6$8A&$S47JO& 01@$XX/& 0;VN$018K*O85KVXKV%:]KVO;B MO:]KVY:Y!BRBK&E;"R_[,3_: ^N@]:NNW!_U>]4/^.P-\$:6O>6AC2S,=*!M M$(^404K^A!*NB]4?OWW3_2'TCK])TP&KT?J2=75QUU5P#?)'I2>C;)_1\38K MZ*M/,K1FU8M$'_TC 0L%ZG]"&0%WT/JSU[TG3_2[P+U]74Z%&K7752VE*4KW MFWR*RE*48RE*48U:=4?I1QI[973%\.<(JRU5HU2>E'&G;_KE=,7PYPCWN6K+ MU!BKC\ UV#B>Y+*4I5:,I2E&,KR_)[H??M7M>7Y/=#[]J,:N6EOZFT@^SIJ: M_")R;5CJKCI;^IM(-G/IJ:_"(R;M^[5CJ# ?:U5B>)[V4I2C1E*4HQE*4HQE M5KU1<40QO[9+3%]W.L%M5E*K5JBXXAC?VR>F'[F=H+>HK#&EXORO%_4U3B.( M[VLK2E*HP%,-C1E*4HQE*4HQE*4HQE5@Q7ZH[5)[&#?O <^7^?)LJS]5?Q7Z MH[5)_ ;]X#G1M)P7^J/XTM:"E*4;+*4I1C*4I1C*4I1C5,U[>HU4U%_ MW-:Y@JZ?=>WJ'-9'M5-1?P-S6N8*C78.)[DMV85\!@ 8&X1AL(-[7M>U[;;7 MM>VP0;VOQ7"*W$(-]H16VA%:]KWM7SJ''W/V)(],UV.ULP3+)PU-A#P\Q2/M MK[*WYB;EA0#V]0_ML5:GI0P^BB0H5+PFL)2U$+" ",M"0,2!Q-& $ MX GA>W\2S3+IP<'H4E<, 837201O#7D*S%$!4OG#;ZXN%]%3H\-=-'HWUSC&<-T(/D>K37)/8TH M$C=4F,Y(]&NP("S*SE3B:S,1;.0?& -*8Y G4,R%,WI+71'FD)=@G2-%WK+F M ].^*(XPQ[%D7R8WYJ=(PC;E!++N0B[)2[B?WB?LV-W'HMU-4G. MJ22C76/'P)EJJ5*,PX3GF8<895Q0+/#5JOC.!4VGZ;:?6'"*F\I="$ 25ZF* M"3RV(%7Q](FUS,?(LX2U>YMD.'%U9]QO+6F2(Y&#A4]_0G'T3$2645TL1,:I626NN78Y^=U+@]F62(#FII:>E M0DK4!2B04J42"*@4(2*@&I4"I0%!F231NK>+"4C8:* 3_P 2J@J(!I1"2 BN MRX 5-+.6M>UK6O?;?9QWY-M^W?BVQAFB(%N)$9RG!(O/F-(\$%I7A W2EG2NY#:\)B33 MR4[NVV57;W0D@\\@M>F4 ).-*L P75)6E1(2:D4K<;JX8C;LS;I5(4D J%*U MX@BE0Q6FPVM/-6YZ13,N0LB9!=,U39FR-.YD6[MYB56%TLA;;.\19$:V:(2!4O&JQJ]%2+%E@J9H MQE.BX]O?2U2- VRR'PF5L>/3G >HF=Z]^FZ+OTGQVBB>7YK*B,KH8_$I(2S8 M8E^C/$>/H%'VM!.DZ]I7I#LX1;-H7)J:D*YS879><]+RFQ#,$2U9 43Q3NJL M)C;=CR.226PQEB.D")Q7&Z")1/%CVTVEK;@)HC;FUO\ *Y#E,INB>:&?/8G6 M=(7.V))U#7B.-[%%B)$3%7*0MB#!I4W$C TSNRIUUOZJ@;%13VA@":TJ,L>R M_E45_4Q%N6V3W%7*29E,2L@K$F:VA#,\2Z7<3E1YL3*7A0LM'HZWZ7(RM9D:QT6G! ZA;%"LPN/-: MHR)WR%;IM RIE=D=Y\W-B5KE4FC$B01YOB M\M?.%E$353 BY1)%]YW&[KQO%+Z[&H)(_* R%VRE,3Q-YQIALO5!]&:F.8$R M1I>19M;9'BE[FH6.R$Z!L9$M8L3R+(J[(^5,0S.0LTD"&8R">1&8.\*%-71F MC[R@8W\N2+V9[D"U8ZNF0:DM#\6U"3E5D9URO/X+)F?%L:QUB$V)OBUG;,6S M!ER^R9E39$2,Z%Y;&V8O:Z90?%@ QV3D*60M#C]"D3$<(Z+# :SF+$>ZG0-! MDI79OE1,]RK,Y=+SY!AI]PTVM[AJ>6Z;=$L(QIE7)Z>8')VY1IJ:7O'F=&7) M#%&&43LOD2>R]LQJX1YSA(F/#(U*M>N8<]2_%R=W=)[-L5NF/)G/O1A3B:6: M;X[E5CUS&D-4BQ=Z'V=))"HA&\(,)Y%H=+#F3-:*/1]P=@QY=/3%TND.A2F! M!NN.X@5KNW]@;(!K6H%"!44Y[!3R1BU\@;F5,5C,V6O2@$(1R;KE)1CR1#31A_>#XHV)E3 O8']6-Q M26VQGI:@6+9;D?(R]^=LE:@$*Q8YN,>;8@NR'$8+&']E.1-+TF99(U MHVV I%1"^5(5HT0E2@U*2A$7<\VER3'>IS(6F;3B1*(7FX[.>/\ 4KAZ=96Z MLDGQ0XNQS_"HVH'/)Q"5<%DBB(CQ:=-CS54-9T25B462FFW10IG:KI48*I2C M%^ZIG8G48XEZS4%DV,RW!$,0R8<;EVF]NRF=J!R/I*?XS,DKH^/9;+%T^#X7 MGM.F72YA9DF_3/CZSKF1#,<9D2B.@7# $UI3?0"AJ< /GFUO.*@,:X;3?AB3 MEA3 MO&T_8V9,-XAA6-&&2VE;5$T"I"D?AA0E&. %CHX/7"#*0'J$@+ALZV M ))PPB*"6;M_3-E3":I3D%C../)**+M:XS3#0%E@M<5@6N,P8@@#M%>P;;X5 MMHK[+;;\5:'<'XZUXX4*:VEQQ/D!QAJ8[,JJ"0?$DIPW TJC*Y:.)6QT[Z@7 MXUP3JE.(W^/-1[$UO;,FF,G1RD,DQ=]-,@RY)"AF#]T8R(&.2_*,&S-(G M-+"-4.,(NP/$@Q86W-S%,IQHKRGC4_*< ?LMY%8Y 2"T0U%1://SM(9[)6]R M8()9\ S)S&A4D@5<+M@PV8#MK=B:4.UI2IQ'$D;:;]]^P7WW-THW,+MMVC!; M>_KMH@\7L\?%[M?4:K2D<%8Y005<\XM.18PXLNYQYV^N425OQ!X0TRP!W++! MOACL 5PAO8(MFC($/W4>1S0QE<7W*\7CRC-L':LOR%NE.("&=YB2S5*L4^5 M,%0MJ0,&5IYSN:7?8,O#641@OLM?8($%?Q!OLO:]K[!6M?9>VR_)?BH?#O\ M/Q8+R!FW&49_9#?\<=_]T=?&NGZ*[FEI!=XS'G5;CQX&LO*#.?GRO@&(]%W2 M&^?OGJ9C935>/5K368S.M%J*A6DEI6AOI45P)%[?LW!?[0K0I#0<)#KD&D@K M<0T.Y64R:SA25.G2$**2;6 E)(J"0#3$"A Y8Z5U.=C T;\W3UY09S\^4[&! MHWYNGKR@SGY\KA_!9TB?^8V3_M&:;OZEW][=5^,0T)?5_25_8MG/]6[^_(MR MQTKJ<[&!HWYNGKR@SGY\IV,#1OS=/7E!G/SY3\%G2+_YC9/^T9G_ )*S\8AH M2^K^DK^Q;.?ZMW]^1;EE!_9"O\<3_P#=!773@_ZOFJ'_ !N!?@D35&-MS!T< M6O:]L=/.T(@BM>^09SQ7#>PK7_9S9?CM;BOQ7J6,.E (U$:K22[;"R5^#2@6 MVWOL 7BD@ ;;;\=]@;6X[\=^6]?0.@K17:+1H;3F?Q,IB/ID2?U7Z+B(I_J> MH?2?3=/ZS!0>I7UQUT>ITFMJKUM6B=;XN]+OTB+$:>DV#^XZ7VE@39<6G,Q^ MZ&"EL'TOTT;."$]4^CYO-.DU/HJ)Z?I>@U-9SJ=)K+U+5TI2OH-OBME*4HQE M*4HQJTZH_2CC39^Z4TQ?#G"-OW*LM5:-4GI1QI[973%]W.<'JR]08JX_ -=@ MXGN2RE*56C*4I1C*\OR>Z'W[5[7E^3W0^_:C&KEI;^IM(/LZ:FOPBGFOSG-H:GE$> MVN[*$#BD3KD)X=NW>G(U91R8VVWC_1E"XZPM.M05ICL!RV$$;*@X MC9BVD+U*U%:TO!*5 BM"".)J""#E4 CF]Q9EO3Q&W43=CS=0YWG7#XVIUZ7, M&I(_A34%D,OHHDP8V..3V4(\J9I5QPJR@/H?#P,ZQIO*3-F/W#(#^SO,_ M68W;4+4GB1[^99:Q1M_RLC"$(;; VM:W'Q6MLMQ\=ZRAWJ&NL3=2E*#9>:DDF M[.E^%P;3Q[K_ )H&^ZN(/YJ4BM1>2"); M/['#8HYD1@UJ8ZWL+9:RYBYN68'<823EB!O+D^ M,D9R:@LOQMD^-R&(R&"SS%4WO=&YW;&F8162K!-[W9J4 MA^U5H:8TV8\!OQIO;"*!2:TI45J*CB1M Q(VY'!M%,Y.D&-,,OF=W] \M\MR M3BN$P/3QI\AZ\EZ6X[Q<[D$)]/<& >'@;RG+\\4R$F82P28!-TKT[. CDZE8 M[;6?HFTJ8B5X#TTX$PJXJRG!VQ9B+'T$>W$B^U.XOT;C#89KB.I;6@?$27?&UU#MB/!T/D;A-H]'IPN' MO1Y0R-(UK2R-DIG3 D*+309 U-RQDB"DTQ_2NJEW2LQ;/N$M:P;6"&UK6M;9 M:UN2UNY;UJXG#LH!4H44JEU:ZJ0* $X5VFEPP%!<.5^\"M5(H0FOM"M"32X# M(4QO)-22223[2E*YVX&^-@!M??;VVW;>^WU[\M_9OR7OR[+6MR6M:O=ENY;D MV)Y;VH VD#J/@TL[+=RW;[ M5NWR_;V6V^Q2]K7Y;6OQ;..UN2W);V+5$W4TD?/9ECP<6^:ZG4TD?/9ECP<6 M^:ZG5W;OGRX,H/>'(^#2ULMW+[[-? )8 WN((;6N*^T6SMWM:UM]>W) M<6RU@[Z_'O0A#MWH;6M%'4TD?/9ECP<6^:ZG4TD?/9ECP<6^:ZE3EEM&ZO*_ MEO90>\.1\&EG9;N6Y=O)V^[[--ENY;M=JW:Y/M=JHFZFDCY[,L>#BWS74ZFD MCY[,L>#BWS74J#BWS74ZFDCY[,L>#BWS74J';X-+.RW3MVY+UYO0W MO86RVVW)?DOL[G%VN*W%R<5JB?J:2/GLRQX.+?-=3J:2/GLRQX.+?-=2IR[1 MN[K^6]E![PY'P:6J5$O4TD?/9ECP<6^:ZG4TD?/9ECP<6^:ZE3EEM&ZO*_EO M90>\.1\&EJE1+U-)'SV98\'%OFNIU-)'SV98\'%OFNI4Y=V[Y\M[*#WAR/AQ M\FZ6JA/4KZG7/7V%\J?>'(*_2ZFDCY[,L>#BWS75#NH?'L@28!SBJ-S%D]>4 M1A[)YIB%8'&ETBPLN#/PAIE/0V-4JG@#PVN69=,I3J A%<1)Y1M@F!=7=N^? M+@U %1>,1L.8W>>ZQ\"])$/_ ,EH[_H5#66U7V$8YD1T-B9HS+'@XM\UU!6@N MV#+=YZN%909CM\&EJE1+U-)'SV98\'%OFNIU-)'SV98\'%OFNI4Y=HW?/EO9 M0>\.1\&EJE1+U-)'SV98\'%OFNIU-)'SV98\'%OFNI4Y=HW>)Y;V4'O#D?#C MY-TM55C$>WKC=6/<]$\([/)63MJ3>II(^>S+'@XM\UU5KQ9!']3J U2(P9:R M0E,1N6%+'+DQ6-@K'"XL7%B+$L$;CDY-:Y !<"#H-,CL:&UC%5CS[<-2IR[> M'B>6]M "BKQ^2*XW>TG=G=VM>ZE1+U-)'SV98\'%OFNIU-)'SV98\'%OFNI4 MY=O#Q/+>V:#WAR/@TM4J)>II(^>S+'@XM\UU.II(^>S+'@XM\UU*G+M&[Q/+ M>R@]X'(^'' MR;L"U2>E'&GME=,/PYP>K+U1W4K 'Y'$\=B-R[DQP"=J*TV)@EK08WWA!JG- M<-3E+2;I,#BWS74ZFDCY[,L>#BWS75:G+M&[ MY\M[2@]X'B>6]E![P MY'P:6J\OR>Z'W[5$W4TD?/9ECP<6^:ZG4UD=ME^K9EB^P0>4.+;V_76[74OV M7]B_%?M\5.KNW?/EP90>\.WP;"]+?U-I!]G34U^$3DVK'52331CY_5XZ?#"L MOY.0!!FO4<1II(^>S+'@XM\UU!LH+L :C"Z_O/5O:D"IO&)V'/@TM4J)>II(^>S+'@X MM\UU.II(^>S+'@XM\UU*G++:-U>5_+>TH/>';X-+5*B7J:2/GLRQX.+?-=3J M:2/GLRQX.+?-=2IR[MWSY<&4'O#D?!I:I42]321\]F6/!Q;YKJ=321\]F6/! MQ;YKJ=1[/'S0[JJ#,=O@TM56O5%Z4,;^V2TQ?#K!JSKJ:2/GLRQX.+?-=5>- M2F/WY)$L?"-R[DQ?8[41IM3! L#C?>D&JPTYD5A2A%2+[KKQYXC)JD"H]H8C//@UX:5$O4TD?/9ECP<6^:Z MG4TD?/9ECP<6^:ZJ*@ 4PH,1N^?+>TH/>'(^#2U2HEZFDCY[,L>#BWS74ZFD MCY[,L>#BWS74JII(^>S+'@XM\UU.II(^>S+'@XM\U MU.KNW>>KA64'O#M\&EJJP8K]4=JD_@-V^ST@.?XME2+U-)'SV98\'%OFNJN. M-(&_GZ@=3"0.6\D)C$W40N:N3E8VLL7;Z N5B^B[FXY.36X -K@!T&E2<+:_ M"*NB#K!,LJBE1+U-)'SV98\'%OFNIU- M)'SV98\'%OFNI4Y=O#Q/+>V:#WAR/AQ\X2U2HEZFDCY[,L>#BWS74ZFDCY[, ML>#BWS74JII(^>S+'@XM\UU.II(^>S+'@XM\UU M*G+NW?/EO90>\.1\./G"6J5$O4TD?/9ECP<6^:ZG4TD?/9ECP<6^:ZE3EV\/ M$\M[*#,=O@T3:]O4.:R/:J:B_@;FMN"!/S;HOU=+S\MY*=R$FEW4*> M$]3:Y^RY@J-Y0C[](LB9&U Q=_%.Y( M^9'@*^+0!A:\3LBEP/8%1;@G(7N:DM86>%*2? ^'];>NW7Q/M#$,Q;DF(Z*# M<\[FO*]:61+.> V[.)[E+X[F[&N)T*2+(Y[*84M9\=3!JFAD]BJA7<]\''5S M$4M$8>>:K!*C#SL\0SSS;I I6KO1;JESPY:B]1^A'5N/'\FSSIXBF,,NQ7,^ M)XP\06#YVP'F-9*6>)RE1C1ZD,Q78YR)$Y-#7N+3^.HI9(XRL57;GJ,N0$JI M4WH?ANJ>H_5=I5PG$\UZ]K6MRWOQ6M[M M?D)']B<'-V9$+RU+7AAZ ]'&I(XHU+DS>BJ82UK]%4))PU3==R1@&K066%$7 M6)@#4)K&DAN.T%:K&3-D3@S1>=RC&Z65QN!R=X3A:H[,G5D>7%8VHT9KDCU33S3#KT#D#)^8]+EYK MA*8Y*/T_L;$@RYER+S,AHAT>TMYE@LR59C;T,PR0W3B6Q+*[SC543(RGV:/H MU30W.<6/-/@3A?,LA.F3$%F'*#SA@*)* ,PT80!$*WP;71M>&Y"[M M+@B')_'&=1D?$+L]8FC\A@N,PW>4K?AEL;HBE=<3OS YRU&AZ8F-^R M VYVJ6)$28]8L5)TB1*0L;ZB&1M?&YQ9T ETQ/03Y\205;%[QIK87&^O5 MQR[6:M]*CCLV>/9RZ#BW)O-6J6XM#$RU2T/:Y2I4W5N$ M3> &(WUS%K^C&D7=(44,G,G>%SRKRUFZ/.2/-C$NR+C)=!I9(D>YJ:?L8L$O M61.X3(7TY&:ML:O*,^1)$MAW:R5"HTDO'[BB)"UC0W&H-,#?O&77EUL"0:>T M+^R\8[<\,M[= *:8Q):V!>D=W<"8A)GJ33"-H(X"7S!G122-?Q8+TU;I'BN'8)QPUJLD1\ MK'\8Q)'$CJNS[%9-!&!+C^891'J1#D5HEY")X58[1W M9DK^=@)TB[[TT*FZX[, =Q/4.TY4909CSAXG(;[FZ#+7M>VVU[7M?DO:^VU_ M=M7M0%I7A^1H%IPP?%,PR&32K+K5BZ$@RO()A)$\ND#IDY3'T"S(*A8_H;!: MEI?3"D(&,E+'DC>6E1L*-*T$(R 3[6FRRH3U*^IUSU]A?*GWAR"ILJ%=2 M5K7T\9XM?DOAG*=K^QTB/]0F@)R;21521FH"_"\[6SN!"#:$0_:(-OZEHYRW MM_Q*A]>LMWX/VP?"M^6N01DUV:O$[,T)T^>)@20G:FU.246DBM@EDD(4Y10+ M;8[>]]Z ;;17N*^S:*]Q7O>_P"IU^6L+G]F?\DBOT>E58ITM;M4@M2 M2[44$AS*;RDT)'_M7;0D=5=K?H"Y_P!G5I9?.G3Y%LM'82]=H>I"HRTNL$O$ MI6 :69(K0WT)%S>S\7-I;^N6CG]\M-_IGCY%_7/OP?M@^%;\M59Q'>UM1N MK&][VM:[GA#9?;;FK*]?[7=KF^Z_+6%S^S/^217Z.5@4=UJ:J&Z:9!>T&:Y4 ME=I(?%#'U>4CC/#N0V6/6;&P1^_8!EANE0_T.'@ $V,#:PS[&G6L975PWI16 M-B7,P?ID-ITIET([C'P4YE55NWD? RX)=TFI&N'T>[6=8A/1(7?K:J5=NC?] MGSI5E\3*(1[:_1\M<[F#R60ZG<7:,H=/G4JF4X4\?%5G$D.BXE+]T"[#Q?3/ M7(* [Z1XCLDWX/VP?"M^6F_!^V#X5ORUR,=?EK"Y_9G_ "2*_1RG7Y:PN?V9 M_P DBOT/D7]<^_!^V#X5ORTWX/VP?"M^6N M1CK\M87/[,_Y)%?HY3K\M87/[,_Y)%?HY3\*VQ/U?M3O_H93N_K;CV,_%S:6 M_KEHY_?+3?Z9X^1?THZHQ!O$<:;+VO\ URNF'DO:_P#ASA'<]B]68KE*Q/JR MU&Y0SIIWA&09/I8MU,4PZ7ZGSB%@XE3Q M(AHB)=]$I$8[2DEX%ZR5U2 3\LZ;-#%H=!EJX*R%I9E)IK'QLBA9^[B)$]C MGL&F%C(V80#MRM4P@9>^$0E[+'RUI2Y4[#MXZ*7JE%:4*4I7GC>GF4I2C&5Y M?D]T/OVKVO+\GNA]^U&-7+2W]3:0?9TU-?A$Y-JQU5QTM_4VD'V=-37X1.3: ML=4& ID&JL3Q/>RE*56C*4I1C*4I1C*K7JB]*&-_;):8ONYU@UJLI5:]47I0 MQO[9/3#\.T%][EK*L#U=X:IQ'$=[64I2E::,I2E&,I2E&,I2E&,JL&*_5':I M/X#;?^0'._X_Y[:L_57\5^J.U2?P&W_\@.5OQ4;2<%_JC^-+6@I2E&RRE*48 MRE*48RE*48U3->WJ'-9'M5-1?P-S6N8*NGW7MZAS61[5347\# MY+=F%*4HT92E*,92E*,92E*,92E*,;49--S:QYG+=-LH:J-1^ L%9KQ5?2;I MLQCA]1E&*1+(CS%,IXXRYGR93A>UQR4,[F!A)-99Q!AD/)-[7X+>A@ M;W_(U-XXUA98XS>@;7=4XRGK5T/CEFY[J]'NE&(QN,)&;(NF=\A43< M9"O;V%JCN,]6V)?AUM7_4YDQ_P]@V:S>*IT!\L)-CD;B0G9(J<&5%*LAS:/X^C# MN_H4*I"L61YC>Y6WO3^E3+D)Q[0@6E 6I+BZ(+H2?KSROC+*V0L-9-@J>29L M?K=FV0SFZAC,'*WY&[N#B\$/#V):X%/#DY.I:@+BXK5)XU MK=\:>#:DHYNN:^\OG4@<(HZO<$D5F5=AN!)T\. M:G].MD^&]SV''(=*<@#D8HZB*.S1J]T;F:SM+(FD&=(-7 M6K&58)49(1ON/\8P[PMMRH$T MO#DZD.XRS!R9<%(1(6MK4IUR$&TM9IRP X)'% NPCB-6A>&!7%'9&IQM##DK MI%U\=B$071QP3&,HDZQA61/'T"C"EH/*&WFQZ$1%G$GZ C;,0B_5C^#L,Q** MMT%BN*,;QN$M$I0SAKB##!XRT1ANFC8^IY0W2]"PM[8F:TDH029&CD:-_(2@ M=4[\D3O!2H+D2!3;(2=T^)9 XYAL:P\ M]9-R?/"8PR,K23-8;"4;E+'S4+D#3<'T54K1/)480&RK&S])%8^"=+MS8,QD M3$.+RW'D#_&B&ZM.$[CK#:/Z8I2DR3/8[BK).-,>RC+V+6!-(L/Y9POE;-K) M-'V>!4.,8B;VB8L)9#:%\&,L\N5G,AB7EN=XVLD+W%-C39IMT],LF>)HS8,Q M TS&0RA/-WZ5MF-8:WR1[F:-S5O:26NSXC9B7)QDJ5Z7KGA,^*U)SD2ZK5CD M!19:K4GF_0_Z8].4K8@1>3X%PW(HV6V0YD+8'S&4*=F8#-CM(^(("T ;%[(H M1EM<)0R>3(HF@ 2%+'D4C?T;64F2O+B2IU?Y[*5!QVUJ;\2RZ['97?GM%*;. MUJ/1'=+K9&4MSA%L#S1LQ8\Y_P 8X$ZL\HE$<;(Q&C\F8J@63$TQEC6@1OSI M'$I*C*D QU%VUX G13+*3T3&[O[&T'MD@=KQZ<,@R3)^%X++YDG:T\P5-Z]I MEWH$G5HV)3*8J_/$0D3@Q(EZA6M0LCH\,"QS:$*Q8M5(FY8F2J%BHTH2@S]5 MQP)A-V/;UCAB7'"I>T2\O(3.XF0F-W<6;(!#2VL2:>-"VS;92V31(SLK*VHI M0B,(>D2-E9B$JPH#4WV3Y= H+%<8PJ*X\@[26QQ&%L#7&8XU 4*UHD30SI"T M:(H]P<5"MRPTV5XFF[[ MIXSQ]AG*7WB/]354*:D[[-.^>+WY+88RG?[4$ M?ZAP/"G-M)_*3^L.]N+IJ_8QO_\ @4?_ *8JOT*VG1WWW'G4)SC8>]GHR8_937=_ M5V_L+:F*5MF[#SJ$YQL/_P LF'%_Y9_+7O8>=0G.-A[V.C)A]&-GW:?>7TI? M4N;\H;^89^%=Z._Z5;/?LIKN_J[?V'=74Q6+M/I@DO\ C&G_ $;:MQ_8>=0G M.-A[^63#Z,5%,/W*W-[[DG+D223W%A;A!%4#))!?4MT @1\9 MH@ID][$*>B"B+\/>_ V,*MOZ[M+M#VDQU!3]V\L=-4+BI2X<0Z2(:KU\B?R. M*4[3_O'Y0AX9^]ONU7:KZT!\;GGI0Z 8J:6.?P^D^0/'4NM'%1D:M+N:4AX9 M=DK3P"7RZR\>R8R.A(<:NL==\F[5UE#7=2MLW8>=0G.-A_\ EDO^C-.P\ZA. M<;#_ /+)?]&:[3]Y?2E]2YORAOYAO)?PKO1W_2K9W]G-?\N\T.ZNIFE;9[;C MSJ$YQL/>S=9,/Q1GW[4[#SJ$YQL/7_\ G)A]KTLV_GVZ?>7TI?4N;\H;^8:? MA7>CO^E6SW[*:[OZNW]A;4Q2ML_8>=0G.-A[^63'Z,?[*\[#SJ$YQVEC8MW#1 M6ITBX9Y+)0Y0^ =K>)U%/7#Y(J0:H544HWY7>FU;^QND?2Q)I]8>?P=HY0XL M+*I8^CH%,0ET[CW$ZM%$/H50B7+AYTCMQ%PSU1""C5?)HHD* 4I2O?#?'K*4 MI1C*\OR>Z'W[5[7E^3W0^_:C&KEI;^IM(/LZ:FOPB,FU8ZJXZ6_J;2#[.FIK M\(G)M6.J# < U5B>)[V4I2JT92E*,92E*,95:M47I0QO[9/3#\.T%JRM5KU1 M>E#&^W]TEIB^'6"[/NUE6!NKA=UAJG$<1WM92E/9I6FC*4I1C*4I1C*4I1C* MK!BOU1VJ3UK8-^\!SO\ CJS]5?Q7ZH[5)_ ;]X#G^*C:3@O]4?QI:T%*4HV6 M4I2C&4I2C&4I2C&J9KV]0YK(]JIJ+^!N:US!5T^Z]O4.ZR-O[E345\#Y+=F%*4HT92E*,92E*,92E*,92E>7OLM[H;?;%:U_?HQO:5R8S+=XM M5L?F$M8$6-L!F(V*4R1E1F*(]/1J!I&A[7MJ8:@8,B%@&>,A*6(X8"RP"-N, M0"RPWL"V-]GZU;GWQ <=AO#=>5*Y#> MS]:MN;/3[XN3_P X].S]:MN;/3[XN3_SCTU#NV=M/'L.ZMZ!YD.8W>(;KRI7 M(;V?K5MS9Z??%R?^<>G9^M6W-GI]\7)_YQZ:AY?(_%G0/,AS&[Q#=>5*Y#>S M\ZM^;/3YXN3_ ,Y%.S]:MN;/3[XN3_SCTU3RQW7 _'95A<>FH;AG\O%J'#PX <]]/BW7E2N0ZV[\ZMKWM;J9Z?>.^STN3_ ,X] M+[OSJVM>]NIGI]XK[/2Y/_./35.[S3Q':P.'A- !S;KQI7(;V?G5OS9Z??%R M?^<>G9^=6W-GI]\7)_YQZ:IR\U ^+.@>4K04XANO*H3U*^IUSU]A?*GWAR"N M7GL_6K;FST^^+D_\X]8Q-MW-U2SZ&RV"N^.<$)VJ:1B01)S4((_.BEZ=ODK0 ML95BA"8?D%006L(3+C34HSB#R0G@+N<0<5890VHKG7;E2O>P.5U!H* YY$>( M;KL@7I(A_P#DM'?]"H:RVN/YJW>C5>S-;:T)L:X!&G:V]"VD#-CT^$:82WI" M491AMPY%"&YI@" C-N ( <((7!@ #>@#^A?=^=6UO\&>GWDM?TN3_MVV\X]- M0B@IV[!3QXM.A7D.?G-NO&EGWQO;[OSJVM>]NIGI]XO^KD_ M\X]-4W87X==/'O9T#S&@Y\/$-UXU5G$=OZXW5C?NN>$?N8L*]?\ )7-IV?G5 MMLV]3/3[RVMZ7)_V]O[X_K5@<>W;74Y&9GD&=H<=X--=LEGQ-0]IU+#.1H48 MX='K1I!9L++R 6<4%4D#90MZ*/5W$JXTUTQ%^!IJ$TWM0Y> $4'M 7XFJ3U M7-V6TKD-[/UJVYL]/OBY/_./7O9^=6U]OZF>GVVRUO[W)_ZUN-*Y#>S]:MN;/3[XN3_SCT[/SJVYL]/OBY/\ SCTU#<,_ MEXLZ%>["N.RH'Q#=>5*Y#>S\ZMN;/3[XN3_SCT[/UJVYL]/OBY/_ #CT""[FW2WJD]*.-/;*Z8ON9S@]67KC7G>[=ZH,B-K(UO&/,&)2&";P M6?I#&Y@G)9QCMCN4MDQ:$A]U&0%(!-ZMQ:$Q#B "U(T8S0)5*4T5C@YQ;=^ M-6U]GZFFGWC_ .KD_P#^5^^/ZWW:FJ0"32AH1P('QKVM2Y70"[$G'80*-UX4 MKD-[/UJVYL]/OBY/_./3L_.K;FST^^+D_P#./5U2<+_L!V\6>KO*TH*G>&Z\ MJ5R']GXU;;-O4TT^\EK^ER?]N][S]:MN;/3[XN3_SCU0A1KA=C?AA MX][.@>8T'/AXANO*O+\GNA]^UG9^M6VVWZF>GV^R M]K[.ES(''LOM[61[7^U>U^Y>U345EVCSO^=S.@>5I07TVYX-TR:6_J;2#[.F MIK\(G)M6.KC:@F[?:H<GWQ.^STN3_P X]+[OSJVM>]NIGI]XO^KD M_P#./34.[S3Q[#N8'#PX (;KRJM>J'TH8W]LEIB^'6#5S0]GZU;GWQ< MG_G'K"IUNW6I_(S:RM+SCS!J4AAF\#GZ0UM8)P4<8[8[E;7,FA*?T3/U18F] M8Y,Z9.XE@ 6I&C&&:A4+L*X[Q0\;J^%6HJ/\ BJZJKA3NZ]IS M:= \&P<^!^(;KQI7(;V?K5MS9Z??%R?^<>O.S\ZM^;33YXMY \Y% DG >: _ M%G0/,AA7$8%NO.EGWQ#8.? _$-UY4KD-[/UJVYL]/OBY/_./7O9^=6VS;U,]/O+:WI77"\T%^WR6Z\:J_BOU1VJ3^ W[P'/\5 MW4ST^\5[_P![D_\ ./6#L.[<:G8Y,YY/$6.\&&.V1NE+T93J&&7T6G4B/7=$J%6^4!!T+T,3OBA0))P\W _$-0Y710H+QJB_;5)[ MF[*J5R&WW?G5M;_!GI][5_2Y/^W;;SCT[/SJWYL]/GBY/_.14U2147WTZ[L^ M+3U=Y=<+\+QN\0W7E2N0WL_6K;FST^^+D_\ ./3L_6K;FST^^+D_\X]74.[S M3Q["SH'F0O%<1@W7E2N0ZV[\ZMKWM;J9Z?;;?^KD_O\ _P!CVKSL_6K;FST^ M^+D_\X] DFNZ[K^7V,#AX< .>^GQ;KRI7(;V?G5MS9Z??%R?^<>O>S\ZMMNS MJ9Z?>3;Z7)_W-O./345EVAIT*]W-NC[7MZAS61[5347\#@^VJ^45D@C9V\/@>QKT*Z4H,2<#?_]D! end GRAPHIC 30 g716831.jpg G716831.JPG begin 644 g716831.jpg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g1042755.jpg G1042755.JPG begin 644 g1042755.jpg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

    "4A5>B=:D2#@UG+$KK?U*%6DP!P6=??(.8&6.2I MM&>5#8-Q_6A:9N\UJ8LEL@8(:JXIVI(I=EK^OX^0)&L!B+%;I+@*EX25 8P -JDJ"1DC /NG&01C;E521C& D MX3R$G!R<;@4G/NDG&3@\CG=@5N:O577&R F-AUXJ:2':ULS;R86S3L*&]+-M M,BOE&1<8>.*U-CN!,B23GQ)==)!1DCYX\W],/@PE"C# MO@:\O9QE:D.$O_"E3KV6TY7_ $G,IQCSGD1-9VF"H-Z= A7WW-2[@E#9:IE/ M#O M4O8C12P;/194,I+1404;(-X4T$:.,Z+(IS'Y;RI*E'0H\UA;2G"7,!9>3DA"',[:DE)4 M@+! 7C@$G!!R/!604G'&?C6%0.0,J(\.I/EC!QR,8/3ITK%].K?B*\[K^494 M+-:_(7"*;RE>&)"O+(*=JD['NJ;;P4#(Q"4#.O8_;:EHZ4#>QA\9>5;>Y'#: M6;GJRKR]^J]Y=,$AE,R$K 7MG\<"-$>-8$0%&2HJ0Y*'<]YB4L>?K6WG<-8? M6A*5*5(QM2E-MJ7C"5J0E2DXSA6$JSC&;PO&?#F4K3UU&V4T11\R%QPB'M%0.="MX:R\6B3$9\Y>7G&-QD@$C"LCA7D3@CE/('F"0>@Q;/&T\@'( M]/,? ]?B/4UCRL$V@8J'L=,2W 2\>\T6S*&Q9^'6W<^WZ.1C!U/)3E:,X5E3 M))267,>/D0M/R8T2[K6YZ?0>1K93MYUR1@A7]44.$0G.3&Z3(EJ<:6M MSY7U+@Y%&!C&\(%PMYU7OY(>U/V86'>(J(47)33+HRV8Z8*>!#-&P^VDQCZ] ME#J@R,C*6L9];+S6'D)0ZVI*\Y3B-%V$?9)B?JMEJDC4;77F1#B@7R&9**DH MF2?*' EH*8'2V@X-YX(IAQ#HXY [[*D.MXPI&*E)(!( VY]Y.>N,J_3=.7&@W^4T;3(&D[3/J%FB6 M!W(QN%N%4G)2,+&0+EIY;BX9Q]W.$8*BU-C.8<0M;J,96A..IVW09[33>E(' M7=D1>S:TFA"ZG)J4L(F#F?HL JDI"7=!;@AH>'/PJ? QCHKC[)3.1BK%8X)W$Y! )P00. M/>P=R>F/JD8P/,_SA 7(R'BHYYU#[P$: $Z^VC#;;S@@C(ZW4-X_H(<4WE:$ M?DA*L)_=SM...?Y?V\I@[9>I M)=*3LBQ:HTQ#00F:E*Y@IV[V0-- 0R"!P$ @NJ6"HZ066X<4R] MD<8=EM#KMP=HG1*O6[!93U80!7825G35Y\^$"1 !$@0K/C[^$M#*SG'[\?;] M_/-Y 4.,[)U9Y-JEF*KL+$M.3U9V"4&X3'G8L4B7-G5.\I$\&9AER9SI4+8A MTD&5PEYYA\RPQI#MDUA<[$W9+'99ZK?<;X+B^J2T4I>;8@)CI0VEY1'L M_?O2LI=24**HY;#J I6=V]CFFK'<7[OJ#4UN3<;/9EV^+W+B7'&4R+@J2LRE MQ6TJ,Q$5N($.Q]KF$2N^[ETM!(H@WQL68VGV9Z_2<@?'V>R+*I>Q+6XSEMH0 MB_;&V;);;NL80U'JQB-<&20)"'@C?$1'BBX#5A"A\-I]G'4#>G[1;=3>V5"Q(E@1Y+T7>1)V$!D0Y,G$5^B9Y*FI5V,>*C&$_B; M4:Z@3!A!27V$*6TSEO"L:_LO:%*=U7IN))M+:8,V5;[9)C7%EJ7)7/FRPPF; M%DNQT2&U1UNM.I5N'?(2\7FPKNW&]Y]H&G].WG0\Y^UWI F:?M-SN$%ZUW - MLKCM->V2HW]$UJ!GTON15MH50,40*]\)PC[L+$R@$F 5[599. ,2P8*][58P\VG"TJ0 MI:D0<'6(8R^$2I(TA&R0BOII )[*4O MM)3CW>SY&W8ST&%W=?\ :%JGS=GU8UC47E[#,2S]V<@DV&@S)%;L;?9Y65:S^&N&!1:8J)#>=D7CBW4X977<1[V\IV A"<#)R!D8.<<@;B M=P2H?6'(,@?P[0K<1D\^AR",$GQP,$@_5)(QB]$-2S&/*O8I]YAN1"*PA"6Y!AW#2<883 MYT"SV/AK3J-ZC*U!>&;*=4%U-VM&5QZ,HX:W8O$0V^9:Y#(<;#U@5&4%N$EM MC% ,-9;0.IYMMU>5RH&Z#8&5$F19!#0(P85JS] X M6I4H+)8RZXXZZVI0GG#Z\(><:V$='RER5L;0UVFQI3ZRC1DG 6)D# 4 MN['2+Y4?@N7%:?="?/B9L ,E1(B0T%_)YP,QE6/9F^LKH\: #3K?A<1L6"CF M!)B*/SAIZ90!A07Z30;BL_%+0\M@?ZW#X:W%A./.#&ML.HQA6(;2'(J5MJ&[ M8&+.F1X>/-K=^:A7/G(+H!Z%2+$LV(A6$'IK4G'.3N;404X/4[?KE.]$@]A]V>R/=/]+NSG8'2],ZM;[A MNN>M]):#O$5K)P1F,T_JO:TCNG94N%7I2VW6:V=*;,>$J,+,F-:]C*15PVPZ M[*31\Y*O3GTSG^>* MMM/AS@ G'D<8_/GP'G5\W-;6K5T#;IX>?D#[*$2W%)@C1H.P&PHDQ#I/7)) ME, 9:*<:0:XMWW"EB/+2I3#CBV5K;S3S+^J]N_7F3K?=O;LUI"GT[;]/8WU-^R/6NZCZ)E>NU3VOV I^@SNRFQ(73H?9R^5*TU4^_6NF:VU= MK%VA]?[]9(796Q44VPNYL>U(^NZUJDT)$0#DQ8G+"\97H44D84,@X\#Z$?S^ M&?MD)6",<'PYYP?TZ?>*NOAH"#KPV H*)CH<3'MSD>-#'#;6I*?;AQW##:,O M.YQY]SSN5NKSE2E+RI6EZ=ZWWU[4T--EW"4/VQL/8F=9:LV\Y'E:Z_1H2.I(<#7 M-D-5>>;-LLO*.W<;(D8(N+&)+7";JOL&R3W2:"]77L'V3[&VR15IO9';.WZ) MH=UCH'0M.J437+E-+Z]0.IHFN($F,ZXB@&:F?.7.:E;]([#@#)Z=L0##C\"+ M((_A&!X<8'&,XX\,U&T\Y//'KDGD#^_I5\'GQ_D_+.?\G^7\N.>:^W>H?V&W MP/U\AYC5NP=$)_U;OIF335^J$7V)I-%NM(WGN>5A;WU_F9K<>H]+GVVSU$&) M!Q=U5D.PZYV)3[1$S!H\(01GV,,-(3((.".A_N^>OPS0 MI*>O7.,?8#^O3J/OQ8OQQQR:K3CCCBE....*4XXXXI3CCCBE....*4XXXXI3 MCCCBE....*4XXXXI6K-M;NU)HFOB6G<.Q*EKF!D91J$C)"V3(L2W*3#PY!J( MJ*:>5DJ4D, AFR#@<>P2^S'A&'O(;#$(?;P%/ =DD+(Y>=:2+-'VOVRVWJ.(BG=I:]L$U,]MC M[ BT1-UVO4Y-5SU_$TZNW&R!P;^JPW)F3M8U/O#DI#E5=N),J20<8X\\9XX\ MOM\#TZ=,V 21DG[.A\?/[.?7TJ>T;V;T!,6ABG1>W*(=/E:D;WT*,-/#.BE: M7=>0.WM$:73_ -)"**I]>&OTD9DEQJ5X6E3RSOM9[TU!N0$>1U;L6J7L M,J)Q.CNUN4:D^@+CR6VE+^/SFO;KCTJ MW#U\A;GJ&<.U3O;5VSNMU=UY,S5S!F*YBK3.L]<1.K:II==! 'EP+=HJVQ4I M;K'*2B9."ML=.FVP^Q W"=OCLR!#?=/IY=H:U1F+*F]6;?)0E<,H=5ZX11=P MO-,K\;*1_8R-HD5,WO9.T:+;+3 Z2QMVN%T+9-M>DKJ!+UJ-?FXY04-69JI0 M5* !QX\\'C\_U.3C'!JVU!S[W@,'CD\9X.".<]? =37HERXG'G.?=C&,9SG. M4+QCQC[YSYRGQ]L??/\ #']7-?5G;>L[G9;)3JI>JQ8;33S9&.M%?B)88Z7@ M3H@P>/E!)0%E2GA'X\XL40MMQ.,L/OM-K\*7C'*893TKMR*HN&X'=M3%OEQA MKO#;G78![A,B[$KUML.E)FNUM^P&G3RX<_6 VOK:)3+N#5R)B*Q^P@.R*F19*7/W^K2$;>!QMAD5R%F8^==L#>+GEF2.L MYY<5*2)$HDY\MR)81*/2#C(SK3< M1G 'H?.KV/D1]OOGQGSXSE*L8\X\?;SG'CS]_'C\_.,X\>4Y\?OE'W4+I_V* MTOV]JA]VE+'?ZEKG3MNB+KONUY*C9#:=IM6LNKM&J]4BOJMD7"7ME8I!FH[U M+P;]@KM9)JN;#*M/)>FIV3FK=>#RP.<\8(\/D"JD 8P0> >/7P^SY%1$[U7% MVF]7MHDBE."GS\;'TP);?G"E*MLL'#&MXSY^WOB7Y%.<;PA.!$^SQ[<>,YQE2?ME.?MCVXSG\L^W'C[?;.)#^J3;\_@6GM9C/ MJ^6Q6J3MW&,YQ]\?[G\\??/G.%>//QIVO71%Q[3I3.\%C3EB@ MPE#<"E,J5ON;R@,D!19F1VUX .6@#]05]4Z!M[EN[+8"D)(D:FU#.G((&%JB MQ>YM;22>"4I>ARG$#D .DCE6:CGO&5%8>>CQL-IR^YG"TIQC"5XQGPO.4IQX M5CQ[E?M8SX\X\?E]Y0>FS0DE;+LER<'S]/6:,,-25G.990A&4X2E+ MN(R+-SXQ^33_ -L?M*5F EED%V:TO.95E;+3J\95G.%8\)5E2LY^WY?LYQ]L M??QGE[O1O7*J/I./F2V?AE-@&.6I]"DY2XU%*;2#7F%8S_N51K&#T^,_;\0\ M>,9PK'/+]C=H7J7M+AS^[*H=D[^[.JQ[J?9PEF$ >1O]M?8<">#M;<4![BC7 MK^U2Y)TQV9O6X.;9MY]GMJ0#[RB^H/2R1G)2(;+[:E8PE3C:3]<9F5QQQS[T MKXFK5N\8A5@TQMJ"2G*U36LK_$I1C\UYDJA,A83C\_NK+^,8_KYI?T_C"0RQ\ISCSA6'QW6LISC/VSC/O\9QG[9\^.0C],0Q1OIW=)'%^?>QU>TM'K MPK&<*2Y%46(BW$92KQE.6UAY1[QQ*%^,^WQFJT!8_M#E)!((5@@<@@XYP>>11*MI]#@* M& 01D'H00>F>E1-HI&Z:7K!RYLQ%+*C9!DJ_S8U@E)XN_P F/+-MR)CV(\<8,:OQ\FWEAIWG9UF=KT5(LWZ0L=5%9DAT$C66R%2 M TE/0A*EK:?JT =)2MO(B"6%91$R,Y/K9.0IHB,K(["F'B-9VJ$W[4Q:MU[A M;G5KS'6<,V-!45%2,)L MR+6]'-I!(8DFI5H(&>1U'3G=F/P2=^3[IP= MH(QP>3X\8(P#D'PU-NK;M?D[KJAR]0Y4=HUFS%O2[%I3B-/M%3B-B7GR4NNJ;62EM/N3IO M4>-+RM]VD[M.H4VG7QF=;Q"4^Z!UD$.!UVY#QSD S%@JS^!(EG/E*+LBQ_DE MF2R&TEJ0PAO&()45)!+94XL%6X$%.T).W( P%;2 "/%1!/O&@VXR K"4XX.0 MK<1R1XX)&2,#A/'05N70\\?".6;0=J);?M&NFL8@R7\+=Q.T0['B$D/8ZIW+ MN0\/($*:RZI2!UCM.)PIM?,4L^W5@DT2K;;@B*K<(6\5V38+;2XBD6K )3D> MHV%F%K2RUE#!_P"+,QIZVVQRAD#K)R]\+:M:3?P0([NZM8$D6:N:DOT1L>$#J2S*"CFS!E9E\#Y1E"&XQA1,!*)&RV4*V MX"8OZH9))6U.1VIVLYEF!Z_/'34>\3K%F0>EQV7G95B1_$ZI*P3;,?*X7_AE MP[YK#2"%H^G*8:?4A+"DL-9D3SD(*B"2,#@I'4@%*21GQPHD=/"L2L9X\,@\ M8Z$@''AD8.!]_4!QQQR]5IQQQQ2G'''%*<<<<4J&>X>@'5?>.T7-U7:AV2,V MH;7X6ISUZU=M[/*VJ53H[+F;=7-_4\V'?V7MXFJPE3[3!GB=AZU1*>1?W:M MK:#VX[)G2]PC:!#UP8VRO?I0R@>P-,R+5AW'(P,YP,_RJ@MBA=F^S45N$JJ M["G&++BS,^*/,8I-QMLW5XJ1:29"1<8_E;BYX<<;1Y#[O+ MI^5-ROZQ^\UK+7NGM=ZKD-D2E#KS<"=MW81>UMC$)D):0FK?8K?;[ M;4(/:>WXG2EIM5_AY:!O-@L?7D&^LZ)FI.XQD[,IM#TAKM]N>.DS)B39)F7E M2')P\<8& ,# Z9&:9/7)SYYJ$M&]/'JGKVO5ZHP-*N9]6IM]U!LFCURZ;QWO ML:$H-HT')&R^G\T"-V!LJS"TF HTA(DNQE0K3<;52FUS2T&31LC)/9/L$]+2*_J#'< M-+,4R/AH9MEEO9?')P/*F3YFG'''%13CCCBE....*4XXXXI3CCCBE....*4X MXXXI3CCCBE....*4XXXXI3CCCBE.5?=]=%["VU?*!*5K35EW!%QNEMXU*MD5 M_:,+K5&K-V6Z>U05K3:,A(2=WJN?$$>!'G_/(XJCB)UEZILQ=0:E8-I;%B:V3IC11 ! M,JQC3-,]72!_51!%2UNO#V;'J:Y76XREVTLL-)4UK'30G8?6%JJ\,U3(Y_7S M=Q/W?(Z_FHG,P969&%B(6OP,N'.5^?K]]GC'Y^,>?X_XO\GVX\8_ACE=GAN5 MC@=?+'\L'S!\^:L%G.=J3CS''W9^<"JA.C^L?4&US;M:_K^L4B1K@.A3M$L5 M%?GM:2E6J M3T_UG:UC)5MNN!IL[T[)[.1V.$GY0V.3]5)ZG R .I..@'/)/0>9Q49W*&<#) )\.O4^/Q]*\ZG:C:#>XN MV%@>&*^HK&OWFZ' 9QGRRI$$\\J>-;^_M5];8WI'"74XQ\HPHOG^AC.?BV)> MV!8$>'">2IS+?QH2A6,YQE:7?JV'?;\90Q#)3*ULNH4K((%1

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end GRAPHIC 25 g365644.jpg G365644.JPG begin 644 g365644.jpg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�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end GRAPHIC 26 g710914.jpg G710914.JPG begin 644 g710914.jpg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end GRAPHIC 14 g29819.jpg G29819.JPG begin 644 g29819.jpg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